0001140361-16-060287.txt : 20160405 0001140361-16-060287.hdr.sgml : 20160405 20160405165645 ACCESSION NUMBER: 0001140361-16-060287 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20160229 FILED AS OF DATE: 20160405 DATE AS OF CHANGE: 20160405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Walgreens Boots Alliance, Inc. CENTRAL INDEX KEY: 0001618921 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 471758322 STATE OF INCORPORATION: DE FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36759 FILM NUMBER: 161555214 BUSINESS ADDRESS: STREET 1: 108 WILMOT ROAD CITY: DEERFIELD STATE: IL ZIP: 60015 BUSINESS PHONE: (847) 315-2500 MAIL ADDRESS: STREET 1: 108 WILMOT ROAD CITY: DEERFIELD STATE: IL ZIP: 60015 10-Q 1 form10q.htm WALGREENS BOOTS ALLIANCE, INC. 10-Q 2-29-2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended February 29, 2016

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______to _______


Commission File Number
001-36759

WALGREENS BOOTS ALLIANCE, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
47-1758322
(State of Incorporation)
 
(I.R.S. Employer Identification No.)

108 Wilmot Road, Deerfield, Illinois
 
60015
(Address of principal executive offices)
 
(Zip Code)

(847) 315-2500
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes        No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes ☑      No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
Accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company)
Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes         No

The number of shares outstanding of the registrant’s Common Stock, $.01 par value, as of March 31, 2016 was 1,080,245,720.
 


WALGREENS BOOTS ALLIANCE, INC.

FORM 10-Q FOR THE QUARTER ENDED FEBRUARY 29, 2016

TABLE OF CONTENTS

PART I.
FINANCIAL INFORMATION

 
Item 1.
3
   
a)
3
   
b)
4
   
c)
5
   
d)
6
   
e)
7
   
f)
8
 
Item 2.
33
 
Item 3.
50
 
Item 4.
51
 
PART II.
OTHER INFORMATION

 
Item 1.
51
 
Item 1A.
51
 
Item 2.
52
 
Item 6.
52
 
PART I. FINANCIAL INFORMATION
Item 1.
Consolidated Condensed Financial Statements (Unaudited)

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
(UNAUDITED)
(In millions, except per share amounts)

   
February 29,
2016
   
August 31,
2015
 
Assets
           
Current Assets:
           
Cash and cash equivalents
 
$
3,586
   
$
3,000
 
Accounts receivable, net
   
6,733
     
6,849
 
Inventories
   
9,025
     
8,678
 
Other current assets
   
1,034
     
1,130
 
Total Current Assets
   
20,378
     
19,657
 
Non-Current Assets:
               
Property, plant and equipment, at cost, less accumulated depreciation and amortization
   
14,552
     
15,068
 
Goodwill
   
15,796
     
16,372
 
Intangible assets
   
11,122
     
12,351
 
Other non-current assets
   
4,537
     
5,334
 
Total Non-Current Assets
   
46,007
     
49,125
 
Total Assets
 
$
66,385
   
$
68,782
 
                 
Liabilities and Equity
               
Current Liabilities:
               
Short-term borrowings
 
$
1,052
   
$
1,068
 
Trade accounts payable
   
9,873
     
10,088
 
Accrued expenses and other liabilities
   
5,050
     
5,225
 
Income taxes
   
297
     
176
 
Total Current Liabilities
   
16,272
     
16,557
 
Non-Current Liabilities:
               
Long-term debt
   
12,974
     
13,315
 
Deferred income taxes
   
3,107
     
3,538
 
Other non-current liabilities
   
4,114
     
4,072
 
Total Non-Current Liabilities
   
20,195
     
20,925
 
Commitments and Contingencies (see Note 12)
               
Equity:
               
Preferred stock $.01 par value; authorized 32 million shares, none issued
   
-
     
-
 
Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at February 29, 2016 and August 31, 2015
   
12
     
12
 
Paid-in capital
   
10,041
     
9,953
 
Employee stock loan receivable
   
(1
)
   
(2
)
Retained earnings
   
26,348
     
25,089
 
Accumulated other comprehensive (loss) income
   
(1,868
)
   
(214
)
Treasury stock, at cost; 92,853,639 shares at February 29, 2016 and 82,603,274 at August 31, 2015
   
(5,026
)
   
(3,977
)
Total Walgreens Boots Alliance, Inc. Shareholders’ Equity
   
29,506
     
30,861
 
Noncontrolling interests
   
412
     
439
 
Total Equity
   
29,918
     
31,300
 
Total Liabilities and Equity
 
$
66,385
   
$
68,782
 

The accompanying Notes to Consolidated Condensed Financial Statements are an integral part of these Statements.
 
WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENT OF EQUITY
(UNAUDITED)
For the six month period ended February 29, 2016
(In millions, except per share amounts)

   
Equity attributable to Walgreens Boots Alliance, Inc.
             
   
Common Stock
Shares
   
Common
Stock
Amount
   
Treasury
Stock
Amount
   
Paid-In
Capital
   
Employee
Stock
Loan
Receivable
   
Accumulated
Other
Comprehensive
Income (Loss)
   
Retained
Earnings
   
Noncontrolling
Interests
   
Total
Equity
 
August 31, 2015
   
1,089,910,344
   
$
12
   
$
(3,977
)
 
$
9,953
   
$
(2
)
 
$
(214
)
 
$
25,089
   
$
439
   
$
31,300
 
Net earnings
   
-
     
-
     
-
     
-
     
-
     
-
     
2,040
     
9
     
2,049
 
Other comprehensive income (loss), net of tax
   
-
     
-
     
-
     
-
     
-
     
(1,654
)
   
-
     
(36
)
   
(1,690
)
Dividends declared ($0.72 per share)
   
-
     
-
     
-
     
-
     
-
     
-
     
(781
)
   
-
     
(781
)
Treasury stock purchases
   
(13,815,558
)
   
-
     
(1,152
)
   
-
     
-
     
-
     
-
     
-
     
(1,152
)
Employee stock purchase and option plans
   
3,565,193
     
-
     
103
     
28
     
-
     
-
     
-
     
-
     
131
 
Employee stock loan receivable
   
-
     
-
     
-
     
-
     
1
     
-
     
-
     
-
     
1
 
Stock-based compensation
   
-
     
-
     
-
     
60
     
-
     
-
     
-
     
-
     
60
 
February 29, 2016
   
1,079,659,979
   
$
12
   
$
(5,026
)
 
$
10,041
   
$
(1
)
 
$
(1,868
)
 
$
26,348
   
$
412
   
$
29,918
 

The accompanying Notes to Consolidated Condensed Financial Statements are an integral part of these Statements.
 
WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
(UNAUDITED)
(In millions, except per share amounts)

   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
                         
Net sales
 
$
30,184
   
$
26,573
   
$
59,217
   
$
46,127
 
Cost of sales
   
22,240
     
19,691
     
43,771
     
33,949
 
Gross Profit
   
7,944
     
6,882
     
15,446
     
12,178
 
                                 
Selling, general and administrative expenses
   
6,084
     
5,606
     
12,118
     
10,062
 
Equity earnings in Alliance Boots
   
-
     
101
     
-
     
315
 
Operating Income
   
1,860
     
1,377
     
3,328
     
2,431
 
                                 
Gain on previously held equity interest
   
-
     
706
     
-
     
706
 
Other income (expense)
   
(496
)
   
504
     
(553
)
   
703
 
Earnings Before Interest and Income Tax Provision
   
1,364
     
2,587
     
2,775
     
3,840
 
                                 
Interest expense, net
   
140
     
144
     
278
     
199
 
Earnings Before Income Tax Provision
   
1,224
     
2,443
     
2,497
     
3,641
 
Income tax provision
   
301
     
391
     
468
     
712
 
Post tax earnings from equity method investments
   
9
     
8
     
20
     
8
 
Net Earnings
   
932
     
2,060
     
2,049
     
2,937
 
Net earnings attributable to noncontrolling interests
   
2
     
18
     
9
     
45
 
Net Earnings Attributable to Walgreens Boots Alliance, Inc.
 
$
930
   
$
2,042
   
$
2,040
   
$
2,892
 
                                 
                                 
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. – basic
 
$
0.86
   
$
1.96
   
$
1.88
   
$
2.91
 
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. – diluted
 
$
0.85
   
$
1.93
   
$
1.87
   
$
2.88
 
                                 
Dividends declared per share
 
$
0.3600
   
$
0.3375
   
$
0.7200
   
$
0.6750
 
                                 
Average shares outstanding
   
1,080.2
     
1,043.6
     
1,084.6
     
994.7
 
Dilutive effect of stock options
   
8.2
     
11.1
     
8.9
     
10.6
 
Average diluted shares
   
1,088.4
     
1,054.7
     
1,093.5
     
1,005.3
 

The accompanying Notes to Consolidated Condensed Financial Statements are an integral part of these Statements.
 
WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
(In millions)

   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Comprehensive Income
                       
                         
Net Earnings
 
$
932
   
$
2,060
   
$
2,049
   
$
2,937
 
                                 
Other comprehensive income (loss), net of tax:
                               
Pension/postretirement obligations
   
(2
)
   
(8
)
   
1
     
(9
)
Unrealized gain (loss) on cash flow hedges
   
1
     
-
     
2
     
(12
)
Unrecognized gain (loss) on available-for-sale investments
   
(88
)
   
90
     
(87
)
   
189
 
Share of other comprehensive income (loss) of Alliance Boots
   
-
     
92
     
-
     
113
 
Currency translation adjustments
   
(1,156
)
   
(301
)
   
(1,606
)
   
(490
)
Total Other Comprehensive Income (Loss)
   
(1,245
)
   
(127
)
   
(1,690
)
   
(209
)
Total Comprehensive Income (Loss)
   
(313
)
   
1,933
     
359
     
2,728
 
                                 
Comprehensive income (loss) attributable to noncontrolling interests
   
(33
)
   
13
     
(27
)
   
40
 
Comprehensive Income (Loss) Attributable to Walgreens Boots Alliance, Inc.
 
$
(280
)
 
$
1,920
   
$
386
   
$
2,688
 

The accompanying Notes to Consolidated Condensed Financial Statements are an integral part of these Statements.
 
WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In millions)

   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
 
             
Cash Flows from Operating Activities:
           
Net earnings
 
$
2,049
   
$
2,937
 
Adjustments to reconcile net earnings to net cash provided by operating activities -
               
Depreciation and amortization
   
824
     
826
 
Change in fair value of warrants and related amortization
   
586
     
(859
)
Gain on previously held equity interest
   
-
     
(706
)
Deferred income taxes
   
(171
)
   
181
 
Stock compensation expense
   
60
     
65
 
Equity earnings from equity method investments
   
(20
)
   
(315
)
Other
   
196
     
322
 
Changes in operating assets and liabilities -
               
Accounts receivable, net
   
(152
)
   
(391
)
Inventories
   
(553
)
   
106
 
Other current assets
   
33
     
21
 
Trade accounts payable
   
160
     
363
 
Accrued expenses and other liabilities
   
(79
)
   
(20
)
Income taxes
   
92
     
(99
)
Other non-current assets and liabilities
   
60
     
(94
)
Net cash provided by operating activities
   
3,085
     
2,337
 
                 
Cash Flows from Investing Activities:
               
Additions to property, plant and equipment
   
(657
)
   
(643
)
Proceeds from sale leaseback transactions
   
60
     
562
 
Proceeds from sale of business
   
43
     
-
 
Proceeds from sale of other assets
   
85
     
17
 
Alliance Boots acquisition, net of cash received
   
-
     
(4,461
)
Other business and intangible asset acquisitions, net of cash received
   
(86
)
   
(92
)
Purchases of short-term investments held to maturity
   
(30
)
   
(29
)
Proceeds from short-term investments held to maturity
   
36
     
29
 
Other
   
(3
)
   
(91
)
Net cash used for investing activities
   
(552
)
   
(4,708
)
                 
Cash Flows from Financing Activities:
               
Proceeds (payments) of short-term borrowings, net
   
61
     
(330
)
Proceeds from issuance of long-term debt
   
-
     
12,279
 
Payments of long-term debt
   
(81
)
   
(7,817
)
Stock purchases
   
(1,152
)
   
(594
)
Proceeds related to employee stock plans
   
129
     
293
 
Cash dividends paid
   
(787
)
   
(642
)
Other
   
(29
)
   
(360
)
Net cash (used for) provided by financing activities
   
(1,859
)
   
2,829
 
                 
Effect of exchange rate changes on cash and cash equivalents
   
(88
)
   
(99
)
                 
Changes in Cash and Cash Equivalents:
               
Net increase in cash and cash equivalents
   
586
     
359
 
Cash and cash equivalents at beginning of period
   
3,000
     
2,646
 
Cash and cash equivalents at end of period
 
$
3,586
   
$
3,005
 

The accompanying Notes to Consolidated Condensed Financial Statements are an integral part of these Statements.
 
WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)

Note 1.  Organization
Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance”) and subsidiaries are a global pharmacy-led health and wellbeing enterprise. Its operations are conducted through three reportable segments (Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale). See Note 18, Segment Reporting for further information.

On December 31, 2014, Walgreens Boots Alliance became the successor of Walgreen Co. (“Walgreens”) pursuant to a merger designed to effect a reorganization of Walgreens into a holding company structure (the “Reorganization”). Pursuant to the Reorganization, Walgreens became a wholly-owned subsidiary of Walgreens Boots Alliance, a Delaware corporation formed for the purposes of the Reorganization, and each issued and outstanding share of Walgreens common stock converted on a one-to-one basis into Walgreens Boots Alliance common stock. References to the “Company” refer to Walgreens Boots Alliance and its subsidiaries from and after the effective time of the Reorganization on December 31, 2014 and, prior to that time, to the predecessor registrant Walgreens and its subsidiaries, except as otherwise indicated or the context otherwise requires.

On December 31, 2014, following the completion of the Reorganization, Walgreens Boots Alliance completed the acquisition of the remaining 55% of Alliance Boots GmbH (“Alliance Boots”) that Walgreens did not previously own (the “Second Step Transaction”) in exchange for £3.133 billion in cash and approximately 144.3 million shares of Walgreens Boots Alliance common stock. Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method immediately upon completion of the Second Step Transaction. For financial reporting and accounting purposes, Walgreens Boots Alliance was the acquirer of Alliance Boots. The consolidated financial statements (and other data) reflect the results of operations and financial position of Walgreens and its subsidiaries for periods prior to December 31, 2014 and of Walgreens Boots Alliance and its subsidiaries for periods from and after the effective time of the Reorganization on December 31, 2014.

As part of the Second Step Transaction, the Company acquired the remaining 27.5% noncontrolling interest in Walgreens Boots Alliance Development GmbH (“WBAD”), a global sourcing enterprise established by the Company and Alliance Boots. The Company already owned a 50% direct ownership in WBAD and indirectly owned an additional ownership interest through its previous 45% investment in Alliance Boots, representing a direct and indirect economic interest of 72.5%. The Company’s acquisition of the remaining 27.5% effective ownership in WBAD as part of the Second Step Transaction was accounted for as an equity transaction as it has historically been consolidated by the Company. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. (“AHID”), which is not a member of the Company’s consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000.

Note 2. Accounting Policies
Basis of Presentation
The consolidated condensed financial statements of Walgreens Boots Alliance included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. The consolidated condensed financial statements include all subsidiaries in which the Company holds a controlling interest. Investments in less than majority-owned entities in which the Company does not have a controlling interest, but does have significant influence, are accounted for as equity method investments. All intercompany transactions have been eliminated.

The Consolidated Condensed Balance Sheet as of February 29, 2016, the Consolidated Condensed Statements of Equity for the six-month period ended February 29, 2016, and the Consolidated Condensed Statements of Earnings, the Consolidated Condensed Statements of Comprehensive Income and the Consolidated Condensed Statements of Cash Flows for the three month and six month periods ended February 29, 2016 and February 28, 2015, have not been audited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.
 
In the opinion of the Company, the unaudited consolidated condensed financial statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present a fair statement of the results for such interim periods. Because of the acquisition of Alliance Boots, influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company’s operations, net earnings for any interim period may not be comparable to the same interim period in previous years or indicative of net earnings for the full fiscal year. In addition, with respect to the Company’s Retail Pharmacy USA segment, the positive impact on gross profit margins and gross profit dollars typically has been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a “generic conversion.” In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on Retail Pharmacy USA segment’s sales, gross profit margins and gross profit dollars.

The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experience and other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. For a discussion of the Company’s significant accounting policies, please see the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.

Note 3. Restructuring
On April 8, 2015, the Walgreens Boots Alliance Board of Directors approved a plan to implement a new restructuring program (the “Cost Transformation Program”) as part of an initiative to reduce costs and increase operating efficiencies. The Cost Transformation Program implemented and built on the cost-reduction initiative previously announced by the Company on August 6, 2014 and included plans to close approximately 200 stores across the U.S.; reorganize corporate and field operations; drive operating efficiencies; and streamline information technology and other functions. The actions under the Cost Transformation Program focus primarily on Retail Pharmacy USA segment, but includes activities from all segments and are expected to be substantially complete by the end of the Company’s 2017 fiscal year. The Company estimates that it will recognize cumulative pre-tax charges to its GAAP financial results of between $1.6 billion and $1.8 billion, including costs associated with lease obligations and other real estate payments, asset impairments and employee termination and other business transition and exit costs. The Company expects to incur pre-tax charges of between $525 million and $600 million for real estate costs, including lease obligations (net of estimated sublease income); between $650 million and $725 million for asset impairment charges relating primarily to asset write-offs from store closures, information technology, inventory and other non-operational real estate asset write-offs; and between $425 million and $475 million for employee severance and other business transition and exit costs. The Company incurred pre-tax charges of $28 million and $118 million related to the Cost Transformation Program during the three and six months ended February 29, 2016. No charges were incurred with respect to the Cost Transformation Program in the three and six months ended February 28, 2015. From inception through February 29, 2016, the Company incurred pre-tax charges of $660 million ($254 million in real estate costs, $248 million related to asset impairment charges and $158 million in severance and other business transition and exit costs) related to the Cost Transformation Program. All charges related to the Cost Transformation Program have been recorded within selling, general and administrative expenses. As the program is implemented, the restructuring charges will be recognized as the costs are incurred over time in accordance with GAAP.

In March 2014, the Walgreens Board of Directors approved a plan to close underperforming stores in efforts to optimize and focus resources within Retail Pharmacy USA segment in a manner intended to increase stockholder value. As of August 31, 2015, this plan was completed and no additional charges related to the plan are expected. There were no charges incurred in the three month period ended February 28, 2015. For the six months ended February 28, 2015, the Company incurred pre-tax charges of $17 million, which were primarily related to lease termination costs. All charges related to this plan have been recorded within selling, general and administrative expenses.

Restructuring costs by segment are as follows (in millions):

   
Retail Pharmacy
             
Three Months Ended February 29, 2016
 
USA
   
International
   
Pharmaceutical
Wholesale
   
Consolidated
 
Real estate costs
 
$
-
   
$
-
   
$
-
   
$
-
 
Asset impairments
   
-
     
-
     
-
     
-
 
Severance and other business transition and exit costs
   
25
     
3
     
-
     
28
 
Total restructuring costs
 
$
25
   
$
3
   
$
-
   
$
28
 
                                 
Three Months Ended February 28, 2015
                               
Real estate costs
 
$
-
   
$
-
   
$
-
   
$
-
 
Asset impairments
   
-
     
-
     
-
     
-
 
Severance and other business transition and exit costs
   
-
     
-
     
-
     
-
 
Total restructuring costs
 
$
-
   
$
-
   
$
-
   
$
-
 
 
   
Retail Pharmacy
             
Six Months Ended February 29, 2016
 
USA
   
International
   
Pharmaceutical
Wholesale
   
Consolidated
 
Real estate costs
 
$
52
   
$
-
   
$
-
   
$
52
 
Asset impairments
   
25
     
-
     
-
     
25
 
Severance and other business transition and exit costs
   
33
     
8
     
-
     
41
 
Total restructuring costs
 
$
110
   
$
8
   
$
-
   
$
118
 
                                 
Six Months Ended February 28, 2015
                               
Real estate costs
 
$
17
   
$
-
   
$
-
   
$
17
 
Asset impairments
   
-
     
-
     
-
     
-
 
Severance and other business transition and exit costs
   
-
     
-
     
-
     
-
 
Total restructuring costs
 
$
17
   
$
-
   
$
-
   
$
17
 

Note 4. Operating Leases
Initial terms for leased premises in the U.S. are typically 15 to 25 years, followed by additional terms containing renewal options at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.

The Company provides for future costs related to closed locations. The liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date. During the three and six months ended February 29, 2016, the Company recorded charges of $9 million and $75 million, respectively, for facilities that were closed or relocated under long-term leases, including stores closed through the Company’s restructuring activities. This compares to no charges for the three months ended and $26 million for the six months ended February 28, 2015. Charges are reported in selling, general and administrative expenses on the Consolidated Condensed Statements of Earnings.

The changes in reserve for facility closings and related lease termination charges include the following (in millions):
 
     
Six Month
Period Ended
February 29,
2016
   
Twelve Month
Period Ended
August 31,
2015
 
Balance – beginning of period
 
$
446
   
$
257
 
Provision for present value of non-cancellable lease payments on closed facilities
   
77
     
231
 
Assumptions about future sublease income, terminations and changes in interest rates
   
(14
)
   
(6
)
Interest accretion
   
12
     
27
 
Liability assumed through acquisition of Alliance Boots
   
-
     
13
 
Cash payments, net of sublease income
   
(54
)
   
(76
)
Balance – end of period
 
$
467
   
$
446
 

The Company remains secondarily liable on 79 leases. The maximum potential undiscounted future payments are $348 million at February 29, 2016. Lease option dates vary, with some extending to 2039.
 
Note 5. Equity Method Investments
Equity method investments as of February 29, 2016 and August 31, 2015 were as follows (in millions, except percentages):

   
February 29, 2016
   
August 31, 2015
 
   
Carrying
Value
   
Ownership
Percentage
   
Carrying
Value
   
Ownership
Percentage
 
Equity method investments
 
$
1,217
     
12% - 50
%
 
$
1,242
     
12% - 50
%

The Company's principal equity method investments include its investments in Guangzhou Pharmaceuticals Corporation and Nanjing Pharmaceutical Corporation Limited, the Company’s pharmaceutical wholesale investments in China; and the equity method investment retained through the sale of a majority interest in Option Care Inc. in fiscal 2015. See Note 20, Subsequent Event for further information.

Equity method investments of the Company are recorded within other non-current assets on the Consolidated Condensed Balance Sheets. The Company reported $9 million and $20 million of post-tax equity earnings in equity method investments for the three and six month periods ended February 29, 2016, respectively, in the Consolidated Condensed Statements of Earnings. The Company reported $8 million of post-tax equity earnings from equity method investments other than Alliance Boots for the three and six month periods ended February 28, 2015. Additionally, for the three and six month periods ended February 28, 2015, the Company reported equity earnings in Alliance Boots of $101 million and $315 million, respectively, as its own line in the Consolidated Condensed Statements of Earnings.

Summarized Financial Information
Summarized financial information for the Company’s equity method investments is as follows:
 
Balance Sheets (in millions)
   
February 29, 2016(1)
   
August 31, 2015(1)
 
Current assets
 
$
5,687
   
$
5,015
 
Noncurrent assets
   
1,592
     
1,548
 
Current liabilities
   
4,598
     
3,936
 
Noncurrent liabilities
   
876
     
837
 
Shareholders’ equity(2)
   
1,805
     
1,790
 
 
Statements of Earnings (in millions)
   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016(3)
   
February 28,
2015(3)(4)
   
February 29,
2016(3)
   
February 28,
2015(3)(4)
 
                         
Net sales
 
$
3,286
   
$
5,317
   
$
6,489
   
$
14,978
 
Gross Profit
   
374
     
979
     
702
     
3,168
 
Net Income
   
26
     
246
     
50
     
743
 
Share of income from equity method investments
   
9
     
109
     
20
     
323
 

(1)
Balance sheet information of foreign equity method investments are translated at their respective February 29, 2016 and August 31, 2015 spot rates.
(2)
Shareholders’ equity at February 29, 2016 and August 31, 2015 includes $170 million and $163 million, respectively, related to noncontrolling interests.
(3)
Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates.
(4)
Includes equity method investment in Alliance Boots from Walgreen Co.’s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization.
 
Note 6. Available-for-Sale Investments
Walgreens, Alliance Boots and AmerisourceBergen Corporation (“AmerisourceBergen”) entered into a Framework Agreement, dated as of March 18, 2013, pursuant to which Walgreens and Alliance Boots together were granted the right to purchase a minority equity position in AmerisourceBergen, including the right, but not the obligation, to purchase up to 19,859,795 shares of AmerisourceBergen common stock in open market transactions.

In conjunction with its long-term relationship with AmerisourceBergen, as of February 29, 2016, the Company held 11.5 million shares, approximately 5.6% of AmerisourceBergen’s outstanding common stock, at a total fair value of $993 million. The Company did not acquire any AmerisourceBergen common shares in the three and six month periods ended February 29, 2016.

Pursuant to Accounting Standards Codification (“ASC”) Topic 320, Investments – Debt and Equity Securities, the Company, as of February 29, 2016, accounted for its investment in AmerisourceBergen shares as an available-for-sale investment reported at fair value within other non-current assets in the Consolidated Condensed Balance Sheets. As an available-for-sale investment, changes in the fair value are recorded through other comprehensive income. The value of the investment is recorded at the closing price of AmerisourceBergen common stock as of the balance sheet date. See Note 20, Subsequent Event for further information.

A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions):

   
February 29, 2016
 
   
Amortized
cost basis
   
Gross
unrealized
gains
   
Gross
unrealized
losses
   
Fair value
 
AmerisourceBergen common stock
 
$
717
   
$
276
   
$
-
   
$
993
 
Other investments
   
38
     
-
     
(4
)
   
34
 
Total available-for-sale investments
 
$
755
   
$
276
   
$
(4
)
 
$
1,027
 
 
   
August 31, 2015
 
   
Amortized
cost basis
   
Gross
unrealized
gains
   
Gross
unrealized
losses
   
Fair value
 
AmerisourceBergen common stock
 
$
717
   
$
430
   
$
-
   
$
1,147
 
Other investments
   
37
     
-
     
(1
)
   
36
 
Total available-for-sale investments
 
$
754
   
$
430
   
$
(1
)
 
$
1,183
 

For the three and six month periods ended February 29, 2016, there were $1 million and $3 million, respectively, of available-for-sale securities sold. There were no sales of available-for-sale investments for the three and six month periods ended February 28, 2015.

The Company’s other available-for-sale investments are classified within other current assets in the Consolidated Condensed Balance Sheets.

Note 7. Acquisitions
Alliance Boots
The Second Step Transaction closed on December 31, 2014, resulting in the acquisition by the Company of 55% of the issued and outstanding share capital of Alliance Boots, increasing its interest to 100%. The Company previously accounted for its 45% interest in Alliance Boots as an equity method investment. As a result of the Second Step Transaction, the Company significantly expanded its operations to include pharmacy-led health and beauty retailing and pharmaceutical wholesaling and distribution businesses in major international markets.

As a result of the closing of the Second Step Transaction, the Company increased its interest in WBAD, a global sourcing enterprise between Walgreens and Alliance Boots, to 100%. Because Walgreens held, prior to the Second Step Transaction, a 50% direct interest and an additional indirect interest in WBAD through its 45% ownership of Alliance Boots, the financial results of WBAD were fully consolidated into the Walgreens financial statements with the remaining 27.5% effective interest being recorded as a noncontrolling interest. The acquisition of the 27.5% noncontrolling interest was accounted for as an equity transaction with no gain or loss recorded in the statement of earnings under ASC Topic 805, Business Combinations. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. (“AHID”), which is not a member of the Company’s consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000.
 
The Company has completed the purchase accounting of the Second Step Transaction. The total purchase price of the Second Step Transaction of $15.9 billion included £3.133 billion in cash (approximately $4.9 billion at the December 31, 2014 spot rate of $1.56 to £1.00) and 144.3 million of the Company’s common shares at a fair value of $11.0 billion (based on the December 30, 2014 closing market price of $76.05). Of the total purchase price, $13.3 billion was allocated to acquire the 55% ownership interest in Alliance Boots and $2.6 billion was allocated to acquire the noncontrolling interest in WBAD. The purchase price attributed to the acquisition of the noncontrolling interest in WBAD was determined based on the relative fair value of Alliance Boots and WBAD, respectively.

The impact of the equity transaction is as follows (in millions):

   
Amount
 
Consideration attributable to WBAD
 
$
2,559
 
Less:  Carrying value of the Company’s pre-existing noncontrolling interest
   
130
 
Impact to additional paid in capital
 
$
2,429
 

The following table summarizes the consideration paid to acquire the remaining 55% interest in Alliance Boots and the amounts of identified assets acquired and liabilities assumed at the date of the Second Step Transaction (in millions).

Consideration paid
     
Cash
 
$
4,874
 
Common stock
   
10,977
 
Total consideration transferred
   
15,851
 
Less: consideration attributed to WBAD
   
(2,559
)
     
13,292
 
Fair value of the investment in Alliance Boots held before the Second Step Transaction
   
8,149
 
Total consideration
 
$
21,441
 
         
Identifiable assets acquired and liabilities assumed including noncontrolling interests
       
Cash and cash equivalents
 
$
413
 
Accounts receivable
   
3,799
 
Inventories
   
3,713
 
Other current assets
   
894
 
Property, plant and equipment
   
3,806
 
Intangible assets
   
11,691
 
Other non-current assets
   
2,217
 
Trade accounts payable, accrued expenses and other liabilities
   
(7,696
)
Borrowings
   
(9,010
)
Deferred income taxes
   
(2,452
)
Other non-current liabilities
   
(383
)
Noncontrolling interests
   
(412
)
Total identifiable net assets and noncontrolling interests
   
6,580
 
Goodwill
 
$
14,861
 

As a result of the Company acquiring the remaining 55% interest in Alliance Boots, the Company’s previously held 45% interest was re-measured at fair value, resulting in a gain of $563 million. The gain has been recognized as Gain on previously held equity interest in the Consolidated Statements of Earnings for the fiscal year ended August 31, 2015.
 
The fair value of the previously held equity interest of $8.1 billion in Alliance Boots was determined using the income approach methodology. The fair value for trade names and trademarks was determined using the relief from royalty method of the income approach; pharmacy licenses and customer relationships were determined using the excess earnings method of the income approach; and loyalty card holders were determined using the incremental cash flow method, which is a form of the income approach. Personal property fair values were determined primarily using the indirect cost approach, while real property fair values were determined using the income, market and/or cost approach. The fair value measurements of the previously held equity interest and intangible assets are based on significant inputs not observable in the market, and thus represent Level 3 measurements. The fair value estimates for the previously held equity interest and intangible assets are based on (a) projected discounted cash flows, (b) historical and projected financial information, (c) synergies including cost savings, and (d) attrition rates, as relevant, that market participants would consider when estimating fair values.

The identified definite and indefinite lived intangible assets were as follows:

Definite-Lived Intangible Assets
 
Weighted-Average Useful
Life (in years)
   
Amount (in millions)
 
Customer relationships
  12    
$
1,311
 
Loyalty card holders
  20      
742
 
Trade names and trademarks
  9      
399
 
Favorable lease interests
  7      
93
 
Total
       
$
2,545
 

Indefinite-Lived Intangible Assets
 
Amount (in millions)
 
Trade names and trademarks
 
$
6,657
 
Pharmacy licenses
   
2,489
 
Total
 
$
9,146
 

The goodwill of $14.9 billion arising from the Second Step Transaction primarily reflects the expected purchasing synergies, operating efficiencies by benchmarking performance and applying best practices across the Company, consolidation of operations, reductions in selling, general and administrative expenses and combining workforces.

Following the completion of the Second Step Transaction, the Company realigned its operations into three reportable segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company determined that the goodwill should be allocated across all segments recognizing that each segment will benefit from the expected synergies.

The goodwill allocated to the Retail Pharmacy USA segment of $7.3 billion is comprised of $3.5 billion of synergy benefits allocable to the segment on a source of procurement benefit basis and $3.8 billion determined on a “with-and-without” basis. The source of procurement benefit basis allocates the synergy benefits to the segment whose purchase gave rise to the benefit. The “with-and-without” basis computes the difference between the fair value of the pre-existing business before the combination and its fair value after the combination, and since the pre-existing Walgreens business is now within the Retail Pharmacy USA segment, all of this difference is allocated to this segment. The “with-and-without” computation recognized that if the Second Step Transaction did not happen, then this was likely to negatively impact the existing Walgreens business, which already had a 45% interest in Alliance Boots, as the expected purchasing synergies and other benefits resulting from a full combination would not be fully realized.

Of the remaining goodwill, $3.9 billion was allocated to the Retail Pharmacy International segment and $3.7 billion was allocated to the Pharmaceutical Wholesale segment. Substantially all of the goodwill recognized is not expected to be deductible for income tax purposes.

The Company incurred legal and other professional services costs related to the Second Step Transaction, which were included in selling, general and administrative expenses, of $87 million in fiscal 2015 ($59 million and $83 million in the three and six months ended February 28, 2015, respectively). No costs related to the Second Step Transaction were incurred in the three and six month periods ended February 29, 2016.

The fair value of the assets acquired includes inventory having an estimated fair value of $3.7 billion. This fair value includes a $106 million fair value adjustment to capitalize the estimated profit in acquired finished goods inventory as of the date of the Second Step Transaction, which was expensed to cost of sales over the first inventory turn.
 
The following table presents supplemental unaudited condensed pro forma consolidated information for the three and six months ended February 28, 2015 as if the Second Step Transaction had occurred on September 1, 2014, the first day of the Company’s 2015 fiscal year. The unaudited condensed pro forma information reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased amortization expense based on the fair valuation of assets acquired, the impact of acquisition financing, transaction costs and the related income tax effects. The unaudited condensed pro forma information does not include any anticipated synergies that may be achievable subsequent to the date of the Second Step Transaction. The unaudited condensed pro forma information also excludes certain non-recurring items such as transaction related costs. Accordingly, the unaudited condensed pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company’s results would have been had the Second Step Transaction occurred at the beginning of the periods presented or the results which may occur in the future.

   
Pro forma
Three Months Ended
February 28,
2015
   
Pro forma
Six Months Ended
February 28,
2015
 
(in millions, except per share amounts)
           
Net sales
 
$
30,202
   
$
59,173
 
Net earnings
   
1,253
     
2,621
 
                 
Net earnings per common share:
               
Basic
 
$
1.20
   
$
2.51
 
Diluted
   
1.19
     
2.49
 

Other Acquisitions
The aggregate purchase price of all other businesses, net of cash received was $86 million for the six month period ended February 29, 2016. These acquisitions, primarily of an international beauty brand and prescription files, added $19 million to goodwill and $72 million to intangible assets. The remaining fair value relates to immaterial amounts of tangible assets, less liabilities assumed. Operating results of the businesses acquired have been included in the Consolidated Condensed Statements of Earnings from their respective acquisition dates forward. Pro forma results of the Company, assuming all of the other acquisitions had occurred at the beginning of each period presented, would not be materially different from the results reported.

Note 8. Goodwill and Other Intangible Assets
Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions):

   
Retail Pharmacy
USA
   
Retail Pharmacy
International
   
Pharmaceutical
Wholesale
   
Total
 
August 31, 2015
 
$
8,940
   
$
3,898
   
$
3,534
   
$
16,372
 
Acquisitions
   
-
     
19
     
-
     
19
 
Other (1)
   
-
     
(3
)
   
13
     
10
 
Currency translation adjustments
   
-
     
(309
)
   
(296
)
   
(605
)
February 29, 2016
 
$
8,940
   
$
3,605
   
$
3,251
   
$
15,796
 

(1) Other represents immaterial purchase accounting adjustments for prior year Company acquisitions.
 
The carrying amount and accumulated amortization of intangible assets consist of the following (in millions):

   
February 29, 2016
   
August 31, 2015
 
Gross Amortizable Intangible Assets
           
Customer relationships
 
$
1,293
   
$
1,409
 
Purchased prescription files
   
904
     
885
 
Loyalty card holders
   
661
     
730
 
Trade names and trademarks
   
678
     
675
 
Favorable lease interests
   
457
     
440
 
Non-compete agreements
   
158
     
154
 
Purchasing and payer contracts
   
95
     
94
 
Total gross amortizable intangible assets
   
4,246
     
4,387
 
                 
Accumulated amortization
               
Customer relationships
   
182
     
132
 
Purchased prescription files
   
536
     
470
 
Loyalty card holders
   
41
     
41
 
Trade names and trademarks
   
114
     
83
 
Favorable lease interests
   
246
     
207
 
Non-compete agreements
   
106
     
92
 
Purchasing and payer contracts
   
68
     
65
 
Total accumulated amortization
   
1,293
     
1,090
 
Total amortizable intangible assets, net
 
$
2,953
   
$
3,297
 
                 
Indefinite Lived Intangible Assets
               
Trade names and trademarks
 
$
5,947
   
$
6,590
 
Pharmacy licenses
   
2,222
     
2,464
 
Total indefinite lived intangible assets
 
$
8,169
   
$
9,054
 
                 
Total intangible assets, net
 
$
11,122
   
$
12,351
 

Amortization expense for intangible assets was $124 million and $216 million for the three and six months ended February 29, 2016, respectively, and $209 million and $276 million for the three and six months ended February 28, 2015, respectively.

Estimated annual amortization expense for intangible assets recorded at February 29, 2016 is as follows (in millions):

   
2016
   
2017
   
2018
   
2019
   
2020
 
Estimated annual amortization expense
 
$
401
   
$
358
   
$
318
   
$
289
   
$
254
 

Note 9. Short-Term Borrowings and Long-Term Debt
Short-term borrowings and long-term debt consist of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):

   
February 29, 2016
   
August 31, 2015
 
Short-Term Borrowings(1)
           
Unsecured variable rate notes due 2016
 
$
749
   
$
747
 
Other(2)
   
303
     
321
 
Total short-term borrowings
 
$
1,052
   
$
1,068
 
                 
Long-Term Debt(1)
               
Unsecured Pound Sterling variable rate term loan due 2019(3)
 
$
2,013
   
$
2,229
 
1.750% unsecured notes due 2017
   
747
     
746
 
5.250% unsecured notes due 2019(4)
   
253
     
250
 
2.700% unsecured notes due 2019
   
1,244
     
1,243
 
2.875% unsecured Pound Sterling notes due 2020(3)
   
552
     
612
 
3.300% unsecured notes due 2021
   
1,241
     
1,241
 
3.100% unsecured notes due 2022
   
1,193
     
1,193
 
3.800% unsecured notes due 2024
   
1,986
     
1,985
 
3.600% unsecured Pound Sterling notes due 2025(3)
   
414
     
459
 
2.125% unsecured Euro notes due 2026(5)
   
811
     
836
 
4.500% unsecured notes due 2034
   
494
     
494
 
4.400% unsecured notes due 2042
   
492
     
492
 
4.800% unsecured notes due 2044
   
1,492
     
1,491
 
Other(6)
   
42
     
44
 
Total long-term debt
 
$
12,974
   
$
13,315
 
 
(1)
All notes are presented net of unamortized discount and debt issuance costs, where applicable.
(2)
Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts.
(3)
Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively.
(4)
Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures.
(5)
Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively.
(6)
Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
 
$8.0 Billion Note Issuance
On November 18, 2014, Walgreens Boots Alliance received net proceeds (after deducting underwriting discounts and estimated offering expenses) of $7.9 billion from a public offering of notes with varying maturities and interest rates, the majority of which are fixed rate. The notes are unsecured, unsubordinated debt obligations of Walgreens Boots Alliance and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance from time to time outstanding. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged. Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $44 million. The fair value of the notes as of February 29, 2016 was $7.9 billion. Fair value for these notes was determined based upon quoted market prices.

The following table summarizes each tranche of notes issued:

Notes Issued
(in millions)
 
 
Maturity Date
 
 
Interest Rate
 
 
Interest Payment Dates
$
750
 
May 18, 2016
 
Variable; three month U.S. dollar LIBOR, reset quarterly, plus 45 basis points
 
February 18, May 18, August 18, and November 18; commencing on February 18, 2015
 
750
 
November 17, 2017
 
Fixed 1.750%
 
May 17 and November 17; commencing on May 17, 2015
 
1,250
 
November 18, 2019
 
Fixed 2.700%
 
May 18 and November 18; commencing on May 18, 2015
 
1,250
 
November 18, 2021
 
Fixed 3.300%
 
May 18 and November 18; commencing on May 18, 2015
 
2,000
 
November 18, 2024
 
Fixed 3.800%
 
May 18 and November 18; commencing on May 18, 2015
 
500
 
November 18, 2034
 
Fixed 4.500%
 
May 18 and November 18; commencing on May 18, 2015
 
1,500
 
November 18, 2044
 
Fixed 4.800%
 
May 18 and November 18; commencing on May 18, 2015
$
8,000
             
 
Redemption Option
Walgreens Boots Alliance may redeem (a) the notes due 2017, at any time in whole or from time to time in part, (b) the notes due 2019, at any time prior to October 18, 2019 in whole or from time to time prior to October 18, 2019 in part, (c) the notes due 2021, at any time prior to September 18, 2021 in whole or from time to time prior to September 18, 2021 in part, (d) the notes due 2024, at any time prior to August 18, 2024 in whole or from time to time prior to August 18, 2024 in part, (e) the notes due 2034, at any time prior to May 18, 2034 in whole or from time to time prior to May 18, 2034 in part, and (f) the notes due 2044, at any time prior to May 18, 2044 in whole or from time to time prior to May 18, 2044 in part, in each case, at Walgreens Boots Alliance’s option for the sum of accrued and unpaid interest plus a redemption price equal to the greater of:
 
(1) 100% of the principal amount of the fixed rate notes being redeemed; and
 
(2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 15 basis points for the notes due 2017, 15 basis points for the notes due 2019, 20 basis points for the notes due 2021, 20 basis points for the notes due 2024, 20 basis points for the notes due 2034 and 25 basis points for the notes due 2044.
 
In addition, at any time on or after October 18, 2019 with respect to the notes due 2019, September 18, 2021 with respect to the notes due 2021, August 18, 2024 with respect to the notes due 2024, May 18, 2034 with respect to the notes due 2034, or May 18, 2044 with respect to the notes due 2044, Walgreens Boots Alliance may redeem some or all of the applicable series of fixed rate notes at its option, at a redemption price equal to 100% of the principal amount of the applicable fixed rate notes being redeemed, plus accrued and unpaid interest on the fixed rate notes being redeemed to, but excluding, the redemption date.

Change in Control
If Walgreens Boots Alliance experiences a change of control triggering event, unless Walgreens Boots Alliance has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, Walgreens Boots Alliance will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest.

£700 Million and €750 Million Notes Issuance
On November 20, 2014, Walgreens Boots Alliance issued three series of debt securities denominated in Euros and Pound Sterling in a public offering, each with varying maturities and interest rates. Interest on all notes is payable annually on November 20, commencing on November 20, 2015. The notes are unsecured, unsubordinated debt obligations of Walgreens Boots Alliance and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance from time to time outstanding. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged. Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $11 million. The fair value of the notes as of February 29, 2016 was $1.8 billion. Fair value for these notes was determined based upon quoted market prices.

The following table details each tranche of Euro and Pound Sterling notes issued:

Notes Issued (in millions)
 
Maturity Date
Interest Rate
Euro Notes:
      
750
 
November 20, 2026
Fixed 2.125%
           
Pound Sterling Notes:
      
£
400
 
November 20, 2020
Fixed 2.875%
 
300
 
November 20, 2025
Fixed 3.600%
£
700
      

Redemption Option
Walgreens Boots Alliance may redeem (a) the Euro notes, at any time prior to August 20, 2026, in whole or, from time to time prior to August 20, 2026, in part, (b) the Pound Sterling notes due 2020, at any time prior to October 20, 2020, in whole or, from time to time prior to October 20, 2020, in part, and (c) the Pound Sterling notes due 2025, at any time prior to August 20, 2025, in whole or, from time to time prior to August 20, 2025, in part, in each case, at Walgreens Boots Alliance’s option for the sum of accrued and unpaid interest plus at a redemption price equal to the greater of:
 
(1) 100% of the principal amount of the notes to be redeemed; and
 
(2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on an annual basis at the applicable Comparable Government Bond Rate (as defined in the applicable series of notes), plus 20 basis points for the Euro notes, 20 basis points for the Pound Sterling notes due 2020 and 20 basis points for Pound Sterling the notes due 2025.
 
In addition, at any time on or after August 20, 2026 with respect to the Euro notes, October 20, 2020 with respect to the Pound Sterling notes due 2020, or August 20, 2025 with respect to the Pound Sterling notes due 2025, Walgreens Boots Alliance may redeem some or all of the applicable series of notes at its option at a redemption price equal to 100% of the principal amount of the applicable notes to be redeemed plus, in every case, accrued and unpaid interest on the notes to be redeemed to, but excluding, the redemption date.
 
Change in Control
If Walgreens Boots Alliance experiences a change of control triggering event, unless Walgreens Boots Alliance has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, Walgreens Boots Alliance will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest.
 
$4.0 Billion Note Issuance
On September 13, 2012, Walgreens obtained net proceeds from a public offering of $4.0 billion of notes with varying maturities and interest rates, the majority of which, at issuance, were fixed rate. The notes are unsecured senior debt obligations and rank equally with all other unsecured and unsubordinated indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance. Total issuance costs relating to the notes, including underwriting discounts and fees, were $26 million. On August 10, 2015, the 1.8000% fixed rate notes due September 15, 2017 in the aggregate principal amount of $1.0 billion were redeemed in full. The redemption price was equal to 101.677% of the aggregate principal amount of the notes redeemed, plus accrued interest thereon to, but excluding, the redemption date, and included a $17 million make whole premium, which was recorded as interest expense on the Company’s Consolidated Statements of Earnings. Additionally, the Company repaid the $750 million 1.000% fixed rate notes on their March 13, 2015 maturity date and the $550 million variable rate notes on their March 13, 2014 maturity date.
 
The following table details each tranche of outstanding notes as of February 29, 2016:
 
Notes Issued
(in millions)
 
Maturity Date
Interest Rate
Interest Payment Dates
$
1,200
 
September 15, 2022
Fixed 3.100%
March 15 and September 15; commencing on March 15, 2013
 
500
 
September 15, 2042
Fixed 4.400%
March 15 and September 15; commencing on March 15, 2013
$
1,700
         
 
The fair value of the notes outstanding as of February 29, 2016 was $1.6 billion. Fair value for these notes was determined based upon quoted market prices.
 
Redemption Option and Change in Control
Walgreens may redeem the fixed rate notes at its option, at any time in whole, or from time to time in part, at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes being redeemed; and (b) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 12 basis points for the notes due 2015, 22 basis points for the notes due 2022 and 25 basis points for the notes due 2042. If a change of control triggering event occurs, Walgreens will be required, unless it has exercised its right to redeem the notes, to offer to purchase the notes at a purchase price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, on the notes repurchased to the date of repurchase.
 
$1.0 Billion Note Issuance
On January 13, 2009, Walgreens issued notes totaling $1.0 billion bearing an interest rate of 5.250% paid semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2009. The notes will mature on January 15, 2019. The notes are unsecured senior debt obligations and rank equally with all other unsecured senior indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance. The notes are not convertible or exchangeable. Total issuance costs relating to this offering, including underwriting discounts and fees, were $8 million. On August 10, 2015, $750 million aggregate principal amount of the notes were redeemed. The redemption price was equal to 111.734% of the aggregate principal amount of the notes redeemed plus accrued interest thereon to, but excluding, the redemption date; and included a $88 million make whole premium, which was recorded as interest expense on the Company’s Consolidated Statements of Earnings. The partial redemption of the notes resulted in $250 million aggregate principal amount of the notes remaining outstanding. The fair value of the notes outstanding as of February 29, 2016 was $270 million. Fair value for these notes was determined based upon quoted market prices.
 
Redemption Option and Change in Control
Walgreens may redeem the notes, at any time in whole or from time to time in part, at its option at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes to be redeemed; or (b) the sum of the present values of the remaining scheduled payments of principal and interest, discounted to the date of redemption on a semiannual basis at the Treasury Rate (as defined in the applicable series of notes), plus 45 basis points, plus accrued interest on the notes to be redeemed to, but excluding, the date of redemption. If a change of control triggering event occurs, unless Walgreens has exercised its option to redeem the notes, it will be required to offer to repurchase the notes at a purchase price equal to 101% of the principal amount of the notes plus accrued and unpaid interest to the date of redemption.
 
Other Borrowings
The Company periodically borrows under its commercial paper program and may borrow under it in future periods. There were no commercial paper borrowings outstanding as of February 29, 2016 or February 28, 2015, respectively. The Company had average daily short-term borrowings of $20 million of commercial paper outstanding at a weighted average interest rate of 0.62% for the six month period ended February 29, 2016. We had average daily short-term borrowings of $4 million of commercial paper outstanding at a weighted average interest rate of 0.46% for the six months ended February 28, 2015.

2014 Term Loan Agreement and Revolving Credit Agreement

On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a term loan credit agreement (the “Term Loan Agreement”), which provides Walgreens Boots Alliance and Walgreens with the ability to borrow up to £1.45 billion on an unsecured basis. Borrowings under the Term Loan Agreement bear interest at a fluctuating rate per annum equal to the reserve adjusted LIBOR plus an applicable margin based on the Company’s credit ratings. As of February 29, 2016, Walgreens Boots Alliance had borrowed £1.45 billion ($2.0 billion at the February 29, 2016 spot rate of $1.39 to £1) under the Term Loan Agreement. The fair value of the Term Loan Agreement as of February 29, 2016 was $2.0 billion. Fair value of the borrowings under the Term Loan Agreement was determined based upon quoted market prices.

On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a five-year unsecured, multicurrency revolving credit agreement (the “Revolving Credit Agreement”), replacing prior Walgreens agreements dated July 20, 2011 and July 23, 2012. The new unsecured revolving credit agreement initially totaled $2.25 billion, of which $375 million was available for the issuance of letters of credit. On December 29, 2014, upon the affirmative vote of the majority of common shares of Walgreens represented and entitled to vote at the Walgreens special meeting of shareholders to approve the issuance of the shares necessary to complete the Second Step Transaction, the available credit increased to $3.0 billion, of which $500 million is available for the issuance of letters of credit. The issuance of letters of credit reduces the aggregate amount otherwise available under the Revolving Credit Agreement for the making of revolving loans. Borrowings under the Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance’s option, the alternate base rate or the reserve adjusted LIBOR, in each case, plus an applicable margin calculated based on the Company’s credit ratings. As of February 29, 2016, there were no borrowings or letters of credit issued pursuant to the Revolving Credit Agreement.

Total upfront fees related to the Term Loan Agreement and Revolving Credit Agreement were $14 million. The Company pays a facility fee to the financing banks to keep these lines of credit active.

In accordance with the terms of each of the Term Loan Agreement and the Revolving Credit Agreement, Walgreens guaranteed the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of all of Walgreens Boots Alliance’s obligations under the Term Loan Agreement and Revolving Credit Agreement, as applicable until August 10, 2015, when such guarantees automatically terminated, without penalty to Walgreens or Walgreens Boots Alliance, and the obligations of Walgreens thereunder were unconditionally released and discharged.

On December 19, 2014, Walgreens Boots Alliance and Walgreens entered into a Revolving Credit Agreement (as amended, the “364-Day Credit Agreement”) with the lenders party thereto. The 364-Day Credit Agreement was a $750 million, 364-day unsecured, multicurrency revolving facility. On July 9, 2015, Walgreens Boots Alliance amended the 364-Day Credit Agreement to remove Walgreens as a borrower thereunder, eliminate Walgreens’ guarantee of all obligations of Walgreens Boots Alliance thereunder and make certain conforming changes to effectuate those modifications, including modifications and deletions of certain definitions and cross-references. On December 17, 2015, the Company terminated the 364-Day Credit Agreement.  The 364-Day Credit Agreement remained undrawn as of the date of termination and would have matured on December 30, 2015.
 
The Term Loan Agreement, Revolving Credit Agreement and the 364-Day Revolving Credit Agreement each contain or contained a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants.

2015 Bridge Credit Agreement and Term Loan Credit Agreement

On October 27, 2015, the Company entered into an Agreement and Plan of Merger with Rite Aid Corporation (“Rite Aid”) and Victoria Merger Sub, Inc., a wholly-owned subsidiary of the Company (the “Merger Agreement”). In connection with the Merger Agreement, the Company entered into a bridge facility commitment letter (as amended and restated as of November 19, 2015, the “Commitment Letter”), with UBS Securities LLC and UBS AG, Stamford Branch for a $12.8 billion senior unsecured bridge facility.
 
On December 18, 2015, Walgreens Boots Alliance entered into a Bridge Term Loan Credit Agreement with the lenders party thereto and UBS AG, Stamford Branch, as administrative agent (as amended on January 20, 2016, the “Bridge Credit Agreement”) and a Term Loan Credit Agreement with the lenders party thereto and Bank of America, N.A., as administrative agent (as amended on January 20, 2016, the “Term Loan Credit Agreement” and together with the Bridge Credit Agreement, the “2015 Credit Agreements”). The Commitment Letter and the commitments contemplated thereby terminated upon Walgreens Boots Alliance entering into the 2015 Credit Agreements.
 
The Bridge Credit Agreement is a 364-day unsecured bridge term loan facility. The aggregate commitments of all lenders under the Bridge Credit Agreement are equal to $7.8 billion, provided that Walgreens Boots Alliance may increase the commitments under the Bridge Credit Agreement at any time prior to the funding of the loans thereunder by up to $2.0 billion, subject to obtaining commitments from existing lenders and/or new lenders selected by Walgreens Boots Alliance and reasonably acceptable to the administrative agent. Walgreens Boots Alliance can extend up to $3.0 billion of the loans under the Bridge Credit Agreement for an additional 90-day period if desired. As of February 29, 2016, there were no borrowings under the Bridge Credit Agreement.
 
The Term Loan Credit Agreement is a two-tranche unsecured term loan facility, with the first tranche maturing three years after the earlier of the funding date and October 27, 2016, and the second tranche maturing five years after the earlier of the funding date and October 27, 2016. The aggregate commitments of all lenders under the Term Loan Credit Agreement are equal to $5.0 billion. As of February 29, 2016, there were no borrowings under the Term Loan Credit Agreement.
 
Walgreens Boots Alliance will be the borrower under each of the 2015 Credit Agreements. The ability of Walgreens Boots Alliance to request the making of loans under each of the 2015 Credit Agreements is subject to the satisfaction (or waiver) of certain conditions set forth therein and will terminate upon the occurrence of certain events set forth therein. Borrowings under each of the 2015 Credit Agreements will bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance’s option, the alternate base rate or the reserve adjusted Eurocurrency rate, in each case, plus an applicable margin calculated based on Walgreens Boots Alliance’s credit ratings. Upfront fees paid to date in connection with the 2015 Credit Agreements totaled $30 million. A maximum of a further $5 million in upfront fees is payable prior to, or at funding, subject to certain conditions. In addition, Walgreens Boots Alliance will also pay to the lenders under each of the 2015 Credit Agreements certain customary fees, including a ticking fee based on the aggregate outstanding commitments of the lenders under the applicable 2015 Credit Agreement starting at 90 days after signing. Each of the 2015 Credit Agreements contains a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants, which restrictive covenants shall not be in effect until the funding of the loans under the applicable 2015 Credit Agreement.

Note 10. Financial Instruments
The Company uses derivative instruments to manage its exposure to interest rate and foreign currency exchange risks.

The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of February 29, 2016, excluding warrants which are presented separately in this footnote, were as follows (in millions):

   
Notional(1)
   
Fair Value
 
Location in Consolidated
Condensed Balance Sheets
Derivatives designated as fair value hedges:
               
Interest rate swaps
 
$
250
   
$
5
 
Other non-current assets
Derivatives not designated as hedges:
                   
Foreign currency forwards
   
465
     
1
 
Other current assets
Foreign currency forwards
   
768
     
16
 
Other current liabilities
Basis swap
   
2
     
1
 
Other current liabilities

(1) Amounts are presented in U.S. dollar equivalents.
 
The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2015, excluding warrants which are presented separately in this footnote, are as follows (in millions):

   
Notional(1)
   
Fair Value
 
Location in Consolidated
Condensed Balance Sheets
Derivatives designated as fair value hedges:
               
Interest rate swaps
 
$
250
   
$
2
 
Other non-current assets
Derivatives not designated as hedges:
                   
Foreign currency forwards
   
1,205
     
34
 
Other current assets
Foreign currency forwards
   
495
     
9
 
Other current liabilities
Basis swap
   
1
     
-
 
Other current assets

(1) Amounts are presented in U.S. dollar equivalents.

The Company uses interest rate swaps to manage the interest rate exposure associated with some of its fixed-rate borrowings and designates them as fair value hedges. The Company uses forward starting interest rate swaps to hedge its interest rate exposure of some of its anticipated debt issuances and designates them as cash flow hedges.

The Company utilizes foreign currency forward contracts and other foreign currency derivatives to hedge significant committed and highly probable future transactions and cash flows denominated in currencies other than the functional currency of the Company or its subsidiaries. The Company has significant non-US dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk.

Fair Value Hedges
The Company entered into a series of interest rate swaps, converting $750 million of its 5.250% fixed rate notes to a floating interest rate based on the six month LIBOR in arrears plus a constant spread and an interest rate swap converting $250 million of its 5.250% fixed rate notes to a floating interest rate based on the one-month LIBOR in arrears plus a constant spread. All swap termination dates coincide with the notes maturity date, January 15, 2019. These swaps were designated as fair value hedges. On August 10, 2015, the Company terminated $500 million of the six month LIBOR in arrears swaps and all of the one-month LIBOR in arrears swaps in connection with the repayment of the associated debt as described in Note 9, Short-Term Borrowings and Long-Term Debt.

The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk were recognized as follows (in millions):

 
Location in Consolidated
 
Three Months Ended
   
Six Months Ended
 
 
Condensed Statements of
Earnings
 
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Interest rate swaps
Interest expense, net
 
$
(2
)
 
$
4
   
$
(3
)
 
$
(6
)
Notes
Interest expense, net
   
2
     
(4
)
   
3
     
6
 

The changes in fair value of the Company’s debt that was swapped from fixed to variable rate and designated as fair value hedges are included in short-term and long-term debt on the Consolidated Condensed Balance Sheets (see Note 9, Short-Term Borrowings and Long-Term Debt). At February 29, 2016 and August 31, 2015, the cumulative fair value adjustments resulted in an increase in long-term debt of $4 million and $1 million, respectively. No material gains or losses were recorded from ineffectiveness during the three and six months ended February 29, 2016 and February 28, 2015.
 
Derivatives not Designated as Hedges
The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of interest rate and foreign currency risks. The gains and losses due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):

  Location in Consolidated  
Three Months Ended
   
Six Months Ended
 
Condensed Statements of
Earnings
 
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Interest rate swaps
Interest expense, net
 
$
-
   
$
(1
)
 
$
-
   
$
(1
)
Foreign currency forwards
Selling, general and administrative expenses
   
(23
)
   
(28
)
   
(25
)
   
(28
)
Second Step Transaction foreign currency forwards
Other income (expense)
   
-
     
(70
)
   
-
     
(166
)
Foreign currency forwards
Other income (expense)
   
33
     
-
     
33
     
-
 

Warrants
As of February 29, 2016, the Company held (a) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share, exercisable during a six month period beginning in March 2016, (“Warrant 1”), and (b) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $52.50 per share, exercisable during a six month period beginning in March 2017 (“Warrant 2” and together with Warrant 1, the “Warrants”). Warrant 1 was exercised in full on March 18, 2016. See Note 20, Subsequent Event for further information.

The Company reports the Warrants at fair value. The fair value and balance sheet presentation of the Warrants was as follows (in millions):

Location in Consolidated
Condensed Balance Sheets 
 
February 29,
2016
   
August 31,
2015
 
Asset derivatives not designated as hedges:
             
Warrants
Other non-current assets
 
$
1,546
   
$
2,140
 

The gains and losses due to changes in fair value of the Warrants recognized in earnings were as follows (in millions):

      
Three Months Ended
   
Six Months Ended
 
 
Location in Consolidated
Condensed Statements of Earnings
 
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Warrants
Other income (expense)
 
$
(532
)
 
$
559
   
$
(594
)
 
$
849
 

Derivatives Credit Risk
Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty.

Derivatives Offsetting
The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.

Note 11. Fair Value Measurements
The Company measures certain assets and liabilities in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels:

Level 1 - Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2 - Observable inputs other than quoted prices in active markets.
Level 3 - Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
 
Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):

   
February 29, 2016
   
Level 1
   
Level 2
   
Level 3
 
Assets:
                       
Restricted cash (1)
 
$
175
   
$
175
   
$
-
   
$
-
 
Money market funds (2)
   
2,659
     
2,659
     
-
     
-
 
Available-for-sale investments (3)
   
1,027
     
1,027
     
-
     
-
 
Interest rate swaps (4)
   
5
     
-
     
5
     
-
 
Foreign currency forwards (5)
   
1
     
-
     
1
     
-
 
Warrants (6)
   
1,546
     
-
     
1,546
     
-
 
Liabilities:
                               
Basis swaps (5)
   
1
     
-
     
1
     
-
 
Foreign currency forwards (5)
   
16
     
-
     
16
     
-
 

   
August 31, 2015
   
Level 1
   
Level 2
   
Level 3
 
Assets:
                       
Restricted cash (1)
 
$
184
   
$
184
   
$
-
   
$
-
 
Money market funds (2)
   
2,043
     
2,043
     
-
     
-
 
Available-for-sale investments (3)
   
1,183
     
1,183
     
-
     
-
 
Interest rate swaps (4)
   
2
     
-
     
2
     
-
 
Foreign currency forwards (5)
   
34
     
-
     
34
     
-
 
Warrants (6)
   
2,140
     
-
     
2,140
     
-
 
Liabilities:
                               
Foreign currency forwards (5)
   
9
     
-
     
9
     
-
 

(1) Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.
(2) Money market funds are valued at the closing price reported by the fund sponsor.
(3) Fair values of quoted investments are based on current bid prices as of the balance sheet dates.  See Note 6, Available-for-Sale Investments for additional information.
(4) The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information.
(5) The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
(6) Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen’s common stock; AmerisourceBergen’s common stock price at the valuation date; AmerisourceBergen’s equity volatility; the number of shares of AmerisourceBergen’s common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the Warrants.

There were no transfers between levels for the three and six month periods ended February 29, 2016 and February 28, 2015, respectively.

The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company’s debt in the footnotes to the consolidated financial statements. Unless otherwise noted, the fair value for all notes was determined based upon quoted market prices and therefore categorized as Level 1. See Note 9, Short-Term Borrowings and Long-Term Debt for further information. The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.

Note 12. Commitments and Contingencies
The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries and similar actions by governmental authorities, arising in the normal course of the Company’s business, including the matters described below. Legal proceedings, in general, and securities and class action litigation, in particular, can be expensive and disruptive. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit, and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s consolidated financial position. However, substantial unanticipated verdicts, fines and rulings do sometimes occur. As a result, the Company could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.
 
On a quarterly basis, the Company assesses its liabilities and contingencies for outstanding legal proceedings and reserves are established on a case-by-case basis for those legal claims for which management concludes that it is probable that a loss will be incurred and that the amount of such loss can be reasonably estimated. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. With respect to litigation and other legal proceedings where the Company has determined that a loss is reasonably possible, the Company is unable to estimate the amount or range of reasonably possible loss in excess of amounts reserved due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Company’s assessments are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause the Company to change those estimates and assumptions. Therefore, it is possible that an unfavorable resolution of one or more pending litigation or other contingencies could have a material adverse effect on the Company’s consolidated financial statements in a future fiscal period. Management’s assessment of current litigation and other legal proceedings, including the corresponding accruals, could change because of the discovery of facts with respect to legal actions or other proceedings pending against the Company which are not presently known. Adverse rulings or determinations by judges, juries, governmental authorities or other parties could also result in changes to management’s assessment of current liabilities and contingencies. Accordingly, the ultimate costs of resolving these claims may be substantially higher or lower than the amounts reserved.
 
On December 5 and 12, 2014, putative shareholders filed class actions in federal court in the Northern District of Illinois against the Walgreens Board of Directors, Walgreen Co., and Walgreens Boots Alliance, Inc. arising out of the Company’s definitive proxy statement/prospectus filed with the SEC in connection with the special meeting of Walgreens shareholders on December 29, 2014. The actions asserted claims that the definitive proxy statement/prospectus was false or misleading in various respects. On December 23, 2014, solely to avoid the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, Walgreens entered into a memorandum of understanding with the plaintiffs in both actions, pursuant to which Walgreens made certain supplemental disclosures. The proposed settlement was subject to, among other things, court approval. On July 8, 2015, the Court preliminarily approved the settlement, and on November 20, 2015, the Court entered an order of final approval of the settlement. On December 17, 2015, a purported class member who had objected to the settlement appealed the Court’s order. The appeal was docketed with the United States Court of Appeals for the Seventh Circuit, and is in an early stage.
 
On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co., and Walgreen Co. as a nominal defendant, arising out of certain public statements the Company made regarding its former fiscal 2016 goals. The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. On April 10, 2015, the defendants filed a motion to dismiss. On May 18, 2015, the case was stayed in light of the securities class action that was filed on April 10, 2015, which is described below.
 
On April 10, 2015, a putative shareholder filed a securities class action in federal court in the Northern District of Illinois against Walgreen Co. and certain former officers of Walgreen Co. The action asserts claims for violation of the federal securities laws arising out of certain public statements the Company made regarding its former fiscal 2016 goals. On June 16, 2015, the Court entered an order appointing a lead plaintiff. Pursuant to the Court’s order, lead plaintiff filed an amended complaint on August 17, 2015, and defendants moved to dismiss the amended complaint on October 16, 2015. Lead plaintiff filed a response to the motion to dismiss on December 22, 2015, and defendants filed a reply in support of the motion on February 5, 2016.
 
As of February 29, 2016, the Company was aware of ten putative class action lawsuits (the “Rite Aid actions”) filed by purported Rite Aid stockholders against Rite Aid and its board of directors, Walgreens Boots Alliance and Victoria Merger Sub, Inc. for claims arising out of the transactions contemplated by the Merger Agreement (the “Rite Aid Transactions”). Eight of the Rite Aid actions were filed in the Court of Chancery of the State of Delaware (the “Delaware actions”), one Rite Aid action was filed in the State of Pennsylvania in the Court of Common Pleas of Cumberland County (the “Pennsylvania action”), and one Rite Aid action was filed in the United States District Court for the Middle District of Pennsylvania (the “federal action”). The Delaware actions and the Pennsylvania action primarily allege that the Rite Aid board of directors breached its fiduciary duties in connection with the Rite Aid Transactions by, among other things, agreeing to an unfair and inadequate price, agreeing to deal protection devices that preclude other bidders from making successful competing offers for Rite Aid, and failing to disclose all allegedly material information concerning the proposed merger; and also allege that Walgreens Boots Alliance and Victoria Merger Sub, Inc. aided and abetted these alleged breaches of fiduciary duty. The federal action alleges, among other things, that Rite Aid and its board of directors disseminated an allegedly false and misleading proxy statement in connection with the Rite Aid Transactions. The Delaware actions were consolidated, and plaintiffs filed a motion for expedited proceedings and a motion for preliminary injunction seeking to enjoin the Rite Aid shareholder vote on the Rite Aid Transactions. The plaintiffs in the federal action also filed a motion for preliminary injunction seeking to enjoin the same Rite Aid shareholder vote. All such motions were denied, and the Rite Aid shareholders approved the Rite Aid Transactions at a special meeting on February 4, 2016. Each of the Rite Aid actions is still pending.
 
Note 13. Retirement Benefits
The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan. The Company uses an August 31 annual measurement date for its pension plans.

Defined Benefit Pension Plans (non-US plans)
The principal defined benefit pension plan is the Boots Pension Plan, which covers certain employees in the United Kingdom (the “Boots Plan”). The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010, with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis. The Company also has two smaller defined benefit pension plans in the United Kingdom, both of which were closed to future accruals effective July 1, 2010. Other defined benefit pension plans include smaller plans in Germany and France.

The obligation related to the Company’s pension plans was acquired as a result of the Second Step Transaction. The pension costs presented for 2015 represent the costs for the period from December 31, 2014 through February 28, 2015. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, pension costs for fiscal 2015 prior to the date of the Second Step Transaction were reflected within Equity earnings in Alliance Boots on the Consolidated Condensed Statement of Earnings.

Components of net periodic pension costs for the defined benefit pension plans (in millions):

   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Service costs
 
$
-
   
$
1
   
$
2
   
$
1
 
Interest costs
   
77
     
53
     
159
     
53
 
Expected returns on plan assets
   
(62
)
   
(43
)
   
(127
)
   
(43
)
Settlements
   
-
     
1
     
-
     
1
 
Total net periodic pension costs
 
$
15
   
$
12
   
$
34
   
$
12
 

The Company made cash contributions to its defined benefit pension plans of $9 million for the period ended February 29, 2016, which primarily related to committed funded payments. The Company plans to contribute an additional $66 million to its defined benefit pension plans in fiscal 2016.

Defined Contribution Plans
The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company’s contribution, which has historically related to adjusted FIFO earnings before interest and taxes and a portion of which is in the form of a guaranteed match, is determined annually at the discretion of the Walgreens Boots Alliance Board of Directors (or Compensation Committee thereof). The profit-sharing provision was an expense of $53 million and $111 million for the three and six months ended February 29, 2016, respectively, compared to a benefit of $21 million for the three months and expense of $54 million for the six months ended February 28, 2015, respectively.

The Company also has a contract based defined contribution arrangement, the Alliance Boots Retirement Savings Plan, to which both the Company and participating employees contribute. The obligation related to the Alliance Boots Retirement Savings Plan was acquired as a result of the Second Step Transaction. The cost recognized in the Consolidated Condensed Statements of Earnings for the three and six month periods ended February 29, 2016 was $34 million and $69 million, respectively compared to $22 million in the prior year three and six month periods. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, such costs for fiscal 2015 prior to the date of the Second Step Transaction were reflected within Equity earnings in Alliance Boots on the Consolidated Condensed Statement of Earnings.
 
Postretirement Healthcare Plan
The Company provides certain health insurance benefits to retired U.S. employees who meet eligibility requirements, including age, years of service and date of hire. The costs of these benefits are accrued over the service life of the employee. The Company’s postretirement health benefit plan is not funded.

Components of net periodic benefit cost for the postretirement health benefit plan (in millions):

   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Service cost
 
$
2
   
$
2
   
$
5
   
$
5
 
Interest cost
   
5
     
4
     
10
     
8
 
Amortization of actuarial loss
   
5
     
5
     
9
     
10
 
Amortization of prior service cost
   
(7
)
   
(6
)
   
(14
)
   
(12
)
Total postretirement benefit cost
 
$
5
   
$
5
   
$
10
   
$
11
 

Note 14. Earnings Per Share
The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. There were 3.2 million outstanding options to purchase common shares that were anti-dilutive and excluded from the second quarter earnings per share calculation as of February 29, 2016 compared to 3.4 million as of February 28, 2015. Anti-dilutive shares excluded from the year to date earnings per share calculation were 2.2 million compared to 5.0 million for the periods ending February 29, 2016 and February 28, 2015, respectively.

Note 15. Depreciation and Amortization
The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):

   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Depreciation expense
 
$
346
   
$
311
   
$
644
   
$
567
 
Intangible asset and other amortization
   
96
     
196
     
180
     
259
 
Total depreciation and amortization expense
 
$
442
   
$
507
   
$
824
   
$
826
 

The depreciation and amortization expense presented for 2015 include Alliance Boots costs for the period from December 31, 2014 through February 28, 2015. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, depreciation and amortization expense were included for fiscal 2015 prior to the date of the Second Step Transaction within Equity earnings in Alliance Boots.

Note 16. Supplemental Cash Flow Disclosures
Cash interest paid was $302 million and $90 million in the six months ended February 29, 2016 and February 28, 2015, respectively. Cash paid for income taxes was $481 million and $553 million in the six months ended February 29, 2016 and February 28, 2015, respectively.
 
Note 17. Accumulated Other Comprehensive Income (Loss)
The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for the three and six months ended February 29, 2016 and February 28, 2015 (in millions):
 
   
Pension/Post-
retirement
Obligations
   
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
   
Unrealized
Gain (Loss) on
Cash Flow
Hedges
   
Currency
Translation
Adjustments
   
Total
 
Balance at November 30, 2015
 
$
32
   
$
260
   
$
(39
)
 
$
(911
)
 
$
(658
)
Other comprehensive income (loss) before reclassification adjustments
   
(4
)
   
(139
)
   
-
     
(1,121
)
   
(1,264
)
Amounts reclassified from accumulated OCI
   
-
     
-
     
2
     
-
     
2
 
Tax benefit (provision)
   
2
     
51
     
(1
)
   
-
     
52
 
Net other comprehensive income (loss)
   
(2
)
   
(88
)
   
1
     
(1,121
)
   
(1,210
)
Balance at February 29, 2016
 
$
30
   
$
172
   
$
(38
)
 
$
(2,032
)
 
$
(1,868
)
 
   
Pension/Post-
retirement
Obligations
   
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
   
Unrealized
Gain (Loss) on
Cash Flow
Hedges
   
Currency
Translation
Adjustments
   
Total
 
Balance at August 31, 2015
 
$
29
   
$
259
   
$
(40
)
 
$
(462
)
 
$
(214
)
Other comprehensive income (loss) before reclassification adjustments
   
(1
)
   
(144
)
   
-
     
(1,570
)
   
(1,715
)
Amounts reclassified from accumulated OCI
   
-
     
-
     
3
     
-
     
3
 
Tax benefit (provision)
   
2
     
57
     
(1
)
   
-
     
58
 
Net other comprehensive income (loss)
   
1
     
(87
)
   
2
     
(1,570
)
   
(1,654
)
Balance at February 29, 2016
 
$
30
   
$
172
   
$
(38
)
 
$
(2,032
)
 
$
(1,868
)
 
   
Pension/Post-
retirement
Obligations
   
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
   
Unrealized
Gain (Loss) on
Cash Flow
Hedges
   
Share of
Alliance
Boots
OCI
   
Cumulative
Translation
Adjustments
   
Total
 
Balance at November 30, 2014
 
$
14
   
$
206
   
$
(39
)
 
$
(92
)
 
$
(35
)
 
$
54
 
Other comprehensive income (loss) before reclassification adjustments
   
(8
)
   
140
     
2
     
(89
)
   
(358
)
   
(313
)
Amounts reclassified from accumulated OCI
   
-
     
-
     
(1
)
   
230
     
80
     
309
 
Tax benefit (provision)
   
-
     
(50
)
   
(1
)
   
(49
)
   
(18
)
   
(118
)
Net other comprehensive income (loss)
 
$
(8
)
 
$
90
   
$
-
   
$
92
   
$
(296
)
 
$
(122
)
Balance at February 28, 2015
 
$
6
   
$
296
   
$
(39
)
 
$
-
   
$
(331
)
 
$
(68
)
 
   
Pension/Post-
retirement
Obligations
   
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
   
Unrealized
Gain (Loss) on
Cash Flow
Hedges
   
Share of
Alliance
Boots
OCI
   
Cumulative
Translation
Adjustments
   
Total
 
Balance at August 31, 2014
 
$
15
   
$
107
   
$
(27
)
 
$
(113
)
 
$
154
   
$
136
 
Other comprehensive income (loss) before reclassification adjustments
   
(10
)
   
297
     
(18
)
   
(57
)
   
(648
)
   
(436
)
Amounts reclassified from accumulated OCI
   
-
     
-
     
(1
)
   
230
     
80
     
309
 
Tax benefit (provision)
   
1
     
(108
)
   
7
     
(60
)
   
83
     
(77
)
Net other comprehensive income (loss)
 
$
(9
)
 
$
189
   
$
(12
)
 
$
113
   
$
(485
)
 
$
(204
)
Balance at February 28, 2015
 
$
6
   
$
296
   
$
(39
)
 
$
-
   
$
(331
)
 
$
(68
)
 
Note 18. Segment Reporting
The Company has three reportable segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments, which have been aggregated as described below. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.

· The Retail Pharmacy USA segment consists of the legacy Walgreens business, which includes the operation of retail drugstores and convenient care clinics and the provision of specialty pharmacy services. Revenues for the segment are principally derived from the sale of prescription drugs and a wide assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards and convenience foods.

· The Retail Pharmacy International segment consists primarily of the legacy Alliance Boots pharmacy-led health and beauty stores, optical practices, and related contract manufacturing operations. Stores are located in the United Kingdom, Mexico, Chile, Thailand, Norway, the Republic of Ireland, The Netherlands and Lithuania. Revenues for the segment are principally derived from the sale of prescription drugs and retail health, beauty, toiletries and other consumer products.

· The Pharmaceutical Wholesale segment consists of the legacy Alliance Boots pharmaceutical wholesaling and distribution businesses. Wholesale operations are located in France, the United Kingdom, Germany, Turkey, Spain, Russia, The Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Revenues for the segment are principally derived from wholesaling and distribution of a comprehensive offering of brand-name pharmaceuticals (including specialty pharmaceutical products) and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment, and related services to pharmacies and other healthcare providers.

The results of operations for each reportable segment include synergy benefits, including WBAD operations and an allocation of corporate-related overhead costs. The “Eliminations and Unallocated Items” column contains items not allocable to the reportable segments, as the information is not utilized by the chief operating decision maker to assess segment performance and allocate resources.

The segment information reflects the operating results of the Company’s business segments. The Company began recording revenue and expense transactions using the new segments effective January 1, 2015. Beginning January 1, 2015, synergy benefits including WBAD operations have been allocated to the Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale segments on a source of procurement benefit basis. Under this method, the synergy benefits are allocated to the segment whose purchase gave rise to the benefit. A synergy arising on the purchase of an item for use in an entity in the Retail Pharmacy USA segment is recognized in the Retail Pharmacy USA segment and similarly for the Retail Pharmacy International and Pharmaceutical Wholesale segments. Procurement service income related to third parties is recognized in the Pharmaceutical Wholesale segment. Corporate costs have been allocated to segments based on their respective gross profit.

Our Retail Pharmacy International and Pharmaceutical Wholesale segments were acquired as part of the Second Step Transaction in which we acquired the 55% of Alliance Boots that we did not already own on December 31, 2014. The Company has determined that it is impracticable to restate segment information for periods prior the completion of the Second Step Transaction, as well as to provide disclosures for such periods under both the old basis and new basis of reporting for certain items. Specifically, WBAD operations prior to December 31, 2014 were recorded in the Retail Pharmacy USA segment and have not been restated, as the Company believes it is impracticable to separate the information to the individual reportable segments. Equity earnings from Alliance Boots prior to the completion of the Second Step Transaction has been recorded within the Retail Pharmacy USA segment. The equity earnings of the 45% interest in Alliance Boots have not been separated into the Retail Pharmacy International and Pharmaceutical Wholesale segments for the prior period, as the Company believes it is impracticable. Accordingly, only two months of results (January and February 2015) have been reported for these segments for the three and six months ended February 28, 2015.
 
The following table reflects results of operations of the Company’s reportable segments (in millions):

   
Retail Pharmacy
                   
   
USA
   
International
   
Pharmaceutical
Wholesale
   
Eliminations
and
Unallocated
 Items
   
Consolidated
 
Three Months Ended February 29, 2016
                             
Sales to external customers
 
$
21,500
   
$
3,627
   
$
5,057
   
$
-
   
$
30,184
 
Intersegment sales
   
-
     
62
     
570
     
(632
)
   
-
 
Total Sales
 
$
21,500
   
$
3,689
   
$
5,627
   
$
(632
)
 
$
30,184
 
                                         
Adjusted Operating Income
 
$
1,632
   
$
335
   
$
155
   
$
(2
)
 
$
2,120
 
                                         
Three Months Ended February 28, 2015
                                       
Sales to external customers
 
$
21,048
   
$
2,017
   
$
3,508
   
$
-
   
$
26,573
 
Intersegment sales
   
-
     
30
     
357
     
(387
)
   
-
 
Total Sales
 
$
21,048
   
$
2,047
   
$
3,865
   
$
(387
)
 
$
26,573
 
                                         
Adjusted Operating Income
 
$
1,598
   
$
125
   
$
121
   
$
(4
)
 
$
1,840
 

   
Retail Pharmacy
                   
   
USA
   
International
   
Pharmaceutical
Wholesale
   
Eliminations
and
Unallocated
 Items
   
Consolidated
 
Six Months Ended February 29, 2016
                             
Sales to external customers
 
$
41,870
   
$
7,086
   
$
10,261
   
$
-
   
$
59,217
 
Intersegment sales
   
-
     
134
     
1,162
     
(1,296
)
   
-
 
Total Sales
 
$
41,870
   
$
7,220
   
$
11,423
   
$
(1,296
)
 
$
59,217
 
                                         
Adjusted Operating Income
 
$
2,875
   
$
650
   
$
321
   
$
(7
)
 
$
3,839
 
                                         
Six Months Ended February 28, 2015
                                       
Sales to external customers
 
$
40,602
   
$
2,017
   
$
3,508
   
$
-
   
$
46,127
 
Intersegment sales
   
-
     
30
     
357
     
(387
)
   
-
 
Total Sales
 
$
40,602
   
$
2,047
   
$
3,865
   
$
(387
)
 
$
46,127
 
                                         
Adjusted Operating Income
 
$
2,716
   
$
125
   
$
121
   
$
(4
)
 
$
2,958
 
 
The following table reconciles adjusted operating income to operating income (in millions):

   
Retail Pharmacy
                   
   
USA
   
International
   
Pharmaceutical
Wholesale
   
Eliminations
and
Unallocated
Items
   
Consolidated
 
Three Months Ended February 29, 2016
                             
Adjusted Operating Income
 
$
1, 632
   
$
335
   
$
155
   
$
(2
)
 
$
2,120
 
Acquisition-related amortization
                                   
(101
)
Cost transformation
                                   
(28
)
LIFO provision
                                   
(68
)
Acquisition-related costs
                                   
(33
)
Asset impairment
                                   
(30
)
Operating Income
                                 
$
1,860
 
                                         
Three Months Ended February  28, 2015
                                       
Adjusted Operating Income
 
$
1,598
   
$
125
   
$
121
   
$
(4
)
 
$
1,840
 
(Decrease) increase in fair market value of warrants
                                   
(6
)
Acquisition-related amortization
                                   
(217
)
LIFO provision
                                   
(55
)
Acquisition-related costs
                                   
(59
)
Asset impairment
                                   
(110
)
Store closures and other optimization costs
                                   
(16
)
Operating Income
                                 
$
1,377
 

   
Retail Pharmacy
                   
   
USA
   
International
   
Pharmaceutical
Wholesale
   
Eliminations
and
Unallocated
Items
   
Consolidated
 
Six Months Ended February 29, 2016
                             
Adjusted Operating Income
 
$
2,875
   
$
650
   
$
321
   
$
(7
)
 
$
3,839
 
Acquisition-related amortization
                                   
(182
)
Cost transformation
                                   
(118
)
LIFO provision
                                   
(114
)
Acquisition-related costs
                                   
(67
)
Asset impairment
                                   
(30
)
Operating Income
                                 
$
3,328
 
                                         
Six Months Ended February 28, 2015
                                       
Adjusted Operating Income
 
$
2,716
   
$
125
   
$
121
   
$
(4
)
 
$
2,958
 
(Decrease) increase in fair market value of warrants
                                   
123
 
Acquisition-related amortization
                                   
(306
)
LIFO provision
                                   
(107
)
Acquisition-related costs
                                   
(83
)
Asset impairment
                                   
(110
)
Store closures and other optimization costs
                                   
(44
)
Operating Income
                                 
$
2,431
 
 
Note 19. Recent Accounting Pronouncements
In February 2016, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which supersedes Topic 840, Leases. This ASU increases the transparency and comparability of organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed. At the lease commencement date, lessee recognizes a lease liability and right-of-use asset, which is initially measured at the present value of future lease payments. There are two approaches for amortizing the right-of use asset. Under the finance lease approach, interest on the lease liability is recognized separately from amortization of the right-of-use asset. Repayments of the principal portion of the lease liability will be classified as financing activities and payments of interest on the lease liability and variable lease payments will be classified as operating activities in the statement of cash flows. Under the operating lease approach, the cost of the lease is calculated on a straight-line basis over the life of the lease term. All cash payments are classified as operating activities in the statement of cash flows. For sale and leaseback transactions, in order for a sale to occur, the transfer of the asset must meet all criteria in Topic 606. If there is no sale for the seller-lessee, the buyer-lessor does not account for a purchase. Any consideration paid for the asset is accounted for as a financing transaction. For transactions previously accounted for as a sale and leaseback, the transition guidance in Topic 842 does not require an entity to assess whether the transaction would have qualified as a sale and a leaseback in accordance with Topic 842. Additionally, gains recorded under sale and leaseback transactions are recognized at the transaction date and no longer deferred over the lease term. This ASU is effective for annual periods beginning after December 15, 2018 (fiscal 2020). In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach which includes a number of optional practical expedients that entities may elect to apply. For a description of the Company’s lease obligations, please refer to the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2015. The Company has begun evaluating and planning for the adoption and implementation of this ASU, including assessing the overall impact. This ASU will have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is being evaluated. The impact of this ASU is non-cash in nature and will not affect the Company’s cash position.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10). This ASU requires equity investments (except those under the equity method of accounting or those that result in the consolidation of an investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. This simplifies the impairment assessment of equity investments previous held at cost. Separate presentation of financial assets and liabilities by measurement category is required. This ASU is effective prospectively for annual periods beginning after December 15, 2017 (fiscal 2019). Early application is not permitted. The Company is evaluating the effect of adopting this new accounting guidance.

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). This ASU simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as non-current in a classified statement of financial position. This ASU may be applied either prospectively to all deferred tax assets and liabilities, or retrospectively to all periods presented for annual periods beginning after December 16, 2016 and interim periods thereafter (fiscal 2018), with early adoption permitted, and may require additional disclosure based on the application method selected. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company’s financial position.

In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805). This ASU simplifies the accounting for adjustments made to provisional amounts recognized in a business combination by eliminating the requirements to retrospectively account for those adjustments. This guidance applies to all entities that have reported provisional amounts for items in a business combination for which the accounting is incomplete by the end of the reporting period in which the combination occurs and during the measurement period having an adjustment to provisional amounts recognized. This ASU is effective prospectively for annual periods beginning after December 31, 2016 and interim periods thereafter (fiscal 2018) with early adoption permitted. The Company adopted this ASU on March 1, 2016. The adoption of this ASU did not have a material impact on the Company’s results of operations, cash flows or financial position.

In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), an update to ASU 2014-09. This ASU amends ASU 2014-09 to defer the effective date by one year for annual reporting periods beginning after December 15, 2017 (fiscal 2019). This ASU removes inconsistencies, complexities and allows transparency and comparability of revenue transactions across entities, industries, jurisdictions and capital markets by providing a single comprehensive principles-based model with additional disclosures regarding uncertainties. The principles-based revenue recognition model has a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Early adoption is permitted for annual reporting periods beginning after December 15, 2016 (fiscal 2018). In transition, the ASU may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is evaluating the effect of adopting this new accounting guidance including the transition method.

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330). This ASU simplifies current accounting treatments by requiring entities to measure most inventories at “the lower of cost and net realizable value” rather than using lower of cost or market. This guidance does not apply to inventories measured using last-in, first-out method or the retail inventory method. This ASU is effective prospectively for annual periods beginning after December 15, 2016 and interim periods thereafter (fiscal 2018) with early adoption permitted. Upon transition, entities must disclose the accounting change. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company’s results of operations, cash flows or financial position.
 
Note 20. Subsequent Event
On March 18, 2016, the Company exercised Warrant 1 (described in Note 10, Financial Instruments) in full, resulting in the acquisition from AmerisourceBergen of 22,696,912 shares of AmerisourceBergen common stock for an aggregate exercise price payment of $1.17 billion. The transaction was funded using existing cash on hand. Following the exercise of Warrant 1, the Company owned 34,157,955 outstanding AmerisourceBergen common shares representing approximately 15.2% of the outstanding AmerisourceBergen common stock (based on shares outstanding as of March 16, 2016 adjusted to give effect to the exercise of Warrant 1, as reported by AmerisourceBergen in its Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2016). The Company continues to hold Warrant 2, which the Company has the right to exercise beginning in March 2017.

Effective March 18, 2016, the Company accounts for its investment in AmerisourceBergen using the equity method of accounting, subject to a two-month reporting lag, with the net earnings attributable to its investment being classified within the operating income of the Company’s Pharmaceutical Wholesale segment.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read together with the financial statements and the related notes included elsewhere herein and the consolidated financial statements, accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations and other disclosures contained in the Walgreens Boots Alliance, Inc. Annual Report on Form 10-K for the fiscal year ended August 31, 2015. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed in forward-looking statements. Factors that might cause a difference include, but are not limited to, those discussed under “Cautionary Note Regarding Forward-Looking Statements” and in Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended August 31, 2015. References herein to the “Company”, “we”, “us”, or “our” refer to Walgreens Boots Alliance, Inc. and its subsidiaries from and after the effective time of the Reorganization (as defined below) on December 31, 2014 and, prior to that time, to its predecessor Walgreen Co. and its subsidiaries, except as otherwise indicated or the context otherwise requires.

INTRODUCTION
On December 31, 2014, Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance”) became the successor to Walgreen Co. (“Walgreens”) pursuant to a merger to effect a reorganization of Walgreen Co. into a holding company structure (the “Reorganization”), with Walgreens Boots Alliance becoming the parent holding company. Pursuant to the Reorganization, Walgreens became a wholly owned subsidiary of Walgreens Boots Alliance, a Delaware corporation formed for the purposes of Reorganization, and each issued and outstanding share of Walgreens common stock converted on a one-to-one basis into Walgreens Boots Alliance common stock. Also on December 31, 2014, following the completion of the Reorganization, Walgreens Boots Alliance completed the acquisition of the remaining 55% of Alliance Boots GmbH (“Alliance Boots”) that Walgreens did not previously own (the “Second Step Transaction”) in exchange for £3.133 billion in cash and 144.3 million shares of Walgreens Boots Alliance common stock. Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method immediately upon completion of the Second Step Transaction. For financial reporting and accounting purposes, Walgreens Boots Alliance was the acquirer of Alliance Boots. The consolidated financial statements (and other data, such as prescriptions filled) reflect the results of operations and financial position of Walgreens and its subsidiaries for periods prior to December 31, 2014 and of Walgreens Boots Alliance and its subsidiaries for periods from and after the effective time of the Reorganization on December 31, 2014.

On October 27, 2015, Walgreens Boots Alliance entered into an Agreement and Plan of Merger with Rite Aid Corporation (“Rite Aid”) and Victoria Merger Sub, Inc., a wholly-owned subsidiary of Walgreens Boots Alliance (the “Merger Agreement”), pursuant to which we agreed, subject to the terms and conditions thereof, to acquire Rite Aid, a drugstore chain in the United States with 4,560 stores in 31 states and the District of Columbia as of the date of the most recent Rite Aid Quarterly Report on Form 10-Q. The Merger Agreement was approved by Rite Aid stockholders in February 2016. The transaction is expected to close in the second half of calendar year 2016, subject to regulatory approvals and other customary closing conditions.

SEGMENTS
Prior to December 31, 2014, our operations were within one reportable segment. Following the completion of the Reorganization and the Second Step Transaction on December 31, 2014, we organized our operations to reflect our new structure. Our operations are organized into three divisions, which are also our reportable segments:

· Retail Pharmacy USA;
· Retail Pharmacy International; and
· Pharmaceutical Wholesale.
 
COMPARABILITY
As a result of the completion of the Second Step Transaction on December 31, 2014, there are a number of items that affect comparability of reported results. Prior to December 31, 2014, our operations were within one reportable segment that included the results of the Retail Pharmacy USA division and corporate costs, along with the full consolidated results of Walgreens Boots Alliance Development GmbH (“WBAD”), a global sourcing enterprise formed by Walgreens and Alliance Boots, and equity earnings from Alliance Boots (on a three month reporting lag). Upon completion of the Second Step Transaction, Alliance Boots became a consolidated subsidiary and we eliminated the three month reporting lag. Prior period results have been recast to reflect the elimination of the reporting lag. Additionally, following the completion of the Reorganization and the Second Step Transaction on December 31, 2014, we now report results in three segments. Segmental reporting includes the allocation of synergy benefits, including WBAD’s results, and the combined corporate costs for periods subsequent to December 31, 2014. We have determined that it is impracticable to allocate historical results to the current segmental presentation. Accordingly, our Retail Pharmacy USA segment results for periods prior to December 31, 2014 include all corporate costs of Walgreen Co., the full consolidated results of WBAD and equity income from Walgreen Co.'s pre-closing 45 percent interest in Alliance Boots. 
 
The completion of the Second Step Transaction on December 31, 2014 also means that results for the three and six month periods ended February 29, 2016 include the results of Alliance Boots on a fully consolidated basis, while the three and six month periods ended February 28, 2015 include the results of Alliance Boots for two months (January and February 2015) on a fully consolidated basis and as equity income from Walgreen Co.’s pre-merger 45 percent interest in Alliance Boots for one month (December 2014) and four months (September through December 2014), respectively.

Period-over-period comparisons of results require consideration of the foregoing factors and are not directly comparable.

In addition, our sales results are affected by a number of factors, including our sales performance during holiday periods and during the cough, cold and flu season; foreign currency fluctuations; significant weather conditions; timing of our own or competitor discount programs and pricing actions; levels of reimbursement from governmental agencies and other third party payers; and general economic conditions in the markets in which we operate.

AMERISOURCEBERGEN CORPORATION RELATIONSHIP
On March 19, 2013, Walgreens, Alliance Boots and AmerisourceBergen Corporation (“AmerisourceBergen”) announced various agreements and arrangements, including a ten-year pharmaceutical distribution agreement between Walgreens and AmerisourceBergen pursuant to which branded and generic pharmaceutical products will be sourced from AmerisourceBergen; an agreement which provides AmerisourceBergen the ability to access generics and related pharmaceutical products through WBAD, a global sourcing enterprise; and agreements and arrangements pursuant to which we have the right, but not the obligation, to purchase a minority equity position in AmerisourceBergen over time through open market purchases and pursuant to warrants to acquire AmerisourceBergen common stock and gain associated representation on AmerisourceBergen’s Board of Directors in certain circumstances. In addition to the information in this report, please refer to our Current Report on Form 8-K filed on March 20, 2013 for more detailed information regarding these agreements and arrangements.

As of February 29, 2016, we held (a) 11,461,043 outstanding shares of AmerisourceBergen common stock acquired in open market transactions; (b) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share exercisable during a six-month period beginning in March 2016 (“Warrant 1”); and (c) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $52.50 per share exercisable during a six-month period beginning in March 2017 (“Warrant 2” and together with Warrant 1, the “Warrants”). We can acquire up to a total of 19,859,795 AmerisourceBergen shares in the open market. The amount of permitted open market purchases is subject to increase in certain circumstances.

On March 18, 2016, we exercised Warrant 1 in full, resulting in the acquisition from AmerisourceBergen of 22,696,912 shares of AmerisourceBergen common stock for an aggregate exercise price payment of $1.17 billion. Following the exercise of Warrant 1, the Company owned 34,157,955 outstanding AmerisourceBergen common shares representing approximately 15.2% of the outstanding AmerisourceBergen common stock (based on shares outstanding as of March 16, 2016 adjusted to give effect to the exercise of Warrant 1, as reported by AmerisourceBergen in its Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2016).

Effective March 18, 2016, we account for our investment in AmerisourceBergen using the equity method of accounting, subject to a two-month reporting lag, with the net earnings attributable to our investment being classified within the operating income of our Pharmaceutical Wholesale segment. Due to the March 18, 2016 effective date and the two-month reporting lag, the results for our fiscal quarter ending May 31, 2016 will include approximately two weeks of equity method income relating to our investment in AmerisourceBergen.
 
RESTRUCTURING PROGRAMS
On April 8, 2015, the Walgreens Boots Alliance Board of Directors approved a plan to implement a new restructuring program (the “Cost Transformation Program”) as part of an initiative to reduce costs and increase operating efficiencies. The Cost Transformation Program implements and builds on the planned three-year, $1.0 billion cost-reduction initiative previously announced by Walgreens on August 6, 2014 and includes a number of elements designed to help achieve profitable growth through increased cost efficiencies. We have identified additional opportunities for cost savings that increase the total expected cost savings of the Cost Transformation Program by $500 million to a projected $1.5 billion by the end of fiscal 2017. Significant areas of focus include plans to close approximately 200 stores across the U.S.; reorganize divisional and field operations; drive operating efficiencies; and streamline information technology and other functions. The actions under the Cost Transformation Program focus primarily on our Retail Pharmacy USA segment, and are expected to be substantially completed by the end of fiscal 2017.

We currently estimate that we will recognize cumulative pre-tax charges to our GAAP financial results of between $1.6 billion and $1.8 billion, including costs associated with lease obligations and other real estate payments, asset impairments and employee termination and other business transition and exit costs. We expect to incur pre-tax charges of between $525 million and $600 million for real estate costs, including lease obligations (net of estimated sublease income); between $650 million and $725 million for asset impairment charges relating primarily to asset write-offs from store closures, information technology, inventory and other non-operational real estate asset write-offs; and between $425 million and $475 million for employee severance and other business transition and exit costs. We estimate that approximately 60% of the cumulative pre-tax charges will result in immediate or future cash expenditures, primarily related to lease and other real estate payments and employee separation costs.

The Company incurred pre-tax charges of $28 million and $118 million related to the Cost Transformation Program during the three and six month periods ended February 29, 2016. No charges were incurred with respect to the Cost Transformation Program in the three and six month periods ended February 28, 2015. From inception through February 29, 2016, the Company incurred pre-tax charges of $660 million ($254 million in real estate costs, $248 million related to asset impairment charges and $158 million in severance and other business transition and exit costs) related to the Cost Transformation Program. All charges related to the Cost Transformation Program have been recorded within selling, general and administrative expenses.

In March 2014, the Walgreens Board of Directors approved a plan to close underperforming stores in efforts to optimize and focus resources within Retail Pharmacy USA segment in a manner intended to increase stockholder value. As of August 31, 2015, this plan was completed and no additional charges related to the plan are expected. There were no charges incurred in the three month period ended February 28, 2015. For the six months ended February 28, 2015, the Company incurred pre-tax charges of $17 million, which were primarily related to lease termination costs. All charges related to this plan have been recorded within selling, general and administrative expenses.

Restructuring costs by segment are as follows (in millions):

   
Retail Pharmacy
             
Three Months Ended February 29, 2016
 
USA
   
International
   
Pharmaceutical
Wholesale
   
Consolidated
 
Real estate costs
 
$
-
   
$
-
   
$
-
   
$
-
 
Asset impairments
   
-
     
-
     
-
     
-
 
Severance and other business transition and exit costs
   
25
     
3
     
-
     
28
 
Total restructuring costs
 
$
25
   
$
3
   
$
-
   
$
28
 
                                 
Three Months Ended February 28, 2015
                               
Real estate costs
 
$
-
   
$
-
   
$
-
   
$
-
 
Asset impairments
   
-
     
-
     
-
     
-
 
Severance and other business transition and exit costs
   
-
     
-
     
-
     
-
 
Total restructuring costs
 
$
-
   
$
-
   
$
-
   
$
-
 
 
   
Retail Pharmacy
             
Six Months Ended February 29, 2016
 
USA
   
International
   
Pharmaceutical
Wholesale
   
Consolidated
 
Real estate costs
 
$
52
   
$
-
   
$
-
   
$
52
 
Asset impairments
   
25
     
-
     
-
     
25
 
Severance and other business transition and exit costs
   
33
     
8
     
-
     
41
 
Total restructuring costs
 
$
110
   
$
8
   
$
-
   
$
118
 
                                 
Six Months Ended February 28, 2015
                               
Real estate costs
 
$
17
   
$
-
   
$
-
   
$
17
 
Asset impairments
   
-
     
-
     
-
     
-
 
Severance and other business transition and exit costs
   
-
     
-
     
-
     
-
 
Total restructuring costs
 
$
17
   
$
-
   
$
-
   
$
17
 

As the program is implemented, the restructuring charges will be recognized as the costs are incurred over time in accordance with GAAP.

The amounts and timing of all estimates are subject to change until finalized. The actual amounts and timing may vary materially based on various factors. See “Cautionary Note Regarding Forward-Looking Statements” below.

EXECUTIVE SUMMARY
The following table presents certain key financial statistics for the three and six months ended February 29, 2016 and February 28, 2015, respectively. As a result of the completion of the Second Step Transaction, the Company ceased recording equity earnings in Alliance Boots on December 31, 2014. As such, the three and six month periods ended February 29, 2016 reflects the full consolidation of Alliance Boots results, while the three and six month periods ended February 28, 2015 include the results of Alliance Boots as equity income from Walgreens’ pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively.

   
(in millions, except per share amounts)
 
   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Net sales
 
$
30,184
   
$
26,573
   
$
59,217
   
$
46,127
 
Gross Profit
   
7,944
     
6,882
     
15,446
     
12,178
 
Selling, general and administrative expenses
   
6,084
     
5,606
     
12,118
     
10,062
 
Operating Income
   
1,860
     
1,377
     
3,328
     
2,431
 
Adjusted Operating Income (Non-GAAP measure)(1)
   
2,120
     
1,840
     
3,839
     
2,958
 
Earnings Before Interest and Tax Provision
   
1,364
     
2,587
     
2,775
     
3,840
 
Net Earnings Attributable to Walgreens Boots Alliance, Inc.
   
930
     
2,042
     
2,040
     
2,892
 
Adjusted Net Earnings Attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)(1)
   
1,423
     
1,244
     
2,555
     
1,993
 
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. – diluted
   
0.85
     
1.93
     
1.87
     
2.88
 
Adjusted net earnings per common share attributable to Walgreens Boots Alliance, Inc. – diluted (Non-GAAP measure)(1)
   
1.31
     
1.18
     
2.34
     
1.98
 
 
   
Percentage Increases/(Decreases)
 
   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Net sales
   
13.6
     
35.5
     
28.4
     
21.6
 
Gross Profit
   
15.4
     
21.8
     
26.8
     
12.7
 
Selling, general and administrative expenses
   
8.5
     
22.7
     
20.4
     
12.4
 
Operating Income
   
35.1
     
13.1
     
36.9
     
11.3
 
Adjusted Operating Income (Non-GAAP measure)(1)
   
15.2
     
30.7
     
29.8
     
19.7
 
Earnings Before Interest and Tax Provision
   
(47.3
)
   
123.4
     
(27.7
)
   
63.4
 
Net Earnings Attributable to Walgreens Boots Alliance, Inc.
   
(54.5
)
   
185.2
     
(29.5
)
   
101.0
 
Adjusted Net Earnings Attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)(1)
   
14.4
     
33.2
     
28.2
     
22.9
 
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. – diluted
   
(56.0
)
   
160.8
     
(35.1
)
   
93.3
 
Adjusted net earnings per common share attributable to Walgreens Boots Alliance, Inc. – diluted (Non-GAAP measure)(1)
   
11.0
     
21.6
     
18.2
     
17.2
 
 
   
Percent to Net Sales
 
   
Three Months Ended
   
Six Months Ended
 
 
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Gross Margin
   
26.3
     
25.9
     
26.1
     
26.4
 
Selling, general and administrative expenses
   
20.2
     
21.1
     
20.5
     
21.8
 

(1)
See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP.

WALGREENS BOOTS ALLIANCE RESULTS OF OPERATIONS
Our results for the three and six months ended February 29, 2016 as compared to the prior year periods are impacted by the Second Step Transaction, which resulted in the full consolidation of Alliance Boots results of operations beginning December 31, 2014. The completion of the Second Step Transaction on December 31, 2014 means that results for the three and six month periods ended February 29, 2016, include the results of Alliance Boots on a fully consolidated basis, while the three and six months ended February 28, 2015 include the results of Alliance Boots for two months (January and February 2015) on a fully consolidated basis and as equity income from Walgreen Co.’s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively.

Net earnings attributable to Walgreens Boots Alliance for the quarter ended February 29, 2016 were $930 million, or $0.85 per diluted share as compared to $2.0 billion, or $1.93 per diluted share in the comparable prior year period. The decrease in net earnings per diluted share for the three month period ended February 29, 2016 was attributable to last year’s second quarter non-cash gain of $814 million associated with the remeasurement to fair value on December 31, 2014 of the Company’s previously-held equity investment in Alliance Boots and the fair value adjustments on AmerisourceBergen warrants.

Net earnings attributable to Walgreens Boots Alliance for the six months ended February 29, 2016 were $2.0 billion, or $1.87 per diluted share as compared to $2.9 billion, or $2.88 per diluted share in the comparable prior year period. The decrease in net earnings per diluted share for the six month period ended February 29, 2016 was attributable to fair value adjustments on AmerisourceBergen warrants and last year’s second quarter non-cash gain of $814 million associated with the remeasurement to fair value on December 31, 2014 of the Company’s previously-held equity investment in Alliance Boots.

Other income (expense) for the three and six months ended February 29, 2016 was a loss of $496 million and $553 million, respectively, as compared to income of $504 million and $703 million in the three and six months ended February 28, 2015, respectively. Following the completion of the Second Step Transaction, fair value adjustments related to the AmerisourceBergen warrants held by a subsidiary are recorded within other income (expense) rather than equity earnings in Alliance Boots. The change in fair value of our AmerisourceBergen warrants resulted in recording a loss of $529 million in the current quarter and $586 million for the six month period ended February 29, 2016 as compared to income of $559 million and $849 million for the three and six months ended February 28, 2015, primarily attributable to the change in the price of AmerisourceBergen’s common stock. We also recognized a gain of $33 million for the three and six months ended February 29, 2016 on derivative contracts that were not designated as accounting hedges, compared to losses of $60 million and $156 million, respectively, in the comparable three and six month prior year periods. The prior year losses primarily relate to foreign currency forward contracts entered into in consideration of the delivery of foreign cash consideration related to the Second Step Transaction.

Interest was a net expense of $140 million for the three months ended February 29, 2016 and $278 million for the six months ended February 29, 2016 compared to $144 million and $199 million for the comparable prior year quarter and the six months ended February 28, 2015. The increase in interest expense for the six month period is primarily due to the notes we issued to fund a portion of the cash consideration payable in connection with the Second Step Transaction and to subsequently refinance substantially all of Alliance Boots outstanding borrowings following completion of the Second Step Transaction.
 
The effective tax rate for the three months ended February 29, 2016 was 24.6% compared to 16.0% for the three months ended February 28, 2015. The increase in the effective tax rate is primarily attributable to reduced discrete tax benefits, partly offset by a lower estimated annual tax rate.  During the three months ended February 28, 2015 we recorded net discrete tax benefits, primarily related to the previously held equity investment gain associated with our acquisition of the 55% interest in Alliance Boots that we did not previously own in the Second Step Transaction.  Those discrete tax benefits did not recur during the three months ended February 29, 2016.  The lower estimated annual tax rate results from changes in the geographic mix of our forecasted pre-tax earnings as well as increased permanent book-tax differences that favorably impacted our estimated annual tax rate and reduced permanent book-tax differences that negatively impacted our estimated annual tax rate.

The effective tax rate for the six months ended February 29, 2016 was 18.7% compared to 19.6% for the six months ended February 28, 2015. The decrease in the effective tax rate is primarily attributable to a lower estimated annual tax rate, which was partly offset by the reduced impact of discrete tax benefits during the current period.  The lower estimated annual tax rate results from changes in the geographic mix of our forecasted pre-tax earnings as well as increased permanent book-tax differences that favorably impacted our estimated annual tax rate and reduced permanent book-tax differences that negatively impacted our estimated annual tax rate.  For the six months ended February 28, 2015 discrete tax items favorably impacted the tax rate by 12.1% as compared to 6.9% for the six months ended February 29, 2016.  The discrete tax benefits for the six months ended February 28, 2015 primarily related to recognizing the benefits of previously unrecognized deferred tax assets due to our generation of capital gain income from sale-leaseback transactions and the tax impact related to the previously-held equity investment gain associated with our acquisition of the remaining 55% interest in Alliance Boots that we did not previously own in the Second Step Transaction.  The discrete tax benefits for the six months ended February 29, 2016 primarily relate to the $178 million deferred tax impact of certain tax rate reductions enacted by the United Kingdom.

Walgreens Boots Alliance Adjusted Net Earnings Per Diluted Share (Non-GAAP measure)
Adjusted net earnings attributable to Walgreens Boots Alliance for the quarter ended February 29, 2016 were $1.4 billion, or $1.31 per diluted share as compared to $1.2 billion, or $1.18 per diluted share in the comparable prior year period. The increase in adjusted net earnings and adjusted net earnings per diluted share for the three months ended February 29, 2016 was primarily attributable to higher sales and lower selling, general and administrative expenses as a percentage of sales offset partially by a higher effective tax rate. Adjusted net earnings attributable to Walgreens Boots Alliance for the six months ended February 29, 2016 were $2.6 billion, or $2.34 per diluted share as compared to $2.0 billion, or $1.98 per diluted share in the comparable prior year period. The increase in adjusted net earnings and adjusted net earnings per diluted share for the six months ended February 29, 2016 was primarily attributable to higher sales and lower selling, general and administrative expenses as a percentage of sales and offset partially by lower gross margins and a higher effective tax rate. See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable GAAP measure.

RESULTS OF OPERATIONS BY SEGMENT

Retail Pharmacy USA
As a result of the completion of the Second Step Transaction, the Company ceased recording equity earnings in Alliance Boots as of December 31, 2014. As such, the three and six month periods ended February 28, 2015 include equity income from Walgreen Co.’s pre-merger 45 percent interest in Alliance Boots for one month (December 2014) and four months (September through December 2014), respectively.

   
(in millions, except location amounts)
 
   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Total Sales
 
$
21,500
   
$
21,048
   
$
41,870
   
$
40,602
 
Gross Profit
   
5,895
     
5,746
     
11,340
     
11,042
 
Selling, general and administrative expenses
   
4,466
     
4,555
     
8,883
     
9,011
 
Operating Income
   
1,429
     
1,292
     
2,457
     
2,346
 
Adjusted Operating Income (Non-GAAP measure)(1)
   
1,632
     
1,598
     
2,875
     
2,716
 
Number of Prescriptions(2)
   
187
     
182
     
373
     
363
 
30 Day Equivalent Prescriptions(2)(3)
   
233
     
224
     
464
     
446
 
Number of Locations at period end
   
8,196
     
8,333
     
8,196
     
8,333
 
 
   
Percentage Increases/(Decreases)
 
   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Total Sales
   
2.1
     
7.4
     
3.1
     
7.0
 
Gross Profit
   
2.6
     
1.7
     
2.7
     
2.2
 
Selling, general and administrative expenses
   
(2.0
)
   
(0.3
)
   
(1.4
)
   
0.7
 
Operating Income
   
10.6
     
6.2
     
4.7
     
7.4
 
Adjusted Operating Income (Non-GAAP measure)(1)
   
2.1
     
13.5
     
5.9
     
9.9
 
Comparable Store Sales(4)
   
2.2
     
6.9
     
4.0
     
6.3
 
Pharmacy Sales
   
3.2
     
10.1
     
4.9
     
9.5
 
Comparable Pharmacy Sales(4)
   
3.7
     
9.7
     
6.5
     
8.9
 
Retail Sales
   
0.3
     
2.8
     
(0.3
)
   
2.6
 
Comparable Retail Sales(4)
   
(0.3
)
   
2.5
     
(0.4
)
   
2.0
 
Comparable Number of Prescriptions(2)(4)
   
1.3
     
4.2
     
2.4
     
3.5
 
Comparable 30 Day Equivalent Prescriptions(2)(3)(4)
   
2.8
     
5.0
     
3.8
     
4.6
 

   
Percent to Total Sales
 
   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Gross Margin
   
27.4
     
27.3
     
27.1
     
27.2
 
Selling, general and administrative expenses
   
20.8
     
21.6
     
21.2
     
22.2
 

(1) See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable GAAP measure and related disclosures.
(2) Includes immunizations.
(3) Includes the adjustment to convert prescriptions greater than 84 days to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
(4) The three and six month periods ended February 29, 2016 figures include an adjustment to remove February 29, 2016 results due to the leap year.

Sales for the Three Months Ended February 29, 2016 compared to February 28, 2015
The Retail Pharmacy USA division’s total sales for the quarter ended February 29, 2016 increased to $21.5 billion, a 2.1% increase over the comparable prior year quarter. Sales in comparable store sales increased 2.2% from the comparable prior year quarter. The increase was driven by growth in Medicare Part D prescriptions, partially offset by the impact from the sale of a majority interest in our infusion business in fiscal 2015 and a weak cough, cold and flu season. Comparable stores are defined as those that have been open for at least twelve consecutive months without closure for seven or more consecutive days and without a major remodel or a natural disaster in the past twelve months. Relocated and acquired stores are not included as comparable stores for the first twelve months after the relocation or acquisition. Comparable store data has also been adjusted to remove the effects of February 29, 2016 due to the leap year.

Pharmacy sales increased by 3.2% in the three months ended February 29, 2016 and represented 65.0% of the division’s total sales. In the three months ended February 28, 2015, pharmacy sales were up 10.1% and represented 64.4% of the division’s total sales. Comparable pharmacy sales were up 3.7% in the three months ended February 29, 2016 compared to an increase of 9.7% in the three months ended February 28, 2015. The effect of generic drugs, which have a lower retail price, replacing brand name drugs reduced prescription sales by 1.9% in the current quarter versus a reduction of 1.4% in the same period last year. The effect of generics on division total sales was a reduction of 1.1% in the current quarter compared to a reduction of 0.8% for the prior year quarter. Third party sales, where reimbursement is received from managed care organizations, governmental agencies, employers or private insurers, were 97.2% of prescription sales for the three month period ended February 29, 2016 compared to 96.4% for the three month period last year. The total number of prescriptions (including immunizations) filled for the current quarter was approximately 187 million compared to 182 million for the same period last year. Prescriptions (including immunizations) adjusted to 30 day equivalents were 233 million in the current quarter versus 224 million in the prior year quarter.
 
Retail sales increased 0.3% for the three months ended February 29, 2016 and were 35.0% of the division’s total sales. In comparison, for the three months ended February 28, 2015, retail sales increased 2.8% and comprised 35.6% of the division’s total sales. Comparable retail sales decreased 0.3% for the current quarter compared to an increase of 2.5% in the prior period. The decrease in comparable retail sales in the current quarter was primarily due to a weak cough, cold and flu season. This decrease was partially offset by increased sales of giftable products during the holiday season, vitamins and first aid products.

Operating Income for the Three Months Ended February 29, 2016 compared to February 28, 2015
Retail Pharmacy USA division’s operating income for the three months ended February 29, 2016 increased to $1.4 billion, a 10.6% increase over the comparable prior year quarter. The increase is primarily due to higher sales and lower selling, general and administrative expenses as a percentage of sales and higher gross margins, partially offset by having no equity earnings in Alliance Boots in the current period versus one month in the comparable prior year period.

Gross margin as a percent of sales was 27.4% in the current quarter compared to 27.3% in the comparable quarter last year. Pharmacy margins were positively impacted in the quarter by procurement efficiencies and additional brand-to-generic drug conversions compared with the prior year period. The increase in pharmacy margins was partially offset by lower third-party reimbursements including new Medicare Part D rates that came into effect on January 1, 2016 and an increase in Medicare Part D mix, including the strategy to continue driving 90-day prescriptions at retail. Retail margins were positively impacted in the current quarter primarily from household, grocery and beauty categories partially offset by seasonal and snacks categories.

Selling, general and administrative expenses as a percentage of sales were 20.8% for the current quarter compared to 21.6% in the same period a year ago. As a percentage of sales, expenses in the current quarter were lower primarily due to increased store labor efficiencies and cost controls.

Adjusted Operating Income (Non-GAAP measure) for the Three Months Ended February 29, 2016 compared to February 28, 2015
Retail Pharmacy USA division’s adjusted operating income for the three months ended February 29, 2016 increased to $1.6 billion, a 2.1% increase over the comparable prior year quarter. The increase is primarily due to higher sales, lower selling, general and administrative expenses as a percentage of sales and higher gross margins partially offset by having no equity earnings in Alliance Boots in the current period versus one month in the comparable prior year period. See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable GAAP measure.

Sales for the Six Months Ended February 29, 2016 compared to February 28, 2015
The Retail Pharmacy USA division’s total sales for the six months ended February 29, 2016 increased to $41.9 billion, a 3.1% increase over the comparable prior year period. Total sales increased primarily due to higher comparable store sales, which increased 4.0% over the comparable prior year period, partially offset by the impact from the sale of a majority interest in our infusion business in fiscal 2015 and store closures during the six months ended February 29, 2016. Comparable store data has been adjusted to remove the effects of February 29, 2016 due to the leap year. We operated 8,196 locations (8,187 drugstores) as of February 29, 2016, compared to 8,333 locations (8,232 drugstores) as of February 28, 2015 (which included 90 infusion and respiratory services facilities in which we sold a majority interest in fiscal 2015).

Pharmacy sales increased by 4.9% in the six months ended February 29, 2016 and represented 66.7% of the division’s total sales. In the six months ended February 28, 2015, pharmacy sales were up 9.5% and represented 65.5% of the division’s sales. Comparable pharmacy sales were up 6.5% in the six months ended February 29, 2016 compared to an increase of 8.9% in the six months ended February 28, 2015. The effect of generic drugs, which have a lower retail price, replacing brand name drugs reduced prescription sales by 2.2% in the current six month period ended February 29, 2016 versus a reduction of 1.6% in the comparable period last year. The effect of generics on division total sales was a reduction of 1.3% in the current six month period compared to a reduction of 0.9% for the prior year’s period. Third party sales, where reimbursement is received from managed care organizations, governmental agencies, employers or private insurers, were 97.2% of prescription sales for the six month period ended February 29, 2016 compared to 96.5% for the six month period last year. The total number of prescriptions (including immunizations) filled for the six months ended February 29, 2016 was approximately 373 million compared to 363 million for the same period last year. Prescriptions (including immunizations) adjusted to 30 day equivalents were 464 million in the current six month period versus 446 million in the comparable prior year period.

Retail sales decreased 0.3% for the six months ended February 29, 2016 and were 33.3% of the division’s total sales. In comparison, for the six months ended February 28, 2015 retail sales increased 2.6% and comprised 34.5% of the division’s total sales. Comparable retail sales decreased 0.4% for the current six month period compared to an increase of 2.0% in the comparable prior year period. The decrease in comparable retail sales in the six months ended February 29, 2016 was primarily attributable to decreased customer traffic partially offset by an increase in basket size.
 
Operating Income for the Six Months Ended February 29, 2016 compared to February 28, 2015
Retail Pharmacy USA division’s operating income for the six months ended February 29, 2016 increased to $2.5 billion, a 4.7% increase over the comparable prior year period. The increase is primarily due to higher sales and lower selling, general and administrative expenses as a percentage of sales, partially offset by having no equity earnings in Alliance Boots in the current period versus four months in the comparable prior year period.

Gross margin as a percent of sales was 27.1% for the six months ended February 29, 2016 compared to 27.2% in the comparable period last year. Pharmacy margins were negatively impacted in the period by lower third-party reimbursements (including new Medicare Part D rates that came into effect on January 1, 2016) and an increase in Medicare Part D mix, including the strategy to continue driving 90-day prescriptions at retail. The decrease in pharmacy margins was partially offset by procurement efficiencies and additional brand-to-generic drug conversions compared with the prior year period. Retail margins were positively impacted in the current period primarily from the household, grocery and personal care categories partially offset by the snacks category.

Selling, general and administrative expenses as a percentage of sales were 21.2% for the six month period ended February 29, 2016 compared to 22.2% in the same period a year ago. As a percentage of sales, expenses in the current period were lower primarily due to increased store labor efficiencies and cost controls.

Adjusted Operating Income (Non-GAAP measure) for the Six Months Ended February 29, 2016 compared to February 28, 2015
Retail Pharmacy USA division’s adjusted operating income for the six months ended February 29, 2016 increased to $2.9 billion, a 5.9% increase over the comparable prior year period. The increase is primarily due to higher sales and lower selling, general and administrative expenses as a percentage of sales, partially offset by having no equity earnings in Alliance Boots in the current period versus four months in the comparable prior year period and lower gross margins. See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable GAAP measure.

Retail Pharmacy International

   
(in millions, except location amounts)
 
   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Total Sales
 
$
3,689
   
$
2,047
   
$
7,220
   
$
2,047
 
Gross Profit
   
1,516
     
753
     
3,021
     
753
 
Selling, general and administrative expenses
   
1,217
     
745
     
2,420
     
745
 
Operating Income
   
299
     
8
     
601
     
8
 
Adjusted Operating Income (Non-GAAP measure)(1)
   
335
     
125
     
650
     
125
 
Number of Locations at period end
   
4,603
     
4,559
     
4,603
     
4,559
 

   
Percent to Total Sales
 
   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Gross Margin
   
41.1
     
36.8
     
41.8
     
36.8
 
Selling, general and administrative expenses
   
33.0
     
36.4
     
33.5
     
36.4
 

(1) See “--Non-GAAP Measures” below for reconciliations to the most directly comparable GAAP measure and related disclosures.

The businesses included in our Retail Pharmacy International division were acquired as part of the Second Step Transaction. The Retail Pharmacy International division's results, including the increases in total sales, gross profit, selling, general and administrative expenses and operating income, for the three and six months ended February 29, 2016 as compared to the comparable prior year periods were primarily impacted by the Second Step Transaction, which resulted in the full consolidation of Alliance Boots results of operations beginning December 31, 2014. Accordingly, the results for this segment for the three and six month periods ended February 28, 2015 include only two months (January and February 2015) of results and directly comparable prior period financial results are not presented.
 
Pharmaceutical Wholesale

   
(in millions)
 
   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Total Sales
 
$
5,627
   
$
3,865
   
$
11,423
   
$
3,865
 
Gross Profit
   
535
     
387
     
1,092
     
387
 
Selling, general and administrative expenses
   
401
     
306
     
815
     
306
 
Operating Income
   
134
     
81
     
277
     
81
 
Adjusted Operating Income (Non-GAAP measure)(1)
   
155
     
121
     
321
     
121
 

   
Percent to Total Sales
 
   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Gross Margin
   
9.5
     
10.0
     
9.6
     
10.0
 
Selling, general and administrative expenses
   
7.1
     
7.9
     
7.1
     
7.9
 

(1) See “--Non-GAAP Measures” below for reconciliations to the most directly comparable GAAP measure and related disclosures.

The businesses included in our Pharmaceutical Wholesale division were acquired as part of the Second Step Transaction. The Pharmaceutical Wholesale division's results, including the increases in total sales, gross profit, selling, general and administrative expenses and operating income, for the three and six months ended February 29, 2016 as compared to the comparable prior year periods were primarily impacted by the Second Step Transaction, which resulted in the full consolidation of Alliance Boots results of operations beginning December 31, 2014. Accordingly, the results for this segment for the three and six month periods ended February 28, 2015 include only two months (January and February 2015) of results and directly comparable prior period financial results are not presented.
 
NON-GAAP MEASURES
The following tables provide reconciliations of adjusted operating income and adjusted net earnings per common share attributable to Walgreens Boots Alliance that are non-GAAP financial measures, as defined under the rules of the Securities and Exchange Commission, to the most directly comparable financial measures calculated and presented in accordance with GAAP. We have provided these non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures are presented because our management has evaluated our financial results, both including and excluding the adjusted items, and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of our business from period to period and trends in our historical operating results. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

   
(in millions)
 
   
Three Months Ended February 29, 2016
 
   
Retail
Pharmacy
USA
   
Retail
Pharmacy
International
   
Pharmaceutical
Wholesale
   
Eliminations
and Other
   
Consolidated
 
Operating Income (GAAP)
 
$
1,429
   
$
299
   
$
134
   
$
(2
)
 
$
1,860
 
Acquisition-related amortization
   
47
     
33
     
21
     
-
     
101
 
Cost transformation
   
25
     
3
     
-
     
-
     
28
 
LIFO provision
   
68
     
-
     
-
     
-
     
68
 
Acquisition-related costs
   
33
     
-
     
-
     
-
     
33
 
Asset impairment
   
30
     
-
     
-
     
-
     
30
 
Adjusted Operating Income (Non-GAAP measure)
 
$
1,632
   
$
335
   
$
155
   
$
(2
)
 
$
2,120
 
 
   
(in millions)
 
   
Three Months Ended February 28, 2015
 
   
Retail
Pharmacy
USA
   
Retail
Pharmacy
International
   
Pharmaceutical
Wholesale
   
Eliminations
and Other
   
Consolidated
 
Operating Income (GAAP)
 
$
1,292
   
$
8
   
$
81
   
$
(4
)
 
$
1,377
 
Decrease (increase) in fair market value of warrants
   
6
     
-
     
-
     
-
     
6
 
Acquisition-related amortization
   
67
     
117
     
33
     
-
     
217
 
LIFO provision
   
55
     
-
     
-
     
-
     
55
 
Acquisition-related costs
   
52
     
-
     
7
     
-
     
59
 
Asset impairment
   
110
     
-
     
-
     
-
     
110
 
Store closures and other optimization costs
   
16
     
-
     
-
     
-
     
16
 
Adjusted Operating Income (Non-GAAP measure)
 
$
1,598
   
$
125
   
$
121
   
$
(4
)
 
$
1,840
 

   
(in millions)
 
   
Six Months Ended February 29, 2016
 
   
Retail
Pharmacy
USA
   
Retail
Pharmacy
International
   
Pharmaceutical
Wholesale
   
Eliminations
and Other
   
Consolidated
 
Operating Income (GAAP)
 
$
2,457
   
$
601
   
$
277
   
$
(7
)
 
$
3,328
 
Acquisition-related amortization
   
97
     
41
     
44
     
-
     
182
 
Cost transformation
   
110
     
8
     
-
     
-
     
118
 
LIFO provision
   
114
     
-
     
-
     
-
     
114
 
Acquisition-related costs
   
67
     
-
     
-
     
-
     
67
 
Asset impairment
   
30
     
-
     
-
     
-
     
30
 
Adjusted Operating Income (Non-GAAP measure)
 
$
2,875
   
$
650
   
$
321
   
$
(7
)
 
$
3,839
 

   
(in millions)
 
   
Six Months Ended February 28, 2015
 
   
Retail
Pharmacy
USA
   
Retail
Pharmacy
International
   
Pharmaceutical
Wholesale
   
Eliminations
and Other
   
Consolidated
 
Operating Income (GAAP)
 
$
2,346
   
$
8
   
$
81
   
$
(4
)
 
$
2,431
 
Decrease (increase) in fair market value of warrants
   
(123
)
   
-
     
-
     
-
     
(123
)
Acquisition-related amortization
   
156
     
117
     
33
     
-
     
306
 
LIFO provision
   
107
     
-
     
-
     
-
     
107
 
Acquisition-related costs
   
76
     
-
     
7
     
-
     
83
 
Asset impairment
   
110
     
-
     
-
     
-
     
110
 
Store closures and other optimization costs
   
44
     
-
     
-
     
-
     
44
 
Adjusted Operating Income (Non-GAAP measure)
 
$
2,716
   
$
125
   
$
121
   
$
(4
)
 
$
2,958
 
 
    (in millions)  
   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Net earnings attributable to Walgreens Boots Alliance, Inc. (GAAP)
 
$
930
   
$
2,042
   
$
2,040
   
$
2,892
 
Decrease (increase) in fair market value of warrants
   
379
     
(376
)
   
420
     
(655
)
Acquisition-related amortization
   
72
     
157
     
130
     
215
 
Cost transformation
   
20
     
-
     
84
     
-
 
LIFO provision
   
49
     
42
     
82
     
76
 
Acquisition-related costs
   
24
     
43
     
48
     
59
 
Asset impairment
   
21
     
78
     
21
     
78
 
United Kingdom tax rate change
   
-
     
-
     
(178
)
   
-
 
Adjusted tax rate true-up
   
(40
)
   
(69
)
   
(60
)
   
(69
)
Net investment hedging gain
   
(32
)
   
-
     
(32
)
   
-
 
Transaction foreign currency hedging loss
   
-
     
70
     
-
     
166
 
Alliance Boots equity method non-cash tax
   
-
     
38
     
-
     
71
 
Store closures and other optimization costs
   
-
     
12
     
-
     
30
 
Prefunded interest expenses
   
-
     
21
     
-
     
30
 
Gain on previously held equity interest
   
-
     
(814
)
   
-
     
(814
)
Release of capital loss valuation allowance
   
-
     
-
     
-
     
(86
)
Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)
 
$
1,423
   
$
1,244
   
$
2,555
   
$
1,993
 

   
Three Months Ended
   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
   
February 29,
2016
   
February 28,
2015
 
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. – diluted (GAAP)
 
$
0.85
   
$
1.93
   
$
1.87
   
$
2.88
 
Decrease (increase) in fair market value of warrants
   
0.35
     
(0.35
)
   
0.38
     
(0.65
)
Acquisition-related amortization
   
0.07
     
0.15
     
0.12
     
0.21
 
Cost transformation
   
0.02
     
-
     
0.08
     
-
 
LIFO provision
   
0.05
     
0.04
     
0.07
     
0.08
 
Acquisition-related costs
   
0.02
     
0.04
     
0.04
     
0.06
 
Asset impairment
   
0.02
     
0.07
     
0.02
     
0.08
 
United Kingdom tax rate change
   
-
     
-
     
(0.16
)
   
-
 
Adjusted tax rate true-up
   
(0.04
)
   
(0.07
)
   
(0.05
)
   
(0.07
)
Net investment hedging gain
   
(0.03
)
   
-
     
(0.03
)
   
-
 
Transaction foreign currency hedging loss
   
-
     
0.07
     
-
     
0.16
 
Alliance Boots equity method non-cash tax
   
-
     
0.04
     
-
     
0.07
 
Store closures and other optimization costs
   
-
     
0.01
     
-
     
0.03
 
Prefunded interest expenses
   
-
     
0.02
     
-
     
0.03
 
Gain on previously held equity interest
   
-
     
(0.77
)
   
-
     
(0.81
)
Release of capital loss valuation allowance
   
-
     
-
     
-
     
(0.09
)
Adjusted net earnings per common share attributable to Walgreens Boots Alliance, Inc. – diluted (Non-GAAP measure)
 
$
1.31
   
$
1.18
   
$
2.34
   
$
1.98
 
 
LIQUIDITY AND CAPITAL RESOURCES
Cash and cash equivalents were $3.6 billion (including $1.6 billion in non-U.S. jurisdictions) as of February 29, 2016, compared to $3.0 billion (including $0.8 billion in non-U.S. jurisdictions) at February 28, 2015. Short-term investment objectives are primarily to minimize risk and maintain liquidity. To attain these objectives, investment limits are placed on the amount, type and issuer of securities. Investments are principally in U.S. Treasury money market funds and AAA-rated money market funds.

Our long-term capital policy is to maintain a strong balance sheet and financial flexibility, reinvest in our core strategies, invest in strategic opportunities that reinforce our core strategies and meet return requirements, and return surplus cash flow to shareholders in the form of dividends and share repurchases over the long term.

Cash provided by operations and the issuance of debt are the principal sources of funds for expansion, investments, acquisitions, remodeling programs, dividends to shareholders and stock repurchases. Net cash provided by operating activities for the six months ended February 29, 2016 was $3.1 billion, compared to $2.3 billion for the comparable prior year period.

Net cash used for investing activities was $0.6 billion for the six month period ended February 29, 2016, compared to $4.7 billion in the comparable prior year period. The Alliance Boots acquisition used $4.5 billion of cash in the comparable prior year period. Business acquisitions in the six month period ended February 29, 2016 were $86 million compared to $92 million in the comparable prior year period. Business acquisitions in the current period include the acquisition of an international beauty brand and prescription files. Other business acquisitions in the prior year period were primarily the purchase of prescription files.

For the six months ended February 29, 2016, additions to property, plant and equipment were $657 million compared to $643 million in the comparable prior year period. Capital expenditures by reporting segment were as follows:

   
Six Months Ended
 
   
February 29,
2016
   
February 28,
2015
 
Retail Pharmacy USA
 
$
386
   
$
550
 
Retail Pharmacy International(1)
   
222
     
82
 
Pharmaceutical Wholesale(1)
   
49
     
11
 
Total
 
$
657
   
$
643
 
 
(1)
Our Retail Pharmacy International and Pharmaceutical Wholesale segments were acquired as part of the Second Step Transaction in which we acquired the 55% of Alliance Boots that we did not already own on December 31, 2014. As a result of the timing of the acquisition, only two months of capital expenditures (January and February 2015) have been reported for these divisions in the six months ended February 28, 2015.
 
For the six month period ended February 29, 2016, our Retail Pharmacy USA segment opened or acquired 55 locations compared to 71 locations for the comparable period last year. Significant Retail Pharmacy International capital expenditures primarily relate to investments in our stores and information technology projects. Pharmaceutical Wholesale capital expenditures primarily relate to investments in warehouses and operations and information technology projects.

Additionally, investing activities for the six month period ended February 29, 2016 included proceeds related to sale-leaseback transactions of $60 million, compared to $562 million in the comparable prior year period, and the sale of a pharmaceutical wholesale operation for $43 million in the six month period ended February 29, 2016.
 
Net cash used by financing activities for the six months ended February 29, 2016 was $1.9 billion, compared to net cash provided of $2.8 billion in the comparable prior year period. We repurchased shares to support the needs of the employee stock plans totaling $1.0 billion in the six month period ended February 29, 2016, compared to $0.6 billion in the six month period ended February 28, 2015. Proceeds related to employee stock plans were $129 million during the six months ended February 29, 2016, compared to $293 million for the six month period ended February 28, 2015. Cash dividends paid were $787 million during the six month period ended February 29, 2016, compared to $642 million for the same period a year ago. We currently intend to continue to maintain a long-term dividend payout ratio target of approximately 30 to 35 percent of adjusted net earnings attributable to Walgreens Boots Alliance.

In August 2014, the Walgreens Board of Directors authorized the 2014 stock repurchase program (the “2014 stock repurchase program”), which authorizes the repurchase of up to $3.0 billion of Walgreens’ (or, after the Reorganization, Walgreens Boots Alliance’s) common stock prior to the program’s expiration on August 31, 2016. We purchased 1.3 million shares under the 2014 stock repurchase program in the six months ended February 29, 2016 at a total cost of $110 million. We determine the timing and amount of repurchases based on our assessment of various factors, including prevailing market conditions, alternate uses of capital, liquidity and the economic environment. Because the consideration payable to Rite Aid stockholders will be paid in cash, we suspended activity under the 2014 stock repurchase program (other than share repurchases to offset dilution from our equity incentive plans – see Part II, Item 2 below) following our entry into the Merger Agreement. The timing and amount of purchases under the 2014 stock repurchase program may change at any time and from time to time. We have repurchased, and may from time to time in the future repurchase, shares on the open market through Rule 10b5-1 plans, which enable us to repurchase shares at times when we otherwise might be precluded from doing so under insider trading laws.

The Company periodically borrows under its commercial paper program and may borrow under it in future periods. There were no commercial paper borrowings outstanding as of February 29, 2016 or February 28, 2015, respectively. The Company had average daily short-term borrowings of $20 million of commercial paper outstanding at a weighted average interest rate of 0.62% for the six month period ended February 29, 2016. We had average daily short-term borrowings of $4 million of commercial paper outstanding at a weighted average interest rate of 0.46% for the six months ended February 28, 2015.

On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a term loan credit agreement (the “Term Loan Agreement”), which provides Walgreens Boots Alliance and Walgreens with the ability to borrow up to £1.45 billion on an unsecured basis. Borrowings under the Term Loan Agreement bear interest at a fluctuating rate per annum equal to the reserve adjusted LIBOR plus an applicable margin based on our credit ratings. As of February 29, 2016, we have borrowed £1.45 billion ($2.0 billion at the February 29, 2016 spot rate of $1.39 to £1) under the Term Loan Agreement.

On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a five-year unsecured, multicurrency revolving credit agreement (the “Revolving Credit Agreement”), which replaced prior Walgreens agreements dated July 20, 2011 and July 23, 2012. The new unsecured revolving credit agreement initially totaled $2.25 billion, of which $375 million was available for the issuance of letters of credit. On December 29, 2014, upon the affirmative vote of the majority of common shares of Walgreens represented and entitled to vote at the Walgreens special meeting of shareholders to approve the issuance of the shares necessary to complete the Second Step Transaction, the available credit increased to $3.0 billion, of which $500 million is available for the issuance of letters of credit. The issuance of letters of credit reduces the aggregate amount otherwise available under the Revolving Credit Agreement for the making of revolving loans. Borrowings under the Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to, at our option, the alternate base rate or the reserve adjusted LIBOR, in each case, plus an applicable margin calculated based on our credit ratings. As of February 29, 2016, there were no borrowings or letters of credit issued pursuant to the Revolving Credit Agreement.

Total upfront fees related to the Term Loan Agreement and Revolving Credit Agreement were $14 million. We pay a facility fee to the financing banks to keep these lines of credit active.

Walgreens guaranteed the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of all obligations of Walgreens Boots Alliance under the Term Loan Agreement and the Revolving Credit Agreement until August 10, 2015, when such guarantees were unconditionally released and discharged (as described below).

On November 18, 2014, we issued several series of unsecured, unsubordinated notes totaling $8.0 billion, with maturities ranging from 2016 to 2044. All such notes have fixed interest rates, with the exception of the $750 million notes due 2016, which have a floating rate based on the three month LIBOR plus a fixed spread of 45 basis points.

On November 20, 2014, we issued a series of unsecured, unsubordinated notes that included total Pound Sterling denominated debt of £700 million ($1.1 billion based on the November 20, 2014 exchange rate) with maturities due 2020 and 2025 and Euro denominated debt of €750 million ($940 million based on the November 20, 2014 exchange rate) due 2026. All notes issued on November 20, 2014 have fixed interest rates. The notes issued on November 18, 2014 and November 20, 2014 are collectively referred to as the “WBA notes”. The WBA notes were, upon initial issuance, fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens.
 
On December 19, 2014, Walgreens Boots Alliance and Walgreens entered into a Revolving Credit Agreement (as amended, the “364-Day Credit Agreement”) with the lenders party thereto. The 364-Day Credit Agreement was a $750 million, 364-day unsecured, multicurrency revolving facility. On July 9, 2015, the 364-Day Credit Agreement was amended to remove Walgreens as a borrower thereunder, eliminate Walgreens’ guarantee of all obligations of Walgreens Boots Alliance thereunder and make certain conforming changes to effectuate those modifications, including modifications and deletions of certain definitions and cross-references. On December 17, 2015, the Company terminated the 364-Day Credit Agreement. The 364-Day Credit Agreement remained undrawn as of the date of termination and would have matured on December 30, 2015.

The 364-Day Credit Agreement and the Term Loan Agreement and Revolving Credit Agreement described above each contain or contained (as applicable) a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants. As of February 29, 2016, we were in compliance with all such applicable covenants.

In addition, on July 9, 2015, pursuant to an indenture, dated as of July 17, 2008, between Walgreens and Wells Fargo Bank, National Association, as trustee, notices of redemption were given to (i) holders of 1.800% unsecured notes due 2017 (the “2017 Notes”) and (ii) holders of 5.25% unsecured notes due 2019 (the “2019 Notes”), in each case issued by Walgreens under the indenture. As a result, on August 10, 2015 (the “redemption date”), the 2017 Notes in the aggregate principal amount of $1.0 billion were redeemed in full and $750 million aggregate principal amount of the 2019 Notes were redeemed. The partial redemption of the 2019 Notes resulted in $250 million aggregate principal amount of 2019 Notes remaining outstanding. The redemption price with respect to the 2017 Notes was equal to 101.677% of the aggregate principal amount of such notes to be redeemed, plus accrued interest thereon to, but excluding, the redemption date. The redemption price with respect to the 2019 Notes was equal to 111.734% of the aggregate principal amount of such notes to be redeemed, plus accrued interest thereon to, but excluding, the redemption date.

On August 10, 2015, upon the completion of the redemptions described above, the Walgreens guarantees of the WBA notes and the Term Loan Agreement and the Revolving Credit Agreement were unconditionally released and discharged in accordance with their terms.

Pending Rite Aid Transaction. The cash consideration payable to Rite Aid stockholders pursuant to the Merger Agreement described under “Introduction” above is expected to be financed with a combination of cash on hand and debt financing. In connection with the Merger Agreement, Walgreens Boots Alliance entered into a bridge facility commitment letter (as amended and restated as of November 19, 2015, the “Commitment Letter”) with UBS Securities LLC and UBS AG, Stamford Branch for a $12.8 billion senior unsecured bridge facility.

On December 18, 2015, Walgreens Boots Alliance entered into a Bridge Term Loan Credit Agreement with the lenders party thereto and UBS AG, Stamford Branch, as administrative agent (as amended on January 20, 2016, the “Bridge Credit Agreement”) and a Term Loan Credit Agreement with the lenders party thereto and Bank of America, N.A., as administrative agent (as amended on January 20, 2016, the “Term Loan Credit Agreement” and, together with the Bridge Credit Agreement, the “2015 Credit Agreements”). The Commitment Letter and the commitments contemplated thereby terminated upon Walgreens Boots Alliance entering into the 2015 Credit Agreements.

The Bridge Credit Agreement is a 364-day unsecured bridge term loan facility. The aggregate commitments of all lenders under the Bridge Credit Agreement are equal to $7.8 billion, provided that Walgreens Boots Alliance may increase the commitments under the Bridge Credit Agreement at any time prior to the funding of the loans thereunder by up to $2.0 billion, subject to obtaining commitments from existing lenders and/or new lenders selected by Walgreens Boots Alliance and reasonably acceptable to the administrative agent. Walgreens Boots Alliance can extend up to $3.0 billion of the loans under the Bridge Credit Agreement for an additional 90-day period if desired. As of February 29, 2016, there were no borrowings under the Bridge Credit Agreement.

The Term Loan Credit Agreement is a two-tranche unsecured term loan facility, with the first tranche maturing three years after the earlier of the funding date and October 27, 2016, and the second tranche maturing five years after the earlier of the funding date and October 27, 2016. The aggregate commitments of all lenders under the Term Loan Credit Agreement are equal to $5.0 billion. As of February 29, 2016, there were no borrowings under the Term Loan Credit Agreement.
 
Walgreens Boots Alliance will be the borrower under each of the 2015 Credit Agreements. The ability of Walgreens Boots Alliance to request the making of loans under each of the 2015 Credit Agreements is subject to the satisfaction (or waiver) of certain conditions set forth therein and will terminate upon the occurrence of certain events set forth therein. Borrowings under each of the 2015 Credit Agreements will bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance’s option, the alternate base rate or the reserve adjusted Eurocurrency rate, in each case, plus an applicable margin calculated based on Walgreens Boots Alliance’s credit ratings. Upfront fees paid to date in connection with the 2015 Credit Agreements totaled $30 million. A maximum of a further $5 million in upfront fees is payable prior to, or at funding, subject to certain conditions. In addition, Walgreens Boots Alliance will also pay to the lenders under each of the 2015 Credit Agreements certain customary fees, including a ticking fee based on the aggregate outstanding commitments of the lenders under the applicable 2015 Credit Agreement starting at 90 days after signing. Each of the 2015 Credit Agreements contains a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants, which restrictive covenants shall not be in effect until the funding of the loans under the applicable 2015 Credit Agreement.

The foregoing description of the 2015 Credit Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the 2015 Credit Agreements and the amendments thereto, which are filed as Exhibits 10.6 through Exhibit 10.9 to this report.

As of April 4, 2016, the credit ratings of Walgreens Boots Alliance were:

Rating Agency
Long-Term Debt Rating
 
Commercial
Paper Rating
 
Outlook
Moody’s
Baa2
 
P-2
 
On review for downgrade
Standard & Poor’s
BBB
 
A-2
 
Negative

In assessing our credit strength, both Moody’s and Standard & Poor’s consider various factors including our business model, capital structure, financial policies and financial performance. There can be no assurance that any particular rating will be assigned or maintained. Our credit ratings impact our borrowing costs, access to capital markets and operating lease costs. The rating agency ratings are not recommendations to buy, sell or hold our debt securities or commercial paper. Each rating may be subject to revision or withdrawal at any time by the assigning rating agency and should be evaluated independently of any other rating.

Pursuant to our arrangements with AmerisourceBergen, we have the right, but not the obligation, to purchase a minority equity position in AmerisourceBergen over time through open market purchases and pursuant to warrants to acquire AmerisourceBergen common stock, as described under “-AmerisourceBergen Corporation Relationship” above.   As of February 29, 2016, we had purchased a total of approximately 11.5 million AmerisourceBergen shares in the open market. Share purchases may be made from time to time in open market transactions or pursuant to instruments and plans complying with Rule 10b5-1. Our ability to invest in equity in AmerisourceBergen above certain thresholds is subject to the receipt of regulatory approvals.

On March 18, 2016, we exercised Warrant 1 in full, resulting in the acquisition from AmerisourceBergen of 22,696,912 shares of AmerisourceBergen common stock for an aggregate cash exercise price payment of $1.17 billion. See Note 20, Subsequent Event. If we elect to exercise Warrant 2 in full when permitted during a six month period beginning in March 2017, we would, subject to the terms and conditions of Warrant 2, be required to make a cash payment of $1.19 billion to AmerisourceBergen in connection with the exercise of Warrant 2.

We believe that cash flow from operations, availability under our existing credit facilities and arrangements, current cash and investment balances and our ability to obtain other financing, if necessary, will provide adequate cash funds for foreseeable working capital needs, capital expenditures at existing facilities, dividend payments and debt service obligations for at least the next 12 months. Our cash requirements are subject to change as business conditions warrant and opportunities arise. The timing and size of any new business ventures or acquisitions that we may complete may also impact our cash requirements.

See Item 3 (Qualitative and Quantitative Disclosures about Market Risk) below for a discussion of certain financing and market risks.

OFF-BALANCE SHEET ARRANGEMENTS
We do not have any unconsolidated special purpose entities and, except as described herein, we do not have significant exposure to any off-balance sheet arrangements. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have: (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.
 
As of February 29, 2016, we have issued $342 million in letters of credit, primarily related to insurance obligations. We also had $50 million of guarantees outstanding as of February 29, 2016. We remain secondarily liable on 79 leases. The maximum potential undiscounted future payments related to these leases was $348 million as of February 29, 2016.

CONTINGENCIES
The information set forth in Note 12, Commitments and Contingencies, to the Consolidated Condensed Financial Statements (Unaudited) included in this Quarterly Report on Form 10-Q is incorporated herein by reference.

CONTRACTUAL OBLIGATIONS AND COMMITMENTS
Other than our obligations under the Merger Agreement and the transactions contemplated thereby, there have been no material changes, outside of the ordinary course of business, in our outstanding contractual obligations disclosed in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.

CRITICAL ACCOUNTING POLICIES
The consolidated financial statements are prepared in accordance with GAAP and include amounts based on management’s prudent judgments and estimates. Actual results may differ from these estimates. Management believes that any reasonable deviation from those judgments and estimates would not have a material impact on our consolidated financial position or results of operations. To the extent that the estimates used differ from actual results, however, adjustments to the statement of earnings and corresponding balance sheet accounts would be necessary. These adjustments would be made in future periods. For a discussion of our significant accounting policies, please see the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015. Some of the more significant estimates include business combinations, goodwill and other intangible asset impairment, allowance for doubtful accounts, vendor allowances, asset impairments, liability for closed locations, cost of sales and inventory, equity method investments, pension and postretirement benefits and income taxes. There have been no significant changes in those accounting policies.

RECENT ACCOUNTING PRONOUNCEMENTS
The discussion of recent accounting pronouncements in Note 19, Recent Accounting Pronouncements, to the Consolidated Condensed Financial Statements (Unaudited) included in this Quarterly Report on Form 10-Q is incorporated herein by reference.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report and other documents that we file or furnish with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about our future performance, our business, our beliefs and our management’s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases or written statements, on the Company’s website or in our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls, conference calls and other communications. Some of such forward-looking statements may be based on certain data and forecasts relating to our business and industry that we have obtained from internal surveys, market research, publicly available information and industry publications. Industry publications, surveys and market research generally state that the information they provide has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. Statements that are not historical facts are forward-looking statements, including, without limitation, those regarding estimates of and goals for future financial and operating performance as well as forward-looking statements concerning the expected execution and effect of our business strategies, our cost-savings and growth initiatives and restructuring activities and the amounts and timing of their expected impact, our pending Merger Agreement with Rite Aid and the transactions contemplated thereby and their possible effects, our commercial agreement with AmerisourceBergen, the arrangements and transactions contemplated by our framework agreement with AmerisourceBergen and their possible effects, estimates of the impact of developments on our earnings, earnings per share and other financial and operating metrics, cough/cold and flu season, prescription volume, pharmacy sales trends, prescription margins, changes in generic prescription drug prices, retail margins, number and location of new store openings, network participation, vendor, payer and customer relationships and terms, possible new contracts or contract extensions, competition, economic and business conditions, outcomes of litigation and regulatory matters, the level of capital expenditures, industry trends, demographic trends, growth strategies, financial results, cost reduction initiatives, impairment or other charges, acquisition and joint venture synergies, competitive strengths and changes in legislation or regulations. Words such as “expect,” “likely,” “outlook,” “forecast,” “preliminary,” “would,” “could,” “should,” “can,” “will,” “project,” “intend,” “plan,” “goal,” “guidance,” “target,” “aim,” “continue,” “sustain,” “synergy,” “on track,” “headwind,” “tailwind,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,” “assume,” variations of such words and similar expressions are intended to identify such forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
 
These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that could cause actual results to vary materially from those indicated or anticipated, including, but not limited to, those relating to the impact of private and public third-party payers’ efforts to reduce prescription drug reimbursements, the timing and severity of cough/cold and flu season, fluctuations in foreign currency exchange rates, the timing and magnitude of the impact of branded to generic drug conversions and changes in generic drug prices, our ability to realize synergies and achieve financial, tax and operating results in the amounts and at the times anticipated, supply arrangements including our commercial agreement with AmerisourceBergen, the arrangements and transactions contemplated by our framework agreement with AmerisourceBergen and their possible effects, the risks associated with equity investments in AmerisourceBergen including whether the outstanding warrants to invest in AmerisourceBergen will be exercised and the ramifications thereof, the occurrence of any event, change or other circumstance that could give rise to the termination, cross-termination or modification of any of our contractual obligations, the amount of costs, fees, expenses and charges incurred in connection with strategic transactions, whether the costs associated with restructuring activities will exceed estimates, our ability to realize expected savings and benefits from cost-savings initiatives, restructuring activities and acquisitions in the amounts and at the times anticipated, the timing and amount of any impairment or other charges, changes in management’s assumptions, the risks associated with governance and control matters, the ability to retain key personnel, changes in economic and business conditions generally or in particular markets in which we participate, changes in financial markets and interest rates, the risks associated with international business operations, the risk of unexpected costs, liabilities or delays, changes in vendor, customer and payer relationships and terms, including changes in network participation and reimbursement terms, risks of inflation in the cost of goods, risks associated with the operation and growth of our customer loyalty programs, competition, risks associated with new business areas and activities, risks associated with acquisitions, divestitures, joint ventures and strategic investments, including those relating to our ability to satisfy the closing conditions and consummate the pending acquisition of Rite Aid and related financing matters on a timely basis or at all, the risks associated with the integration of complex businesses, outcomes of legal and regulatory matters, including with respect to regulatory review and actions in connection with the pending acquisition of Rite Aid, and changes in legislation, regulations or interpretations thereof. These and other risks, assumptions and uncertainties are described in Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended August 31, 2015 and in other documents that we file or furnish with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, we do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date the statement is made, whether as a result of new information, future events, changes in assumptions or otherwise.
 
Item 3. Quantitative and Qualitative Disclosure about Market Risk
Interest Rate Risk
We are exposed to interest rate volatility with regard to existing debt issuances. Primary exposures include U.S. Treasury rates, LIBOR and commercial paper rates. From time to time, we use interest rate swaps and forward-starting interest rate swaps to hedge our exposure to the impact of interest rate changes on existing debt and future debt issuances respectively, to reduce the volatility of our financing costs and, based on current and projected market conditions, achieve a desired proportion of fixed versus floating-rate debt. Generally under these swaps, we agree with a counterparty to exchange the difference between fixed-rate and floating-rate interest amounts based on an agreed upon notional principal amount.

We also use interest rate caps to protect from rising interest rates on existing floating-rate debt. Information regarding our interest rate swaps, forward starting interest rate swaps, and interest rate caps transactions are set forth in Note 10, Financial Instruments to our unaudited Consolidated Condensed Financial Statements. These financial instruments are sensitive to changes in interest rates. On February 29, 2016, we had approximately $3 billion in long-term debt obligations that had floating interest rates. A one percentage point increase or decrease in interest rates for the various debt held by us would increase or decrease the annual interest expense we recognize and the cash we pay for interest expense by approximately $30 million. The amounts exclude the impact of any associated interest rate swaps, forward starting interest rate swaps and interest rate caps.
 
Foreign Currency Exchange Rate Risk
We are exposed to fluctuations in foreign currency exchange rates, primarily with respect to the British Pound Sterling and Euro, and certain other foreign currencies, including the Mexican Peso, Chilean Peso, Norwegian Krone and Turkish Lira may affect our net investment in foreign subsidiaries and may cause fluctuations in cash flows related to foreign denominated transactions. We are also exposed to the translation of foreign currency earnings to the U.S. dollar. We enter into foreign currency forward contracts to hedge against the effect of exchange rate fluctuations on non-functional currency cash flows of certain entities denominated in foreign currencies. These transactions are almost exclusively less than 12 months in maturity. In addition, we enter into foreign currency forward contracts that are not designated in hedging relationships to offset, in part, the impacts of certain intercompany activities (primarily associated with intercompany financing transactions). As circumstances warrant, we also use basis swaps as hedging instruments to hedge portions of our net investments in foreign operations. The foreign currency derivative instruments are sensitive to changes in exchange rates. A 1% increase or decrease in exchange rates would increase or decrease our pre-tax income by approximately $9 million due to changes in the value of foreign currency derivative instruments. Excluded from the computation were anticipated transactions, foreign currency trade payables and receivables, and net investments in foreign subsidiaries, which the abovementioned instruments are intended to partially hedge.
 
Equity Price Risk
Changes in AmerisourceBergen common stock price and equity volatility may have a significant impact on the value of the warrants to acquire AmerisourceBergen common stock described in Note 10, Financial Instruments and Note 20, Subsequent Event to our unaudited Consolidated Condensed Financial Statements. As of March 18, 2016, a one dollar change in AmerisourceBergen’s common stock would, holding other factors constant, increase or decrease the fair value of our outstanding AmerisourceBergen warrants by approximately $23 million. See “- AmerisourceBergen Corporation Relationship” above.
 
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Management conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of the Company’s management, including its Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”). Based upon the controls evaluation, our CEO and CFO have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the SEC, and that such information is accumulated and communicated to management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting
In connection with the evaluation pursuant to Exchange Act Rule 13a-15(d) of the Company’s internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) by the Company’s management, including its CEO and CFO, no changes during the quarter ended February 29, 2016 were identified that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls
Our management, including the CEO and CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

PART II.  OTHER INFORMATION

Item 1. Legal Proceedings
The information in response to this item is incorporated herein by reference to Note 12, Commitments and Contingencies of the Consolidated Condensed Financial Statements of this Quarterly Report.

Item 1A. Risk Factors
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended August 31, 2015, which could materially and adversely affect our business, financial condition or future results. These risks are not the only risks that we face. Our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations.
 
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(c) The following table provides information about purchases by the Company during the quarter ended February 29, 2016 of equity securities that are registered by the Company pursuant to Section 12 of the Exchange Act. Subject to applicable law, share purchases may be made in open market transactions, privately negotiated transactions, or pursuant to instruments and plans complying with Rule 10b5-1.

   
Issuer Purchases of Equity Securities
 
Period
 
Total
Number of
Shares
Purchased
   
Average Price
Paid per Share
   
Total Number of Shares
Purchased as Part of
Publicly Announced
Repurchase Programs(1)
   
Approximate Dollar Value
of Shares That May Yet be
Purchased Under the Plans
or Program(1)
 
12/1/15 - 12/31/15
   
7,306,591
   
$
83.84
     
-
   
$
2,163,991,385
 
1/1/16 - 1/31/16
   
122,596
     
86.92
     
-
     
2,163,991,385
 
2/1/16 – 2/29/16(2)
   
-
     
-
     
-
     
2,163,991,385
 
Total
   
7,429,187
   
$
83.89
     
-
   
$
2,163,991,385
 

(1) In August 2014, the Walgreens Board of Directors approved the 2014 share repurchase program which authorizes the purchase of up to $3.0 billion of Walgreens’ (or, after December 31, 2014 Walgreens Boots Alliance) common stock prior to the program’s expiration on August 31, 2016.
(2) We purchased 7,429,187 shares of our common stock in open-market transactions for future issuance under our Omnibus Incentive Plan and employee stock purchase plan.
 
Item 6. Exhibits
The agreements included as exhibits to this report are included to provide information regarding their terms and not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement that were made solely for the benefit of the other parties to the applicable agreement, and:

 
should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;

 
may have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;

 
may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and

 
were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time.
 
Exhibit
No.
Description
 
SEC Document Reference
       
3.1
Amended and Restated Certificate of Incorporation of Walgreens Boots Alliance, Inc.
 
Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K12B (File No. 001-36759) filed with the SEC on December 31, 2014.
       
3.2
Amended and Restated Bylaws of Walgreens Boots Alliance, Inc.
 
Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on October 16, 2015.
       
4.1
Indenture, dated as of December 17, 2015, between Walgreens Boots Alliance, Inc. and Wells Fargo Bank, National Association, as trustee.
 
Incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-3 (File No. 333-208587) filed with the SEC on December 17, 2015.
       
Form of Performance Share Award agreement for CEO (February 2016).
 
Filed herewith.
       
Form of Stock Option Award agreement for CEO (February 2016).
 
Filed herewith.
       
Form of Restricted Stock Unit Award agreement for Executive Chairman (February 2016).
 
Filed herewith.
       
10.4*
Consulting Services Agreement between Walgreens Boots Alliance, Inc. and Timothy Theriault dated December 2, 2015.
 
Incorporated by reference to Exhibit 10.9 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q (File No. 001-36759) filed with the SEC on January 7, 2016.
       
10.5*
Extension, dated January 27, 2016, to Assignment Letter between Alexander Gourlay and Walgreens Boots Alliance Services Limited (formerly Alliance Boots Management Services Ltd.).
 
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on February 1, 2016.
       
10.6
Bridge Term Loan Credit Agreement, dated as of December 18, 2015, by and among Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and UBS AG, Stamford Branch, as administrative agent.
 
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on December 21, 2015.
       
Amendment, dated as of January 20, 2016, to the Bridge Term Loan Credit Agreement dated as of December 18, 2015, by and among Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and UBS AG, Stamford Branch, as administrative agent.
 
Filed herewith.
       
10.8
Term Loan Credit Agreement, dated as of December 18, 2015, by and among Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and Bank of America, N.A., as administrative agent.
 
Incorporated by reference to Exhibit 10.2 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on December 21, 2015.
       
Amendment, dated as of January 20, 2016, to the Term Loan Credit Agreement, dated as of December 18, 2015, by and among Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and Bank of America, N.A., as administrative agent.
 
Filed herewith.
       
Computation of Ratio of Earnings to Fixed Charges.
 
Filed herewith.
       
Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
Filed herewith.
       
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
Filed herewith.
 
Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.
 
Furnished herewith.
       
Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.
 
Furnished herewith.
       
101.INS
XBRL Instance Document
 
Filed herewith.
       
101.SCH
XBRL Taxonomy Extension Schema Document
 
Filed herewith.
       
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
 
Filed herewith.
       
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
 
Filed herewith.
       
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
 
Filed herewith.
       
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
 
Filed herewith.
 


*
Management contract or compensatory plan or arrangement.
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
Walgreens Boots Alliance, Inc.
 
(Registrant)
   
Dated :  April 5, 2016
/s/ George R. Fairweather
 
George R. Fairweather
 
Executive Vice President and Global Chief Financial Officer
   
Dated :  April 5, 2016
/s/ Kimberly R. Scardino
 
Kimberly R. Scardino
 
Senior Vice President, Global Controller and Chief Accounting Officer
 
(Principal Accounting Officer)


- 55 -

EX-10.1 2 ex10_1.htm EXHIBIT 10.1

Exhibit 10.1
 
WALGREENS BOOTS ALLIANCE, INC.

2013 OMNIBUS INCENTIVE PLAN

PERFORMANCE SHARE AWARD AGREEMENT

These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by your company, not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments.  These materials were prepared by your company, which is solely responsible for their contents and for compliance with legal and regulatory requirements.  Fidelity is not connected with any offering or acting as an underwriter in connection with any offering of your company's securities or financial instruments.  Fidelity does not review, approve or endorse the contents of these materials and is not responsible for their content.
 

WALGREENS BOOTS ALLIANCE, INC.

2013 OMNIBUS INCENTIVE PLAN

PERFORMANCE SHARE AWARD AGREEMENT

Participant Name:  Stefano Pessina

Participant ID:  [____]

Grant Date:  February 12, 2016 (the "Grant Date")

Performance Period:   Fiscal Years –  2016 - 2018 (the "Performance Period")

Shares Granted:  65,090

Acceptance Date:

Electronic Signature:

This document (referred to below as this “Agreement”) spells out the terms and conditions of the Performance Share Award (the “Award”) granted to you by Walgreens Boots Alliance, Inc., a Delaware corporation (the “Company”), pursuant to the Walgreens Boots Alliance, Inc. 2013 Omnibus Incentive Plan (the “Plan”) on and as of the Grant Date designated above.  Except as otherwise defined herein, capitalized terms used in this Agreement have the respective meanings set forth in the Plan.  For purposes of this Agreement, "Employer" means the entity (the Company or the Affiliate) that employs you on the applicable date.  The Plan as it may be amended from time to time, is incorporated into this Agreement by this reference.

You and the Company agree as follows:

1.          Grant of Performance Shares.  Pursuant to the approval and direction of the Compensation Committee of the Company’s Board of Directors (the “Committee”), the Company hereby grants you the target number of Performance Shares specified above (the "Performance Shares"), subject to the terms and conditions of the Plan and this Agreement.  This “target” number of shares is computed by dividing a target award dollar amount approved for you by the Committee by the average closing stock price of the Company’s common stock, par value US$.01 per share (“Stock”) for the last 30 trading days of the fiscal year preceding the Grant Date.

2.          Performance Measure. The number of Performance Shares earned at the end of the three-year Performance Period will vary depending on the degree to which cumulative adjusted earnings per share performance goals for the Performance Period, as established by the Committee, are met.

3.          Determination of Performance Shares Earned.  At the target levels, 100% of the Performance Shares will be earned.  At the threshold levels, 50% of the Performance Shares will be earned.  Below the threshold levels of performance, no Performance Shares are earned.  At the maximum levels or more, 150% of the Performance Shares will be earned.  Performance between minimum and target, and between target and maximum, will earn Performance Shares on a pro-rated basis between 50% and 100%, and 100% and 150%, respectively.
 

The amount earned will be calculated according to the following:

         
Percent of
 
Performance
=
Target
X
Target
 
Shares Awarded
 
Performance Shares
 
Performance Shares Earned

4.          Disability or Death.  If during the Performance Period you have a Termination of Service by reason of Disability or death, then the number of Performance Shares earned (based on performance as of the end of the Performance Period) shall become vested at the end of the Performance Period.  Any Performance Shares becoming vested by reason of your Termination of Service by reason of Disability or death shall be paid at the same time Performance Shares are paid to other Participants.

5.          Retirement.  If prior to the 12-month anniversary of the Grant Date you have a Termination of Service by reason of retirement from the Company’s Board of Directors, as reasonably determined by the Committee, then the number of Performance Shares earned (based on performance as of the end of the Performance Period) will be prorated to reflect the portion of the Performance Period during which you remained employed by the Company.  Such prorated portion shall equal the number of Performance Shares that you would otherwise have earned, multiplied by a fraction equal to the number of full months of the Performance Period completed as of your Termination of Service, divided by the number of months in the Performance Period. If on or after the 12-month anniversary of the Grant Date, you have a Termination of Service by reason of retirement from the Company’s Board of Directors, as reasonably determined by the Committee, then the full number of Performance Shares earned (based on performance as of the end of the Performance Period) shall become vested at the end of the Performance Period.  Any Performance Shares becoming vested by reason of your retirement shall be paid at the same time Performance Shares are paid to other Participants.

6.          Termination of Service Following a Change in Control.  If during the Performance Period there is a Change in Control of the Company and within the one-year period thereafter you have a Termination of Service initiated by your Employer other than for Cause (as defined in Section 7), then your earned Award shall equal your target number of Performance Shares, prorated to reflect the portion of the Performance Period during which you remained employed by the Company.  Such prorated portion shall equal your target number of Performance Shares, multiplied by a fraction equal to the number of full months of the Performance Period completed as of your Termination of Service, divided by the number of months in the Performance Period.  This prorated award will be settled in cash (subject to required tax withholdings) in accordance with Section 9.01(b) of the Plan within 45 days after your Termination of Service.  For purposes of this Section 6, a Termination of Service initiated by your Employer shall include a Termination of Employment for Good Reason under - and pursuant to the terms and conditions of – the Walgreens Boots Alliance, Inc. Executive Severance and Change in Control Plan, but only to the extent applicable to you as an eligible participant in such Plan.

7.          Other Termination of Service. If during the Performance Period you have a voluntary or involuntary Termination of Service for any reason other than as set forth in Section 4, 5 or 6 above, as determined by the Committee, then all of your Performance Shares shall be forfeited.  For purposes of this Agreement, “Cause” means any one or more of the following, as determined by the Committee in its sole discretion:

(a) your commission of a felony or any crime of moral turpitude;

(b) your dishonesty or material violation of standards of integrity in the course of fulfilling your duties to the Company or any Affiliate;
 

(c) your material violation of a material written policy of the Company or any Affiliate violation of which is grounds for immediate termination;

(d) your willful and deliberate failure to perform your duties to the Company or any Affiliate in any material respect, after reasonable notice of such failure and an opportunity to correct it; or

(e) your failure to comply in any material respect with the United States ("U.S.") Foreign Corrupt Practices Act, the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, the U.S. Sarbanes-Oxley Act of 2002, the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the U.S. Truth in Negotiations Act, or any rules or regulations thereunder.

8.          Settlement of Earned Performance Shares. At the end of the Performance Period actual performance for the entire Performance Period shall be reviewed, and the amount of the earned Award shall be determined based on this performance and communicated to you.  Subject to the requirements of Section 12 below, the Company shall transfer to you one share of Stock for each Performance Share earned at that time, net of any applicable tax withholding requirements in accordance with Section 9 below.  Performance Shares payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals.  Accordingly, Performance Shares will be settled in Stock no later than the 15th day of the third month following the end of the fiscal year of the Company (or if later, the calendar year) in which the Performance Shares are earned.

Notwithstanding the foregoing, if you are resident or employed outside of the U.S., the Company, in its sole discretion, may provide for the settlement of the Performance Shares in the form of:

(a)          a cash payment (in an amount equal to the Fair Market Value of the Stock that corresponds with the number of earned Performance Shares) to the extent that settlement in shares of Stock (i) is prohibited under local law, (ii) would require you, the Company or an Affiliate to obtain the approval of any governmental or regulatory body in your country of residence (or country of employment, if different), (iii) would result in adverse tax consequences for you, the Company or an Affiliate or (iv) is administratively burdensome; or

(b)          shares of Stock, but require you to sell such shares of Stock immediately or within a specified period following your Termination of Service (in which case, you hereby agree that the Company shall have the authority to issue sale instructions in relation to such shares of Stock on your behalf).

9.          Responsibility for Taxes; Tax Withholding.

(a)          You acknowledge that, regardless of any action taken by the Company or your Employer, the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you ("Tax-Related Items"), is and remains your responsibility and may exceed the amount actually withheld by the Company or your Employer.  You further acknowledge that the Company and/or your Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including, but not limited to, the grant, vesting or settlement of the Award, the subsequent sale of shares of Stock acquired pursuant to such settlement and the receipt of any dividends;  and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result.  Further, if you are subject to Tax-Related Items in more than one jurisdiction between the Grant Date and the date of any relevant taxable or tax withholding event, as applicable, you acknowledge that the Company and/or your Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
 

 (b)          Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or your Employer to satisfy all Tax-Related Items.  In this regard, you authorize the Company, your Employer or its agent to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following:  (i) withholding from your wages or other cash compensation paid to you by the Company and/or your Employer; (ii) withholding from proceeds of the sale of Stock acquired upon settlement of the Award either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization without further consent); or (iii) withholding from the shares of Stock to be delivered upon settlement of the Award that number of shares of Stock having a Fair Market Value equal to (but not in excess of) the minimum amount required by law to be withheld.

Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable statutory minimum withholding rates (as determined by the Company in good faith and in its sole discretion) or other applicable withholding rates, including maximum applicable rates, in which case you will receive a refund of any over-withheld amount in cash and will have no entitlement to the share equivalent.  If the obligation for Tax-Related Items is satisfied by withholding from the shares of Stock to be delivered upon settlement of the Award, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the earned Award, notwithstanding that a number of the shares of Stock are held back solely for the purpose of paying the Tax-Related Items.

You agree to pay to the Company or your Employer any amount of Tax-Related Items that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described.  The Company may refuse to issue or deliver the shares of Stock (or cash payment) or the proceeds from the sale of shares of Stock if you fail to comply with your obligations in connection with the Tax-Related Items.

10.          Nontransferability.  During the Performance Period and thereafter until Stock is transferred to you in settlement thereof, you may not sell, transfer, pledge, assign or otherwise alienate or hypothecate the Performance Shares, whether voluntarily or involuntarily or by operation of law, other than by beneficiary designation effective upon your death, or by will or by the laws of intestacy.

11.          Rights as Shareholder.  You shall have no rights as a shareholder of the Company with respect to the Performance Shares until such time as a certificate of stock for the Stock issued in settlement of the Performance Shares has been issued to you or such shares of Stock have been recorded in your name in book entry form.  Except as provided in Section 17 below, no adjustment shall be made for dividends or distributions or other rights with respect to such shares for which the record date is prior to the date on which you become the holder of record thereof.  Anything herein to the contrary notwithstanding, if a law or any regulation of the U.S. Securities and Exchange Commission or of any other body having jurisdiction shall require the Company or you to take any action before shares of Stock can be delivered to you hereunder, then the date of delivery of such shares may be delayed accordingly.

12.          Securities Laws. If a Registration Statement under the U.S. Securities Act of 1933, as amended, is not in effect with respect to the shares of Stock to be delivered pursuant to this Agreement, you hereby represent that you are acquiring the shares of Stock for investment and with no present intention of selling or transferring them and that you will not sell or otherwise transfer the shares except in compliance with all applicable securities laws and requirements of any stock exchange on which the shares of Stock may then be listed.
 

13.          Not a Public Offering.  If you are resident outside the U.S., the grant of the Performance Shares is not intended to be a public offering of securities in your country of residence (or country of employment, if different).  The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and the grant of the Performance Shares is not subject to the supervision of the local securities authorities.

14.          Insider Trading/Market Abuse Laws.  Your country of residence may have insider trading and/or market abuse laws that may affect your ability to acquire or sell shares of Stock under the Plan during such times you are considered to have "inside information" (as defined in the laws in your country).  These laws may be the same or different from any Company insider trading policy.  You acknowledge that it is your responsibility to be informed of and compliant with such regulations, and you are advised to speak to your personal advisor on this matter.

15.          Repatriation; Compliance with Law.  If you are resident or employed outside the U.S., as a condition of the Award, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan in accordance with applicable foreign exchange rules and regulations in your country of residence (and country of employment, if different).  In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and its Affiliates, as may be required to allow the Company and its Affiliates to comply with local laws, rules and/or regulations in your country of residence (and country of employment, if different).  Finally, you agree to take any and all actions as may be required to comply with your personal obligations under local laws, rules and/or regulations in your country of residence and country of employment, if different).

16.          No Advice Regarding Grant.  No employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock underlying the Performance Shares.  You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

17.          Change in Stock.  In the event of any change in the Stock, by reason of any stock dividend, recapitalization, reorganization, split-up, merger, consolidation, exchange of shares, or of any similar change affecting Stock, the number of Performance Shares subject to this Award Agreement shall be equitably adjusted by the Committee.

18.          Nature of the Award.  In accepting the Award, you acknowledge, understand and agree that:

(a)          the Plan is established voluntarily by the Company, it is discretionary in nature and limited induration, and it may be modified, amended, suspended or terminated by the Company, in its sole discretion, at any time;

(b)          the grant of the Award is voluntary and occasional and does not create any contractual or other right to receive future grants of Performance Shares, or benefits in lieu of Performance Shares, even if Performance Shares have been granted in the past;

(c)          all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company, including, but not limited to, the form and timing of the Award, the number of shares subject to the Award, and the earning provisions applicable to the Award;
 
(d)           the Award and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company or any Affiliate and shall not interfere with the ability of the Company, your Employer or an Affiliate, as applicable, to terminate your employment or service relationship;
 

(e)          you are voluntarily participating in the Plan;

(f)          the Award and the shares of Stock subject to the Award are not intended to replace any pension rights or compensation;

(g)          the Award, the shares of Stock subject to the Award and the value of same, is an extraordinary item of compensation outside the scope of your employment (and employment contract, if any) and is not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;

(h)          the future value of the shares of Stock underlying the Award is unknown, indeterminable and cannot be predicted with certainty;

(i)          unless otherwise determined by the Committee in its sole discretion, a Termination of Service shall be effective from the date on which active employment or service ends and shall not be extended by any statutory or common law notice of termination period;

(j)          no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from a Termination of Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and in consideration of the grant of the Award to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company, your Employer or any Affiliate, waive your ability, if any, to bring any such claim, and release the Company, the Employer and all Affiliates from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim;

(k)          unless otherwise provided herein, in the Plan or by the Company in its discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of Stock of the Company; and

(l)          neither the Company nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Award or of any amounts due to you pursuant to the settlement of the Award or the subsequent sale of any shares of Stock acquired upon settlement of the Award.

19.          Committee Authority; Recoupment.  It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate for the administration of the Plan and this Agreement, including the enforcement of any recoupment policy, all of which shall be binding upon you and any claimant.  Any inconsistency between this Agreement and the Plan shall be resolved in favor of the Plan.
 

20.          Consent to Collection/Processing/Transfer of Personal Data.  Pursuant to applicable personal data protection laws, the Company hereby notifies you of the following in relation to your personal data and the collection, processing and transfer of such data in relation to the Company's grant of the Performance Shares and your participation in the Plan.  The collection, processing and transfer of personal data is necessary for the Company’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of personal data may affect your participation in the Plan.  As such, you voluntarily acknowledge and consent (where required under applicable law) to the collection, use, processing and transfer of personal data as described herein:

 (a)          The Company and your Employer hold certain personal information about you, including (but not limited to) your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all entitlements to shares of Stock awarded, canceled, purchased, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan ("Data").  The Data may be provided by you or collected, where lawful, from the Company, its Affiliates and/or third parties, and the Company and your Employer will process the Data for the exclusive purpose of implementing, administering and managing your participation in the Plan.  The Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations in your country of residence (or country of employment, if different).  Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought.  Data will be accessible within the organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and for the participation in the Plan.

(b)          The Company and your Employer will transfer Data internally as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and/or your Employer may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Plan.  These recipients may be located in the European Economic Area, or elsewhere throughout the world, such as the United States.  You hereby authorize (where required under applicable law) the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, as may be required for the administration of the Plan and/or the subsequent holding of the shares of Stock on your behalf, to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.

(c)          You may, at any time, exercise your rights provided under applicable personal data protection laws, which may include the right to (i) obtain confirmation as to the existence of the Data, (ii) verify the content, origin and accuracy of the Data, (iii) request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of the Data, (iv) oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and/or operation of the Plan and your participation in the Plan, and (v) withdraw your consent to the collection, processing or transfer of Data as provided hereunder (in which case, your Performance Shares will become null and void).  You may seek to exercise these rights by contacting your Human Resources manager or the Company's Human Resources Department, who may direct the matter to the applicable Company privacy official.

21.          Addendum to Agreement.  Notwithstanding any provision of this Agreement to the contrary, the Performance Shares shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as set forth in the addendum to the Agreement, attached hereto as Exhibit A (the “Addendum”).  Further, if you transfer your residence and/or employment to another country reflected in the Addendum, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Performance Shares and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  The Addendum shall constitute part of this Agreement.
 

22.          Additional Requirements.  The Company reserves the right to impose other requirements on the Performance Shares, any shares of Stock acquired pursuant to the Performance Shares and your participation in the Plan to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Performance Shares and the Plan.  Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

23.          Amendment or Modification, Waiver.  Except as set forth in the Plan, no provision of this Agreement may be amended or waived unless the amendment or waiver is agreed to in writing, signed by you and by a duly authorized officer of the Company. No waiver of any condition or provision of this Agreement shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time.

24.          Electronic Delivery.  The Company may, in its sole discretion, deliver by electronic means any documents related to the Award or your future participation in the Plan.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

25.          Governing Law and Jurisdiction.  This Agreement is governed by the substantive and procedural laws of the state of Illinois.  You and the Company shall submit to the exclusive jurisdiction of, and venue in, the courts in Illinois in any dispute relating to this Agreement without regard to any choice of law rules thereof which might apply the laws of any other jurisdiction.

26.          English Language.  If you are resident in a country where English is not an official language, you acknowledge and agree that it is your express intent that this Agreement, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Award, be drawn up in English.  If you have received this Agreement, the Plan or any other documents related to the Award translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

27.          Conformity with Applicable Law.  If any provision of this Agreement is determined to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision of this Agreement or the validity, legality or enforceability of such provision in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

28.          Successors.  This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall, upon your death, acquire any rights hereunder.
 

****
 
This Agreement contains highly sensitive and confidential information.  Please handle it accordingly.
 
Please read the attached Exhibit A.  Once you have read and understood this Agreement and Exhibit A, please click the acceptance box to certify and confirm your agreement to be bound by the terms and conditions of this Agreement and Exhibit A and to acknowledge your receipt of the Prospectus, the Plan and this Agreement and your acceptance of the terms and conditions of the Award granted hereunder.
 

EXHIBIT A

ADDENDUM TO THE
WALGREENS BOOTS ALLIANCE, INC. 2013 OMNIBUS INCENTIVE PLAN
PERFORMANCE SHARE AWARD AGREEMENT

In addition to the terms of the Plan and the Agreement, the Award is subject to the following additional terms and conditions to the extent you reside and/or are employed in one of the countries addressed herein.  Pursuant to Section 21 of the Agreement, if you transfer your residence and/or employment to another country reflected in this Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Performance Shares and the Plan (or the Company may establish alternative terms as may be necessary or advisable to accommodate your transfer).  All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.

CHILE

Private Placement.  The following provision shall replace Section 13 of the Agreement:

The grant of the Performance Shares hereunder is not intended to be a public offering of securities in Chile but instead is intended to be a private placement.

a) The starting date of the offer will be the Grant Date, and this offer conforms to general ruling no. 336 of the Chilean superintendence of securities and insurance;
b) The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean superintendence of securities and insurance, and therefore such securities are not subject to its oversight;
c) The issuer is not obligated to provide public information in Chile regarding the foreign securities, since such securities are not registered with the Chilean superintendence of securities and insurance; and
d) The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.
 
a) La fecha de inicio de la oferta será el de la fecha de otorgamiento y esta oferta se acoge a la norma de carácter general n° 336 de la superintendencia de valores y seguros chilena;
b) La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva la superintendencia de valores y seguros chilena, por lo que tales valores no están sujetos a la fiscalización de ésta;
c) Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información pública respecto de esos valores; y
d) Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores correspondiente.
 
FRANCE

1.          Nature of Grant.  The Performance Shares are not granted under the French specific regime provided by Articles L225-197-1 and seq. of the French commercial code.
 
2.          Use of English Language.  You acknowledge that it is your express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  Vous reconnaissez avoir expressément exigé la rédaction en anglais de la présente Convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou indirectement, relatifs à, ou suite à, la présente Convention.
 

HONG KONG

1.          Form of Payment.  Notwithstanding any provision in the Agreement or Plan to the contrary, Performance Shares shall be settled only in Shares (and not in cash).

2.          IMPORTANT NOTICE.  WARNING: The contents of the Agreement the Addendum, the Plan, the Plan prospectus, the Plan administrative rules and all other materials pertaining to the Performance Shares and/or the Plan have not been reviewed by any regulatory authority in Hong Kong.  You are hereby advised to exercise caution in relation to the offer thereunder.  If you have any doubts about any of the contents of the aforesaid materials, you should obtain independent professional advice.

3.          Wages.  The Performance Shares and shares of Stock subject to the Performance Shares do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

MEXICO

1.          Commercial Relationship.  You expressly recognize that your participation in the Plan and the Company’s grant of Performance Shares does not constitute an employment relationship between you and the Company.  You have been granted the Performance Shares as a consequence of the commercial relationship between the Company and the Affiliate in Mexico that employs you, and the Company’s Affiliate in Mexico is your sole employer.  Based on the foregoing, you expressly recognize that (a) the Plan and the benefits you may derive from your participation in the Plan do not establish any rights between you and the Company’s Affiliate in Mexico that employs you, (b) the Plan and the benefits you may derive from your participation in the Plan are not part of the employment conditions and/or benefits provided by the Company’s Affiliate in Mexico that employs you, and (c) any modifications or amendments of the Plan by the Company, or a termination of the Plan by the Company, shall not constitute a change or impairment of the terms and conditions of your employment with the Company’s Affiliate in Mexico that employs you.

2.          Extraordinary Item of Compensation.  You expressly recognize and acknowledge that your participation in the Plan is a result of the discretionary and unilateral decision of the Company, as well as your free and voluntary decision to participate in the Plan in accordance with the terms and conditions of the Plan, the Agreement and this Addendum.  As such, you acknowledge and agree that the Company, in its sole discretion, may amend and/or discontinue your participation in the Plan at any time and without any liability.  The Award, the shares of Stock subject to the Award and the value of same is an extraordinary item of compensation outside the scope of your employment contract, if any, and is not part of your regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of the Company’s Affiliate in Mexico that employs you.
 

MONACO

Use of English Language.  You acknowledge that it is your express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  Vous reconnaissez avoir expressément exigé la rédaction en anglais de la présente Convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou indirectement, relatifs à, ou suite à, la présente Convention.

NETHERLANDS

Exclusion of Claim.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Performance Shares, whether or not as a result of your Termination of Service (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Performance Shares.  Upon the grant of Performance Shares, you shall be deemed irrevocably to have waived any such entitlement.

ROMANIA

Voluntary Termination of Service.  For the sake of clarity, a voluntary Termination of Service shall include the situation where your employment contract is terminated by operation of law on the date you reach the standard retirement age and have completed the minimum contribution record for receipt of state retirement pension or the relevant authorities award you an early-retirement pension of any type.

RUSSIA

1.          No Offering of Securities in Russia.  The grant of Performance Shares is not intended to be an offering of securities within the territory of the Russian Federation, and you acknowledge and agree that you will be unable to make any subsequent sale of the shares of Stock acquired pursuant to the Performance Shares in the Russian Federation.

2.          Cash Payments to a Russian Bank Account.  If you are a Russian citizen, any sale proceeds resulting from the sale of shares of Stock acquired upon settlement of the Performance Shares may be delivered only to a bank account that you maintain with an authorized bank in Russia.

SPAIN

1.         Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement:

In accepting the Award, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Performance Shares under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis.  Consequently, you understand that the Performance Shares are granted on the assumption and condition that the Performance Shares and the shares of Stock acquired upon settlement of the Performance Shares shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Award shall be null and void.
 

Further, you understand and agree that the earning of the Performance Shares is expressly conditioned on your continued and active rendering of service, such that upon a Termination of Service, the Performance Shares may be forfeited effective on the date of your Termination of Service (unless otherwise specifically provided in Section 4, 5 or 6 of the Agreement).  This will be the case, for example, even if (a) you are considered to be unfairly dismissed without good cause; (b) you are dismissed for disciplinary or objective reasons or due to a collective dismissal; (c) you terminate service due to a change of work location, duties or any other employment or contractual condition, (d) you terminate service due to a unilateral breach of contract by the Company or an Affiliate.  Consequently, upon a Termination of Service for any of the above reasons, you may automatically lose any rights to Performance Shares as of the date of your Termination of Service, as described in the Plan and Agreement.

You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a Termination of Service on your Award.

2.         Termination for Cause.  “Cause” shall be defined as indicated in Section 7 of the Agreement, irrespective of whether the termination is or is not considered a fair termination (i.e., “despido procedente”) under Spanish legislation.

UNITED KINGDOM

1.         Responsibility for Taxes; Tax Withholding.  The following provision supplements Section 9 of the Agreement:

If payment or withholding of the income tax due in connection with the Award is not made within ninety (90) days after the end of the U.K. tax year in which the event giving rise to the income tax liability occurred or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003 (the “Due Date”), the amount of any uncollected income tax shall constitute a loan owed by you to your Employer, effective as of the Due Date.  You agree that the loan will bear interest at the then-current official rate of Her Majesty’s Revenue & Customs (“HMRC”), it shall be immediately due and repayable, and the Company or Employer may recover it at any time thereafter by any of the means referred to in Section 9 of the Agreement.  Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), will not be eligible for a loan to cover the income tax liability.  In the event that you are a director or executive officer and the income tax is not collected from or paid by you by the Due Date, the amount of any uncollected income tax may constitute a benefit to you on which additional income tax and national insurance contributions (“NICs”) will be payable.  You will be responsible for paying and reporting any income tax due on this additional benefit directly to HMRC under the self-assessment regime, and for reimbursing the Company or your Employer (as applicable) the value of any employee NICs due on this additional benefit.

2.         Exclusion of Claim.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Performance Shares, whether or not as a result of your Termination of Service (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Performance Shares.  Upon the grant of Performance Shares, you shall be deemed irrevocably to have waived any such entitlement.
 
***                    ***                    ***                    ***                    ***
By clicking the acceptance box for this grant agreement, I acknowledge receipt of the Performance Share Award Agreement to which this Addendum is attached as Exhibit A, and I agree to the terms and conditions expressed in this Addendum.
 
 

EX-10.2 3 ex10_2.htm EXHIBIT 10.2

Exhibit 10.2
 
WALGREENS BOOTS ALLIANCE, INC.

2013 OMNIBUS INCENTIVE PLAN

STOCK OPTION AWARD AGREEMENT

These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by your company, not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments.  These materials were prepared by your company, which is solely responsible for their contents and for compliance with legal and regulatory requirements.  Fidelity is not connected with any offering or acting as an underwriter in connection with any offering of your company's securities or financial instruments.  Fidelity does not review, approve or endorse the contents of these materials and is not responsible for their content.
 


WALGREENS BOOTS ALLIANCE, INC.
 
2013 OMNIBUS INCENTIVE PLAN
 
STOCK OPTION AWARD AGREEMENT

Participant Name:  Stefano Pessina

Participant ID:  [___]

Grant Date:  February 12, 2016 (the "Grant Date")

Grant Price:  $77.08

Shares Granted:  263,273 (the "Shares Granted")

Vesting:  Three years from the Grant Date (the "Vesting Date")

Expiration Date:  February 12, 2026 (the "Expiration Date")

Acceptance Date:

Electronic Signature:

This document (referred to below as this “Agreement”) spells out the terms and conditions of the stock option (the “Option”) granted to you by Walgreens Boots Alliance, Inc., a Delaware corporation (the “Company”), pursuant to the Walgreens Boots Alliance, Inc. 2013 Omnibus Incentive Plan (the “Plan”) on and as of the Grant Date designated above.  Except as otherwise defined herein, capitalized terms used in this Agreement have the respective meanings set forth in the Plan.  For purposes of this Agreement, "Employer" means the entity (the Company or the Affiliate) that employs you on the applicable date.  The Plan, as in effect on the date of this Agreement and as it may be amended from time to time, is incorporated into this Agreement by this reference.

You and the Company agree as follows:

1.         Grant of Option.  Pursuant to the approval and direction of the Compensation Committee of the Company’s Board of Directors (the “Committee”), the Company hereby grants you an Option to purchase all or any part of the number of Shares Granted set forth above of common stock of the Company, par value US$.01 ("Stock"), at the per-share exercise price, which is 100% of the fair market value of a share of Stock on the Grant Date (the "Exercise Price"), subject to the terms and conditions of the Plan and this Agreement.  This stock option is intended to be a "non-qualified stock option" and shall not be treated as an incentive stock option within the meaning of Section 422 of the Code.

2.         Vesting/Exercise/Expiration.  The Employee may not exercise the Option prior to the Vesting Date or Dates set forth above absent action by the Committee to waive or alter such restrictions or as may be permitted under the below paragraphs.  Thereafter, except as hereinafter provided, the Employee may exercise the Option, to the extent it is vested, at any time and from time to time until the close of business on the Expiration Date set forth above.  The Option may be exercised to purchase any number of whole shares of Stock, except that no purchase shall be for less than ten (10) full shares, or the remaining unexercised shares, if less.  This Option is deemed to be "outstanding" until it has been exercised in full or expired pursuant to the terms of this Agreement.
 

3.         Disability.  If, without having fully exercised this Option, you have a Termination of Service due to Disability, then any Shares Granted under the Option that are not yet vested at that time shall thereupon become vested and (a) you may exercise this Option for the full number of Shares Granted (less any shares for which this Option was previously exercised), but (b) your right to exercise this Option shall terminate upon the earlier of the Expiration Date or a date which is one (1) year following the date of your Termination of Service.

4.         Death.  If, without having fully exercised this Option, you have a Termination of Service due to your death, then any Shares Granted under the Option that are not yet vested at that time shall be fully vested and (a) the Option may be exercised by the executor or administrator of your estate or by such person or persons who shall have acquired your rights hereunder by bequest or inheritance or by designation as your beneficiary for the full number of Shares Granted (less any shares for which this Option was previously exercised), but (b), such person’s right to exercise this Option shall terminate upon the earlier of the Expiration Date or a date which is one (1) year after the date of your death.

5.         Retirement.  If without having fully exercised this Option you have a Termination of Service by reason of retirement from the Company’s Board of Directors, as reasonably determined by the Committee, then (a) if your Termination of Service is prior to the 12-month anniversary of the Grant Date, a pro-rated number of the Shares Granted under the Option shall become vested as of the date of your Termination of Service, with the pro-rated number of Shares calculated based on your number of full months of service from the Grant Date through your Termination of Service divided by 36 months, or (b) if your Termination of Service is on or after the one-year anniversary of the Grant Date, the full number of Shares Granted under the Option shall remain or become vested as of your Termination of Service, and (c) your right to exercise any portion of the Option that is vested upon your Termination of Service due to retirement shall terminate upon the earlier of the Expiration Date or a date which is one (1) year after the date of your Termination of Service.  Shares Granted for which you cannot exercise the Option under this Section 5 shall be forfeited.

6.         Termination of Service Following a Change in Control.  If there is a Change in Control of the Company and within the one-year period thereafter you have a Termination of Service initiated by your Employer other than for Cause (as defined in Section 8), then any Shares Granted under the Option that are not yet vested at that time shall thereupon become vested and (a) you may exercise this Option for the full number of Shares Granted (less any shares for which this Option was previously exercised), but (b) your right to exercise this Option shall terminate upon the earlier of the Expiration Date or a date which is ninety (90) days after the date of your Termination of Service, subject to the right of the Committee to extend the exercise period of this Option.  Shares Granted for which you cannot exercise the Option under this Section 6 shall be forfeited.  The foregoing is also subject to the Committee’s exercise of its discretion under Section 9.01 of the Plan. For purposes of this Section 6, a Termination of Service initiated by your Employer shall include a Termination of Employment for Good Reason under - and pursuant to the terms and conditions of – the Walgreens Boots Alliance, Inc. Executive Severance and Change in Control Plan, but only to the extent applicable to you as an eligible participant in such Plan.
 


7.         Other Termination of Service.  If without having fully exercised this Option you have a voluntary or involuntary Termination of Service for any reason other than as set forth in Section 3, 4, 5 or 6 above, as determined by the Committee, then (a) for any Shares Granted with respect to which such Termination of Service is prior to the applicable Vesting Date, this Option shall be forfeited, and (b) for any Shares Granted with respect to which such Termination of Service is on or after the applicable Vesting Date, then your right to exercise this Option shall terminate upon the earlier of the Expiration Date or a date which is ninety (90) days after the date of your Termination of Service.  The foregoing is subject to the right of the Committee to extend the exercise period of this Option, including any extension granted by the Committee or its delegate as needed to allow your right to exercise to extend beyond a period during which you are restricted from exercising the Option due to a Company-designated trading blackout period, and is subject to earlier expiration as provided in Section 8 below.

8.         Forfeiture of Outstanding Options Upon Termination for Cause or Following Termination of Service.  Notwithstanding any provision of this Agreement to the contrary, your remaining right, if any, to exercise the Option shall immediately terminate if you are terminated for Cause or if and when you violate any post-employment obligation that you may have to the Company, including but not limited to any non-competition, non-solicitation, confidentiality, non-disparagement or other restrictive covenant.  For purposes of this Agreement, “Cause” means any one or more of the following, as determined by the Committee in its sole discretion:

(a)        your commission of a felony or any crime of moral turpitude;

(b)       your dishonesty or material violation of standards of integrity in the course of fulfilling your duties to the Company or any Affiliate;

(c)       your material violation of a material written policy of the Company or any Affiliate violation of which is grounds for immediate termination;

(d)       your willful and deliberate failure to perform your duties to the Company or any Affiliate in any material respect, after reasonable notice of such failure and an opportunity to correct it; or
 
(e)       your failure to comply in any material respect with the United States ("U.S.") Foreign Corrupt Practices Act, the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, the U.S. Sarbanes-Oxley Act of 2002, the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the U.S. Truth in Negotiations Act, or any rules or regulations thereunder.
 
9.         Exercise Process.  This Option may be exercised by giving notice to Fidelity, the third party administrator to administer the Option exercise process.  The exercise notice (a) shall be signed by you or (in the event of your death) your legal representative, (b) shall specify the number of full shares of Stock then elected to be purchased, and (c) shall be accompanied by payment in full of the Exercise Price of the shares to be purchased.  Payment may be made in cash or by check payable to the order of the Company, and such payment shall include any income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan that are required to be withheld ("Tax-Related Items"), as set forth in Section 10 below.  Alternatively, the Committee may allow for one or more of the following methods of exercising this Option:

(a)         Payment for shares as to which this Option is being exercised and/or payment of any Tax-Related Items may be made by transfer to the Company of shares of Stock you already own, or any combination of such shares and cash, having a fair market value determined at the time of exercise of the Option equal to, but not exceeding, the Exercise Price and/or the tax withholding obligation, as the case may be.
 
(b)       A “same day sale” transaction pursuant to which a third party (engaged by you or the Company) loans funds to you to enable you to purchase the shares of Stock and pay any Tax-Related Items, and then sells a sufficient number of the exercised shares on your behalf to enable you to repay the loan and any fees.  The remaining shares and/or cash are then delivered by the third party to you.
 

(c)       A “net exercise” transaction, pursuant to which the Company delivers to you the net number of whole shares of Stock remaining from the portion of the Option being exercised after deduction of a number of shares of Stock with a fair market value equal to the Exercise Price and a number of shares of Stock with a fair market value equal to the amount of any Tax-Related Items

As promptly as practicable after receipt of such notice of exercise and payment (including payment with respect to any Tax-Related Items), subject to Section 13 below, the Company shall cause to be issued and delivered to you (or in the event of your death to your legal representative, as the case may be), certificates for the shares of Stock so purchased.  Alternatively, such shares of Stock may be issued and held in book entry form.

Notwithstanding any provision within the Agreement to the contrary, if you are resident or employed outside of the U.S., the Committee may require that you (or in the event of your death, your legal representative, as the case may be) exercise the Option in a method other than as specified above, may require you to exercise the Option only by means of a “same day sale” transaction (either a “sell-all” transaction or a “sell-to-cover” transaction) as it shall determine in its sole discretion, or may require you to sell any shares of Stock you acquire under the Plan immediately or within a specified period following your Termination of Service (in which case, you hereby agree that the Company shall have the authority to issue sale instructions in relation to such shares of Stock on your behalf).

10.       Responsibility for Taxes; Tax Withholding.
 
(a)       You acknowledge that, regardless of any action taken by the Company or your Employer, the ultimate liability for all Tax-Related Items related to your participation in the Plan and legally applicable to you is and remains your responsibility and may exceed the amount actually withheld by the Company or your Employer.  You further acknowledge that the Company and/or your Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Option, including, but not limited to, the grant, vesting or exercise of the Option, the subsequent sale of shares of Stock acquired pursuant to such exercise and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result.  Further, if you are subject to Tax-Related Items in more than one jurisdiction between the Grant Date and the date of any relevant taxable or tax withholding event, as applicable, you acknowledge that the Company and/or your Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
 
(b)       Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or your Employer to satisfy all Tax-Related Items.  In this regard, you authorize the Company, your Employer or its agent to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following:  (i) withholding from your wages or other cash compensation paid to you by the Company and/or your Employer; (ii) withholding from proceeds of the sale of Stock acquired upon exercise of the Option either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization without further consent); or (iii) withholding from the shares of Stock to be delivered upon exercise of the Option that number of shares of Stock having a Fair Market Value equal to (but not in excess of) the minimum amount required by law to be withheld. For purposes of the foregoing, no fractional shares of Stock will be withheld or issued pursuant to the grant of the Option and the issuance of shares of Stock hereunder.
 

Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable statutory minimum withholding rates (as determined by the Company in good faith and in its sole discretion) or other applicable withholding rates, including maximum applicable rates, in which case you will receive a refund of any over-withheld amount in cash and will have no entitlement to the share equivalent.  If the obligation for Tax-Related Items is satisfied by withholding from the shares of Stock to be delivered upon exercise of the Option, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the exercised Option, notwithstanding that a number of the shares of Stock are held back solely for the purpose of paying the Tax-Related Items.

You agree to pay to the Company or your Employer any amount of Tax-Related Items that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described.  The Company may refuse to issue or deliver the shares of Stock or the proceeds from the sale of shares of Stock if you fail to comply with your obligations in connection with the Tax-Related Items.
 
11.       Limited Transferability.  You may not sell, transfer, pledge, assign or otherwise alienate or hypothecate this Option, whether voluntarily or involuntarily or by operation of law, other than by beneficiary designation effective upon your death, by will or by the laws of intestacy.  During your lifetime, this Option and all rights granted hereunder shall be exercisable only by you.  Notwithstanding the foregoing, you may transfer this Option, in whole or in part, by gift to a Permitted Transferee in accordance with rules and subject to any conditions specified by the Committee under the Plan.

12.       Rights as Stockholder.  You shall have no rights as a stockholder of the Company with respect to the shares of Stock subject to this Option until such time as the Exercise Price has been paid and a certificate of stock for such shares has been issued to you or such shares of Stock have been recorded in your name in book entry form.  Except as provided in Section 18 below, no adjustment shall be made for dividends or distributions or other rights with respect to such shares for which the record date is prior to the date on which you become the holder of record thereof.  Anything herein to the contrary notwithstanding, if a law or any regulation of the U.S. Securities and Exchange Commission or of any other body having jurisdiction shall require the Company or you to take any action before shares of Stock can be delivered to you hereunder, then the date of delivery of such shares may be delayed accordingly.

13.       Securities Laws.  If a Registration Statement under the U.S. Securities Act of 1933, as amended, is not in effect with respect to the shares of Stock to be delivered pursuant to this Agreement, you hereby represent that you are acquiring the shares of Stock for investment and with no present intention of selling or transferring them and that you will not sell or otherwise transfer the shares except in compliance with all applicable securities laws and requirements of any stock exchange on which the shares of Stock may then be listed.

14.       Not a Public Offering.  If you are resident outside the U.S., the grant of the Option is not intended to be a public offering of securities in your country of residence (or country of employment, if different).  The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and the grant of the Option is not subject to the supervision of the local securities authorities.
 


15.       Insider Trading/Market Abuse Laws.  Your country of residence may have insider trading and/or market abuse laws that may affect your ability to acquire or sell shares of Stock under the Plan during such times you are considered to have "inside information" (as defined in the laws in your country).  These laws may be the same or different from any Company insider trading policy.  You acknowledge that it is your responsibility to be informed of and compliant with such regulations, and you are advised to speak to your personal advisor on this matter.
 
16.       Repatriation; Compliance with Law; Method of Exercise.  If you are resident or employed outside the U.S., as a condition of the Option, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan in accordance with applicable foreign exchange rules and regulations in your country of residence (and country of employment, if different).  In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and its Affiliates, as may be required to allow the Company and its Affiliates to comply with local laws, rules and/or regulations in your country of residence (and country of employment, if different).  Finally, you agree to take any and all actions as may be required to comply with your personal obligations under local laws, rules and/or regulations in your country of residence and country of employment, if different).

17.       No Advice Regarding Grant.  No employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock underlying the Option.  Investment in shares of Stock involves a degree of risk.  Before deciding to purchase shares of Stock pursuant to the Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan and you should carefully review all of the materials related to the Option and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

18.       Change in Stock.  In the event of any change in Stock by reason of any stock dividend, recapitalization, reorganization, split-up, merger, consolidation, exchange of shares, or of any similar change affecting Stock, the number of shares of Stock subject to this Option and the Exercise Price shall be equitably adjusted by the Committee.

19.       Nature of the Option.  In accepting the Option, you acknowledge, understand and agree that:

(a)        the Plan is established voluntarily by the Company, it is discretionary in nature and limited induration, and it may be modified, amended, suspended or terminated by the Company, in its sole discretion, at any time;

(b)       the grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future grants of stock options, or benefits in lieu of stock options, even if stock options have been granted in the past;
 
(c)        all decisions with respect to future grants of stock options or other grants, if any, will be at the sole discretion of the Company, including, but not limited to, the form and timing of any grant, the number of shares of Stock subject to the stock options, vesting provisions, and the exercise price applicable to the stock option;

(d)       the Option and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company or any Affiliate and shall not interfere with the ability of the Company, your Employer or an Affiliate, as applicable, to terminate your employment or service relationship;
 

(e)        you are voluntarily participating in the Plan;
 
(f)        the Option and the shares of Stock subject to the Option are not intended to replace any pension rights or compensation;

(g)       the Option, the shares of Stock subject to the Option and the value of same, is an extraordinary item of compensation outside the scope of your employment (and employment contract, if any) and is not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;

(h)       the future value of the shares of Stock underlying the Option is unknown, indeterminable and cannot be predicted with certainty;

(i)         unless otherwise determined by the Committee in its sole discretion, a Termination of Service shall be effective from the date on which active employment or service ends and shall not be extended by any statutory or common law notice of termination period;

(j)         no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from a Termination of Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and in consideration of the grant of the Option to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company, your Employer or any Affiliate, waive your ability, if any, to bring any such claim, and release the Company, the Employer and all Affiliates from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim;

(k)       unless otherwise provided herein, in the Plan or by the Company in its discretion, the Option and the benefits evidenced by this Agreement do not create any entitlement to have the Option or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of Stock of the Company; and

(l)        neither the Company nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Option or of any amounts due to you pursuant to the settlement of the Option or the subsequent sale of any shares of Stock acquired upon settlement of the Option.

20.       Committee Authority; Recoupment.  It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate for the administration of the Plan and this Agreement, including the enforcement of any recoupment policy, all of which shall be binding upon you and any claimant.  Any inconsistency between this Agreement and the Plan shall be resolved in favor of the Plan.
 


21.       Consent to Collection/Processing/Transfer of Personal Data.  Pursuant to applicable personal data protection laws, the Company hereby notifies you of the following in relation to your personal data and the collection, processing and transfer of such data in relation to the Company's grant of this Option and your participation in the Plan.  The collection, processing and transfer of personal data is necessary for the Company’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of personal data may affect your participation in the Plan.  As such, you voluntarily acknowledge and consent (where required under applicable law) to the collection, use, processing and transfer of personal data as described herein:

(a)       The Company and your Employer hold certain personal information about you, including (but not limited to) your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all entitlements to shares of Stock awarded, canceled, purchased, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan ("Data").  The Data may be provided by you or collected, where lawful, from the Company, its Affiliates and/or third parties, and the Company and your Employer will process the Data for the exclusive purpose of implementing, administering and managing your participation in the Plan.  The Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations in your country of residence (or country of employment, if different).  Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought.  Data will be accessible within the organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and for the participation in the Plan.

(b)       The Company and your Employer will transfer Data internally as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and/or your Employer may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Plan.  These recipients may be located in the European Economic Area, or elsewhere throughout the world, such as the United States.  You hereby authorize (where required under applicable law) the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, as may be required for the administration of the Plan and/or the subsequent holding of the shares of Stock on your behalf, to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.
 
(c)       You may, at any time, exercise your rights provided under applicable personal data protection laws, which may include the right to (i) obtain confirmation as to the existence of the Data, (ii) verify the content, origin and accuracy of the Data, (iii) request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of the Data, (iv) oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and/or operation of the Plan and your participation in the Plan, and (v) withdraw your consent to the collection, processing or transfer of Data as provided hereunder (in which case, your Option will become null and void).  You may seek to exercise these rights by contacting your Human Resources manager or the Company's Human Resources Department, who may direct the matter to the applicable Company privacy official.
 

22.       Non-Competition, Non-Solicitation and Confidentiality.  As a condition to the receipt of this Option, you must agree to the Non-Competition, Non-Solicitation and Confidentiality Agreement attached hereto as Exhibit A by executing that Agreement.  Failure to execute and return the Non-Competition, Non-Solicitation and Confidentiality Agreement within 120 days of the Grant Date shall constitute your decision to decline to accept this Award.

23.       Addendum to Agreement.  Notwithstanding any provision of this Agreement to the contrary, the Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as set forth in the addendum to the Agreement, attached hereto as Exhibit B (the “Addendum”).  Further, if you transfer your residence and/or employment to another country reflected in the Addendum, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Option and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  The Addendum shall constitute part of this Agreement.

24.       Additional Requirements.  The Company reserves the right to impose other requirements on the Option, any shares of Stock acquired pursuant to the Option and your participation in the Plan to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Option and the Plan.  Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

25.        Amendment or Modification, Waiver.  Except as set forth in the Plan, no provision of this Agreement may be amended or waived unless the amendment or waiver is agreed to in writing, signed by you and by a duly authorized officer of the Company. No waiver of any condition or provision of this Agreement shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time.

26.       Electronic Delivery.  The Company may, in its sole discretion, deliver by electronic means any documents related to the Option or your future participation in the Plan.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

27.       Governing Law and Jurisdiction.  This Agreement is governed by the substantive and procedural laws of the state of Illinois.  You and the Company shall submit to the exclusive jurisdiction of, and venue in, the courts in Illinois in any dispute relating to this Agreement without regard to any choice or law rules thereof which might apply the laws of any other jurisdiction.

28.       English Language.  If you are resident in a country where English is not an official language, you acknowledge and agree that it is your express intent that this Agreement, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Option, be drawn up in English.  If you have received this Agreement, the Plan or any other documents related to the Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.
 


29.       Conformity with Applicable Law.  If any provision of this Agreement is determined to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision of this Agreement or the validity, legality or enforceability of such provision in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

30.       Successors.  This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall, upon your death, acquire any rights hereunder.

****
This Agreement contains highly sensitive and confidential information.  Please handle it accordingly.

Please read the attached Exhibits A and B. Once you have read and understood this Agreement and Exhibits A and B, please click the acceptance box to certify and confirm your agreement to be bound by the terms and conditions of this Agreement and Exhibits A and B, and to acknowledge your receipt of the Prospectus, the Plan and this Agreement and your acceptance of the terms and conditions of the Option granted hereunder.
 

EXHIBIT A

WALGREENS BOOTS ALLIANCE, INC. NON-COMPETITION, NON-SOLICITATION AND CONFIDENTIALITY AGREEMENT

This Exhibit forms a part of the Stock Option Award Agreement covering Options awarded to an employee of Walgreens Boots Alliance, Inc., on behalf of itself, its affiliates, subsidiaries, and successors (collectively referred to as “Employee” and the “Company”).

WHEREAS, the Company develops and/or uses valuable business, technical, proprietary, customer and patient information it protects by limiting its disclosure and by keeping it secret or confidential;

WHEREAS, Employee acknowledges that during the course of employment, he or she has or will receive, contribute, or develop such confidential information; and

WHEREAS, the Company desires to protect from its competitors such confidential information and also desires to protect its legitimate business interests and goodwill in maintaining its employee and customer relationships.

NOW THEREFORE, in consideration of the Stock Option issued to Employee pursuant the Agreement to which this is attached as Exhibit A, Employee agrees to be bound by the terms of this Agreement:

1.        Confidentiality.  At all times during and after the termination of my employment with the Company, I will not, without the Company’s prior written permission, directly or indirectly for any purpose other than performance of my duties for the Company, utilize or disclose to anyone outside of the Company any confidential information, of the Company or any information received by the Company in confidence from or about third parties, as long as such matters remain trade secrets or confidential.  Trade secrets and other confidential information shall include any information or material which is not generally known to the public, and which (a) is generated or collected by or utilized in the operations of the Company and relates to the actual or anticipated business of the Company or the Company’s actual or prospective vendors or clients; or (b) is suggested by or results from any task assigned to me by the Company or work performed by me for or on behalf of the Company or any client of the Company.  Confidential information shall not be considered generally known to the public if revealed improperly to the public by me or others without the Company’s express written consent and/or in violation of an obligation of confidentiality to the Company.   Examples of confidential information include, but are not limited to, customer and supplier identification and contacts, confidential information about customers, business relationships, contract provisions, pricing, margins, business plans, marketing plans, identities of contractors and terms of payment, identities of customer referral sources, financial data, business and customer strategy, techniques, formulations, technical know-how, formulae, research, development and production information, processes, designs, architecture, prototypes, models, software, solutions, discussion guides, personal or performance information about employees, research and development, patent applications and plans, projections, proposals or legal advice related to the foregoing. The restrictions set forth in this paragraph are in addition to and not in lieu of any obligations I have by law with respect to the Company’s confidential information, including any obligations I may owe under the Trade Secrets Act of any state or similar statutes.  Further, the confidentiality obligations herein shall not prevent me from revealing evidence of criminal wrongdoing to law enforcement or prohibit me from divulging confidential information or trade secrets by order of court or agency of competent jurisdiction or as required by law; however, I shall promptly inform the Company of any such situations and shall take reasonable steps to prevent disclosure of confidential information or trade secrets until the Company has been informed of such required disclosure and has had a reasonable opportunity to seek a protective order.
 

2.        Non-Competition.  I agree that during my employment with the Company and for one year after the termination of my employment, I will not, directly or indirectly, invest in, own, operate, finance, control, or provide Competing Services to any Competing Business Line, in both cases as defined below.  I understand that the restrictions in this paragraph apply no matter whether my employment is terminated by me or the Company and no matter whether that termination is voluntary or involuntary.  The above restrictions shall not apply to passive investments of less than 5% ownership interest in any entity. I understand that the term “Competing Business Line” used in this Agreement means any business that is in competition with any business engaged in by the Company with respect to which I provide substantial services during the last two years of my employment with the Company.
I understand that I will be deemed to be providing “Competing Services” if the nature of such services are sufficiently similar in position scope and geographic scope to any position held by me during the last two years of my employment with the Company, such that my engaging in such services on behalf of a Competing Business Line may pose competitive harm to the Company.

3.        Non-Solicitation.  I agree that during my employment with the Company and for two years after the termination of my employment from the Company for any reason, whether voluntary or involuntary:

(a)
I will not directly or indirectly, solicit any Restricted Customer for purposes of providing Competing Products or Services, or offer, provide or sell Competing Products or Services to any Restricted Customer.  For purposes of this Agreement, “Competing Products or Services” means products or services that are competitive with products or services offered by, developed by, designed by or distributed by the Company to any Restricted Customer, and “Restricted Customer” means any person, company or entity which was a customer, potential customer or referral source of the Company and with which I had direct contact or about which I learned confidential information at any time during the last two years of my employment with the Company; and
 
(b)
I will not, nor will I assist any third party to, directly or indirectly (i) raid, hire, solicit, or attempt to persuade any employee of the Company or any person who was an employee of the Company during the 6 months preceding the termination of my employment with the Company,  who possesses or had access to confidential information of the Company, to leave the employ of the Company; (ii) interfere with the performance by any such persons of their duties for the Company; or (iii) communicate with any such persons for the purposes described in items (i) and (ii) in this paragraph.

4.         Non-Inducement.  I will not directly or indirectly assist or encourage any person or entity in carrying out or conducting any activity that would be prohibited by this Agreement if such activity were carried out or conducted by me.

5.         Non-Disparagement.  I agree (whether or not I am then an Employee) not to make negative comments or otherwise disparage the Company, its Affiliates, or any of their officers, directors, employees, shareholders, members, agents or products other than in the good faith performance of my duties to the Company and its Affiliates while I am employed by the Company and its Affiliates and thereafter.  The foregoing shall not be violated by truthful statements in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings).
 

6.          Intellectual Property.  The term "Intellectual Property" shall mean all trade secrets, ideas, inventions, designs, developments, devices, software, computer programs, methods and processes (whether or not patented or patentable, reduced to practice or included in the Confidential Information) and all patents and patent applications related thereto, all copyrights, copyrightable works and mask works (whether or not included in the Confidential Information) and all registrations and  applications for registration related thereto, all Confidential Information, and all other proprietary rights contributed to, or conceived or created by, or reduced to practice by Employee or anyone acting on its behalf (whether alone or jointly with others) at any time from the beginning of Employee’s employment with Walgreens Boots Alliance, Inc. to the termination of that employment plus ninety (90) days (i) relate to the business or to the actual or anticipated research or development of Walgreens Boots Alliance, Inc.; (ii) result from any services that Employee or anyone acting on its behalf perform for Walgreens; or (iii) are created using the equipment, supplies or facilities of Walgreens Boots Alliance, Inc. or any Confidential Information.

a.
Ownership.  All Intellectual Property is, shall be and shall remain the exclusive property of the Company.  Employee hereby assigns to the Company all right, title and interest, if any, in and to the Intellectual Property; provided, however, that, when applicable, the Company shall own the copyrights in all copyrightable works included in the Intellectual Property pursuant to the "work-made-for-hire" doctrine (rather than by assignment), as such term is defined in the 1976 Copyright Act.  All Intellectual Property shall be owned by the Company irrespective of any copyright notices or confidentiality legends to the contrary which may be placed on such works by Employee or by others.  Employee shall ensure that all copyright notices and confidentiality legends on all work product authored by Employee or anyone acting on its behalf shall conform to the Company's practices and shall specify the Company as the owner of the work.  The Company hereby provides notice to Employee that the obligation to assign does not apply to an invention for which no equipment, supplies, facility, or trade secret information of the Company was used and which was developed entirely on the Employee's own time, unless (a) the invention relates (i) to the business of the Company, or (ii) to the Company’s actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by Employee for the Company.

b.
Keep Records.  Employee shall keep and maintain, or cause to be kept and maintained by anyone acting on its behalf, adequate and current written records of all Intellectual Property in the form of notes, sketches, drawings, computer files, reports or other documents relating thereto.  Such records shall be and shall remain the exclusive property of the Company and shall be available to the Company at all times during the term of this Agreement.

c.
Assistance. Employee shall supply all assistance requested in securing for Company’s benefit any patent, copyright, trademark, service mark, license, right or other evidence of ownership of any such Intellectual Property, and will provide full information regarding any such item and execute all appropriate documentation prepared by Company in applying or otherwise registering, in Company’s name, all rights to any such item or the defense and protection of such Intellectual Property.


d. Prior Inventions.  I have disclosed to the Company any continuing obligations to any third party with respect to Intellectual Property.  I claim no rights to any inventions created prior to my employment for which a patent application has not previously been filed, unless I have described them in detail on a schedule attached to this Agreement.

7.          Return of Company Property.  I agree that I will not take any of the Company’s property or information with me when I leave the Company’s employ, no matter what form that property or information is in and no matter how I acquired it.  When my employment with the Company terminates, I will immediately return to the Company any and all Company information, documents, and electronics.

8.          Consideration and Acknowledgments.  I acknowledge and agree that the covenants described in this Agreement are essential terms, and the underlying Stock Option Award would not be provided by the Company in the absence of these covenants.  I further acknowledges that these covenants are supported by adequate consideration as set forth in this Agreement, that full compliance with these covenants will not prevent me from earning a livelihood following the termination of my employment, and that these covenants do not place undue restraint on me and are not in conflict with any public interest.  I further acknowledge and agree that I fully understand these covenants, have had full and complete opportunity to discuss and resolve any ambiguities or uncertainties regarding these covenants before signing this Agreement, and have voluntarily agreed to comply with these covenants for their stated terms.  I further acknowledge and agree that these covenants are reasonable and enforceable in all respects.  I agree that in the event I am offered employment with a Competing Business at any time in the future, I shall immediately notify the Competing Business of the existence of the covenants set forth above.

9.         Enforceability; General Provisions.

(a)
I agree that the restrictions contained in this Agreement are reasonable and necessary to protect the Company’s legitimate business interests and that full compliance with the terms of this Agreement will not prevent me from earning a livelihood following the termination of my employment, and that these covenants do not place undue restraint on me.

(b)
Because the Company’s current base of operations is in Illinois, I consent to the jurisdiction of the state and federal courts of Illinois with respect to any claim arising out of this Agreement.
 
(c)
Because the Company’s current base of operations is in Illinois, I agree that this Agreement shall be governed by the laws of Illinois without regard to its choice of law rules.

(d)
In the event of a breach or a threatened breach of this Agreement, I acknowledge that the Company will face irreparable injury which may be difficult to calculate in dollar terms and that the Company shall be entitled, in addition to all remedies otherwise available in law or in equity, to temporary restraining orders and preliminary and final injunctions enjoining such breach or threatened breach in any court of competent jurisdiction without the necessity of posting a surety bond, as well as to obtain an equitable accounting of all profits or benefits arising out of any violation of this Agreement.
 

(e)
I agree that if a court determines that any of the provisions in this Agreement is unenforceable or unreasonable in duration, territory, or scope, then that court shall modify those provisions so they are reasonable and enforceable, and enforce those provisions as modified.

(f)
If any phrase or provision of this Agreement is declared invalid or unenforceable by a court of competent jurisdiction, that phrase, clause or provision shall be deemed severed from this Agreement, and will not affect the enforceability of any other provisions of this Agreement, which shall otherwise remain in full force and effect.

(g)
Notwithstanding the foregoing provisions of this Agreement, the non-competition provisions of Paragraph 2 above shall not restrict Employee from performing legal services as a licensed attorney for a Competing Business to the extent that the attorney licensure requirements in the applicable jurisdiction do not permit Employee to agree to the otherwise applicable restrictions of Paragraph 2.

(h)
Waiver of any of the provisions of this Agreement by the Company in any particular instance shall not be deemed to be a waiver of any provision in any other instance and/or of the Company’s other rights at law or under this Agreement.
 
(i)
I agree that the Company may assign this Agreement to its successors and that any such successor may stand in the Company’s shoes for purposes of enforcing this Agreement.

(j)
I agree to reimburse Company for all attorneys’ fees, costs, and expenses that it reasonably incurs in connection with enforcing its rights and remedies under this Agreement, but only to the extent the Company is ultimately the prevailing party in the applicable legal proceedings.

(k)
If I violate this Agreement, then the restrictions set out in Paragraphs 2 - 6 shall be extended by the same period of time as the period of time during which the violation(s) occurred.

(l)
I fully understand my obligations in this Agreement, have had full and complete opportunity to discuss and resolve any ambiguities or uncertainties regarding these covenants before signing this Agreement, and have voluntarily agreed to comply with these covenants for their stated terms.
 
10.      Relationship of Parties.  I acknowledge that my relationship with the Company is “terminable at will” by either party and that the Company or I can terminate the relationship with or without cause and without following any specific procedures.  Nothing contained in this Agreement is intended to or shall be relied upon to alter the “terminable at will” relationship between the parties.

11.       Modifications and Other Agreements.  I agree that the terms of this Agreement may not be modified except by a written agreement signed by both me and the Company.  This Agreement shall not supersede any other restrictive covenants to which I may be subject under an employment contract, benefit program or otherwise, such that the Company may enforce the terms of any and all restrictive covenants to which I am subject.
 

12.       Notification.  I agree that in the event I am offered employment at any time in the future with any entity that may be considered a Competing Business Line, I shall immediately notify such Competing business of the existence and terms of this Agreement.  I also understand and agree that the Company may notify anyone later employing me of the existence and provisions of this Agreement.

***                    ***                    ***                    ***                    ***
 
By clicking the acceptance box for this grant agreement, I acknowledge receipt of the Stock Option Award Agreement to which this Agreement is attached as Exhibit A, and I agree to the terms and conditions expressed in this Agreement.
 

EXHIBIT B

ADDENDUM TO THE
WALGREENS BOOTS ALLIANCE, INC. 2013 OMNIBUS INCENTIVE PLAN
STOCK OPTION AWARD AGREEMENT

In addition to the terms of the Plan and the Agreement, the Option is subject to the following additional terms and conditions to the extent you reside and/or are employed in one of the countries addressed herein.  Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in this Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Option and the Plan (or the Company may establish alternative terms as may be necessary or advisable to accommodate your transfer).  All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.

CHILE

Private Placement.  The following provision shall replace Section 14 of the Agreement:

The grant of the Option hereunder is not intended to be a public offering of securities in Chile but instead is intended to be a private placement.

a)
The starting date of the offer will be the Grant Date, and this offer conforms to general ruling no. 336 of the Chilean superintendence of securities and insurance;
b)
The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean superintendence of securities and insurance, and therefore such securities are not subject to its oversight;
c)
The issuer is not obligated to provide public information in Chile regarding the foreign securities, since such securities are not registered with the Chilean superintendence of securities and insurance; and
d)
The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.
 
a)
La fecha de inicio de la oferta será el de la fecha de otorgamiento y esta oferta se acoge a la norma de carácter general n° 336 de la superintendencia de valores y seguros chilena;
b)
La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva la superintendencia de valores y seguros chilena, por lo que tales valores no están sujetos a la fiscalización de ésta;
c)
Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información pública respecto de esos valores; y
d) Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores correspondiente.

FRANCE

1.          Nature of Grant.  The Option is not granted under the French specific regime provided by Articles L.225-177 and seq. of the French commercial code.
 

2.          Use of English Language.  You acknowledge that it is your express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  Vous reconnaissez avoir expressément exigé la rédaction en anglais de la présente Convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou indirectement, relatifs à, ou suite à, la présente Convention.

HONG KONG

1.          Sale of Shares of Stock.  Shares of Stock purchased upon exercise of the Option are accepted as a personal investment.  In the event that shares of Stock are issued in respect of the Option within six (6) months after the Grant Date, you agree that the shares of Stock may not be offered to the public or otherwise disposed of prior to the six-month anniversary of the Grant Date.

2.          IMPORTANT NOTICE.  WARNING: The contents of the Agreement the Addendum, the Plan, the Plan prospectus, the Plan administrative rules and all other materials pertaining to the Option and/or the Plan have not been reviewed by any regulatory authority in Hong Kong.  You are hereby advised to exercise caution in relation to the offer thereunder.  If you have any doubts about any of the contents of the aforesaid materials, you should obtain independent professional advice.

3.          Wages.  The Option and shares of Stock subject to the Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

ITALY

Mandatory Same Day, Sell-All Exercise.  Notwithstanding any provision in the Agreement or the Plan to the contrary, as permitted under Section 9 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Option shall be limited to mandatory same day, sell-all exercise.

MEXICO

1.          Commercial Relationship.  You expressly recognize that your participation in the Plan and the Company’s grant of the Option does not constitute an employment relationship between you and the Company.  You have been granted the Option as a consequence of the commercial relationship between the Company and the Affiliate in Mexico that employs you, and the Company’s Affiliate in Mexico is your sole employer.  Based on the foregoing, you expressly recognize that (a) the Plan and the benefits you may derive from your participation in the Plan do not establish any rights between you and the Company’s Affiliate in Mexico that employs you, (b) the Plan and the benefits you may derive from your participation in the Plan are not part of the employment conditions and/or benefits provided by the Company’s Affiliate in Mexico that employs you, and (c) any modifications or amendments of the Plan by the Company, or a termination of the Plan by the Company, shall not constitute a change or impairment of the terms and conditions of your employment with the Company’s Affiliate in Mexico that employs you.
 
2.          Extraordinary Item of Compensation.  You expressly recognize and acknowledge that your participation in the Plan is a result of the discretionary and unilateral decision of the Company, as well as your free and voluntary decision to participate in the Plan in accordance with the terms and conditions of the Plan, the Agreement and this Addendum.  As such, you acknowledge and agree that the Company, in its sole discretion, may amend and/or discontinue your participation in the Plan at any time and without any liability.  The Option, the shares of Stock subject to the Option and the value of same is an extraordinary item of compensation outside the scope of your employment contract, if any, and is not part of your regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of the Company’s Affiliate in Mexico that employs you.
 

MONACO

Use of English Language.  You acknowledge that it is your express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  Vous reconnaissez avoir expressément exigé la rédaction en anglais de la présente Convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou indirectement, relatifs à, ou suite à, la présente Convention.

NETHERLANDS

Exclusion of Claim.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Option, whether or not as a result of your Termination of Service (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Option.  Upon the grant of the Option, you shall be deemed irrevocably to have waived any such entitlement.

ROMANIA

Voluntary Termination of Service.  For the sake of clarity, a voluntary Termination of Service shall include the situation where your employment contract is terminated by operation of law on the date you reach the standard retirement age and have completed the minimum contribution record for receipt of state retirement pension or the relevant authorities award you an early-retirement pension of any type.

RUSSIA

1.          No Offering of Securities in Russia.  The grant of the Option is not intended to be an offering of securities within the territory of the Russian Federation, and you acknowledge and agree that you will be unable to make any subsequent sale of the shares of Stock acquired pursuant to the Option in the Russian Federation.

2.          Cash Payments to a Russian Bank Account.  If you are a Russian citizen, any sale proceeds resulting from the sale of shares of Stock acquired upon exercise of the Option may be delivered only to a bank account that you maintain with an authorized bank in Russia.

SPAIN

1.         Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement:
 
In accepting the Award, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.
 


You understand that the Company has unilaterally, gratuitously and in its sole discretion granted the Option under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis.  Consequently, you understand that the Option is granted on the assumption and condition that the Option and the shares of Stock acquired upon exercise of the Option shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Option shall be null and void.

Further, you understand and agree that the vesting of the Option is expressly conditioned on your continued and active rendering of service, such that upon a Termination of Service, the Option may cease vesting immediately, in whole or in part, effective on the date of your Termination of Service (unless otherwise specifically provided in Section 3, 4, 5 or 6 of the Agreement). This will be the case, for example, even if (a) you are considered to be unfairly dismissed without good cause; (b) you are dismissed for disciplinary or objective reasons or due to a collective dismissal; (c) you terminate service due to a change of work location, duties or any other employment or contractual condition, (d) you terminate service due to a unilateral breach of contract by the Company or an Affiliate.  Consequently, upon a Termination of Service for any of the above reasons, you may automatically lose any rights to the Option that were not vested on the date of your Termination of Service, as described in the Plan and Agreement.  In addition, you understand and agree that the post-Termination of Service exercise period specified in the Agreement shall run from the date of your Termination of Service, as determined by the Committee, in its sole discretion.

You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a Termination of Service on your Option.

2.         Termination for Cause.  “Cause” shall be defined as indicated in Section 8 of the Agreement, irrespective of whether the termination is or is not considered a fair termination (i.e., “despido procedente”) under Spanish legislation.

UNITED KINGDOM

1.         Responsibility for Taxes; Tax Withholding.  The following provision supplements Section 10 of the Agreement:

If payment or withholding of the income tax due in connection with the Option is not made within ninety (90) days after the end of the U.K. tax year in which the event giving rise to the income tax liability occurred or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003 (the “Due Date”), the amount of any uncollected income tax shall constitute a loan owed by you to your Employer, effective as of the Due Date.  You agree that the loan will bear interest at the then-current official rate of Her Majesty’s Revenue & Customs (“HMRC”), it shall be immediately due and repayable, and the Company or Employer may recover it at any time thereafter by any of the means referred to in Section 10 of the Agreement.  Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), will not be eligible for a loan to cover the income tax liability.  In the event that you are a director or executive officer and the income tax is not collected from or paid by you by the Due Date, the amount of any uncollected income tax may constitute a benefit to you on which additional income tax and national insurance contributions (“NICs”) will be payable.  You will be responsible for paying and reporting any income tax due on this additional benefit directly to HMRC under the self-assessment regime, and for reimbursing the Company or your Employer (as applicable) the value of any employee NICs due on this additional benefit.
 

2.         Exclusion of Claim.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Option, whether or not as a result of your Termination of Service (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Option.  Upon the grant of the Option, you shall be deemed irrevocably to have waived any such entitlement.

***                    ***                    ***                    ***                    ***
 
By clicking the acceptance box for this grant agreement, I acknowledge receipt of the Stock Option Award Agreement to which this Addendum is attached as Exhibit B, and I agree to the terms and conditions expressed in this Addendum.
 
 

EX-10.3 4 ex10_3.htm EXHIBIT 10.3

Exhibit 10.3
 
WALGREENS BOOTS ALLIANCE, INC.

2013 OMNIBUS INCENTIVE PLAN

RESTRICTED STOCK UNIT AWARD AGREEMENT

These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by Walgreens Boots Alliance, Inc., not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments.  These materials were prepared by Walgreens Boots Alliance, Inc., which is solely responsible for their contents and for compliance with legal and regulatory requirements.  Fidelity is not connected with any offering or acting as an underwriter in connection with any offering of securities or financial instruments of Walgreens Boots Alliance, Inc.  Fidelity does not review, approve or endorse the contents of these materials and is not responsible for their content.
 

WALGREENS BOOTS ALLIANCE, INC.

2013 OMNIBUS INCENTIVE PLAN

RESTRICTED STOCK UNIT AWARD AGREEMENT

Participant Name:  James A. Skinner

Participant ID:  [____]

Grant Date:  February 12, 2016 (the "Grant Date")

Units Granted:  77,841

Vesting:  Three years from Grant Date (the "Vesting Date")

Acceptance Date:

Electronic Signature:
 
This document (referred to below as this “Agreement”) spells out the terms and conditions of the Restricted Stock Unit Award (the “Award”) granted to you by Walgreens Boots Alliance, Inc., a Delaware corporation (the “Company”), pursuant to the Walgreens Boots Alliance, Inc. 2013 Omnibus Incentive Plan (the “Plan”) on and as of the Grant Date designated above.  Except as otherwise defined herein, capitalized terms used in this Agreement have the respective meanings set forth in the Plan.  For purposes of this Agreement, "Employer" means the entity (the Company or the Affiliate) that employs you on the applicable date.  The Plan, as it may be amended from time to time, is incorporated into this Agreement by this reference.
 
You and the Company agree as follows:

1.            Grant of Restricted Stock Units.  Pursuant to the approval and direction of the Compensation Committee of the Company’s Board of Directors (the “Committee”), the Company hereby grants you the number of Restricted Stock Units specified above (the “Restricted Stock Units”), subject to the terms and conditions of the Plan and this Agreement.

2.            Restricted Stock Unit Account and Dividend Equivalents.  The Company will maintain an account (the “Account”) on its books in your name to reflect the number of Restricted Stock Units awarded to you as well as any additional Restricted Stock Units credited as a result of Dividend Equivalents.  The Account will be administered as follows:

 
(a)          The Account is for recordkeeping purposes only, and no assets or other amounts shall be set aside from the Company’s general assets with respect to such Account.

(b)          As of each record date with respect to which a cash dividend is to be paid with respect to shares of Company common stock par value US$.01 per share (“Stock”), the Company will credit your Account with an equivalent amount of Restricted Stock Units determined by dividing the value of the cash dividend that would have been paid on your Restricted Stock Units if they had been shares of Stock, divided by the value of Stock on such date.

(c)          If dividends are paid in the form of shares of Stock rather than cash, then your Account will be credited with one additional Restricted Stock Unit for each share of Stock that would have been received as a dividend had your outstanding Restricted Stock Units been shares of Stock.
 
1

(d)          Additional Restricted Stock Units credited via Dividend Equivalents shall vest or be forfeited at the same time as the Restricted Stock Units to which they relate.

3.            Restricted Period.  The period prior to the vesting date with respect each Restricted Stock Unit is referred to as the “Restricted Period.”  Subject to the provisions of the Plan and this Agreement, unless vested or forfeited earlier as described in Section 4, 5, 6 or 7 of this Agreement, as applicable, your Restricted Stock Units will become vested and be settled as described in Section 8 below, as of the vesting date or dates indicated in the introduction to this Agreement, provided the performance goal in this Section 3 (“Performance Goal”) is satisfied as of the end of the applicable performance period.  The Performance Goal will be established and certified by the Committee and cover one or more Company performance goals over the course of the second half of the Company’s 2016 fiscal year.  If the Performance Goal is not attained as of the end of this performance period, the Restricted Stock Units awarded hereunder shall be thereupon forfeited.

4.            Disability or Death.  If during the Restricted Period you have a Termination of Service by reason of Disability or death, then the Restricted Stock Units will become fully vested as of the date of your Termination of Service and the Vesting Date shall become the date of your Termination of Service.  Any Restricted Stock Units becoming vested by reason of your Termination of Service by reason of Disability or death shall be settled as provided in Section 8.

5.            Retirement.  If prior to the end of the first 12 months of the Restricted Period you have a Termination of Service by reason of retirement from the Company’s Board of Directors, as reasonably determined by the Committee, then, subject to satisfaction of the Performance Goal, the Restricted Stock Units will become vested on a prorated basis as of the later of the end of the performance period for the Performance Goal and the date of your Termination of Service, with such pro-ration based on the number of full months of service completed during the Restricted Period, divided by 36 months.  If on or after the end of the first 12 months of the Restricted Period you have a Termination of Service by reason of retirement from the Company’s Board of Directors, as reasonably determined by the Committee, then, subject to satisfaction of the Performance Goal, the Restricted Stock Units will become fully vested as of the date of your Termination of Service.  Any Restricted Stock Units becoming vested by reason of your retirement shall be settled as provided in Section 8.

6.            Termination of Service Following a Change in Control.  If during the Restricted Period there is a Change in Control of the Company and within the one-year period thereafter you have a Termination of Service initiated by your Employer other than for Cause (as defined in Section 7), then your Restricted Stock Units shall become fully vested, and they shall be settled in accordance with Section 9.  For purposes of this Section 6, a Termination of Service initiated by your Employer shall include a Termination of Employment for Good Reason under - and pursuant to the terms and conditions of – the Walgreens Boots Alliance, Inc. Executive Severance and Change in Control Plan, but only to the extent applicable to you as an eligible participant in such Plan.

7.            Other Termination of Service.  If during the Restricted Period you have a voluntary or involuntary Termination of Service for any reason other than as set forth in Section 4, 5 or 6 above or Section 9 below, as determined by the Committee, then you shall thereupon forfeit any Restricted Stock Units that are still in a Restricted Period on your termination date.  For purposes of this Agreement, “Cause” means any one or more of the following, as determined by the Committee in its sole discretion:
 
2

(a)          your commission of a felony or any crime of moral turpitude;

(b)          your dishonesty or material violation of standards of integrity in the course of fulfilling your duties to the Company or any Affiliate;

(c)          your material violation of a material written policy of the Company or any Affiliate violation of which is grounds for immediate termination;

(d)          your willful and deliberate failure to perform your duties to the Company or any Affiliate in any material respect, after reasonable notice of such failure and an opportunity to correct it; or

(e)          your failure to comply in any material respect with the United States (“U.S.”) Foreign Corrupt Practices Act, the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, the U.S. Sarbanes-Oxley Act of 2002, the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the U.S. Truth in Negotiations Act, or any rules or regulations thereunder.

8.            Settlement of Vested Restricted Stock Units.  Subject to the requirements of Section 13 below, as promptly as practicable after the applicable Vesting Date, whether occurring upon your Separation from Service or otherwise, but in no event later than 75 days after the Vesting Date, the Company shall transfer to you one share of Stock for each Restricted Stock Unit becoming vested at such time, net of any applicable tax withholding requirements in accordance with Section 10 below; provided, however, that, if you are a Specified Employee at the time of Separation from Service, then to the extent your Restricted Stock Units are deferred compensation subject to Section 409A of the Code, settlement of which is triggered by your Separation from Service (other than for death), payment shall not be made until the date which is six months after your Separation from Service.

Notwithstanding the foregoing, if you are resident or employed outside of the U.S., the Company, in its sole discretion, may provide for the settlement of the Restricted Stock Units in the form of:

(a)          a cash payment (in an amount equal to the Fair Market Value of the Stock that corresponds with the number of vested Restricted Stock Units) to the extent that settlement in shares of Stock (i) is prohibited under local law, (ii) would require you, the Company or an Affiliate to obtain the approval of any governmental or regulatory body in your country of residence (or country of employment, if different), (iii) would result in adverse tax consequences for you, the Company or an Affiliate or (iv) is administratively burdensome; or

(b)          shares of Stock, but require you to sell such shares of Stock immediately or within a specified period following your Termination of Service (in which case, you hereby agree that the Company shall have the authority to issue sale instructions in relation to such shares of Stock on your behalf).

9.            Settlement Following Change in Control.  Notwithstanding any provision of this Agreement to the contrary, the Company may, in its sole discretion, fulfill its obligation with respect to all or any portion of the Restricted Stock Units that become vested in accordance with Section 6 above, by:
 
3

(a)          delivery of (i) the number of shares of Stock that corresponds with the number of Restricted Stock Units that have become vested or (ii) such other ownership interest as such shares of Stock that correspond with the vested Restricted Stock Units may be converted into by virtue of the Change in Control transaction;

(b)          payment of cash in an amount equal to the Fair Market Value of the Stock that corresponds with the number of vested Restricted Stock Units at that time; or

(c)          delivery of any combination of shares of Stock (or other converted ownership interest) and cash having an aggregate Fair Market Value equal to the Fair Market Value of the Stock that corresponds with the number of Restricted Stock Units that have become vested at that time.

Settlement shall be made as soon as practical after the Restricted Stock Units become fully vested under Section 6, but in no event later than 30 days after such date.

10.          Responsibility for Taxes; Tax Withholding.

(a)          You acknowledge that, regardless of any action taken by the Company or your Employer, the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you ("Tax-Related Items"), is and remains your responsibility and may exceed the amount actually withheld by the Company or your Employer.  You further acknowledge that the Company and/or your Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including, but not limited to, the grant, vesting or settlement of the Award, the subsequent sale of shares of Stock acquired pursuant to such settlement and the receipt of any Dividend Equivalents and/or dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result.  Further, if you are subject to Tax-Related Items in more than one jurisdiction between the Grant Date and the date of any relevant taxable or tax withholding event, as applicable, you acknowledge that the Company and/or your Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

(b)          Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or your Employer to satisfy all Tax-Related Items.  In this regard, you authorize the Company, your Employer or its agent to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following:  (i) withholding from your wages or other cash compensation paid to you by the Company and/or your Employer; (ii) withholding from proceeds of the sale of shares of Stock acquired upon settlement of the Award either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization without further consent); or (iii) withholding from the shares of Stock to be delivered upon settlement of the Award that number of shares of Stock having a Fair Market Value equal to (but not in excess of) the minimum amount required by law to be withheld.
 
4

Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable statutory minimum withholding rates (as determined by the Company in good faith and in its sole discretion) or other applicable withholding rates, including maximum applicable rates, in which case you will receive a refund of any over-withheld amount in cash and will have no entitlement to the share equivalent.  If the obligation for Tax-Related Items is satisfied by withholding from the shares of Stock to be delivered upon settlement of the Award, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the vested Award, notwithstanding that a number of the shares of Stock are held back solely for the purpose of paying the Tax-Related Items.

You agree to pay to the Company or your Employer any amount of Tax-Related Items that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described.  The Company may refuse to issue or deliver the shares of Stock (or cash payment) or the proceeds from the sale of shares of Stock if you fail to comply with your obligations in connection with the Tax-Related Items.

11.          Nontransferability.  During the Restricted Period and thereafter until Stock is transferred to you in settlement thereof, you may not sell, transfer, pledge, assign or otherwise alienate or hypothecate the Restricted Stock Units whether voluntarily or involuntarily or by operation of law, other than by beneficiary designation effective upon your death, or by will or by the laws of intestacy.

12.          Rights as Shareholder.  You shall have no rights as a shareholder of the Company with respect to the Restricted Stock Units until such time as a certificate of stock for the Stock issued in settlement of such Restricted Stock Units has been issued to you or such shares of Stock have been recorded in your name in book entry form. Until that time, you shall not have any voting rights with respect to the Restricted Stock Units.  Except as provided in Section 9 above, no adjustment shall be made for dividends or distributions or other rights with respect to such shares for which the record date is prior to the date on which you become the holder of record thereof.  Anything herein to the contrary notwithstanding, if a law or any regulation of the U.S. Securities and Exchange Commission or of any other body having jurisdiction shall require the Company or you to take any action before shares of Stock can be delivered to you hereunder, then the date of delivery of such shares may be delayed accordingly.

13.          Securities Laws.  If a Registration Statement under the U.S. Securities Act of 1933, as amended, is not in effect with respect to the shares of Stock to be delivered pursuant to this Agreement, you hereby represent that you are acquiring the shares of Stock for investment and with no present intention of selling or transferring them and that you will not sell or otherwise transfer the shares except in compliance with all applicable securities laws and requirements of any stock exchange on which the shares of Stock may then be listed.

14.          Not a Public Offering.  If you are resident outside the U.S., the grant of the Restricted Stock Units is not intended to be a public offering of securities in your country of residence (or country of employment, if different).  The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and the grant of the Restricted Stock Units is not subject to the supervision of the local securities authorities.

15.          Insider Trading/Market Abuse Laws.  Your country of residence may have insider trading and/or market abuse laws that may affect your ability to acquire or sell shares of Stock under the Plan during such times you are considered to have “inside information” (as defined in the laws in your country).  These laws may be the same or different from any Company insider trading policy.  You acknowledge that it is your responsibility to be informed of and compliant with such regulations, and you are advised to speak to your personal advisor on this matter.
 
5

16.          Repatriation; Compliance with Law.  If you are resident or employed outside the U.S., as a condition of the Award, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan in accordance with applicable foreign exchange rules and regulations in your country of residence (and country of employment, if different).  In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and its Affiliates, as may be required to allow the Company and its Affiliates to comply with local laws, rules and/or regulations in your country of residence (and country of employment, if different).  Finally, you agree to take any and all actions as may be required to comply with your personal obligations under local laws, rules and/or regulations in your country of residence and country of employment, if different).

17.          No Advice Regarding Grant.  No employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock underlying the Restricted Stock Units.  You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

18.          Change in Stock.  In the event of any change in Stock, by reason of any stock dividend, recapitalization, reorganization, split-up, merger, consolidation, exchange of shares, or of any similar change affecting Stock, the number of Restricted Stock Units subject to this Agreement shall be equitably adjusted by the Committee.

19.          Nature of the Award.  In accepting the Award, you acknowledge, understand and agree that:

(a)          the Plan is established voluntarily by the Company, it is discretionary in nature and limited in duration, and it may be modified, amended, suspended or terminated by the Company, in its sole discretion, at any time;

(b)          the grant of the Award is voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past;

(c)          all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company, including, but not limited to, the form and timing of the Award, the number of shares subject to the Award, and the vesting provisions applicable to the Award;

(d)          the Award and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company or any Affiliate and shall not interfere with the ability of the Company, your Employer or an Affiliate, as applicable, to terminate your employment or service relationship;

(e)          you are voluntarily participating in the Plan;
 
6

 (f)          the Award and the shares of Stock subject to the Award are not intended to replace any pension rights or compensation;

(g)          the Award, the shares of Stock subject to the Award and the value of same, is an extraordinary item of compensation outside the scope of your employment (and employment contract, if any) and is not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;

(h)          the future value of the shares of Stock underlying the Award is unknown, indeterminable and cannot be predicted with certainty;

(i)          unless otherwise determined by the Committee in its sole discretion, a Termination of Service shall be effective from the date on which active employment or service ends and shall not be extended by any statutory or common law notice of termination period;

(j)          no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from a Termination of Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and in consideration of the grant of the Award to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company, your Employer or any Affiliate, waive your ability, if any, to bring any such claim, and release the Company, the Employer and all Affiliates from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim;

(k)          unless otherwise provided herein, in the Plan or by the Company in its discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of Stock of the Company; and

(l)          neither the Company nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Award or of any amounts due to you pursuant to the settlement of the Award or the subsequent sale of any shares of Stock acquired upon settlement of the Award.

20.          Committee Authority; Recoupment.  It is expressly understood that the Committee is authorized to administer, construe and make all determinations necessary or appropriate for the administration of the Plan and this Agreement, including the enforcement of any recoupment policy, all of which shall be binding upon you and any claimant.  Any inconsistency between this Agreement and the Plan shall be resolved in favor of the Plan.
 
21.          Non-Competition, Non-Solicitation and Confidentiality.  As a condition to the receipt of this Award, you must agree to the Non-Competition, Non-Solicitation and Confidentiality Agreement attached hereto as Exhibit A by executing that Agreement.  Failure to execute and return the Non-Competition, Non-Solicitation and Confidentiality Agreement within 120 days of the Grant Date shall constitute your decision to decline to accept this Award.
 
7

22.          Consent to Collection/Processing/Transfer of Personal Data.  Pursuant to applicable personal data protection laws, the Company hereby notifies you of the following in relation to your personal data and the collection, processing and transfer of such data in relation to the Company's grant of the Restricted Stock Units and your participation in the Plan.  The collection, processing and transfer of personal data is necessary for the Company’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of personal data may affect your participation in the Plan.  As such, you voluntarily acknowledge and consent (where required under applicable law) to the collection, use, processing and transfer of personal data as described herein:

(a)          The Company and your Employer hold certain personal information about you, including (but not limited to) your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all entitlements to shares of Stock awarded, canceled, purchased, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan ("Data").  The Data may be provided by you or collected, where lawful, from the Company, its Affiliates and/or third parties, and the Company and your Employer will process the Data for the exclusive purpose of implementing, administering and managing your participation in the Plan.  The Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations in your country of residence (or country of employment, if different).  Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought.  Data will be accessible within the organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and for the participation in the Plan.

(b)          The Company and your Employer will transfer Data internally as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and/or your Employer may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Plan.  These recipients may be located in the European Economic Area, or elsewhere throughout the world, such as the United States.  You hereby authorize (where required under applicable law) the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, as may be required for the administration of the Plan and/or the subsequent holding of the shares of Stock on your behalf, to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.
 
8

(c)         You may, at any time, exercise your rights provided under applicable personal data protection laws, which may include the right to (i) obtain confirmation as to the existence of the Data, (ii) verify the content, origin and accuracy of the Data, (iii) request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of the Data, (iv) oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and/or operation of the Plan and your participation in the Plan, and (v) withdraw your consent to the collection, processing or transfer of Data as provided hereunder (in which case, your Restricted Stock Units will become null and void).  You may seek to exercise these rights by contacting your Human Resources manager or the Company's Human Resources Department, who may direct the matter to the applicable Company privacy official.

23.          Addendum to Agreement.  Notwithstanding any provision of this Agreement to the contrary, the Restricted Stock Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as set forth in the addendum to the Agreement, attached hereto as Exhibit B (the “Addendum”).  Further, if you transfer your residence and/or employment to another country reflected in the Addendum, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock Units and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).  The Addendum shall constitute part of this Agreement.

24.          Additional Requirements.  The Company reserves the right to impose other requirements on the Restricted Stock Units, any shares of Stock acquired pursuant to the Restricted Stock Units and your participation in the Plan to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock Units and the Plan.  Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

25.          Amendment or Modification, Waiver.  Except as set forth in the Plan, no provision of this Agreement may be amended or waived unless the amendment or waiver is agreed to in writing, signed by you and by a duly authorized officer of the Company. No waiver of any condition or provision of this Agreement shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time.

26.          Electronic Delivery.  The Company may, in its sole discretion, deliver by electronic means any documents related to the Award or your future participation in the Plan.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

27.          Governing Law and Jurisdiction.  This Agreement is governed by the substantive and procedural laws of the state of Illinois.  You and the Company shall submit to the exclusive jurisdiction of, and venue in, the courts in Illinois in any dispute relating to this Agreement without regard to any choice of law rules thereof which might apply the laws of any other jurisdictions.

28.          English Language.  If you are resident in a country where English is not an official language, you acknowledge and agree that it is your express intent that this Agreement, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Award, be drawn up in English.  If you have received this Agreement, the Plan or any other documents related to the Award translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.
 
9

29.          Conformity with Applicable Law.  If any provision of this Agreement is determined to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision of this Agreement or the validity, legality or enforceability of such provision in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

30.          Successors.  This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall, upon your death, acquire any rights hereunder.
****
This Agreement contains highly sensitive and confidential information.  Please handle it accordingly.

Please read the attached Exhibits A and B.  Once you have read and understood this Agreement and Exhibits A and B, please click the acceptance box to certify and confirm your agreement to be bound by the terms and conditions of this Agreement and Exhibits A and B, and to acknowledge your receipt of the Prospectus, the Plan and this Agreement and your acceptance of the terms and conditions of the Award granted hereunder.
 
10

EXHIBIT A

WALGREENS BOOTS ALLIANCE, INC. NON-COMPETITION, NON-SOLICITATION AND CONFIDENTIALITY AGREEMENT

This Exhibit forms a part of the Restricted Stock Unit Agreement covering Restricted Stock Units awarded to an employee of Walgreens Boots Alliance, Inc., on behalf of itself, its affiliates, subsidiaries, and successors (collectively referred to as “Employee” and the “Company”).

WHEREAS, the Company develops and/or uses valuable business, technical, proprietary, customer and patient information it protects by limiting its disclosure and by keeping it secret or confidential;

WHEREAS, Employee acknowledges that during the course of employment, he or she has or will receive, contribute, or develop such confidential information; and

WHEREAS, the Company desires to protect from its competitors such confidential information and also desires to protect its legitimate business interests and goodwill in maintaining its employee and customer relationships.

NOW THEREFORE, in consideration of the Restricted Stock Unit Award issued to Employee pursuant the Agreement to which this is attached as Exhibit A, Employee agrees to be bound by the terms of this Agreement:

1.            Confidentiality.  I understand that during the course of my employment with the Company, I have or will have access to the Company’s Confidential Information, meaning information which is not generally ascertainable by proper means by the public, or which has limited disclosure within the Company, or which is treated or designated as confidential; the disclosure of which could reasonably be harmful to the Company’s legitimate business interests.
 
I understand that “Confidential Information” includes, but is not limited to, the following:

(a) business or marketing plans, trade secrets, selling and pricing procedures and techniques, customer records,
(b) customer lists, requirements, and information,
(c) databases and software developed or used by the Company, financial information and projections, and other information for which the Company has assumed an obligation of confidentiality.

I agree to only use the Company’s Confidential Information as necessary to perform my job during my employment with the Company.  I agree not to disclose any Confidential Information to anyone outside the Company without the Company’s prior written consent, unless as necessary to perform my job during my employment with the Company.  I agree that these obligations apply during my employment with the Company and at all times thereafter.
 
2.            Non-Competition.  I agree that during my employment with the Company and for one year after the termination of my employment, I will not, directly or indirectly, invest in, own, operate, finance, control, or provide Competing Services to any Competing Business Line, in both cases as defined below.  I understand that the restrictions in this paragraph apply no matter whether my employment is terminated by me or the Company and no matter whether that termination is voluntary or involuntary.  The above restrictions shall not apply to passive investments of less than 5% ownership interest in any entity. I understand that the term “Competing Business Line” used in this Agreement means any business that is in competition with any business engaged in by the Company with respect to which I provide substantial services during the last two years of my employment with the Company.
 
11

I understand that I will be deemed to be providing “Competing Services” if the nature of such services are sufficiently similar in position scope and geographic scope to any position held by me during the last two years of my employment with the Company, such that my engaging in such services on behalf of a Competing Business Line may pose competitive harm to the Company.
 
3.            Non-Solicitation.  I agree that during my employment with the Company and for two years after the termination of my employment from the Company for any reason, whether voluntary or involuntary:

(a) I will not directly or indirectly, offer, provide or sell or participate in offering, providing or selling, products or services competitive with or similar to products or services offered by, developed by, designed by or distributed by the Company to any person, company or entity which was a customer, potential customer or referral source of the Company for such products or services and with which I had direct contact or about which I learned confidential information regarding such products or services at any time during the last two years of my employment with the Company;

(b) I will not directly or indirectly solicit or participate in soliciting products or services competitive with or similar to products or services offered by, developed by, designed by or distributed by the Company to any person, company or entity which was a customer, potential customer or referral source of the Company for such products or services and with which I had direct contact or about which I learned confidential information regarding such products or services at any time during the last two years of my employment with the Company

(c) I will not, nor will I assist any third party to, directly or indirectly (i) raid, hire, solicit, or attempt to persuade any employee of the Company or any person who was an employee of the Company during the 6 months preceding the termination of my employment with the Company,  who possesses or had access to confidential information of the Company, to leave the employ of the Company; (ii) interfere with the performance by any such persons of their duties for the Company; or (iii) communicate with any such persons for the purposes described in items (i) and (ii) in this paragraph.

4.            Non-Inducement.  I will not directly or indirectly assist or encourage any person or entity in carrying out or conducting any activity that would be prohibited by this Agreement if such activity were carried out or conducted by me.

5.            Nondisparagement.  I agree (whether or not I am then an Employee) not to make negative comments or otherwise disparage the Company, its Affiliates, or any of their officers, directors, employees, shareholders, members, agents or products other than in the good faith performance of my duties to the Company and its Affiliates while I am employed by the Company and its Affiliates and thereafter.  The foregoing shall not be violated by truthful statements in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings).
 
12

6.            Intellectual Property.  The term "Intellectual Property" shall mean all trade secrets, ideas, inventions, designs, developments, devices, software, computer programs, methods and processes (whether or not patented or patentable, reduced to practice or included in the Confidential Information) and all patents and patent applications related thereto, all copyrights, copyrightable works and mask works (whether or not included in the Confidential Information) and all registrations and  applications for registration related thereto, all Confidential Information, and all other proprietary rights contributed to, or conceived or created by, or reduced to practice by Employee or anyone acting on its behalf (whether alone or jointly with others) at any time from the beginning of Employee’s employment with Walgreens Boots Alliance, Inc. to the termination of that employment plush ninety (90) days (i) relate to the business or to the actual or anticipated research or development of Walgreens Boots Alliance, Inc.; (ii) result from any services that Employee or anyone acting on its behalf perform for Walgreens; or (iii) are created using the equipment, supplies or facilities of Walgreens Boots Alliance, Inc. or any Confidential Information.

a. Ownership.  All Intellectual Property is, shall be and shall remain the exclusive property of the Company.  Employee hereby assigns to the Company all right, title and interest, if any, in and to the Intellectual Property; provided, however, that, when applicable, the Company shall own the copyrights in all copyrightable works included in the Intellectual Property pursuant to the "work-made-for-hire" doctrine (rather than by assignment), as such term is defined in the 1976 Copyright Act.  All Intellectual Property shall be owned by the Company irrespective of any copyright notices or confidentiality legends to the contrary which may be placed on such works by Employee or by others.  Employee shall ensure that all copyright notices and confidentiality legends on all work product authored by Employee or anyone acting on its behalf shall conform to the Company's practices and shall specify the Company as the owner of the work.  The Company hereby provides notice to Employee that the obligation to assign does not apply to an invention for which no equipment, supplies, facility, or trade secret information of the Company was used and which was developed entirely on the Employee's own time, unless (a) the invention relates (i) to the business of the Company, or (ii) to the Company’s actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by Employee for the Company.

b. Keep Records.  Employee shall keep and maintain, or cause to be kept and maintained by anyone acting on its behalf, adequate and current written records of all Intellectual Property in the form of notes, sketches, drawings, computer files, reports or other documents relating thereto.  Such records shall be and shall remain the exclusive property of the Company and shall be available to the Company at all times during the term of this Agreement.

c. Assistance. Employee shall supply all assistance requested in securing for Company’s benefit any patent, copyright, trademark, service mark, license, right or other evidence of ownership of any such Intellectual Property, and will provide full information regarding any such item and execute all appropriate documentation prepared by Company in applying or otherwise registering, in Company’s name, all rights to any such item or the defense and protection of such Intellectual Property.
 
13

d. Prior Inventions.  I have disclosed to the Company any continuing obligations to any third party with respect to Intellectual Property.  I claim no rights to any inventions created prior to my employment for which a patent application has not previously been filed, unless I have described them in detail on a schedule attached to this Agreement.

7.            Return of Company Property.  I agree that I will not take any of the Company’s property or information with me when I leave the Company’s employ, no matter what form that property or information is in and no matter how I acquired it.  When my employment with the Company terminates, I will immediately return to the Company any and all Company information, documents, and electronics.

8.            Consideration and Acknowledgments.  I acknowledge and agree that the covenants described in this Agreement are essential terms, and the underlying Restricted Stock Unit Award would not be provided by the Company in the absence of these covenants.  I further acknowledges that these covenants are supported by adequate consideration as set forth in this Agreement, that full compliance with these covenants will not prevent me from earning a livelihood following the termination of my employment, and that these covenants do not place undue restraint on me and are not in conflict with any public interest.  I further acknowledge and agree that I fully understand these covenants, have had full and complete opportunity to discuss and resolve any ambiguities or uncertainties regarding these covenants before signing this Agreement, and have voluntarily agreed to comply with these covenants for their stated terms.  I further acknowledge and agree that these covenants are reasonable and enforceable in all respects.  I agree that in the event I am offered employment with a Competing Business at any time in the future, I shall immediately notify the Competing Business of the existence of the covenants set forth above.

9.            Enforceability; General Provisions.

(a) I agree that the restrictions contained in this Agreement are reasonable and necessary to protect the Company’s legitimate business interests and that full compliance with the terms of this Agreement will not prevent me from earning a livelihood following the termination of my employment, and that these covenants do not place undue restraint on me.

(b) Because the Company’s current base of operations is in Illinois, I consent to the jurisdiction of the state and federal courts of Illinois with respect to any claim arising out of this Agreement.

(c) Because the Company’s current base of operations is in Illinois, I agree that this Agreement shall be governed by the laws of Illinois without regard to its choice of law rules.

(d) In the event of a breach or a threatened breach of this Agreement, I acknowledge that the Company will face irreparable injury which may be difficult to calculate in dollar terms and that the Company shall be entitled, in addition to all remedies otherwise available in law or in equity, to temporary restraining orders and preliminary and final injunctions enjoining such breach or threatened breach in any court of competent jurisdiction without the necessity of posting a surety bond, as well as to obtain an equitable accounting of all profits or benefits arising out of any violation of this Agreement.
 
14

 (e) I agree that if a court determines that any of the provisions in this Agreement is unenforceable or unreasonable in duration, territory, or scope, then that court shall modify those provisions so they are reasonable and enforceable, and enforce those provisions as modified.

(f) If any phrase or provision of this Agreement is declared invalid or unenforceable by a court of competent jurisdiction, that phrase, clause or provision shall be deemed severed from this Agreement, and will not affect the enforceability of any other provisions of this Agreement, which shall otherwise remain in full force and effect.

(g) Notwithstanding the foregoing provisions of this Agreement, the non-competition provisions of Paragraph 2 above shall not restrict Employee from performing legal services as a licensed attorney for a Competing Business to the extent that the attorney licensure requirements in the applicable jurisdiction do not permit Employee to agree to the otherwise applicable restrictions of Paragraph 2.

(h) Waiver of any of the provisions of this Agreement by the Company in any particular instance shall not be deemed to be a waiver of any provision in any other instance and/or of the Company’s other rights at law or under this Agreement.

(i) I agree that the Company may assign this Agreement to its successors and that any such successor may stand in the Company’s shoes for purposes of enforcing this Agreement.

(j) I agree to reimburse Company for all attorneys’ fees, costs, and expenses that it reasonably incurs in connection with enforcing its rights and remedies under this Agreement, but only to the extent the Company is ultimately the prevailing party in the applicable legal proceedings.

(k) If I violate this Agreement, then the restrictions set out in Paragraphs 2 - 6 shall be extended by the same period of time as the period of time during which the violation(s) occurred.

(l) I fully understand my obligations in this Agreement, have had full and complete opportunity to discuss and resolve any ambiguities or uncertainties regarding these covenants before signing this Agreement, and have voluntarily agreed to comply with these covenants for their stated terms.
 
15

10.          Relationship of Parties.  I acknowledge that my relationship with the Company is “terminable at will” by either party and that the Company or I can terminate the relationship with or without cause and without following any specific procedures.  Nothing contained in this Agreement is intended to or shall be relied upon to alter the “terminable at will” relationship between the parties.

11.          Modifications and Other Agreements.  I agree that the terms of this Agreement may not be modified except by a written agreement signed by both me and the Company.  This Agreement shall not supersede any other restrictive covenants to which I may be subject under an employment contract, benefit program or otherwise, such that the Company may enforce the terms of any and all restrictive covenants to which I am subject.

12.          Notification.  I agree that in the event I am offered employment at any time in the future with any entity that may be considered a Competing Business Line, I shall immediately notify such Competing business of the existence and terms of this Agreement.  I also understand and agree that the Company may notify anyone later employing me of the existence and provisions of this Agreement.

***                    ***                    ***                    ***                    ***
 
By clicking the acceptance box for this grant agreement, I acknowledge receipt of the Restricted Stock Unit Agreement to which this Agreement is attached as Exhibit A, and I agree to the terms and conditions expressed in this Agreement.
 
16

EXHIBIT B

ADDENDUM TO THE
WALGREENS BOOTS ALLIANCE, INC. 2013 OMNIBUS INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT

In addition to the terms of the Plan and the Agreement, the Award is subject to the following additional terms and conditions to the extent you reside and/or are employed in one of the countries addressed herein.  Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in this Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock Units and the Plan (or the Company may establish alternative terms as may be necessary or advisable to accommodate your transfer).  All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.

FRANCE

Use of English Language.  You acknowledge that it is your express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  Vous reconnaissez avoir expressément exigé la rédaction en anglais de la présente Convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou indirectement, relatifs à, ou suite à, la présente Convention.

MEXICO

1.            Commercial Relationship.  You expressly recognize that your participation in the Plan and the Company’s grant of Restricted Stock Units does not constitute an employment relationship between you and the Company.  You have been granted the Restricted Stock Units as a consequence of the commercial relationship between the Company and the Affiliate in Mexico that employs you, and the Company’s Affiliate in Mexico is your sole employer.  Based on the foregoing, you expressly recognize that (a) the Plan and the benefits you may derive from your participation in the Plan does not establish any rights between you and the Company’s Affiliate in Mexico that employs you, (b) the Plan and the benefits you may derive from your participation in the Plan are not part of the employment conditions and/or benefits provided by the Company’s Affiliate in Mexico that employs you, and (c) any modifications or amendments of the Plan by the Company, or a termination of the Plan by the Company, shall not constitute a change or impairment of the terms and conditions of your employment with the Company’s Affiliate in Mexico that employs you.

2.            Extraordinary Item of Compensation.  You expressly recognize and acknowledge that your participation in the Plan is a result of the discretionary and unilateral decision of the Company, as well as your free and voluntary decision to participate in the Plan in accordance with the terms and conditions of the Plan, the Agreement and this Addendum.  As such, you acknowledge and agree that the Company, in its sole discretion, may amend and/or discontinue your participation in the Plan at any time and without any liability.  The Award, the shares of Stock subject to the Award and the value of same is an extraordinary item of compensation outside the scope of your employment contract, if any, and is not part of your regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of the Company’s Affiliate in Mexico that employs you.
 
17

MONACO

Use of English Language.  You acknowledge that it is your express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  Vous reconnaissez avoir expressément exigé la rédaction en anglais de la présente Convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou indirectement, relatifs à, ou suite à, la présente Convention.

NETHERLANDS

Exclusion of Claim.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Restricted Stock Units, whether or not as a result of your Termination of Service (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Restricted Stock Units.  Upon the grant of Restricted Stock Units, you shall be deemed irrevocably to have waived any such entitlement.

SPAIN

1.            Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement:
 
In accepting the Award, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.
 
You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Restricted Stock Units under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis.  Consequently, you understand that the Restricted Stock Units are granted on the assumption and condition that the Restricted Stock Units and the shares of Stock acquired upon settlement of the Restricted Stock Units shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Award shall be null and void.
 
18

Further, you understand and agree that the vesting of the Restricted Stock Units is expressly conditioned on your continued and active rendering of service, such that upon a Termination of Service, the Restricted Stock Units may cease vesting immediately, in whole or in part, effective on the date of your Termination of Service (unless otherwise specifically provided in Section 4, 5 or 6 of the Agreement).  This will be the case, for example, even if (a) you are considered to be unfairly dismissed without good cause; (b) you are dismissed for disciplinary or objective reasons or due to a collective dismissal; (c) you terminate service due to a change of work location, duties or any other employment or contractual condition, (d) you terminate service due to a unilateral breach of contract by the Company or an Affiliate.  Consequently, upon a Termination of Service for any of the above reasons, you may automatically lose any rights to Restricted Stock Units that were not vested on the date of your Termination of Service, as described in the Plan and Agreement.

You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a Termination of Service on your Award.

2.             Termination for Cause.  “Cause” shall be defined as indicated in Section 7 of the Agreement, irrespective of whether the termination is or is not considered a fair termination (i.e., “despido procedente”) under Spanish legislation.

UNITED KINGDOM

1.             Responsibility for Taxes; Tax Withholding.  The following provision supplements Section 10 of the Agreement:

If payment or withholding of the income tax due in connection with the Award is not made within ninety (90) days after the end of the U.K. tax year in which the event giving rise to the income tax liability occurred or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003 (the “Due Date”), the amount of any uncollected income tax shall constitute a loan owed by you to your Employer, effective as of the Due Date.  You agree that the loan will bear interest at the then-current official rate of Her Majesty’s Revenue & Customs (“HMRC”), it shall be immediately due and repayable, and the Company or Employer may recover it at any time thereafter by any of the means referred to in Section 10 of the Agreement.  Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), will not be eligible for a loan to cover the income tax liability.  In the event that you are a director or executive officer and the income tax is not collected from or paid by you by the Due Date, the amount of any uncollected income tax may constitute a benefit to you on which additional income tax and national insurance contributions (“NICs”) will be payable.  You will be responsible for paying and reporting any income tax due on this additional benefit directly to HMRC under the self-assessment regime, and for reimbursing the Company or your Employer (as applicable) the value of any employee NICs due on this additional benefit.

2.            Exclusion of Claim.  You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Restricted Stock Units, whether or not as a result of your Termination of Service (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Restricted Stock Units.  Upon the grant of Restricted Stock Units, you shall be deemed irrevocably to have waived any such entitlement.

***                    ***                    ***                    ***                    ***
 
By clicking the acceptance box for this grant agreement, I acknowledge receipt of the Restricted Stock Unit Award Agreement to which this Addendum is attached as Exhibit B, and I agree to the terms and conditions expressed in this Addendum.
 
 
19

EX-10.7 5 ex10_7.htm EXHIBIT 10.7

Exhibit 10.7

Execution Version
 
AMENDMENT AGREEMENT

AMENDMENT AGREEMENT dated as of January 20, 2016 (this “Amendment”) to the Bridge Term Loan Credit Agreement dated as of December 18, 2015 (the “Credit Agreement”), among Walgreens Boots Alliance, Inc., as the Borrower, UBS AG, Stamford Branch, as Administrative Agent, and the Lenders from time to time party thereto.

1.          Defined Terms.  Capitalized terms used and not otherwise defined herein have the meanings assigned to them in the Credit Agreement as amended hereby (the “Amended Credit Agreement”).

2.          Amendments to the Credit Agreement.  Each of the parties hereto agrees that, effective on the Amendment Effective Date (as defined below): (a) Section 4.02(k)(i) of the Credit Agreement is hereby amended by (i) inserting “with respect to the Borrower under Section 7.05 or Section 7.06” immediately after the words “no Default or Unmatured Default” in clause (x) thereof and (ii) inserting “constituting Specified Representations” immediately after the words “the representations and warranties contained in Article 5” in clause (y) thereof and (b) Exhibit H of the Credit Agreement is hereby amended by (i) inserting “with respect to the Borrower under Section 7.05 or Section 7.06” immediately after the words “no Default or Unmatured Default” in clause (x) of the second paragraph thereof and (ii) inserting “constituting Specified Representations” immediately after the words “the representations and warranties contained in Article 5 of the Credit Agreement” in clause (y) of the second paragraph thereof.

3.          Conditions to Effectiveness.  This Amendment shall become effective on the date (the “Amendment Effective Date”) when the Administrative Agent shall have received counterparts to this Amendment executed by (i) the Borrower, (ii) the Administrative Agent and (iii) the Required Lenders.

4.          Ratification.  Except to the extent hereby amended, the Credit Agreement and each of the Loan Documents remain in full force and effect and are hereby ratified and affirmed.

5.          Indemnities.  The Borrower agrees that this Amendment constitutes a Loan Document and Section 9.06 of the Credit Agreement is hereby incorporated by reference herein and shall extend to the preparation, execution and delivery of this Amendment.

6.          Limitation.  This Amendment shall be limited precisely as written and except as expressly provided herein, shall not be deemed (a) to be a consent granted pursuant to, or a waiver or modification of, any term or condition of the Credit Agreement or any of the instruments or agreements referred to therein or (b) to prejudice any right or rights which the Administrative Agent or the Lenders may now have or have in the future under or in connection with the Credit Agreement or any of the instruments or agreements referred to therein. Unless the context indicates otherwise, on and after the Amendment Effective Date, whenever the Credit Agreement is referred to in the Credit Agreement, the other Loan Documents or any of the instruments, agreements or other documents or papers executed or delivered in connection therewith, such reference shall be deemed to mean the Credit Agreement as amended by this Amendment.
 

7.          Counterparts.  This Amendment may be executed in any number of counterparts and by the different parties hereto in separate counterparts, each of which shall be an original and all of which, when taken together, shall constitute but one and the same instrument.  A facsimile or .pdf copy of a counterpart signature page shall serve as the functional equivalent of a manually executed copy for all purposes.

8.          Governing Law.  THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

[SIGNATURE PAGES FOLLOW]
 
2

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the day and year first above written.

 
WALGREENS BOOTS ALLIANCE, INC.
 
 
as the Borrower
 
     
 
By:
/s/ Jan Stern Reed
 
   
Name:
Jan Stern Reed  
   
Title:
SVP, General Counsel, Corp. Sec  
       
 
By:
/s/ Aidan Clare
 
   
Name:
Aidan Clare  
   
Title:
Global Treasurer  
 

 
UBS AG, STAMFORD BRANCH
 
  as Administrative Agent  
     
 
By:
/s/ Houssem Daly
 
   
Name:
Houssem Daly  
   
Title:
Associate Director  
       
 
By:
/s/ Craig Pearson
 
   
Name:
Craig Pearson  
   
Title:
Associate Director  
       
 

 
UBS AG, Stamford Branch,
 
 
as Lender
 
     
 
By:
/s/ Houssem Daly
 
   
Name:
Houssem Daly
 
   
Title:
Associate Director
 
       
 
By:
/s/ Craig Pearson
 
   
Name:
Craig Pearson
 
   
Title:
Associate Director
 
 

 
Bank of America, N.A.,
 
 
as a Lender
 
     
 
By:
/s/ J. Casey Cosgrove
 
   
Name:
J. Casey Cosgrove
 
   
Title:
Director
 
 

 
HSBC BANK PLC,
 
 
as a Lender
 
     
 
By:
/s/ Colette Pithie
 
   
Name:
Colette Pithie
 
   
Title:
Associate Director
 
 

 
HSBC Bank USA, N.A.,
 
 
as a Lender
 
     
 
By:
/s/ Roderick Feltzer
 
   
Name:
Roderick Feltzer
 
   
Title:
Vice President
 
 

 
JPMORGAN CHASE BANK, N.A.,
 
 
as a Lender
 
     
 
By:
/s/ Dawn Lee Lum
 
   
Name:
Dawn Lee Lum
 
   
Title:
Executive Director
 
 

LLOYDS BANK PLC,
 
 
as a Lender
 
     
 
By:
/s/ Erin Doherty
 
   
Name:
Erin Doherty
 
   
Title:
Assistant Vice President – D006
 
         
 
By:
/s/ Daven Popat
 
   
Name:
Daven Popat
 
   
Title:
Senior Vice President – P003
 
 

 
Mizuho Bank, Ltd.,
 
 
as a Lender
 
     
 
By:
/s/ David Lim
 
   
Name:
David Lim
 
 
 
Title:
Authorized Signatory
 
 

 
The Bank of Tokyo-Mitsubishi UFJ, Ltd.
 
 
as a Lender
 
     
 
By:
/s/ Mark Maloney
 
   
Name:
Mark Maloney
 
   
Title:
Authorized Signatory
 
 

 
UniCredit Bank AG, London Branch
 
 
as a Lender
 
     
 
By:
/s/ David Vials
 
   
Name:
David Vials
 
   
Title:
Managing Director
 
         
 
By:
/s/ Michael Cook
 
   
Name:
Michael Cook
 
   
Title:
Director
 
 

 
WELLS FARGO BANK, N.A.,
 
 
as a Lender
 
     
 
By:
/s/ Matthew Olson
 
   
Name:
Matthew Olson
 
   
Title:
Director
 
 

 
Banco Santander, S.A.
 
 
as a Lender
 
     
 
By:
/s/ Aitor Elustondo
 
   
Name:
Aitor Elustondo
 
   
Title:
Managing Director
 
         
 
By:
/s/ Federico Robin
 
   
Name:
Federico Robin
 
   
Title:
Vice President Senior
 
 

 
Deutsche Bank Luxembourg S.A.,
 
 
as a Lender
 
     
 
By:
/s/ Philippi
 
   
Name:
Philippi
 
   
Title:
AVP
 
         
 
By:
/s/ A. Breyer-Simski
 
   
Name:
A. Breyer-Simski
 
   
Title:
AVP
 
 

 
Intesa Sanpaolo S.p.A.,
 
 
as a Lender
 
     
 
By:
/s/ Neil Derfler
 
   
Name:
Neil Derfler
 
   
Title:
Vice President
 
         
 
By:
/s/ Serena Palumbo
 
   
Name:
Serena Palumbo, Esq
 
   
Title:
Vice President
 
 

 
SOCIETE GENERALE,
 
 
as a Lender
 
     
 
By:
/s/ Alexandre Huet
 
   
Name:
Alexandre Huet
 
   
Title:
Head of Strategic and Acquisition Finance
 
 

 
Sumitomo Mitsui Banking Corporation,
 
 
as a Lender
 
     
 
By:
/s/Alan Krouk
 
   
Name:
Alan Krouk
 
   
Title:
Managing Director
 
 

 
U.S. BANK NATIONAL ASSOCIATION,
 
 
as a Lender
 
     
 
By:
/s/ Conan Schleicher
 
   
Name:
Conan Schleicher
 
   
Title:
Senior Vice President
 
 
 

EX-10.9 6 ex10_9.htm EXHIBIT 10.9

Exhibit 10.9
 
Execution Version
 
AMENDMENT AGREEMENT

AMENDMENT AGREEMENT dated as of January 20, 2016 (this “Amendment”) to the Term Loan Credit Agreement dated as of December 18, 2015 (the “Credit Agreement”), among Walgreens Boots Alliance, Inc., as the Borrower, Bank of America, N.A., as Administrative Agent, and the Lenders from time to time party thereto.
 
1.          Defined Terms.  Capitalized terms used and not otherwise defined herein have the meanings assigned to them in the Credit Agreement as amended hereby (the “Amended Credit Agreement”).

2.          Amendments to the Credit Agreement.  Each of the parties hereto agrees that, effective on the Amendment Effective Date (as defined below): (a) Section 4.02(k)(i) of the Credit Agreement is hereby amended by (i) inserting “with respect to the Borrower under Section 7.05 or Section 7.06” immediately after the words “no Default or Unmatured Default” in clause (x) thereof and (ii) inserting “constituting Specified Representations” immediately after the words “the representations and warranties contained in Article 5” in clause (y) thereof and (b) Exhibit H of the Credit Agreement is hereby amended by (i) inserting “with respect to the Borrower under Section 7.05 or Section 7.06” immediately after the words “no Default or Unmatured Default” in clause (x) of the second paragraph thereof and (ii) inserting “constituting Specified Representations” immediately after the words “the representations and warranties contained in Article 5 of the Credit Agreement” in clause (y) of the second paragraph thereof.

3.          Conditions to Effectiveness.  This Amendment shall become effective on the date (the “Amendment Effective Date”) when the Administrative Agent shall have received counterparts to this Amendment executed by (i) the Borrower, (ii) the Administrative Agent and (iii) the Required Lenders.
 
4.          Ratification.  Except to the extent hereby amended, the Credit Agreement and each of the Loan Documents remain in full force and effect and are hereby ratified and affirmed.
 
5.          Indemnities.  The Borrower agrees that this Amendment constitutes a Loan Document and Section 9.06 of the Credit Agreement is hereby incorporated by reference herein and shall extend to the preparation, execution and delivery of this Amendment.
 
6.          Limitation.  This Amendment shall be limited precisely as written and except as expressly provided herein, shall not be deemed (a) to be a consent granted pursuant to, or a waiver or modification of, any term or condition of the Credit Agreement or any of the instruments or agreements referred to therein or (b) to prejudice any right or rights which the Administrative Agent or the Lenders may now have or have in the future under or in connection with the Credit Agreement or any of the instruments or agreements referred to therein. Unless the context indicates otherwise, on and after the Amendment Effective Date, whenever the Credit Agreement is referred to in the Credit Agreement, the other Loan Documents or any of the instruments, agreements or other documents or papers executed or delivered in connection therewith, such reference shall be deemed to mean the Credit Agreement as amended by this Amendment.
 

7.          Counterparts.  This Amendment may be executed in any number of counterparts and by the different parties hereto in separate counterparts, each of which shall be an original and all of which, when taken together, shall constitute but one and the same instrument.  A facsimile or .pdf copy of a counterpart signature page shall serve as the functional equivalent of a manually executed copy for all purposes.
 
8.          Governing Law.  THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.
 
[SIGNATURE PAGES FOLLOW]
 
2

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the day and year first above written.
 
  WALGREENS BOOTS ALLIANCE, INC.  
  as the Borrower  
     
By:
/s/ Jan Stern Reed
 
 
Name:
Jan Stern Reed
 
 
Title:
SVP, General Counsel, Corp. Sec.
 
         
By:
/s/ Aidan Clare
 
 
Name:
Aidan Clare
 
 
Title:
Global Treasurer
 
 

  BANK OF AMERICA, N.A.  
  as Administrative Agent  
     
  By:
/s/ J. Casey Cosgrove
 
   
Name:
J. Casey Cosgrove
 
   
Title:
Director
 
 

  Bank of America, N.A.,  
  as a Lender  
     
  By:
/s/ J. Casey Cosgrove
 
   
Name:
J. Casey Cosgrove
 
   
Title:
Director
 
 

  HSBC BANK PLC,  
  as a Lender  
     
  By:
/s/ Colette Pithie
 
   
Name:
Colette Pithie
 
   
Title:
Associate Director
 
 

  HSBC BANK USA, N.A.,  
  as a Lender  
     
 
By:
/s/ Roderick Feltzer
 
   
Name:
Roderick Feltzer
 
   
Title:
Vice President
 
 

  UBS AG, Stamford Branch,  
  as Lender  
     
  By:
/s/ Houssem Daly
 
   
Name:
Houssem Daly
 
   
Title:
Associate Director
 
         
 
By:
/s/ Craig Pearson   
   
Name:
Craig Pearson
 
   
Title:
Associate Director
 
 

  JPMORGAN CHASE BANK, N.A.,  
  as a Lender  
     
 
By:
/s/ Dawn Lee Lum
 
   
Name:
Dawn Lee Lum
 
   
Title:
Executive Director
 
 

  LLOYDS BANK PLC,  
  as a Lender  
     
 
By:
/s/ Erin Doherty
 
   
Name:
Erin Doherty
 
   
Title:
Assistant Vice President – D006
 
         
  By: /s/ Daven Popat  
   
Name:
Daven Popat
 
   
Title:
Senior Vice President – P003
 
 

  Mizuho Bank, Ltd.,  
  as a Lender  
     
  By:
/s/ David Lim
 
   
Name:
David Lim
 
   
Title:
Authorized Signatory
 
 

  The Bank of Tokyo-Mitsubishi UFJ, Ltd.  
  as a Lender  
     
 
By:
/s/ Mark Maloney
 
   
Name:
Mark Maloney
 
   
Title:
Authorized Signatory
 
 

  UniCredit Bank AG, London Branch  
  as a Lender  
     
 
By:
/s/ David Vials
 
   
Name:
David Vials
 
   
Title:
Managing Director
 
         
 
By:
/s/ Michael Cook  
   
Name:
Michael Cook
 
   
Title:
Director
 
 

  UniCredit Bank AG, New York Branch  
  as a Lender  
     
 
By:
/s/ Marc Fussbahn
 
   
Name:
Marc Fussbahn
 
   
Title:
Managing Director
 
         
 
By:
/s/ Thilo Huber  
   
Name:
Thilo Huber
 
   
Title:
Associate Director
 
 

  WELLS FARGO BANK, N.A.,  
 
as a Lender
 
     
 
By:
/s/ Matthew Olson
 
   
Name:
Matthew Olson
 
   
Title:
Director
 
 

  Deutsche Bank Luxembourg S.A.,  
  as a Lender  
     
 
By:
/s/ Philippi
 
   
Name:
Philippi
 
   
Title:
AVP
 
         
 
By:
/s/ A. Breyer-Simski  
   
Name:
A. Breyer-Simski
 
   
Title:
AVP
 
 

  Intesa Sanpaolo Bank Luxembourg SA  
  as a Lender  
     
  By:
/s/ Gian Franco Pizzulto
 
   
Name:
Gian Franco Pizzulto
 
   
Title:
CEO
 
         
  By: /s/ Paolo Elia  
   
Name:
Paolo Elia
 
   
Title:
Head of Credit
 
 

  Santander Bank, N.A.,  
  as a Lender  
     
   By:
/s/ Gonzalo Acha
 
   
Name:
Gonzalo Acha
 
   
Title:
Executive Director
 
 

  SOCIETE GENERALE,  
  as a Lender  
     
 
By:
/s/ Alexandre Huet  
 
Name:
Alexandre Huet
 
 
Title:
Head of Strategic and Acquisition Finance
 
 

  Sumitomo Mitsui Banking Corporation,  
  as a Lender  
     
 
By:
/s/ David W. Kee  
 
Name:
David W. Kee
 
 
Title: 
Managing Director
 
 

  U.S. BANK NATIONAL ASSOCIATION,  
  as a Lender  
     
 
By:
/s/ Conan Schleicher  
 
Name:
Conan Schleicher
 
 
Title:
Senior Vice President
 
 

  STATE BANK OF INDIA, NEW YORK,  
  as a Lender  
     
 
By:
/s/ Manoranjan Panda  
 
Name:
Manoranjan Panda
 
 
Title:
VP & Head (Credit Management Cell)
 
 

  Bank of China, Chicago Branch  
  as a Lender  
     
  By:
/s/ Kefei Xu
 
   
Name:
Kefei Xu
 
   
Title:
Senior Vice President & Branch Manager
 
 

  THE NORTHERN TRUST COMPANY  
  as a Lender  
     
 
By:
/s/ Peter J. Hallan  
 
Name:
Peter J. Hallan
 
 
Title:
Vice President
 
 

  The Royal Bank of Scotland plc,  
  as a Lender  
     
  By:
/s/ M.A. Collins
 
   
Name:
M.A. Collins
 
   
Title:
Executive Director
 
         
  By: /s/ G. R. Parker  
   
Name:
G. R. Parker
 
   
Title:
Managing Director
 
 

  BRANCH BANKING AND TRUST COMPANY,  
  as a Lender  
     
 
By:
/s/ John P. Malloy  
 
Name:
John P. Malloy
 
 
Title:
Senior Vice President
 
 


EX-12 7 ex12.htm EXHIBIT 12

Exhibit 12

Walgreens Boots Alliance, Inc.
Computation of Historical Ratios of Earnings to Fixed Charges (a)
(in millions, except ratio data)

   
Six Months Ended,
         
Twelve Months Ended,
 
   
February 29, 2016
   
2015
   
2014
   
2013
   
2012
   
2011
 
Income before income tax provision
 
$
2,497
   
$
5,311
   
$
3,557
   
$
4,047
   
$
3,376
   
$
4,294
 
Add:
                                               
Minority Interests
   
-
     
-
     
-
     
5
     
-
     
-
 
Fixed charges
   
1,022
     
2,054
     
1,376
     
1,383
     
1,260
     
1,212
 
Amortization of capitalized interest
   
-
     
1
     
6
     
7
     
6
     
5
 
Less:
                                               
Equity earnings
   
(20
)
   
(315
)
   
(617
)
   
(496
)
   
-
     
-
 
Capitalized interest
   
-
     
(1
)
   
(6
)
   
(7
)
   
(9
)
   
(10
)
Earnings as defined
 
$
3,499
   
$
7,050
   
$
4,316
   
$
4,939
   
$
4,633
   
$
5,501
 
                                                 
Interest expense, net of capitalized interest
 
$
288
   
$
632
   
$
168
   
$
193
   
$
94
   
$
77
 
Capitalized interest
   
-
     
1
     
6
     
7
     
9
     
10
 
Portions of rentals representative of the interest factor
   
734
     
1,421
     
1,202
     
1,183
     
1,157
     
1,125
 
Fixed charges as defined
 
$
1,022
   
$
2,054
   
$
1,376
   
$
1,383
   
$
1,260
   
$
1,212
 
                                                 
Ratio of earnings to fixed charges
   
3.42
     
3.43
     
3.14
     
3.57
     
3.68
     
4.54
 

(a) For the purpose of computing these ratios, "earnings" consist of earnings before income tax provision and before adjustment for income or loss from equity investees, interest, distributed income of equity-method investees, and the portions of rentals representative of the interest factor.  "Fixed charges" consist of interest expense (which includes amortization of capitalized debt issuance costs), capitalized interest and the portions of rentals representative of the interest factor.
 
Walgreens Boots Alliance, Inc. is the successor of Walgreen Co. See Note 1 of the consolidated financial statements for further information
 

EX-31.1 8 ex31_1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION

I, Stefano Pessina, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Walgreens Boots Alliance, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/
Stefano Pessina
Chief Executive Officer
Date:  April 5, 2016
 
Stefano Pessina
   

 

EX-31.2 9 ex31_2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION

I, George Fairweather, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Walgreens Boots Alliance, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/
George Fairweather
Global Chief Financial Officer
Date:  April 5, 2016
 
George Fairweather
   
 
 

EX-32.1 10 ex32_1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), on Form 10-Q for the quarter ended February 29, 2016 as filed with the Securities and Exchange Commission (the "Report"), I, Stefano Pessina, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge:

(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Stefano Pessina
 
Stefano Pessina
 
Chief Executive Officer
 
Dated:  April 5, 2016
 

A signed original of this written statement required by Section 906 has been provided to Walgreens Boots Alliance, Inc. and will be retained by Walgreens Boots Alliance, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
 
 

EX-32.2 11 ex32_2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), on Form 10-Q for the quarter ended February 29, 2016 as filed with the Securities and Exchange Commission (the "Report"), I, George Fairweather, Global Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge:

(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ George Fairweather
 
George Fairweather
 
Global Chief Financial Officer
 
Dated:  April 5, 2016
 

A signed original of this written statement required by Section 906 has been provided to Walgreens Boots Alliance, Inc. and will be retained by Walgreens Boots Alliance, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
 
 

EX-101.INS 12 wba-20160229.xml XBRL INSTANCE DOCUMENT 0001618921 2015-09-01 2016-02-29 0001618921 2016-03-31 0001618921 2015-08-31 0001618921 2016-02-29 0001618921 wba:EmployeeStockLoanReceivableMember 2015-08-31 0001618921 us-gaap:RetainedEarningsMember 2015-08-31 0001618921 us-gaap:TreasuryStockMember 2015-08-31 0001618921 us-gaap:CommonStockMember 2015-08-31 0001618921 us-gaap:NoncontrollingInterestMember 2015-08-31 0001618921 us-gaap:AdditionalPaidInCapitalMember 2015-08-31 0001618921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-08-31 0001618921 us-gaap:NoncontrollingInterestMember 2015-09-01 2016-02-29 0001618921 us-gaap:AdditionalPaidInCapitalMember 2015-09-01 2016-02-29 0001618921 us-gaap:TreasuryStockMember 2015-09-01 2016-02-29 0001618921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-09-01 2016-02-29 0001618921 wba:EmployeeStockLoanReceivableMember 2015-09-01 2016-02-29 0001618921 us-gaap:RetainedEarningsMember 2015-09-01 2016-02-29 0001618921 us-gaap:CommonStockMember 2015-09-01 2016-02-29 0001618921 us-gaap:CommonStockMember 2016-02-29 0001618921 us-gaap:TreasuryStockMember 2016-02-29 0001618921 wba:EmployeeStockLoanReceivableMember 2016-02-29 0001618921 us-gaap:NoncontrollingInterestMember 2016-02-29 0001618921 us-gaap:RetainedEarningsMember 2016-02-29 0001618921 us-gaap:AdditionalPaidInCapitalMember 2016-02-29 0001618921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-02-29 0001618921 2014-12-01 2015-02-28 0001618921 2014-09-01 2015-02-28 0001618921 2015-12-01 2016-02-29 0001618921 2014-08-31 0001618921 2015-02-28 0001618921 wba:EuroAndPoundSterlingNotesMember 2015-09-01 2016-02-29 0001618921 wba:DebtIssuanceNoteTwoMember 2015-09-01 2016-02-29 0001618921 wba:DebtIssuanceNoteOneMember 2015-09-01 2016-02-29 0001618921 us-gaap:DesignatedAsHedgingInstrumentMember 2015-09-01 2016-02-29 0001618921 us-gaap:NondesignatedMember 2015-09-01 2016-02-29 0001618921 us-gaap:WarrantMember us-gaap:NondesignatedMember 2015-09-01 2016-02-29 0001618921 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2015-09-01 2016-02-29 0001618921 wba:BootsPensionPlanMember 2015-09-01 2016-02-29 0001618921 wba:WalgreensBootsAllianceMember 2014-12-31 0001618921 wba:WalgreensBootsAllianceDevelopmentGmbhMember 2016-02-29 0001618921 wba:WalgreensBootsAllianceMember 2014-12-31 2014-12-31 0001618921 wba:AllianceBootsMember 2014-12-31 0001618921 wba:AllianceHealthcareItaliaDistribuzioneSPAMember 2015-01-01 0001618921 wba:AllianceHealthcareItaliaDistribuzioneSPAMember 2015-09-01 2016-02-29 0001618921 wba:CostTransformationRestructuringProgramMember 2016-02-29 0001618921 wba:CostTransformationRestructuringProgramMember wba:AssetImpairmentRestructuringChargesMember us-gaap:MaximumMember 2016-02-29 0001618921 us-gaap:EmployeeSeveranceMember wba:CostTransformationRestructuringProgramMember us-gaap:MinimumMember 2016-02-29 0001618921 wba:CostTransformationRestructuringProgramMember us-gaap:MaximumMember 2016-02-29 0001618921 us-gaap:MinimumMember wba:CostTransformationRestructuringProgramMember 2016-02-29 0001618921 wba:AssetImpairmentRestructuringChargesMember us-gaap:MinimumMember wba:CostTransformationRestructuringProgramMember 2016-02-29 0001618921 us-gaap:MinimumMember wba:RealEstateCostMember wba:CostTransformationRestructuringProgramMember 2016-02-29 0001618921 us-gaap:EmployeeSeveranceMember us-gaap:MaximumMember wba:CostTransformationRestructuringProgramMember 2016-02-29 0001618921 wba:RealEstateCostMember wba:CostTransformationRestructuringProgramMember us-gaap:MaximumMember 2016-02-29 0001618921 wba:CostTransformationRestructuringProgramMember wba:AssetImpairmentRestructuringChargesMember 2014-09-02 2016-02-29 0001618921 wba:CostTransformationRestructuringProgramMember 2015-12-01 2016-02-29 0001618921 wba:CostTransformationRestructuringProgramMember us-gaap:EmployeeSeveranceMember 2014-09-02 2016-02-29 0001618921 wba:CostTransformationRestructuringProgramMember wba:RealEstateCostMember 2014-09-02 2016-02-29 0001618921 us-gaap:ContractTerminationMember 2014-12-01 2015-02-28 0001618921 2014-09-02 2016-02-29 0001618921 wba:CostTransformationRestructuringProgramMember 2015-09-01 2016-02-29 0001618921 wba:CostTransformationRestructuringProgramMember 2014-12-01 2015-02-28 0001618921 wba:CostTransformationRestructuringProgramMember 2014-09-01 2015-02-28 0001618921 wba:RetailPharmacyInternationalMember us-gaap:EmployeeSeveranceMember 2015-12-01 2016-02-29 0001618921 wba:RetailPharmacyInternationalMember 2015-12-01 2016-02-29 0001618921 wba:RetailPharmacyUSAMember us-gaap:EmployeeSeveranceMember 2015-12-01 2016-02-29 0001618921 wba:AssetImpairmentRestructuringChargesMember 2015-09-01 2016-02-29 0001618921 wba:RetailPharmacyUSAMember wba:RealEstateCostMember 2015-09-01 2016-02-29 0001618921 us-gaap:EmployeeSeveranceMember wba:RetailPharmacyInternationalMember 2014-09-01 2015-02-28 0001618921 wba:AssetImpairmentRestructuringChargesMember 2015-12-01 2016-02-29 0001618921 us-gaap:EmployeeSeveranceMember wba:PharmaceuticalWholesaleMember 2014-12-01 2015-02-28 0001618921 wba:RetailPharmacyInternationalMember 2014-12-01 2015-02-28 0001618921 wba:AssetImpairmentRestructuringChargesMember wba:RetailPharmacyInternationalMember 2014-09-01 2015-02-28 0001618921 us-gaap:EmployeeSeveranceMember 2014-09-01 2015-02-28 0001618921 wba:AssetImpairmentRestructuringChargesMember wba:RetailPharmacyInternationalMember 2015-09-01 2016-02-29 0001618921 wba:RealEstateCostMember 2015-12-01 2016-02-29 0001618921 us-gaap:EmployeeSeveranceMember 2014-12-01 2015-02-28 0001618921 wba:RetailPharmacyInternationalMember us-gaap:EmployeeSeveranceMember 2014-12-01 2015-02-28 0001618921 wba:RetailPharmacyUSAMember 2015-12-01 2016-02-29 0001618921 wba:PharmaceuticalWholesaleMember wba:AssetImpairmentRestructuringChargesMember 2015-09-01 2016-02-29 0001618921 us-gaap:EmployeeSeveranceMember wba:RetailPharmacyInternationalMember 2015-09-01 2016-02-29 0001618921 wba:RealEstateCostMember wba:RetailPharmacyUSAMember 2014-12-01 2015-02-28 0001618921 wba:RealEstateCostMember wba:PharmaceuticalWholesaleMember 2015-12-01 2016-02-29 0001618921 wba:PharmaceuticalWholesaleMember wba:AssetImpairmentRestructuringChargesMember 2015-12-01 2016-02-29 0001618921 wba:RetailPharmacyInternationalMember wba:RealEstateCostMember 2014-09-01 2015-02-28 0001618921 wba:PharmaceuticalWholesaleMember wba:AssetImpairmentRestructuringChargesMember 2014-12-01 2015-02-28 0001618921 wba:RetailPharmacyUSAMember wba:AssetImpairmentRestructuringChargesMember 2014-12-01 2015-02-28 0001618921 wba:RealEstateCostMember 2014-12-01 2015-02-28 0001618921 wba:AssetImpairmentRestructuringChargesMember wba:PharmaceuticalWholesaleMember 2014-09-01 2015-02-28 0001618921 wba:RetailPharmacyInternationalMember wba:RealEstateCostMember 2015-12-01 2016-02-29 0001618921 wba:RetailPharmacyInternationalMember 2014-09-01 2015-02-28 0001618921 wba:RetailPharmacyUSAMember wba:RealEstateCostMember 2014-09-01 2015-02-28 0001618921 wba:AssetImpairmentRestructuringChargesMember 2014-12-01 2015-02-28 0001618921 wba:RealEstateCostMember wba:PharmaceuticalWholesaleMember 2015-09-01 2016-02-29 0001618921 us-gaap:EmployeeSeveranceMember 2015-12-01 2016-02-29 0001618921 wba:AssetImpairmentRestructuringChargesMember 2014-09-01 2015-02-28 0001618921 wba:RetailPharmacyUSAMember us-gaap:EmployeeSeveranceMember 2015-09-01 2016-02-29 0001618921 wba:RetailPharmacyUSAMember wba:AssetImpairmentRestructuringChargesMember 2015-12-01 2016-02-29 0001618921 us-gaap:EmployeeSeveranceMember 2015-09-01 2016-02-29 0001618921 wba:RealEstateCostMember wba:RetailPharmacyInternationalMember 2014-12-01 2015-02-28 0001618921 wba:RetailPharmacyUSAMember 2014-12-01 2015-02-28 0001618921 wba:AssetImpairmentRestructuringChargesMember wba:RetailPharmacyInternationalMember 2014-12-01 2015-02-28 0001618921 wba:PharmaceuticalWholesaleMember 2014-12-01 2015-02-28 0001618921 wba:PharmaceuticalWholesaleMember us-gaap:EmployeeSeveranceMember 2015-12-01 2016-02-29 0001618921 wba:RetailPharmacyUSAMember us-gaap:EmployeeSeveranceMember 2014-09-01 2015-02-28 0001618921 us-gaap:EmployeeSeveranceMember wba:PharmaceuticalWholesaleMember 2015-09-01 2016-02-29 0001618921 wba:PharmaceuticalWholesaleMember 2015-12-01 2016-02-29 0001618921 wba:RetailPharmacyUSAMember wba:AssetImpairmentRestructuringChargesMember 2015-09-01 2016-02-29 0001618921 wba:PharmaceuticalWholesaleMember wba:RealEstateCostMember 2014-09-01 2015-02-28 0001618921 wba:RealEstateCostMember 2014-09-01 2015-02-28 0001618921 wba:AssetImpairmentRestructuringChargesMember wba:RetailPharmacyUSAMember 2014-09-01 2015-02-28 0001618921 wba:PharmaceuticalWholesaleMember wba:RealEstateCostMember 2014-12-01 2015-02-28 0001618921 wba:RealEstateCostMember 2015-09-01 2016-02-29 0001618921 wba:RetailPharmacyUSAMember 2015-09-01 2016-02-29 0001618921 wba:PharmaceuticalWholesaleMember 2015-09-01 2016-02-29 0001618921 wba:RetailPharmacyUSAMember 2014-09-01 2015-02-28 0001618921 wba:PharmaceuticalWholesaleMember 2014-09-01 2015-02-28 0001618921 wba:RetailPharmacyUSAMember us-gaap:EmployeeSeveranceMember 2014-12-01 2015-02-28 0001618921 wba:RealEstateCostMember wba:RetailPharmacyInternationalMember 2015-09-01 2016-02-29 0001618921 wba:RealEstateCostMember wba:RetailPharmacyUSAMember 2015-12-01 2016-02-29 0001618921 us-gaap:EmployeeSeveranceMember wba:PharmaceuticalWholesaleMember 2014-09-01 2015-02-28 0001618921 wba:RetailPharmacyInternationalMember wba:AssetImpairmentRestructuringChargesMember 2015-12-01 2016-02-29 0001618921 wba:RetailPharmacyInternationalMember 2015-09-01 2016-02-29 0001618921 2014-09-01 2015-08-31 0001618921 us-gaap:MaximumMember 2016-02-29 0001618921 us-gaap:MinimumMember 2015-08-31 0001618921 us-gaap:MaximumMember 2015-08-31 0001618921 us-gaap:MinimumMember 2016-02-29 0001618921 wba:AllianceBootsMember 2014-09-01 2015-02-28 0001618921 wba:AllianceBootsMember 2014-12-01 2015-02-28 0001618921 wba:EquityMethodInvestmentsOtherMember 2014-12-01 2015-02-28 0001618921 wba:EquityMethodInvestmentsOtherMember 2015-12-01 2016-02-29 0001618921 wba:EquityMethodInvestmentsOtherMember 2014-09-01 2015-02-28 0001618921 wba:EquityMethodInvestmentsOtherMember 2015-09-01 2016-02-29 0001618921 us-gaap:CommonStockMember 2016-02-29 0001618921 us-gaap:CommonStockMember 2014-09-01 2015-02-28 0001618921 us-gaap:CommonStockMember 2014-12-01 2015-02-28 0001618921 us-gaap:CommonStockMember 2015-09-01 2016-02-29 0001618921 us-gaap:CommonStockMember 2015-12-01 2016-02-29 0001618921 wba:OtherEquityInvestmentsEquitySecuritiesMember 2015-08-31 0001618921 us-gaap:CommonStockMember 2015-08-31 0001618921 wba:OtherEquityInvestmentsEquitySecuritiesMember 2016-02-29 0001618921 wba:AllianceBootsMember 2014-12-31 0001618921 us-gaap:ScenarioPreviouslyReportedMember wba:AllianceBootsMember 2016-02-29 0001618921 wba:AllianceHealthcareItaliaDistribuzioneSPAMember 2015-01-15 0001618921 wba:WalgreensBootsAllianceDevelopmentGmbhMember 2016-02-29 0001618921 wba:WalgreensBootsAllianceDevelopmentGmbhMember 2014-12-31 0001618921 wba:AllianceHealthcareItaliaDistribuzioneSPAMember 2016-02-29 0001618921 wba:AllianceHealthcareItaliaDistribuzioneSPAMember 2015-09-01 2016-02-29 0001618921 2014-12-31 2014-12-31 0001618921 2014-12-31 0001618921 2014-12-30 0001618921 wba:AllianceBootsMember 2015-09-01 2016-02-29 0001618921 wba:AllianceBootsMember 2016-02-29 0001618921 wba:AllianceBootsMember us-gaap:CustomerRelationshipsMember 2015-09-01 2016-02-29 0001618921 wba:AllianceBootsMember us-gaap:LeasesAcquiredInPlaceMember 2015-09-01 2016-02-29 0001618921 wba:AllianceBootsMember us-gaap:TrademarksAndTradeNamesMember 2015-09-01 2016-02-29 0001618921 wba:AllianceBootsMember wba:LoyaltyCardHoldersMember 2015-09-01 2016-02-29 0001618921 wba:PharmacyLicensesMember wba:AllianceBootsMember 2015-09-01 2016-02-29 0001618921 wba:AllianceBootsMember us-gaap:TrademarksAndTradeNamesMember 2015-09-01 2016-02-29 0001618921 wba:PharmaceuticalWholesaleMember 2016-02-29 0001618921 wba:RetailPharmacyInternationalMember 2016-02-29 0001618921 wba:RetailPharmacyUSAMember 2016-02-29 0001618921 wba:AllianceBootsMember 2015-12-01 2016-02-29 0001618921 wba:AllianceBootsMember 2014-09-01 2015-02-28 0001618921 wba:AllianceBootsMember 2014-09-01 2015-08-31 0001618921 wba:AllianceBootsMember 2014-12-01 2015-02-28 0001618921 wba:OtherAcquisitionMember 2015-09-01 2016-02-29 0001618921 wba:OtherAcquisitionMember 2016-02-29 0001618921 wba:RetailPharmacyUSAMember 2015-08-31 0001618921 wba:PharmaceuticalWholesaleMember 2015-08-31 0001618921 wba:RetailPharmacyInternationalMember 2015-08-31 0001618921 wba:PurchasingAndPayerContractMember 2015-08-31 0001618921 wba:PurchasedPrescriptionFileMember 2016-02-29 0001618921 us-gaap:TradeNamesMember 2016-02-29 0001618921 wba:PurchasedPrescriptionFileMember 2015-08-31 0001618921 us-gaap:CustomerRelationshipsMember 2016-02-29 0001618921 wba:PurchasingAndPayerContractMember 2016-02-29 0001618921 us-gaap:NoncompeteAgreementsMember 2016-02-29 0001618921 wba:LoyaltyCardHoldersMember 2016-02-29 0001618921 us-gaap:NoncompeteAgreementsMember 2015-08-31 0001618921 us-gaap:TradeNamesMember 2015-08-31 0001618921 us-gaap:LeaseAgreementsMember 2016-02-29 0001618921 us-gaap:LeaseAgreementsMember 2015-08-31 0001618921 us-gaap:CustomerRelationshipsMember 2015-08-31 0001618921 wba:LoyaltyCardHoldersMember 2015-08-31 0001618921 wba:PharmacyLicensesMember 2016-02-29 0001618921 wba:PharmacyLicensesMember 2015-08-31 0001618921 wba:NotesPayableDue2016Member 2015-08-31 0001618921 wba:NotesPayableDue2016Member 2016-02-29 0001618921 wba:OtherShortTermDebtMember 2016-02-29 0001618921 wba:OtherShortTermDebtMember 2015-08-31 0001618921 wba:NotesPayableDue2016Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2021Member 2016-02-29 0001618921 wba:NotesPayableDue2019OneMember 2016-02-29 0001618921 wba:NotesPayableDue2042Member 2015-08-31 0001618921 wba:NotesPayableDue2020Member 2016-02-29 0001618921 wba:NotesPayableDue2025Member 2016-02-29 0001618921 wba:NotesPayableDue2034Member 2015-08-31 0001618921 wba:NotesPayableDue2019TwoMember 2016-02-29 0001618921 wba:NotesPayableDue2020Member 2015-08-31 0001618921 wba:NotesPayableDue2019TwoMember 2015-08-31 0001618921 wba:NotesPayableDue2017TwoMember 2015-08-31 0001618921 wba:NotesPayableDue2024Member 2015-08-31 0001618921 wba:NotesPayableDue2044Member 2016-02-29 0001618921 wba:NotesPayableDue2026Member 2016-02-29 0001618921 wba:NotesDue2019Member 2016-02-29 0001618921 wba:NotesPayableDue2022Member 2015-08-31 0001618921 wba:NotesPayableDue2022Member 2016-02-29 0001618921 wba:NotesPayableDue2021Member 2015-08-31 0001618921 wba:NotesPayableDue2017TwoMember 2016-02-29 0001618921 wba:NotesPayableDue2026Member 2015-08-31 0001618921 wba:NotesPayableDue2034Member 2016-02-29 0001618921 wba:NotesPayableDue2044Member 2015-08-31 0001618921 wba:NotesPayableDue2019OneMember 2015-08-31 0001618921 wba:NotesPayableDue2024Member 2016-02-29 0001618921 wba:NotesDue2019Member 2015-08-31 0001618921 wba:NotesPayableDue2042Member 2016-02-29 0001618921 wba:NotesPayableDue2025Member 2015-08-31 0001618921 wba:NotesPayableDue2022Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2042Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2021Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2024Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2026Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2017TwoMember 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2025Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2019TwoMember 2015-09-01 2016-02-29 0001618921 wba:NotesDue2019Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2020Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2019OneMember 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2044Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2034Member 2015-09-01 2016-02-29 0001618921 wba:UnsecuredNotes1000Due2015Member 2015-09-01 2016-02-29 0001618921 wba:DebtIssuanceNoteThreeMember 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2014Member 2015-09-01 2016-02-29 0001618921 wba:GovernmentBondRateMember wba:UnsecuredPoundSterlingNotesDue2025Member 2015-09-01 2016-02-29 0001618921 wba:UnsecuredNotes3100Due2022Member wba:TreasuryRateMember 2015-09-01 2016-02-29 0001618921 wba:TreasuryRateMember wba:UnsecuredNotesDue2034Member 2015-09-01 2016-02-29 0001618921 wba:UnsecuredNotesDue2021Member wba:TreasuryRateMember 2015-09-01 2016-02-29 0001618921 wba:DebtIssuanceNoteThreeMember wba:TreasuryRateMember 2015-09-01 2016-02-29 0001618921 wba:TreasuryRateMember wba:UnsecuredNotesDue2024Member 2015-09-01 2016-02-29 0001618921 wba:TreasuryRateMember wba:UnsecuredNotes1000Due2015Member 2015-09-01 2016-02-29 0001618921 wba:UnsecuredNotesDue2019Member wba:TreasuryRateMember 2015-09-01 2016-02-29 0001618921 wba:UnsecuredPoundSterlingNotesDue2020Member wba:GovernmentBondRateMember 2015-09-01 2016-02-29 0001618921 wba:UnsecuredNotesDue2017Member wba:TreasuryRateMember 2015-09-01 2016-02-29 0001618921 wba:TreasuryRateMember wba:EuroNotesMember 2015-09-01 2016-02-29 0001618921 wba:TreasuryRateMember wba:UnsecuredNotesDue2044Member 2015-09-01 2016-02-29 0001618921 wba:TreasuryRateMember wba:UnsecuredNotes4400Due2042Member 2015-09-01 2016-02-29 0001618921 wba:DebtIssuanceNoteThreeMember 2016-02-29 0001618921 wba:DebtIssuanceNoteTwoMember 2016-02-29 0001618921 wba:DebtIssuanceNoteOneMember 2016-02-29 0001618921 wba:EuroAndPoundSterlingNotesMember 2016-02-29 0001618921 wba:UnsecuredNotes1800Due2017Member 2015-08-10 0001618921 wba:NotesPayableDue2042Member us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 wba:NotesPayableDue2021Member us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 wba:NotesPayableDue2016Member us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 wba:NotesPayableDue2024Member us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 us-gaap:UnsecuredDebtMember wba:NotesPayableDue2017TwoMember 2016-02-29 0001618921 wba:DebtIssuanceNoteTwoMember us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 wba:NotesPayableDue2022Member us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 us-gaap:UnsecuredDebtMember wba:NotesPayableDue2019Member 2016-02-29 0001618921 wba:NotesPayableDue2034Member us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 wba:UnsecuredPoundSterlingNotesDue2025Member us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 wba:UnsecuredEuroNotesDue2026Member us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 wba:NotesPayableDue2044Member us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 us-gaap:UnsecuredDebtMember wba:DebtIssuanceNoteOneMember 2016-02-29 0001618921 wba:UnsecuredPoundSterlingNotesDue2020Member us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 wba:PoundSterlingNotesMember us-gaap:UnsecuredDebtMember 2016-02-29 0001618921 wba:UnsecuredPoundSterlingNotesDue2020Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2042Member us-gaap:UnsecuredDebtMember 2015-09-01 2016-02-29 0001618921 us-gaap:UnsecuredDebtMember wba:NotesPayableDue2034Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2019Member us-gaap:UnsecuredDebtMember 2015-09-01 2016-02-29 0001618921 us-gaap:UnsecuredDebtMember wba:NotesPayableDue2022Member 2015-09-01 2016-02-29 0001618921 us-gaap:UnsecuredDebtMember wba:UnsecuredPoundSterlingNotesDue2025Member 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2024Member us-gaap:UnsecuredDebtMember 2015-09-01 2016-02-29 0001618921 wba:UnsecuredEuroNotesDue2026Member 2015-09-01 2016-02-29 0001618921 us-gaap:UnsecuredDebtMember wba:NotesPayableDue2016Member 2015-09-01 2016-02-29 0001618921 us-gaap:UnsecuredDebtMember wba:NotesPayableDue2017TwoMember 2015-09-01 2016-02-29 0001618921 wba:NotesPayableDue2021Member us-gaap:UnsecuredDebtMember 2015-09-01 2016-02-29 0001618921 us-gaap:UnsecuredDebtMember wba:NotesPayableDue2044Member 2015-09-01 2016-02-29 0001618921 us-gaap:CommercialPaperMember 2016-02-29 0001618921 us-gaap:CommercialPaperMember 2015-02-28 0001618921 us-gaap:CommercialPaperMember 2014-09-01 2015-02-28 0001618921 us-gaap:CommercialPaperMember 2015-09-01 2016-02-29 0001618921 us-gaap:LoansPayableMember 2016-02-29 0001618921 us-gaap:LetterOfCreditMember 2014-11-10 0001618921 us-gaap:RevolvingCreditFacilityMember 2014-12-29 0001618921 us-gaap:RevolvingCreditFacilityMember 2014-11-10 0001618921 us-gaap:LetterOfCreditMember 2014-12-29 0001618921 currency:GBP 2016-02-29 0001618921 us-gaap:RevolvingCreditFacilityMember 2016-02-29 0001618921 wba:TermLoanCreditAgreementMember 2016-02-29 0001618921 us-gaap:BridgeLoanMember 2016-02-29 0001618921 wba:Three64DayCreditAgreementMember 2016-02-29 0001618921 us-gaap:RevolvingCreditFacilityMember 2015-09-01 2016-02-29 0001618921 wba:Two015CreditAgreementsMember 2016-02-29 0001618921 us-gaap:LineOfCreditMember 2016-02-29 0001618921 wba:AdditionalBridgeLoanMember 2016-02-29 0001618921 wba:Three64DayCreditAgreementMember 2015-09-01 2016-02-29 0001618921 us-gaap:MaximumMember wba:Three64DayCreditAgreementMember 2016-02-29 0001618921 us-gaap:LoansPayableMember us-gaap:MaximumMember 2016-02-29 0001618921 us-gaap:RevolvingCreditFacilityMember us-gaap:MaximumMember 2016-02-29 0001618921 wba:Two015CreditAgreementsMember us-gaap:MaximumMember 2016-02-29 0001618921 2015-10-27 0001618921 2015-12-18 0001618921 wba:AdditionalBridgeLoanMember 2015-12-18 0001618921 wba:TrancheTwoMember 2015-09-01 2016-02-29 0001618921 wba:AdditionalBridgeLoanMember 2015-09-01 2016-02-29 0001618921 us-gaap:BridgeLoanMember 2015-09-01 2016-02-29 0001618921 wba:TrancheOneMember 2015-09-01 2016-02-29 0001618921 wba:TermLoanCreditAgreementMember 2015-09-01 2016-02-29 0001618921 us-gaap:NondesignatedMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2016-02-29 0001618921 us-gaap:OtherAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2015-08-31 0001618921 us-gaap:BasisSwapMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:NondesignatedMember 2016-02-29 0001618921 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2015-08-31 0001618921 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2016-02-29 0001618921 us-gaap:BasisSwapMember us-gaap:NondesignatedMember us-gaap:OtherCurrentAssetsMember 2015-08-31 0001618921 us-gaap:OtherCurrentAssetsMember us-gaap:NondesignatedMember us-gaap:ForeignExchangeForwardMember 2015-08-31 0001618921 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember us-gaap:OtherAssetsMember 2016-02-29 0001618921 us-gaap:InterestRateSwapMember wba:OneMonthLiborMember 2016-02-29 0001618921 us-gaap:InterestRateSwapMember wba:SixMonthLiborMember 2016-02-29 0001618921 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember us-gaap:NondesignatedMember 2015-12-01 2016-02-29 0001618921 wba:OtherIncomeExpensesMember wba:Step2TransactionForeignCurrencyForwardsMember us-gaap:NondesignatedMember 2015-09-01 2016-02-29 0001618921 us-gaap:InterestExpenseMember us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember 2015-09-01 2016-02-29 0001618921 wba:OtherIncomeExpensesMember us-gaap:NondesignatedMember wba:Step2TransactionForeignCurrencyForwardsMember 2015-12-01 2016-02-29 0001618921 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember us-gaap:InterestRateSwapMember 2015-09-01 2016-02-29 0001618921 us-gaap:NondesignatedMember us-gaap:ForeignExchangeForwardMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-12-01 2015-02-28 0001618921 wba:NotesMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2015-12-01 2016-02-29 0001618921 wba:Step2TransactionForeignCurrencyForwardsMember us-gaap:NondesignatedMember wba:OtherIncomeExpensesMember 2014-12-01 2015-02-28 0001618921 wba:NotesMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2014-12-01 2015-02-28 0001618921 wba:OtherIncomeExpensesMember us-gaap:NondesignatedMember wba:Step2TransactionForeignCurrencyForwardsMember 2014-09-01 2015-02-28 0001618921 us-gaap:ForeignExchangeForwardMember wba:OtherIncomeExpensesMember us-gaap:NondesignatedMember 2015-12-01 2016-02-29 0001618921 us-gaap:NondesignatedMember wba:OtherIncomeExpensesMember us-gaap:ForeignExchangeForwardMember 2014-09-01 2015-02-28 0001618921 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember us-gaap:NondesignatedMember 2014-12-01 2015-02-28 0001618921 us-gaap:InterestExpenseMember us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember 2014-09-01 2015-02-28 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-09-01 2015-02-28 0001618921 us-gaap:NondesignatedMember wba:OtherIncomeExpensesMember us-gaap:ForeignExchangeForwardMember 2014-12-01 2015-02-28 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-09-01 2016-02-29 0001618921 us-gaap:DesignatedAsHedgingInstrumentMember wba:NotesMember us-gaap:InterestExpenseMember 2015-09-01 2016-02-29 0001618921 us-gaap:InterestExpenseMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2014-09-01 2015-02-28 0001618921 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2014-12-01 2015-02-28 0001618921 us-gaap:InterestExpenseMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2015-12-01 2016-02-29 0001618921 us-gaap:InterestExpenseMember us-gaap:DesignatedAsHedgingInstrumentMember wba:NotesMember 2014-09-01 2015-02-28 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember wba:OtherIncomeExpensesMember 2015-09-01 2016-02-29 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-12-01 2016-02-29 0001618921 us-gaap:InterestRateSwapMember wba:SixMonthLiborMember 2015-08-10 0001618921 us-gaap:NondesignatedMember us-gaap:OtherAssetsMember us-gaap:WarrantMember 2015-08-31 0001618921 us-gaap:NondesignatedMember us-gaap:OtherAssetsMember us-gaap:WarrantMember 2016-02-29 0001618921 wba:OtherIncomeExpensesMember us-gaap:WarrantMember 2015-09-01 2016-02-29 0001618921 us-gaap:WarrantMember wba:OtherIncomeExpensesMember 2014-09-01 2015-02-28 0001618921 wba:OtherIncomeExpensesMember us-gaap:WarrantMember 2015-12-01 2016-02-29 0001618921 wba:OtherIncomeExpensesMember us-gaap:WarrantMember 2014-12-01 2015-02-28 0001618921 us-gaap:MaximumMember wba:WarrantsExercisableInMarch2016Member wba:AmerisourceBergenCorporationMember 2016-02-29 0001618921 wba:WarrantsExercisableInMarch2017Member us-gaap:MaximumMember wba:AmerisourceBergenCorporationMember 2016-02-29 0001618921 wba:AmerisourceBergenCorporationMember wba:WarrantsExercisableInMarch2016Member 2016-02-29 0001618921 wba:AmerisourceBergenCorporationMember wba:WarrantsExercisableInMarch2017Member 2016-02-29 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2015-08-31 0001618921 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2015-08-31 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2015-08-31 0001618921 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeForwardMember 2016-02-29 0001618921 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-08-31 0001618921 wba:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2015-08-31 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0001618921 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2016-02-29 0001618921 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember wba:RestrictedCashMember us-gaap:FairValueInputsLevel1Member 2015-08-31 0001618921 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2016-02-29 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:AvailableforsaleSecuritiesMember 2016-02-29 0001618921 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-08-31 0001618921 wba:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateSwapMember 2016-02-29 0001618921 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0001618921 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2016-02-29 0001618921 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2016-02-29 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-02-29 0001618921 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2015-08-31 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeForwardMember 2016-02-29 0001618921 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2015-08-31 0001618921 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0001618921 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-02-29 0001618921 us-gaap:FairValueInputsLevel3Member us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0001618921 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0001618921 wba:RestrictedCashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel1Member 2016-02-29 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-08-31 0001618921 us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueMeasurementsRecurringMember 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember wba:RestrictedCashMember us-gaap:FairValueInputsLevel3Member 2016-02-29 0001618921 us-gaap:FairValueInputsLevel2Member us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-08-31 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2016-02-29 0001618921 wba:RestrictedCashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member 2015-08-31 0001618921 us-gaap:FairValueInputsLevel2Member wba:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2015-08-31 0001618921 us-gaap:FairValueInputsLevel2Member wba:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0001618921 us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:InterestRateSwapMember 2016-02-29 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BasisSwapMember 2016-02-29 0001618921 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BasisSwapMember 2016-02-29 0001618921 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BasisSwapMember us-gaap:FairValueInputsLevel1Member 2016-02-29 0001618921 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BasisSwapMember 2016-02-29 0001618921 wba:MiddleDistrictOfPennsylvaniaMember 2016-02-29 0001618921 wba:PennsylvaniaCourtOfCommonPleasOfCumberlandCountyMember 2016-02-29 0001618921 wba:DelawareCourtOfChanceryMember 2016-02-29 0001618921 wba:BootsAndOtherPensionPlansMember 2014-09-01 2015-02-28 0001618921 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2014-09-01 2015-02-28 0001618921 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2014-12-01 2015-02-28 0001618921 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2015-12-01 2016-02-29 0001618921 wba:BootsAndOtherPensionPlansMember 2015-12-01 2016-02-29 0001618921 wba:BootsAndOtherPensionPlansMember 2015-09-01 2016-02-29 0001618921 wba:BootsAndOtherPensionPlansMember 2014-12-01 2015-02-28 0001618921 wba:WalgreenProfitSharingRetirementTrustMember 2015-09-01 2016-02-29 0001618921 wba:WalgreenProfitSharingRetirementTrustMember 2014-12-01 2015-02-28 0001618921 wba:WalgreenProfitSharingRetirementTrustMember 2014-09-01 2015-02-28 0001618921 wba:WalgreenProfitSharingRetirementTrustMember 2015-12-01 2016-02-29 0001618921 wba:AllianceBootsRetirementSavingsPlanMember 2014-09-01 2015-02-28 0001618921 wba:AllianceBootsRetirementSavingsPlanMember 2015-09-01 2016-02-29 0001618921 wba:AllianceBootsRetirementSavingsPlanMember 2015-12-01 2016-02-29 0001618921 wba:AllianceBootsRetirementSavingsPlanMember 2014-12-01 2015-02-28 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-08-31 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2015-11-30 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2014-11-30 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-11-30 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-11-30 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-11-30 0001618921 2014-11-30 0001618921 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-11-30 0001618921 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-08-31 0001618921 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-08-31 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-08-31 0001618921 us-gaap:AociAttributableToNoncontrollingInterestMember 2014-08-31 0001618921 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-11-30 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2015-08-31 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-08-31 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2014-08-31 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-08-31 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-11-30 0001618921 2015-11-30 0001618921 us-gaap:AociAttributableToNoncontrollingInterestMember 2014-11-30 0001618921 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-09-01 2016-02-29 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-12-01 2016-02-29 0001618921 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-09-01 2015-02-28 0001618921 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-12-01 2015-02-28 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-12-01 2015-02-28 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2015-09-01 2016-02-29 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-01 2016-02-29 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-01 2016-02-29 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-01 2015-02-28 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-09-01 2015-02-28 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-09-01 2016-02-29 0001618921 us-gaap:AociAttributableToNoncontrollingInterestMember 2014-09-01 2015-02-28 0001618921 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-12-01 2016-02-29 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-09-01 2016-02-29 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-12-01 2015-02-28 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-09-01 2015-02-28 0001618921 us-gaap:AociAttributableToNoncontrollingInterestMember 2014-12-01 2015-02-28 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2014-09-01 2015-02-28 0001618921 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-02-28 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2015-02-28 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-02-28 0001618921 us-gaap:AociAttributableToNoncontrollingInterestMember 2015-02-28 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2016-02-29 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-02-28 0001618921 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-02-29 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-02-29 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-02-29 0001618921 wba:AllianceBootsMember 2016-02-29 0001618921 wba:EliminationsAndUnallocatedItemsMember 2014-12-01 2015-02-28 0001618921 wba:RetailPharmacyInternationalMember us-gaap:IntersegmentEliminationMember 2014-12-01 2015-02-28 0001618921 wba:RetailPharmacyInternationalMember us-gaap:OperatingSegmentsMember 2014-09-01 2015-02-28 0001618921 us-gaap:IntersegmentEliminationMember wba:RetailPharmacyUSAMember 2015-09-01 2016-02-29 0001618921 wba:PharmaceuticalWholesaleMember us-gaap:OperatingSegmentsMember 2015-12-01 2016-02-29 0001618921 wba:EliminationsAndUnallocatedItemsMember us-gaap:OperatingSegmentsMember 2014-09-01 2015-02-28 0001618921 wba:RetailPharmacyUSAMember us-gaap:OperatingSegmentsMember 2014-09-01 2015-02-28 0001618921 wba:PharmaceuticalWholesaleMember us-gaap:OperatingSegmentsMember 2015-09-01 2016-02-29 0001618921 us-gaap:IntersegmentEliminationMember 2015-12-01 2016-02-29 0001618921 wba:RetailPharmacyInternationalMember us-gaap:OperatingSegmentsMember 2015-09-01 2016-02-29 0001618921 us-gaap:OperatingSegmentsMember 2015-12-01 2016-02-29 0001618921 us-gaap:IntersegmentEliminationMember wba:PharmaceuticalWholesaleMember 2014-12-01 2015-02-28 0001618921 wba:PharmaceuticalWholesaleMember us-gaap:IntersegmentEliminationMember 2014-09-01 2015-02-28 0001618921 us-gaap:IntersegmentEliminationMember 2015-09-01 2016-02-29 0001618921 us-gaap:IntersegmentEliminationMember wba:RetailPharmacyInternationalMember 2014-09-01 2015-02-28 0001618921 us-gaap:IntersegmentEliminationMember wba:RetailPharmacyUSAMember 2015-12-01 2016-02-29 0001618921 us-gaap:IntersegmentEliminationMember wba:RetailPharmacyInternationalMember 2015-09-01 2016-02-29 0001618921 wba:RetailPharmacyInternationalMember us-gaap:OperatingSegmentsMember 2015-12-01 2016-02-29 0001618921 us-gaap:OperatingSegmentsMember wba:PharmaceuticalWholesaleMember 2014-09-01 2015-02-28 0001618921 wba:RetailPharmacyUSAMember us-gaap:OperatingSegmentsMember 2015-09-01 2016-02-29 0001618921 wba:RetailPharmacyUSAMember us-gaap:IntersegmentEliminationMember 2014-12-01 2015-02-28 0001618921 us-gaap:OperatingSegmentsMember wba:EliminationsAndUnallocatedItemsMember 2015-12-01 2016-02-29 0001618921 wba:PharmaceuticalWholesaleMember us-gaap:OperatingSegmentsMember 2014-12-01 2015-02-28 0001618921 us-gaap:IntersegmentEliminationMember wba:PharmaceuticalWholesaleMember 2015-12-01 2016-02-29 0001618921 us-gaap:OperatingSegmentsMember 2015-09-01 2016-02-29 0001618921 us-gaap:IntersegmentEliminationMember wba:RetailPharmacyUSAMember 2014-09-01 2015-02-28 0001618921 us-gaap:OperatingSegmentsMember wba:EliminationsAndUnallocatedItemsMember 2015-09-01 2016-02-29 0001618921 us-gaap:IntersegmentEliminationMember 2014-12-01 2015-02-28 0001618921 wba:RetailPharmacyUSAMember us-gaap:OperatingSegmentsMember 2014-12-01 2015-02-28 0001618921 wba:EliminationsAndUnallocatedItemsMember us-gaap:IntersegmentEliminationMember 2015-12-01 2016-02-29 0001618921 wba:RetailPharmacyUSAMember us-gaap:OperatingSegmentsMember 2015-12-01 2016-02-29 0001618921 us-gaap:IntersegmentEliminationMember wba:EliminationsAndUnallocatedItemsMember 2014-09-01 2015-02-28 0001618921 us-gaap:IntersegmentEliminationMember 2014-09-01 2015-02-28 0001618921 us-gaap:OperatingSegmentsMember wba:RetailPharmacyInternationalMember 2014-12-01 2015-02-28 0001618921 wba:EliminationsAndUnallocatedItemsMember 2015-09-01 2016-02-29 0001618921 us-gaap:IntersegmentEliminationMember wba:EliminationsAndUnallocatedItemsMember 2015-09-01 2016-02-29 0001618921 us-gaap:IntersegmentEliminationMember wba:PharmaceuticalWholesaleMember 2015-09-01 2016-02-29 0001618921 wba:EliminationsAndUnallocatedItemsMember us-gaap:OperatingSegmentsMember 2014-12-01 2015-02-28 0001618921 wba:EliminationsAndUnallocatedItemsMember 2014-09-01 2015-02-28 0001618921 wba:RetailPharmacyInternationalMember us-gaap:IntersegmentEliminationMember 2015-12-01 2016-02-29 0001618921 us-gaap:IntersegmentEliminationMember wba:EliminationsAndUnallocatedItemsMember 2014-12-01 2015-02-28 0001618921 us-gaap:OperatingSegmentsMember 2014-09-01 2015-02-28 0001618921 wba:EliminationsAndUnallocatedItemsMember 2015-12-01 2016-02-29 0001618921 us-gaap:OperatingSegmentsMember 2014-12-01 2015-02-28 0001618921 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2016-03-18 0001618921 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2016-03-18 2016-03-18 xbrli:shares iso4217:USD iso4217:USD xbrli:shares wba:Segment xbrli:pure iso4217:GBP wba:Stores wba:Lease iso4217:USD iso4217:EUR iso4217:USD iso4217:GBP iso4217:EUR wba:Tranche wba:Lawsuit wba:PensionPlan false --08-31 2016-02-29 No No Yes Large Accelerated Filer Walgreens Boots Alliance, Inc. 0001618921 1080245720 2016 Q2 10-Q 9873000000 10088000000 6733000000 6849000000 5050000000 5225000000 -1868000000 -214000000 107000000 -911000000 -35000000 260000000 32000000 206000000 54000000 -39000000 136000000 -27000000 -40000000 15000000 -113000000 -39000000 -462000000 259000000 154000000 29000000 14000000 -658000000 -92000000 -39000000 -331000000 296000000 0 -2032000000 6000000 -38000000 172000000 30000000 -68000000 P12Y P7Y P9Y P20Y 9953000000 10041000000 60000000 0 0 0 0 60000000 0 0 182000000 0 101000000 0 0 0 217000000 306000000 209000000 216000000 276000000 124000000 3200000 3400000 2200000 5000000 30000000 30000000 110000000 110000000 2140000000 0 0 0 0 1000000 2043000000 184000000 1000000 0 2140000000 184000000 0 0 0 175000000 5000000 1546000000 2000000 0 0 1027000000 0 0 0 1183000000 1183000000 0 0 2000000 2659000000 0 5000000 0 0 1027000000 2043000000 1546000000 34000000 0 0 2659000000 175000000 34000000 0 0 0 0 66385000000 68782000000 19657000000 20378000000 46007000000 49125000000 430000000 276000000 0 430000000 0 276000000 0 0 4000000 4000000 1000000 1000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="14" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Amortized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">cost basis</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gross </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gross </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">AmerisourceBergen common stock</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">717</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">276</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">993</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other investments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">38</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total available-for-sale investments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">755</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">276</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,027</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="14" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Amortized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">cost basis</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gross </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gross </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">AmerisourceBergen common stock</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">717</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">430</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,147</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other investments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">37</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">36</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total available-for-sale investments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">754</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">430</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,183</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> 755000000 37000000 717000000 754000000 717000000 38000000 36000000 34000000 1147000000 1027000000 1183000000 993000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Basis of Presentation</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The consolidated condensed financial statements of Walgreens Boots Alliance included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. The consolidated condensed financial statements include all subsidiaries in which the Company holds a controlling interest. Investments in less than majority-owned entities in which the Company does not have a controlling interest, but does have significant influence, are accounted for as equity method investments. All intercompany transactions have been eliminated.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Consolidated Condensed Balance Sheet as of February 29, 2016, the Consolidated Condensed Statements of Equity for the six-month period ended February 29, 2016, and the Consolidated Condensed Statements of Earnings, the Consolidated Condensed Statements of Comprehensive Income and the Consolidated Condensed Statements of Cash Flows for the three month and six month periods ended February 29, 2016 and February 28, 2015, have not been audited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In the opinion of the Company, the unaudited consolidated condensed financial statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present a fair statement of the results for such interim periods. Because of the acquisition of Alliance Boots, influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company&#8217;s operations, net earnings for any interim period may not be comparable to the same interim period in previous years or indicative of net earnings for the full fiscal year. In addition, with respect to the Company&#8217;s Retail Pharmacy USA segment, the positive impact on gross profit margins and gross profit dollars typically has been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a &#8220;generic conversion.&#8221; In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on Retail Pharmacy USA segment&#8217;s sales, gross profit margins and gross profit dollars.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experience and other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. For a discussion of the Company&#8217;s significant accounting policies, please see the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.</div></div> 12800000000 7800000000 3000000000 2452000000 0.55 13300000000 15900000000 15851000000 383000000 21441000000 2.49 1.19 144300000 1.20 2.51 7696000000 9010000000 3799000000 413000000 30202000000 59173000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>Accordingly, the unaudited condensed pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company&#8217;s results would have been had the Second Step Transaction occurred at the beginning of the periods presented or the results which may occur in the future.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pro forma</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pro forma</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in millions, except per share amounts)</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net sales</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,202</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">59,173</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net earnings</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,253</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,621</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net earnings per common share:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Basic</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.20</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.51</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Diluted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.19</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.49</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table></div> 10977000000 2621000000 1253000000 894000000 2217000000 11000000000 8149000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 7. Acquisitions</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Alliance Boots</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Second Step Transaction closed on December 31, 2014, resulting in the acquisition by the Company of 55% of the issued and outstanding share capital of Alliance Boots, increasing its interest to 100%. The Company previously accounted for its 45% interest in Alliance Boots as an equity method investment. As a result of the Second Step Transaction, the Company significantly expanded its operations to include pharmacy-led health and beauty retailing and pharmaceutical wholesaling and distribution businesses in major international markets.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">As a result of the closing of the Second Step Transaction, the Company increased its interest in WBAD, a global sourcing enterprise between Walgreens and Alliance Boots, to 100%. Because Walgreens held, prior to the Second Step Transaction, a 50% direct interest and an additional indirect interest in WBAD through its 45% ownership of Alliance Boots, the financial results of WBAD were fully consolidated into the Walgreens financial statements with the remaining 27.5% effective interest being recorded as a noncontrolling interest. The acquisition of the 27.5% noncontrolling interest was accounted for as an equity transaction with no gain or loss recorded in the statement of earnings under ASC Topic 805, Business Combinations. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. (&#8220;AHID&#8221;), which is not a member of the Company&#8217;s consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company has completed the purchase accounting of the Second Step Transaction. The total purchase price of the Second Step Transaction of $15.9 billion included &#163;3.133 billion in cash (approximately $4.9 billion at the December 31, 2014 spot rate of $1.56 to &#163;1.00) and 144.3 million of the Company&#8217;s common shares at a fair value of $11.0 billion (based on the December 30, 2014 closing market price of $76.05). Of the total purchase price, $13.3 billion was allocated to acquire the 55% ownership interest in Alliance Boots and $2.6 billion was allocated to acquire the noncontrolling interest in WBAD. The purchase price attributed to the acquisition of the noncontrolling interest in WBAD was determined based on the relative fair value of Alliance Boots and WBAD, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The impact of the equity transaction is as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Amount</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Consideration attributable to WBAD</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,559</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Less:&#160; Carrying value of the Company&#8217;s pre-existing noncontrolling interest</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">130</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 88%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Impact to additional paid in capital</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,429</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table summarizes the consideration paid to acquire the remaining 55% interest in Alliance Boots and the amounts of identified assets acquired and liabilities assumed at the date of the Second Step Transaction (in millions).</div><div>&#160;</div><div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Consideration paid</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">&#160;</div></div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,874</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Common stock</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">10,977</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total consideration transferred</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">15,851</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Less: consideration attributed to WBAD</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2,559</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">13,292</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Fair value of the investment in Alliance Boots held before the Second Step Transaction</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,149</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total consideration</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,441</div></td></tr></table>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Identifiable assets acquired and liabilities assumed including noncontrolling interests</div><div>&#160; <table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash and cash equivalents</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">413</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts receivable</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,799</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Inventories</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,713</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other current assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">894</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Property, plant and equipment</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,806</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,691</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other non-current assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,217</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Trade accounts payable, accrued expenses and other liabilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(7,696</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Borrowings</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(9,010</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred income taxes</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2,452</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other non-current liabilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(383</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Noncontrolling interests</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(412</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total identifiable net assets and noncontrolling interests</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,580</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">14,861</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr></table></div><div>&#160;</div><div>As a result of the Company acquiring the remaining 55% interest in Alliance Boots, the Company&#8217;s previously held 45% interest was re-measured at fair value, resulting in a gain of $563 million. The gain has been recognized as Gain on previously held equity interest in the Consolidated Statements of Earnings for the fiscal year ended August 31, 2015.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The fair value of the previously held equity interest of $8.1 billion in Alliance Boots was determined using the income approach methodology. The fair value for trade names and trademarks was determined using the relief from royalty method of the income approach; pharmacy licenses and customer relationships were determined using the excess earnings method of the income approach; and loyalty card holders were determined using the incremental cash flow method, which is a form of the income approach. Personal property fair values were determined primarily using the indirect cost approach, while real property fair values were determined using the income, market and/or cost approach. The fair value measurements of the previously held equity interest and intangible assets are based on significant inputs not observable in the market, and thus represent Level 3 measurements. The fair value estimates for the previously held equity interest and intangible assets are based on (a) projected discounted cash flows, (b) historical and projected financial information, (c) synergies including cost savings, and (d) attrition rates, as relevant, that market participants would consider when estimating fair values.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The identified definite and indefinite lived intangible assets were as follows:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 66%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Definite-Lived Intangible Assets</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;">&#160;</td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Weighted-Average Useful </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Life (in years)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Amount (in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 66%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Customer relationships</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: center; width: 1%; background-color: #cceeff;">12</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,311</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 66%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Loyalty card holders</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: center; width: 1%; background-color: #ffffff;">20</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">742</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 66%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Trade names and trademarks</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: center; width: 1%; background-color: #cceeff;">9</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">399</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 66%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Favorable lease interests</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%; background-color: #ffffff;">7</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">93</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 66%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: center; width: 1%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,545</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 78%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Indefinite-Lived Intangible Assets</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Amount (in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 78%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Trade names and trademarks</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,657</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 78%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Pharmacy licenses</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,489</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 78%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,146</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The goodwill of $14.9 billion arising from the Second Step Transaction primarily reflects the expected purchasing synergies, operating efficiencies by benchmarking performance and applying best practices across the Company, consolidation of operations, reductions in selling, general and administrative expenses and combining workforces.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Following the completion of the Second Step Transaction, the Company realigned its operations into three reportable segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company determined that the goodwill should be allocated across all segments recognizing that each segment will benefit from the expected synergies.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The goodwill allocated to the Retail Pharmacy USA segment of $7.3 billion is comprised of $3.5 billion of synergy benefits allocable to the segment on a source of procurement benefit basis and $3.8 billion determined on a &#8220;with-and-without&#8221; basis. The source of procurement benefit basis allocates the synergy benefits to the segment whose purchase gave rise to the benefit. The &#8220;with-and-without&#8221; basis computes the difference between the fair value of the pre-existing business before the combination and its fair value after the combination, and since the pre-existing Walgreens business is now within the Retail Pharmacy USA segment, all of this difference is allocated to this segment. The &#8220;with-and-without&#8221; computation recognized that if the Second Step Transaction did not happen, then this was likely to negatively impact the existing Walgreens business, which already had a 45% interest in Alliance Boots, as the expected purchasing synergies and other benefits resulting from a full combination would not be fully realized.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Of the remaining goodwill, $3.9 billion was allocated to the Retail Pharmacy International segment and $3.7 billion was allocated to the Pharmaceutical Wholesale segment. Substantially all of the goodwill recognized is not expected to be deductible for income tax purposes.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company incurred legal and other professional services costs related to the Second Step Transaction, which were included in selling, general and administrative expenses, of $87 million in fiscal 2015 ($59 million and $83 million in the three and six months ended February 28, 2015, respectively). No costs related to the Second Step Transaction were incurred in the three and six month periods ended February 29, 2016.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The fair value of the assets acquired includes inventory having an estimated fair value of $3.7 billion. This fair value includes a $106 million fair value adjustment to capitalize the estimated profit in acquired finished goods inventory as of the date of the Second Step Transaction, which was expensed to cost of sales over the first inventory turn.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table presents supplemental unaudited condensed pro forma consolidated information for the three and six months ended February 28, 2015 as if the Second Step Transaction had occurred on September 1, 2014, the first day of the Company&#8217;s 2015 fiscal year. The unaudited condensed pro forma information reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased amortization expense based on the fair valuation of assets acquired, the impact of acquisition financing, transaction costs and the related income tax effects. The unaudited condensed pro forma information does not include any anticipated synergies that may be achievable subsequent to the date of the Second Step Transaction. The unaudited condensed pro forma information also excludes certain non-recurring items such as transaction related costs. Accordingly, the unaudited condensed pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company&#8217;s results would have been had the Second Step Transaction occurred at the beginning of the periods presented or the results which may occur in the future.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pro forma</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pro forma</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in millions, except per share amounts)</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net sales</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,202</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">59,173</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net earnings</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,253</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,621</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net earnings per common share:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Basic</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.20</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.51</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Diluted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.19</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.49</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Other Acquisitions</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The aggregate purchase price of all other businesses, net of cash received was $86 million for the six month period ended February 29, 2016. These acquisitions, primarily of an international beauty brand and prescription files, added $19 million to goodwill and $72 million to intangible assets. The remaining fair value relates to immaterial amounts of tangible assets, less liabilities assumed. Operating results of the businesses acquired have been included in the Consolidated Condensed Statements of Earnings from their respective acquisition dates forward. Pro forma results of the Company, assuming all of the other acquisitions had occurred at the beginning of each period presented, would not be materially different from the results reported.</div></div> 59000000 33000000 67000000 83000000 3713000000 6580000000 3806000000 412000000 0.5 0.5 11691000000 72000000 3000000000 3586000000 2646000000 3005000000 359000000 586000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 16. Supplemental Cash Flow Disclosures</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash interest paid was $302 million and $90 million in the six months ended February 29, 2016 and February 28, 2015, respectively. Cash paid for income taxes was $481 million and $553 million in the six months ended February 29, 2016 and February 28, 2015, respectively.</div></div> 0 0 0 0 -3000000 -28000000 2000000 -70000000 -4000000 -166000000 33000000 0 -1000000 -1000000 -28000000 0 -25000000 3000000 -6000000 4000000 -2000000 6000000 33000000 -23000000 -594000000 849000000 -532000000 559000000 51.50 52.50 19859795 22696912 22696912 22696912 0 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 12. Commitments and Contingencies</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries and similar actions by governmental authorities, arising in the normal course of the Company&#8217;s business, including the matters described below. Legal proceedings, in general, and securities and class action litigation, in particular, can be expensive and disruptive. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit, and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company&#8217;s consolidated financial position. However, substantial unanticipated verdicts, fines and rulings do sometimes occur. As a result, the Company could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On a quarterly basis, the Company assesses its liabilities and contingencies for outstanding legal proceedings and reserves are established on a case-by-case basis for those legal claims for which management concludes that it is probable that a loss will be incurred and that the amount of such loss can be reasonably estimated. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. With respect to litigation and other legal proceedings where the Company has determined that a loss is reasonably possible, the Company is unable to estimate the amount or range of reasonably possible loss in excess of amounts reserved due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Company&#8217;s assessments are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause the Company to change those estimates and assumptions. Therefore, it is possible that an unfavorable resolution of one or more pending litigation or other contingencies could have a material adverse effect on the Company&#8217;s consolidated financial statements in a future fiscal period. Management&#8217;s assessment of current litigation and other legal proceedings, including the corresponding accruals, could change because of the discovery of facts with respect to legal actions or other proceedings pending against the Company which are not presently known. Adverse rulings or determinations by judges, juries, governmental authorities or other parties could also result in changes to management&#8217;s assessment of current liabilities and contingencies. Accordingly, the ultimate costs of resolving these claims may be substantially higher or lower than the amounts reserved.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On December 5 and 12, 2014, putative shareholders filed class actions in federal court in the Northern District of Illinois against the Walgreens Board of Directors, Walgreen Co., and Walgreens Boots Alliance, Inc. arising out of the Company&#8217;s definitive proxy statement/prospectus filed with the SEC in connection with the special meeting of Walgreens shareholders on December 29, 2014. The actions asserted claims that the definitive proxy statement/prospectus was false or misleading in various respects. On December 23, 2014, solely to avoid the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, Walgreens entered into a memorandum of understanding with the plaintiffs in both actions, pursuant to which Walgreens made certain supplemental disclosures. The proposed settlement was subject to, among other things, court approval. On July 8, 2015, the Court preliminarily approved the settlement, and on November 20, 2015, the Court entered an order of final approval of the settlement. On December 17, 2015, a purported class member who had objected to the settlement appealed the Court&#8217;s order. The appeal was docketed with the United States Court of Appeals for the Seventh Circuit, and is in an early stage.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co., and Walgreen Co. as a nominal defendant, arising out of certain public statements the Company made regarding its former fiscal 2016 goals. The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. On April 10, 2015, the defendants filed a motion to dismiss. On May 18, 2015, the case was stayed in light of the securities class action that was filed on April 10, 2015, which is described below.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On April 10, 2015, a putative shareholder filed a securities class action in federal court in the Northern District of Illinois against Walgreen Co. and certain former officers of Walgreen Co. The action asserts claims for violation of the federal securities laws arising out of certain public statements the Company made regarding its former fiscal 2016 goals. On June 16, 2015, the Court entered an order appointing a lead plaintiff. Pursuant to the Court&#8217;s order, lead plaintiff filed an amended complaint on August 17, 2015, and defendants moved to dismiss the amended complaint on October 16, 2015. Lead plaintiff filed a response to the motion to dismiss on December 22, 2015, and defendants filed a reply in support of the motion on February 5, 2016.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">As of February 29, 2016, the Company was aware of ten putative class action lawsuits (the &#8220;Rite Aid actions&#8221;) filed by purported Rite Aid stockholders against Rite Aid and its board of directors, Walgreens Boots Alliance and </font>Victoria Merger Sub, Inc. <font style="font-size: 10pt; font-family: 'Times New Roman';">for claims arising out of the transactions contemplated by the Merger Agreement (the &#8220;Rite Aid Transactions&#8221;). Eight of the Rite Aid actions were filed in the Court of Chancery of the State of Delaware (the &#8220;Delaware actions&#8221;), one Rite Aid action was filed in the State of Pennsylvania in the Court of Common Pleas of Cumberland County (the &#8220;Pennsylvania action&#8221;), and one Rite Aid action was filed in the United States District Court for the Middle District of Pennsylvania (the &#8220;federal action&#8221;). The Delaware actions and the Pennsylvania action primarily allege that the Rite Aid board of directors breached its fiduciary duties in connection with the Rite Aid Transactions by, among other things, agreeing to an unfair and inadequate price, agreeing to deal protection devices that preclude other bidders from making successful competing offers for Rite Aid, and failing to disclose all allegedly material information concerning the proposed merger; and also allege that Walgreens Boots Alliance and </font>Victoria Merger Sub, Inc.<font style="font-size: 10pt; font-family: 'Times New Roman';"> aided and abetted these alleged breaches of fiduciary duty. The federal action alleges, among other things, that Rite Aid and its board of directors disseminated an allegedly false and misleading proxy statement in connection with the Rite Aid Transactions. The Delaware actions were consolidated, and plaintiffs filed a motion for expedited proceedings and a motion for preliminary injunction seeking to enjoin the Rite Aid shareholder vote on the Rite Aid Transactions. The plaintiffs in the federal action also filed a motion for preliminary injunction seeking to enjoin the same Rite Aid shareholder vote. All such motions were denied, and the Rite Aid shareholders approved the Rite Aid Transactions at a special meeting on February 4, 2016. Each of the Rite Aid actions is still pending.</font></div></div> 12000000 12000000 1172513618 1172513618 320 320 3200000000 3200000000 0.7200 0.3600 0.6750 0.3375 0.01 0.01 1089910344 1079659979 1920000000 386000000 2688000000 -280000000 -33000000 13000000 -27000000 40000000 1933000000 359000000 2728000000 -313000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 17. Accumulated Other Comprehensive Income (Loss)</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for the three and six months ended February 29, 2016 and February 28, 2015 (in millions):</div><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pension/Post-</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">retirement </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Obligations</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrecognized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available-for-Sale </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Investments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cash Flow </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Hedges</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Currency </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Translation </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjustments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at November 30, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">32</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">260</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(39</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(911</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(658</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other comprehensive income (loss) before reclassification adjustments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(139</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,264</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amounts reclassified from accumulated OCI</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tax benefit (provision)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">51</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">52</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net other comprehensive income (loss)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(88</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,210</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">172</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(38</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2,032</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,868</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pension/Post-</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">retirement </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Obligations</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrecognized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available-for-Sale </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Investments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cash Flow </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Hedges</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Currency </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Translation </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjustments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at August 31, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">29</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">259</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(40</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(462</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(214</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other comprehensive income (loss) before reclassification adjustments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(144</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,570</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,715</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amounts reclassified from accumulated OCI</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tax benefit (provision)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">57</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">58</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net other comprehensive income (loss)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(87</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,570</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,654</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">172</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(38</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2,032</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,868</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pension/Post-</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">retirement </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Obligations</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrecognized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available-for-Sale </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Investments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cash Flow </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Hedges</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Share of </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Alliance </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Boots </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">OCI</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cumulative </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Translation </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjustments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at November 30, 2014</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">206</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(39</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(92</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(35</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">54</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other comprehensive income (loss) before reclassification adjustments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">140</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(89</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(358</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(313</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amounts reclassified from accumulated OCI</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">230</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">80</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">309</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tax benefit (provision)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(49</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(18</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(118</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net other comprehensive income (loss)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">90</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">92</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(122</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(39</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(331</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(68</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pension/Post-</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">retirement </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Obligations</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrecognized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss)&#160;on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available-for-Sale </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Investments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cash Flow</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Hedges</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Share of </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Alliance </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Boots </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">OCI</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cumulative </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Translation </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjustments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at August 31, 2014</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">107</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(27</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(113</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">154</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">136</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other comprehensive income (loss) before reclassification adjustments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">297</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(18</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(57</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(648</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(436</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amounts reclassified from accumulated OCI</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">230</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">80</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">309</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tax benefit (provision)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(108</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(60</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">83</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(77</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net other comprehensive income (loss)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">189</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">113</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(485</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(204</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(39</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(331</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(68</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table></div> 43771000000 33949000000 22240000000 19691000000 Three-month U.S. Dollar LIBOR 1 1 1 1 1 1 P5Y 0.002 0.0022 0.002 0.002 0.0045 0.002 0.0012 0.0015 0.002 0.0015 0.002 0.0025 0.0025 0.0045 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 9. Short-Term Borrowings and Long-Term Debt</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Short-term borrowings and long-term debt consist of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Short-Term Borrowings<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Unsecured variable rate notes due 2016</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">749</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">747</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">303</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">321</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total short-term borrowings</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,052</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,068</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Long-Term Debt<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Unsecured Pound Sterling variable rate term loan due 2019<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,229</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">1.750% unsecured notes due 2017</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">747</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">746</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">5.250% unsecured notes due 2019<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">253</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">2.700% unsecured notes due 2019</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,244</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,243</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">2.875% unsecured Pound Sterling notes due 2020<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">552</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">612</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">3.300% unsecured notes due 2021</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,241</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,241</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">3.100% unsecured notes due 2022</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,193</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,193</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">3.800% unsecured notes due 2024</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,986</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,985</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">3.600% unsecured Pound Sterling notes due 2025<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">414</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">459</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">2.125% unsecured Euro notes due 2026<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">811</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">836</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">4.500% unsecured notes due 2034</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">494</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">494</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">4.400% unsecured notes due 2042</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">492</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">492</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">4.800% unsecured notes due 2044</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,492</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,491</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(6)</sup></div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">44</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total long-term debt</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,974</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">13,315</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; text-align: left;"><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">All notes are presented net of unamortized discount and debt issuance costs, where applicable.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(6)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.</div></td></tr></table></div><div>&#160;</div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">$8.0 Billion Note Issuance</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On November 18, 2014, Walgreens Boots Alliance received net proceeds (after deducting underwriting discounts and estimated offering expenses) of $7.9 billion from a public offering of notes with varying maturities and interest rates, the majority of which are fixed rate. <font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">The notes are unsecured, unsubordinated debt obligations of </font>Walgreens Boots Alliance<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of </font>Walgreens Boots Alliance<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> from time to time outstanding. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged</font><font style="font-size: 10pt; font-family: 'Times New Roman';">. Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $44 million. The fair value of the notes as of February 29, 2016 was $7.9 billion. Fair value</font><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> for these notes was determined based upon quoted market prices.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table summarizes each tranche of notes issued:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Notes Issued</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">(in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 15%;"><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Maturity Date</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 20%;"><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Interest Rate</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 52%;"><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Interest Payment Dates</div></td></tr><tr><td style="vertical-align: top; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td style="vertical-align: top; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">750</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td style="vertical-align: top; text-align: left; width: 15%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">May 18, 2016</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td style="vertical-align: top; text-align: left; width: 20%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Variable; three month U.S. dollar LIBOR, reset quarterly, plus 45 basis points</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td style="vertical-align: top; text-align: left; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">February 18, May 18, August 18, and November 18; commencing on February 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">750</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 17, 2017</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 1.750%</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 17 and November 17; commencing on May 17, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 18, 2019</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 2.700%</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 18 and November 18; commencing on May 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 18, 2021</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 3.300%</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 18 and November 18; commencing on May 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 18, 2024</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 3.800%</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 18 and November 18; commencing on May 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">500</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 18, 2034</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 4.500%</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 18 and November 18; commencing on May 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,500</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 15%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 18, 2044</div></td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 20%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 4.800%</div></td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 18 and November 18; commencing on May 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 15%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 20%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 52%; background-color: #ffffff;">&#160;&#160;&#160;</td></tr></table><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Redemption Option</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Walgreens Boots Alliance<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> may redeem (a) the notes due 2017, at any time in whole or from time to time in part, (b) the notes due 2019, at any time prior to October 18, 2019 in whole or from time to time prior to October 18, 2019 in part, (c) the notes due 2021, at any time prior to September 18, 2021 in whole or from time to time prior to September 18, 2021 in part, (d) the notes due 2024, at any time prior to August 18, 2024 in whole or from time to time prior to August 18, 2024 in part, (e) the notes due 2034, at any time prior to May 18, 2034 in whole or from time to time prior to May 18, 2034 in part, and (f) the notes due 2044, at any time prior to May 18, 2044 in whole or from time to time prior to May 18, 2044 in part, in each case, at </font>Walgreens Boots Alliance<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">&#8217;s option for the sum of accrued and unpaid interest plus a redemption price equal to the greater of:</font></div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 13.5pt; background-color: #ffffff;">(1) 100% of the principal amount of the fixed rate notes being redeemed; and</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 13.5pt; background-color: #ffffff;">(2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 15 basis points for the notes due 2017, 15 basis points for the notes due 2019, 20 basis points for the notes due 2021, 20 basis points for the notes due 2024, 20 basis points for the notes due 2034 and 25 basis points for the notes due 2044.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In addition, at any time on or after October 18, 2019 with respect to the notes due 2019, September 18, 2021 with respect to the notes due 2021, August 18, 2024 with respect to the notes due 2024, May 18, 2034 with respect to the notes due 2034, or May 18, 2044 with respect to the notes due 2044, </font>Walgreens Boots Alliance<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> may redeem some or all of the applicable series of fixed rate notes at its option, at a redemption price equal to 100% of the principal amount of the applicable fixed rate notes being redeemed, plus accrued and unpaid interest on the fixed rate notes being redeemed to, but excluding, the redemption date.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left; background-color: #ffffff;">Change in Control</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left; background-color: #ffffff;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">If </font>Walgreens Boots Alliance<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> experiences a change of control triggering event, unless </font>Walgreens Boots Alliance<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, </font>Walgreens Boots Alliance<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">&#163;700 Million and &#8364;750 Million Notes Issuance</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On November 20, 2014, Walgreens Boots Alliance issued three series of debt securities denominated in Euros and Pound Sterling in a public offering, each with varying maturities and interest rates. Interest on all notes is payable annually on November 20, commencing on November 20, 2015. <font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">The notes are unsecured, unsubordinated debt obligations of </font>Walgreens Boots Alliance<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of </font>Walgreens Boots Alliance<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> from time to time outstanding. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged. Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $11 million. The fair value of the notes as of February 29, 2016 was $1.8 billion. Fair value for these notes was determined based upon quoted market prices.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table details each tranche of Euro and Pound Sterling notes issued:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%;"><tr><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Notes Issued (in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 35%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Maturity Date</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 34%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Interest Rate</div></td></tr><tr><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Euro Notes:</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 35%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 34%;">&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#8364;</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">750</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 35%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 20, 2026</div></td><td valign="bottom" style="vertical-align: bottom; width: 34%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 2.125%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 35%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 34%; background-color: #ffffff;">&#160;&#160;&#160;</td></tr><tr><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Pound Sterling Notes:</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 35%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 34%; background-color: #cceeff;">&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#163;</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">400</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 35%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 20, 2020</div></td><td valign="bottom" style="vertical-align: bottom; width: 34%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 2.875%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">300</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 35%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 20, 2025</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 34%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 3.600%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#163;</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">700</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 35%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 34%; background-color: #ffffff;">&#160;&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Redemption Option</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Walgreens Boots Alliance may redeem (a) the Euro notes, at any time prior to August 20, 2026, in whole or, from time to time prior to August 20, 2026, in part, (b) the Pound Sterling notes due 2020, at any time prior to October 20, 2020, in whole or, from time to time prior to October 20, 2020, in part, and (c) the Pound Sterling notes due 2025, at any time prior to August 20, 2025, in whole or, from time to time prior to August 20, 2025, in part, in each case, at Walgreens Boots Alliance&#8217;s option for the sum of accrued and unpaid interest plus at a redemption price equal to the greater of:</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 13.5pt;">(1) 100% of the principal amount of the notes to be redeemed; and</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 13.7pt;">(2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on an annual basis at the applicable Comparable Government Bond Rate (as defined in the applicable series of notes), plus 20 basis points for the Euro notes, 20 basis points for the Pound Sterling notes due 2020 and 20 basis points for Pound Sterling the notes due 2025.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In addition, at any time on or after August 20, 2026 with respect to the Euro notes, October 20, 2020 with respect to the Pound Sterling notes due 2020, or August 20, 2025 with respect to the Pound Sterling notes due 2025, Walgreens Boots Alliance may redeem some or all of the applicable series of notes at its option at a redemption price equal to 100% of the principal amount of the applicable notes to be redeemed plus, in every case, accrued and unpaid interest on the notes to be redeemed to, but excluding, the redemption date.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left; background-color: #ffffff;">Change in Control</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left; background-color: #ffffff;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">If Walgreens Boots Alliance experiences a change of control triggering event, unless Walgreens Boots Alliance has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, Walgreens Boots Alliance will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">$4.0 Billion Note Issuance</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On September 13, 2012, Walgreens obtained net proceeds from a public offering of $4.0 billion of notes with varying maturities and interest rates, the majority of which, at issuance, were fixed rate. The notes are unsecured senior debt obligations and rank equally with all other unsecured and unsubordinated indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance. Total issuance costs relating to the notes, including underwriting discounts and fees, were $26 million. On August 10, 2015, the 1.8000% fixed rate notes due September 15, 2017 in the aggregate principal amount of $1.0 billion were redeemed in full. The redemption price was equal to 101.677% of the aggregate principal amount of the notes redeemed, plus accrued interest thereon to, but excluding, the redemption date, and included a $17 million make whole premium, which was recorded as interest expense on the Company&#8217;s Consolidated Statements of Earnings. Additionally, the Company repaid the $750 million 1.000% fixed rate notes on their March 13, 2015 maturity date and the $550 million variable rate notes on their March 13, 2014 maturity date.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table details each tranche of outstanding notes as of February 29, 2016:</div><div>&#160;</div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Notes Issued</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">(in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;">&#160;</td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 18%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Maturity Date</div></td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 20%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Interest Rate</div></td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 51%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Interest Payment Dates</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,200</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 18%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">September 15, 2022</div></td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 3.100%</div></td><td valign="bottom" style="vertical-align: top; width: 51%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">March 15 and September 15; commencing on March 15, 2013</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">500</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 18%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">September 15, 2042</div></td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 20%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 4.400%</div></td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 51%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">March 15 and September 15; commencing on March 15, 2013</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,700</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 18%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 20%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 51%; background-color: #cceeff;">&#160;&#160;&#160;</td></tr></table><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The fair value of the notes outstanding as of February 29, 2016 was $1.6 billion. Fair value for these notes was determined based upon quoted market prices.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left; background-color: #ffffff;">Redemption Option and Change in Control</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Walgreens may redeem the fixed rate notes at its option, at any time in whole, or from time to time in part, at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes being redeemed; and (b) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 12 basis points for the notes due 2015, 22 basis points for the notes due 2022 and 25 basis points for the notes due 2042. If a change of control triggering event occurs, Walgreens will be required, unless it has exercised its right to redeem the notes, to offer to purchase the notes at a purchase price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, on the notes repurchased to the date of repurchase.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">$1.0 Billion Note Issuance</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">On January 13, 2009, Walgreens issued notes totaling $1.0 billion bearing an interest rate of 5.250% paid semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2009. The notes will mature on January 15, 2019. The notes are unsecured senior debt obligations and rank equally with all other unsecured senior indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance. The notes are not convertible or exchangeable. Total issuance costs relating to this offering, including underwriting discounts and fees, were $8 million. On August 10, 2015, $750 million aggregate principal amount of the notes were redeemed. The redemption price was equal to 111.734% of the aggregate principal amount of the notes redeemed plus accrued interest thereon to, but excluding, the redemption date; and included a $88 million make whole premium, which was recorded as interest expense on the Company&#8217;s Consolidated Statements of Earnings. The partial redemption of the notes resulted in $250 million aggregate principal amount of the notes remaining outstanding. The fair value of the notes outstanding as of February 29, 2016 was $270 million. Fair value for these notes was determined based upon quoted market prices.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">&#160;</div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Redemption Option and Change in Control</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Walgreens may redeem the notes, at any time in whole or from time to time in part, at its option at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes to be redeemed; or (b) the sum of the present values of the remaining scheduled payments of principal and interest, discounted to the date of redemption on a semiannual basis at the Treasury Rate (as defined in the applicable series of notes), plus 45 basis points, plus accrued interest on the notes to be redeemed to, but excluding, the date of redemption. If a change of control triggering event occurs, unless Walgreens has exercised its option to redeem the notes, it will be required to offer to repurchase the notes at a purchase price equal to 101% of the principal amount of the notes plus accrued and unpaid interest to the date of redemption.</div><div>&#160;</div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Other Borrowings</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company periodically borrows under its commercial paper program and may borrow under it in future periods. There were no commercial paper borrowings outstanding as of February 29, 2016 or February 28, 2015, respectively. The Company had average daily short-term borrowings of $20 million of commercial paper outstanding at a weighted average interest rate of 0.62% for the six month period ended February 29, 2016. We had average daily short-term borrowings of $4 million of commercial paper outstanding at a weighted average interest rate of 0.46% for the six months ended February 28, 2015.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">2014 Term Loan Agreement and Revolving Credit Agreement</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a term loan credit agreement (the &#8220;Term Loan Agreement&#8221;), which provides Walgreens Boots Alliance and Walgreens with the ability to borrow up to &#163;1.45 billion on an unsecured basis. Borrowings under the Term Loan Agreement bear interest at a fluctuating rate per annum equal to the reserve adjusted LIBOR plus an applicable margin based on the Company&#8217;s credit ratings. As of February 29, 2016, Walgreens Boots Alliance had borrowed &#163;1.45 billion ($2.0 billion at the February 29, 2016 spot rate of $1.39 to &#163;1) under the Term Loan Agreement. The fair value of the Term Loan Agreement as of February 29, 2016 was $2.0 billion. Fair value of the borrowings under the Term Loan Agreement was determined based upon quoted market prices.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a five-year unsecured, multicurrency revolving credit agreement (the &#8220;Revolving Credit Agreement&#8221;), replacing prior Walgreens agreements dated July 20, 2011 and July 23, 2012. The new unsecured revolving credit agreement initially totaled $2.25 billion, of which $375 million was available for the issuance of letters of credit. On December 29, 2014, upon the affirmative vote of the majority of common shares of Walgreens represented and entitled to vote at the Walgreens special meeting of shareholders to approve the issuance of the shares necessary to complete the Second Step Transaction, the available credit increased to $3.0 billion, of which $500 million is available for the issuance of letters of credit. The issuance of letters of credit reduces the aggregate amount otherwise available under the Revolving Credit Agreement for the making of revolving loans. Borrowings under the Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance&#8217;s option, the alternate base rate or the reserve adjusted LIBOR, in each case, plus an applicable margin calculated based on the Company&#8217;s credit ratings. As of February 29, 2016, there were no borrowings or letters of credit issued pursuant to the Revolving Credit Agreement.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Total upfront fees related to the Term Loan Agreement and Revolving Credit Agreement were $14 million. The Company pays a facility fee to the financing banks to keep these lines of credit active.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In accordance with the terms of each of the Term Loan Agreement and the Revolving Credit Agreement, Walgreens guaranteed the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of all of Walgreens Boots Alliance&#8217;s obligations under the Term Loan Agreement and Revolving Credit Agreement, as applicable until August 10, 2015, when such guarantees automatically terminated, without penalty to Walgreens or Walgreens Boots Alliance, and the obligations of Walgreens thereunder were unconditionally released and discharged.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On December 19, 2014, Walgreens Boots Alliance and Walgreens entered into a Revolving Credit Agreement (as amended, the &#8220;364-Day Credit Agreement&#8221;) with the lenders party thereto. The 364-Day Credit Agreement was a $750 million, 364-day unsecured, multicurrency revolving facility. On July 9, 2015, Walgreens Boots Alliance amended the 364-Day Credit Agreement to remove Walgreens as a borrower thereunder, eliminate Walgreens&#8217; guarantee <font style="font-size: 10pt; font-family: 'Times New Roman';">of all obligations of Walgreens Boots Alliance thereunder</font> and make certain conforming changes to effectuate those modifications, including modifications and deletions of certain definitions and cross-references. On December 17, 2015, the Company terminated the 364-Day Credit Agreement. The 364-Day Credit Agreement remained undrawn as of the date of termination and would have matured on December 30, 2015.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Term Loan Agreement, Revolving Credit Agreement and the 364-Day Revolving Credit Agreement each contain or contained a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">2015 Bridge Credit Agreement and Term Loan Credit Agreement</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On October 27, 2015, the Company entered into an Agreement and Plan of Merger with Rite Aid Corporation (&#8220;Rite Aid&#8221;) and Victoria Merger Sub, Inc., a wholly-owned subsidiary of the Company (the &#8220;Merger Agreement&#8221;). In connection with the Merger Agreement, the Company entered into a bridge facility commitment letter (as amended and restated as of November 19, 2015, the &#8220;Commitment Letter&#8221;), with UBS Securities LLC and UBS AG, Stamford Branch for a $12.8 billion senior unsecured bridge facility.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On December 18, 2015, Walgreens Boots Alliance entered into a Bridge Term Loan Credit Agreement with the lenders party thereto and UBS AG, Stamford Branch, as administrative agent (as amended on January 20, 2016, the &#8220;Bridge Credit Agreement&#8221;) and a Term Loan Credit Agreement with the lenders party thereto and Bank of America, N.A., as administrative agent (as amended on January 20, 2016, the &#8220;Term Loan Credit Agreement&#8221; and together with the Bridge Credit Agreement, the &#8220;2015 Credit Agreements&#8221;). The Commitment Letter and the commitments contemplated thereby terminated upon Walgreens Boots Alliance entering into the 2015 Credit Agreements.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Bridge Credit Agreement is a 364-day unsecured bridge term loan facility. The aggregate commitments of all lenders under the Bridge Credit Agreement are equal to $7.8 billion, provided that Walgreens Boots Alliance may increase the commitments under the Bridge Credit Agreement at any time prior to the funding of the loans thereunder by up to $2.0 billion, subject to obtaining commitments from existing lenders and/or new lenders selected by Walgreens Boots Alliance and reasonably acceptable to the administrative agent. Walgreens Boots Alliance can extend up to $3.0 billion of the loans under the Bridge Credit Agreement for an additional 90-day period if desired. As of February 29, 2016, there were no borrowings under the Bridge Credit Agreement.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Term Loan Credit Agreement is a two-tranche unsecured term loan facility, with the first tranche maturing three years after the earlier of the funding date and October 27, 2016, and the second tranche maturing five years after the earlier of the funding date and October 27, 2016. The aggregate commitments of all lenders under the Term Loan Credit Agreement are equal to $5.0 billion. As of February 29, 2016, there were no borrowings under the Term Loan Credit Agreement.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Walgreens Boots Alliance will be the borrower under each of the 2015 Credit Agreements. The ability of Walgreens Boots Alliance to request the making of loans under each of the 2015 Credit Agreements is subject to the satisfaction (or waiver) of certain conditions set forth therein and will terminate upon the occurrence of certain events set forth therein. Borrowings under each of the 2015 Credit Agreements will bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance&#8217;s option, the alternate base rate or the reserve adjusted Eurocurrency rate, in each case, plus an applicable margin calculated based on Walgreens Boots Alliance&#8217;s credit ratings. Upfront fees paid to date in connection with the 2015 Credit Agreements totaled $30 million. A maximum of a further $5 million in upfront fees is payable prior to, or at funding, subject to certain conditions. In addition, Walgreens Boots Alliance will also pay to the lenders under each of the 2015 Credit Agreements certain customary fees, including a ticking fee based on the aggregate outstanding commitments of the lenders under the applicable 2015 Credit Agreement starting at 90 days after signing. Each of the 2015 Credit Agreements contains a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants, which restrictive covenants shall not be in effect until the funding of the loans under the applicable 2015 Credit Agreement.</div></div> 44000000 11000000 26000000 8000000 270000000 1600000000 7900000000 1800000000 2000000000 2020-11-20 2042-09-15 2034-11-18 2019-11-18 2022-09-15 2025-11-20 2024-11-18 2026-11-20 2016-05-18 2017-11-17 2021-11-18 2044-11-18 30000000 14000000 5000000 May 18 and November 18; commencing on May 18, 2015 February 18, May 18, August 18, and November 18; commencing on February 18, 2015 May 18 and November 18; commencing on May 18, 2015 March 15 and September 15; commencing on March 15, 2013 May 17 and November 17; commencing on May 17, 2015 March 15 and September 15; commencing on March 15, 2013 May 18 and November 18; commencing on May 18, 2015 May 18 and November 18; commencing on May 18, 2015 May 18 and November 18; commencing on May 18, 2015 250000000 500000000 1250000000 750000000 2000000000 750000000 1700000000 1200000000 1250000000 500000000 300000000 750000000 1500000000 8000000000 400000000 700000000 5000000000 0.031 0.033 0.0525 0.027 0.044 0.0175 0.02125 0.036 0.048 0.045 0.02875 0.038 0.0525 0.018 0.027 0.048 0.038 0.036 0.045 0.0175 0.031 0.02875 0.044 0.033 0.02125 -171000000 181000000 297000000 176000000 3107000000 3538000000 9000000 -1000000 -1000000 0 0 -10000000 -5000000 -5000000 -9000000 -7000000 -12000000 -14000000 -6000000 4000000 159000000 10000000 77000000 8000000 53000000 5000000 53000000 11000000 34000000 5000000 12000000 5000000 12000000 15000000 10000000 43000000 43000000 127000000 62000000 22000000 69000000 34000000 22000000 5000000 1000000 5000000 2000000 2000000 0 2000000 1000000 826000000 824000000 507000000 442000000 346000000 567000000 311000000 644000000 768000000 250000000 2000000 495000000 465000000 1000000 1205000000 250000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;"><u>Note 10. Financial Instruments</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company uses derivative instruments to manage its exposure to interest rate and foreign currency exchange risks.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 0.9pt;">The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of February 29, 2016, excluding warrants which are presented separately in this footnote, were as follows (in millions):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 46%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Notional<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;">&#160;</td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 30%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 4.5pt; margin-right: 4.5pt;">Location in Consolidated </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 4.5pt; margin-right: 4.5pt;">Condensed Balance Sheets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Derivatives designated as fair value hedges</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Interest rate swaps</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other non-current assets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Derivatives not designated as hedges</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #ffffff;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">465</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current assets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">768</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current liabilities</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Basis swap</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current liabilities</div></td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 17.45pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Amounts are presented in U.S. dollar equivalents.</td></tr></table></div><div style="text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2015, excluding warrants which are presented separately in this footnote, are as follows (in millions):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 46%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Notional<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;">&#160;</td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 30%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 4.5pt; margin-right: 4.5pt;">Location in Consolidated </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 4.5pt; margin-right: 4.5pt;">Condensed Balance Sheets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Derivatives designated as fair value hedges</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Interest rate swaps</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other non-current assets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Derivatives not designated as hedges</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #ffffff;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,205</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current assets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">495</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current liabilities</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Basis swap</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current assets</div></td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 17.45pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Amounts are presented in U.S. dollar equivalents.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company uses interest rate swaps to manage the interest rate exposure associated with some of its fixed-rate borrowings and designates them as fair value hedges. The Company uses forward starting interest rate swaps to hedge its interest rate exposure of some of its anticipated debt issuances and designates them as cash flow hedges.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company utilizes foreign currency forward contracts and other foreign currency derivatives to hedge significant committed and highly probable future transactions and cash flows denominated in currencies other than the functional currency of the Company or its subsidiaries. The Company has significant non-US dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Fair Value Hedges</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company entered into a series of interest rate swaps, converting $750 million of its 5.250% fixed rate notes to a floating interest rate based on the six month LIBOR in arrears plus a constant spread and an interest rate swap converting $250 million of its 5.250% fixed rate notes to a floating interest rate based on the one-month LIBOR in arrears plus a constant spread. All swap termination dates coincide with the notes maturity date, January 15, 2019. These swaps were designated as fair value hedges. On August 10, 2015, the Company terminated $500 million of the six month LIBOR in arrears swaps and all of the one-month LIBOR in arrears swaps in connection with the repayment of the associated debt as described in Note 9, <font style="font-size: 10pt; font-family: 'Times New Roman';">Short-Term Borrowings and Long-Term Debt</font>.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk were recognized as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Location in Consolidated</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">&#160;</div></td><td style="vertical-align: top; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Condensed Statements of </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Earnings</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Interest rate swaps</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 0.8pt;">Interest expense, net</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Notes</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 0.8pt;">Interest expense, net</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The changes in fair value of the Company&#8217;s debt that was swapped from fixed to variable rate and designated as fair value hedges are included in short-term and long-term debt on the Consolidated Condensed Balance Sheets (see Note 9, Short-Term Borrowings and Long-Term Debt). At February 29, 2016 and August 31, 2015, the cumulative fair value adjustments resulted in an increase in long-term debt of $4 million and $1 million, respectively. No material gains or losses were recorded from ineffectiveness during the three and six months ended February 29, 2016 and February 28, 2015.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Derivatives not Designated as Hedges</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of interest rate and foreign currency risks. The gains and losses due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td style="vertical-align: bottom; white-space: nowrap; font-weight: bold; padding-bottom: 2px; text-align: center;">Location in Consolidated</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; padding-left: 15%;"></td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Condensed Statements of </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Earnings</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.55pt;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.55pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Interest rate swaps</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9.15pt; margin-right: 0.8pt; text-indent: -4.65pt;">Interest expense, net</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9.15pt; margin-right: 0.8pt; text-indent: -4.65pt;">Selling, general and administrative expenses</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(23</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(28</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(28</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Second Step Transaction foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9.15pt; margin-right: 0.8pt; text-indent: -4.65pt;">Other income (expense)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(70</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(166</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9.15pt; margin-right: 0.8pt; text-indent: -4.65pt;">Other income (expense)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">33</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">33</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Warrants</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">As of February 29, 2016, the Company held (a) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share, exercisable during a six month period beginning in March 2016, (&#8220;Warrant 1&#8221;), and (b) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $52.50 per share, exercisable during a six month period beginning in March 2017 (&#8220;Warrant 2&#8221; and together with Warrant 1, the &#8220;Warrants&#8221;). Warrant 1 was exercised in full on March 18, 2016. See Note 20, Subsequent Event for further information.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company reports the Warrants at fair value. The fair value and balance sheet presentation of the Warrants was as follows (in millions):</div><div style="text-align: left;"><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 4.5pt;">Location in Consolidated </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 4.5pt;">Condensed Balance Sheets&#160;</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.5pt;">February 29,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.55pt;">August 31, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.55pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset derivatives not designated as hedges:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 38%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 38%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 4.5pt; margin-right: 0.8pt;">Other non-current assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,546</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,140</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 18pt;">The gains and losses due to changes in fair value of the Warrants recognized in earnings were as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.5pt;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; padding-left: 10%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">&#160;</div></td><td style="vertical-align: top; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Location in Consolidated</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Condensed Statements of Earnings</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 0.8pt; text-indent: 4.5pt;">Other income (expense)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(532</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">559</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(594</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">849</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-right: 18pt;">Derivatives Credit Risk</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-right: 18pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 18pt;">Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-right: 18pt;">Derivatives Offsetting</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-right: 18pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.</div></div> 2140000000 1546000000 0.0525 0.0525 1000000 0 250000000 16000000 34000000 2000000 5000000 9000000 1000000 750000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 19. Recent Accounting Pronouncements</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In February 2016, the Financial Accounting Standard Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, Leases (Topic 842), which supersedes Topic 840, Leases. This ASU increases the transparency and comparability of organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed. At the lease commencement date, lessee recognizes a lease liability and right-of-use asset, which is initially measured at the present value of future lease payments. There are two approaches for amortizing the right-of use asset. Under the finance lease approach, interest on the lease liability is recognized separately from amortization of the right-of-use asset. Repayments of the principal portion of the lease liability will be classified as financing activities and payments of interest on the lease liability and variable lease payments will be classified as operating activities in the statement of cash flows. Under the operating lease approach, the cost of the lease is calculated on a straight-line basis over the life of the lease term. All cash payments are classified as operating activities in the statement of cash flows. For sale and leaseback transactions, in order for a sale to occur, the transfer of the asset must meet all criteria in Topic 606. If there is no sale for the seller-lessee, the buyer-lessor does not account for a purchase. Any consideration paid for the asset is accounted for as a financing transaction. For transactions previously accounted for as a sale and leaseback, the transition guidance in Topic 842 does not require an entity to assess whether the transaction would have qualified as a sale and a leaseback in accordance with Topic 842. Additionally, gains recorded under sale and leaseback transactions are recognized at the transaction date and no longer deferred over the lease term. This ASU is effective for annual periods beginning after December 15, 2018 (fiscal 2020). In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach which includes a number of optional practical expedients that entities may elect to apply. For a description of the Company&#8217;s lease obligations, please refer to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended August 31, 2015. The Company has begun evaluating and planning for the adoption and implementation of this ASU, including assessing the overall impact. This ASU will have a material impact on the Company&#8217;s financial statements. The impact on the Company&#8217;s results of operations is being evaluated. The impact of this ASU is non-cash in nature and will not affect the Company&#8217;s cash position.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In January 2016, the FASB issued ASU 2016-01, Financial Instruments &#8211; Overall (Subtopic 825-10). This ASU requires equity investments (except those under the equity method of accounting or those that result in the consolidation of an investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. This simplifies the impairment assessment of equity investments previous held at cost. Separate presentation of financial assets and liabilities by measurement category is required. This ASU is effective prospectively for annual periods beginning after December 15, 2017 (fiscal 2019). Early application is not permitted. The Company is evaluating the effect of adopting this new accounting guidance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). This ASU simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as non-current in a classified statement of financial position. This ASU may be applied either prospectively to all deferred tax assets and liabilities, or retrospectively to all periods presented for annual periods beginning after December 16, 2016 and interim periods thereafter (fiscal 2018), with early adoption permitted, and may require additional disclosure based on the application method selected. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company&#8217;s financial position.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805). This ASU simplifies the accounting for adjustments made to provisional amounts recognized in a business combination by eliminating the requirements to retrospectively account for those adjustments. This guidance applies to all entities that have reported provisional amounts for items in a business combination for which the accounting is incomplete by the end of the reporting period in which the combination occurs and during the measurement period having an adjustment to provisional amounts recognized. This ASU is effective prospectively for annual periods beginning after December 31, 2016 and interim periods thereafter (fiscal 2018) with early adoption permitted. The Company adopted this ASU on March 1, 2016. The adoption of this ASU did not have a material impact on the Company&#8217;s results of operations, cash flows or financial position.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), an update to ASU 2014-09. This ASU amends ASU 2014-09 to defer the effective date by one year for annual reporting periods beginning after December 15, 2017 (fiscal 2019). This ASU removes inconsistencies, complexities and allows transparency and comparability of revenue transactions across entities, industries, jurisdictions and capital markets by providing a single comprehensive principles-based model with additional disclosures regarding uncertainties. The principles-based revenue recognition model has a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Early adoption is permitted for annual reporting periods beginning after December 15, 2016 (fiscal 2018). In transition, the ASU may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company&#160;is evaluating the effect of adopting this new accounting guidance including the&#160;transition method.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330). This ASU simplifies current accounting treatments by requiring entities to measure most inventories at &#8220;the lower of cost and net realizable value&#8221; rather than using lower of cost or market. This guidance does not apply to inventories measured using last-in, first-out method or the retail inventory method. This ASU is effective prospectively for annual periods beginning after December 15, 2016 and interim periods thereafter (fiscal 2018) with early adoption permitted. Upon transition, entities must disclose the accounting change. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company&#8217;s results of operations, cash flows or financial position.</div></div> 781000000 0 0 0 0 0 0 781000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 14. Earnings Per Share</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. There were 3.2 million outstanding options to purchase common shares that were anti-dilutive and excluded from the second quarter earnings per share calculation as of February 29, 2016 compared to 3.4 million as of February 28, 2015. Anti-dilutive shares excluded from the year to date earnings per share calculation were 2.2 million compared to 5.0 million for the periods ending February 29, 2016 and February 28, 2015, respectively.</div></div> -88000000 -99000000 163000000 170000000 1805000000 1790000000 837000000 876000000 0.45 0.05 0.725 0.5 0.12 0.5 0.12 0.45 0.05 0.45 0.45 26000000 50000000 246000000 743000000 1548000000 1592000000 3286000000 14978000000 6489000000 5317000000 3168000000 702000000 374000000 979000000 5015000000 5687000000 4598000000 3936000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 5. Equity Method Investments</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Equity method investments as of February 29, 2016 and August 31, 2015 were as follows (in millions, except percentages):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Carrying</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Ownership</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Percentage</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Carrying</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Ownership</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Percentage</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equity method investments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,217</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12% - 50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,242</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12% - 50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">%</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company's principal equity method investments include its&#160;investments in Guangzhou Pharmaceuticals Corporation and Nanjing Pharmaceutical Corporation Limited, the Company&#8217;s pharmaceutical wholesale investments in China; and the equity method investment retained through the sale of a majority interest in Option Care Inc. in fiscal 2015. See Note 20, Subsequent Event for further information.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Equity method investments of the Company are recorded within other non-current assets on the Consolidated Condensed Balance Sheets.<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> The Company </font>reported $9 million and $20 million of post-tax equity earnings in equity method investments for the three and six month periods ended February 29, 2016, respectively, in the Consolidated Condensed Statements of Earnings. The Company reported $8 million of post-tax equity earnings from equity method investments other than Alliance Boots for the three and six month periods ended February 28, 2015. Additionally, for the three and six month periods ended February 28, 2015, the Company reported equity earnings in Alliance Boots of $101 million and $315 million, respectively, as its own line in the Consolidated Condensed Statements of Earnings.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Summarized Financial Information</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Summarized financial information for the Company&#8217;s equity method investments is as follows:</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Balance Sheets (in millions)</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, 2016<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31, 2015<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Current assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,687</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Noncurrent assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,592</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,548</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Current liabilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,598</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,936</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Noncurrent liabilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">876</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">837</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Shareholders&#8217; equity<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,805</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,790</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Statements of Earnings (in millions)</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)(4)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)(4)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net sales</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,286</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,317</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,489</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">14,978</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Gross Profit</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">374</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">979</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">702</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,168</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net Income</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">246</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">743</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Share of income from equity method investments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">109</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">20</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">323</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Balance sheet information of foreign equity method investments are translated at their respective February 29, 2016 and August 31, 2015 spot rates.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Shareholders&#8217; equity at February 29, 2016 and August 31, 2015 includes $170 million and $163 million, respectively, related to noncontrolling interests.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Includes equity method investment in Alliance Boots from Walgreen Co.&#8217;s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization.</div></td></tr></table></div></div> 1242000000 1217000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Equity method investments as of February 29, 2016 and August 31, 2015 were as follows (in millions, except percentages):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Carrying</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Ownership</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Percentage</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Carrying</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Ownership</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Percentage</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equity method investments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,217</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12% - 50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,242</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12% - 50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">%</div></td></tr></table></div> 2545000000 1311000000 399000000 742000000 93000000 6000000 -123000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-right: 0.8pt;"><u>Note 11. Fair Value Measurements</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company measures certain assets and liabilities in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels:</div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; width: 45pt; align: right;">Level 1 -</td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; width: 45pt; align: right;">Level 2 -</td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Observable inputs other than quoted prices in active markets.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; width: 45pt; align: right;">Level 3 -</td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</td></tr></table></div><div style="text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4pt;">February 29, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; margin-right: 0.7pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Assets</font>:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Restricted cash <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">175</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">175</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Money market funds <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,659</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,659</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Available-for-sale investments <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,027</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,027</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Interest rate swaps <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Foreign currency forwards <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Warrants <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(6)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,546</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,546</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; margin-right: 0.7pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Liabilities</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Basis swaps <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Foreign currency forwards <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.35pt;">August 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Assets</font>:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Restricted cash <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">184</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">184</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Money market funds <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,043</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,043</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Available-for-sale investments <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,183</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,183</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Interest rate swaps <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Warrants <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(6)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,140</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,140</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Liabilities</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Money market funds are valued at the closing price reported by the fund sponsor.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Fair values of quoted investments are based on current bid prices as of the balance sheet dates.&#160; See Note 6, Available-for-Sale Investments for additional information.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(6)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen&#8217;s common stock; AmerisourceBergen&#8217;s common stock price at the valuation date; AmerisourceBergen&#8217;s equity volatility; the number of shares of AmerisourceBergen&#8217;s common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the Warrants.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">There were no transfers between levels for the three and six month periods ended February 29, 2016 and February 28, 2015, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company&#8217;s debt in the footnotes to the consolidated financial statements. Unless otherwise noted, the fair value for all notes was determined based upon quoted market prices and therefore categorized as Level 1. See Note 9, Short-Term Borrowings and Long-Term Debt for further information. The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.</div></div> 3700000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4pt;">February 29, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; margin-right: 0.7pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Assets</font>:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Restricted cash <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">175</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">175</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Money market funds <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,659</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,659</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Available-for-sale investments <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,027</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,027</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Interest rate swaps <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Foreign currency forwards <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Warrants <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(6)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,546</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,546</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; margin-right: 0.7pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Liabilities</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Basis swaps <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; margin-right: 0.7pt; text-indent: -7.2pt;">Foreign currency forwards <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.35pt;">August 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Assets</font>:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Restricted cash <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">184</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">184</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Money market funds <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,043</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,043</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Available-for-sale investments <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,183</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,183</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Interest rate swaps <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Warrants <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(6)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,140</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,140</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Liabilities</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Money market funds are valued at the closing price reported by the fund sponsor.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Fair values of quoted investments are based on current bid prices as of the balance sheet dates.&#160; See Note 6, Available-for-Sale Investments for additional information.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(6)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen&#8217;s common stock; AmerisourceBergen&#8217;s common stock price at the valuation date; AmerisourceBergen&#8217;s equity volatility; the number of shares of AmerisourceBergen&#8217;s common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the Warrants.</td></tr></table></div></div> 182000000 246000000 83000000 132000000 114000000 106000000 68000000 41000000 41000000 92000000 207000000 1090000000 65000000 1293000000 470000000 536000000 2953000000 3297000000 318000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The identified definite and indefinite lived intangible assets were as follows:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 66%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Definite-Lived Intangible Assets</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;">&#160;</td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Weighted-Average Useful </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Life (in years)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Amount (in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 66%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Customer relationships</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: center; width: 1%; background-color: #cceeff;">12</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,311</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 66%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Loyalty card holders</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: center; width: 1%; background-color: #ffffff;">20</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">742</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 66%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Trade names and trademarks</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: center; width: 1%; background-color: #cceeff;">9</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">399</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 66%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Favorable lease interests</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%; background-color: #ffffff;">7</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">93</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 66%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: center; width: 1%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,545</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 78%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Indefinite-Lived Intangible Assets</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Amount (in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 78%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Trade names and trademarks</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,657</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 78%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Pharmacy licenses</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,489</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 78%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,146</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> 94000000 904000000 678000000 885000000 1293000000 95000000 4246000000 158000000 661000000 154000000 675000000 457000000 440000000 4387000000 1409000000 730000000 289000000 254000000 358000000 401000000 1.56 1.00 1.39 706000000 706000000 0 0 563000000 15796000000 16372000000 14861000000 3251000000 3605000000 8940000000 8940000000 3534000000 3898000000 19000000 0 19000000 19000000 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 8. Goodwill and Other Intangible Assets</u></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions):</div><div><br /></div></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">August 31, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,940</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,898</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,534</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16,372</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisitions</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">19</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">19</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">13</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Currency translation adjustments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(309</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(605</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,940</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,605</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,251</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15,796</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Other represents immaterial purchase accounting adjustments for prior year Company acquisitions.</td></tr></table></div><div style="text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">The carrying amount and accumulated amortization of intangible assets</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">consist of the following (in millions):</font></div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Gross Amortizable Intangible Assets</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Customer relationships</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div>$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div>1,293</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,409</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Purchased prescription files</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">904</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">885</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Loyalty card holders</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">661</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">730</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Trade names and trademarks</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">678</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">675</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Favorable lease interests</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">457</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">440</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Non-compete agreements</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">158</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">154</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Purchasing and payer contracts</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">95</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">94</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 25.2pt; text-indent: -7.2pt;">Total gross amortizable intangible assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,246</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,387</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accumulated amortization</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Customer relationships</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">182</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">132</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Purchased prescription files</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">536</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">470</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Loyalty card holders</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Trade names and trademarks</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">114</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">83</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Favorable lease interests</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">246</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">207</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Non-compete agreements</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">106</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">92</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Purchasing and payer contracts</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">68</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">65</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 25.2pt; text-indent: -7.2pt;">Total accumulated amortization</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,293</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,090</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total amortizable intangible assets, net</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,953</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,297</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Indefinite Lived Intangible Assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Trade names and trademarks</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,947</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,590</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Pharmacy licenses</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,222</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,464</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total indefinite lived intangible assets</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,169</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,054</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total intangible assets, net</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,122</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,351</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">Amortization expense for intangible assets was $124 million and $216 million for the three and six months ended February 29, 2016, respectively, and $209 million and $276 million for the three and six months ended February 28, 2015, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">Estimated annual amortization expense for intangible assets recorded at February 29, 2016 is as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2019</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2020</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Estimated annual amortization expense</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">401</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">358</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">318</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">289</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">254</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> 0 309000000 605000000 296000000 -13000000 -10000000 3000000 0 15446000000 6882000000 12178000000 7944000000 9146000000 2489000000 6657000000 0.86 2.91 1.96 1.88 315000000 101000000 8000000 9000000 8000000 20000000 109000000 20000000 9000000 323000000 2443000000 1224000000 3641000000 2497000000 1.87 0.85 2.88 1.93 2775000000 2587000000 3840000000 1364000000 301000000 391000000 712000000 468000000 553000000 481000000 -99000000 92000000 160000000 363000000 60000000 -94000000 553000000 -106000000 -20000000 -79000000 391000000 152000000 -33000000 -21000000 2222000000 5947000000 2464000000 8169000000 6590000000 9054000000 11122000000 12351000000 140000000 144000000 199000000 278000000 90000000 302000000 106000000 8678000000 9025000000 11500000 34157955 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 6. Available-for-Sale Investments</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Walgreens, Alliance Boots and AmerisourceBergen Corporation (&#8220;AmerisourceBergen&#8221;) entered into a Framework Agreement, dated as of March 18, 2013, pursuant to which Walgreens and Alliance Boots together were granted the right to purchase a minority equity position in AmerisourceBergen, including&#160;the right, but not the obligation, to purchase up to 19,859,795 shares of AmerisourceBergen common stock in open market transactions.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In conjunction with its long-term relationship with AmerisourceBergen, as of February 29, 2016, the Company held 11.5 million shares, approximately 5.6% of AmerisourceBergen&#8217;s outstanding common stock, at a total fair value of $993 million. The Company did not acquire any AmerisourceBergen common shares in the three and six month periods ended February 29, 2016.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 320, Investments &#8211; Debt and Equity Securities, the Company, as of February 29, 2016, accounted for its investment in AmerisourceBergen shares as an available-for-sale investment reported at fair value within other non-current assets in the Consolidated Condensed Balance Sheets. As an available-for-sale investment, changes in the fair value are recorded through other comprehensive income. The value of the investment is recorded at the closing price of AmerisourceBergen common stock as of the balance sheet date. See Note 20, Subsequent Event for further information.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="14" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Amortized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">cost basis</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gross </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gross </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">AmerisourceBergen common stock</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">717</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">276</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">993</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other investments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">38</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total available-for-sale investments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">755</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">276</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,027</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="14" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Amortized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">cost basis</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gross </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gross </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">AmerisourceBergen common stock</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">717</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">430</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,147</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other investments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">37</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">36</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total available-for-sale investments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">754</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">430</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,183</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">For the three and six month periods ended February 29, 2016, there were $1 million and $3 million, respectively, of available-for-sale securities sold. There were no sales of available-for-sale investments for the three and six month periods ended February 28, 2015.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company&#8217;s other available-for-sale investments are classified within <font style="font-size: 10pt; font-family: 'Times New Roman';">other current assets in the Consolidated Condensed Balance Sheets.</font></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 4. Operating Leases</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">Initial terms for leased premises in the U.S. are typically 15 to 25 years, followed by additional terms containing renewal options at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.</div><div><br /></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company provides for future costs related to closed locations. The liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date. During the three and six months ended February 29, 2016, the Company recorded charges of $9 million and $75 million, respectively, for facilities that were closed or relocated under long-term leases, including stores closed through the Company&#8217;s restructuring activities. This compares to no charges for the three months ended and $26 million for the six months ended February 28, 2015. Charges are reported in selling, general and administrative expenses on the Consolidated Condensed Statements of Earnings.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The changes in reserve for facility closings and related lease termination charges include the following (in millions):</div></div><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;&#160;&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Month </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Period Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Twelve Month </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Period Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance &#8211; beginning of period</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">446</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">257</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Provision for present value of non-cancellable lease payments on closed facilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">77</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">231</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Assumptions about future sublease income, terminations and changes in interest rates</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Interest accretion</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">27</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Liability assumed through acquisition of Alliance Boots</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">13</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash payments, net of sublease income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(54</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(76</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance &#8211; end of period</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">467</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">446</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company remains secondarily liable on 79 leases. The maximum potential undiscounted future payments are $348 million at February 29, 2016. Lease option dates vary, with some extending to 2039.</div></div> 16557000000 16272000000 20195000000 20925000000 1000000 0 9000000 0 0 0 9000000 16000000 16000000 0 0 1000000 68782000000 66385000000 2015-12-17 0 0 0 750000000 2000000000 1450000000 2000000000 375000000 3000000 2250000000 500000000 1450000000 P5Y P90D P364D P3Y 4000000 1000000 12974000000 13315000000 0.55 0.275 0.275 1 1 439000000 412000000 2600000000 -552000000 -4708000000 3085000000 2337000000 2040000000 2042000000 2892000000 930000000 -1859000000 2829000000 9000000 2000000 18000000 45000000 3 1377000000 3328000000 2431000000 1860000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 1.&#160; Organization</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Walgreens Boots Alliance, Inc. (&#8220;Walgreens Boots Alliance&#8221;) and subsidiaries are a global pharmacy-led health and wellbeing enterprise. Its operations are conducted through three reportable segments (Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale). See Note 18, Segment Reporting for further information.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On December 31, 2014, Walgreens Boots Alliance became the successor of Walgreen Co. (&#8220;Walgreens&#8221;) pursuant to a merger designed to effect a reorganization of Walgreens into a holding company structure (the &#8220;Reorganization&#8221;). Pursuant to the Reorganization, Walgreens became a wholly-owned subsidiary of Walgreens Boots Alliance, a Delaware corporation formed for the purposes of the Reorganization, and each issued and outstanding share of Walgreens common stock converted on a one-to-one basis into Walgreens Boots Alliance common stock. References to the &#8220;Company&#8221; refer to Walgreens Boots Alliance and its subsidiaries from and after the effective time of the Reorganization on December 31, 2014 and, prior to that time, to the predecessor registrant Walgreens and its subsidiaries, except as otherwise indicated or the context otherwise requires.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On December 31, 2014, following the completion of the Reorganization, Walgreens Boots Alliance completed the acquisition of the remaining 55% of Alliance Boots GmbH (&#8220;Alliance Boots&#8221;) that Walgreens did not previously own (the &#8220;Second Step Transaction&#8221;) in exchange for &#163;3.133 billion in cash and approximately 144.3 million shares of Walgreens Boots Alliance common stock. Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method immediately upon completion of the Second Step Transaction. For financial reporting and accounting purposes, Walgreens Boots Alliance was the acquirer of Alliance Boots. The consolidated financial statements (and other data) reflect the results of operations and financial position of Walgreens and its subsidiaries for periods prior to December 31, 2014 and of Walgreens Boots Alliance and its subsidiaries for periods from and after the effective time of the Reorganization on December 31, 2014.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">As part of the Second Step Transaction, the Company acquired the remaining 27.5% noncontrolling interest in Walgreens Boots Alliance Development GmbH (&#8220;WBAD&#8221;), a global sourcing enterprise established by the Company and Alliance Boots. The Company already owned a 50% direct ownership in WBAD and indirectly owned an additional ownership interest through its previous 45% investment in Alliance Boots, representing a direct and indirect economic interest of 72.5%. The Company&#8217;s acquisition of the remaining 27.5% effective ownership in WBAD as part of the Second Step Transaction was accounted for as an equity transaction as it has historically been consolidated by the Company. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. (&#8220;AHID&#8221;), which is not a member of the Company&#8217;s consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000.</div></div> -1000000 8000000 2000000 9000000 113000000 -122000000 1000000 -12000000 -1570000000 189000000 -485000000 90000000 -204000000 -8000000 2000000 -1654000000 92000000 1000000 -88000000 0 -87000000 -9000000 -296000000 -2000000 -1121000000 -1210000000 0 -4000000 -1715000000 -313000000 -18000000 2000000 -8000000 -1570000000 -1121000000 -139000000 -358000000 -436000000 -10000000 -144000000 -57000000 0 -1000000 140000000 297000000 -89000000 -1264000000 -648000000 -87000000 -88000000 90000000 189000000 -301000000 -1156000000 -1606000000 -490000000 5334000000 4537000000 504000000 703000000 -496000000 -553000000 -77000000 2000000 -50000000 -18000000 2000000 1000000 -108000000 57000000 52000000 51000000 -60000000 -1000000 -1000000 -49000000 0 58000000 -118000000 -1000000 83000000 7000000 0 0 1130000000 1034000000 0 12000000 -2000000 -1000000 42000000 44000000 4072000000 4114000000 322000000 196000000 1052000000 1068000000 303000000 321000000 -92000000 -113000000 0 0 0 -1690000000 -1654000000 0 0 -36000000 0 0 -209000000 -127000000 -1245000000 1152000000 594000000 3000000 91000000 4461000000 0 86000000 642000000 787000000 3133000000 4900000000 3133000000 4874000000 1170000000 643000000 657000000 30000000 29000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 13. Retirement Benefits</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan. The Company uses an August 31 annual measurement date for its pension plans.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Defined Benefit Pension Plans (non-US plans)</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The principal defined benefit pension plan is the Boots Pension Plan, which covers certain employees in the United Kingdom (the &#8220;Boots Plan&#8221;). The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010, with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis. <font style="font-size: 10pt; font-family: 'Times New Roman';">The Company also has two smaller defined benefit pension plans in the United Kingdom, both of which were closed to future accruals effective July 1, 2010.</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">Other defined benefit pension plans include smaller plans in Germany and France.</font></div><div style="background-color: #ffffff;"><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The obligation related to the Company&#8217;s pension plans was acquired as a result of the Second Step Transaction<font style="font-size: 10pt; font-family: 'Times New Roman';">. </font>The pension costs presented for 2015 represent the costs for the period from December 31, 2014 through February 28, 2015. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, pension costs for fiscal 2015 prior to the date of the Second Step Transaction were reflected within Equity earnings in Alliance Boots on the Consolidated Condensed Statement of Earnings.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Components of net periodic pension costs for the defined benefit pension plans (in millions):</div><div><br /></div></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr style="height: 12px;"><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Service costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Interest costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">77</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">53</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">159</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">53</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Expected returns on plan assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(62</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(43</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(127</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(43</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Settlements</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;">&#160;-</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total net periodic pension costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div style="background-color: #ffffff;"><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company made cash contributions to its defined benefit pension plans of $9 million for the period ended February 29, 2016, which primarily related to committed funded payments. The Company plans to contribute an additional $66 million to its defined benefit pension plans in fiscal 2016.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Defined Contribution Plans</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company&#8217;s contribution, which has historically related to adjusted FIFO earnings before interest and taxes and a portion of which is in the form of a guaranteed match, is determined annually at the discretion of the Walgreens Boots Alliance Board of Directors (or Compensation Committee thereof). The profit-sharing provision was an expense of $53 <font style="font-size: 10pt; font-family: 'Times New Roman';">million and $111 million for the three and six months ended February 29, 2016, respectively, compared to a benefit of $21 million for the three months and expense of $54 million for the six months ended February 28, 2015, respectively.</font></div></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">The Company also has a contract based defined contribution arrangement, the Alliance Boots Retirement Savings Plan, to which both the Company and participating employees contribute. The obligation related to the Alliance Boots Retirement Savings Plan was acquired as a result of the Second Step Transaction. The cost recognized in the Consolidated Condensed Statements of Earnings for the three and six month periods ended February 29, 2016 was $34 million and $69 million, respectively compared to $22 million in the prior year three and six month periods. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such,&#160;such costs for fiscal 2015 prior to the date of the Second Step Transaction were reflected within Equity earnings in Alliance Boots on the Consolidated Condensed Statement of Earnings.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Postretirement Healthcare Plan</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company provides certain health insurance benefits to retired U.S. employees who meet eligibility requirements, including age, years of service and date of hire. The costs of these benefits are accrued over the service life of the employee. The Company&#8217;s postretirement health benefit plan is not funded.</div><div><br /></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Components of net periodic benefit cost for the postretirement health benefit plan (in millions):</div><div><br /></div></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Service cost</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Interest cost</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amortization of actuarial loss</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amortization of prior service cost</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(7</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total postretirement benefit cost</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> 0.01 0.01 0 0 0 0 32000000 32000000 -360000000 -29000000 750000000 750000000 1000000000 550000000 61000000 -330000000 17000000 85000000 12279000000 0 4000000000 1000000000 7900000000 0 43000000 36000000 29000000 293000000 129000000 9000000 0 0 0 0 2040000000 0 2049000000 2060000000 2937000000 932000000 14552000000 15068000000 0.60 0.60 0.60 0.60 80000000 0 0 0 80000000 -1000000 0 3000000 0 230000000 0 0 3000000 2000000 0 230000000 309000000 309000000 0 2000000 -1000000 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table reflects results of operations of the Company&#8217;s reportable segments (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Eliminations </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">and </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unallocated</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">&#160;Items</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Three Months Ended February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Sales to external customers</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,500</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,627</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,057</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,184</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intersegment sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">62</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">570</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(632</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,500</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,689</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,627</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(632</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,184</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,632</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">335</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">155</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,120</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Three Months Ended February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Sales to external customers</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,048</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,508</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26,573</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intersegment sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">357</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(387</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,048</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,047</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,865</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(387</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26,573</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,598</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">125</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,840</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Eliminations </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">and </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unallocated</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">&#160;Items</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Six Months Ended February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Sales to external customers</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41,870</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,086</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10,261</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">59,217</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intersegment sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">134</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,162</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41,870</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,220</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,423</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">59,217</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,875</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">650</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">321</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(7</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,839</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Six Months Ended February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Sales to external customers</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">40,602</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,508</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">46,127</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intersegment sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">357</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(387</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">40,602</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,047</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,865</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(387</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">46,127</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,716</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">125</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,958</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table reconciles adjusted operating income to operating income (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Eliminations </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">and </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unallocated </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Items</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Three Months Ended&#160;February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1, 632</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">335</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">155</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,120</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related amortization</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(101</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cost transformation</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(28</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">LIFO provision</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(68</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(33</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairment</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,860</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Three Months Ended&#160;February&#160; 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,598</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">125</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,840</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(Decrease) increase in fair market value of warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related amortization</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(217</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">LIFO provision</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(55</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(59</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairment</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(110</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Store closures and other optimization costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,377</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Eliminations </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">and </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unallocated </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Items</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Six Months Ended&#160;February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,875</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">650</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">321</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(7</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,839</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related amortization</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(182</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cost transformation</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(118</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">LIFO provision</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(114</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(67</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairment</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,328</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Six Months Ended&#160;February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,716</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">125</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,958</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(Decrease) increase in fair market value of warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">123</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related amortization</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(306</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">LIFO provision</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(107</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(83</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairment</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(110</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Store closures and other optimization costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(44</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,431</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> 81000000 7817000000 3000000 3000000 25000000 25000000 52000000 0 0 0 0 0 0 0 0 0 0 25000000 0 8000000 0 0 0 17000000 0 0 118000000 0 0 0 0 0 0 17000000 0 0 28000000 0 28000000 33000000 0 41000000 0 0 0 0 0 0 0 0 25000000 0 17000000 0 0 52000000 110000000 0 17000000 0 0 0 0 0 0 8000000 248000000 28000000 158000000 254000000 17000000 660000000 118000000 0 0 725000000 425000000 1800000000 1600000000 650000000 525000000 475000000 600000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 3. Restructuring</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">On April 8, 2015, the Walgreens Boots Alliance Board of Directors approved a plan to implement a new restructuring program (the &#8220;Cost Transformation Program&#8221;) as part of an initiative to reduce costs and increase operating efficiencies. The Cost Transformation Program implemented and built on the cost-reduction initiative previously announced by the Company on August 6, 2014 and included plans to close approximately 200 stores across the U.S.; reorganize corporate and field operations; drive operating efficiencies; and streamline information technology and other functions.</font> The actions under the Cost Transformation Program focus primarily on Retail Pharmacy USA segment, but includes activities from all segments and are expected to be substantially complete by the end of the Company&#8217;s 2017 fiscal year. The Company estimates that it will recognize cumulative pre-tax charges to its GAAP financial results of between $1.6 billion and $1.8 billion, including costs associated with lease obligations and other real estate payments, asset impairments and employee termination and other business transition and exit costs. The Company expects to incur pre-tax charges of between $525 million and $600 million for real estate costs, including lease obligations (net of estimated sublease income); between $650 million and $725 million for asset impairment charges relating primarily to asset write-offs from store closures, information technology, inventory and other non-operational real estate asset write-offs; and between $425 million and $475 million for employee severance and other business transition and exit costs. <font style="font-size: 10pt; font-family: 'Times New Roman';">The Company incurred pre-tax charges of $28 million and $118 million related to the Cost Transformation Program during the three and six months ended February 29, 2016.</font> No charges were incurred with respect to the Cost Transformation Program in the three and six months ended February 28, 2015. From inception through February 29, 2016, the Company incurred pre-tax charges of <font style="font-size: 10pt; font-family: 'Times New Roman';">$660 million ($254 million in real estate costs, $248 million related to asset impairment charges and $158 million in severance and other business transition and exit costs) related to the Cost Transformation Program. All charges related to the Cost Transformation Program have been recorded within selling, general and administrative expenses. </font>As the program is implemented, the restructuring charges will be recognized as the costs are incurred over time in accordance with GAAP.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">In March 2014, the Walgreens Board of Directors approved a plan to close underperforming stores in efforts to optimize and focus resources </font>within Retail Pharmacy USA segment <font style="font-size: 10pt; font-family: 'Times New Roman';">in a manner intended to increase stockholder value. As of August 31, 2015, this plan was completed and no additional charges related to the plan are expected. There were no charges incurred in the three month period ended February 28, 2015. For the six months ended February 28, 2015, the Company incurred pre-tax charges of $17 million, which were primarily related to lease termination costs. All charges related to this plan have been recorded within selling, general and administrative expenses.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Restructuring costs by segment are as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Three Months Ended February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Real estate costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Asset impairments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Severance and other business transition and exit costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">28</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total restructuring costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">28</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Three Months Ended February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Real estate costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Asset impairments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Severance and other business transition and exit costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total restructuring costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Six Months Ended February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Real estate costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">52</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">52</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Severance and other business transition and exit costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">33</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total restructuring costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">110</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">118</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Six Months Ended February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Real estate costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Severance and other business transition and exit costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total restructuring costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table></div> 26348000000 25089000000 -387000000 30000000 2017000000 0 5057000000 40602000000 41870000000 2047000000 3865000000 11423000000 0 40602000000 10261000000 0 7084000000 30184000000 357000000 357000000 0 30000000 0 3689000000 134000000 3627000000 3508000000 41870000000 0 0 3508000000 570000000 59217000000 0 5627000000 0 0 21048000000 7220000000 -632000000 21500000000 -387000000 0 2017000000 21500000000 26573000000 3865000000 2047000000 59217000000 1296000000 1296000000 1162000000 0 -387000000 62000000 21048000000 -387000000 46127000000 46127000000 -632000000 26573000000 30184000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">Estimated annual amortization expense for intangible assets recorded at February 29, 2016 is as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2019</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2020</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Estimated annual amortization expense</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">401</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">358</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">318</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">289</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">254</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> 76.05 60000000 562000000 26573000000 59217000000 46127000000 30184000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Identifiable assets acquired and liabilities assumed including noncontrolling interests</div><div>&#160; <table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash and cash equivalents</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">413</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts receivable</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,799</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Inventories</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,713</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other current assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">894</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Property, plant and equipment</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,806</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,691</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other non-current assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,217</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Trade accounts payable, accrued expenses and other liabilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(7,696</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Borrowings</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(9,010</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred income taxes</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2,452</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other non-current liabilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(383</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Noncontrolling interests</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(412</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total identifiable net assets and noncontrolling interests</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,580</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">14,861</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk were recognized as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Location in Consolidated</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">&#160;</div></td><td style="vertical-align: top; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Condensed Statements of </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Earnings</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Interest rate swaps</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 0.8pt;">Interest expense, net</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Notes</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 0.8pt;">Interest expense, net</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>The gains and losses due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td style="vertical-align: bottom; white-space: nowrap; font-weight: bold; padding-bottom: 2px; text-align: center;">Location in Consolidated</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; padding-left: 15%;"></td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Condensed Statements of </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Earnings</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.55pt;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.55pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Interest rate swaps</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9.15pt; margin-right: 0.8pt; text-indent: -4.65pt;">Interest expense, net</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9.15pt; margin-right: 0.8pt; text-indent: -4.65pt;">Selling, general and administrative expenses</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(23</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(28</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(28</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Second Step Transaction foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9.15pt; margin-right: 0.8pt; text-indent: -4.65pt;">Other income (expense)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(70</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(166</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9.15pt; margin-right: 0.8pt; text-indent: -4.65pt;">Other income (expense)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">33</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">33</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 18pt;">The gains and losses due to changes in fair value of the Warrants recognized in earnings were as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.5pt;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; padding-left: 10%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">&#160;</div></td><td style="vertical-align: top; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Location in Consolidated</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 0.8pt;">Condensed Statements of Earnings</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 26%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 0.8pt; text-indent: 4.5pt;">Other income (expense)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(532</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">559</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(594</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">849</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company reports the Warrants at fair value. The fair value and balance sheet presentation of the Warrants was as follows (in millions):</div><div style="text-align: left;"><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 4.5pt;">Location in Consolidated </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-right: 4.5pt;">Condensed Balance Sheets&#160;</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.5pt;">February 29,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.55pt;">August 31, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 4.55pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset derivatives not designated as hedges:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 38%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 38%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 4.5pt; margin-right: 0.8pt;">Other non-current assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,546</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,140</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Consideration paid</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">&#160;</div></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,874</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Common stock</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">10,977</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total consideration transferred</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">15,851</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Less: consideration attributed to WBAD</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2,559</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">13,292</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Fair value of the investment in Alliance Boots held before the Second Step Transaction</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,149</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 88%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total consideration</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,441</div></td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Components of net periodic benefit cost for the postretirement health benefit plan (in millions):</div><div><br /></div></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Service cost</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Interest cost</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amortization of actuarial loss</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amortization of prior service cost</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(7</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total postretirement benefit cost</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Components of net periodic pension costs for the defined benefit pension plans (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr style="height: 12px;"><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Service costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Interest costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">77</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">53</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">159</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">53</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Expected returns on plan assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(62</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(43</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(127</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(43</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Settlements</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;">&#160;-</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total net periodic pension costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table details each tranche of Euro and Pound Sterling notes issued:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%;"><tr><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Notes Issued (in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 35%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Maturity Date</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 34%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Interest Rate</div></td></tr><tr><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Euro Notes:</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 35%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 34%;">&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#8364;</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">750</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 35%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 20, 2026</div></td><td valign="bottom" style="vertical-align: bottom; width: 34%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 2.125%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 35%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 34%; background-color: #ffffff;">&#160;&#160;&#160;</td></tr><tr><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Pound Sterling Notes:</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 35%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 34%; background-color: #cceeff;">&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#163;</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">400</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 35%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 20, 2020</div></td><td valign="bottom" style="vertical-align: bottom; width: 34%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 2.875%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">300</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 35%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 20, 2025</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 34%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 3.600%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#163;</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">700</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 35%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 34%; background-color: #ffffff;">&#160;&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table details each tranche of outstanding notes as of February 29, 2016:</div><div>&#160;</div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Notes Issued</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">(in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;">&#160;</td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 18%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Maturity Date</div></td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 20%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Interest Rate</div></td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 51%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Interest Payment Dates</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,200</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 18%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">September 15, 2022</div></td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 3.100%</div></td><td valign="bottom" style="vertical-align: top; width: 51%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">March 15 and September 15; commencing on March 15, 2013</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">500</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 18%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">September 15, 2042</div></td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 20%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 4.400%</div></td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 51%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">March 15 and September 15; commencing on March 15, 2013</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,700</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 18%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 20%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 51%; background-color: #cceeff;">&#160;&#160;&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table summarizes each tranche of notes issued:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Notes Issued</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">(in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 15%;"><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Maturity Date</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 20%;"><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Interest Rate</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 52%;"><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Interest Payment Dates</div></td></tr><tr><td style="vertical-align: top; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td style="vertical-align: top; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">750</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td style="vertical-align: top; text-align: left; width: 15%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">May 18, 2016</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td style="vertical-align: top; text-align: left; width: 20%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Variable; three month U.S. dollar LIBOR, reset quarterly, plus 45 basis points</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td style="vertical-align: top; text-align: left; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">February 18, May 18, August 18, and November 18; commencing on February 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">750</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 17, 2017</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 1.750%</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 17 and November 17; commencing on May 17, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 18, 2019</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 2.700%</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 18 and November 18; commencing on May 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 18, 2021</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 3.300%</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 18 and November 18; commencing on May 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 18, 2024</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 3.800%</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 18 and November 18; commencing on May 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">500</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 18, 2034</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 4.500%</div></td><td valign="bottom" style="vertical-align: top; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 18 and November 18; commencing on May 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,500</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 15%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">November 18, 2044</div></td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 20%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed 4.800%</div></td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">May 18 and November 18; commencing on May 18, 2015</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 15%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 20%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 52%; background-color: #ffffff;">&#160;&#160;&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">The carrying amount and accumulated amortization of intangible assets</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">consist of the following (in millions):</font></div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Gross Amortizable Intangible Assets</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Customer relationships</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div>$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div>1,293</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,409</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Purchased prescription files</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">904</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">885</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Loyalty card holders</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">661</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">730</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Trade names and trademarks</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">678</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">675</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Favorable lease interests</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">457</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">440</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Non-compete agreements</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">158</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">154</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Purchasing and payer contracts</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">95</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">94</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 25.2pt; text-indent: -7.2pt;">Total gross amortizable intangible assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,246</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,387</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accumulated amortization</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Customer relationships</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">182</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">132</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Purchased prescription files</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">536</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">470</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Loyalty card holders</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Trade names and trademarks</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">114</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">83</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Favorable lease interests</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">246</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">207</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Non-compete agreements</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">106</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">92</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Purchasing and payer contracts</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">68</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">65</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 25.2pt; text-indent: -7.2pt;">Total accumulated amortization</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,293</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,090</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total amortizable intangible assets, net</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,953</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,297</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Indefinite Lived Intangible Assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Trade names and trademarks</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,947</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,590</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Pharmacy licenses</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,222</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,464</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total indefinite lived intangible assets</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,169</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,054</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total intangible assets, net</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,122</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,351</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 0.9pt;">The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of February 29, 2016, excluding warrants which are presented separately in this footnote, were as follows (in millions):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 46%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Notional<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;">&#160;</td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 30%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 4.5pt; margin-right: 4.5pt;">Location in Consolidated </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 4.5pt; margin-right: 4.5pt;">Condensed Balance Sheets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Derivatives designated as fair value hedges</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Interest rate swaps</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other non-current assets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Derivatives not designated as hedges</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #ffffff;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">465</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current assets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">768</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current liabilities</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Basis swap</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current liabilities</div></td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 17.45pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Amounts are presented in U.S. dollar equivalents.</td></tr></table></div><div style="text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2015, excluding warrants which are presented separately in this footnote, are as follows (in millions):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 46%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Notional<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;">&#160;</td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; width: 30%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 4.5pt; margin-right: 4.5pt;">Location in Consolidated </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 4.5pt; margin-right: 4.5pt;">Condensed Balance Sheets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Derivatives designated as fair value hedges</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Interest rate swaps</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other non-current assets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Derivatives not designated as hedges</font>:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #ffffff;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,205</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current assets</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Foreign currency forwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">495</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current liabilities</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Basis swap</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 30%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-right: 4.5pt;">Other current assets</div></td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 17.45pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Amounts are presented in U.S. dollar equivalents.</td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for the three and six months ended February 29, 2016 and February 28, 2015 (in millions):</div><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pension/Post-</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">retirement </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Obligations</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrecognized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available-for-Sale </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Investments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cash Flow </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Hedges</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Currency </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Translation </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjustments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at November 30, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">32</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">260</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(39</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(911</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(658</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other comprehensive income (loss) before reclassification adjustments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(139</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,264</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amounts reclassified from accumulated OCI</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tax benefit (provision)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">51</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">52</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net other comprehensive income (loss)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(88</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,210</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">172</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(38</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2,032</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,868</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pension/Post-</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">retirement </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Obligations</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrecognized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available-for-Sale </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Investments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cash Flow </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Hedges</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Currency </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Translation </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjustments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at August 31, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">29</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">259</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(40</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(462</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(214</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other comprehensive income (loss) before reclassification adjustments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(144</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,570</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,715</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amounts reclassified from accumulated OCI</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tax benefit (provision)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">57</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">58</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net other comprehensive income (loss)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(87</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,570</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,654</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">172</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(38</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2,032</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,868</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pension/Post-</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">retirement </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Obligations</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrecognized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available-for-Sale </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Investments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cash Flow </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Hedges</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Share of </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Alliance </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Boots </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">OCI</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cumulative </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Translation </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjustments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at November 30, 2014</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">206</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(39</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(92</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(35</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">54</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other comprehensive income (loss) before reclassification adjustments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">140</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(89</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(358</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(313</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amounts reclassified from accumulated OCI</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">230</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">80</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">309</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tax benefit (provision)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(49</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(18</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(118</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net other comprehensive income (loss)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">90</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">92</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(122</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(39</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(331</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(68</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pension/Post-</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">retirement </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Obligations</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrecognized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss)&#160;on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available-for-Sale </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Investments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gain (Loss) on </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cash Flow</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Hedges</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Share of </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Alliance </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Boots </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">OCI</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cumulative </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Translation </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjustments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at August 31, 2014</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">107</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(27</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(113</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">154</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">136</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other comprehensive income (loss) before reclassification adjustments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">297</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(18</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(57</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(648</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(436</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amounts reclassified from accumulated OCI</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">230</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">80</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">309</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tax benefit (provision)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(108</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(60</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">83</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(77</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 28%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net other comprehensive income (loss)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">189</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">113</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(485</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(204</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 28%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(39</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(331</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(68</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The impact of the equity transaction is as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Amount</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Consideration attributable to WBAD</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,559</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Less:&#160; Carrying value of the Company&#8217;s pre-existing noncontrolling interest</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">130</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 88%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Impact to additional paid in capital</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,429</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Long-Term Debt<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Unsecured Pound Sterling variable rate term loan due 2019<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,229</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">1.750% unsecured notes due 2017</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">747</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">746</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">5.250% unsecured notes due 2019<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">253</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">2.700% unsecured notes due 2019</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,244</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,243</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">2.875% unsecured Pound Sterling notes due 2020<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">552</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">612</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">3.300% unsecured notes due 2021</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,241</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,241</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">3.100% unsecured notes due 2022</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,193</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,193</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">3.800% unsecured notes due 2024</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,986</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,985</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">3.600% unsecured Pound Sterling notes due 2025<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">414</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">459</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">2.125% unsecured Euro notes due 2026<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">811</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">836</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">4.500% unsecured notes due 2034</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">494</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">494</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">4.400% unsecured notes due 2042</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">492</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">492</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">4.800% unsecured notes due 2044</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,492</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,491</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(6)</sup></div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">44</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total long-term debt</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,974</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">13,315</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div>&#160;</div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">All notes are presented net of unamortized discount and debt issuance costs, where applicable.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(6)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.</div></td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions):</div><div><br /></div></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">August 31, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,940</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,898</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,534</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16,372</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisitions</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">19</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">19</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other <sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">13</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Currency translation adjustments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(309</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(605</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,940</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,605</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,251</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15,796</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="vertical-align: top; width: 18pt; align: right;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">Other represents immaterial purchase accounting adjustments for prior year Company acquisitions.</td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Restructuring costs by segment are as follows (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Three Months Ended February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Real estate costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Asset impairments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Severance and other business transition and exit costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">28</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total restructuring costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">28</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Three Months Ended February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Real estate costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Asset impairments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Severance and other business transition and exit costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total restructuring costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Six Months Ended February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Real estate costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">52</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">52</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Severance and other business transition and exit costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">33</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total restructuring costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">110</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">118</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Six Months Ended February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Real estate costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Severance and other business transition and exit costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total restructuring costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Short-term borrowings and long-term debt consist of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Short-Term Borrowings<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Unsecured variable rate notes due 2016</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">749</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">747</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">303</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">321</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total short-term borrowings</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,052</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,068</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div>&#160;</div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">All notes are presented net of unamortized discount and debt issuance costs, where applicable.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(6)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.</div></td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 18. Segment Reporting</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company has three reportable segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The operating segments have been identified based on the financial data utilized by the Company&#8217;s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company&#8217;s operating segments, which have been aggregated as described below. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.</div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">&#183;</td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">The Retail Pharmacy USA segment consists of the legacy Walgreens business, which includes the operation of retail drugstores and convenient care clinics and the provision of specialty pharmacy services. Revenues for the segment are principally derived from the sale of prescription drugs and a wide assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards and convenience foods.</td></tr></table></div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">&#183;</td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">The Retail Pharmacy International segment consists primarily of the legacy Alliance Boots pharmacy-led health and beauty stores, optical practices, and related contract manufacturing operations. Stores are located in the United Kingdom, Mexico, Chile, Thailand, Norway, the Republic of Ireland, The Netherlands and Lithuania. Revenues for the segment are principally derived from the sale of prescription drugs and retail health, beauty, toiletries and other consumer products.</td></tr></table></div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">&#183;</td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; text-align: left; width: auto;">The Pharmaceutical Wholesale segment consists of the legacy Alliance Boots pharmaceutical wholesaling and distribution businesses. Wholesale operations are located in France, the United Kingdom, Germany, Turkey, Spain, Russia, The Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Revenues for the segment are principally derived from wholesaling and distribution of a comprehensive offering of brand-name pharmaceuticals (including specialty pharmaceutical products) and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment, and related services to pharmacies and other healthcare providers.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The results of operations for each reportable segment include synergy benefits, including WBAD operations and an allocation of corporate-related overhead costs. The &#8220;Eliminations and Unallocated Items&#8221; column contains items not allocable to the reportable segments, as the information is not utilized by the chief operating decision maker to assess segment performance and allocate resources.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The segment information reflects the operating results of the Company&#8217;s business segments. The Company began recording revenue and expense transactions using the new segments effective January 1, 2015. Beginning January 1, 2015, synergy benefits including WBAD operations have been allocated to the Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale segments on a source of procurement benefit basis. Under this method, the synergy benefits are allocated to the segment whose purchase gave rise to the benefit. A synergy arising on the purchase of an item for use in an entity in the Retail Pharmacy USA segment is recognized in the Retail Pharmacy USA segment and similarly for the Retail Pharmacy International and Pharmaceutical Wholesale segments. Procurement service income related to third parties is recognized in the Pharmaceutical Wholesale segment. Corporate costs have been allocated to segments based on their respective gross profit.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Our Retail Pharmacy International and Pharmaceutical Wholesale segments were acquired as part of the Second Step Transaction in which we acquired the 55% of Alliance Boots that we did not already own on December 31, 2014. The Company has determined that it is impracticable to restate segment information for periods prior the completion of the Second Step Transaction, as well as to provide disclosures for such periods under both the old basis and new basis of reporting for certain items. Specifically, WBAD operations prior to December 31, 2014 were recorded in the Retail Pharmacy USA segment and have not been restated, as the Company believes it is impracticable to separate the information to the individual reportable segments. Equity earnings from Alliance Boots prior to the completion of the Second Step Transaction has been recorded within the Retail Pharmacy USA segment. The equity earnings of the 45% interest in Alliance Boots have not been separated into the Retail Pharmacy International and Pharmaceutical Wholesale segments for the prior period, as the Company believes it is impracticable. Accordingly, only two months of results (January and February 2015) have been reported for these segments for the three and six months ended February 28, 2015.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table reflects results of operations of the Company&#8217;s reportable segments (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Eliminations </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">and </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unallocated</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">&#160;Items</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Three Months Ended February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Sales to external customers</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,500</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,627</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,057</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,184</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intersegment sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">62</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">570</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(632</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,500</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,689</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,627</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(632</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,184</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,632</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">335</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">155</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,120</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Three Months Ended February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Sales to external customers</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,048</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,508</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26,573</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intersegment sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">357</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(387</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,048</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,047</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,865</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(387</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26,573</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,598</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">125</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,840</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Eliminations </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">and </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unallocated</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">&#160;Items</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Six Months Ended February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Sales to external customers</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41,870</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,086</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10,261</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">59,217</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intersegment sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">134</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,162</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41,870</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,220</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,423</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">59,217</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,875</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">650</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">321</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(7</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,839</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Six Months Ended February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Sales to external customers</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">40,602</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,508</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">46,127</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intersegment sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">357</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(387</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Sales</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">40,602</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,047</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,865</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(387</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">46,127</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,716</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">125</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,958</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table reconciles adjusted operating income to operating income (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Eliminations </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">and </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unallocated </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Items</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Three Months Ended&#160;February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1, 632</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">335</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">155</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,120</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related amortization</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(101</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cost transformation</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(28</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">LIFO provision</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(68</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(33</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairment</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,860</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Three Months Ended&#160;February&#160; 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,598</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">125</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,840</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(Decrease) increase in fair market value of warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related amortization</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(217</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">LIFO provision</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(55</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(59</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairment</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(110</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Store closures and other optimization costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,377</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Retail Pharmacy</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">USA</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">International</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Pharmaceutical </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Wholesale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Eliminations </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">and </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unallocated </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Items</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Six Months Ended&#160;February 29, 2016</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,875</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">650</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">321</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(7</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,839</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related amortization</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(182</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cost transformation</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(118</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">LIFO provision</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(114</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(67</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairment</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(30</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,328</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Six Months Ended&#160;February 28, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Adjusted Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,716</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">125</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,958</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(Decrease) increase in fair market value of warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">123</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related amortization</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(306</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">LIFO provision</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(107</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Acquisition-related costs</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(83</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Asset impairment</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(110</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 40%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Store closures and other optimization costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(44</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 40%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Operating Income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,431</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> 12118000000 10062000000 6084000000 5606000000 0 83000000 87000000 0 59000000 60000000 65000000 1068000000 1052000000 0.0046 0.0062 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 2. Accounting Policies</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Basis of Presentation</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The consolidated condensed financial statements of Walgreens Boots Alliance included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. The consolidated condensed financial statements include all subsidiaries in which the Company holds a controlling interest. Investments in less than majority-owned entities in which the Company does not have a controlling interest, but does have significant influence, are accounted for as equity method investments. All intercompany transactions have been eliminated.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Consolidated Condensed Balance Sheet as of February 29, 2016, the Consolidated Condensed Statements of Equity for the six-month period ended February 29, 2016, and the Consolidated Condensed Statements of Earnings, the Consolidated Condensed Statements of Comprehensive Income and the Consolidated Condensed Statements of Cash Flows for the three month and six month periods ended February 29, 2016 and February 28, 2015, have not been audited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In the opinion of the Company, the unaudited consolidated condensed financial statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present a fair statement of the results for such interim periods. Because of the acquisition of Alliance Boots, influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company&#8217;s operations, net earnings for any interim period may not be comparable to the same interim period in previous years or indicative of net earnings for the full fiscal year. In addition, with respect to the Company&#8217;s Retail Pharmacy USA segment, the positive impact on gross profit margins and gross profit dollars typically has been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a &#8220;generic conversion.&#8221; In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on Retail Pharmacy USA segment&#8217;s sales, gross profit margins and gross profit dollars.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experience and other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. For a discussion of the Company&#8217;s significant accounting policies, please see the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.</div></div> 144300000 29918000000 31300000000 -2000000 25089000000 -3977000000 12000000 439000000 9953000000 -214000000 12000000 -5026000000 -1000000 412000000 26348000000 10041000000 -1868000000 29506000000 30861000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><u>Note 20. Subsequent Event</u></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On March 18, 2016, the Company exercised Warrant 1 (described in Note 10, Financial Instruments) in full, resulting in the acquisition from AmerisourceBergen of 22,696,912 shares of AmerisourceBergen common stock for an aggregate exercise price payment of $1.17 billion. The transaction was funded using existing cash on hand. Following the exercise of Warrant 1, the Company owned 34,157,955 outstanding AmerisourceBergen common shares representing approximately 15.2% of the outstanding AmerisourceBergen common stock (based on shares outstanding as of March 16, 2016 adjusted to give effect to the exercise of Warrant 1, as reported by AmerisourceBergen in its Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2016). The Company continues to hold Warrant 2, which the Company has the right to exercise beginning in March 2017.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Effective March 18, 2016, the Company accounts for its investment in AmerisourceBergen using the equity method of accounting, subject to a two-month reporting lag, with the net earnings attributable to its investment being classified within the operating income of the Company&#8217;s Pharmaceutical Wholesale segment.</div></div> 13815558 82603274 92853639 0 1152000000 0 0 0 0 1152000000 0 5026000000 3977000000 747000000 749000000 11100000 8900000 8200000 10600000 1080200000 1084600000 994700000 1043600000 1054700000 1093500000 1005300000 1088400000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Note 15. </u></font><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Depreciation and Amortization</u></font></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Depreciation expense</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">346</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">311</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">644</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">567</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible asset and other amortization</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">96</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">196</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">180</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">259</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total depreciation and amortization expense</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">442</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">507</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">824</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">826</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">The depreciation and amortization expense presented for 2015 include Alliance Boots costs for the period from December 31, 2014 through February 28, 2015. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, depreciation and amortization expense were included for fiscal 2015 prior to the date of the Second Step Transaction within Equity earnings in Alliance Boots.</div></div> 96000000 196000000 180000000 259000000 -92000000 -86000000 20000000 315000000 -586000000 859000000 2016 2022 2042 2021 2024 2026 2017 2025 2019 2019 2020 2019 2044 2034 1241000000 253000000 492000000 552000000 414000000 494000000 1244000000 612000000 1243000000 746000000 1985000000 1492000000 811000000 2013000000 1193000000 1193000000 1241000000 747000000 836000000 494000000 1491000000 250000000 1986000000 2229000000 492000000 459000000 1.54 1.09 1.54 1.39 1.39 1.12 13292000000 2559000000 103000000 0 0 131000000 0 28000000 0 0 3565193 0 0 0 1000000 0 1000000 0 0 1000000 2000000 P15Y 79 348000000 26000000 0 75000000 9000000 54000000 76000000 13000000 0 12000000 27000000 446000000 257000000 467000000 77000000 231000000 14000000 6000000 P25Y P5Y 111000000 21000000 54000000 53000000 66000000 2 1.01 1.01 1.01 1.01 17000000 88000000 1.01677 1.11734 10 1 1 8 100000 100000 2429000000 -130000000 200 8100000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28, </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Depreciation expense</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">346</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">311</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">644</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">567</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible asset and other amortization</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">96</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">196</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">180</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">259</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total depreciation and amortization expense</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">442</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">507</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">824</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">826</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Summarized financial information for the Company&#8217;s equity method investments is as follows:</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Balance Sheets (in millions)</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29, 2016<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31, 2015<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Current assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,687</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Noncurrent assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,592</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,548</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Current liabilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,598</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,936</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Noncurrent liabilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">876</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">837</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Shareholders&#8217; equity<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,805</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,790</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Statements of Earnings (in millions)</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)(4)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 28,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)(4)</sup></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net sales</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,286</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,317</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,489</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">14,978</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Gross Profit</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">374</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">979</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">702</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,168</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net Income</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">246</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">743</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Share of income from equity method investments</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">109</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">20</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">323</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Balance sheet information of foreign equity method investments are translated at their respective February 29, 2016 and August 31, 2015 spot rates.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Shareholders&#8217; equity at February 29, 2016 and August 31, 2015 includes $170 million and $163 million, respectively, related to noncontrolling interests.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Includes equity method investment in Alliance Boots from Walgreen Co.&#8217;s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization.</div></td></tr></table></div></div> 0.056 0.152 2000000000 4000000 20000000 2 44000000 16000000 55000000 114000000 107000000 68000000 1632000000 -4000000 1632000000 121000000 1598000000 125000000 1840000000 -7000000 321000000 2958000000 121000000 125000000 125000000 650000000 2120000000 121000000 321000000 650000000 1598000000 155000000 -4000000 1840000000 125000000 2716000000 121000000 2716000000 2875000000 2120000000 2875000000 3839000000 -2000000 2958000000 335000000 155000000 335000000 3839000000 118000000 28000000 0 0 3000000 1000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The changes in reserve for facility closings and related lease termination charges include the following (in millions):</div><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;&#160;&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Six Month </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Period Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">February 29,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Twelve Month </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Period Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">August 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance &#8211; beginning of period</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">446</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">257</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Provision for present value of non-cancellable lease payments on closed facilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">77</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">231</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Assumptions about future sublease income, terminations and changes in interest rates</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Interest accretion</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">27</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Liability assumed through acquisition of Alliance Boots</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">13</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash payments, net of sublease income</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(54</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(76</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance &#8211; end of period</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">467</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">446</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;">&#160;</td></tr></table></div> 3500000000 3800000000 0 101000000 0 315000000 8000000 20000000 9000000 8000000 500000000 Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen's common stock; AmerisourceBergen's common stock price at the valuation date; AmerisourceBergen's equity volatility; the number of shares of AmerisourceBergen's common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the warrants.price at the valuation date; AmerisourceBergen's equity volatility; the number of shares of AmerisourceBergen's common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the warrants. The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information. Money market funds are valued at the closing price reported by the fund sponsor. Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations. Fair values of quoted investments are based on current bid prices as of the balance sheet dates. See Note 6, Available-for-Sale Investments for additional information. All notes are presented net of unamortized discount and debt issuance costs, where applicable. Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures. Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively. Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively. Amounts are presented in U.S. dollar equivalents. Shareholders' equity at February 29, 2016 and August 31, 2015 includes $170 million and $163 million, respectively, related to noncontrolling interests. Balance sheet information of foreign equity method investments are translated at their respective February 29, 2016 and August 31, 2015 spot rates. Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates. Includes equity method investment in Alliance Boots from Walgreen Co.'s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization. Other represents immaterial purchase accounting adjustments for prior year Company acquisitions. Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities. Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts. EX-101.SCH 13 wba-20160229.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 020100 - Statement - CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 050000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Accounting Policies link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Operating Leases link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Equity Method Investments link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Available-for-Sale Investments link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Short-Term Borrowings and Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - Retirement Benefits link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 061500 - Disclosure - Depreciation and Amortization link:presentationLink link:calculationLink link:definitionLink 061600 - Disclosure - Supplemental Cash Flow Disclosures link:presentationLink link:calculationLink link:definitionLink 061700 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 061800 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 061900 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 062000 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 070200 - Disclosure - Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Operating Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - Equity Method Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - Available-for-Sale Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - Short-Term Borrowings and Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 081100 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 081300 - Disclosure - Retirement Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 081500 - Disclosure - Depreciation and Amortization (Tables) link:presentationLink link:calculationLink link:definitionLink 081700 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 081800 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Equity Method Investments, Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 090502 - Disclosure - Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 090504 - Disclosure - Equity Method Investments, Summarized Financial Information of Equity Method Investees (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Available-for-Sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 090702 - Disclosure - Acquisitions, Consideration Paid (Details) link:presentationLink link:calculationLink link:definitionLink 090704 - Disclosure - Acquisitions, Identifiable Assets Acquired and Liabilities Assumed Including Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 090706 - Disclosure - Acquisitions, The Identified Definite and Indefinite Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 090708 - Disclosure - Acquisitions, Unaudited Pro Forma Results Prepared for Comparative Purposes (Details) link:presentationLink link:calculationLink link:definitionLink 090710 - Disclosure - Acquisitions, Actual Results from Alliance Boots Operations Included in the Consolidated Condensed Statements of Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - Goodwill and Other Intangible Assets, Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 090802 - Disclosure - Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets by Major Class (Details) link:presentationLink link:calculationLink link:definitionLink 090804 - Disclosure - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 090806 - Disclosure - Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - Short-Term Borrowings and Long-Term Debt, Short-Term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 090902 - Disclosure - Short-Term Borrowings and Long-Term Debt, Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 090904 - Disclosure - Short-Term Borrowings and Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 090906 - Disclosure - Short-Term Borrowings and Long-Term Debt, Debt Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 090908 - Disclosure - Short-Term Borrowings and Long-Term Debt, Other Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - Retirement Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 091400 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 091500 - Disclosure - Depreciation and Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 091600 - Disclosure - Supplemental Cash Flow Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 091700 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 091800 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 092000 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 14 wba-20160229_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 15 wba-20160229_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 16 wba-20160229_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Share of Alliance Boots OCI [Member] AOCI Attributable to Noncontrolling Interest [Member] Available-for-sale Investments [Member] Accounting Policies [Abstract] Trade accounts payable Accounts Payable, Current Accounts receivable, net Accounts Receivable, Net, Current Accrued expenses and other liabilities Accrued Liabilities, Current Cumulative Currency Translation Adjustments [Member] Unrecognized Gain (Loss) on Available-for-Sale Investments [Member] Accumulated Other Comprehensive Income (Loss) [Abstract] Unrealized Gain (Loss) on Cash Flow Hedges [Member] Pension/Post-retirement Obligations [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Member] Accumulated other comprehensive (loss) income Ending Balance Beginning Balance Accumulated Other Comprehensive Income (Loss), Net of Tax Weighted-Average Useful Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Paid-in capital Additional Paid in Capital Paid-In Capital [Member] Stock-based compensation Adjustments to reconcile net earnings to net cash provided by operating activities - Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Acquisition-related amortization Amortization of Acquisition Costs Amortization expense for intangible assets Antidilutive securities excluded from EPS calculations (in shares) Asset impairment Asset Impairment Charges Assets [Abstract] Assets, Fair Value Disclosure [Abstract] Assets Assets [Abstract] Fair value of assets Assets, Fair Value Disclosure Total Assets Assets Total Current Assets Assets, Current Current Assets: Assets, Current [Abstract] Total Non-Current Assets Assets, Noncurrent Non-Current Assets: Assets, Noncurrent [Abstract] Gross unrealized gains Available-for-sale Equity Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized losses Available-for-sale Equity Securities, Accumulated Gross Unrealized Loss, before Tax Summary of Cost and Fair Value of Available-for-Sale Securities Available-for-sale Securities [Table Text Block] Summary of cost and fair value of available-for-sale securities [Abstract] Available-for-sale Equity Securities, Amortized Cost Basis [Abstract] Amortized cost basis Available-for-sale Equity Securities, Amortized Cost Basis Fair value Available-for-sale Securities, Equity Securities Balance Sheet Location [Axis] Balance Sheet Location [Domain] Basis Swaps [Member] Basis Swaps [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Bridge Credit Agreement [Member] Bridge Loan [Member] Senior unsecured bridge facility Bridge Loan Deferred income taxes Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Business Acquisition, Percentage of issued and outstanding capital acquired Business Acquisition, Percentage of Voting Interests Acquired Total consideration transferred Total purchase price Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Other non-current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Total consideration Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination Diluted (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Number of shares exchanged in acquisition (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Basic (in dollars per share) Trade accounts payable, accrued expenses and other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Borrowings Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Accounts receivable Cash and cash equivalents Net sales Business Acquisition, Pro Forma Revenue Business Acquisition, Acquiree [Domain] Schedule of Unaudited Pro Forma Results Prepared for Comparative Purposes Common stock Net earnings Business Acquisition, Pro Forma Net Income (Loss) Other current assets Business Acquisition [Axis] Other non-current assets Fair value of the investment in Alliance Boots held before the Second Step Transaction Purchase price consideration common shares fair value Acquisitions [Abstract] Business Acquisition [Line Items] Business Acquisition [Line Items] Consideration paid [Abstract] Business Combination, Consideration Transferred [Abstract] Acquisitions Business Combination Disclosure [Text Block] Acquisition-related costs Business Combination, Acquisition Related Costs Inventories Total identifiable net assets and noncontrolling interests Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Property, plant and equipment Noncontrolling interests Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Ownership interest percentage prior to Second Step Transaction Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Intangible assets Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash Flow Hedging [Member] Supplemental Cash Flow Disclosures Cash Flow, Supplemental Disclosures [Text Block] Gains and losses due to changes in fair value of derivative instruments Warrant exercise price (in dollars per share) Class of Warrant or Right [Domain] Class of Warrant or Right [Axis] Warrant exercised to purchase common stock (in shares) Maximum number of shares in minority equity position (in shares) Warrant issued to purchase common stock (in shares) Class of Warrant or Right [Line Items] Class of Warrant or Right [Table] Commercial Paper [Member] Balance outstanding at fiscal year-end Commitments and Contingencies (see Note 12) Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies [Abstract] Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at February 29, 2016 and August 31, 2015 Common Stock, Value, Issued Common shares transfer (in shares) Common stock, issued (in shares) Common Stock, Shares, Issued Common stock, authorized shares (in shares) Common Stock, Shares Authorized Cash dividends declared (in dollars per share) Dividends declared per share (in dollars per share) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common Stock [Member] AmerisourceBergen Common Stock [Member] Beginning Balance (in shares) Ending Balance (in shares) Common Stock, Shares, Outstanding Retirement Benefits [Abstract] Comprehensive Income (Loss) Attributable to Walgreens Boots Alliance, Inc. Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income (loss) attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Total Comprehensive Income (Loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Accumulated Other Comprehensive Income (Loss) Consolidation Items [Domain] Consolidation Items [Axis] Lease Termination Costs [Member] Contract Termination [Member] Cost of sales Cost of Goods and Services Sold Currency [Axis] Customer Relationships [Member] Designated as Hedging Instrument [Member] Debt instrument, description of variable rate basis Debt Instrument, Description of Variable Rate Basis Percentage of principal amount of fixed rate notes can be redeemed Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Debt Instrument [Line Items] Percentage of redemption price Debt Instrument, Redemption Price, Percentage Term of facility Debt Instrument, Term Short-Term Borrowings and Long-Term Debt [Abstract] Schedule of Long-term Debt Instruments [Table] Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Debt Instrument [Axis] Short-Term Borrowings and Long-Term Debt Debt Disclosure [Text Block] Total issuance costs Fair value of the notes Debt Instrument, Fair Value Disclosure Maturity date Fees related to borrowings Debt Instrument, Fee Amount Interest payment dates Debt Instrument, Name [Domain] Face amount of notes issued Face amount of notes issued Term loan amount Interest rate Stated interest rate Long-Term Debt [Abstract] Debt Instruments [Abstract] Deferred income taxes Deferred Income Tax Expense (Benefit) Income taxes Deferred Tax Liabilities, Net, Current Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Employer cash contributions to defined benefit pension plans Settlements Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements Defined Contribution Plan Name [Axis] Defined Contribution Plan [Table] Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Name [Domain] Amortization of actuarial loss Defined Benefit Plan, Amortization of Gains (Losses) Amortization of prior service cost Defined Benefit Plan Disclosure [Line Items] Interest costs Total net periodic pension costs Defined Benefit Plan, Net Periodic Benefit Cost Components of net periodic benefit costs [Abstract] Expected returns on plan assets Defined Benefit Plan, Expected Return on Plan Assets Cost recognized in the consolidated condensed statements of earnings Defined Contribution Plan, Cost Recognized Defined Benefit Plans and Other Postretirement Benefit Plans [Axis] Service costs Defined Benefit Postretirement Health Benefit Plan [Member] Postretirement Health Benefit Plan[Member] Defined Benefit Plan and Other Postretirement Benefit Plan [Domain] Total depreciation and amortization expense Depreciation and amortization Depreciation, Depletion and Amortization Depreciation and Amortization [Abstract] Depreciation expense Derivatives assets, Notional Amount Derivative [Line Items] Financial Instruments Derivative [Table] Financial Instruments [Abstract] Derivative asset Derivative Asset Fixed interest rate percentage Derivative, Fixed Interest Rate Derivatives assets, Fair Value Derivative Asset, Fair Value, Gross Asset Derivative, by Nature [Axis] Derivative, by Nature [Axis] Derivative, Name [Domain] Derivative, Name [Domain] Hedging Relationship [Axis] Derivatives, Fair Value [Line Items] Recent Accounting Pronouncements Description of New Accounting Pronouncements Not yet Adopted [Text Block] Dividends declared ($0.72 per share) Dividends, Common Stock, Cash Earnings Per Share Earnings Per Share [Text Block] Earnings Per Share [Abstract] Net earnings per common share [Abstract] Effect of Fair Value Hedges on Results of Operations [Abstract] Effect of exchange rate changes on cash and cash equivalents Cash Flow Hedges [Abstract] Severance and Other Business Transition and Exit Costs [Member] Non-controlling interests Equity Method Investment, Summarized Financial Information, Noncontrolling Interest Shareholders' equity Equity Method Investment, Summarized Financial Information, Equity Excluding Noncontrolling Interests Noncurrent liabilities Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities Statements of Earnings [Abstract] Equity Method Investment, Summarized Financial Information, Income Statement [Abstract] Equity method investment ownership interest percentage Equity interest in Alliance Boots Ownership percentage Investment, Name [Domain] Investment, Name [Domain] Investment, Name [Domain] Net Income Equity Method Investment, Summarized Financial Information, Net Income (Loss) Noncurrent assets Equity Method Investment, Summarized Financial Information, Noncurrent Assets Net sales Equity Method Investment, Summarized Financial Information, Revenue Gross Profit Equity Method Investment, Summarized Financial Information, Gross Profit (Loss) Current assets Equity Method Investment, Summarized Financial Information, Current Assets Current liabilities Equity Method Investment, Summarized Financial Information, Current Liabilities Equity Component [Domain] Equity Method Investments [Abstract] Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Carrying Value Equity Method Investments Equity Method Investments Equity Method Investments [Table Text Block] Amount Finite-lived Intangible Assets Acquired (Decrease) increase in fair market value of warrants Fair Value Adjustment of Warrants Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Recurring [Member] Fair Value, Measurements, Recurring [Member] Fair Value Measurements [Abstract] Measurement Frequency [Axis] Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair value of the assets acquired Fair Value, Measurement Frequency [Domain] Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Financial Instrument [Axis] Accumulated amortization Estimated annual intangible assets amortization expense [Abstract] Total amortizable intangible assets, net Finite-Lived Intangible Assets, Net 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Three Schedule of Identified Definite and Indefinite Lived Intangible Assets Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Gross Amortizable Intangible Assets Schedule of Finite-Lived Intangible Assets by Major Class [Table] Finite-Lived Intangible Assets by Major Class [Axis] 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Two Definite-Lived Intangible Assets [Roll Forward] 2016 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Foreign Currency Forwards [Member] Foreign Exchange Forward [Member] Spot rate Foreign Currency Exchange Rate, Translation Forward Interest Rate Swaps [Member] Forward Contracts [Member] Gain on previously held equity interest Gain on previously held equity interest Gain on previously held equity interest Goodwill Net book value - Ending Period Net book value - Beginning Period Goodwill Goodwill Acquisitions Goodwill, Acquired During Period Goodwill and Other Intangible Assets Currency translation adjustments Goodwill, Translation Adjustments Other Goodwill, Other Changes Goodwill [Roll Forward] Goodwill and Other Intangible Assets [Abstract] Gross Profit Gross Profit Hedging Designation [Axis] Hedging Designation [Domain] Hedging Relationship [Domain] Amount Indefinite-lived Intangible Assets Acquired Intersegment Eliminations [Member] Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - basic (in dollars per share) Share of income from equity method investments Equity earnings Income Statement Location [Axis] CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (UNAUDITED) [Abstract] Earnings Before Income Tax Provision Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - diluted (in dollars per share) Earnings Before Interest and Income Tax Provision Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income Statement Location [Domain] Income tax provision Income Tax Expense (Benefit) Cash paid for income taxes Income taxes Increase (Decrease) in Income Taxes Payable Trade accounts payable Increase (Decrease) in Accounts Payable, Trade Other non-current assets and liabilities Increase (Decrease) in Other Operating Liabilities Changes in operating assets and liabilities - Increase (Decrease) in Operating Capital [Abstract] Inventories Increase (Decrease) in Inventories Accrued expenses and other liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Accounts receivable, net Increase (Decrease) in Receivables Increase (Decrease) in Stockholders' Equity [Roll Forward] Other current assets Increase (Decrease) in Prepaid Expense and Other Assets Indefinite-Lived Intangible Assets [Roll Forward] Indefinite-lived Intangible Assets [Roll Forward] Total indefinite lived intangible assets Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets [Axis] Intangible assets Total intangible assets, net Interest expense, net Cash paid for interest Interest Rate Swaps [Member] Interest Rate Swap [Member] Fair Value Hedges [Abstract] Interest Expense, Net [Member] Estimated manufacturing profit in acquired finished goods inventory capitalized Inventory, Noncurrent, Fair Value Disclosure Inventories Inventory, Net Number of shares held (in shares) Outstanding shares owned (in shares) Investments in and Advances to Affiliates, Balance, Shares Available-for-Sale Investments Available-for-Sale Investments [Abstract] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Favorable Lease Interests [Member] Lease Agreements [Member] Operating Leases [Abstract] Operating Leases Favorable Lease Interests [Member] Leases, Acquired-in-Place [Member] Letter of Credit [Member] Total Current Liabilities Liabilities, Current Total Non-Current Liabilities Liabilities, Noncurrent Current Liabilities: Liabilities, Current [Abstract] Non-Current Liabilities: Liabilities, Noncurrent [Abstract] Liabilities and Equity: Liabilities and Shareholders' Equity Liabilities [Abstract] Fair value of liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Total Liabilities and Equity Liabilities and Equity Line of Credit Facility [Table] Termination of credit agreement Line of Credit Facility [Axis] Amount borrowed Long-term Line of Credit Maximum borrowing capacity Line of Credit Facility, Lender [Domain] Term Loan and Revolving Credit Agreement [Member] Line of Credit [Member] Line of Credit Facility [Line Items] Term of credit agreement Litigation Case Type [Domain] Litigation Case [Axis] Term Loan [Member] Loans Payable [Member] Cumulative fair value adjustments resulted in increase in long-term debt Long-term Debt, Fair Value Long-term debt Total long term debt Long-term Debt, Excluding Current Maturities Loss Contingencies [Table] Loss Contingencies [Line Items] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Axis] Long-Term Debt [Abstract] Maximum [Member] Minimum [Member] Noncontrolling interest Ownership percentage of WBA Noncontrolling interests Noncontrolling interest acquired Money Market Funds [Member] Cash Flows from Financing Activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash Flows from Operating Activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net cash used for investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Earnings Attributable to Walgreens Boots Alliance, Inc. Net Income (Loss) Attributable to Parent Cash Flows from Investing Activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Net cash (used for) provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net earnings attributable to noncontrolling interests Recent Accounting Pronouncements [Abstract] Non-compete Agreements [Member] Number of reportable segment Number of reportable segments Noncontrolling Interests [Member] Not Designated as Hedging Instrument [Member] Reportable Segments [Member] Operating Income Operating Income (Loss) Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization [Abstract] Other Current Liabilities [Member] Other Current Liabilities [Member] Pension/postretirement obligations Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax Other Noncurrent Liabilities [Member] Other Current Assets [Member] Net other comprehensive income (loss) Other comprehensive income (loss) before reclassification adjustments Unrecognized gain (loss) on available-for-sale investments Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax Currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other non-current assets Other Assets, Noncurrent Other income (expense) Tax benefit (provision) Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Other current assets Other Assets, Current Unrealized gain (loss) on cash flow hedges Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax Other Other Long-term Debt Other non-current liabilities Other Liabilities, Noncurrent Other Other Noncash Expense Short-term borrowings Other Other Short-term Borrowings Share of other comprehensive income (loss) of Alliance Boots Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest Other Non-currents Assets [Member] Other comprehensive income (loss), net of tax Total Other Comprehensive Income (Loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Stock purchases Payments for Repurchase of Common Stock Other Payments for (Proceeds from) Other Investing Activities Aggregate purchase price Alliance Boots acquisition, net of cash received Cash dividends paid Payments of Dividends Cash Total purchase price cash consideration Warrants aggregate exercise price payment Payments for Repurchase of Warrants Additions to property, plant and equipment Payments to Acquire Property, Plant, and Equipment Purchases of short-term investments held to maturity Payments to Acquire Held-to-maturity Securities Retirement Benefits Postemployment Benefits Disclosure [Text Block] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock $.01 par value; authorized 32 million shares, none issued Preferred Stock, Value, Issued Preferred stock, issued (in shares) Preferred Stock, Shares Issued Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Other Proceeds from (Payments for) Other Financing Activities Repayment of debt Proceeds (payments) of short-term borrowings, net Proceeds from sale of other assets Proceeds from Sale of Other Assets, Investing Activities Proceeds from issuance of long-term debt Proceeds from Issuance of Unsecured Debt Net proceeds from notes payable Proceeds from Notes Payable Proceeds from sale of business Proceeds from short-term investments held to maturity Proceeds from Sale of Held-to-maturity Securities Proceeds related to employee stock plans Proceeds from Stock Plans Net earnings Net Earnings Net Earnings Property, plant and equipment, at cost, less accumulated depreciation and amortization Property, Plant and Equipment, Net Range [Domain] Range [Axis] Debt to total capitalization ratio Amounts reclassified from accumulated OCI Reconciliation of Revenue from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Payments of long-term debt Repayments of Long-term Debt Restructuring Plan [Axis] Total restructuring costs Restructuring Plan [Domain] Pre-tax charges incurred during the period Restructuring [Abstract] Restructuring Reserve Disclosures [Abstract] Expected pre-tax charges Restructuring Restructuring Type [Axis] Restructuring Type [Axis] Retained Earnings [Member] Retained earnings Retained Earnings (Accumulated Deficit) Sales Revolving Credit Facility [Member] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Closing market price per share (in dollars per share) Sale of Stock, Price Per Share Proceeds from sale leaseback transactions Net sales Revenue, Net Previously Reported [Member] Scenario, Previously Reported [Member] Scenario, Unspecified [Domain] Schedule of Identifiable Assets Acquired and Liabilities Assumed Including Noncontrolling Interests Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Gains and Losses due to Changes in Fair Value Recognized in Earnings Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Schedule of Derivative Assets at Fair Value Schedule of Business Acquisition Total Consideration Paid Schedule of Business Acquisitions, by Acquisition [Table Text Block] Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Details of Each Tranche of Notes Issued Schedule of Debt [Table Text Block] Schedule of Finite-Lived Intangible Assets by Major Class Notional Amounts of Derivative Instruments Outstanding Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Components of Accumulated Other Comprehensive Income (Loss) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Impact of Equity Transaction Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Line Items] Schedule of Business Acquisitions, by Acquisition [Table] Long-Term Debt Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Defined Benefit Plans Disclosures [Table] Investment, Name [Axis] Investment, Name [Axis] Schedule of Goodwill Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Costs by Segment Schedule of Segment Reporting Information, by Segment [Table] Schedule of Short-term Debt [Table] Short-Term Borrowings Segment Reporting [Abstract] Segments [Domain] Segment Reporting Information [Line Items] Segment Reporting Segment Reporting Information, Operating Income (Loss) [Abstract] Selling, general and administrative expenses Selling, General and Administrative Expense Selling, General and Administrative Expenses [Member] Stock compensation expense Share-based Compensation Short-Term Borrowings [Abstract] Short Term Debt Type [Axis] Short-term Debt, Type [Axis] Total short-term borrowings Short-term Debt Weighted-average interest rate Short-term Debt, Weighted Average Interest Rate Short Term Debt Type [Domain] Short-term Debt, Type [Domain] Short-term Debt [Line Items] Accounting Policies Statement [Line Items] CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) [Abstract] CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) [Abstract] CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) [Abstract] Equity Components [Axis] Equity Components [Axis] Statement [Table] Scenario [Axis] Segments [Axis] CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) [Abstract] Purchase price consideration, common shares (in shares) Stock Issued During Period, Shares, Acquisitions Equity: Equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Beginning Balance Ending Balance Total Equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total Walgreens Boots Alliance, Inc. Shareholders' Equity Stockholders' Equity Attributable to Parent Subsequent Event Type [Axis] Subsequent Event [Line Items] Subsequent Event [Member] Subsequent Event Subsequent Event [Abstract] Subsequent Event Type [Domain] Subsequent Event [Table] Supplemental Cash Flow Disclosures [Abstract] Trade Names and Trademarks [Member] Trade Names [Member] Trade Names and Trademarks [Member] Trademarks and Trade Names [Member] Financial Instruments [Domain] Treasury stock purchases (in shares) Treasury Stock, Shares, Acquired Treasury stock, at cost (in shares) Treasury Stock, Shares Treasury Stock [Member] Treasury stock purchases Treasury Stock, Value, Acquired, Cost Method Treasury stock, at cost; 92,853,639 shares at February 29, 2016 and 82,603,274 at August 31, 2015 Treasury Stock, Value Type of Restructuring [Domain] Unsecured Notes Unsecured Debt, Current Unsecured Debt [Member] Unsecured Debt [Member] Unsecured Debt [Member] Variable Rate [Axis] Variable Rate [Domain] Warrants [Member] Warrant [Member] Warrants [Abstract] Warrants and Rights Note Disclosure [Abstract] Dilutive effect of stock options (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Average diluted shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Euro Member Countries, Euro United Kingdom, Pounds All Currencies [Domain] The entire disclosure for depreciation and amortization. Depreciation And Amortization [Text Block] Depreciation and Amortization The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. Intangible Assets And Other Amortization Intangible asset and other amortization The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. This item also includes the cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Business and intangible asset acquisitions, net of cash received Other business and intangible asset acquisitions, net of cash received Changes In Cash And Cash Equivalents [Abstract] Changes in Cash and Cash Equivalents: This item represents the entity's proportionate share for the period of the net income (loss) of Alliance Boots (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee. Equity earnings in Alliance Boots Equity earnings from equity method investments Represents the fair market value changes of the AmerisourceBergen Corporation warrants and related amortization. Change in fair value of warrants and related amortization Change in fair value of warrants and related amortization A written promise to pay a note to a third party. Notes payable due 2017 one [Member] Notes Due 2017 One [Member] A written promise to pay a note to a third party. Notes Payable, Due 2025 [Member] 3.600% Unsecured Pound Sterling Notes Due 2025 [Member] A written promise to pay a note to a third party. Notes Payable, Due 2014 [Member] Notes Due 2014 [Member] A written promise to pay a note to a third party. Notes Payable Due 2019 One [Member] 5.250% Unsecured Notes Due 2019 [Member] A written promise to pay a note to a third party. Notes Payable, Due 2044 [Member] 4.800% Unsecured Notes Due 2044 [Member] This element details information about the assumed loans related to the purchase of land, buildings and equipment. Assumed Loans [Member] A written promise to pay a note to a third party. Notes Due 2019 [Member] Unsecured Pound Sterling Variable Rate Term Loan Due 2019 [Member] A written promise to pay a note to a third party. Notes Payable Due 2020 [Member] 2.875% Unsecured Pound Sterling Notes Due 2020 [Member] A written promise to pay a note to a third party. Notes Payable, Due 2024 [Member] 3.800% Unsecured Notes Due 2024 [Member] A written promise to pay a note to a third party. Notes Payable, Due 2042 [Member] 4.400% Unsecured Notes Due 2042 [Member] A written promise to pay a note to a third party. Notes Payable Due 2017 Two [Member] 1.750% Unsecured Notes Due 2017 [Member] A written promise to pay a note to a third party. Notes Payable, Due 2022 [Member] 3.100% Unsecured Notes Due 2022 [Member] A written promise to pay a note to a third party. Notes Payable, Due 2026 [Member] 2.125% Unsecured Euro Notes Due 2026 [Member] A written promise to pay a note to a third party. Notes Payable, Due 2015 [Member] Notes Due 2015 [Member] A written promise to pay a note to a third party. Notes payable due 2016 [Member] Notes Due 2016 [Member] Unsecured Variable Rate Notes Due 2016 [Member] A written promise to pay a note to a third party. Notes Payable, Due 2034 [Member] 4.500% Unsecured Notes Due 2034 [Member] A written promise to pay a note to a third party. Notes Payable Due 2021 [Member] 3.300% Unsecured Notes Due 2021 [Member] Year when the debt instrument is scheduled to be fully repaid. Debt Instrument Maturity Year Maturity year Including current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and after deducting unamortized discount or premiums and unamortized fair market value adjustments, if any. Long Term Debt Net Discount And Fair Market Value Adjustments Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency. Variable spot rate Spot rate A written promise to pay a note to a third party. Notes Payable Due 2019 Two [Member] 2.700% Unsecured Notes Due 2019 [Member] Amount of net consideration after transferred to acquiree, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Net Consideration After Attributable To Acquiree Total consideration after attributed amount to WBAD Amount of consideration transferred to acquiree, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Less: consideration attributed to WBAD Less: consideration attributed to WBAD Consideration attributable to WBAD An equity method investee of the company. Alliance Boots [Member] An equity method investee of the company. Other Acquisition [Member] Aggregate change in value for stock issued during the period as a result of employee stock purchase and stock option plans. Employee stock purchase and option plans, amount Employee stock purchase and option plans Number of shares issued during the period as a result of an employee stock purchase and stock option plans. Employee stock purchase and option plans, shares Employee stock purchase and option plans (in shares) Amounts receivable from employees resulting from the sale of stock to employees through our employee stock ownership plans before the cash payment is received. Employee Stock Loan Receivable [Member] Amounts receivable from employees resulting from the sale of stock to employees through our employee stock ownership plans before the cash payment is received. Employee stock loan receivable Employee stock loan receivable Amounts receivable from employees resulting from the sale of stock to employees through our employee stock ownership plans before the cash payment is received. Receivable from Employees for Issuance Of Capital Stock Employee stock loan receivable Represents other types of short-term debt arrangements not previously listed in the taxonomy. Other Short Term Debt [Member] Other Short-Term Debt [Member] Boots plan designed to provide participants with a pension benefit. Excludes other postretirement benefit plans. Boots Pension Plan [Member] Boots Pension Plan [Member] Initial term of lease, at lower range, under an operating lease agreement. Initial Term of operating lease, lower range Initial term of operating lease, lower range The number of leases assigned where the entity has secondary liability. Number of assigned leases Number of leases Maximum potential amount of future payments (undiscounted) the entity could be required to make under assigned lease. Maximum potential undiscounted future payments Maximum potential undiscounted future payments Charges related to facilities that were closed or relocated under long-term leases. These charges are reported in selling, general and administrative expenses. Charges related to facilities that were closed or relocated A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Changes in Reserve for Facility Closings and Related Lease Termination Charges [Abstract] Changes in reserve for facility closings and related lease termination charges [Roll Forward] Decrease in reserve due to cash payments, net of sublease income, related to facility's closings and lease termination. Reserve Facility Closings and Lease Termination, Cash payments, net of sublease income Cash payments, net of sublease income Change in reserve due to liability assumed through acquisition in facility's closings and lease termination. Reserve Facility Closings and Lease Termination, Liability Assumed Through Acquisition of Alliance Boots Liability assumed through acquisition of Alliance Boots Increase in reserve due to interest accretion related to facility's closings and lease termination. Reserve Facility Closings and Lease Termination, Interest accretion Interest accretion Carrying amount as of the balance sheet date pertaining to a specified type of cost associated with a facility's closings and lease termination. Reserve Facility Closings and Lease Termination, Balance Balance - end of period Balance - beginning of period Increase in reserve representing the present value of non-cancellable lease payments of closed facilities. Reserve Facility Closings and Lease Termination, Provision for present value of non-cancellable lease payments of closed facilities Provision for present value of non-cancellable lease payments on closed facilities Change in reserve due to assumptions about future sublease income, terminations, and changes in interest rates in facility's closings and lease termination. Reserve Facility Closings and Lease Termination, Assumptions about future sublease income, terminations, and changes in interest rates Assumptions about future sublease income, terminations and changes in interest rates Initial term of lease, at upper range, under an operating lease agreement. Initial term of operating lease, upper range Interval period of renewal options under an operating lease agreement. Interval period of renewal options Boots and Other pension plan designed to provide participants with a benefit at retirement. Boots and Other Pension Plans [Member] The amount of the cost recognized during the period for defined contribution plans profit sharing provision benefit expense amount. Defined Contribution Plan Profit Sharing Provision Benefit Expense Amount Profit sharing provision expense Represents information pertaining to Alliance Boots Retirement Savings Plan to which both the Company and participating employees contribute. Alliance Boots Retirement Savings Plan [Member] Represents information pertaining to Walgreen Profit Sharing Retirement Trust to which both the Company and participating employees contribute. Walgreen Profit Sharing Retirement Trust [Member] Additional amount of discretionary contributions made by an employer to a defined contribution plan. Employee expected additional contribution in current fiscal year Refers to number of defined benefit pension plans. Number of defined benefit pension plans Number of defined benefit pension plans This element details information about the total $4.0 billion debt issuance. Debt Issuance Note Two [Member] Total $4.0 Billion Debt Issuance [Member] This element details information about the total $8.0 billion debt issuance. Debt Issuance Note One [Member] Total $8.0 Billion Debt Issuance [Member] This element details information about the unsecured euro and Pound Sterling notes. Euro and Pound Sterling Notes [Member] Purchase price, represented as a percentage of the principal amount, required to repurchase the notes if a change of control triggering event occurs and the notes have not previously been redeemed. Required Purchase Price On Triggering Event Percentage of principal amount required on triggering event to repurchase notes Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index. Treasury Rate [Member] Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index. Government Bond Rate [Member] The available amount of borrowing from the redemption premium obtained during the period. Debt Instrument Redemption Premium Debt instrument redemption premium Percentage price of original principal amount plus accrued interest of debt at which debt can be redeemed by the issuer. Debt Instrument Redemption Price Percentage Including Accrued Interest Percentage of redemption price including accrued interest Refers to other immaterial fixed and variable rate borrowings in various foreign currencies. Variable Rate Borrowings [Member] This element details information about the unsecured notes bearing interest at 1.750% due in 2017. Unsecured Notes Due 2017 [Member] 1.750% Unsecured Notes Due 2017 [Member] This element details information about the unsecured notes bearing interest at 1.800% due in 2017. Unsecured Notes 1.800 Due 2017 [Member] 1.800% Unsecured Notes Due 2017 [Member] This element details information about the unsecured notes bearing interest at 3.300% due in 2021. Unsecured Notes Due 2021 [Member] 3.300% Unsecured Notes Due 2021 [Member] This element details information about the unsecured Pound Sterling notes bearing interest at 3.600% due in 2025. Unsecured Pound Sterling Notes Due 2025 [Member] Unsecured Pound Sterling Notes Due 2025 [Member] 3.600% Unsecured Pound Sterling Notes Due 2025 [Member] This element details information about the unsecured Euro notes. Euro Notes [Member] This element details information about the unsecured variable rate notes due in 2016. Unsecured Variable Rate Notes Due 2016 [Member] This element details information about the unsecured notes bearing interest at 3.800% due in 2024. Unsecured Notes Due 2024 [Member] 3.800% Unsecured Notes Due 2024 [Member] This element details information about the total $1.0 billion debt issuance. Debt Issuance Note Three [Member] Total $1.0 Billion Debt Issuance [Member] This element details information about the unsecured senior notes bearing interest at 5.250% due in 2019. Unsecured Notes Due 2019 [Member] 2.700% Unsecured Notes Due 2019 [Member] This element details information about the unsecured notes bearing interest at 3.100% due in 2022. Unsecured Notes 3.100 Due 2022 [Member] 3.100% Unsecured Notes Due 2022 [Member] This element details information about the unsecured notes bearing interest at 4.500% due in 2034. Unsecured Notes Due 2034 [Member] 4.500% Unsecured Notes Due 2034 [Member] This element details information about the unsecured Pound Sterling notes bearing interest at 2.875% due in 2020. Unsecured Pound Sterling Notes Due 2020 [Member] Unsecured Pound Sterling Notes Due 2020 [Member] 2.875% Unsecured Pound Sterling Notes Due 2020 [Member] This element details information about the unsecured notes bearing interest at 4.400% due in 2042. Unsecured Notes 4.400 Due 2042 [Member] 4.400% Unsecured Notes Due 2042 [Member] This element details information about the unsecured notes bearing interest at 1.000% due in 2015. Unsecured Notes 1.000% Due 2015 [Member] 1.000% Unsecured Notes Due 2015 [Member] This element details information about the unsecured notes bearing interest at 4.800% due in 2044. Unsecured Notes Due 2044 [Member] 4.800% Unsecured Notes Due 2044 [Member] Refers to putative class action lawsuits were filed by purported Rite Aid stockholders arising out of the Company's proposed acquisition of Rite Aid. Number of lawsuits filed Refers to the location of the court. Delaware Court of Chancery [Member] Court of Chancery of the State of Delaware [Member] Refers to the location of the court. Pennsylvania Court of Common Pleas of Cumberland County [Member] State of Pennsylvania in the Court of Common Pleas of Cumberland County [Member] Refers to the location of the court. Middle District of Pennsylvania [Member] An equity method investee of the company. Alliance Healthcare Italia Distribuzione S.p.A. [Member] An equity method investee of the company. Walgreens Boots Alliance Development GmbH [Member] Walgreens Boots Alliance Development GmbH [Member] Represents equity method ownership option to repurchase shares amount. Equity Method Ownership Option To Repurchase Shares Amount Equity method ownership option to repurchase shares, amount Impact of equity transactions [Abstract] Impact of equity transactions [Abstract] Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. Impact to Additional Paid in Capital Impact to additional paid in capital Refers to carrying value of entity's pre-existing noncontrolling interest. Carrying Value of Entity's Pre-existing Noncontrolling Interest Less: Carrying value of the Company's pre-existing noncontrolling interest Refers to restructuring of real estate cost. Real Estate Cost [Member] Real Estate Costs [Member] Cost transformation program is a restructuring plan to reduce costs and increase operating efficiencies. Cost Transformation restructuring Program [Member] Cost Transformation Program [Member] Refers to restructuring of assets impairment and related activities. Asset Impairment Restructuring Charges [Member] Asset Impairments [Member] Identifies division of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity. Pharmaceutical Wholesale [Member] Pharmaceutical Wholesale [Member] Identifies division of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity. Retail Pharmacy USA [Member] Retail Pharmacy USA [Member] Approximate number of store closed as a part of the restructuring program. Approximate number of store closed Number of stores planned to be closed Identifies division of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity. Retail Pharmacy International [Member] Retail Pharmacy International [Member] Document and Entity Information [Abstract] The fair value unissued stock by equity investees made to investors outside the consolidated group that is not reported as operating income. Represents the difference in the parent company's carrying amount of the equity interest in the subsidiary or equity investee immediately before and after the transaction. Fair Value Of Previously Unissued Stock By Equity Investee Fair value of previously held equity interest The disclosure of depreciation and amortization expense allocated by major categories. Depreciation And Amortization By Major Category [Text Block] Depreciation and Amortization by Major Category This element details information about the unsecured Euro notes bearing interest at 2.125% due in 2026. Unsecured Euro Notes Due 2026 [Member] 2.125% Unsecured Euro Notes Due 2026 [Member] This element details information about the unsecured Pound Sterling notes. Pound Sterling Notes [Member] A written promise to pay a note to a third party. Notes Payable, Due 2019 [Member] 2.700% Unsecured Notes Due 2019 [Member] Tabular disclosure of summarized financial information for the company's equity method investees. Equity Method Investment, Summarized Financial Information [Table Text Block] Summarized Financial Information of Equity Method Investees Percentage of outstanding common shares of affiliates held for management investment companies. Percentage of Outstanding Common Stock Percentage of outstanding common stock held Percentage of outstanding common shares owned Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract] Balance Sheet [Abstract] Investment in other than stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition. Equity Method Investments Other [Member] Other Equity Method Investments [Member] Refers to additional short-term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing. Additional senior unsecured bridge facility Average daily short-term borrowings under the credit facility. Average Daily Short Term Borrowings Average daily short-term borrowings Refers to tranche two periodic payment. Tranche Two [Member] Tranche Two [Member] Additional borrowing supported by a written promise to pay an obligation. Additional Term Loan [Member] Additional Term Loan [Member] Refers to Term Loan Credit Agreement together with the Bridge Credit Agreement. 2015 Credit Agreements [Member] Additional short-term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing. Additional Bridge Loan [Member] Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount. 364 Day Credit Agreement [Member] 364-Day Credit Agreement [Member] Refers to borrowing supported by a written promise to pay an obligation. Term Loan Credit Agreement [Member] Refers to tranche one periodic payment. Tranche One [Member] Tranche One [Member] Refers to number of tranches during the period. Number of Tranches Number of tranches Other utility cost incurred related to store closures and other optimization costs produced and sold during the reporting period. Store closures and other optimization costs Store closures and other optimization costs The amount of LIFO (last in first out) provision present at the reporting date when inventory is also valued using different valuation methods. LIFO provision LIFO provision The total amount of adjusted operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation. Adjusted Operating Income The aggregate cost incurred for transformation of goods produced and sold and services rendered during the reporting period. Cost transformation Cost transformation Identifies division of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity. Eliminations And Unallocated Items [Member] Eliminations and Unallocated Items [Member] An equity method investee of the company. Walgreens Boots Alliance [Member] Walgreens Boots Alliance [Member] The aggregate value of securities held, which were categorized neither as trading nor held-to-maturity, for which the interest rate reset through an auction process, that failed to be liquidated through auction, and which were sold during the period. Available For Sale Securities Sold Sale of acquired available-for-sale securities Other equity investments, equity securities. Other Equity Investments Equity Securities [Member] Other Investments [Member] Tabular disclosure of an entity's reserve for facility closings and related lease termination charges. This element may be used to encapsulate the roll forward presentations of an entity's reserve for facility closings and related lease termination charges. Reserve for Facility Closings and Related Lease Termination Charges [Table Text Block] Reserve for Facility Closings and Related Lease Termination Charges Refers to cash and cash equivalent items which are restricted as to withdrawal or usage. Restricted Cash [Member] Restricted Cash [Member] Amount of increase in asset representing future economic benefits arising from synergies in a business combination that are directly attributable to the segment. Goodwill arising from synergies Goodwill arising from synergies It refers to loyalty card, similar to a credit card, debit card, or digital card that identifies the card holder as a member in a loyalty program. Loyalty Card Holders [Member] Pharmacy Licenses given to the company. Pharmacy Licenses [Member] Goodwill based on a with and without analysis whereby the difference between the fair value of a segment before the acquisition and its fair value after the acquisition represents the amount of goodwill assigned to that segment. Goodwill based on a with and without analysis Goodwill based on a with and without analysis This item represents the entity's proportionate share for the period of the net income (loss) of Alliance Boots (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee. Income from equity method investments Equity earnings in Alliance Boots This item represents the entity's proportionate share for the period of the net income (loss), net of taxes of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee. Income Loss From Equity Method Investments Net of Tax Post tax earnings from equity method investments List of prescription files Purchased Prescription File [Member] Purchased Prescription Files [Member] An asset acquired in a business combination representing an entity's purchasing and payer contract. Purchasing and Payer Contract [Member] Purchasing and Payer Contracts [Member] Derivative instrument used to hedge an expected debt issuance rather than the interest payments from a current debt issuance. Forward Interest Rate Swaps [Member] A note is a bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, debt holders receive priority for [must receive] repayment. Notes [Member] Step 2 transaction foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate. Step 2 Transaction Foreign Currency Forwards [Member] Second Step Transaction Foreign Currency Forwards [Member] Refers to derivative notional amount cancelled. Derivative Notional Amount Terminated Derivative notional amount terminated Represents information related to warrants exercisable in beginning of March 2016. Warrants Exercisable in March 2016 [Member] Represents information related to warrants exercisable in beginning of March 2017. Warrants Exercisable in March 2017 [Member] Primary financial statement caption encompassing other expense and revenues. Other income/(expenses) [Member] Other Income (Expense) [Member] Period relating the average interest rate estimated by leading banks in London that they would be charged if borrowing from other banks. Six Month LIBOR [Member] Six-month LIBOR [Member] Period relating the average interest rate estimated by leading banks in London that they would be charged if borrowing from other banks. One Month LIBOR [Member] One-month LIBOR [Member] An equity method investee of the company. AmerisourceBergen Corporation [Member] AmerisourceBergen Corporation [Member] EX-101.PRE 17 wba-20160229_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 18 R1.htm IDEA: XBRL DOCUMENT v3.3.1.900
Document and Entity Information - shares
6 Months Ended
Feb. 29, 2016
Mar. 31, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name Walgreens Boots Alliance, Inc.  
Entity Central Index Key 0001618921  
Current Fiscal Year End Date --08-31  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   1,080,245,720
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Feb. 29, 2016  
XML 19 R2.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Feb. 29, 2016
Aug. 31, 2015
Current Assets:    
Cash and cash equivalents $ 3,586 $ 3,000
Accounts receivable, net 6,733 6,849
Inventories 9,025 8,678
Other current assets 1,034 1,130
Total Current Assets 20,378 19,657
Non-Current Assets:    
Property, plant and equipment, at cost, less accumulated depreciation and amortization 14,552 15,068
Goodwill 15,796 16,372
Intangible assets 11,122 12,351
Other non-current assets 4,537 5,334
Total Non-Current Assets 46,007 49,125
Total Assets 66,385 68,782
Current Liabilities:    
Short-term borrowings 1,052 1,068
Trade accounts payable 9,873 10,088
Accrued expenses and other liabilities 5,050 5,225
Income taxes 297 176
Total Current Liabilities 16,272 16,557
Non-Current Liabilities:    
Long-term debt [1] 12,974 13,315
Deferred income taxes 3,107 3,538
Other non-current liabilities 4,114 4,072
Total Non-Current Liabilities $ 20,195 $ 20,925
Commitments and Contingencies (see Note 12)
Equity:    
Preferred stock $.01 par value; authorized 32 million shares, none issued $ 0 $ 0
Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at February 29, 2016 and August 31, 2015 12 12
Paid-in capital 10,041 9,953
Employee stock loan receivable (1) (2)
Retained earnings 26,348 25,089
Accumulated other comprehensive (loss) income (1,868) (214)
Treasury stock, at cost; 92,853,639 shares at February 29, 2016 and 82,603,274 at August 31, 2015 (5,026) (3,977)
Total Walgreens Boots Alliance, Inc. Shareholders' Equity 29,506 30,861
Noncontrolling interests 412 439
Total Equity 29,918 31,300
Total Liabilities and Equity $ 66,385 $ 68,782
[1] All notes are presented net of unamortized discount and debt issuance costs, where applicable.
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares
Feb. 29, 2016
Aug. 31, 2015
Equity:    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 32,000,000 32,000,000
Preferred stock, issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares (in shares) 3,200,000,000 3,200,000,000
Common stock, issued (in shares) 1,172,513,618 1,172,513,618
Treasury stock, at cost (in shares) 92,853,639 82,603,274
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) - 6 months ended Feb. 29, 2016 - USD ($)
$ in Millions
Common Stock [Member]
Treasury Stock [Member]
Paid-In Capital [Member]
Employee Stock Loan Receivable [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Retained Earnings [Member]
Noncontrolling Interests [Member]
Total
Beginning Balance at Aug. 31, 2015 $ 12 $ (3,977) $ 9,953 $ (2) $ (214) $ 25,089 $ 439 $ 31,300
Beginning Balance (in shares) at Aug. 31, 2015 1,089,910,344              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net earnings $ 0 0 0 0 0 2,040 9 2,049
Other comprehensive income (loss), net of tax 0 0 0 0 (1,654) 0 (36) (1,690)
Dividends declared ($0.72 per share) 0 0 0 0 0 (781) 0 (781)
Treasury stock purchases $ 0 (1,152) 0 0 0 0 0 (1,152)
Treasury stock purchases (in shares) (13,815,558)              
Employee stock purchase and option plans $ 0 103 28 0 0 0 0 131
Employee stock purchase and option plans (in shares) 3,565,193              
Employee stock loan receivable $ 0 0 0 1 0 0 0 1
Stock-based compensation 0 0 60 0 0 0 0 60
Ending Balance at Feb. 29, 2016 $ 12 $ (5,026) $ 10,041 $ (1) $ (1,868) $ 26,348 $ 412 $ 29,918
Ending Balance (in shares) at Feb. 29, 2016 1,079,659,979              
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) (Parenthetical) - $ / shares
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) [Abstract]        
Cash dividends declared (in dollars per share) $ 0.3600 $ 0.3375 $ 0.7200 $ 0.6750
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (UNAUDITED) [Abstract]        
Net sales $ 30,184 $ 26,573 $ 59,217 $ 46,127
Cost of sales 22,240 19,691 43,771 33,949
Gross Profit 7,944 6,882 15,446 12,178
Selling, general and administrative expenses 6,084 5,606 12,118 10,062
Equity earnings in Alliance Boots 0 101 0 315
Operating Income 1,860 1,377 3,328 2,431
Gain on previously held equity interest 0 706 0 706
Other income (expense) (496) 504 (553) 703
Earnings Before Interest and Income Tax Provision 1,364 2,587 2,775 3,840
Interest expense, net 140 144 278 199
Earnings Before Income Tax Provision 1,224 2,443 2,497 3,641
Income tax provision 301 391 468 712
Post tax earnings from equity method investments 9 8 20 8
Net Earnings 932 2,060 2,049 2,937
Net earnings attributable to noncontrolling interests 2 18 9 45
Net Earnings Attributable to Walgreens Boots Alliance, Inc. $ 930 $ 2,042 $ 2,040 $ 2,892
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - basic (in dollars per share) $ 0.86 $ 1.96 $ 1.88 $ 2.91
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - diluted (in dollars per share) 0.85 1.93 1.87 2.88
Dividends declared per share (in dollars per share) $ 0.3600 $ 0.3375 $ 0.7200 $ 0.6750
Average shares outstanding (in shares) 1,080.2 1,043.6 1,084.6 994.7
Dilutive effect of stock options (in shares) 8.2 11.1 8.9 10.6
Average diluted shares (in shares) 1,088.4 1,054.7 1,093.5 1,005.3
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) [Abstract]        
Net Earnings $ 932 $ 2,060 $ 2,049 $ 2,937
Other comprehensive income (loss), net of tax:        
Pension/postretirement obligations (2) (8) 1 (9)
Unrealized gain (loss) on cash flow hedges 1 0 2 (12)
Unrecognized gain (loss) on available-for-sale investments (88) 90 (87) 189
Share of other comprehensive income (loss) of Alliance Boots 0 92 0 113
Currency translation adjustments (1,156) (301) (1,606) (490)
Total Other Comprehensive Income (Loss) (1,245) (127) (1,690) (209)
Total Comprehensive Income (Loss) (313) 1,933 359 2,728
Comprehensive income (loss) attributable to noncontrolling interests (33) 13 (27) 40
Comprehensive Income (Loss) Attributable to Walgreens Boots Alliance, Inc. $ (280) $ 1,920 $ 386 $ 2,688
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Cash Flows from Operating Activities:    
Net earnings $ 2,049 $ 2,937
Adjustments to reconcile net earnings to net cash provided by operating activities -    
Depreciation and amortization 824 826
Change in fair value of warrants and related amortization 586 (859)
Gain on previously held equity interest 0 (706)
Deferred income taxes (171) 181
Stock compensation expense 60 65
Equity earnings from equity method investments (20) (315)
Other 196 322
Changes in operating assets and liabilities -    
Accounts receivable, net (152) (391)
Inventories (553) 106
Other current assets 33 21
Trade accounts payable 160 363
Accrued expenses and other liabilities (79) (20)
Income taxes 92 (99)
Other non-current assets and liabilities 60 (94)
Net cash provided by operating activities 3,085 2,337
Cash Flows from Investing Activities:    
Additions to property, plant and equipment (657) (643)
Proceeds from sale leaseback transactions 60 562
Proceeds from sale of business 43 0
Proceeds from sale of other assets 85 17
Alliance Boots acquisition, net of cash received 0 (4,461)
Other business and intangible asset acquisitions, net of cash received (86) (92)
Purchases of short-term investments held to maturity (30) (29)
Proceeds from short-term investments held to maturity 36 29
Other (3) (91)
Net cash used for investing activities (552) (4,708)
Cash Flows from Financing Activities:    
Proceeds (payments) of short-term borrowings, net 61 (330)
Proceeds from issuance of long-term debt 0 12,279
Payments of long-term debt (81) (7,817)
Stock purchases (1,152) (594)
Proceeds related to employee stock plans 129 293
Cash dividends paid (787) (642)
Other (29) (360)
Net cash (used for) provided by financing activities (1,859) 2,829
Effect of exchange rate changes on cash and cash equivalents (88) (99)
Changes in Cash and Cash Equivalents:    
Net increase in cash and cash equivalents 586 359
Cash and cash equivalents at beginning of period 3,000 2,646
Cash and cash equivalents at end of period $ 3,586 $ 3,005
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization
6 Months Ended
Feb. 29, 2016
Organization [Abstract]  
Organization
Note 1.  Organization
Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance”) and subsidiaries are a global pharmacy-led health and wellbeing enterprise. Its operations are conducted through three reportable segments (Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale). See Note 18, Segment Reporting for further information.

On December 31, 2014, Walgreens Boots Alliance became the successor of Walgreen Co. (“Walgreens”) pursuant to a merger designed to effect a reorganization of Walgreens into a holding company structure (the “Reorganization”). Pursuant to the Reorganization, Walgreens became a wholly-owned subsidiary of Walgreens Boots Alliance, a Delaware corporation formed for the purposes of the Reorganization, and each issued and outstanding share of Walgreens common stock converted on a one-to-one basis into Walgreens Boots Alliance common stock. References to the “Company” refer to Walgreens Boots Alliance and its subsidiaries from and after the effective time of the Reorganization on December 31, 2014 and, prior to that time, to the predecessor registrant Walgreens and its subsidiaries, except as otherwise indicated or the context otherwise requires.

On December 31, 2014, following the completion of the Reorganization, Walgreens Boots Alliance completed the acquisition of the remaining 55% of Alliance Boots GmbH (“Alliance Boots”) that Walgreens did not previously own (the “Second Step Transaction”) in exchange for £3.133 billion in cash and approximately 144.3 million shares of Walgreens Boots Alliance common stock. Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method immediately upon completion of the Second Step Transaction. For financial reporting and accounting purposes, Walgreens Boots Alliance was the acquirer of Alliance Boots. The consolidated financial statements (and other data) reflect the results of operations and financial position of Walgreens and its subsidiaries for periods prior to December 31, 2014 and of Walgreens Boots Alliance and its subsidiaries for periods from and after the effective time of the Reorganization on December 31, 2014.

As part of the Second Step Transaction, the Company acquired the remaining 27.5% noncontrolling interest in Walgreens Boots Alliance Development GmbH (“WBAD”), a global sourcing enterprise established by the Company and Alliance Boots. The Company already owned a 50% direct ownership in WBAD and indirectly owned an additional ownership interest through its previous 45% investment in Alliance Boots, representing a direct and indirect economic interest of 72.5%. The Company’s acquisition of the remaining 27.5% effective ownership in WBAD as part of the Second Step Transaction was accounted for as an equity transaction as it has historically been consolidated by the Company. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. (“AHID”), which is not a member of the Company’s consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000.
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.3.1.900
Accounting Policies
6 Months Ended
Feb. 29, 2016
Accounting Policies [Abstract]  
Accounting Policies
Note 2. Accounting Policies
Basis of Presentation
The consolidated condensed financial statements of Walgreens Boots Alliance included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. The consolidated condensed financial statements include all subsidiaries in which the Company holds a controlling interest. Investments in less than majority-owned entities in which the Company does not have a controlling interest, but does have significant influence, are accounted for as equity method investments. All intercompany transactions have been eliminated.

The Consolidated Condensed Balance Sheet as of February 29, 2016, the Consolidated Condensed Statements of Equity for the six-month period ended February 29, 2016, and the Consolidated Condensed Statements of Earnings, the Consolidated Condensed Statements of Comprehensive Income and the Consolidated Condensed Statements of Cash Flows for the three month and six month periods ended February 29, 2016 and February 28, 2015, have not been audited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.
 
In the opinion of the Company, the unaudited consolidated condensed financial statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present a fair statement of the results for such interim periods. Because of the acquisition of Alliance Boots, influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company’s operations, net earnings for any interim period may not be comparable to the same interim period in previous years or indicative of net earnings for the full fiscal year. In addition, with respect to the Company’s Retail Pharmacy USA segment, the positive impact on gross profit margins and gross profit dollars typically has been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a “generic conversion.” In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on Retail Pharmacy USA segment’s sales, gross profit margins and gross profit dollars.

The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experience and other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. For a discussion of the Company’s significant accounting policies, please see the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.3.1.900
Restructuring
6 Months Ended
Feb. 29, 2016
Restructuring [Abstract]  
Restructuring
Note 3. Restructuring
On April 8, 2015, the Walgreens Boots Alliance Board of Directors approved a plan to implement a new restructuring program (the “Cost Transformation Program”) as part of an initiative to reduce costs and increase operating efficiencies. The Cost Transformation Program implemented and built on the cost-reduction initiative previously announced by the Company on August 6, 2014 and included plans to close approximately 200 stores across the U.S.; reorganize corporate and field operations; drive operating efficiencies; and streamline information technology and other functions. The actions under the Cost Transformation Program focus primarily on Retail Pharmacy USA segment, but includes activities from all segments and are expected to be substantially complete by the end of the Company’s 2017 fiscal year. The Company estimates that it will recognize cumulative pre-tax charges to its GAAP financial results of between $1.6 billion and $1.8 billion, including costs associated with lease obligations and other real estate payments, asset impairments and employee termination and other business transition and exit costs. The Company expects to incur pre-tax charges of between $525 million and $600 million for real estate costs, including lease obligations (net of estimated sublease income); between $650 million and $725 million for asset impairment charges relating primarily to asset write-offs from store closures, information technology, inventory and other non-operational real estate asset write-offs; and between $425 million and $475 million for employee severance and other business transition and exit costs. The Company incurred pre-tax charges of $28 million and $118 million related to the Cost Transformation Program during the three and six months ended February 29, 2016. No charges were incurred with respect to the Cost Transformation Program in the three and six months ended February 28, 2015. From inception through February 29, 2016, the Company incurred pre-tax charges of $660 million ($254 million in real estate costs, $248 million related to asset impairment charges and $158 million in severance and other business transition and exit costs) related to the Cost Transformation Program. All charges related to the Cost Transformation Program have been recorded within selling, general and administrative expenses. As the program is implemented, the restructuring charges will be recognized as the costs are incurred over time in accordance with GAAP.

In March 2014, the Walgreens Board of Directors approved a plan to close underperforming stores in efforts to optimize and focus resources within Retail Pharmacy USA segment in a manner intended to increase stockholder value. As of August 31, 2015, this plan was completed and no additional charges related to the plan are expected. There were no charges incurred in the three month period ended February 28, 2015. For the six months ended February 28, 2015, the Company incurred pre-tax charges of $17 million, which were primarily related to lease termination costs. All charges related to this plan have been recorded within selling, general and administrative expenses.

Restructuring costs by segment are as follows (in millions):

  
Retail Pharmacy
       
Three Months Ended February 29, 2016
 
USA
  
International
  
Pharmaceutical
Wholesale
  
Consolidated
 
Real estate costs
 
$
-
  
$
-
  
$
-
  
$
-
 
Asset impairments
  
-
   
-
   
-
   
-
 
Severance and other business transition and exit costs
  
25
   
3
   
-
   
28
 
Total restructuring costs
 
$
25
  
$
3
  
$
-
  
$
28
 
                 
Three Months Ended February 28, 2015
                
Real estate costs
 
$
-
  
$
-
  
$
-
  
$
-
 
Asset impairments
  
-
   
-
   
-
   
-
 
Severance and other business transition and exit costs
  
-
   
-
   
-
   
-
 
Total restructuring costs
 
$
-
  
$
-
  
$
-
  
$
-
 
 
  
Retail Pharmacy
       
Six Months Ended February 29, 2016
 
USA
  
International
  
Pharmaceutical
Wholesale
  
Consolidated
 
Real estate costs
 
$
52
  
$
-
  
$
-
  
$
52
 
Asset impairments
  
25
   
-
   
-
   
25
 
Severance and other business transition and exit costs
  
33
   
8
   
-
   
41
 
Total restructuring costs
 
$
110
  
$
8
  
$
-
  
$
118
 
                 
Six Months Ended February 28, 2015
                
Real estate costs
 
$
17
  
$
-
  
$
-
  
$
17
 
Asset impairments
  
-
   
-
   
-
   
-
 
Severance and other business transition and exit costs
  
-
   
-
   
-
   
-
 
Total restructuring costs
 
$
17
  
$
-
  
$
-
  
$
17
 
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.3.1.900
Operating Leases
6 Months Ended
Feb. 29, 2016
Operating Leases [Abstract]  
Operating Leases
Note 4. Operating Leases
Initial terms for leased premises in the U.S. are typically 15 to 25 years, followed by additional terms containing renewal options at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.

The Company provides for future costs related to closed locations. The liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date. During the three and six months ended February 29, 2016, the Company recorded charges of $9 million and $75 million, respectively, for facilities that were closed or relocated under long-term leases, including stores closed through the Company’s restructuring activities. This compares to no charges for the three months ended and $26 million for the six months ended February 28, 2015. Charges are reported in selling, general and administrative expenses on the Consolidated Condensed Statements of Earnings.

The changes in reserve for facility closings and related lease termination charges include the following (in millions):
 
    
Six Month
Period Ended
February 29,
2016
  
Twelve Month
Period Ended
August 31,
2015
 
Balance – beginning of period
 
$
446
  
$
257
 
Provision for present value of non-cancellable lease payments on closed facilities
  
77
   
231
 
Assumptions about future sublease income, terminations and changes in interest rates
  
(14
)
  
(6
)
Interest accretion
  
12
   
27
 
Liability assumed through acquisition of Alliance Boots
  
-
   
13
 
Cash payments, net of sublease income
  
(54
)
  
(76
)
Balance – end of period
 
$
467
  
$
446
 

The Company remains secondarily liable on 79 leases. The maximum potential undiscounted future payments are $348 million at February 29, 2016. Lease option dates vary, with some extending to 2039.
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.3.1.900
Equity Method Investments
6 Months Ended
Feb. 29, 2016
Equity Method Investments [Abstract]  
Equity Method Investments
Note 5. Equity Method Investments
Equity method investments as of February 29, 2016 and August 31, 2015 were as follows (in millions, except percentages):

  
February 29, 2016
  
August 31, 2015
 
  
Carrying
Value
  
Ownership
Percentage
  
Carrying
Value
  
Ownership
Percentage
 
Equity method investments
 
$
1,217
   
12% - 50
%
 
$
1,242
   
12% - 50
%

The Company's principal equity method investments include its investments in Guangzhou Pharmaceuticals Corporation and Nanjing Pharmaceutical Corporation Limited, the Company’s pharmaceutical wholesale investments in China; and the equity method investment retained through the sale of a majority interest in Option Care Inc. in fiscal 2015. See Note 20, Subsequent Event for further information.

Equity method investments of the Company are recorded within other non-current assets on the Consolidated Condensed Balance Sheets. The Company reported $9 million and $20 million of post-tax equity earnings in equity method investments for the three and six month periods ended February 29, 2016, respectively, in the Consolidated Condensed Statements of Earnings. The Company reported $8 million of post-tax equity earnings from equity method investments other than Alliance Boots for the three and six month periods ended February 28, 2015. Additionally, for the three and six month periods ended February 28, 2015, the Company reported equity earnings in Alliance Boots of $101 million and $315 million, respectively, as its own line in the Consolidated Condensed Statements of Earnings.

Summarized Financial Information
Summarized financial information for the Company’s equity method investments is as follows:
 
Balance Sheets (in millions)
  
February 29, 2016(1)
  
August 31, 2015(1)
 
Current assets
 
$
5,687
  
$
5,015
 
Noncurrent assets
  
1,592
   
1,548
 
Current liabilities
  
4,598
   
3,936
 
Noncurrent liabilities
  
876
   
837
 
Shareholders’ equity(2)
  
1,805
   
1,790
 
 
Statements of Earnings (in millions)
  
Three Months Ended
  
Six Months Ended
 
  
February 29,
2016(3)
  
February 28,
2015(3)(4)
  
February 29,
2016(3)
  
February 28,
2015(3)(4)
 
             
Net sales
 
$
3,286
  
$
5,317
  
$
6,489
  
$
14,978
 
Gross Profit
  
374
   
979
   
702
   
3,168
 
Net Income
  
26
   
246
   
50
   
743
 
Share of income from equity method investments
  
9
   
109
   
20
   
323
 

(1)
Balance sheet information of foreign equity method investments are translated at their respective February 29, 2016 and August 31, 2015 spot rates.
(2)
Shareholders’ equity at February 29, 2016 and August 31, 2015 includes $170 million and $163 million, respectively, related to noncontrolling interests.
(3)
Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates.
(4)
Includes equity method investment in Alliance Boots from Walgreen Co.’s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization.
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.3.1.900
Available-for-Sale Investments
6 Months Ended
Feb. 29, 2016
Available-for-Sale Investments [Abstract]  
Available-for-Sale Investments
Note 6. Available-for-Sale Investments
Walgreens, Alliance Boots and AmerisourceBergen Corporation (“AmerisourceBergen”) entered into a Framework Agreement, dated as of March 18, 2013, pursuant to which Walgreens and Alliance Boots together were granted the right to purchase a minority equity position in AmerisourceBergen, including the right, but not the obligation, to purchase up to 19,859,795 shares of AmerisourceBergen common stock in open market transactions.

In conjunction with its long-term relationship with AmerisourceBergen, as of February 29, 2016, the Company held 11.5 million shares, approximately 5.6% of AmerisourceBergen’s outstanding common stock, at a total fair value of $993 million. The Company did not acquire any AmerisourceBergen common shares in the three and six month periods ended February 29, 2016.

Pursuant to Accounting Standards Codification (“ASC”) Topic 320, Investments – Debt and Equity Securities, the Company, as of February 29, 2016, accounted for its investment in AmerisourceBergen shares as an available-for-sale investment reported at fair value within other non-current assets in the Consolidated Condensed Balance Sheets. As an available-for-sale investment, changes in the fair value are recorded through other comprehensive income. The value of the investment is recorded at the closing price of AmerisourceBergen common stock as of the balance sheet date. See Note 20, Subsequent Event for further information.

A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions):

  
February 29, 2016
 
  
Amortized
cost basis
  
Gross
unrealized
gains
  
Gross
unrealized
losses
  
Fair value
 
AmerisourceBergen common stock
 
$
717
  
$
276
  
$
-
  
$
993
 
Other investments
  
38
   
-
   
(4
)
  
34
 
Total available-for-sale investments
 
$
755
  
$
276
  
$
(4
)
 
$
1,027
 
 
  
August 31, 2015
 
  
Amortized
cost basis
  
Gross
unrealized
gains
  
Gross
unrealized
losses
  
Fair value
 
AmerisourceBergen common stock
 
$
717
  
$
430
  
$
-
  
$
1,147
 
Other investments
  
37
   
-
   
(1
)
  
36
 
Total available-for-sale investments
 
$
754
  
$
430
  
$
(1
)
 
$
1,183
 

For the three and six month periods ended February 29, 2016, there were $1 million and $3 million, respectively, of available-for-sale securities sold. There were no sales of available-for-sale investments for the three and six month periods ended February 28, 2015.

The Company’s other available-for-sale investments are classified within other current assets in the Consolidated Condensed Balance Sheets.
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisitions
6 Months Ended
Feb. 29, 2016
Acquisitions [Abstract]  
Acquisitions
Note 7. Acquisitions
Alliance Boots
The Second Step Transaction closed on December 31, 2014, resulting in the acquisition by the Company of 55% of the issued and outstanding share capital of Alliance Boots, increasing its interest to 100%. The Company previously accounted for its 45% interest in Alliance Boots as an equity method investment. As a result of the Second Step Transaction, the Company significantly expanded its operations to include pharmacy-led health and beauty retailing and pharmaceutical wholesaling and distribution businesses in major international markets.

As a result of the closing of the Second Step Transaction, the Company increased its interest in WBAD, a global sourcing enterprise between Walgreens and Alliance Boots, to 100%. Because Walgreens held, prior to the Second Step Transaction, a 50% direct interest and an additional indirect interest in WBAD through its 45% ownership of Alliance Boots, the financial results of WBAD were fully consolidated into the Walgreens financial statements with the remaining 27.5% effective interest being recorded as a noncontrolling interest. The acquisition of the 27.5% noncontrolling interest was accounted for as an equity transaction with no gain or loss recorded in the statement of earnings under ASC Topic 805, Business Combinations. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. (“AHID”), which is not a member of the Company’s consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000.
 
The Company has completed the purchase accounting of the Second Step Transaction. The total purchase price of the Second Step Transaction of $15.9 billion included £3.133 billion in cash (approximately $4.9 billion at the December 31, 2014 spot rate of $1.56 to £1.00) and 144.3 million of the Company’s common shares at a fair value of $11.0 billion (based on the December 30, 2014 closing market price of $76.05). Of the total purchase price, $13.3 billion was allocated to acquire the 55% ownership interest in Alliance Boots and $2.6 billion was allocated to acquire the noncontrolling interest in WBAD. The purchase price attributed to the acquisition of the noncontrolling interest in WBAD was determined based on the relative fair value of Alliance Boots and WBAD, respectively.

The impact of the equity transaction is as follows (in millions):

  
Amount
 
Consideration attributable to WBAD
 
$
2,559
 
Less:  Carrying value of the Company’s pre-existing noncontrolling interest
  
130
 
Impact to additional paid in capital
 
$
2,429
 

The following table summarizes the consideration paid to acquire the remaining 55% interest in Alliance Boots and the amounts of identified assets acquired and liabilities assumed at the date of the Second Step Transaction (in millions).
 
Consideration paid
 
Cash
 
$
4,874
 
Common stock
  
10,977
 
Total consideration transferred
  
15,851
 
Less: consideration attributed to WBAD
  
(2,559
)
   
13,292
 
Fair value of the investment in Alliance Boots held before the Second Step Transaction
  
8,149
 
Total consideration
 
$
21,441
 
Identifiable assets acquired and liabilities assumed including noncontrolling interests
 
Cash and cash equivalents
 
$
413
 
Accounts receivable
  
3,799
 
Inventories
  
3,713
 
Other current assets
  
894
 
Property, plant and equipment
  
3,806
 
Intangible assets
  
11,691
 
Other non-current assets
  
2,217
 
Trade accounts payable, accrued expenses and other liabilities
  
(7,696
)
Borrowings
  
(9,010
)
Deferred income taxes
  
(2,452
)
Other non-current liabilities
  
(383
)
Noncontrolling interests
  
(412
)
Total identifiable net assets and noncontrolling interests
  
6,580
 
Goodwill
 
$
14,861
 
 
As a result of the Company acquiring the remaining 55% interest in Alliance Boots, the Company’s previously held 45% interest was re-measured at fair value, resulting in a gain of $563 million. The gain has been recognized as Gain on previously held equity interest in the Consolidated Statements of Earnings for the fiscal year ended August 31, 2015.
 
The fair value of the previously held equity interest of $8.1 billion in Alliance Boots was determined using the income approach methodology. The fair value for trade names and trademarks was determined using the relief from royalty method of the income approach; pharmacy licenses and customer relationships were determined using the excess earnings method of the income approach; and loyalty card holders were determined using the incremental cash flow method, which is a form of the income approach. Personal property fair values were determined primarily using the indirect cost approach, while real property fair values were determined using the income, market and/or cost approach. The fair value measurements of the previously held equity interest and intangible assets are based on significant inputs not observable in the market, and thus represent Level 3 measurements. The fair value estimates for the previously held equity interest and intangible assets are based on (a) projected discounted cash flows, (b) historical and projected financial information, (c) synergies including cost savings, and (d) attrition rates, as relevant, that market participants would consider when estimating fair values.

The identified definite and indefinite lived intangible assets were as follows:

Definite-Lived Intangible Assets
 
Weighted-Average Useful
Life (in years)
  
Amount (in millions)
 
Customer relationships
 12  
$
1,311
 
Loyalty card holders
 20   
742
 
Trade names and trademarks
 9   
399
 
Favorable lease interests
 7   
93
 
Total
    
$
2,545
 

Indefinite-Lived Intangible Assets
 
Amount (in millions)
 
Trade names and trademarks
 
$
6,657
 
Pharmacy licenses
  
2,489
 
Total
 
$
9,146
 

The goodwill of $14.9 billion arising from the Second Step Transaction primarily reflects the expected purchasing synergies, operating efficiencies by benchmarking performance and applying best practices across the Company, consolidation of operations, reductions in selling, general and administrative expenses and combining workforces.

Following the completion of the Second Step Transaction, the Company realigned its operations into three reportable segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company determined that the goodwill should be allocated across all segments recognizing that each segment will benefit from the expected synergies.

The goodwill allocated to the Retail Pharmacy USA segment of $7.3 billion is comprised of $3.5 billion of synergy benefits allocable to the segment on a source of procurement benefit basis and $3.8 billion determined on a “with-and-without” basis. The source of procurement benefit basis allocates the synergy benefits to the segment whose purchase gave rise to the benefit. The “with-and-without” basis computes the difference between the fair value of the pre-existing business before the combination and its fair value after the combination, and since the pre-existing Walgreens business is now within the Retail Pharmacy USA segment, all of this difference is allocated to this segment. The “with-and-without” computation recognized that if the Second Step Transaction did not happen, then this was likely to negatively impact the existing Walgreens business, which already had a 45% interest in Alliance Boots, as the expected purchasing synergies and other benefits resulting from a full combination would not be fully realized.

Of the remaining goodwill, $3.9 billion was allocated to the Retail Pharmacy International segment and $3.7 billion was allocated to the Pharmaceutical Wholesale segment. Substantially all of the goodwill recognized is not expected to be deductible for income tax purposes.

The Company incurred legal and other professional services costs related to the Second Step Transaction, which were included in selling, general and administrative expenses, of $87 million in fiscal 2015 ($59 million and $83 million in the three and six months ended February 28, 2015, respectively). No costs related to the Second Step Transaction were incurred in the three and six month periods ended February 29, 2016.

The fair value of the assets acquired includes inventory having an estimated fair value of $3.7 billion. This fair value includes a $106 million fair value adjustment to capitalize the estimated profit in acquired finished goods inventory as of the date of the Second Step Transaction, which was expensed to cost of sales over the first inventory turn.
 
The following table presents supplemental unaudited condensed pro forma consolidated information for the three and six months ended February 28, 2015 as if the Second Step Transaction had occurred on September 1, 2014, the first day of the Company’s 2015 fiscal year. The unaudited condensed pro forma information reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased amortization expense based on the fair valuation of assets acquired, the impact of acquisition financing, transaction costs and the related income tax effects. The unaudited condensed pro forma information does not include any anticipated synergies that may be achievable subsequent to the date of the Second Step Transaction. The unaudited condensed pro forma information also excludes certain non-recurring items such as transaction related costs. Accordingly, the unaudited condensed pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company’s results would have been had the Second Step Transaction occurred at the beginning of the periods presented or the results which may occur in the future.

  
Pro forma
Three Months Ended
February 28,
2015
  
Pro forma
Six Months Ended
February 28,
2015
 
(in millions, except per share amounts)
      
Net sales
 
$
30,202
  
$
59,173
 
Net earnings
  
1,253
   
2,621
 
         
Net earnings per common share:
        
Basic
 
$
1.20
  
$
2.51
 
Diluted
  
1.19
   
2.49
 

Other Acquisitions
The aggregate purchase price of all other businesses, net of cash received was $86 million for the six month period ended February 29, 2016. These acquisitions, primarily of an international beauty brand and prescription files, added $19 million to goodwill and $72 million to intangible assets. The remaining fair value relates to immaterial amounts of tangible assets, less liabilities assumed. Operating results of the businesses acquired have been included in the Consolidated Condensed Statements of Earnings from their respective acquisition dates forward. Pro forma results of the Company, assuming all of the other acquisitions had occurred at the beginning of each period presented, would not be materially different from the results reported.
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.3.1.900
Goodwill and Other Intangible Assets
6 Months Ended
Feb. 29, 2016
Goodwill and Other Intangible Assets [Abstract]  
Goodwill and Other Intangible Assets
Note 8. Goodwill and Other Intangible Assets
Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions):

  
Retail Pharmacy
USA
  
Retail Pharmacy
International
  
Pharmaceutical
Wholesale
  
Total
 
August 31, 2015
 
$
8,940
  
$
3,898
  
$
3,534
  
$
16,372
 
Acquisitions
  
-
   
19
   
-
   
19
 
Other (1)
  
-
   
(3
)
  
13
   
10
 
Currency translation adjustments
  
-
   
(309
)
  
(296
)
  
(605
)
February 29, 2016
 
$
8,940
  
$
3,605
  
$
3,251
  
$
15,796
 

(1)Other represents immaterial purchase accounting adjustments for prior year Company acquisitions.
 
The carrying amount and accumulated amortization of intangible assets consist of the following (in millions):

  
February 29, 2016
  
August 31, 2015
 
Gross Amortizable Intangible Assets
      
Customer relationships
 
$
1,293
  
$
1,409
 
Purchased prescription files
  
904
   
885
 
Loyalty card holders
  
661
   
730
 
Trade names and trademarks
  
678
   
675
 
Favorable lease interests
  
457
   
440
 
Non-compete agreements
  
158
   
154
 
Purchasing and payer contracts
  
95
   
94
 
Total gross amortizable intangible assets
  
4,246
   
4,387
 
         
Accumulated amortization
        
Customer relationships
  
182
   
132
 
Purchased prescription files
  
536
   
470
 
Loyalty card holders
  
41
   
41
 
Trade names and trademarks
  
114
   
83
 
Favorable lease interests
  
246
   
207
 
Non-compete agreements
  
106
   
92
 
Purchasing and payer contracts
  
68
   
65
 
Total accumulated amortization
  
1,293
   
1,090
 
Total amortizable intangible assets, net
 
$
2,953
  
$
3,297
 
         
Indefinite Lived Intangible Assets
        
Trade names and trademarks
 
$
5,947
  
$
6,590
 
Pharmacy licenses
  
2,222
   
2,464
 
Total indefinite lived intangible assets
 
$
8,169
  
$
9,054
 
         
Total intangible assets, net
 
$
11,122
  
$
12,351
 

Amortization expense for intangible assets was $124 million and $216 million for the three and six months ended February 29, 2016, respectively, and $209 million and $276 million for the three and six months ended February 28, 2015, respectively.

Estimated annual amortization expense for intangible assets recorded at February 29, 2016 is as follows (in millions):

  
2016
  
2017
  
2018
  
2019
  
2020
 
Estimated annual amortization expense
 
$
401
  
$
358
  
$
318
  
$
289
  
$
254
 
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.3.1.900
Short-Term Borrowings and Long-Term Debt
6 Months Ended
Feb. 29, 2016
Short-Term Borrowings and Long-Term Debt [Abstract]  
Short-Term Borrowings and Long-Term Debt
Note 9. Short-Term Borrowings and Long-Term Debt
Short-term borrowings and long-term debt consist of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):

  
February 29, 2016
  
August 31, 2015
 
Short-Term Borrowings(1)
      
Unsecured variable rate notes due 2016
 
$
749
  
$
747
 
Other(2)
  
303
   
321
 
Total short-term borrowings
 
$
1,052
  
$
1,068
 
 
Long-Term Debt(1)
        
Unsecured Pound Sterling variable rate term loan due 2019(3)
 
$
2,013
  
$
2,229
 
1.750% unsecured notes due 2017
  
747
   
746
 
5.250% unsecured notes due 2019(4)
  
253
   
250
 
2.700% unsecured notes due 2019
  
1,244
   
1,243
 
2.875% unsecured Pound Sterling notes due 2020(3)
  
552
   
612
 
3.300% unsecured notes due 2021
  
1,241
   
1,241
 
3.100% unsecured notes due 2022
  
1,193
   
1,193
 
3.800% unsecured notes due 2024
  
1,986
   
1,985
 
3.600% unsecured Pound Sterling notes due 2025(3)
  
414
   
459
 
2.125% unsecured Euro notes due 2026(5)
  
811
   
836
 
4.500% unsecured notes due 2034
  
494
   
494
 
4.400% unsecured notes due 2042
  
492
   
492
 
4.800% unsecured notes due 2044
  
1,492
   
1,491
 
Other(6)
  
42
   
44
 
Total long-term debt
 
$
12,974
  
$
13,315
 
 
(1)
All notes are presented net of unamortized discount and debt issuance costs, where applicable.
(2)
Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts.
(3)
Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively.
(4)
Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures.
(5)
Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively.
(6)
Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
 
$8.0 Billion Note Issuance
On November 18, 2014, Walgreens Boots Alliance received net proceeds (after deducting underwriting discounts and estimated offering expenses) of $7.9 billion from a public offering of notes with varying maturities and interest rates, the majority of which are fixed rate. The notes are unsecured, unsubordinated debt obligations of Walgreens Boots Alliance and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance from time to time outstanding. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged. Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $44 million. The fair value of the notes as of February 29, 2016 was $7.9 billion. Fair value for these notes was determined based upon quoted market prices.

The following table summarizes each tranche of notes issued:

Notes Issued
(in millions)
 
 
Maturity Date
 
 
Interest Rate
 
 
Interest Payment Dates
$
750
 
May 18, 2016
 
Variable; three month U.S. dollar LIBOR, reset quarterly, plus 45 basis points
 
February 18, May 18, August 18, and November 18; commencing on February 18, 2015
 
750
 
November 17, 2017
 
Fixed 1.750%
 
May 17 and November 17; commencing on May 17, 2015
 
1,250
 
November 18, 2019
 
Fixed 2.700%
 
May 18 and November 18; commencing on May 18, 2015
 
1,250
 
November 18, 2021
 
Fixed 3.300%
 
May 18 and November 18; commencing on May 18, 2015
 
2,000
 
November 18, 2024
 
Fixed 3.800%
 
May 18 and November 18; commencing on May 18, 2015
 
500
 
November 18, 2034
 
Fixed 4.500%
 
May 18 and November 18; commencing on May 18, 2015
 
1,500
 
November 18, 2044
 
Fixed 4.800%
 
May 18 and November 18; commencing on May 18, 2015
$
8,000
        
 
Redemption Option
Walgreens Boots Alliance may redeem (a) the notes due 2017, at any time in whole or from time to time in part, (b) the notes due 2019, at any time prior to October 18, 2019 in whole or from time to time prior to October 18, 2019 in part, (c) the notes due 2021, at any time prior to September 18, 2021 in whole or from time to time prior to September 18, 2021 in part, (d) the notes due 2024, at any time prior to August 18, 2024 in whole or from time to time prior to August 18, 2024 in part, (e) the notes due 2034, at any time prior to May 18, 2034 in whole or from time to time prior to May 18, 2034 in part, and (f) the notes due 2044, at any time prior to May 18, 2044 in whole or from time to time prior to May 18, 2044 in part, in each case, at Walgreens Boots Alliance’s option for the sum of accrued and unpaid interest plus a redemption price equal to the greater of:
 
(1) 100% of the principal amount of the fixed rate notes being redeemed; and
 
(2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 15 basis points for the notes due 2017, 15 basis points for the notes due 2019, 20 basis points for the notes due 2021, 20 basis points for the notes due 2024, 20 basis points for the notes due 2034 and 25 basis points for the notes due 2044.
 
In addition, at any time on or after October 18, 2019 with respect to the notes due 2019, September 18, 2021 with respect to the notes due 2021, August 18, 2024 with respect to the notes due 2024, May 18, 2034 with respect to the notes due 2034, or May 18, 2044 with respect to the notes due 2044, Walgreens Boots Alliance may redeem some or all of the applicable series of fixed rate notes at its option, at a redemption price equal to 100% of the principal amount of the applicable fixed rate notes being redeemed, plus accrued and unpaid interest on the fixed rate notes being redeemed to, but excluding, the redemption date.

Change in Control
 
If Walgreens Boots Alliance experiences a change of control triggering event, unless Walgreens Boots Alliance has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, Walgreens Boots Alliance will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest.

£700 Million and €750 Million Notes Issuance
On November 20, 2014, Walgreens Boots Alliance issued three series of debt securities denominated in Euros and Pound Sterling in a public offering, each with varying maturities and interest rates. Interest on all notes is payable annually on November 20, commencing on November 20, 2015. The notes are unsecured, unsubordinated debt obligations of Walgreens Boots Alliance and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance from time to time outstanding. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged. Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $11 million. The fair value of the notes as of February 29, 2016 was $1.8 billion. Fair value for these notes was determined based upon quoted market prices.

The following table details each tranche of Euro and Pound Sterling notes issued:

Notes Issued (in millions)
 
Maturity Date
Interest Rate
Euro Notes:
    
750
 
November 20, 2026
Fixed 2.125%
       
Pound Sterling Notes:
    
£
400
 
November 20, 2020
Fixed 2.875%
 
300
 
November 20, 2025
Fixed 3.600%
£
700
    

Redemption Option
 
Walgreens Boots Alliance may redeem (a) the Euro notes, at any time prior to August 20, 2026, in whole or, from time to time prior to August 20, 2026, in part, (b) the Pound Sterling notes due 2020, at any time prior to October 20, 2020, in whole or, from time to time prior to October 20, 2020, in part, and (c) the Pound Sterling notes due 2025, at any time prior to August 20, 2025, in whole or, from time to time prior to August 20, 2025, in part, in each case, at Walgreens Boots Alliance’s option for the sum of accrued and unpaid interest plus at a redemption price equal to the greater of:
 
(1) 100% of the principal amount of the notes to be redeemed; and
 
(2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on an annual basis at the applicable Comparable Government Bond Rate (as defined in the applicable series of notes), plus 20 basis points for the Euro notes, 20 basis points for the Pound Sterling notes due 2020 and 20 basis points for Pound Sterling the notes due 2025.
 
In addition, at any time on or after August 20, 2026 with respect to the Euro notes, October 20, 2020 with respect to the Pound Sterling notes due 2020, or August 20, 2025 with respect to the Pound Sterling notes due 2025, Walgreens Boots Alliance may redeem some or all of the applicable series of notes at its option at a redemption price equal to 100% of the principal amount of the applicable notes to be redeemed plus, in every case, accrued and unpaid interest on the notes to be redeemed to, but excluding, the redemption date.
 
Change in Control
 
If Walgreens Boots Alliance experiences a change of control triggering event, unless Walgreens Boots Alliance has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, Walgreens Boots Alliance will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest.
 
$4.0 Billion Note Issuance
On September 13, 2012, Walgreens obtained net proceeds from a public offering of $4.0 billion of notes with varying maturities and interest rates, the majority of which, at issuance, were fixed rate. The notes are unsecured senior debt obligations and rank equally with all other unsecured and unsubordinated indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance. Total issuance costs relating to the notes, including underwriting discounts and fees, were $26 million. On August 10, 2015, the 1.8000% fixed rate notes due September 15, 2017 in the aggregate principal amount of $1.0 billion were redeemed in full. The redemption price was equal to 101.677% of the aggregate principal amount of the notes redeemed, plus accrued interest thereon to, but excluding, the redemption date, and included a $17 million make whole premium, which was recorded as interest expense on the Company’s Consolidated Statements of Earnings. Additionally, the Company repaid the $750 million 1.000% fixed rate notes on their March 13, 2015 maturity date and the $550 million variable rate notes on their March 13, 2014 maturity date.
 
The following table details each tranche of outstanding notes as of February 29, 2016:
 
Notes Issued
(in millions)
 
Maturity Date
Interest Rate
Interest Payment Dates
$
1,200
 
September 15, 2022
Fixed 3.100%
March 15 and September 15; commencing on March 15, 2013
 
500
 
September 15, 2042
Fixed 4.400%
March 15 and September 15; commencing on March 15, 2013
$
1,700
      
 
The fair value of the notes outstanding as of February 29, 2016 was $1.6 billion. Fair value for these notes was determined based upon quoted market prices.
 
Redemption Option and Change in Control
Walgreens may redeem the fixed rate notes at its option, at any time in whole, or from time to time in part, at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes being redeemed; and (b) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 12 basis points for the notes due 2015, 22 basis points for the notes due 2022 and 25 basis points for the notes due 2042. If a change of control triggering event occurs, Walgreens will be required, unless it has exercised its right to redeem the notes, to offer to purchase the notes at a purchase price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, on the notes repurchased to the date of repurchase.
 
$1.0 Billion Note Issuance
On January 13, 2009, Walgreens issued notes totaling $1.0 billion bearing an interest rate of 5.250% paid semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2009. The notes will mature on January 15, 2019. The notes are unsecured senior debt obligations and rank equally with all other unsecured senior indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance. The notes are not convertible or exchangeable. Total issuance costs relating to this offering, including underwriting discounts and fees, were $8 million. On August 10, 2015, $750 million aggregate principal amount of the notes were redeemed. The redemption price was equal to 111.734% of the aggregate principal amount of the notes redeemed plus accrued interest thereon to, but excluding, the redemption date; and included a $88 million make whole premium, which was recorded as interest expense on the Company’s Consolidated Statements of Earnings. The partial redemption of the notes resulted in $250 million aggregate principal amount of the notes remaining outstanding. The fair value of the notes outstanding as of February 29, 2016 was $270 million. Fair value for these notes was determined based upon quoted market prices.
 
Redemption Option and Change in Control
Walgreens may redeem the notes, at any time in whole or from time to time in part, at its option at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes to be redeemed; or (b) the sum of the present values of the remaining scheduled payments of principal and interest, discounted to the date of redemption on a semiannual basis at the Treasury Rate (as defined in the applicable series of notes), plus 45 basis points, plus accrued interest on the notes to be redeemed to, but excluding, the date of redemption. If a change of control triggering event occurs, unless Walgreens has exercised its option to redeem the notes, it will be required to offer to repurchase the notes at a purchase price equal to 101% of the principal amount of the notes plus accrued and unpaid interest to the date of redemption.
 
Other Borrowings
The Company periodically borrows under its commercial paper program and may borrow under it in future periods. There were no commercial paper borrowings outstanding as of February 29, 2016 or February 28, 2015, respectively. The Company had average daily short-term borrowings of $20 million of commercial paper outstanding at a weighted average interest rate of 0.62% for the six month period ended February 29, 2016. We had average daily short-term borrowings of $4 million of commercial paper outstanding at a weighted average interest rate of 0.46% for the six months ended February 28, 2015.

2014 Term Loan Agreement and Revolving Credit Agreement

On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a term loan credit agreement (the “Term Loan Agreement”), which provides Walgreens Boots Alliance and Walgreens with the ability to borrow up to £1.45 billion on an unsecured basis. Borrowings under the Term Loan Agreement bear interest at a fluctuating rate per annum equal to the reserve adjusted LIBOR plus an applicable margin based on the Company’s credit ratings. As of February 29, 2016, Walgreens Boots Alliance had borrowed £1.45 billion ($2.0 billion at the February 29, 2016 spot rate of $1.39 to £1) under the Term Loan Agreement. The fair value of the Term Loan Agreement as of February 29, 2016 was $2.0 billion. Fair value of the borrowings under the Term Loan Agreement was determined based upon quoted market prices.

On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a five-year unsecured, multicurrency revolving credit agreement (the “Revolving Credit Agreement”), replacing prior Walgreens agreements dated July 20, 2011 and July 23, 2012. The new unsecured revolving credit agreement initially totaled $2.25 billion, of which $375 million was available for the issuance of letters of credit. On December 29, 2014, upon the affirmative vote of the majority of common shares of Walgreens represented and entitled to vote at the Walgreens special meeting of shareholders to approve the issuance of the shares necessary to complete the Second Step Transaction, the available credit increased to $3.0 billion, of which $500 million is available for the issuance of letters of credit. The issuance of letters of credit reduces the aggregate amount otherwise available under the Revolving Credit Agreement for the making of revolving loans. Borrowings under the Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance’s option, the alternate base rate or the reserve adjusted LIBOR, in each case, plus an applicable margin calculated based on the Company’s credit ratings. As of February 29, 2016, there were no borrowings or letters of credit issued pursuant to the Revolving Credit Agreement.

Total upfront fees related to the Term Loan Agreement and Revolving Credit Agreement were $14 million. The Company pays a facility fee to the financing banks to keep these lines of credit active.

In accordance with the terms of each of the Term Loan Agreement and the Revolving Credit Agreement, Walgreens guaranteed the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of all of Walgreens Boots Alliance’s obligations under the Term Loan Agreement and Revolving Credit Agreement, as applicable until August 10, 2015, when such guarantees automatically terminated, without penalty to Walgreens or Walgreens Boots Alliance, and the obligations of Walgreens thereunder were unconditionally released and discharged.

On December 19, 2014, Walgreens Boots Alliance and Walgreens entered into a Revolving Credit Agreement (as amended, the “364-Day Credit Agreement”) with the lenders party thereto. The 364-Day Credit Agreement was a $750 million, 364-day unsecured, multicurrency revolving facility. On July 9, 2015, Walgreens Boots Alliance amended the 364-Day Credit Agreement to remove Walgreens as a borrower thereunder, eliminate Walgreens’ guarantee of all obligations of Walgreens Boots Alliance thereunder and make certain conforming changes to effectuate those modifications, including modifications and deletions of certain definitions and cross-references. On December 17, 2015, the Company terminated the 364-Day Credit Agreement. The 364-Day Credit Agreement remained undrawn as of the date of termination and would have matured on December 30, 2015.
 
The Term Loan Agreement, Revolving Credit Agreement and the 364-Day Revolving Credit Agreement each contain or contained a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants.

2015 Bridge Credit Agreement and Term Loan Credit Agreement

On October 27, 2015, the Company entered into an Agreement and Plan of Merger with Rite Aid Corporation (“Rite Aid”) and Victoria Merger Sub, Inc., a wholly-owned subsidiary of the Company (the “Merger Agreement”). In connection with the Merger Agreement, the Company entered into a bridge facility commitment letter (as amended and restated as of November 19, 2015, the “Commitment Letter”), with UBS Securities LLC and UBS AG, Stamford Branch for a $12.8 billion senior unsecured bridge facility.
 
On December 18, 2015, Walgreens Boots Alliance entered into a Bridge Term Loan Credit Agreement with the lenders party thereto and UBS AG, Stamford Branch, as administrative agent (as amended on January 20, 2016, the “Bridge Credit Agreement”) and a Term Loan Credit Agreement with the lenders party thereto and Bank of America, N.A., as administrative agent (as amended on January 20, 2016, the “Term Loan Credit Agreement” and together with the Bridge Credit Agreement, the “2015 Credit Agreements”). The Commitment Letter and the commitments contemplated thereby terminated upon Walgreens Boots Alliance entering into the 2015 Credit Agreements.
 
The Bridge Credit Agreement is a 364-day unsecured bridge term loan facility. The aggregate commitments of all lenders under the Bridge Credit Agreement are equal to $7.8 billion, provided that Walgreens Boots Alliance may increase the commitments under the Bridge Credit Agreement at any time prior to the funding of the loans thereunder by up to $2.0 billion, subject to obtaining commitments from existing lenders and/or new lenders selected by Walgreens Boots Alliance and reasonably acceptable to the administrative agent. Walgreens Boots Alliance can extend up to $3.0 billion of the loans under the Bridge Credit Agreement for an additional 90-day period if desired. As of February 29, 2016, there were no borrowings under the Bridge Credit Agreement.
 
The Term Loan Credit Agreement is a two-tranche unsecured term loan facility, with the first tranche maturing three years after the earlier of the funding date and October 27, 2016, and the second tranche maturing five years after the earlier of the funding date and October 27, 2016. The aggregate commitments of all lenders under the Term Loan Credit Agreement are equal to $5.0 billion. As of February 29, 2016, there were no borrowings under the Term Loan Credit Agreement.
 
Walgreens Boots Alliance will be the borrower under each of the 2015 Credit Agreements. The ability of Walgreens Boots Alliance to request the making of loans under each of the 2015 Credit Agreements is subject to the satisfaction (or waiver) of certain conditions set forth therein and will terminate upon the occurrence of certain events set forth therein. Borrowings under each of the 2015 Credit Agreements will bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance’s option, the alternate base rate or the reserve adjusted Eurocurrency rate, in each case, plus an applicable margin calculated based on Walgreens Boots Alliance’s credit ratings. Upfront fees paid to date in connection with the 2015 Credit Agreements totaled $30 million. A maximum of a further $5 million in upfront fees is payable prior to, or at funding, subject to certain conditions. In addition, Walgreens Boots Alliance will also pay to the lenders under each of the 2015 Credit Agreements certain customary fees, including a ticking fee based on the aggregate outstanding commitments of the lenders under the applicable 2015 Credit Agreement starting at 90 days after signing. Each of the 2015 Credit Agreements contains a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants, which restrictive covenants shall not be in effect until the funding of the loans under the applicable 2015 Credit Agreement.
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.3.1.900
Financial Instruments
6 Months Ended
Feb. 29, 2016
Financial Instruments [Abstract]  
Financial Instruments
Note 10. Financial Instruments
The Company uses derivative instruments to manage its exposure to interest rate and foreign currency exchange risks.

The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of February 29, 2016, excluding warrants which are presented separately in this footnote, were as follows (in millions):

  
Notional(1)
  
Fair Value
 
Location in Consolidated
Condensed Balance Sheets
Derivatives designated as fair value hedges:
         
Interest rate swaps
 
$
250
  
$
5
 
Other non-current assets
Derivatives not designated as hedges:
           
Foreign currency forwards
  
465
   
1
 
Other current assets
Foreign currency forwards
  
768
   
16
 
Other current liabilities
Basis swap
  
2
   
1
 
Other current liabilities

(1)Amounts are presented in U.S. dollar equivalents.
 
The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2015, excluding warrants which are presented separately in this footnote, are as follows (in millions):

  
Notional(1)
  
Fair Value
 
Location in Consolidated
Condensed Balance Sheets
Derivatives designated as fair value hedges:
         
Interest rate swaps
 
$
250
  
$
2
 
Other non-current assets
Derivatives not designated as hedges:
           
Foreign currency forwards
  
1,205
   
34
 
Other current assets
Foreign currency forwards
  
495
   
9
 
Other current liabilities
Basis swap
  
1
   
-
 
Other current assets

(1)Amounts are presented in U.S. dollar equivalents.

The Company uses interest rate swaps to manage the interest rate exposure associated with some of its fixed-rate borrowings and designates them as fair value hedges. The Company uses forward starting interest rate swaps to hedge its interest rate exposure of some of its anticipated debt issuances and designates them as cash flow hedges.

The Company utilizes foreign currency forward contracts and other foreign currency derivatives to hedge significant committed and highly probable future transactions and cash flows denominated in currencies other than the functional currency of the Company or its subsidiaries. The Company has significant non-US dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk.

Fair Value Hedges
The Company entered into a series of interest rate swaps, converting $750 million of its 5.250% fixed rate notes to a floating interest rate based on the six month LIBOR in arrears plus a constant spread and an interest rate swap converting $250 million of its 5.250% fixed rate notes to a floating interest rate based on the one-month LIBOR in arrears plus a constant spread. All swap termination dates coincide with the notes maturity date, January 15, 2019. These swaps were designated as fair value hedges. On August 10, 2015, the Company terminated $500 million of the six month LIBOR in arrears swaps and all of the one-month LIBOR in arrears swaps in connection with the repayment of the associated debt as described in Note 9, Short-Term Borrowings and Long-Term Debt.

The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk were recognized as follows (in millions):

 
Location in Consolidated
 
Three Months Ended
  
Six Months Ended
 
 
Condensed Statements of
Earnings
 
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Interest rate swaps
Interest expense, net
 
$
(2
)
 
$
4
  
$
(3
)
 
$
(6
)
Notes
Interest expense, net
  
2
   
(4
)
  
3
   
6
 

The changes in fair value of the Company’s debt that was swapped from fixed to variable rate and designated as fair value hedges are included in short-term and long-term debt on the Consolidated Condensed Balance Sheets (see Note 9, Short-Term Borrowings and Long-Term Debt). At February 29, 2016 and August 31, 2015, the cumulative fair value adjustments resulted in an increase in long-term debt of $4 million and $1 million, respectively. No material gains or losses were recorded from ineffectiveness during the three and six months ended February 29, 2016 and February 28, 2015.
 
Derivatives not Designated as Hedges
The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of interest rate and foreign currency risks. The gains and losses due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):

 Location in Consolidated 
Three Months Ended
  
Six Months Ended
 
Condensed Statements of
Earnings
 
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Interest rate swaps
Interest expense, net
 
$
-
  
$
(1
)
 
$
-
  
$
(1
)
Foreign currency forwards
Selling, general and administrative expenses
  
(23
)
  
(28
)
  
(25
)
  
(28
)
Second Step Transaction foreign currency forwards
Other income (expense)
  
-
   
(70
)
  
-
   
(166
)
Foreign currency forwards
Other income (expense)
  
33
   
-
   
33
   
-
 

Warrants
As of February 29, 2016, the Company held (a) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share, exercisable during a six month period beginning in March 2016, (“Warrant 1”), and (b) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $52.50 per share, exercisable during a six month period beginning in March 2017 (“Warrant 2” and together with Warrant 1, the “Warrants”). Warrant 1 was exercised in full on March 18, 2016. See Note 20, Subsequent Event for further information.

The Company reports the Warrants at fair value. The fair value and balance sheet presentation of the Warrants was as follows (in millions):

Location in Consolidated
Condensed Balance Sheets 
 
February 29,
2016
  
August 31,
2015
 
Asset derivatives not designated as hedges:
       
Warrants
Other non-current assets
 
$
1,546
  
$
2,140
 

The gains and losses due to changes in fair value of the Warrants recognized in earnings were as follows (in millions):

    
Three Months Ended
  
Six Months Ended
 
 
Location in Consolidated
Condensed Statements of Earnings
 
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Warrants
Other income (expense)
 
$
(532
)
 
$
559
  
$
(594
)
 
$
849
 

Derivatives Credit Risk
 
Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty.

Derivatives Offsetting
 
The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.3.1.900
Fair Value Measurements
6 Months Ended
Feb. 29, 2016
Fair Value Measurements [Abstract]  
Fair Value Measurements
Note 11. Fair Value Measurements
The Company measures certain assets and liabilities in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels:

Level 1 -Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2 -Observable inputs other than quoted prices in active markets.
Level 3 -Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
 
Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):

  
February 29, 2016
  
Level 1
  
Level 2
  
Level 3
 
Assets:
            
Restricted cash (1)
 
$
175
  
$
175
  
$
-
  
$
-
 
Money market funds (2)
  
2,659
   
2,659
   
-
   
-
 
Available-for-sale investments (3)
  
1,027
   
1,027
   
-
   
-
 
Interest rate swaps (4)
  
5
   
-
   
5
   
-
 
Foreign currency forwards (5)
  
1
   
-
   
1
   
-
 
Warrants (6)
  
1,546
   
-
   
1,546
   
-
 
Liabilities:
                
Basis swaps (5)
  
1
   
-
   
1
   
-
 
Foreign currency forwards (5)
  
16
   
-
   
16
   
-
 

  
August 31, 2015
  
Level 1
  
Level 2
  
Level 3
 
Assets:
            
Restricted cash (1)
 
$
184
  
$
184
  
$
-
  
$
-
 
Money market funds (2)
  
2,043
   
2,043
   
-
   
-
 
Available-for-sale investments (3)
  
1,183
   
1,183
   
-
   
-
 
Interest rate swaps (4)
  
2
   
-
   
2
   
-
 
Foreign currency forwards (5)
  
34
   
-
   
34
   
-
 
Warrants (6)
  
2,140
   
-
   
2,140
   
-
 
Liabilities:
                
Foreign currency forwards (5)
  
9
   
-
   
9
   
-
 

(1)Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.
(2)Money market funds are valued at the closing price reported by the fund sponsor.
(3)Fair values of quoted investments are based on current bid prices as of the balance sheet dates.  See Note 6, Available-for-Sale Investments for additional information.
(4)The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information.
(5)The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
(6)Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen’s common stock; AmerisourceBergen’s common stock price at the valuation date; AmerisourceBergen’s equity volatility; the number of shares of AmerisourceBergen’s common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the Warrants.

There were no transfers between levels for the three and six month periods ended February 29, 2016 and February 28, 2015, respectively.

The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company’s debt in the footnotes to the consolidated financial statements. Unless otherwise noted, the fair value for all notes was determined based upon quoted market prices and therefore categorized as Level 1. See Note 9, Short-Term Borrowings and Long-Term Debt for further information. The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.3.1.900
Commitments and Contingencies
6 Months Ended
Feb. 29, 2016
Commitments and Contingencies [Abstract]  
Commitments and Contingencies
Note 12. Commitments and Contingencies
The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries and similar actions by governmental authorities, arising in the normal course of the Company’s business, including the matters described below. Legal proceedings, in general, and securities and class action litigation, in particular, can be expensive and disruptive. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit, and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s consolidated financial position. However, substantial unanticipated verdicts, fines and rulings do sometimes occur. As a result, the Company could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.
 
On a quarterly basis, the Company assesses its liabilities and contingencies for outstanding legal proceedings and reserves are established on a case-by-case basis for those legal claims for which management concludes that it is probable that a loss will be incurred and that the amount of such loss can be reasonably estimated. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. With respect to litigation and other legal proceedings where the Company has determined that a loss is reasonably possible, the Company is unable to estimate the amount or range of reasonably possible loss in excess of amounts reserved due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Company’s assessments are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause the Company to change those estimates and assumptions. Therefore, it is possible that an unfavorable resolution of one or more pending litigation or other contingencies could have a material adverse effect on the Company’s consolidated financial statements in a future fiscal period. Management’s assessment of current litigation and other legal proceedings, including the corresponding accruals, could change because of the discovery of facts with respect to legal actions or other proceedings pending against the Company which are not presently known. Adverse rulings or determinations by judges, juries, governmental authorities or other parties could also result in changes to management’s assessment of current liabilities and contingencies. Accordingly, the ultimate costs of resolving these claims may be substantially higher or lower than the amounts reserved.
 
On December 5 and 12, 2014, putative shareholders filed class actions in federal court in the Northern District of Illinois against the Walgreens Board of Directors, Walgreen Co., and Walgreens Boots Alliance, Inc. arising out of the Company’s definitive proxy statement/prospectus filed with the SEC in connection with the special meeting of Walgreens shareholders on December 29, 2014. The actions asserted claims that the definitive proxy statement/prospectus was false or misleading in various respects. On December 23, 2014, solely to avoid the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, Walgreens entered into a memorandum of understanding with the plaintiffs in both actions, pursuant to which Walgreens made certain supplemental disclosures. The proposed settlement was subject to, among other things, court approval. On July 8, 2015, the Court preliminarily approved the settlement, and on November 20, 2015, the Court entered an order of final approval of the settlement. On December 17, 2015, a purported class member who had objected to the settlement appealed the Court’s order. The appeal was docketed with the United States Court of Appeals for the Seventh Circuit, and is in an early stage.
 
On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co., and Walgreen Co. as a nominal defendant, arising out of certain public statements the Company made regarding its former fiscal 2016 goals. The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. On April 10, 2015, the defendants filed a motion to dismiss. On May 18, 2015, the case was stayed in light of the securities class action that was filed on April 10, 2015, which is described below.
 
On April 10, 2015, a putative shareholder filed a securities class action in federal court in the Northern District of Illinois against Walgreen Co. and certain former officers of Walgreen Co. The action asserts claims for violation of the federal securities laws arising out of certain public statements the Company made regarding its former fiscal 2016 goals. On June 16, 2015, the Court entered an order appointing a lead plaintiff. Pursuant to the Court’s order, lead plaintiff filed an amended complaint on August 17, 2015, and defendants moved to dismiss the amended complaint on October 16, 2015. Lead plaintiff filed a response to the motion to dismiss on December 22, 2015, and defendants filed a reply in support of the motion on February 5, 2016.
 
As of February 29, 2016, the Company was aware of ten putative class action lawsuits (the “Rite Aid actions”) filed by purported Rite Aid stockholders against Rite Aid and its board of directors, Walgreens Boots Alliance and Victoria Merger Sub, Inc. for claims arising out of the transactions contemplated by the Merger Agreement (the “Rite Aid Transactions”). Eight of the Rite Aid actions were filed in the Court of Chancery of the State of Delaware (the “Delaware actions”), one Rite Aid action was filed in the State of Pennsylvania in the Court of Common Pleas of Cumberland County (the “Pennsylvania action”), and one Rite Aid action was filed in the United States District Court for the Middle District of Pennsylvania (the “federal action”). The Delaware actions and the Pennsylvania action primarily allege that the Rite Aid board of directors breached its fiduciary duties in connection with the Rite Aid Transactions by, among other things, agreeing to an unfair and inadequate price, agreeing to deal protection devices that preclude other bidders from making successful competing offers for Rite Aid, and failing to disclose all allegedly material information concerning the proposed merger; and also allege that Walgreens Boots Alliance and Victoria Merger Sub, Inc. aided and abetted these alleged breaches of fiduciary duty. The federal action alleges, among other things, that Rite Aid and its board of directors disseminated an allegedly false and misleading proxy statement in connection with the Rite Aid Transactions. The Delaware actions were consolidated, and plaintiffs filed a motion for expedited proceedings and a motion for preliminary injunction seeking to enjoin the Rite Aid shareholder vote on the Rite Aid Transactions. The plaintiffs in the federal action also filed a motion for preliminary injunction seeking to enjoin the same Rite Aid shareholder vote. All such motions were denied, and the Rite Aid shareholders approved the Rite Aid Transactions at a special meeting on February 4, 2016. Each of the Rite Aid actions is still pending.
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.3.1.900
Retirement Benefits
6 Months Ended
Feb. 29, 2016
Retirement Benefits [Abstract]  
Retirement Benefits
Note 13. Retirement Benefits
The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan. The Company uses an August 31 annual measurement date for its pension plans.

Defined Benefit Pension Plans (non-US plans)
The principal defined benefit pension plan is the Boots Pension Plan, which covers certain employees in the United Kingdom (the “Boots Plan”). The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010, with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis. The Company also has two smaller defined benefit pension plans in the United Kingdom, both of which were closed to future accruals effective July 1, 2010. Other defined benefit pension plans include smaller plans in Germany and France.

The obligation related to the Company’s pension plans was acquired as a result of the Second Step Transaction. The pension costs presented for 2015 represent the costs for the period from December 31, 2014 through February 28, 2015. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, pension costs for fiscal 2015 prior to the date of the Second Step Transaction were reflected within Equity earnings in Alliance Boots on the Consolidated Condensed Statement of Earnings.

Components of net periodic pension costs for the defined benefit pension plans (in millions):

  
Three Months Ended
  
Six Months Ended
 
  
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Service costs
 
$
-
  
$
1
  
$
2
  
$
1
 
Interest costs
  
77
   
53
   
159
   
53
 
Expected returns on plan assets
  
(62
)
  
(43
)
  
(127
)
  
(43
)
Settlements
  
-
   
1
    -   
1
 
Total net periodic pension costs
 
$
15
  
$
12
  
$
34
  
$
12
 

The Company made cash contributions to its defined benefit pension plans of $9 million for the period ended February 29, 2016, which primarily related to committed funded payments. The Company plans to contribute an additional $66 million to its defined benefit pension plans in fiscal 2016.

Defined Contribution Plans
The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company’s contribution, which has historically related to adjusted FIFO earnings before interest and taxes and a portion of which is in the form of a guaranteed match, is determined annually at the discretion of the Walgreens Boots Alliance Board of Directors (or Compensation Committee thereof). The profit-sharing provision was an expense of $53 million and $111 million for the three and six months ended February 29, 2016, respectively, compared to a benefit of $21 million for the three months and expense of $54 million for the six months ended February 28, 2015, respectively.

The Company also has a contract based defined contribution arrangement, the Alliance Boots Retirement Savings Plan, to which both the Company and participating employees contribute. The obligation related to the Alliance Boots Retirement Savings Plan was acquired as a result of the Second Step Transaction. The cost recognized in the Consolidated Condensed Statements of Earnings for the three and six month periods ended February 29, 2016 was $34 million and $69 million, respectively compared to $22 million in the prior year three and six month periods. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, such costs for fiscal 2015 prior to the date of the Second Step Transaction were reflected within Equity earnings in Alliance Boots on the Consolidated Condensed Statement of Earnings.
 
Postretirement Healthcare Plan
The Company provides certain health insurance benefits to retired U.S. employees who meet eligibility requirements, including age, years of service and date of hire. The costs of these benefits are accrued over the service life of the employee. The Company’s postretirement health benefit plan is not funded.

Components of net periodic benefit cost for the postretirement health benefit plan (in millions):

  
Three Months Ended
  
Six Months Ended
 
  
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Service cost
 
$
2
  
$
2
  
$
5
  
$
5
 
Interest cost
  
5
   
4
   
10
   
8
 
Amortization of actuarial loss
  
5
   
5
   
9
   
10
 
Amortization of prior service cost
  
(7
)
  
(6
)
  
(14
)
  
(12
)
Total postretirement benefit cost
 
$
5
  
$
5
  
$
10
  
$
11
 
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.3.1.900
Earnings Per Share
6 Months Ended
Feb. 29, 2016
Earnings Per Share [Abstract]  
Earnings Per Share
Note 14. Earnings Per Share
The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. There were 3.2 million outstanding options to purchase common shares that were anti-dilutive and excluded from the second quarter earnings per share calculation as of February 29, 2016 compared to 3.4 million as of February 28, 2015. Anti-dilutive shares excluded from the year to date earnings per share calculation were 2.2 million compared to 5.0 million for the periods ending February 29, 2016 and February 28, 2015, respectively.
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.3.1.900
Depreciation and Amortization
6 Months Ended
Feb. 29, 2016
Depreciation and Amortization [Abstract]  
Depreciation and Amortization
Note 15. Depreciation and Amortization
The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):

  
Three Months Ended
  
Six Months Ended
 
  
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Depreciation expense
 
$
346
  
$
311
  
$
644
  
$
567
 
Intangible asset and other amortization
  
96
   
196
   
180
   
259
 
Total depreciation and amortization expense
 
$
442
  
$
507
  
$
824
  
$
826
 

The depreciation and amortization expense presented for 2015 include Alliance Boots costs for the period from December 31, 2014 through February 28, 2015. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, depreciation and amortization expense were included for fiscal 2015 prior to the date of the Second Step Transaction within Equity earnings in Alliance Boots.
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.3.1.900
Supplemental Cash Flow Disclosures
6 Months Ended
Feb. 29, 2016
Supplemental Cash Flow Disclosures [Abstract]  
Supplemental Cash Flow Disclosures
Note 16. Supplemental Cash Flow Disclosures
Cash interest paid was $302 million and $90 million in the six months ended February 29, 2016 and February 28, 2015, respectively. Cash paid for income taxes was $481 million and $553 million in the six months ended February 29, 2016 and February 28, 2015, respectively.
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.3.1.900
Accumulated Other Comprehensive Income (Loss)
6 Months Ended
Feb. 29, 2016
Accumulated Other Comprehensive Income (Loss) [Abstract]  
Accumulated Other Comprehensive Income (Loss)
Note 17. Accumulated Other Comprehensive Income (Loss)
The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for the three and six months ended February 29, 2016 and February 28, 2015 (in millions):
 
  
Pension/Post-
retirement
Obligations
  
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
  
Unrealized
Gain (Loss) on
Cash Flow
Hedges
  
Currency
Translation
Adjustments
  
Total
 
Balance at November 30, 2015
 
$
32
  
$
260
  
$
(39
)
 
$
(911
)
 
$
(658
)
Other comprehensive income (loss) before reclassification adjustments
  
(4
)
  
(139
)
  
-
   
(1,121
)
  
(1,264
)
Amounts reclassified from accumulated OCI
  
-
   
-
   
2
   
-
   
2
 
Tax benefit (provision)
  
2
   
51
   
(1
)
  
-
   
52
 
Net other comprehensive income (loss)
  
(2
)
  
(88
)
  
1
   
(1,121
)
  
(1,210
)
Balance at February 29, 2016
 
$
30
  
$
172
  
$
(38
)
 
$
(2,032
)
 
$
(1,868
)
 
  
Pension/Post-
retirement
Obligations
  
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
  
Unrealized
Gain (Loss) on
Cash Flow
Hedges
  
Currency
Translation
Adjustments
  
Total
 
Balance at August 31, 2015
 
$
29
  
$
259
  
$
(40
)
 
$
(462
)
 
$
(214
)
Other comprehensive income (loss) before reclassification adjustments
  
(1
)
  
(144
)
  
-
   
(1,570
)
  
(1,715
)
Amounts reclassified from accumulated OCI
  
-
   
-
   
3
   
-
   
3
 
Tax benefit (provision)
  
2
   
57
   
(1
)
  
-
   
58
 
Net other comprehensive income (loss)
  
1
   
(87
)
  
2
   
(1,570
)
  
(1,654
)
Balance at February 29, 2016
 
$
30
  
$
172
  
$
(38
)
 
$
(2,032
)
 
$
(1,868
)
 
  
Pension/Post-
retirement
Obligations
  
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
  
Unrealized
Gain (Loss) on
Cash Flow
Hedges
  
Share of
Alliance
Boots
OCI
  
Cumulative
Translation
Adjustments
  
Total
 
Balance at November 30, 2014
 
$
14
  
$
206
  
$
(39
)
 
$
(92
)
 
$
(35
)
 
$
54
 
Other comprehensive income (loss) before reclassification adjustments
  
(8
)
  
140
   
2
   
(89
)
  
(358
)
  
(313
)
Amounts reclassified from accumulated OCI
  
-
   
-
   
(1
)
  
230
   
80
   
309
 
Tax benefit (provision)
  
-
   
(50
)
  
(1
)
  
(49
)
  
(18
)
  
(118
)
Net other comprehensive income (loss)
 
$
(8
)
 
$
90
  
$
-
  
$
92
  
$
(296
)
 
$
(122
)
Balance at February 28, 2015
 
$
6
  
$
296
  
$
(39
)
 
$
-
  
$
(331
)
 
$
(68
)
 
  
Pension/Post-
retirement
Obligations
  
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
  
Unrealized
Gain (Loss) on
Cash Flow
Hedges
  
Share of
Alliance
Boots
OCI
  
Cumulative
Translation
Adjustments
  
Total
 
Balance at August 31, 2014
 
$
15
  
$
107
  
$
(27
)
 
$
(113
)
 
$
154
  
$
136
 
Other comprehensive income (loss) before reclassification adjustments
  
(10
)
  
297
   
(18
)
  
(57
)
  
(648
)
  
(436
)
Amounts reclassified from accumulated OCI
  
-
   
-
   
(1
)
  
230
   
80
   
309
 
Tax benefit (provision)
  
1
   
(108
)
  
7
   
(60
)
  
83
   
(77
)
Net other comprehensive income (loss)
 
$
(9
)
 
$
189
  
$
(12
)
 
$
113
  
$
(485
)
 
$
(204
)
Balance at February 28, 2015
 
$
6
  
$
296
  
$
(39
)
 
$
-
  
$
(331
)
 
$
(68
)
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Reporting
6 Months Ended
Feb. 29, 2016
Segment Reporting [Abstract]  
Segment Reporting
Note 18. Segment Reporting
The Company has three reportable segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments, which have been aggregated as described below. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.

·The Retail Pharmacy USA segment consists of the legacy Walgreens business, which includes the operation of retail drugstores and convenient care clinics and the provision of specialty pharmacy services. Revenues for the segment are principally derived from the sale of prescription drugs and a wide assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards and convenience foods.

·The Retail Pharmacy International segment consists primarily of the legacy Alliance Boots pharmacy-led health and beauty stores, optical practices, and related contract manufacturing operations. Stores are located in the United Kingdom, Mexico, Chile, Thailand, Norway, the Republic of Ireland, The Netherlands and Lithuania. Revenues for the segment are principally derived from the sale of prescription drugs and retail health, beauty, toiletries and other consumer products.

·The Pharmaceutical Wholesale segment consists of the legacy Alliance Boots pharmaceutical wholesaling and distribution businesses. Wholesale operations are located in France, the United Kingdom, Germany, Turkey, Spain, Russia, The Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Revenues for the segment are principally derived from wholesaling and distribution of a comprehensive offering of brand-name pharmaceuticals (including specialty pharmaceutical products) and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment, and related services to pharmacies and other healthcare providers.

The results of operations for each reportable segment include synergy benefits, including WBAD operations and an allocation of corporate-related overhead costs. The “Eliminations and Unallocated Items” column contains items not allocable to the reportable segments, as the information is not utilized by the chief operating decision maker to assess segment performance and allocate resources.

The segment information reflects the operating results of the Company’s business segments. The Company began recording revenue and expense transactions using the new segments effective January 1, 2015. Beginning January 1, 2015, synergy benefits including WBAD operations have been allocated to the Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale segments on a source of procurement benefit basis. Under this method, the synergy benefits are allocated to the segment whose purchase gave rise to the benefit. A synergy arising on the purchase of an item for use in an entity in the Retail Pharmacy USA segment is recognized in the Retail Pharmacy USA segment and similarly for the Retail Pharmacy International and Pharmaceutical Wholesale segments. Procurement service income related to third parties is recognized in the Pharmaceutical Wholesale segment. Corporate costs have been allocated to segments based on their respective gross profit.

Our Retail Pharmacy International and Pharmaceutical Wholesale segments were acquired as part of the Second Step Transaction in which we acquired the 55% of Alliance Boots that we did not already own on December 31, 2014. The Company has determined that it is impracticable to restate segment information for periods prior the completion of the Second Step Transaction, as well as to provide disclosures for such periods under both the old basis and new basis of reporting for certain items. Specifically, WBAD operations prior to December 31, 2014 were recorded in the Retail Pharmacy USA segment and have not been restated, as the Company believes it is impracticable to separate the information to the individual reportable segments. Equity earnings from Alliance Boots prior to the completion of the Second Step Transaction has been recorded within the Retail Pharmacy USA segment. The equity earnings of the 45% interest in Alliance Boots have not been separated into the Retail Pharmacy International and Pharmaceutical Wholesale segments for the prior period, as the Company believes it is impracticable. Accordingly, only two months of results (January and February 2015) have been reported for these segments for the three and six months ended February 28, 2015.
 
The following table reflects results of operations of the Company’s reportable segments (in millions):

  
Retail Pharmacy
          
  
USA
  
International
  
Pharmaceutical
Wholesale
  
Eliminations
and
Unallocated
 Items
  
Consolidated
 
Three Months Ended February 29, 2016
               
Sales to external customers
 
$
21,500
  
$
3,627
  
$
5,057
  
$
-
  
$
30,184
 
Intersegment sales
  
-
   
62
   
570
   
(632
)
  
-
 
Total Sales
  
21,500
   
3,689
   
5,627
   
(632
)
  
30,184
 
                     
Adjusted Operating Income
 
$
1,632
  
$
335
  
$
155
  
$
(2
)
 
$
2,120
 
                     
Three Months Ended February 28, 2015
                    
Sales to external customers
 
$
21,048
  
$
2,017
  
$
3,508
  
$
-
  
$
26,573
 
Intersegment sales
  
-
   
30
   
357
   
(387
)
  
-
 
Total Sales
  
21,048
   
2,047
   
3,865
   
(387
)
  
26,573
 
                     
Adjusted Operating Income
 
$
1,598
  
$
125
  
$
121
  
$
(4
)
 
$
1,840
 

  
Retail Pharmacy
          
  
USA
  
International
  
Pharmaceutical
Wholesale
  
Eliminations
and
Unallocated
 Items
  
Consolidated
 
Six Months Ended February 29, 2016
               
Sales to external customers
 
$
41,870
  
$
7,086
  
$
10,261
  
$
-
  
$
59,217
 
Intersegment sales
  
-
   
134
   
1,162
   
(1,296
)
  
-
 
Total Sales
  
41,870
   
7,220
   
11,423
   
(1,296
)
  
59,217
 
                     
Adjusted Operating Income
 
$
2,875
  
$
650
  
$
321
  
$
(7
)
 
$
3,839
 
                     
Six Months Ended February 28, 2015
                    
Sales to external customers
 
$
40,602
  
$
2,017
  
$
3,508
  
$
-
  
$
46,127
 
Intersegment sales
  
-
   
30
   
357
   
(387
)
  
-
 
Total Sales
  
40,602
   
2,047
   
3,865
   
(387
)
  
46,127
 
                     
Adjusted Operating Income
 
$
2,716
  
$
125
  
$
121
  
$
(4
)
 
$
2,958
 
 
The following table reconciles adjusted operating income to operating income (in millions):

  
Retail Pharmacy
          
  
USA
  
International
  
Pharmaceutical
Wholesale
  
Eliminations
and
Unallocated
Items
  
Consolidated
 
Three Months Ended February 29, 2016
               
Adjusted Operating Income
 
$
1, 632
  
$
335
  
$
155
  
$
(2
)
 
$
2,120
 
Acquisition-related amortization
                  
(101
)
Cost transformation
                  
(28
)
LIFO provision
                  
(68
)
Acquisition-related costs
                  
(33
)
Asset impairment
                  
(30
)
Operating Income
                 
$
1,860
 
                     
Three Months Ended February  28, 2015
                    
Adjusted Operating Income
 
$
1,598
  
$
125
  
$
121
  
$
(4
)
 
$
1,840
 
(Decrease) increase in fair market value of warrants
                  
(6
)
Acquisition-related amortization
                  
(217
)
LIFO provision
                  
(55
)
Acquisition-related costs
                  
(59
)
Asset impairment
                  
(110
)
Store closures and other optimization costs
                  
(16
)
Operating Income
                 
$
1,377
 

  
Retail Pharmacy
          
  
USA
  
International
  
Pharmaceutical
Wholesale
  
Eliminations
and
Unallocated
Items
  
Consolidated
 
Six Months Ended February 29, 2016
               
Adjusted Operating Income
 
$
2,875
  
$
650
  
$
321
  
$
(7
)
 
$
3,839
 
Acquisition-related amortization
                  
(182
)
Cost transformation
                  
(118
)
LIFO provision
                  
(114
)
Acquisition-related costs
                  
(67
)
Asset impairment
                  
(30
)
Operating Income
                 
$
3,328
 
                     
Six Months Ended February 28, 2015
                    
Adjusted Operating Income
 
$
2,716
  
$
125
  
$
121
  
$
(4
)
 
$
2,958
 
(Decrease) increase in fair market value of warrants
                  
123
 
Acquisition-related amortization
                  
(306
)
LIFO provision
                  
(107
)
Acquisition-related costs
                  
(83
)
Asset impairment
                  
(110
)
Store closures and other optimization costs
                  
(44
)
Operating Income
                 
$
2,431
 
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.3.1.900
Recent Accounting Pronouncements
6 Months Ended
Feb. 29, 2016
Recent Accounting Pronouncements [Abstract]  
Recent Accounting Pronouncements
Note 19. Recent Accounting Pronouncements
In February 2016, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which supersedes Topic 840, Leases. This ASU increases the transparency and comparability of organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed. At the lease commencement date, lessee recognizes a lease liability and right-of-use asset, which is initially measured at the present value of future lease payments. There are two approaches for amortizing the right-of use asset. Under the finance lease approach, interest on the lease liability is recognized separately from amortization of the right-of-use asset. Repayments of the principal portion of the lease liability will be classified as financing activities and payments of interest on the lease liability and variable lease payments will be classified as operating activities in the statement of cash flows. Under the operating lease approach, the cost of the lease is calculated on a straight-line basis over the life of the lease term. All cash payments are classified as operating activities in the statement of cash flows. For sale and leaseback transactions, in order for a sale to occur, the transfer of the asset must meet all criteria in Topic 606. If there is no sale for the seller-lessee, the buyer-lessor does not account for a purchase. Any consideration paid for the asset is accounted for as a financing transaction. For transactions previously accounted for as a sale and leaseback, the transition guidance in Topic 842 does not require an entity to assess whether the transaction would have qualified as a sale and a leaseback in accordance with Topic 842. Additionally, gains recorded under sale and leaseback transactions are recognized at the transaction date and no longer deferred over the lease term. This ASU is effective for annual periods beginning after December 15, 2018 (fiscal 2020). In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach which includes a number of optional practical expedients that entities may elect to apply. For a description of the Company’s lease obligations, please refer to the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2015. The Company has begun evaluating and planning for the adoption and implementation of this ASU, including assessing the overall impact. This ASU will have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is being evaluated. The impact of this ASU is non-cash in nature and will not affect the Company’s cash position.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10). This ASU requires equity investments (except those under the equity method of accounting or those that result in the consolidation of an investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. This simplifies the impairment assessment of equity investments previous held at cost. Separate presentation of financial assets and liabilities by measurement category is required. This ASU is effective prospectively for annual periods beginning after December 15, 2017 (fiscal 2019). Early application is not permitted. The Company is evaluating the effect of adopting this new accounting guidance.

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). This ASU simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as non-current in a classified statement of financial position. This ASU may be applied either prospectively to all deferred tax assets and liabilities, or retrospectively to all periods presented for annual periods beginning after December 16, 2016 and interim periods thereafter (fiscal 2018), with early adoption permitted, and may require additional disclosure based on the application method selected. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company’s financial position.

In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805). This ASU simplifies the accounting for adjustments made to provisional amounts recognized in a business combination by eliminating the requirements to retrospectively account for those adjustments. This guidance applies to all entities that have reported provisional amounts for items in a business combination for which the accounting is incomplete by the end of the reporting period in which the combination occurs and during the measurement period having an adjustment to provisional amounts recognized. This ASU is effective prospectively for annual periods beginning after December 31, 2016 and interim periods thereafter (fiscal 2018) with early adoption permitted. The Company adopted this ASU on March 1, 2016. The adoption of this ASU did not have a material impact on the Company’s results of operations, cash flows or financial position.

In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), an update to ASU 2014-09. This ASU amends ASU 2014-09 to defer the effective date by one year for annual reporting periods beginning after December 15, 2017 (fiscal 2019). This ASU removes inconsistencies, complexities and allows transparency and comparability of revenue transactions across entities, industries, jurisdictions and capital markets by providing a single comprehensive principles-based model with additional disclosures regarding uncertainties. The principles-based revenue recognition model has a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Early adoption is permitted for annual reporting periods beginning after December 15, 2016 (fiscal 2018). In transition, the ASU may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is evaluating the effect of adopting this new accounting guidance including the transition method.

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330). This ASU simplifies current accounting treatments by requiring entities to measure most inventories at “the lower of cost and net realizable value” rather than using lower of cost or market. This guidance does not apply to inventories measured using last-in, first-out method or the retail inventory method. This ASU is effective prospectively for annual periods beginning after December 15, 2016 and interim periods thereafter (fiscal 2018) with early adoption permitted. Upon transition, entities must disclose the accounting change. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company’s results of operations, cash flows or financial position.
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.3.1.900
Subsequent Event
6 Months Ended
Feb. 29, 2016
Subsequent Event [Abstract]  
Subsequent Event
Note 20. Subsequent Event
On March 18, 2016, the Company exercised Warrant 1 (described in Note 10, Financial Instruments) in full, resulting in the acquisition from AmerisourceBergen of 22,696,912 shares of AmerisourceBergen common stock for an aggregate exercise price payment of $1.17 billion. The transaction was funded using existing cash on hand. Following the exercise of Warrant 1, the Company owned 34,157,955 outstanding AmerisourceBergen common shares representing approximately 15.2% of the outstanding AmerisourceBergen common stock (based on shares outstanding as of March 16, 2016 adjusted to give effect to the exercise of Warrant 1, as reported by AmerisourceBergen in its Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2016). The Company continues to hold Warrant 2, which the Company has the right to exercise beginning in March 2017.

Effective March 18, 2016, the Company accounts for its investment in AmerisourceBergen using the equity method of accounting, subject to a two-month reporting lag, with the net earnings attributable to its investment being classified within the operating income of the Company’s Pharmaceutical Wholesale segment.
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.3.1.900
Accounting Policies (Policies)
6 Months Ended
Feb. 29, 2016
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The consolidated condensed financial statements of Walgreens Boots Alliance included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. The consolidated condensed financial statements include all subsidiaries in which the Company holds a controlling interest. Investments in less than majority-owned entities in which the Company does not have a controlling interest, but does have significant influence, are accounted for as equity method investments. All intercompany transactions have been eliminated.

The Consolidated Condensed Balance Sheet as of February 29, 2016, the Consolidated Condensed Statements of Equity for the six-month period ended February 29, 2016, and the Consolidated Condensed Statements of Earnings, the Consolidated Condensed Statements of Comprehensive Income and the Consolidated Condensed Statements of Cash Flows for the three month and six month periods ended February 29, 2016 and February 28, 2015, have not been audited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.
 
In the opinion of the Company, the unaudited consolidated condensed financial statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present a fair statement of the results for such interim periods. Because of the acquisition of Alliance Boots, influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company’s operations, net earnings for any interim period may not be comparable to the same interim period in previous years or indicative of net earnings for the full fiscal year. In addition, with respect to the Company’s Retail Pharmacy USA segment, the positive impact on gross profit margins and gross profit dollars typically has been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a “generic conversion.” In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on Retail Pharmacy USA segment’s sales, gross profit margins and gross profit dollars.

The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experience and other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. For a discussion of the Company’s significant accounting policies, please see the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.3.1.900
Restructuring (Tables)
6 Months Ended
Feb. 29, 2016
Restructuring [Abstract]  
Restructuring Costs by Segment
Restructuring costs by segment are as follows (in millions):

  
Retail Pharmacy
       
Three Months Ended February 29, 2016
 
USA
  
International
  
Pharmaceutical
Wholesale
  
Consolidated
 
Real estate costs
 
$
-
  
$
-
  
$
-
  
$
-
 
Asset impairments
  
-
   
-
   
-
   
-
 
Severance and other business transition and exit costs
  
25
   
3
   
-
   
28
 
Total restructuring costs
 
$
25
  
$
3
  
$
-
  
$
28
 
                 
Three Months Ended February 28, 2015
                
Real estate costs
 
$
-
  
$
-
  
$
-
  
$
-
 
Asset impairments
  
-
   
-
   
-
   
-
 
Severance and other business transition and exit costs
  
-
   
-
   
-
   
-
 
Total restructuring costs
 
$
-
  
$
-
  
$
-
  
$
-
 
 
  
Retail Pharmacy
       
Six Months Ended February 29, 2016
 
USA
  
International
  
Pharmaceutical
Wholesale
  
Consolidated
 
Real estate costs
 
$
52
  
$
-
  
$
-
  
$
52
 
Asset impairments
  
25
   
-
   
-
   
25
 
Severance and other business transition and exit costs
  
33
   
8
   
-
   
41
 
Total restructuring costs
 
$
110
  
$
8
  
$
-
  
$
118
 
                 
Six Months Ended February 28, 2015
                
Real estate costs
 
$
17
  
$
-
  
$
-
  
$
17
 
Asset impairments
  
-
   
-
   
-
   
-
 
Severance and other business transition and exit costs
  
-
   
-
   
-
   
-
 
Total restructuring costs
 
$
17
  
$
-
  
$
-
  
$
17
 
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.3.1.900
Operating Leases (Tables)
6 Months Ended
Feb. 29, 2016
Operating Leases [Abstract]  
Reserve for Facility Closings and Related Lease Termination Charges
The changes in reserve for facility closings and related lease termination charges include the following (in millions):
 
    
Six Month
Period Ended
February 29,
2016
  
Twelve Month
Period Ended
August 31,
2015
 
Balance – beginning of period
 
$
446
  
$
257
 
Provision for present value of non-cancellable lease payments on closed facilities
  
77
   
231
 
Assumptions about future sublease income, terminations and changes in interest rates
  
(14
)
  
(6
)
Interest accretion
  
12
   
27
 
Liability assumed through acquisition of Alliance Boots
  
-
   
13
 
Cash payments, net of sublease income
  
(54
)
  
(76
)
Balance – end of period
 
$
467
  
$
446
 
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.3.1.900
Equity Method Investments (Tables)
6 Months Ended
Feb. 29, 2016
Equity Method Investments [Abstract]  
Equity Method Investments
Equity method investments as of February 29, 2016 and August 31, 2015 were as follows (in millions, except percentages):

  
February 29, 2016
  
August 31, 2015
 
  
Carrying
Value
  
Ownership
Percentage
  
Carrying
Value
  
Ownership
Percentage
 
Equity method investments
 
$
1,217
   
12% - 50
%
 
$
1,242
   
12% - 50
%
Summarized Financial Information of Equity Method Investees
Summarized financial information for the Company’s equity method investments is as follows:
 
Balance Sheets (in millions)
  
February 29, 2016(1)
  
August 31, 2015(1)
 
Current assets
 
$
5,687
  
$
5,015
 
Noncurrent assets
  
1,592
   
1,548
 
Current liabilities
  
4,598
   
3,936
 
Noncurrent liabilities
  
876
   
837
 
Shareholders’ equity(2)
  
1,805
   
1,790
 
 
Statements of Earnings (in millions)
  
Three Months Ended
  
Six Months Ended
 
  
February 29,
2016(3)
  
February 28,
2015(3)(4)
  
February 29,
2016(3)
  
February 28,
2015(3)(4)
 
             
Net sales
 
$
3,286
  
$
5,317
  
$
6,489
  
$
14,978
 
Gross Profit
  
374
   
979
   
702
   
3,168
 
Net Income
  
26
   
246
   
50
   
743
 
Share of income from equity method investments
  
9
   
109
   
20
   
323
 

(1)
Balance sheet information of foreign equity method investments are translated at their respective February 29, 2016 and August 31, 2015 spot rates.
(2)
Shareholders’ equity at February 29, 2016 and August 31, 2015 includes $170 million and $163 million, respectively, related to noncontrolling interests.
(3)
Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates.
(4)
Includes equity method investment in Alliance Boots from Walgreen Co.’s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization.
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.3.1.900
Available-for-Sale Investments (Tables)
6 Months Ended
Feb. 29, 2016
Available-for-Sale Investments [Abstract]  
Summary of Cost and Fair Value of Available-for-Sale Securities
A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions):

  
February 29, 2016
 
  
Amortized
cost basis
  
Gross
unrealized
gains
  
Gross
unrealized
losses
  
Fair value
 
AmerisourceBergen common stock
 
$
717
  
$
276
  
$
-
  
$
993
 
Other investments
  
38
   
-
   
(4
)
  
34
 
Total available-for-sale investments
 
$
755
  
$
276
  
$
(4
)
 
$
1,027
 
 
  
August 31, 2015
 
  
Amortized
cost basis
  
Gross
unrealized
gains
  
Gross
unrealized
losses
  
Fair value
 
AmerisourceBergen common stock
 
$
717
  
$
430
  
$
-
  
$
1,147
 
Other investments
  
37
   
-
   
(1
)
  
36
 
Total available-for-sale investments
 
$
754
  
$
430
  
$
(1
)
 
$
1,183
 
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisitions (Tables)
6 Months Ended
Feb. 29, 2016
Acquisitions [Abstract]  
Schedule of Impact of Equity Transaction
The impact of the equity transaction is as follows (in millions):

  
Amount
 
Consideration attributable to WBAD
 
$
2,559
 
Less:  Carrying value of the Company’s pre-existing noncontrolling interest
  
130
 
Impact to additional paid in capital
 
$
2,429
 
Schedule of Business Acquisition Total Consideration Paid
Consideration paid
 
Cash
 
$
4,874
 
Common stock
  
10,977
 
Total consideration transferred
  
15,851
 
Less: consideration attributed to WBAD
  
(2,559
)
   
13,292
 
Fair value of the investment in Alliance Boots held before the Second Step Transaction
  
8,149
 
Total consideration
 
$
21,441
Schedule of Identifiable Assets Acquired and Liabilities Assumed Including Noncontrolling Interests
Identifiable assets acquired and liabilities assumed including noncontrolling interests
 
Cash and cash equivalents
 
$
413
 
Accounts receivable
  
3,799
 
Inventories
  
3,713
 
Other current assets
  
894
 
Property, plant and equipment
  
3,806
 
Intangible assets
  
11,691
 
Other non-current assets
  
2,217
 
Trade accounts payable, accrued expenses and other liabilities
  
(7,696
)
Borrowings
  
(9,010
)
Deferred income taxes
  
(2,452
)
Other non-current liabilities
  
(383
)
Noncontrolling interests
  
(412
)
Total identifiable net assets and noncontrolling interests
  
6,580
 
Goodwill
 
$
14,861
 
Schedule of Identified Definite and Indefinite Lived Intangible Assets
The identified definite and indefinite lived intangible assets were as follows:

Definite-Lived Intangible Assets
 
Weighted-Average Useful
Life (in years)
  
Amount (in millions)
 
Customer relationships
 12  
$
1,311
 
Loyalty card holders
 20   
742
 
Trade names and trademarks
 9   
399
 
Favorable lease interests
 7   
93
 
Total
    
$
2,545
 

Indefinite-Lived Intangible Assets
 
Amount (in millions)
 
Trade names and trademarks
 
$
6,657
 
Pharmacy licenses
  
2,489
 
Total
 
$
9,146
 
Schedule of Unaudited Pro Forma Results Prepared for Comparative Purposes
Accordingly, the unaudited condensed pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company’s results would have been had the Second Step Transaction occurred at the beginning of the periods presented or the results which may occur in the future.

  
Pro forma
Three Months Ended
February 28,
2015
  
Pro forma
Six Months Ended
February 28,
2015
 
(in millions, except per share amounts)
      
Net sales
 
$
30,202
  
$
59,173
 
Net earnings
  
1,253
   
2,621
 
         
Net earnings per common share:
        
Basic
 
$
1.20
  
$
2.51
 
Diluted
  
1.19
   
2.49
 
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.3.1.900
Goodwill and Other Intangible Assets (Tables)
6 Months Ended
Feb. 29, 2016
Goodwill and Other Intangible Assets [Abstract]  
Schedule of Goodwill
Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions):

  
Retail Pharmacy
USA
  
Retail Pharmacy
International
  
Pharmaceutical
Wholesale
  
Total
 
August 31, 2015
 
$
8,940
  
$
3,898
  
$
3,534
  
$
16,372
 
Acquisitions
  
-
   
19
   
-
   
19
 
Other (1)
  
-
   
(3
)
  
13
   
10
 
Currency translation adjustments
  
-
   
(309
)
  
(296
)
  
(605
)
February 29, 2016
 
$
8,940
  
$
3,605
  
$
3,251
  
$
15,796
 

(1)Other represents immaterial purchase accounting adjustments for prior year Company acquisitions.
Schedule of Finite-Lived Intangible Assets by Major Class
The carrying amount and accumulated amortization of intangible assets consist of the following (in millions):

  
February 29, 2016
  
August 31, 2015
 
Gross Amortizable Intangible Assets
      
Customer relationships
 
$
1,293
  
$
1,409
 
Purchased prescription files
  
904
   
885
 
Loyalty card holders
  
661
   
730
 
Trade names and trademarks
  
678
   
675
 
Favorable lease interests
  
457
   
440
 
Non-compete agreements
  
158
   
154
 
Purchasing and payer contracts
  
95
   
94
 
Total gross amortizable intangible assets
  
4,246
   
4,387
 
         
Accumulated amortization
        
Customer relationships
  
182
   
132
 
Purchased prescription files
  
536
   
470
 
Loyalty card holders
  
41
   
41
 
Trade names and trademarks
  
114
   
83
 
Favorable lease interests
  
246
   
207
 
Non-compete agreements
  
106
   
92
 
Purchasing and payer contracts
  
68
   
65
 
Total accumulated amortization
  
1,293
   
1,090
 
Total amortizable intangible assets, net
 
$
2,953
  
$
3,297
 
         
Indefinite Lived Intangible Assets
        
Trade names and trademarks
 
$
5,947
  
$
6,590
 
Pharmacy licenses
  
2,222
   
2,464
 
Total indefinite lived intangible assets
 
$
8,169
  
$
9,054
 
         
Total intangible assets, net
 
$
11,122
  
$
12,351
 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
Estimated annual amortization expense for intangible assets recorded at February 29, 2016 is as follows (in millions):

  
2016
  
2017
  
2018
  
2019
  
2020
 
Estimated annual amortization expense
 
$
401
  
$
358
  
$
318
  
$
289
  
$
254
 
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.3.1.900
Short-Term Borrowings and Long-Term Debt (Tables)
6 Months Ended
Feb. 29, 2016
Short-Term Borrowings and Long-Term Debt [Abstract]  
Short-Term Borrowings
Short-term borrowings and long-term debt consist of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):

  
February 29, 2016
  
August 31, 2015
 
Short-Term Borrowings(1)
      
Unsecured variable rate notes due 2016
 
$
749
  
$
747
 
Other(2)
  
303
   
321
 
Total short-term borrowings
 
$
1,052
  
$
1,068
 
 
(1)
All notes are presented net of unamortized discount and debt issuance costs, where applicable.
(2)
Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts.
(3)
Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively.
(4)
Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures.
(5)
Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively.
(6)
Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
Long-Term Debt
Long-Term Debt(1)
        
Unsecured Pound Sterling variable rate term loan due 2019(3)
 
$
2,013
  
$
2,229
 
1.750% unsecured notes due 2017
  
747
   
746
 
5.250% unsecured notes due 2019(4)
  
253
   
250
 
2.700% unsecured notes due 2019
  
1,244
   
1,243
 
2.875% unsecured Pound Sterling notes due 2020(3)
  
552
   
612
 
3.300% unsecured notes due 2021
  
1,241
   
1,241
 
3.100% unsecured notes due 2022
  
1,193
   
1,193
 
3.800% unsecured notes due 2024
  
1,986
   
1,985
 
3.600% unsecured Pound Sterling notes due 2025(3)
  
414
   
459
 
2.125% unsecured Euro notes due 2026(5)
  
811
   
836
 
4.500% unsecured notes due 2034
  
494
   
494
 
4.400% unsecured notes due 2042
  
492
   
492
 
4.800% unsecured notes due 2044
  
1,492
   
1,491
 
Other(6)
  
42
   
44
 
Total long-term debt
 
$
12,974
  
$
13,315
 
 
(1)
All notes are presented net of unamortized discount and debt issuance costs, where applicable.
(2)
Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts.
(3)
Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively.
(4)
Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures.
(5)
Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively.
(6)
Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
Total $8.0 Billion Debt Issuance [Member]  
Debt Instrument [Line Items]  
Details of Each Tranche of Notes Issued
The following table summarizes each tranche of notes issued:

Notes Issued
(in millions)
 
 
Maturity Date
 
 
Interest Rate
 
 
Interest Payment Dates
$
750
 
May 18, 2016
 
Variable; three month U.S. dollar LIBOR, reset quarterly, plus 45 basis points
 
February 18, May 18, August 18, and November 18; commencing on February 18, 2015
 
750
 
November 17, 2017
 
Fixed 1.750%
 
May 17 and November 17; commencing on May 17, 2015
 
1,250
 
November 18, 2019
 
Fixed 2.700%
 
May 18 and November 18; commencing on May 18, 2015
 
1,250
 
November 18, 2021
 
Fixed 3.300%
 
May 18 and November 18; commencing on May 18, 2015
 
2,000
 
November 18, 2024
 
Fixed 3.800%
 
May 18 and November 18; commencing on May 18, 2015
 
500
 
November 18, 2034
 
Fixed 4.500%
 
May 18 and November 18; commencing on May 18, 2015
 
1,500
 
November 18, 2044
 
Fixed 4.800%
 
May 18 and November 18; commencing on May 18, 2015
$
8,000
        
Euro and Pound Sterling Notes [Member]  
Debt Instrument [Line Items]  
Details of Each Tranche of Notes Issued
The following table details each tranche of Euro and Pound Sterling notes issued:

Notes Issued (in millions)
 
Maturity Date
Interest Rate
Euro Notes:
    
750
 
November 20, 2026
Fixed 2.125%
       
Pound Sterling Notes:
    
£
400
 
November 20, 2020
Fixed 2.875%
 
300
 
November 20, 2025
Fixed 3.600%
£
700
    
Total $4.0 Billion Debt Issuance [Member]  
Debt Instrument [Line Items]  
Details of Each Tranche of Notes Issued
The following table details each tranche of outstanding notes as of February 29, 2016:
 
Notes Issued
(in millions)
 
Maturity Date
Interest Rate
Interest Payment Dates
$
1,200
 
September 15, 2022
Fixed 3.100%
March 15 and September 15; commencing on March 15, 2013
 
500
 
September 15, 2042
Fixed 4.400%
March 15 and September 15; commencing on March 15, 2013
$
1,700
      
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.3.1.900
Financial Instruments (Tables)
6 Months Ended
Feb. 29, 2016
Financial Instruments [Abstract]  
Notional Amounts of Derivative Instruments Outstanding
The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of February 29, 2016, excluding warrants which are presented separately in this footnote, were as follows (in millions):

  
Notional(1)
  
Fair Value
 
Location in Consolidated
Condensed Balance Sheets
Derivatives designated as fair value hedges:
         
Interest rate swaps
 
$
250
  
$
5
 
Other non-current assets
Derivatives not designated as hedges:
           
Foreign currency forwards
  
465
   
1
 
Other current assets
Foreign currency forwards
  
768
   
16
 
Other current liabilities
Basis swap
  
2
   
1
 
Other current liabilities

(1)Amounts are presented in U.S. dollar equivalents.
 
The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2015, excluding warrants which are presented separately in this footnote, are as follows (in millions):

  
Notional(1)
  
Fair Value
 
Location in Consolidated
Condensed Balance Sheets
Derivatives designated as fair value hedges:
         
Interest rate swaps
 
$
250
  
$
2
 
Other non-current assets
Derivatives not designated as hedges:
           
Foreign currency forwards
  
1,205
   
34
 
Other current assets
Foreign currency forwards
  
495
   
9
 
Other current liabilities
Basis swap
  
1
   
-
 
Other current assets

(1)Amounts are presented in U.S. dollar equivalents.
Schedule of Derivative Assets at Fair Value
The Company reports the Warrants at fair value. The fair value and balance sheet presentation of the Warrants was as follows (in millions):

Location in Consolidated
Condensed Balance Sheets 
 
February 29,
2016
  
August 31,
2015
 
Asset derivatives not designated as hedges:
       
Warrants
Other non-current assets
 
$
1,546
  
$
2,140
 
Designated as Hedging Instrument [Member]  
Derivative [Line Items]  
Gains and Losses due to Changes in Fair Value Recognized in Earnings
The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk were recognized as follows (in millions):

 
Location in Consolidated
 
Three Months Ended
  
Six Months Ended
 
 
Condensed Statements of
Earnings
 
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Interest rate swaps
Interest expense, net
 
$
(2
)
 
$
4
  
$
(3
)
 
$
(6
)
Notes
Interest expense, net
  
2
   
(4
)
  
3
   
6
 
Not Designated as Hedging Instrument [Member]  
Derivative [Line Items]  
Gains and Losses due to Changes in Fair Value Recognized in Earnings
The gains and losses due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):

 Location in Consolidated 
Three Months Ended
  
Six Months Ended
 
Condensed Statements of
Earnings
 
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Interest rate swaps
Interest expense, net
 
$
-
  
$
(1
)
 
$
-
  
$
(1
)
Foreign currency forwards
Selling, general and administrative expenses
  
(23
)
  
(28
)
  
(25
)
  
(28
)
Second Step Transaction foreign currency forwards
Other income (expense)
  
-
   
(70
)
  
-
   
(166
)
Foreign currency forwards
Other income (expense)
  
33
   
-
   
33
   
-
 
Warrant [Member] | Not Designated as Hedging Instrument [Member]  
Derivative [Line Items]  
Gains and Losses due to Changes in Fair Value Recognized in Earnings
The gains and losses due to changes in fair value of the Warrants recognized in earnings were as follows (in millions):

    
Three Months Ended
  
Six Months Ended
 
 
Location in Consolidated
Condensed Statements of Earnings
 
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Warrants
Other income (expense)
 
$
(532
)
 
$
559
  
$
(594
)
 
$
849
 
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.3.1.900
Fair Value Measurements (Tables)
6 Months Ended
Feb. 29, 2016
Fair Value Measurements [Abstract]  
Assets and Liabilities Measured at Fair Value on a Recurring Basis
Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):

  
February 29, 2016
  
Level 1
  
Level 2
  
Level 3
 
Assets:
            
Restricted cash (1)
 
$
175
  
$
175
  
$
-
  
$
-
 
Money market funds (2)
  
2,659
   
2,659
   
-
   
-
 
Available-for-sale investments (3)
  
1,027
   
1,027
   
-
   
-
 
Interest rate swaps (4)
  
5
   
-
   
5
   
-
 
Foreign currency forwards (5)
  
1
   
-
   
1
   
-
 
Warrants (6)
  
1,546
   
-
   
1,546
   
-
 
Liabilities:
                
Basis swaps (5)
  
1
   
-
   
1
   
-
 
Foreign currency forwards (5)
  
16
   
-
   
16
   
-
 

  
August 31, 2015
  
Level 1
  
Level 2
  
Level 3
 
Assets:
            
Restricted cash (1)
 
$
184
  
$
184
  
$
-
  
$
-
 
Money market funds (2)
  
2,043
   
2,043
   
-
   
-
 
Available-for-sale investments (3)
  
1,183
   
1,183
   
-
   
-
 
Interest rate swaps (4)
  
2
   
-
   
2
   
-
 
Foreign currency forwards (5)
  
34
   
-
   
34
   
-
 
Warrants (6)
  
2,140
   
-
   
2,140
   
-
 
Liabilities:
                
Foreign currency forwards (5)
  
9
   
-
   
9
   
-
 

(1)Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.
(2)Money market funds are valued at the closing price reported by the fund sponsor.
(3)Fair values of quoted investments are based on current bid prices as of the balance sheet dates.  See Note 6, Available-for-Sale Investments for additional information.
(4)The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information.
(5)The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
(6)Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen’s common stock; AmerisourceBergen’s common stock price at the valuation date; AmerisourceBergen’s equity volatility; the number of shares of AmerisourceBergen’s common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the Warrants.
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.3.1.900
Retirement Benefits (Tables)
6 Months Ended
Feb. 29, 2016
Boots Pension Plan [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Components of Net Periodic Benefit Cost
Components of net periodic pension costs for the defined benefit pension plans (in millions):

  
Three Months Ended
  
Six Months Ended
 
  
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Service costs
 
$
-
  
$
1
  
$
2
  
$
1
 
Interest costs
  
77
   
53
   
159
   
53
 
Expected returns on plan assets
  
(62
)
  
(43
)
  
(127
)
  
(43
)
Settlements
  
-
   
1
    -   
1
 
Total net periodic pension costs
 
$
15
  
$
12
  
$
34
  
$
12
 
Defined Benefit Postretirement Health Benefit Plan [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Components of Net Periodic Benefit Cost
Components of net periodic benefit cost for the postretirement health benefit plan (in millions):

  
Three Months Ended
  
Six Months Ended
 
  
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Service cost
 
$
2
  
$
2
  
$
5
  
$
5
 
Interest cost
  
5
   
4
   
10
   
8
 
Amortization of actuarial loss
  
5
   
5
   
9
   
10
 
Amortization of prior service cost
  
(7
)
  
(6
)
  
(14
)
  
(12
)
Total postretirement benefit cost
 
$
5
  
$
5
  
$
10
  
$
11
 
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.3.1.900
Depreciation and Amortization (Tables)
6 Months Ended
Feb. 29, 2016
Depreciation and Amortization [Abstract]  
Depreciation and Amortization by Major Category
The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):

  
Three Months Ended
  
Six Months Ended
 
  
February 29,
2016
  
February 28,
2015
  
February 29,
2016
  
February 28,
2015
 
Depreciation expense
 
$
346
  
$
311
  
$
644
  
$
567
 
Intangible asset and other amortization
  
96
   
196
   
180
   
259
 
Total depreciation and amortization expense
 
$
442
  
$
507
  
$
824
  
$
826
 
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.3.1.900
Accumulated Other Comprehensive Income (Loss) (Tables)
6 Months Ended
Feb. 29, 2016
Accumulated Other Comprehensive Income (Loss) [Abstract]  
Components of Accumulated Other Comprehensive Income (Loss)
The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for the three and six months ended February 29, 2016 and February 28, 2015 (in millions):
 
  
Pension/Post-
retirement
Obligations
  
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
  
Unrealized
Gain (Loss) on
Cash Flow
Hedges
  
Currency
Translation
Adjustments
  
Total
 
Balance at November 30, 2015
 
$
32
  
$
260
  
$
(39
)
 
$
(911
)
 
$
(658
)
Other comprehensive income (loss) before reclassification adjustments
  
(4
)
  
(139
)
  
-
   
(1,121
)
  
(1,264
)
Amounts reclassified from accumulated OCI
  
-
   
-
   
2
   
-
   
2
 
Tax benefit (provision)
  
2
   
51
   
(1
)
  
-
   
52
 
Net other comprehensive income (loss)
  
(2
)
  
(88
)
  
1
   
(1,121
)
  
(1,210
)
Balance at February 29, 2016
 
$
30
  
$
172
  
$
(38
)
 
$
(2,032
)
 
$
(1,868
)
 
  
Pension/Post-
retirement
Obligations
  
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
  
Unrealized
Gain (Loss) on
Cash Flow
Hedges
  
Currency
Translation
Adjustments
  
Total
 
Balance at August 31, 2015
 
$
29
  
$
259
  
$
(40
)
 
$
(462
)
 
$
(214
)
Other comprehensive income (loss) before reclassification adjustments
  
(1
)
  
(144
)
  
-
   
(1,570
)
  
(1,715
)
Amounts reclassified from accumulated OCI
  
-
   
-
   
3
   
-
   
3
 
Tax benefit (provision)
  
2
   
57
   
(1
)
  
-
   
58
 
Net other comprehensive income (loss)
  
1
   
(87
)
  
2
   
(1,570
)
  
(1,654
)
Balance at February 29, 2016
 
$
30
  
$
172
  
$
(38
)
 
$
(2,032
)
 
$
(1,868
)
 
  
Pension/Post-
retirement
Obligations
  
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
  
Unrealized
Gain (Loss) on
Cash Flow
Hedges
  
Share of
Alliance
Boots
OCI
  
Cumulative
Translation
Adjustments
  
Total
 
Balance at November 30, 2014
 
$
14
  
$
206
  
$
(39
)
 
$
(92
)
 
$
(35
)
 
$
54
 
Other comprehensive income (loss) before reclassification adjustments
  
(8
)
  
140
   
2
   
(89
)
  
(358
)
  
(313
)
Amounts reclassified from accumulated OCI
  
-
   
-
   
(1
)
  
230
   
80
   
309
 
Tax benefit (provision)
  
-
   
(50
)
  
(1
)
  
(49
)
  
(18
)
  
(118
)
Net other comprehensive income (loss)
 
$
(8
)
 
$
90
  
$
-
  
$
92
  
$
(296
)
 
$
(122
)
Balance at February 28, 2015
 
$
6
  
$
296
  
$
(39
)
 
$
-
  
$
(331
)
 
$
(68
)
 
  
Pension/Post-
retirement
Obligations
  
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
  
Unrealized
Gain (Loss) on
Cash Flow
Hedges
  
Share of
Alliance
Boots
OCI
  
Cumulative
Translation
Adjustments
  
Total
 
Balance at August 31, 2014
 
$
15
  
$
107
  
$
(27
)
 
$
(113
)
 
$
154
  
$
136
 
Other comprehensive income (loss) before reclassification adjustments
  
(10
)
  
297
   
(18
)
  
(57
)
  
(648
)
  
(436
)
Amounts reclassified from accumulated OCI
  
-
   
-
   
(1
)
  
230
   
80
   
309
 
Tax benefit (provision)
  
1
   
(108
)
  
7
   
(60
)
  
83
   
(77
)
Net other comprehensive income (loss)
 
$
(9
)
 
$
189
  
$
(12
)
 
$
113
  
$
(485
)
 
$
(204
)
Balance at February 28, 2015
 
$
6
  
$
296
  
$
(39
)
 
$
-
  
$
(331
)
 
$
(68
)
XML 59 R42.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Reporting (Tables)
6 Months Ended
Feb. 29, 2016
Segment Reporting [Abstract]  
Reconciliation of Revenue from Segments to Consolidated
The following table reflects results of operations of the Company’s reportable segments (in millions):

  
Retail Pharmacy
          
  
USA
  
International
  
Pharmaceutical
Wholesale
  
Eliminations
and
Unallocated
 Items
  
Consolidated
 
Three Months Ended February 29, 2016
               
Sales to external customers
 
$
21,500
  
$
3,627
  
$
5,057
  
$
-
  
$
30,184
 
Intersegment sales
  
-
   
62
   
570
   
(632
)
  
-
 
Total Sales
  
21,500
   
3,689
   
5,627
   
(632
)
  
30,184
 
                     
Adjusted Operating Income
 
$
1,632
  
$
335
  
$
155
  
$
(2
)
 
$
2,120
 
                     
Three Months Ended February 28, 2015
                    
Sales to external customers
 
$
21,048
  
$
2,017
  
$
3,508
  
$
-
  
$
26,573
 
Intersegment sales
  
-
   
30
   
357
   
(387
)
  
-
 
Total Sales
  
21,048
   
2,047
   
3,865
   
(387
)
  
26,573
 
                     
Adjusted Operating Income
 
$
1,598
  
$
125
  
$
121
  
$
(4
)
 
$
1,840
 

  
Retail Pharmacy
          
  
USA
  
International
  
Pharmaceutical
Wholesale
  
Eliminations
and
Unallocated
 Items
  
Consolidated
 
Six Months Ended February 29, 2016
               
Sales to external customers
 
$
41,870
  
$
7,086
  
$
10,261
  
$
-
  
$
59,217
 
Intersegment sales
  
-
   
134
   
1,162
   
(1,296
)
  
-
 
Total Sales
  
41,870
   
7,220
   
11,423
   
(1,296
)
  
59,217
 
                     
Adjusted Operating Income
 
$
2,875
  
$
650
  
$
321
  
$
(7
)
 
$
3,839
 
                     
Six Months Ended February 28, 2015
                    
Sales to external customers
 
$
40,602
  
$
2,017
  
$
3,508
  
$
-
  
$
46,127
 
Intersegment sales
  
-
   
30
   
357
   
(387
)
  
-
 
Total Sales
  
40,602
   
2,047
   
3,865
   
(387
)
  
46,127
 
                     
Adjusted Operating Income
 
$
2,716
  
$
125
  
$
121
  
$
(4
)
 
$
2,958
 
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The following table reconciles adjusted operating income to operating income (in millions):

  
Retail Pharmacy
          
  
USA
  
International
  
Pharmaceutical
Wholesale
  
Eliminations
and
Unallocated
Items
  
Consolidated
 
Three Months Ended February 29, 2016
               
Adjusted Operating Income
 
$
1, 632
  
$
335
  
$
155
  
$
(2
)
 
$
2,120
 
Acquisition-related amortization
                  
(101
)
Cost transformation
                  
(28
)
LIFO provision
                  
(68
)
Acquisition-related costs
                  
(33
)
Asset impairment
                  
(30
)
Operating Income
                 
$
1,860
 
                     
Three Months Ended February  28, 2015
                    
Adjusted Operating Income
 
$
1,598
  
$
125
  
$
121
  
$
(4
)
 
$
1,840
 
(Decrease) increase in fair market value of warrants
                  
(6
)
Acquisition-related amortization
                  
(217
)
LIFO provision
                  
(55
)
Acquisition-related costs
                  
(59
)
Asset impairment
                  
(110
)
Store closures and other optimization costs
                  
(16
)
Operating Income
                 
$
1,377
 

  
Retail Pharmacy
          
  
USA
  
International
  
Pharmaceutical
Wholesale
  
Eliminations
and
Unallocated
Items
  
Consolidated
 
Six Months Ended February 29, 2016
               
Adjusted Operating Income
 
$
2,875
  
$
650
  
$
321
  
$
(7
)
 
$
3,839
 
Acquisition-related amortization
                  
(182
)
Cost transformation
                  
(118
)
LIFO provision
                  
(114
)
Acquisition-related costs
                  
(67
)
Asset impairment
                  
(30
)
Operating Income
                 
$
3,328
 
                     
Six Months Ended February 28, 2015
                    
Adjusted Operating Income
 
$
2,716
  
$
125
  
$
121
  
$
(4
)
 
$
2,958
 
(Decrease) increase in fair market value of warrants
                  
123
 
Acquisition-related amortization
                  
(306
)
LIFO provision
                  
(107
)
Acquisition-related costs
                  
(83
)
Asset impairment
                  
(110
)
Store closures and other optimization costs
                  
(44
)
Operating Income
                 
$
2,431
 
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization (Details)
£ in Millions
6 Months Ended
Dec. 31, 2014
USD ($)
shares
Dec. 31, 2014
GBP (£)
shares
Feb. 29, 2016
USD ($)
Segment
shares
Aug. 31, 2015
shares
Jan. 01, 2015
shares
Schedule of Equity Method Investments [Line Items]          
Number of reportable segment | Segment     3    
Total purchase price cash consideration $ 4,900,000,000 £ 3,133      
Common shares transfer (in shares)     1,172,513,618 1,172,513,618  
Walgreens Boots Alliance [Member]          
Schedule of Equity Method Investments [Line Items]          
Noncontrolling interest 55.00% 55.00%      
Total purchase price cash consideration | £   £ 3,133      
Number of shares exchanged in acquisition (in shares) 144,300,000 144,300,000      
Walgreens Boots Alliance Development GmbH [Member]          
Schedule of Equity Method Investments [Line Items]          
Noncontrolling interest     27.50%    
Ownership interest percentage prior to Second Step Transaction     50.00%    
Ownership percentage     72.50%    
Alliance Boots [Member]          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage 45.00% 45.00% 45.00%    
Alliance Healthcare Italia Distribuzione S.p.A. [Member]          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage         5.00%
Common shares transfer (in shares)         320
Equity method ownership option to repurchase shares, amount | $     $ 100,000    
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.3.1.900
Restructuring (Details)
$ in Millions
3 Months Ended 6 Months Ended 18 Months Ended
Feb. 29, 2016
USD ($)
Stores
Feb. 28, 2015
USD ($)
Feb. 29, 2016
USD ($)
Stores
Feb. 28, 2015
USD ($)
Feb. 29, 2016
USD ($)
Stores
Restructuring Reserve Disclosures [Abstract]          
Pre-tax charges incurred during the period         $ 660
Total restructuring costs $ 28 $ 0 $ 118 $ 17  
Retail Pharmacy USA [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 25 0 110 17  
Retail Pharmacy International [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 3 0 8 0  
Pharmaceutical Wholesale [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 0 0 0 0  
Real Estate Costs [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 0 0 52 17  
Real Estate Costs [Member] | Retail Pharmacy USA [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 0 0 52 17  
Real Estate Costs [Member] | Retail Pharmacy International [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 0 0 0 0  
Real Estate Costs [Member] | Pharmaceutical Wholesale [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 0 0 0 0  
Asset Impairments [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 0 0 25 0  
Asset Impairments [Member] | Retail Pharmacy USA [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 0 0 25 0  
Asset Impairments [Member] | Retail Pharmacy International [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 0 0 0 0  
Asset Impairments [Member] | Pharmaceutical Wholesale [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 0 0 0 0  
Severance and Other Business Transition and Exit Costs [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 28 0 41 0  
Severance and Other Business Transition and Exit Costs [Member] | Retail Pharmacy USA [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 25 0 33 0  
Severance and Other Business Transition and Exit Costs [Member] | Retail Pharmacy International [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs 3 0 8 0  
Severance and Other Business Transition and Exit Costs [Member] | Pharmaceutical Wholesale [Member]          
Restructuring Reserve Disclosures [Abstract]          
Total restructuring costs $ 0 0 $ 0 0  
Lease Termination Costs [Member]          
Restructuring Reserve Disclosures [Abstract]          
Pre-tax charges incurred during the period   17      
Cost Transformation Program [Member]          
Restructuring Reserve Disclosures [Abstract]          
Number of stores planned to be closed | Stores 200   200   200
Pre-tax charges incurred during the period $ 28 $ 0 $ 118 $ 0  
Cost Transformation Program [Member] | Minimum [Member]          
Restructuring Reserve Disclosures [Abstract]          
Expected pre-tax charges 1,600   1,600   $ 1,600
Cost Transformation Program [Member] | Maximum [Member]          
Restructuring Reserve Disclosures [Abstract]          
Expected pre-tax charges 1,800   1,800   1,800
Cost Transformation Program [Member] | Real Estate Costs [Member]          
Restructuring Reserve Disclosures [Abstract]          
Pre-tax charges incurred during the period         254
Cost Transformation Program [Member] | Real Estate Costs [Member] | Minimum [Member]          
Restructuring Reserve Disclosures [Abstract]          
Expected pre-tax charges 525   525   525
Cost Transformation Program [Member] | Real Estate Costs [Member] | Maximum [Member]          
Restructuring Reserve Disclosures [Abstract]          
Expected pre-tax charges 600   600   600
Cost Transformation Program [Member] | Asset Impairments [Member]          
Restructuring Reserve Disclosures [Abstract]          
Pre-tax charges incurred during the period         248
Cost Transformation Program [Member] | Asset Impairments [Member] | Minimum [Member]          
Restructuring Reserve Disclosures [Abstract]          
Expected pre-tax charges 650   650   650
Cost Transformation Program [Member] | Asset Impairments [Member] | Maximum [Member]          
Restructuring Reserve Disclosures [Abstract]          
Expected pre-tax charges 725   725   725
Cost Transformation Program [Member] | Severance and Other Business Transition and Exit Costs [Member]          
Restructuring Reserve Disclosures [Abstract]          
Pre-tax charges incurred during the period         158
Cost Transformation Program [Member] | Severance and Other Business Transition and Exit Costs [Member] | Minimum [Member]          
Restructuring Reserve Disclosures [Abstract]          
Expected pre-tax charges 425   425   425
Cost Transformation Program [Member] | Severance and Other Business Transition and Exit Costs [Member] | Maximum [Member]          
Restructuring Reserve Disclosures [Abstract]          
Expected pre-tax charges $ 475   $ 475   $ 475
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.3.1.900
Operating Leases (Details)
$ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Feb. 29, 2016
USD ($)
Lease
Feb. 28, 2015
USD ($)
Feb. 29, 2016
USD ($)
Lease
Feb. 28, 2015
USD ($)
Aug. 31, 2015
USD ($)
Operating Leases [Abstract]          
Initial term of operating lease, lower range     15 years    
Initial term of operating lease, upper range     25 years    
Interval period of renewal options     5 years    
Charges related to facilities that were closed or relocated $ 9 $ 0 $ 75 $ 26  
Changes in reserve for facility closings and related lease termination charges [Roll Forward]          
Balance - beginning of period     446 $ 257 $ 257
Provision for present value of non-cancellable lease payments on closed facilities     77   231
Assumptions about future sublease income, terminations and changes in interest rates     (14)   (6)
Interest accretion     12   27
Liability assumed through acquisition of Alliance Boots     0   13
Cash payments, net of sublease income     (54)   (76)
Balance - end of period $ 467   $ 467   $ 446
Number of leases | Lease 79   79    
Maximum potential undiscounted future payments $ 348   $ 348    
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.3.1.900
Equity Method Investments, Equity Method Investments (Details) - USD ($)
$ in Millions
Feb. 29, 2016
Aug. 31, 2015
Schedule of Equity Method Investments [Line Items]    
Carrying Value $ 1,217 $ 1,242
Minimum [Member]    
Schedule of Equity Method Investments [Line Items]    
Equity method investment ownership interest percentage 12.00% 12.00%
Maximum [Member]    
Schedule of Equity Method Investments [Line Items]    
Equity method investment ownership interest percentage 50.00% 50.00%
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.3.1.900
Equity Method Investments (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
Aug. 31, 2015
Dec. 31, 2014
Schedule of Equity Method Investments [Line Items]            
Non-controlling interests $ 170   $ 170   $ 163  
Equity earnings [1] $ 9 $ 109 [2] $ 20 $ 323 [2]    
Alliance Boots [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity earnings   101   315    
Equity method investment ownership interest percentage 45.00%   45.00%     45.00%
Other Equity Method Investments [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity earnings $ 9 $ 8 $ 20 $ 8    
[1] Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates.
[2] Includes equity method investment in Alliance Boots from Walgreen Co.'s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization.
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.3.1.900
Equity Method Investments, Summarized Financial Information of Equity Method Investees (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
[4]
Feb. 29, 2016
Feb. 28, 2015
[4]
Aug. 31, 2015
Balance Sheet [Abstract]          
Current assets [1] $ 5,687   $ 5,687   $ 5,015
Noncurrent assets [1] 1,592   1,592   1,548
Current liabilities [1] 4,598   4,598   3,936
Noncurrent liabilities [1] 876   876   837
Shareholders' equity [1],[2] 1,805   1,805   $ 1,790
Statements of Earnings [Abstract]          
Net sales [3] 3,286 $ 5,317 6,489 $ 14,978  
Gross Profit [3] 374 979 702 3,168  
Net Income [3] 26 246 50 743  
Share of income from equity method investments [3] $ 9 $ 109 $ 20 $ 323  
[1] Balance sheet information of foreign equity method investments are translated at their respective February 29, 2016 and August 31, 2015 spot rates.
[2] Shareholders' equity at February 29, 2016 and August 31, 2015 includes $170 million and $163 million, respectively, related to noncontrolling interests.
[3] Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates.
[4] Includes equity method investment in Alliance Boots from Walgreen Co.'s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization.
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.3.1.900
Available-for-Sale Investments (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
Aug. 31, 2015
Summary of cost and fair value of available-for-sale securities [Abstract]          
Amortized cost basis $ 755   $ 755   $ 754
Gross unrealized gains 276   276   430
Gross unrealized losses (4)   (4)   (1)
Fair value $ 1,027   $ 1,027   1,183
AmerisourceBergen Common Stock [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Maximum number of shares in minority equity position (in shares) 19,859,795   19,859,795    
Percentage of outstanding common stock held 5.60%   5.60%    
Sale of acquired available-for-sale securities $ 1 $ 0 $ 3 $ 0  
Number of shares held (in shares) 11,500,000   11,500,000    
Summary of cost and fair value of available-for-sale securities [Abstract]          
Amortized cost basis $ 717   $ 717   717
Gross unrealized gains 276   276   430
Gross unrealized losses 0   0   0
Fair value 993   993   1,147
Other Investments [Member]          
Summary of cost and fair value of available-for-sale securities [Abstract]          
Amortized cost basis 38   38   37
Gross unrealized gains 0   0   0
Gross unrealized losses (4)   (4)   (1)
Fair value $ 34   $ 34   $ 36
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisitions (Details)
$ / shares in Units, £ in Millions
6 Months Ended
Dec. 31, 2014
USD ($)
shares
Dec. 31, 2014
GBP (£)
shares
Feb. 29, 2016
USD ($)
shares
Aug. 31, 2015
USD ($)
shares
Jan. 15, 2015
Dec. 31, 2014
$ / €
Dec. 30, 2014
$ / shares
Business Acquisition [Line Items]              
Common shares transfer (in shares) | shares     1,172,513,618 1,172,513,618      
Total purchase price $ 15,900,000,000   $ 13,300,000,000        
Noncontrolling interest acquired     $ 412,000,000 $ 439,000,000      
Total purchase price cash consideration $ 4,900,000,000 £ 3,133          
Spot rate 1.56 1.56       1.00  
Purchase price consideration, common shares (in shares) | shares 144,300,000 144,300,000          
Purchase price consideration common shares fair value $ 11,000,000,000            
Closing market price per share (in dollars per share) | $ / shares             $ 76.05
Alliance Boots [Member]              
Business Acquisition [Line Items]              
Business Acquisition, Percentage of issued and outstanding capital acquired 55.00% 55.00%          
Equity method investment ownership interest percentage     45.00%        
Noncontrolling interest 100.00% 100.00%          
Total purchase price     $ 15,851,000,000        
Total purchase price cash consideration     4,874,000,000        
Purchase price consideration common shares fair value     8,149,000,000        
Impact of equity transactions [Abstract]              
Consideration attributable to WBAD     2,559,000,000        
Less: Carrying value of the Company's pre-existing noncontrolling interest     130,000,000        
Impact to additional paid in capital     $ 2,429,000,000        
Alliance Boots [Member] | Previously Reported [Member]              
Business Acquisition [Line Items]              
Equity method investment ownership interest percentage     45.00%        
Walgreens Boots Alliance Development GmbH [Member]              
Business Acquisition [Line Items]              
Ownership interest percentage prior to Second Step Transaction     50.00%        
Noncontrolling interest 100.00% 100.00% 27.50%        
Noncontrolling interest acquired     $ 2,600,000,000        
Alliance Healthcare Italia Distribuzione S.p.A. [Member]              
Business Acquisition [Line Items]              
Equity method investment ownership interest percentage         5.00%    
Common shares transfer (in shares) | shares     320        
Equity method ownership option to repurchase shares, amount     $ 100,000        
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisitions, Consideration Paid (Details)
£ in Millions, $ in Millions
6 Months Ended
Dec. 31, 2014
USD ($)
Dec. 31, 2014
GBP (£)
Feb. 29, 2016
USD ($)
Consideration paid [Abstract]      
Cash $ 4,900 £ 3,133  
Total consideration transferred 15,900   $ 13,300
Fair value of the investment in Alliance Boots held before the Second Step Transaction $ 11,000    
Alliance Boots [Member]      
Consideration paid [Abstract]      
Cash     4,874
Common stock     10,977
Total consideration transferred     15,851
Less: consideration attributed to WBAD     (2,559)
Total consideration after attributed amount to WBAD     13,292
Fair value of the investment in Alliance Boots held before the Second Step Transaction     8,149
Total consideration     $ 21,441
XML 69 R52.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisitions, Identifiable Assets Acquired and Liabilities Assumed Including Noncontrolling Interests (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
Aug. 31, 2015
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]          
Goodwill $ 15,796   $ 15,796   $ 16,372
Gain on previously held equity interest 0 $ 706 0 $ 706  
Alliance Boots [Member]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]          
Cash and cash equivalents 413   413    
Accounts receivable 3,799   3,799    
Inventories 3,713   3,713    
Other current assets 894   894    
Property, plant and equipment 3,806   3,806    
Intangible assets 11,691   11,691    
Other non-current assets 2,217   2,217    
Trade accounts payable, accrued expenses and other liabilities (7,696)   (7,696)    
Borrowings (9,010)   (9,010)    
Deferred income taxes (2,452)   (2,452)    
Other non-current liabilities (383)   (383)    
Noncontrolling interests (412)   (412)    
Total identifiable net assets and noncontrolling interests 6,580   6,580    
Goodwill $ 14,861   14,861    
Gain on previously held equity interest     563    
Fair value of previously held equity interest     $ 8,100    
XML 70 R53.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisitions, The Identified Definite and Indefinite Lived Intangible Assets (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
Aug. 31, 2015
Indefinite-Lived Intangible Assets [Roll Forward]          
Goodwill $ 15,796   $ 15,796   $ 16,372
Selling, general and administrative expenses 6,084 $ 5,606 12,118 $ 10,062  
Fair value of the assets acquired     3,700    
Estimated manufacturing profit in acquired finished goods inventory capitalized 106   106    
Retail Pharmacy International [Member]          
Indefinite-Lived Intangible Assets [Roll Forward]          
Goodwill 3,605   3,605   3,898
Retail Pharmacy USA [Member]          
Indefinite-Lived Intangible Assets [Roll Forward]          
Goodwill 8,940   8,940   8,940
Goodwill arising from synergies     3,500    
Goodwill based on a with and without analysis     3,800    
Pharmaceutical Wholesale [Member]          
Indefinite-Lived Intangible Assets [Roll Forward]          
Goodwill 3,251   3,251   3,534
Alliance Boots [Member]          
Definite-Lived Intangible Assets [Roll Forward]          
Amount     2,545    
Indefinite-Lived Intangible Assets [Roll Forward]          
Amount     9,146    
Goodwill $ 14,861   $ 14,861    
Equity interest in Alliance Boots 45.00%   45.00%    
Selling, general and administrative expenses $ 0 $ 59 $ 0 $ 83 $ 87
Trade Names and Trademarks [Member] | Alliance Boots [Member]          
Indefinite-Lived Intangible Assets [Roll Forward]          
Amount     6,657    
Pharmacy Licenses [Member] | Alliance Boots [Member]          
Indefinite-Lived Intangible Assets [Roll Forward]          
Amount     $ 2,489    
Customer Relationships [Member] | Alliance Boots [Member]          
Definite-Lived Intangible Assets [Roll Forward]          
Weighted-Average Useful Life     12 years    
Amount     $ 1,311    
Loyalty Card Holders [Member] | Alliance Boots [Member]          
Definite-Lived Intangible Assets [Roll Forward]          
Weighted-Average Useful Life     20 years    
Amount     $ 742    
Trade Names and Trademarks [Member] | Alliance Boots [Member]          
Definite-Lived Intangible Assets [Roll Forward]          
Weighted-Average Useful Life     9 years    
Amount     $ 399    
Favorable Lease Interests [Member] | Alliance Boots [Member]          
Definite-Lived Intangible Assets [Roll Forward]          
Weighted-Average Useful Life     7 years    
Amount     $ 93    
XML 71 R54.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisitions, Unaudited Pro Forma Results Prepared for Comparative Purposes (Details) - Alliance Boots [Member] - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 6 Months Ended
Feb. 28, 2015
Feb. 28, 2015
Business Acquisition [Line Items]    
Net sales $ 30,202 $ 59,173
Net earnings $ 1,253 $ 2,621
Net earnings per common share [Abstract]    
Basic (in dollars per share) $ 1.20 $ 2.51
Diluted (in dollars per share) $ 1.19 $ 2.49
XML 72 R55.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisitions, Actual Results from Alliance Boots Operations Included in the Consolidated Condensed Statements of Earnings (Details) - USD ($)
$ in Millions
6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Business Acquisition [Line Items]    
Aggregate purchase price $ 0 $ 4,461
Goodwill 19  
Other Acquisition [Member]    
Business Acquisition [Line Items]    
Aggregate purchase price 86  
Goodwill 19  
Intangible assets $ 72  
XML 73 R56.htm IDEA: XBRL DOCUMENT v3.3.1.900
Goodwill and Other Intangible Assets, Schedule of Goodwill (Details)
$ in Millions
6 Months Ended
Feb. 29, 2016
USD ($)
Goodwill [Roll Forward]  
Net book value - Beginning Period $ 16,372
Acquisitions 19
Other 10 [1]
Currency translation adjustments (605)
Net book value - Ending Period 15,796
Retail Pharmacy USA [Member]  
Goodwill [Roll Forward]  
Net book value - Beginning Period 8,940
Acquisitions 0
Other 0 [1]
Currency translation adjustments 0
Net book value - Ending Period 8,940
Retail Pharmacy International [Member]  
Goodwill [Roll Forward]  
Net book value - Beginning Period 3,898
Acquisitions 19
Other (3) [1]
Currency translation adjustments (309)
Net book value - Ending Period 3,605
Pharmaceutical Wholesale [Member]  
Goodwill [Roll Forward]  
Net book value - Beginning Period 3,534
Acquisitions 0
Other 13 [1]
Currency translation adjustments (296)
Net book value - Ending Period $ 3,251
[1] Other represents immaterial purchase accounting adjustments for prior year Company acquisitions.
XML 74 R57.htm IDEA: XBRL DOCUMENT v3.3.1.900
Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets by Major Class (Details) - USD ($)
$ in Millions
Feb. 29, 2016
Aug. 31, 2015
Finite-Lived Intangible Assets [Line Items]    
Gross Amortizable Intangible Assets $ 4,246 $ 4,387
Accumulated amortization 1,293 1,090
Total amortizable intangible assets, net 2,953 3,297
Total indefinite lived intangible assets 8,169 9,054
Total intangible assets, net 11,122 12,351
Customer Relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Amortizable Intangible Assets 1,293 1,409
Accumulated amortization 182 132
Purchased Prescription Files [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Amortizable Intangible Assets 904 885
Accumulated amortization 536 470
Loyalty Card Holders [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Amortizable Intangible Assets 661 730
Accumulated amortization 41 41
Favorable Lease Interests [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Amortizable Intangible Assets 457 440
Accumulated amortization 246 207
Non-compete Agreements [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Amortizable Intangible Assets 158 154
Accumulated amortization 106 92
Purchasing and Payer Contracts [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Amortizable Intangible Assets 95 94
Accumulated amortization 68 65
Trade Names and Trademarks [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Amortizable Intangible Assets 678 675
Accumulated amortization 114 83
Total indefinite lived intangible assets 5,947 6,590
Pharmacy Licenses [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total indefinite lived intangible assets $ 2,222 $ 2,464
XML 75 R58.htm IDEA: XBRL DOCUMENT v3.3.1.900
Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
Goodwill and Other Intangible Assets [Abstract]        
Amortization expense for intangible assets $ 124 $ 209 $ 216 $ 276
XML 76 R59.htm IDEA: XBRL DOCUMENT v3.3.1.900
Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)
$ in Millions
Feb. 29, 2016
USD ($)
Estimated annual intangible assets amortization expense [Abstract]  
2016 $ 401
2017 358
2018 318
2019 289
2020 $ 254
XML 77 R60.htm IDEA: XBRL DOCUMENT v3.3.1.900
Short-Term Borrowings and Long-Term Debt, Short-Term Borrowings (Details) - USD ($)
$ in Millions
6 Months Ended
Feb. 29, 2016
Aug. 31, 2015
Short-Term Borrowings [Abstract]    
Other $ 1,052 $ 1,068
Unsecured Variable Rate Notes Due 2016 [Member]    
Short-Term Borrowings [Abstract]    
Unsecured Notes [1] $ 749 747
Maturity year [1] 2016  
Other Short-Term Debt [Member]    
Short-Term Borrowings [Abstract]    
Other [1],[2] $ 303 321
Total short-term borrowings [1] $ 1,052 $ 1,068
[1] All notes are presented net of unamortized discount and debt issuance costs, where applicable.
[2] Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts.
XML 78 R61.htm IDEA: XBRL DOCUMENT v3.3.1.900
Short-Term Borrowings and Long-Term Debt, Long-Term Debt (Details)
$ in Millions
6 Months Ended
Feb. 29, 2016
USD ($)
$ / €
$ / £
Aug. 31, 2015
USD ($)
$ / €
$ / £
Long-Term Debt [Abstract]    
Other [1],[2] $ 42 $ 44
Total long term debt [1] 12,974 13,315
Unsecured Pound Sterling Variable Rate Term Loan Due 2019 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1],[3] $ 2,013 2,229
Maturity year [1],[3] 2019  
1.750% Unsecured Notes Due 2017 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1] $ 747 746
Interest rate [1] 1.75%  
Maturity year [1] 2017  
5.250% Unsecured Notes Due 2019 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1],[4] $ 253 250
Interest rate [1],[4] 5.25%  
Maturity year [1],[4] 2019  
2.700% Unsecured Notes Due 2019 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1] $ 1,244 1,243
Interest rate [1] 2.70%  
Maturity year [1] 2019  
2.875% Unsecured Pound Sterling Notes Due 2020 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1],[3] $ 552 $ 612
Interest rate [1],[3] 2.875%  
Maturity year [1],[3] 2020  
Spot rate | $ / £ 1.39 1.54
3.300% Unsecured Notes Due 2021 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1] $ 1,241 $ 1,241
Interest rate [1] 3.30%  
Maturity year [1] 2021  
3.100% Unsecured Notes Due 2022 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1] $ 1,193 1,193
Interest rate [1] 3.10%  
Maturity year [1] 2022  
3.800% Unsecured Notes Due 2024 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1] $ 1,986 1,985
Interest rate [1] 3.80%  
Maturity year [1] 2024  
3.600% Unsecured Pound Sterling Notes Due 2025 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1],[3] $ 414 $ 459
Interest rate [1],[3] 3.60%  
Maturity year [1],[3] 2025  
Spot rate | $ / £ 1.39 1.54
2.125% Unsecured Euro Notes Due 2026 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1],[5] $ 811 $ 836
Interest rate [1],[5] 2.125%  
Maturity year [1],[5] 2026  
Spot rate | $ / € 1.09 1.12
4.500% Unsecured Notes Due 2034 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1] $ 494 $ 494
Interest rate [1] 4.50%  
Maturity year [1] 2034  
4.400% Unsecured Notes Due 2042 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1] $ 492 492
Interest rate [1] 4.40%  
Maturity year [1] 2042  
4.800% Unsecured Notes Due 2044 [Member]    
Long-Term Debt [Abstract]    
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment [1] $ 1,492 $ 1,491
Interest rate [1] 4.80%  
Maturity year [1] 2044  
Unsecured Debt [Member] | 1.750% Unsecured Notes Due 2017 [Member]    
Long-Term Debt [Abstract]    
Interest rate 1.75%  
Unsecured Debt [Member] | 3.300% Unsecured Notes Due 2021 [Member]    
Long-Term Debt [Abstract]    
Interest rate 3.30%  
Unsecured Debt [Member] | 3.100% Unsecured Notes Due 2022 [Member]    
Long-Term Debt [Abstract]    
Interest rate 3.10%  
Unsecured Debt [Member] | 3.800% Unsecured Notes Due 2024 [Member]    
Long-Term Debt [Abstract]    
Interest rate 3.80%  
Unsecured Debt [Member] | 4.500% Unsecured Notes Due 2034 [Member]    
Long-Term Debt [Abstract]    
Interest rate 4.50%  
Unsecured Debt [Member] | 4.400% Unsecured Notes Due 2042 [Member]    
Long-Term Debt [Abstract]    
Interest rate 4.40%  
Unsecured Debt [Member] | 4.800% Unsecured Notes Due 2044 [Member]    
Long-Term Debt [Abstract]    
Interest rate 4.80%  
[1] All notes are presented net of unamortized discount and debt issuance costs, where applicable.
[2] Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
[3] Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively.
[4] Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures.
[5] Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively.
XML 79 R62.htm IDEA: XBRL DOCUMENT v3.3.1.900
Short-Term Borrowings and Long-Term Debt (Details)
£ in Millions, $ in Millions
6 Months Ended
Feb. 29, 2016
USD ($)
Feb. 29, 2016
GBP (£)
Aug. 10, 2015
Long-Term Debt [Abstract]      
Percentage of principal amount of fixed rate notes can be redeemed 100.00%    
Total $8.0 Billion Debt Issuance [Member]      
Long-Term Debt [Abstract]      
Net proceeds from notes payable $ 7,900    
Total issuance costs 44    
Fair value of the notes $ 7,900    
Percentage of principal amount of fixed rate notes can be redeemed 100.00%    
Percentage of principal amount required on triggering event to repurchase notes 101.00% 101.00%  
Total $4.0 Billion Debt Issuance [Member]      
Long-Term Debt [Abstract]      
Repayment of debt $ 1,000    
Net proceeds from notes payable 4,000    
Total issuance costs 26    
Fair value of the notes $ 1,600    
Percentage of principal amount of fixed rate notes can be redeemed 100.00%    
Percentage of redemption price 100.00%    
Percentage of principal amount required on triggering event to repurchase notes 101.00% 101.00%  
Percentage of redemption price including accrued interest 101.677%    
Debt instrument redemption premium $ 17    
Total $1.0 Billion Debt Issuance [Member]      
Long-Term Debt [Abstract]      
Repayment of debt 750    
Net proceeds from notes payable 1,000    
Total issuance costs 8    
Fair value of the notes $ 270    
Stated interest rate 5.25% 5.25%  
Percentage of principal amount of fixed rate notes can be redeemed 100.00%    
Percentage of principal amount required on triggering event to repurchase notes 101.00% 101.00%  
Percentage of redemption price including accrued interest 111.734%    
Debt instrument redemption premium $ 88    
Face amount of notes issued $ 250    
Total $1.0 Billion Debt Issuance [Member] | Treasury Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.45%    
Euro and Pound Sterling Notes [Member]      
Long-Term Debt [Abstract]      
Total issuance costs $ 11    
Fair value of the notes $ 1,800    
Percentage of redemption price 100.00%    
Percentage of principal amount required on triggering event to repurchase notes 101.00% 101.00%  
Euro Notes [Member] | Treasury Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.20%    
1.750% Unsecured Notes Due 2017 [Member] | Treasury Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.15%    
2.700% Unsecured Notes Due 2019 [Member] | Treasury Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.15%    
3.300% Unsecured Notes Due 2021 [Member] | Treasury Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.20%    
3.800% Unsecured Notes Due 2024 [Member] | Treasury Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.20%    
4.500% Unsecured Notes Due 2034 [Member] | Treasury Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.20%    
4.800% Unsecured Notes Due 2044 [Member] | Treasury Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.25%    
Notes Due 2014 [Member]      
Long-Term Debt [Abstract]      
Repayment of debt $ 550    
1.000% Unsecured Notes Due 2015 [Member]      
Long-Term Debt [Abstract]      
Repayment of debt $ 750    
1.000% Unsecured Notes Due 2015 [Member] | Treasury Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.12%    
1.800% Unsecured Notes Due 2017 [Member]      
Long-Term Debt [Abstract]      
Stated interest rate     1.80%
3.100% Unsecured Notes Due 2022 [Member] | Treasury Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.22%    
4.400% Unsecured Notes Due 2042 [Member] | Treasury Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.25%    
Unsecured Pound Sterling Notes Due 2020 [Member] | Government Bond Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.20%    
Unsecured Pound Sterling Notes Due 2025 [Member] | Government Bond Rate [Member]      
Long-Term Debt [Abstract]      
Basis spread on variable rate 0.20%    
Unsecured Debt [Member] | Total $8.0 Billion Debt Issuance [Member]      
Long-Term Debt [Abstract]      
Face amount of notes issued $ 8,000    
Unsecured Debt [Member] | Total $4.0 Billion Debt Issuance [Member]      
Long-Term Debt [Abstract]      
Face amount of notes issued $ 1,700    
Unsecured Debt [Member] | Unsecured Pound Sterling Notes Due 2020 [Member]      
Long-Term Debt [Abstract]      
Stated interest rate 2.875% 2.875%  
Face amount of notes issued | £   £ 400  
Unsecured Debt [Member] | Unsecured Pound Sterling Notes Due 2025 [Member]      
Long-Term Debt [Abstract]      
Stated interest rate 3.60% 3.60%  
Face amount of notes issued | £   £ 300  
XML 80 R63.htm IDEA: XBRL DOCUMENT v3.3.1.900
Short-Term Borrowings and Long-Term Debt, Debt Issuance (Details)
€ in Millions, £ in Millions, $ in Millions
6 Months Ended
Feb. 29, 2016
USD ($)
Feb. 29, 2016
GBP (£)
Feb. 29, 2016
EUR (€)
1.750% Unsecured Notes Due 2017 [Member]      
Debt Instrument [Line Items]      
Interest rate 1.75% [1] 1.75% [1] 1.75% [1]
2.875% Unsecured Pound Sterling Notes Due 2020 [Member]      
Debt Instrument [Line Items]      
Maturity date Nov. 20, 2020    
3.300% Unsecured Notes Due 2021 [Member]      
Debt Instrument [Line Items]      
Interest rate 3.30% [1] 3.30% [1] 3.30% [1]
3.100% Unsecured Notes Due 2022 [Member]      
Debt Instrument [Line Items]      
Interest rate 3.10% [1] 3.10% [1] 3.10% [1]
3.800% Unsecured Notes Due 2024 [Member]      
Debt Instrument [Line Items]      
Interest rate 3.80% [1] 3.80% [1] 3.80% [1]
2.125% Unsecured Euro Notes Due 2026 [Member]      
Debt Instrument [Line Items]      
Maturity date Nov. 20, 2026    
4.500% Unsecured Notes Due 2034 [Member]      
Debt Instrument [Line Items]      
Interest rate 4.50% [1] 4.50% [1] 4.50% [1]
4.400% Unsecured Notes Due 2042 [Member]      
Debt Instrument [Line Items]      
Interest rate 4.40% [1] 4.40% [1] 4.40% [1]
4.800% Unsecured Notes Due 2044 [Member]      
Debt Instrument [Line Items]      
Interest rate 4.80% [1] 4.80% [1] 4.80% [1]
Unsecured Debt [Member] | Unsecured Variable Rate Notes Due 2016 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued $ 750    
Maturity date May 18, 2016    
Interest payment dates February 18, May 18, August 18, and November 18; commencing on February 18, 2015    
Debt instrument, description of variable rate basis Three-month U.S. Dollar LIBOR    
Basis spread on variable rate 0.45%    
Unsecured Debt [Member] | 1.750% Unsecured Notes Due 2017 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued $ 750    
Maturity date Nov. 17, 2017    
Interest payment dates May 17 and November 17; commencing on May 17, 2015    
Interest rate 1.75% 1.75% 1.75%
Unsecured Debt [Member] | 2.700% Unsecured Notes Due 2019 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued $ 1,250    
Maturity date Nov. 18, 2019    
Interest payment dates May 18 and November 18; commencing on May 18, 2015    
Interest rate 2.70% 2.70% 2.70%
Unsecured Debt [Member] | 2.875% Unsecured Pound Sterling Notes Due 2020 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued | £   £ 400  
Interest rate 2.875% 2.875% 2.875%
Unsecured Debt [Member] | 3.300% Unsecured Notes Due 2021 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued $ 1,250    
Maturity date Nov. 18, 2021    
Interest payment dates May 18 and November 18; commencing on May 18, 2015    
Interest rate 3.30% 3.30% 3.30%
Unsecured Debt [Member] | 3.100% Unsecured Notes Due 2022 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued $ 1,200    
Maturity date Sep. 15, 2022    
Interest payment dates March 15 and September 15; commencing on March 15, 2013    
Interest rate 3.10% 3.10% 3.10%
Unsecured Debt [Member] | 3.800% Unsecured Notes Due 2024 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued $ 2,000    
Maturity date Nov. 18, 2024    
Interest payment dates May 18 and November 18; commencing on May 18, 2015    
Interest rate 3.80% 3.80% 3.80%
Unsecured Debt [Member] | 3.600% Unsecured Pound Sterling Notes Due 2025 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued | £   £ 300  
Maturity date Nov. 20, 2025    
Interest rate 3.60% 3.60% 3.60%
Unsecured Debt [Member] | 2.125% Unsecured Euro Notes Due 2026 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued | €     € 750
Interest rate 2.125% 2.125% 2.125%
Unsecured Debt [Member] | 4.500% Unsecured Notes Due 2034 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued $ 500    
Maturity date Nov. 18, 2034    
Interest payment dates May 18 and November 18; commencing on May 18, 2015    
Interest rate 4.50% 4.50% 4.50%
Unsecured Debt [Member] | 4.400% Unsecured Notes Due 2042 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued $ 500    
Maturity date Sep. 15, 2042    
Interest payment dates March 15 and September 15; commencing on March 15, 2013    
Interest rate 4.40% 4.40% 4.40%
Unsecured Debt [Member] | 4.800% Unsecured Notes Due 2044 [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued $ 1,500    
Maturity date Nov. 18, 2044    
Interest payment dates May 18 and November 18; commencing on May 18, 2015    
Interest rate 4.80% 4.80% 4.80%
Unsecured Debt [Member] | Pound Sterling Notes [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued | £   £ 700  
Unsecured Debt [Member] | Total $4.0 Billion Debt Issuance [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued $ 1,700    
Unsecured Debt [Member] | Total $8.0 Billion Debt Issuance [Member]      
Debt Instrument [Line Items]      
Face amount of notes issued $ 8,000    
[1] All notes are presented net of unamortized discount and debt issuance costs, where applicable.
XML 81 R64.htm IDEA: XBRL DOCUMENT v3.3.1.900
Short-Term Borrowings and Long-Term Debt, Other Borrowings (Details)
£ in Millions, $ in Millions
6 Months Ended
Feb. 29, 2016
USD ($)
Tranche
Feb. 28, 2015
USD ($)
Feb. 29, 2016
GBP (£)
Dec. 18, 2015
USD ($)
Oct. 27, 2015
USD ($)
Dec. 31, 2014
Dec. 31, 2014
$ / €
Dec. 29, 2014
USD ($)
Nov. 10, 2014
USD ($)
Line of Credit Facility [Line Items]                  
Spot rate           1.56 1.00    
Senior unsecured bridge facility       $ 7,800.0 $ 12,800.0        
Additional senior unsecured bridge facility       2,000.0          
United Kingdom, Pounds                  
Line of Credit Facility [Line Items]                  
Spot rate 1.39   1.39            
Commercial Paper [Member]                  
Line of Credit Facility [Line Items]                  
Balance outstanding at fiscal year-end $ 0.0 $ 0.0              
Average daily short-term borrowings $ 20.0 $ 4.0              
Weighted-average interest rate 0.62% 0.46% 0.62%            
Additional Bridge Loan [Member]                  
Line of Credit Facility [Line Items]                  
Fees related to borrowings $ 5.0                
Senior unsecured bridge facility       $ 3,000.0          
Term of credit agreement 90 days                
Bridge Credit Agreement [Member]                  
Line of Credit Facility [Line Items]                  
Amount borrowed $ 0.0                
Term of credit agreement 364 days                
Term Loan [Member]                  
Line of Credit Facility [Line Items]                  
Maximum borrowing capacity $ 2,000.0   £ 1,450            
Amount borrowed 2,000.0   £ 1,450            
Fair value of the notes $ 2,000.0                
Term Loan [Member] | Maximum [Member]                  
Line of Credit Facility [Line Items]                  
Debt to total capitalization ratio 0.60   0.60            
Revolving Credit Facility [Member]                  
Line of Credit Facility [Line Items]                  
Maximum borrowing capacity               $ 3.0 $ 2,250.0
Amount borrowed $ 0.0                
Term of facility 5 years                
Revolving Credit Facility [Member] | Maximum [Member]                  
Line of Credit Facility [Line Items]                  
Debt to total capitalization ratio 0.60   0.60            
Letter of Credit [Member]                  
Line of Credit Facility [Line Items]                  
Maximum borrowing capacity               $ 500.0 $ 375.0
Term Loan and Revolving Credit Agreement [Member]                  
Line of Credit Facility [Line Items]                  
Fees related to borrowings $ 14.0                
364-Day Credit Agreement [Member]                  
Line of Credit Facility [Line Items]                  
Amount borrowed $ 750.0                
Termination of credit agreement Dec. 17, 2015                
364-Day Credit Agreement [Member] | Maximum [Member]                  
Line of Credit Facility [Line Items]                  
Debt to total capitalization ratio 0.60   0.60            
Term Loan Credit Agreement [Member]                  
Line of Credit Facility [Line Items]                  
Amount borrowed $ 0.0                
Number of tranches | Tranche 2                
Term loan amount $ 5,000.0                
2015 Credit Agreements [Member]                  
Line of Credit Facility [Line Items]                  
Fees related to borrowings $ 30.0                
2015 Credit Agreements [Member] | Maximum [Member]                  
Line of Credit Facility [Line Items]                  
Debt to total capitalization ratio 0.60   0.60            
Tranche One [Member]                  
Line of Credit Facility [Line Items]                  
Term of credit agreement 3 years                
Tranche Two [Member]                  
Line of Credit Facility [Line Items]                  
Term of credit agreement 5 years                
XML 82 R65.htm IDEA: XBRL DOCUMENT v3.3.1.900
Financial Instruments (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
Aug. 31, 2015
Aug. 10, 2015
Effect of Fair Value Hedges on Results of Operations [Abstract]            
Cumulative fair value adjustments resulted in increase in long-term debt $ 4 $ 1 $ 4 $ 1    
Interest Rate Swaps [Member] | One-month LIBOR [Member]            
Derivatives, Fair Value [Line Items]            
Derivatives assets, Fair Value $ 250   $ 250      
Fixed interest rate percentage 5.25%   5.25%      
Interest Rate Swaps [Member] | Six-month LIBOR [Member]            
Derivatives, Fair Value [Line Items]            
Derivatives assets, Fair Value $ 750   $ 750      
Fixed interest rate percentage 5.25%   5.25%      
Cash Flow Hedges [Abstract]            
Derivative notional amount terminated           $ 500
Interest Rate Swaps [Member] | Designated as Hedging Instrument [Member] | Interest Expense, Net [Member]            
Effect of Fair Value Hedges on Results of Operations [Abstract]            
Gains and losses due to changes in fair value of derivative instruments $ (2) 4 $ (3) (6)    
Warrants [Abstract]            
Gains and losses due to changes in fair value of derivative instruments (2) 4 (3) (6)    
Interest Rate Swaps [Member] | Not Designated as Hedging Instrument [Member] | Interest Expense, Net [Member]            
Effect of Fair Value Hedges on Results of Operations [Abstract]            
Gains and losses due to changes in fair value of derivative instruments 0 (1) 0 (1)    
Warrants [Abstract]            
Gains and losses due to changes in fair value of derivative instruments 0 (1) 0 (1)    
Notes [Member] | Designated as Hedging Instrument [Member] | Interest Expense, Net [Member]            
Effect of Fair Value Hedges on Results of Operations [Abstract]            
Gains and losses due to changes in fair value of derivative instruments 2 (4) 3 6    
Warrants [Abstract]            
Gains and losses due to changes in fair value of derivative instruments 2 (4) 3 6    
Warrants [Member] | Other Income (Expense) [Member]            
Effect of Fair Value Hedges on Results of Operations [Abstract]            
Gains and losses due to changes in fair value of derivative instruments (532) 559 (594) 849    
Warrants [Abstract]            
Gains and losses due to changes in fair value of derivative instruments (532) 559 (594) 849    
Foreign Currency Forwards [Member] | Not Designated as Hedging Instrument [Member] | Selling, General and Administrative Expenses [Member]            
Effect of Fair Value Hedges on Results of Operations [Abstract]            
Gains and losses due to changes in fair value of derivative instruments (23) (28) (25) (28)    
Warrants [Abstract]            
Gains and losses due to changes in fair value of derivative instruments (23) (28) (25) (28)    
Foreign Currency Forwards [Member] | Not Designated as Hedging Instrument [Member] | Other Income (Expense) [Member]            
Effect of Fair Value Hedges on Results of Operations [Abstract]            
Gains and losses due to changes in fair value of derivative instruments 33 0 33 0    
Warrants [Abstract]            
Gains and losses due to changes in fair value of derivative instruments 33 0 33 0    
Second Step Transaction Foreign Currency Forwards [Member] | Not Designated as Hedging Instrument [Member] | Other Income (Expense) [Member]            
Effect of Fair Value Hedges on Results of Operations [Abstract]            
Gains and losses due to changes in fair value of derivative instruments 0 (70) 0 (166)    
Warrants [Abstract]            
Gains and losses due to changes in fair value of derivative instruments $ 0 $ (70) $ 0 $ (166)    
Warrants Exercisable in March 2016 [Member] | AmerisourceBergen Corporation [Member]            
Class of Warrant or Right [Line Items]            
Warrant exercise price (in dollars per share) $ 51.50   $ 51.50      
Warrants Exercisable in March 2016 [Member] | AmerisourceBergen Corporation [Member] | Maximum [Member]            
Class of Warrant or Right [Line Items]            
Warrant issued to purchase common stock (in shares) 22,696,912   22,696,912      
Warrants Exercisable in March 2017 [Member] | AmerisourceBergen Corporation [Member]            
Class of Warrant or Right [Line Items]            
Warrant exercise price (in dollars per share) $ 52.50   $ 52.50      
Warrants Exercisable in March 2017 [Member] | AmerisourceBergen Corporation [Member] | Maximum [Member]            
Class of Warrant or Right [Line Items]            
Warrant issued to purchase common stock (in shares) 22,696,912   22,696,912      
Other Current Assets [Member] | Basis Swaps [Member] | Not Designated as Hedging Instrument [Member]            
Derivatives, Fair Value [Line Items]            
Derivatives assets, Notional Amount [1]         $ 1  
Derivatives assets, Fair Value         0  
Other Current Assets [Member] | Foreign Currency Forwards [Member] | Not Designated as Hedging Instrument [Member]            
Derivatives, Fair Value [Line Items]            
Derivatives assets, Notional Amount [1] $ 465   $ 465   1,205  
Derivatives assets, Fair Value 1   1   34  
Other Non-currents Assets [Member] | Interest Rate Swaps [Member] | Designated as Hedging Instrument [Member]            
Derivatives, Fair Value [Line Items]            
Derivatives assets, Notional Amount [1] 250   250   250  
Derivatives assets, Fair Value 5   5   2  
Other Non-currents Assets [Member] | Warrants [Member] | Not Designated as Hedging Instrument [Member]            
Warrants [Abstract]            
Derivative asset 1,546   1,546   2,140  
Other Current Liabilities [Member] | Basis Swaps [Member] | Not Designated as Hedging Instrument [Member]            
Derivatives, Fair Value [Line Items]            
Derivatives assets, Notional Amount [1] 2   2      
Derivatives assets, Fair Value 1   1      
Other Current Liabilities [Member] | Foreign Currency Forwards [Member] | Not Designated as Hedging Instrument [Member]            
Derivatives, Fair Value [Line Items]            
Derivatives assets, Notional Amount [1] 768   768   495  
Derivatives assets, Fair Value $ 16   $ 16   $ 9  
[1] Amounts are presented in U.S. dollar equivalents.
XML 83 R66.htm IDEA: XBRL DOCUMENT v3.3.1.900
Fair Value Measurements (Details) - Recurring [Member] - USD ($)
$ in Millions
Feb. 29, 2016
Aug. 31, 2015
Restricted Cash [Member]    
Assets [Abstract]    
Fair value of assets [1] $ 175 $ 184
Money Market Funds [Member]    
Assets [Abstract]    
Fair value of assets [2] 2,659 2,043
Available-for-sale Investments [Member]    
Assets [Abstract]    
Fair value of assets [3] 1,027 1,183
Interest Rate Swaps [Member]    
Assets [Abstract]    
Fair value of assets [4] 5 2
Foreign Currency Forwards [Member]    
Assets [Abstract]    
Fair value of assets [5] 1 34
Liabilities [Abstract]    
Fair value of liabilities [5] 16 9
Warrants [Member]    
Assets [Abstract]    
Fair value of assets [6] 1,546 2,140
Basis Swaps [Member]    
Liabilities [Abstract]    
Fair value of liabilities [5] 1  
Level 1 [Member] | Restricted Cash [Member]    
Assets [Abstract]    
Fair value of assets [1] 175 184
Level 1 [Member] | Money Market Funds [Member]    
Assets [Abstract]    
Fair value of assets [2] 2,659 2,043
Level 1 [Member] | Available-for-sale Investments [Member]    
Assets [Abstract]    
Fair value of assets [3] 1,027 1,183
Level 1 [Member] | Interest Rate Swaps [Member]    
Assets [Abstract]    
Fair value of assets [4] 0 0
Level 1 [Member] | Foreign Currency Forwards [Member]    
Assets [Abstract]    
Fair value of assets [5] 0 0
Liabilities [Abstract]    
Fair value of liabilities [5] 0 0
Level 1 [Member] | Warrants [Member]    
Assets [Abstract]    
Fair value of assets [6] 0 0
Level 1 [Member] | Basis Swaps [Member]    
Liabilities [Abstract]    
Fair value of liabilities [5] 0  
Level 2 [Member] | Restricted Cash [Member]    
Assets [Abstract]    
Fair value of assets [1] 0 0
Level 2 [Member] | Money Market Funds [Member]    
Assets [Abstract]    
Fair value of assets [2] 0 0
Level 2 [Member] | Available-for-sale Investments [Member]    
Assets [Abstract]    
Fair value of assets [3] 0 0
Level 2 [Member] | Interest Rate Swaps [Member]    
Assets [Abstract]    
Fair value of assets [4] 5 2
Level 2 [Member] | Foreign Currency Forwards [Member]    
Assets [Abstract]    
Fair value of assets [5] 1 34
Liabilities [Abstract]    
Fair value of liabilities [5] 16 9
Level 2 [Member] | Warrants [Member]    
Assets [Abstract]    
Fair value of assets [6] 1,546 2,140
Level 2 [Member] | Basis Swaps [Member]    
Liabilities [Abstract]    
Fair value of liabilities [5] 1  
Level 3 [Member] | Restricted Cash [Member]    
Assets [Abstract]    
Fair value of assets [1] 0 0
Level 3 [Member] | Money Market Funds [Member]    
Assets [Abstract]    
Fair value of assets [2] 0 0
Level 3 [Member] | Available-for-sale Investments [Member]    
Assets [Abstract]    
Fair value of assets [3] 0 0
Level 3 [Member] | Interest Rate Swaps [Member]    
Assets [Abstract]    
Fair value of assets [4] 0 0
Level 3 [Member] | Foreign Currency Forwards [Member]    
Assets [Abstract]    
Fair value of assets [5] 0 0
Liabilities [Abstract]    
Fair value of liabilities [5] 0 0
Level 3 [Member] | Warrants [Member]    
Assets [Abstract]    
Fair value of assets [6] 0 $ 0
Level 3 [Member] | Basis Swaps [Member]    
Liabilities [Abstract]    
Fair value of liabilities [5] $ 0  
[1] Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.
[2] Money market funds are valued at the closing price reported by the fund sponsor.
[3] Fair values of quoted investments are based on current bid prices as of the balance sheet dates. See Note 6, Available-for-Sale Investments for additional information.
[4] The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information.
[5] The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
[6] Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen's common stock; AmerisourceBergen's common stock price at the valuation date; AmerisourceBergen's equity volatility; the number of shares of AmerisourceBergen's common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the warrants.price at the valuation date; AmerisourceBergen's equity volatility; the number of shares of AmerisourceBergen's common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the warrants.
XML 84 R67.htm IDEA: XBRL DOCUMENT v3.3.1.900
Commitments and Contingencies (Details)
Feb. 29, 2016
Lawsuit
Loss Contingencies [Line Items]  
Number of lawsuits filed 10
Court of Chancery of the State of Delaware [Member]  
Loss Contingencies [Line Items]  
Number of lawsuits filed 8
State of Pennsylvania in the Court of Common Pleas of Cumberland County [Member]  
Loss Contingencies [Line Items]  
Number of lawsuits filed 1
Middle District of Pennsylvania [Member]  
Loss Contingencies [Line Items]  
Number of lawsuits filed 1
XML 85 R68.htm IDEA: XBRL DOCUMENT v3.3.1.900
Retirement Benefits (Details)
$ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
USD ($)
Feb. 28, 2015
USD ($)
Feb. 29, 2016
USD ($)
PensionPlan
Feb. 28, 2015
USD ($)
Defined Benefit Plan Disclosure [Line Items]        
Number of defined benefit pension plans | PensionPlan     2  
Employer cash contributions to defined benefit pension plans     $ 9  
Employee expected additional contribution in current fiscal year     66  
Walgreen Profit Sharing Retirement Trust [Member]        
Defined Contribution Plan Disclosure [Line Items]        
Profit sharing provision expense $ 53 $ 21 111 $ 54
Alliance Boots Retirement Savings Plan [Member]        
Defined Contribution Plan Disclosure [Line Items]        
Cost recognized in the consolidated condensed statements of earnings 34 22 69 22
Boots and Other Pension Plans [Member]        
Components of net periodic benefit costs [Abstract]        
Service costs 0 1 2 1
Interest costs 77 53 159 53
Expected returns on plan assets (62) (43) (127) (43)
Settlements 0 1 0 1
Total net periodic pension costs 15 12 34 12
Postretirement Health Benefit Plan[Member]        
Components of net periodic benefit costs [Abstract]        
Service costs 2 2 5 5
Interest costs 5 4 10 8
Amortization of actuarial loss 5 5 9 10
Amortization of prior service cost (7) (6) (14) (12)
Total net periodic pension costs $ 5 $ 5 $ 10 $ 11
XML 86 R69.htm IDEA: XBRL DOCUMENT v3.3.1.900
Earnings Per Share (Details) - shares
shares in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
Earnings Per Share [Abstract]        
Antidilutive securities excluded from EPS calculations (in shares) 3.2 3.4 2.2 5.0
XML 87 R70.htm IDEA: XBRL DOCUMENT v3.3.1.900
Depreciation and Amortization (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
Depreciation and Amortization [Abstract]        
Depreciation expense $ 346 $ 311 $ 644 $ 567
Intangible asset and other amortization 96 196 180 259
Total depreciation and amortization expense $ 442 $ 507 $ 824 $ 826
XML 88 R71.htm IDEA: XBRL DOCUMENT v3.3.1.900
Supplemental Cash Flow Disclosures (Details) - USD ($)
$ in Millions
6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Supplemental Cash Flow Disclosures [Abstract]    
Cash paid for interest $ 302 $ 90
Cash paid for income taxes $ 481 $ 553
XML 89 R72.htm IDEA: XBRL DOCUMENT v3.3.1.900
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
Feb. 28, 2015
Feb. 29, 2016
Feb. 28, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning Balance $ (658) $ 54 $ (214) $ 136
Other comprehensive income (loss) before reclassification adjustments (1,264) (313) (1,715) (436)
Amounts reclassified from accumulated OCI 2 309 3 309
Tax benefit (provision) 52 (118) 58 (77)
Net other comprehensive income (loss) (1,210) (122) (1,654) (204)
Ending Balance (1,868) (68) (1,868) (68)
Pension/Post-retirement Obligations [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning Balance 32 14 29 15
Other comprehensive income (loss) before reclassification adjustments (4) (8) (1) (10)
Amounts reclassified from accumulated OCI 0 0 0 0
Tax benefit (provision) 2 0 2 1
Net other comprehensive income (loss) (2) (8) 1 (9)
Ending Balance 30 6 30 6
Unrecognized Gain (Loss) on Available-for-Sale Investments [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning Balance 260 206 259 107
Other comprehensive income (loss) before reclassification adjustments (139) 140 (144) 297
Amounts reclassified from accumulated OCI 0 0 0 0
Tax benefit (provision) 51 (50) 57 (108)
Net other comprehensive income (loss) (88) 90 (87) 189
Ending Balance 172 296 172 296
Unrealized Gain (Loss) on Cash Flow Hedges [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning Balance (39) (39) (40) (27)
Other comprehensive income (loss) before reclassification adjustments 0 2 0 (18)
Amounts reclassified from accumulated OCI 2 (1) 3 (1)
Tax benefit (provision) (1) (1) (1) 7
Net other comprehensive income (loss) 1 0 2 (12)
Ending Balance (38) (39) (38) (39)
Share of Alliance Boots OCI [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning Balance   (92)   (113)
Other comprehensive income (loss) before reclassification adjustments   (89)   (57)
Amounts reclassified from accumulated OCI   230   230
Tax benefit (provision)   (49)   (60)
Net other comprehensive income (loss)   92   113
Ending Balance   0   0
Cumulative Currency Translation Adjustments [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning Balance (911) (35) (462) 154
Other comprehensive income (loss) before reclassification adjustments (1,121) (358) (1,570) (648)
Amounts reclassified from accumulated OCI 0 80 0 80
Tax benefit (provision) 0 (18) 0 83
Net other comprehensive income (loss) (1,121) (296) (1,570) (485)
Ending Balance $ (2,032) $ (331) $ (2,032) $ (331)
XML 90 R73.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Reporting (Details)
$ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2016
USD ($)
Feb. 28, 2015
USD ($)
Feb. 29, 2016
USD ($)
Segment
Feb. 28, 2015
USD ($)
Dec. 31, 2014
Segment Reporting [Abstract]          
Number of reportable segments | Segment     3    
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales $ 30,184 $ 26,573 $ 59,217 $ 46,127  
Adjusted Operating Income 2,120 1,840 3,839 2,958  
Acquisition-related amortization (101) (217) (182) (306)  
Cost transformation (28)   (118)    
LIFO provision (68) (55) (114) (107)  
Store closures and other optimization costs   (16)   (44)  
Acquisition-related costs (33) (59) (67) (83)  
(Decrease) increase in fair market value of warrants   (6)   123  
Asset impairment (30) (110) (30) (110)  
Operating Income $ 1,860 1,377 $ 3,328 2,431  
Alliance Boots [Member]          
Segment Reporting Information [Line Items]          
Equity interest in Alliance Boots 45.00%   45.00%   45.00%
Walgreens Boots Alliance [Member]          
Segment Reporting Information [Line Items]          
Ownership percentage of WBA         55.00%
Retail Pharmacy USA [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales $ 21,500 21,048 $ 41,870 40,602  
Adjusted Operating Income 1,632 1,598 2,875 2,716  
Acquisition-related amortization 0        
Retail Pharmacy International [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales 3,689 2,047 7,220 2,047  
Adjusted Operating Income 335 125 650 125  
Acquisition-related amortization 0        
Pharmaceutical Wholesale [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales 5,627 3,865 11,423 3,865  
Adjusted Operating Income 155 121 321 121  
Acquisition-related amortization 0        
Eliminations and Unallocated Items [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales (632) (387) 1,296 (387)  
Adjusted Operating Income (2) (4) (7) (4)  
Acquisition-related amortization 0        
Reportable Segments [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales 30,184 26,573 59,217 46,127  
Adjusted Operating Income 2,120 1,840 3,839 2,958  
Reportable Segments [Member] | Retail Pharmacy USA [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales 21,500 21,048 41,870 40,602  
Adjusted Operating Income 1,632 1,598 2,875 2,716  
Reportable Segments [Member] | Retail Pharmacy International [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales 3,627 2,017 7,084 2,017  
Adjusted Operating Income 335 125 650 125  
Reportable Segments [Member] | Pharmaceutical Wholesale [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales 5,057 3,508 10,261 3,508  
Adjusted Operating Income 155 121 321 121  
Reportable Segments [Member] | Eliminations and Unallocated Items [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales 0 0 0 0  
Intersegment Eliminations [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales 0 0 0 0  
Intersegment Eliminations [Member] | Retail Pharmacy USA [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales 0 0 0 0  
Intersegment Eliminations [Member] | Retail Pharmacy International [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales 62 30 134 30  
Intersegment Eliminations [Member] | Pharmaceutical Wholesale [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales 570 357 1,162 357  
Intersegment Eliminations [Member] | Eliminations and Unallocated Items [Member]          
Segment Reporting Information, Operating Income (Loss) [Abstract]          
Sales $ (632) $ (387) $ 1,296 $ (387)  
XML 91 R74.htm IDEA: XBRL DOCUMENT v3.3.1.900
Subsequent Event (Details) - Subsequent Event [Member] - AmerisourceBergen Common Stock [Member]
$ in Millions
Mar. 18, 2016
USD ($)
shares
Subsequent Event [Line Items]  
Warrant exercised to purchase common stock (in shares) 22,696,912
Warrants aggregate exercise price payment | $ $ 1,170
Outstanding shares owned (in shares) 34,157,955
Percentage of outstanding common shares owned 15.20%
EXCEL 92 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

%2&+]);SF 0 MQP4 !D !X;"]W;W)K&ULC93-CILP%(5?Q>(! MQF!("!%!FE!5[:+2:!;MV@DW 8V-J>V$Z=O7/T"3#IED@W_XSN'=%7#H56-:)&$ MPR9XCM9E9@D'_&R@5Q=S9+/OA'BSB^_5)@AM!&"PU]:!FN$,)3!FC M_SYIA9?ST?VKJ]:DWU$%I6"_FDK7)FP8H H.],3TJ^B_P5#"PAKN!5/NB?8G MI04?)0'B]-V/3>O&WK]9A8-L7D & 9D$4?*I(!X$\7\"[).YNKY038M MBFPV0?9 *SP3QY^UXB/C@^"+,]?1(_R@\MBT"NV$-L?7G;*#$!J,1_BT"%!M M;M5IP>"@[30U<^DO&K_0HANOS>GN+OX"4$L#!!0 ( #R'A4CVR4_/ @, M %T, 9 >&PO=V]R:W-H965TD[I@=_1 &C&SI6U=N15V9"GUF+'NB[:?_>DHJ>IC>SSP'.YVW,YX&2IT_$V M94T:5M+&:LEV:O]"R2,*)$0A7DIR8A?OEC3_2NF;_%AMIK8K/9"*K+F4*,3C MG8A0(O&MU!'BEM@D3.P_)=NJ'9BE[YGO!JGS+I6N,%AA M9AJ#7+CH;H4Y\;#Y:EYB%QG@H&.%D8G0R 2?& M0ZXQLPED+.K'Y",PC[>8?K?(-=I5P\(OCDFV^ZU#/_7(= M"$ (?PGD7/R0UZ3=J;Z166MZ;+@^G]UHUYO>8]D(?!F?H>0!&<9SE"Q-XW.< M/)AT%CA9FL9%)9*5J,;MC,BBF/&-,X&84;V7\[FX+#T4._*[:'=EPZQ7RD7[ MHUJ4+:6O_NHR);+UTB\M[K[U1^<'L[-?/&PO=V]R:W-H965TJ_MT-D_VL6W/D>,TVZ,LLN9+=9:E:ME7 M=9&UZK4^.,VYEMFN)Q6Y0UW7=XKL5-K+16_[7B\7U:7-3Z7\7EO-I2BR^M^S MS*OKDTWLP?#C=#BVG<%9+IR1MSL5LFQ.56G59YUY/R_ [DJ M_->LD2]5_NNT:X\J6M>V=G*?7?+V1W5-)6CPN@ZW5=[TO];VTK15,5!LJ\C^ MZO]3V?]?=4O@ @TG4"#0N00&!#82QL!P @<"?R=P(\$#@C<2S'@?\/[.7!T]OK-UUHGJV5,(;-9?Z M/NM^-BT7;TM.V,)YZSJZP= >\Z(QQ'6G,6O C A'18"&06W,!>WI=-I!3"$( M,HU941###8$^])3,\)3.\+0!3\'C,6&W8\)T:ACX\&Y]E'H\NM8[6S+8)AWQ M6T=<.^+@R,?$:,RSQGCNIUB:?KYW.02('P@T8&Y/$-=F8C))W Q!?1BB2>D> M*MT#Z<(@W3-(][5T#2%>2%'IWF<%FK@V$Y-)XF8@\AG3RT>E^R ],$CW'TN' M;KPP0*7[D]+-Q&22N-%$%C+_L72!2A<@/31(%X^E:T@@?%2YF%1NY"63O WP MF'BL.T!U!UHW10LYZ!XPQ"!<8TC@XJ4IF%1N)B8($58Z$$7H/M8>HM4T!%WX M"@V1:CK8)AT1%QWEWMQM(*9Z"B!.F6&< <1H\'FJC&,3 \IC]U7L9N@!Y?,@ MG.XK&6+GH9A16 C!!V X,)A*"X >#( &,<&G03& 0H$*&^1KD' _YW\$)8,[ MXL\13W'Q<#2@Z-%@$$_GB(<#!)K[03M@N &T!I"IEB6 $9S-4,YPY7!@H9Y) M.3,IAY,$@ P3-08(<0V@-8#NZ]WMC&>PQN8('\]/)4CF#VL$?NX@^*'B=JC@ M<$)G[',$W^,);++WHW3K!T!TQKY"\ V5"#RKMWZ&;7?&+8'@&Q@)3.?NP<\ MHG=^G \7I$+6A_YRW5C;ZE*J/EA7^D;S>(-_IMT-Z\[^0J(50>QK$J68/6;1 MBB'VA$4I9H]YM.(8GD"]*,7OL1RL?P_M1BMEC$:T$AA=1BMGC M(%H%&#Z(4LP>A]$JQ/!AE&)VM>>I!+@80[6D:(O:)Q0'RXZJ^XJ#YHU0Q<%F M@"J8BH.UJ-*D.&BV54N*MJA"HEJPS*HJH%JP'*IUJUJP;*F5IEJPO*BUH5KZ M##CO*V"Y.&<'^2VK#Z>RL5ZKMJV*_@/!OJI:J9:4^\6SK:/,=N-++O=M]RC4 M5YF%WD# #W$ &0 M 'AL+W=O)?A7B3-S]VCZXO-?"";UN9(NL^WOF: M%X7,U/7\%Y)^]BD#OU[K[&D_W$[^:];PM2C^Y+OVV*GU76?']]FY:'^)RW<. M8PAEPJTHFOZ_LSTWK2AUB.N4V8?ZS*O^\Z*^B708'D A@ X!Q!P00$#P&<", M 0P"F&T/(02$MCW,(&!V$^"IR>JG>I.U6;*LQ<5I3IDL0++H\%HFZ3([W?PV MW=+U.>M^\9+E>\+H?.F]RT17#.V9E6*([X\S&V &PNL4H#*HBW5!^W ZWL&: M@@AB$#&9Y=DB2PI9YM-C":['$J@I#6!*X^D$[#H!4PF82A#.:IW#GHMZBA&=TT, M"<+I!,1')?3-,H6AA%8 D7@>QE&,[@Q8Y#%R7!;!98'%!A'F.0QD:0CU80:* M[J%Q,1070R%%;*@K@- =K9 U( :'V@!B*.#GNRSCPPGPX8#7,E2(7O( JCOT MY9]IR4?(<5D,K67"[!\!!+=5(>-:<7\EVF#1_:2U*BB.#=#&!DH! M(H39%$2,2P9+9S9OA3ZZD:AOOY$H;K^4F#823!Q M^Y[-6\63*H9BTFCN$%3 M:K&+J,%]M=I))+U#QK7B[DL#B_T#D/%]RH))-6-33/AK-66F+026"E" 2@%' MM6!2S;IQMN)I ,;0.9_8G*@]Y-^TKLE@3I'U#%L_J M1/Z9/EF>L@/_F=6'O&J<5]%V1\O^!+@7HN6=7/^A.X,>>;8;;@J^;^5E=ZIV M:G4N5S>M..F?&8;?.I+_4$L#!!0 ( #R'A4C^F\+UQ0, .@2 9 M>&PO=V]R:W-H965TZCEOJTQ.IDNE_]0>LA M^MW4;7\3'X;A>)TD_=-!-V5_98ZZ'7_9FZXIA_&Q>T[Z8Z?+W6S4U FDJ4J: MLFKC]6I^][U;K\S+4%>M_MY%_4O3E-V_M[HVIYN8Q>[%C^KY,$PODO4J.=OM MJD:W?67:J-/[F_@/=OW Y029$7]7^M2_NX\F\H_&_)H>_MS=Q.G$0=?Z:9A< ME./E56]T74^>QLC_H-.WF)/A^WOG_7X>[DC_L>SUQM0_J]UP&-FF<;33^_*E M'GZ8TX/&,:Q7KVLA8)6\3HX^8&#&W%H, M9VH9LW&8;!FS=;'X,N;.8<0RYMYAY#+FF\-X.#\XS!OG9,P;F3SXF#QNDP?H M(+_L@']T(*P#C@Z*CRS;&:-LUBR&L0PDXXKER]"[1>@B+4'2$I:63*E8F5T4 M%L-DD>+?,G:+6,X_81>)29*81&+,$PPQ#"[1ND,D+T))*9*4LDL?N"=;%B.\ MR6)82NAO3-=E1AG)*,,T 1DFM90LB%U)Y4%M_"B[[KXAZ#+=G*2;(UTR@3;$ MK<6P43P6\V>1FR7D(JF")%4@*>&9U0+K+0U?URPEH\VOIW"2"I>C7EE0IJY2 M&1")T9%0J;D*<$'+'ON"[C%:^!@JW_^7U7O0+8(XD$U%8./Y#%HF0\L=0[U+ MR28HL'D)S%M('%J]F$2JWD$[C?,.^C-HF0RM6DQ=%ODM@IC,)0M>X;0FL$L*&C/%JZ11#CP?H&0$=#R5"^SHT@$! ^.%I> .5%08 +0 M00;H"H*"= 7H4@;<,?"0A&7T:+,OC):N.,B1A7>T#A2PMP&Z,4,1H*+@ZM&G MHB&@K0O' [8WG*YL[BK;M_@1!"I\+\'IRN:NPX<<2^@.S[]RLEDXVO#+B_\> M09P7 7'HYLU=G7K/4-B\(22K=#%S+&;EV>9O$<2H"4S>'<^/Y;/^J^R>J[:/ M'LTPGO3G _G>F$&/?M(K&4<'7>[.#[7>#]-M-MYW]D.,?1C,T7U7.G_<6O\' M4$L#!!0 ( #R'A4AHX&PO=V]R:W-H965T[[V:R&&51#P74TZS)_H0'KY MYD!9AX6BU5U86]"3:IB>OS..GKL/LWPMI MZ;CV@3\MO#7'6JB%H"R"2]R^Z4C/&]I[C!S6_C-852!2$(WXW9"17XT]97Y+ MZ;N:_-RO_5!Y("W9"46!Y>-,-J1M%9-4_FM)/S55X/5X8O^NTY7VMYB3#6W_ M-'M12[>A[^W) 9]:\4;''\3F$"O"'6VY_O5V)RYH-X7X7H<_S+/I]7,T;[+0 MAKD#H V EP (9@.0#4!+ R(;$'T)"$PJNA 5%K@L&!T]/F#5'F EX4R12&9/ M9L]E834GTZ4MBW,9)5$1G!71#09JS,N$B>]C-A,FN8^I)DQZP032I],LO#6+ MC%EH";+'!.B6P"P^(TN0W[KL-28UV5I,'H8N$+#Y&A0""#WV$CF]1$8G=.XLBB$KE!WS<1.,[$U V8*8S A$MD$J=,8JJ&DL<$J;,#TN4= MD#D=9',=8*I>64R61H]5ASEV5,A+0I_E!TH%D33A4^Q[ MM;SM+Y.6'(0:IG+,S/UG)H(.TW5^^:8H_P-02P,$% @ /(>%2.W.GRE< M P BP\ !D !X;"]W;W)K&ULC9=-;^(P$(;_ M2I0[3>Q\(XA42-'N8:6JA]US"@:B)C&;F-+]]^O80PKMV' AB7GG]>.)&3RS M$^_>^CUCPOEHZK:?NWLA#E//Z]=[UI3] S^P5GZSY5U3"OG8[;S^T+%RHX*: MVJ.^'WM-6;5N/E-CSUT^XT=15RU[[IS^V#1E]V_!:GZ:N\0]#[Q4N[T8!KQ\ MYHUQFZIA;5_QUNG8=NX^DNF*!H-$*7Y7[-1?W#L#_"OG;\/#S\W<]0<&5K.U M&"Q*>7EG2U;7@Y.<^2^8?LXY!%[>G]U7:KD2_[7LV9+7?ZJ-V$M:WW4V;%L> M:_'"3S\8K"$:#->\[M6GLS[V@C?G$-=IR@]]K5IU/>EO4A_"\ * 70,&.?! M P(("#X#0FM " 'AO3-$$!#=.T,, ?&7 $\G2Z6Z*$69SSI^6D"C)8K.JN$NU E4<)/0V<8021]J"4&P:';C0&M\,LM2*Q$=AM4MQ MT^7INXMQ,3&ZF%BG/[C#($$W0'+_!DA1@E03H*N$;&I)2 )+KKYKC!P9RI'! M0E(+2 :;-P )$06K]=6$J,TZ XP3@8:,)H&#$&;'A8#(S#UY-"913:W:T MAE*"%MTS#J(RT^"5DNCR%*:V'S>()DF,%^XS#R8S ^'5CL0 9'D1"Q!-,I]8 MN M49@9*<"!=/B,KC]9,:!A9ZD&!RLP\>#$FNHS:)EJ 9A*DUL*#J,PT>$DF MNI3&D8U&:R:A[?^XP%3F4QM>E*D/F\>6'!#%D6W/%YC*C(-794INGYQ 0\(T MMI4>5&;FP2LSI;?/106(HOB.34'QDDOAR(GO/C@,@BB]/,?KB;R+QJ%AW4[U M>+VSYL=6Z$/N.#KVD8]T:#R^C"_(=$F0\8),GW27^&F?SP[ECOTJNUW5]LXK M%[+=45W)EG/!)+#_(/NBO>R,QX>:;<5PF\C[3O>*^D'PP[GU'?OO_#]02P,$ M% @ /(>%2(3A&8TX! [18 !D !X;"]W;W)K&ULE5A=DZ(Z$/TK%#]@(1\$L!RK=G2L>Q^V:FL?[GUF-"JU0+R X]Y_ MOT ZC#/;8/NB@*<[IT]RFICEU=0_FY/6K?>K+*KFR3^U[7D1!,WNI,NL^6+. MNNI^.9BZS-KNMCX&S;G6V7X(*HN AZ$*RBRO_-5R>/:]7BW-I2WR2G^OO>92 MEEG]_[,NS/7)9[Y[\",_GMK^0;!:!F/2F\FI]>/*_LL56)CUD0/R3 MZVMS<^WUY%^-^=G?_+U_\L.>@R[TKNU39-W7FU[KHN@S=2/_!TG?Q^P#;Z]= M]NU0;D?_-6OTVA3_YOOVU+$-?6^O#]FE:'^8ZU\::HCZA#M3-,.GM[LTK2E= MB.^5V2_[G5?#]]7^DH00A@=P".!CP#@.'B @0+P'R-D "0&2.D($ 1%U! 4! MZCU #>);L0:I-UF;K9:UN7K-.>L7(%MT\+I/TF7V.GV;;NJ&G/4P>:OEVTHF M;88%H;3F U@IA%;BQ!Q.F*"CB5*E?L8#3XDX--#K#D0G:&Q MN9OEA9!E"UF2^[6(C[4(*[L V:/[">3'!-(FD*#F1X[5 (FM7A;"HCA5TZ@- M";4%E!(QO\\X0AE'(&N*#6,#GRU&A9^7XRV7M05%*D0)VTP;&(TSEDRG>G&< M0D4H2Z%E*9C).3(*)NO&09.CQ.@H,8R"SC>(%T,Q/6S#(EB,]Q+W/8,Z5SH@"(1Y(P11QW/'_ \1QW/!<4KA:4,DG1%;!$+@YL^L;T$;!#1-!G<\5W-['Z>.!:'] M%'8^ (EFTFSNIWD!2")F-GP.0RD:W[)PZ%&I(*1(< ,D#Q@ ;QD\I1C @I2* M".4*?%%/K3]9=Q=U_8TUMZTYNP. ME\<3[M5O4$L#!!0 ( #R'A4@+BV\9'@( #0& 9 >&PO=V]R:W-H M965TKF6TERWO@:#[=;2)5U5N$!;PNZ6CO-@# MXWW+^:LY_-RM(V0LT([6RB@0O9QH1;O.".G$?[WF>TI#O-R?U;_;:K7[+9&T MXMV?=J<:;19%8$?WY-BI%S[^H+Z$S C6O)/V%]1'J3@[4R+ R)M;V]ZNHWN2 M(T\+$[ GX(DPY0D3$D](/A"@#)"%UAL,4\.4R,T&U,Y3$3 FH'01LX"J7 /D5\)\5GS,TD MR742%]PD5B!-\\<"Z;5 Z@12[V!^[;*WF(6KQ&$2A!&^C:H<*EO&B^2QF2QH M)K,2^?*.%P>)<9;) >(Z_T-=YL*]S_Q]*'PLL@J4LO$ 6LIF[6APFG@6[ MZC"5P^!9]H52\J"3W#L)OF'O)/=.XF#KO97<6TF7'ZS BUO*J#C8Z25!S8^] MVEV#+E9X5]DKO.5=4YT>S+ *-'N'3H:-[ M9;8+O1=NJKF#XL-Y1D\?BO(_4$L#!!0 ( #R'A4@V]<_N$P( %0& 9 M >&PO=V]R:W-H965T5JC[L/AL82%0[SMJ&=/]^?0D!*K?P$MN38<$[)?!*EK4 M$380B_C=PB"O]L@DO^'\W1Q^[I8!-CD A:TR$D0O)ZB!4J.DG?^.HA=/0[S> MG]6?;;DZ_0V14'/ZI]VI1F>+ [2#/3E2]<:'%QAK2(W@EE-IGVA[E(JS,R5 MC'RXM>WL.K@W!1YI?D(\$N*),/GX";.1,+L0$ENIR\S6]8,H4I6"#TCVQ/S: MT4+#A1'1RD@7(W6?K*:PG:K*4Y7BO Q/1N@&$UO,VF&B"1%J=:]%'/CHL:7' M7QO4#A'A!RQFMQ8NN)I9@20I[@LDMP*)$TC&-A2W6786D[LZ' 9_C:B3,8WL M@4)2;QZI59CE/I/,I>$@T?R^1>:UR,92'Q#(O9>C_G]1LX?;F2$O1XVK$V^^VA&3!Y_<@FO+BL#<;!#3*(M/W;*7:0I.@W* M56PN^Z?XV@Q0.P0N,E79DP/\(N+0=A)MN-*CQ-[X/><*=%KX*0U0HT?\=*"P M5V:;Z[UP0\\=%._/,WSZ(ZG^ U!+ P04 " \AX5(LOV.6B$# "M#@ M&0 'AL+W=OQ9L\QD1 MI$VJJCU46NVA/;.)DZ %G&)GL_WW-;9AD^V(3"\!G#?OS9AGXRDNHG^51\Z5 M]]XVG5SY1Z5.RR"0VR-O*_D@3KS3_^Q%WU9*/_:'0)YZ7NU,4-L$- R3H*WJ MSB\+,_;4EX4XJZ;N^%/OR7/;5OV?-6_$9>43?QQXK@]'-0P$91%,<;NZY9VL M1>?U?+_R'\ERPPS$('[6_"*O[KTA^1'[[N5'PXY\(9OU4!1ZMHQ\GL9_ M,.L10SZ;*[@ZNK>\/YB.1GI;<>Z4/6U.HU/7]$B'H_^G\;7NI@@T3I<;"*_K MU>U7"$6PJ3$+/E(JBU-UX#^J_E!WTGL12OS7%2!NVNC&7 P VA( M !D !X;"]W;W)K&ULE9C=CIM*#,=?!?$ A?$P MP*RRD5JJHW,N*E6]:*_9S62#"DP.L)OV[0N,)]UMG8ES$S[RL_EC8^-A<[+# M]_%@S!3]Z-I^O(\/TW2\2Y+Q\6"Z>GQGCZ:?_]G;H:NG^7!X2L;C8.K=:M2U M":1IGG1UT\?;S7KN\[#=V.>I;7KS>8C&YZZKAY\?3&M/][&(_8DOS=-A6DXD MVTURMMLUG>G'QO;18/;W\7MQ5TF]("OQM3&G\=5^M(A_L/;[-R^F,FV[>)JO_#\Z_7W-Q?#UOO?^SWJ[L_R'>C25;;\UN^DPJTWC M:&?V]7,[?;&G?PW>@UH37'EY$X*I $ICBE%'M!;.4BG*KLNI2"E%"A% M!*0X1@@!$-""%$@EKHLI23$EBH'K#C19.II?.B(E):RG+Q8/!@2A*X^LI[)4 M,^0(6HY@%!!"H@REQT.2$5P!M!CL3" 9+B29("%OR!#=4D3&R5"&E9&%0N*@ MLE0,,713$8J3'X0DV6N]& =E!:/!";JM"-]7&-U %'1^BAOR0Q>Q*#GY<5"> M!_I.A5 A.2'1M!C-R8^#LJ"6OYC+;W6ZLP!V%F \;2#([(#@9P?H&@9@9 >A M3 6@RD,9(SM #RH@&=E!Z,*DXL4@E#+>R4#W%<"^ IS@*CH_ZH;\T#4,.2<_ M#A(J$+?J##&Z =## 12<_."+/PWFQT&:\?(!NJV 'PXX&::G [AA/)!T$4O. M>("05H& >(:1'$F/!I(S&B"4AQX4SS#ZDJ2;BO2# 6/-(^G!0-XP&$BZ@"5G M,$ H+X(1\1 G)/1@(#F# 4)"A*84A$K&T"7IGB(YZPT/Z2S4])'*%6<=)NFN M(OV:@S$6RY)^6LH;GA9Z,I Z%!2_2G80 +WR\VLG,WM)WZDX.IAZ=SYHS7Y:=HMY?W"?7MS!9(_^2]+Y M<];V%U!+ P04 " \AX5(VAFG,/@! !N!0 &0 'AL+W=O)U(%S*O\N M@8E^$271*?#6[&MM [C(\<"K&@ZM:D2+).P6T4LR7V<6X0"_&NC5Q1Y9[QLA MWNWA1[6(8FL!&&RU5:!F.4()C%DAD_A/T#RGM,3+_4G]FZO6N-]0!:5@OYM* MU\9L'*$*=O3 ])OHOT,H86(%MX(I]T3;@]*"GR@1XO3#KTWKUMZ_F26!-DX@ M@4 &PI!GG) &0GHF9 \)62!D_YMA$@B3FPS8U^XZMZ*:%KD4/5(=M=85< ,"&PM0ANAS3_@KNI." W&;OQD>EN; MX3<<&.RTW%2#UY:HC* 0 MT@0 !D !X;"]W;W)K&ULC939CILP&(5?Q>(! MQNQD(H+43%6U%Y5&<]%>.^$G6..%VDZ8OGV] $TJE/0&;^><[[=L7(]2O>L> MP* /SH3>1;TQPQ9C?>R!$_TD!Q!VI9.*$V.'ZH3UH("TWL093N.XQ)Q0$36U MGWM532W/AE$!KPKI,^=$_=X#D^,N2J)YXHV>>N,F<%/CQ==2#D)3*9"";A=] M2K;[RBF\X >%45_UD:O](.6[&WQK=U'L2@ &1^,2B&TN\ *,N2 +_C5E_D4Z MXW5_3O_B=VNK/Q -+Y+]I*WI;;%QA%KHR)F9-SE^A6D+A0L\2J;]%QW/VD@^ M6R+$R4=HJ?#M&%8V\61;-Z23(5T,:2@\@'R9GXDA3:WDB/1 W-DE6RM7+L0F M(UN;MMOVFKM [,,&'3&=2O;5^&?"P,CA_D%69ZQY@]02P,$ M% @ /(>%2)\!>6^+ @ 3 D !D !X;"]W;W)K&ULC5;;CILP$/T5Q ?:B?('2:>U+KU:ET[K(/8F,$S2 M8F8)\]\43FJ%>Q=2=2*:7[11_ \:\F%_B3\4C8B.#"I.J)I7&?&)%79@*IBJ,;?-WDXD:[M_E_X'*O\'4$L#!!0 ( #R'A4B&]9.^ MS 8 ,LM 9 >&PO=V]R:W-H965TM-?:1$F,M:U44I+MVU<_0R5*1\S131Q+A]20 M.OPXI+E]+:N?]6-1-*M?Y].EOED_-LW3]693WSX6Y[R^*I^*2WOGOJS.>=-^ MK1XV]5-5Y'=]H?-I([/,;L[Y\;+>;?MKWZK=MGQN3L=+\:U:U<_GZ.Y^)2'\O+JBKN;]9?Q/4AA$[2*_XZ%J_U MN_]77? _RO)G]^6/NYMUUL50G(K;IJLB;S]>BGUQ.G4UM4_^ARI]>V97\/W_ ML?;?^N:VX?_(ZV)?GOX^WC6/;;39>G57W.?/I^9[^?I[06TP786WY:GN_ZYN MG^NF/,L^K\"Q+]?A+]>S$7BJP"=Z+&I"XN4.&ID)E>@Q$DD9 M/@\WL.&&(125"C>DPJ4W'&*X0"0B8T/I+[?/>>>D^2H$^_:$P%^?D'P4$GB! M4<1ZGEX@:=S'83YY@:/( @$K/F#BD1&I@!4;\'O-?JQ( K'P9!,:L%,4I8!! MFM9/P$@6/+L$@41" ED31* M1DA)@-^*AY0B2%G6N]TRM7L2J<258N,AV6&4&62])/B "'D66-04H#'%8^@B<5)T_(PL3@[<*KYD'E2*0V87/&DFG@\:BPPX!0/*F4 CRM@ M+4B:UN)(Q_#+/$7(L\",I/B%GEJPTE,\@Q2RUHNBI*,&C1 AE=IQJOF0>5*I M@#@J (XBC06PH'E.Z0QP5!2E'$6:UE& O37/*!T9A>SJ\(S2"QBE>49IA%$: M8!1I1/ VX:@W%1+RS&86PB@-,"IJ+)!;:YY1&F&4!ABE1T8A]N89I2.C@$Q5 M\XS2"QBE>49IA%$:V9 BD1:)->HABI!D2O.(T@BB]$PR-7549!206QN>409A M5!0E,SLS0@IXF8:'E(F02F9VI/HLLQME2&9G^)6H(>19X'4;?C?=+-A.-SR" MC 8\'D4NA4T2>9'*[*)( : R,]OJ!O!X%'V,>.+Q400D4X8'E;&(QVVJ^Z+' M;?0XTC7\4M00\QR[@!P][LB\6=KC48:L- U/4$-P=$#690+O\8![W/(@LAG@ M<9M*ELCBI-$AA7%&-!\PSRHK (M'4.06'A,60DXW*8VS,C@I)&90H+A M<_QA'((H1Q J*AQ0)[I>$(YA% .()2+A$)^\W<\H5PD%)#5.9Y0;@&A M'$\H!^1(^U$$C!_'@\41#SRPX^IF#@TL6*.AKH' MQHW/V-;Z#&^MYX>>!X;>/HJ0+2;/#RM/(\8#'>;Y]8E?L#[Q_/K$ ULD>[]@ M^\/S(\;38/! INKYWY+\@M^2/#\Y>H>T-F;YR+N=.6A#@\$C5?#SGE\P[P5^ MW@L9T-HH0E*.P(^80(,!V:D+_/YD6+ _&?B9(0 _X^ZC")D.PSAB+O2$[D*Z M"&_^P.>JDPF4-,A^4. GBS",#_UQV3E]3)Q1D-?-#Z(PC \MV9.,\3DTB#R0 M^05^$(693;WI<^)(0_IMYIA9G':2_4:B\'$FWKP[;GHNJH?^W&Z]NBV?+\UP MD&^\.IX-_BJ[XZH?KP=]O6\M]O\[K3?:.X:]8]L[EKWCVCN.O>/;.YZ]$]H[ M_;'ES5M3=MNG_*'X,Z\>CI=Z]:-LFO+B^9;]5R>NO\\5/6Q:+N?]>.Z>:[+ M8C<,.A[6,L_M^ECL3ZOM9KCVO=YNJI?VL#^5W^NL>3D>B_J_Z_)0O5VNQ"I> M^+%_?&K["^OM9CV-V^V/Y:G95Z>L+A\N5U?BXE;DLL<,D'_VY5OSX7O61W]7 M53_['W_M+E=Y'T1Y*._;WD;1?;R6-^7AT)OJ7/\BJ^].^X$?OT?K?PSY=O'? M%4UY4QW^W>_:IR[[?VG:ZAB'K+)C M\7O\W)^&S[?Q/SZG87B I %R&B#%X@!% Q1W@*8!>AH@]'!KQE2&&W%;M,5V M4U=O6?-<]/-#7'3PNC?26O6Q/$9OW:&_J$D0/F>L2\ M(]:==>A"KM!P.0S7ULV[N)$4AIS'W$:,.A^(^AR(&G-5HP%MSAO0GPV,%Z\T M1:!1E"/F>L1HX\X[,=")&0Q(QTC3PC0M/TT'(W"4IOF-"GI_W MXJ$73UXL\F)'+R-&Z_,^ O01R(=;R"0D9")RZ&:X?&YB$(@U,X3 ?B);_9*? M" KSH!L F@]&XF D352."4Q(DAV:'<>:SM58*X5[@8J)'G5N1+#R^"&&]]"I<#%9G.>?X!9QL2WM@P/W7D)RQ] M]&P)Q$E68WKJ2*JEVD<@X3FE7&/JZ0>X[57>YRM3\@6=UD=.-E& M$,./P00U.9E@O,H8 ;,U@I^MP;0RDI'M!.+XP;0RU-$X&ME@@6L2!*Z966(R MG&P-?R8;S!@3R<#HS<;A;%U"MK@1&<_)UB=DBQEC(AD8A<[F,%N;\[.UN!-9 MP+.X-U2R^FI#((9#A"U6+&6"*#Y$P/+-UL@G1SN#.XG)$M@5BOX0XSQA$9 M)*/?.@FS=3(A6]P9G&+,Y B2'#^8,2Z2@=%O'=92+D%+.=P9G#W_#G\;09+1 M+-W,5@8Q1C(ZD,-:RB5H*8<[@^-HJ0B2C/;A,6,\,49Q-F6PEO()6LKCSN Y M6BJ".#798\9X(H/BF,!:RB=H*8\[@^=H*9^@I3QFC"Y&[?YS&9V+ACW/Z*,75B( MND&HA8!F-K1SR7D&$::^/(3UAP,XQ[)^'$XR-=E]]7)JQ_,WT]7IN-35<%AJ M_0[?;IZ+Q_+OHG[A?&C[KYTN MR^KQA-/XHZV>+^G$UG1L;/L_4$L#!!0 ( #R'A4@<6P\EY08 "HQ 9 M >&PO=V]R:W-H965TY0W\Y?FN;U9K&H'U[*?5%_JE[+P^F;I^JX+YK3Q^/SHGX]EL5C M5VF_6\@DL8M]L3W,5\NN[,_C:EF]-;OMH?SS.*O?]OOB^-]=N:O>;^=B'@O^ MVCZ_-&W!8K5][U]V3_ MEZ(N[ZO=/]O'YN5D;C*?/99/Q=NN^:MZ_ZT,G3 MX4.UJ[N?LX>WNJGVL_^-3T(U7$&&"I*MH$(%=:Z@1_$ZX/49+\5H!1,J&+(!&_"6 M;<"%"NYC XM^:#O'9$53K);'ZGU6OQ9MO(J;$_K8557ZY^-82?<#(#G/78\1'Q*'[+FN_:\L6IQ9ALW*.*&5'J:T;;C;K,2:5 MPYAM<(R/ LC:,1\YPD<$T9H@RAFBS271\.A@/14^-$.LU2+% M/DIY'\D$6B$30M;/($FT@S55!MUQA&I("7LKY83>XMV-5$1$1I ;4XT(&HM( MAFA-$.4,T>:2:'ATL*;*H#N.4 UIL(_,!!_AG8ZTC(\"R(VI1@2-^H@@6A-$ M.4.TN20:'AVLJ3+HCG,$A<<^\A-\A+=I,F5\%$ .GJ6BCU+"1P31FB#*&:+- M)='P$0IKJHIR26B=$M!'2O ^4GB?IL)9,/FELX<.U%>]"R!']7;@Q*B(%>0, M8OJ#U4GI0&'&VHD@2[2#]T[*! IX%H_M1!!Q'E-8YU2O!5:,CEL$$0 DA(RD%X&FO+!%P M4<.*I[%V3, %D"%6'HV/)=HS 1=!(QJ9,: <@(8MQM*B@[08)N6(DT9F0M+( M8$$P,7-L4<")D,,-*)T0 6>P(AA&$Q(I@I M:>6!O#*C"&:*(ABL"(91A @RQ%G+8$4PC"*8"8I@L"(81A$B:"SYF#&@'("& M+<:*8,(6WA-+D,6*8"F;N!F>,+5L,."X,)<_W5A#X&@0G<]?[QW6!$"89&$',#;+' M@N"99& $,2N#QX+@&4&(H+'KF8P!Y0 T;#$6!!^N&#Q#@07!3WDK,O!8Q#/Q MYB?$&]8#GS+Q%D#,!B_%LSA-B'B+(&;KF^)U/66>GD30V%53QH!R !JV&"M+ M&D3#$P?9%#\'22<\!TFQ'J2:B+< $E3 I5@04D,$7 0QSR]2/(U3RP1<3"(0 M I?B,T/*O-&(H+%[LXP!Y0 T;#&6EC3N-9B8Q>\FT@GO)D2"%:$OO[KYC3#' MQ)Q(!AZD)3&Y2!F,]_M].=UKO+[WY=]VC/'6T%LEY0AYB*VW)E4H#;XF2N)2.S.((NCAM+'YZ*+TOC\_= M"_AZ]E"]'9K^->BY]/S,_K-L'UK_4GXG;NX%*,_:9_D(+V_N$4\F;]:H/)#EW[\-]!FQ)__J> Q8_NK9:OQ7/Y1W%\WA[JV9>J::K];?L*_*FJFO(T M7LDG,Y^]E,7C^<.N?&K:/T_'MMFQ?\G??VBJU]OPGPGG?X]8_0]02P,$% M @ /(>%2+V,Z=LP!0 A1X !D !X;"]W;W)K&ULE5G=;J-*#'X5E RQ/?YLP\R/5?VKV5K;1G_*8M][B,X^9I:\N\N:@.=M_] M\US59=YVE_4F;@ZUS=>#4%G$/$ET7.:[_6PQ'^[]J!?SZJ4M=GO[HXZ:E[+, MZ[]+6U3'JQF;^1L_=YMMV]^(%_/X)+?>E7;?[*I]5-OGJ]DW=OF@30\9$/_N M[+$Y^QWUQC]6U:_^XGY]-4MZ&VQAG]I>1=Y]O=J5+8I>4[?R;U#ZMF8O>/[; M:[\9W.W,?\P;NZJ*_W;K=MM9F\RBM7W.7XKV9W6\L^"#ZA4^544S?$9/+TU; ME5YD%I7Y'_>]VP_?1_=/EH 8+L!!@)\$>!84$" @W@184$""@*0**!!05 $- M IHJD() >A)@,BB0@4#V)F"" @8$#-6D?L_=SB4?1&*WY4/"7.=MOIC7U3%J M#GE/(W;9X^M>3Z<\ZM*DZ3)P4%L/.;B8ORZT3N?Q:Z_I'88/F*7#L/>(_?#? M;?]??R_NEL37Y3-,)X=UL_%U5PXCI!S'7#N,,GP<\]VO9<8Q-X!)DW',KX]2B@Z&!H6Q"5%A'+?#LS,;3[4E@ +9N/H$"5@B<$L\R]'8>TL$9&/( M%(>1%%/P:L$$3A4 MA(Q2$3A>$?B4BL#QBL"A(F2ABL#I=.:SFPRWR>/L_BBG3;\P[D1T4'8U*1G,*IRM/01FLP**49E$XR""^&M),FJ Y(9().2$8:H< OAJ!!A>F$D E%^A^ .X;2O,4(\/ZE&E=X)P5\FNNW ,(#9V#/ "$"^"](24*/H^+*0.YP$DH#"GY#2GY/Z,"CXAX Y9 M:$.)K<0;L)S2@"5.0LD)R0\@%7I$? "02"F3EL3[M 0ZFXRB0^)1D5.B@K-0 M>A:&!DL ,4KYDC@-I:20*>YO.L5?O!G*C%!U )22RIO$:2@===*/F?2N M[IQ I!S!&:8$Q(7D$\XP M-85A:N3-%*7/*7J?4SC!E 9W42+#V D@4J;@74ZEL SZ;LM[D_HJ2G((9ZH" M$B:D'##X_ID)^Z=Q?FG_ !FJD 2I'>&^-"J&?A+Z9.:H_YJ/L5?G#=:4'@, MJ"]XC* "]N!#JY80%TJGU/B#II[RH*E'7NIJPI.U]BRDM#F-4TP#Q1@IF?!! M4D\9)#7>P33E%0V /D_.\=EA4VGKS7"ZV41/U%2,*)?MUT M!@ Z"H !D !X;"]W;W)K&ULE9K+/)=E&_T\'D[-S>*Y;5^NE\OF_KD\%LVGZJ4\=9\\5O6Q:+NW M]=.R>:G+XF%H=#PL91S;Y;'8GQ;KU7#M2[U>5:_M87\JO]11\WH\%O5_G\M# M]7:S$ MWX>O^Z;GM+RS7J^6YWVJ_5VUU)?3!]P/OJT Q_H_O7 MIJV.KLDB.A8_Q]?]:7A]&S])8VJ&&TAJ(,\-3+B!H@;JW."<&&Z@J8'^U4 ' M&QAJ8+AWL-3 H>2GZ*2ZN.WG= M!^DB1]T(-MWD&&+6P_18KWZL$R%6RQ]]H'<:.6@VHT;$L5^3D^:L6'89P#3D M MU"#LVE_P:WDI(())I/1MDRHNPH2NJ7W(T2DZGI_JKW_56C[8ILE],!]/L M>@R@*8!ZG^5IT"2CJ:-&^Q6W^L.H72CRR1C;CS&\'3&P(X8ZHJ<#6&BEI0!F M.D ",T@H@ U8.6JDB0-676J\B:0PD9022=#,&S6;46.,\6OR2XTWD0PFDE$B MZ70 $<-!&2XS1T4(F(00C'%QHN# )$_&8F3D8RQ(5%X<(#(GPR&AW#TR!@A M,#X$\4,&?+LCD8DYON'J%E3>DL$'@>M;N )GL%+@"A=4XE*&IM(HNH(:._*2 M- $38;:78?P=PER3CFL,BDO,-3F#:Q)S30:YYFQ-T*KX MO:W$HU )DR94P23A%#"FFIQ!-8FI)CE4(U'0DHQA239M2<:U1&&F*<9RTC^C0U,/.V(QPF!B:=G$$]CXFD. M\4BD0M[JR25:S@BSO0CC[Q FG9Y!.NW9<^*0CD1A3R:7:#DCS/8BC+]#F'#: M$8X!28T)IV<03F/":0[A2!1:')/D*@GZ.AEGZ^((RUAS:(PW/0-O&N--!_'F MMC@S?W?<'F<6LL5M3^J1\&>T4?39 MN@UF/W9WEOW[DL6%;=TO3/!W!$MW,=REA,5U:EV=,I82%M>I36:XCNO4IAS7 MTTG7-Z31%I8R/33#(N?L*!(RYG0+U[O-IH=P0Z+0UN"T9$<2Q=A"3O S/B&R M:,9D2O S/A'\F9!@"B22,1-(A&<"V4H:ST^?9"Q'M ,B?Z_P4B%1C(E HL"D MS*?97]^[L/UC;B^%>!Z+JZWZ'K7W^M=:L G7;+= M)\.9SN6OE-:KE^*I_*NHG_:G)OI6M6UU' [D/5956W9]C#^91?1<%@_G-X?R ML>W_[9X(43T>Q!S?M-6+.U=Z/MRZ_A]02P,$% @ /8>%2+]X=T)N!@ MKBL !D !X;"]W;W)K&ULE9K;;MLX$(9?1? # MU!+/#!P#C8/%[L4"12]VKY5$28S:EBLI2??M5X>1&]L_J=%-;(L_J>&$,_PT MXNJCK'[4KT71)+_VNT-]NWAMFN/-\+C;E[M_M4_/:FILNDJ?B.7_;-=_+CS\+FH3N!GPL=W7_-WE\JYMR M/W99)/O\U_"Y/?2?'T.+]=0-=Q#409PZN#3:05('>>J0J6@'11W418?E,)7> M$?=YDZ]75?F1U,>\6Q_932NOND':D9-V]G7KV'[,JG?M>O6^MLJLEN_=0&<: MT6LV@T:$%?>D<"?)LC4 6B'.K1@N?A5DA9T>0)X/((302^S@JD&261W6W)/&J6E;-;15#[9^,B0X@('>,GQO66B!97AK MT*C4(U>8P5V#1A@=$=V3*%5RVEP'S77DL&QZ \=YOD.RU)H0G]YRF4D4D)& M?$:B+!4VXK11E3F&U[(,VTS)00O&$ (Z+A,S/">Q%9+CN4&D,A7SW"""L3FZ M35[DNK"U.(]DE$@TQ^T:^TS/\)G!5AB.SP:1=K$()5$6\]D@D8Q\EED\8\HG MFC,$#O%LC'$=F['CS'@0928VY4'C&>9Z;"YE%&VFAQ I=)I(^4#, *!B4!PD(!$F*!&?]@80HT+R?(92N"$(2AA&,Y2 MQ%0@9F"!Q%@@.5A HCA*D6B"I485"Z8DSAJ2$H)AK%F)L4#.P *)L4!RL(!$ M<: BT010C2H64$F<-21E#!*$K869PD]0@#C&4=C"- S($!C"- <""!1 M')Q(%'O$(0F#% U.)(82B>64B3/H,Y/Q?6;PSFP$PV)TPHWQ@<( ;3OE@ M%$71B403E2A2\2I1!O."H8QB.3&*><%X_G*S.,QMREAN)(HO-Q(QUH'%-& I M75C&HYK%-&!GT(#%-& Y-$"B*$#9:1BXDH2-Q8$/W("@UH]Y@0O^.O, MX_#VDK'.2!189W3HQ[,IP)_2Q(&,Z"[$N^"TX#4$F'/C*74XCF68#'Q@TS^_ M#P6]XYROP4'O+=XHS^]#F<$Q@-OC]^IFXQ5H:==AVZ)ABVE;#&RQ;8N%+:YM<;#%MRT>M;3SO]G0P=3E[VFN M5\?\I?@[KUZVASIY*)NFW/%2+V>9JC4 0 [P4 !D !X M;"]W;W)K&ULC53;;ILP&'X5BP>HL9, B0C2TJG: M+B95O=BNG6 "JHVI[83N[><#L*2R%-_@ ]]1B+\_.F$9(3;8[R#-4@*:D=B3.(TS2#G'1]4I7N[E56I;AHUO7T M50)UX9S(OP?*Q+A/4#)?O'7G5ML+6)5PX=4=I[WJ1 \D;?;)-[0[(&PA#O&[ MHZ.ZV0,;_BC$NSW\K/=):C-01D_:2A"S7.DS9>/2?2_IR7>[F?U%U?7 MQ#\219\%^]/5NC5ITP34M"$7IM_$^(-.'396\"28??NUZ MMX[^39%.M# !3P2\$+ /[HUXPGGB8,?F"@48_:(+O35;>!$\"Q6.!U;W V@NL)H'M? M83*?TF-0^MAC'?18>X]MA, FV'(3WS(+)L@B6GI,A$4>M,BGDNBQ0!$L6<27 MW 83;"-*>DQ$1I0&/=RUK8DC)%"P)T+Q11$.I\ 152?0UZ[PYE\>R)G^(O+< M]0H&PO=V]R:W-H965T"<.3-G&(]MUA=>OS='QEKCLRRJ9F,>V_:TLJQF>V1EUCSS$ZNZ M?_:\+K.V>ZP/5G.J6;831F5A4=OVK3++*S-9'VOV+\)N5WX M;UG#8E[\R7?ML8O6-HT=VV?GHOW%+]\9:/!ZPBTO&O%K;,]-RTME8AIE]BFO M>26N%_F/OP0SW("" 1T,*-$:.&#@S#5PP< =#!RJ-?# P+OS8$GM(G-)UF;A MNN87HSEE?3V150>O>Y*.V>C2U71O0G#6XEV$ZX]PL736UD=/=(.A A-)#+'M M<4P"F %A=1&@85 3LOQEW$$N.XKB8,"G(TF/219S18YS981^;,$01T MN9PF<&\)7$G@0I3>;925P/A2B<30:1<>ZL(#%S[F8B%=2,P,%3[JP@<7"XT* MB?']:1\+U,<"? 33! 'ZK@(@F*%RB4:P% 3!??%?)S*2&,\9A\020HDF5Q)" M"(J1-"EXFE&ZQ$;EB.%>SXRI2@B:4D+FYY10/ H*4=#Q?$1$3=1Q3 P8JN%) M .,OQS'I(\^X) >7Y( D9P:%BR?6!8HYKQ>?]L0#"DUKB0"$5K3*JW?7SY&T M>G<="LGJ/F-% M]XEJ_)IJB !$-+,M5AAMBUI.MKKTD6=\CX7W?@J]G]@S*/#>3\G\%D7QWD]5 M[]>U* #IJG\:D@!$XRA]@(S+P?L^57U?UZ( I"L3@&@J( $(T=6]"F>&'GQO M2F$1PKUKDZD):L/XEM 8VSY MN6KEX6H8';XWO(@C\-UX1%8Q0<83LDKE"?B+/ER?L@/[F=6'O&J,-]YVYVAQ MW-USWK(N7/NYR^V19;OAH6#[MK]=]$F7WQ3D0\M/ZA/)\)TF_ ]02P,$% M @ /8>%2"K*(&GY 0 ;P4 !D !X;"]W;W)K&ULC53;CML@$/T5Y \(-G:R5>18VCA;M0^55OO0/I-D?-&"<8'$V[\OMSB7 M.MF^&!B?<^8PP.2#D.^J =#H@[-.K:)&ZWZ)L=HUP*F:B1XZ\Z<2DE-MEK+& MJI= ]X[$&29QO,"ON70J59T2$*UBIZ3Y4MF$0[PLX5!7ZW5$$IV*]VKQMC-H[0'BIZ8/I- M#-\@;&%N!7>"*?=%NX/2@I\H$>+TPX]MY\;!_UD\!=HT@00"&0ECGFE"&@CI MF9 ])&2!D/UOAGD@S&\R8+]W5[D-U;3(I1B0ZJF]3LG2P*45,?E7Y:[1]-IHZNN5^A1)]KE =BV0>8$L%#R[=MGY0_&GLO:@=$8>@,H3 MZ)'2QH/(M-+"%\5CYC<[PA?7B8.LW4-6:"<.G?;5&:-CKW@F]CK>Q-?)LDPF MXAO36WPK.,L7>4]K^$%EW78*;84VC\#=U4H(#<9L/#/%;4SW&Q<,*FVG3[;J MOB'XA1;]J;V-/;;X"U!+ P04 " ]AX5(S%$D)#\" /!P &0 'AL M+W=O,]+2".\OC^[ M?[/5ZNPW1-*"U[^KG2IULE$8[.B>'&OUSKOOU)>0&,,MKZ7]#;9'J3@[2\* MD4]WK1I[[=R3%'O9L !Y >H%?9QA0>P%\44P'0%[ ?YJA,0+DKL(P-5N.[)SC7N# FVCG0[9+Z)*RGL&>19Z?\&289.!FC&P999ND8&$7C MS,HS/0%T!H-IH' H!+)R-!Z@0#X).)'$0Y?U_RZCB<:WB<:N7[$+ 6>/#?"M M 78&V#<\OM+!>E)?S_/$ 3D&8S1Q0(Y)HL&^ M^ /RL=#4 9V9]*X@WGZWG^6OR(R+N_TEG!=P8'^E M9[\;U1?[/&O)@?XDXE U,MAPI8>4G25[SA75Z49/NK>E_CKUBYKNE;F=F::[ M@>T6BK?GST__#Y)%+D9->PY/ M$JF1,2+_'8"*:8=D,R$Y$)(7:7>F:OK&]&DR*68D!J(_=G1UL"E%3'*R!2C MS#DY3>E.JLA/Q6.TR8.3%;K!Q YS\)AH001&?35%C-?HL:/'[RPC M^L"'QZ2/'V!*C\FRY(V1X.J.,)"MZQV%*C%R[?_?$EW:\TOM!C. M+\?R?!7_ 5!+ P04 " ]AX5(KF"RDBS)/Z^9G^;:LSF66[KI&^7&I/2]8YNGA--]N MNF/?RNVF>*^/AU/VK9Q5[WF>EO\^97WS/2X+>$+\6QZO[.7MZKNLBYR7R6I[_ZS\.I^[ST_PD]:B8WT-1 M#PV&\\@-##4P'PTL;&"I@74]@T\-_)LS+'OM7<_%:9UN-V5QF57GM!U/ZJ&! MERU)PSQKNJMJKD3'67;78KOYN0VUWBQ_MD17&-UAGGJ,\KQQ3$R8 ;%L*A#+ MT'/I%+IK#HJ(-!6A0!&3+,D]RVBAYKI0T_>7H?XRTP3VFL#V!)8(['65IPZS MZGNCQRP"/QP'13W(!SPQ\6@%0$D/4B:85N2+BGQ2Y$LG"7I%/6:A=""6TJ,B M0AEEQD$Q4ZT4.&%"*.LB*Q!E!20K +(":H1QEL#180!:NY91L6L1#$K M$K,"8GJ,C]2LJ.^5.#!)#O$ 2$(\J]6TGE#4$Y(><)*GD,><\H"D 05TQPP* MY-N-5!%*>W9:UEJ4M2998+0\K:F6, #B(T(A3.S$E-PSC8I2GJBJ.]S(,IX# MQ4U,D>TJSBD'WU5:KD(CYZ7.)9!!-P%A9%.EKB4,NI )\_@.DHPLB=,(62^! M%LAX&8-&"V,4DL08ERLMYZ/B@$2^2R!T7T]#XFE(<@<9ER.'H^)T1,Y+(#CH M_&DYDRP)01QF/TH.1<6IB(R70 NH)W 8<<%-M8(@HG$(1B4GH^)H1)Y+( ,' M7(\!PS9VH$GN:,8%R=&H*!N-RU6^B2%V6\XA![?5LN=KS\%M":0#U*\,\E#/ M,LA'ADL@Y3E,.[2297$.(<NPB3TU%S.B+; M)1"\6I.0>!J2W$'&YT2R <&$Q%FX4-%1 1.EN@A&ATF4EK.1LW9 MB-R70(L030\)M(:JF C*HN5CZ.# 6HY(S1&)')A :H5"A4!Z#:W"@2D1F,9E MR5&I*2H_S27'*6ZRB7Q86"_3]O5>FK.%$^S)'I823D\5I+STG!>(O\E$+H%"()FZ3%AT .'>YIQ M07)2&DY*Y,!&358;.6!B!TQ"&(R]'\X,)! MD!R2AD,2&2^!%@;%R0!"WN#"E A,X[+DE#24DL;!--PV-5*^_:V/^S;3.R;P,W;L@L";18*Q0 C#+@9HP99 -X MG6GZ[;OTC3S]MB[[-Y9W792&RG@'!SW]CP2+SH-">IDGN:<8%R49N779R" 0%\58.O%"3/ G7XW)CR6E@7?9R;.@V_GAE M 5> ]G$^..U3.CPA-[*Z6+AC@YO]U)P:$_>=^ -7X(9(W8![_DZD24262]N M^>DU@CPKW[H7.*K92_%^JOM=\>'H\)+(5]V^AG!S_$D]1$HX'JN'I'\%Y(-^ MNSFG;]F?:?EV.%6SYZ*NB[Q[1^&U*.JL*=C[TO3S/DMWPX]C]EJW7U?M!>A? M!.E_U,69WVL97J[9_@=02P,$% @ /8>%2'O*A8O5!@ T2H !D !X M;"]W;W)K&ULE9I-MFIK#[IE)2.(:VV2!3&;__0*M=FQ'+>1+$CM/"TDT;TM-K]Z;]F?W4M=] M]'N_.W1WBY>^?[U=+KN'EWI?=5^:U_HP_.>I:?=5/WQLGY?=:UM7C].@_6XI MX]@N]]7VL%BOIN^^M>M5\];OMH?Z6QMU;_M]U?ZWJ7?-^]U"+/P7W[?/+_WX MQ7*]6A['/6[W]:';-H>HK9_N%E_%[7UB1F0B_M[6[]W)W]'H_(^F^3E^^//Q M;A&//M2[^J$?353#KU]U7N]VHZ7ARO^"T8]KC@-/__;6[Z=P!_=_5%V=-[M_ MMH_]R^!MO(@>ZZ?J;==_;][_J"&&R<.'9M=-/Z.'MZYO]G[((MI7O]WO[6'Z M_>[^D\8P#!\@88 \#I""'*!@@.(.T#! ?PQ(R0$&!ACN%2P,L,MCD8&R]&0WVZX=9/-=KIYZ]6O=:K,:OEK-'3& MR(G9.$;$<9@I@#D2R\$#U VYP"XAI^':)N%+Y(Y16A-N2 C'AIF28><>_(GM M?$#J/"#E\JHF U(R#.AS ]H9T!#)148.$^,&%HY1\Y.PA(= '"S)\I&+&PR $'A@L$I>*>>ZS@ M9RAN 3BR%G9&X,R#QFLC-!J ; M1=R*W$.&>.P*#UVN3.=A 90RI%@H/"P%81'IRP&Z(5/L&"$YON!+CX"U1Q,Q M;P :GEW*8>WG**5_'%,E9BH$*BZP8+EH=22D0&E$F(I*H!2BM*> M$BBI%:-^$OA2+&"=50PE%1>+'I0#PJ]Z' G$EQCA!%UG%W)\"FT 4I>ES2E4 M<*![! I[C*\?P@F_DF;>A(S1O,F8GS>)*ZST"IL1T0*D.&6-Q,53^MJ7XRI> MV$K%KQHEKB_2U[94W0B0%.:R[SA[#H]8K-%'#!Y$P+1($TID/!;;6#+"PU5& M&D;U")"PBJA<J*F;, M4(#4Y=; 660 "4E5J@!90\6%6 J'A:NH$HS9"1!C=BI<0Q5HJ.&8"&P.7*&A M"M=016JHC]5!QDIBWN5 J=22-U%#[:0E4527F+%P;+B *HZ *B^-Y/0$2!(S MH@!(45")6 J'A8NGXHBG8HNGPL53017'FIZX>*HKQ%/AXJDXX@G0#;T&>DJE ME'@")61&-4>8K?"^'"Z>FB.> -U0@7F&Z*H+SU#=YV<[X9!PX=09/QFE>/$4W+T#--"^>8C4O!A=N M \)M."],!#I_C.#/'X.KH)&,^0.0H@LWH&1,;L0#E<24E)68K7!H^!ZF48RY M Q#=5AB_B4E5I #1;05B*1P6OF(86#$,8X$U@3=M5[QJ,[CZ&?)EFT\NO"&+ M#3EOK.]@J <3*!%+2Q7&F+%P;'C-:CCOVP"B"WX/D04_0'3!CU@*AX4O%0:6 M"L.9>QD^<3+^Q+&X[-F8,7$ HA:K>:281\I/2#@O.4T0.$[ D3A[V2 C29U% MBGFD_(2$P\%5S?I.G),1O!.W5W3B%B_H+*<3!\A2Y1PPU$NZ ABAJ%+CLZ'P MZ0Q/" MM2T!;;.<&Z3Q[.HKLHLWLHFAL@LOB0 *[2#!X2)/!7:0X!51XG?X\!TD.%R$ MV7*A+4^.W^WK]GDZ*=E%#\W;H7>GQ([?'D]C?I7C\;V+[S?B-A?(]X6X+=U9 MRP_SZ]5K]5S_5;7/VT,7_6CZOME/9_N>FJ:O!X?C+V81O=35X_'#KG[JQS^' M2*+6G;AT'_KFU1\@/9YB7?\/4$L#!!0 ( #V'A4@@^U\LP0$ ',$ 9 M >&PO=V]R:W-H965T-/\>Y06(0# M_.AA4C=S9+,?A7BSQ;=FCR,; 1BS^A?7 MK4E_I J>!?O9-[HS82.,&FCIA>E7,7V%T$)N!4^"*?=%IXO2@L\4C#A]]V,_ MN''R.YLHT-8)22 D"R$I77!OY&)^IIK6E1034B.U9Q?O#%Q:$:.,3#9EVG:: MTC5>5]=Z4\05N5JA.XPG'F9,LF"(T5\U2>Y-4F^2!('TL4!Z+Y!Y@30(9/H%4*#T8B> M6=J?\ 4$L#!!0 ( #V'A4C ,;+X MD)H 'NO @ 4 >&POU^?DE_29[R#^W4'2"DRL^H]RPR*!-SO<.ZY9Q[^KBQWT7Z3_>L^O<[W MF]W?_VXZGOTN^KQ>;[XV_72;;YW3_\79G]P]_M_N%EOMBOT\TN2C;+Z-5F ME^T.T9L-CY#EF^@R*N^3(BW_[MO=/_S=M_@.OS>.?LPWN_L2WEFFR^JWK]-Y M)^K/XJC?[8VK7_Z8%)UHT M_>6P]_W(U+W=%LMC]G]4WY>$/Z5V&3\ 0/R7K MM/K4S\GJKDC331F]R/-=&5VM5EFR6:0QS++H-(QY#0LJDA4\LDP_1_^8'JK/ M7>^+ A?].BL7\-P_ITF!@(E>)KO:"BXON]/+0:]AJI_3U>KRUTW^N(ENTJ3, M-^DR>E.6^[2HOO!3WC#$'_(5($I2'& YJ[2H'9UN2M;\(=WFQ2[;W$4WNV2W MKSW^S_7#EQ%H^.@:]GB7%S68O$V*NS2Z6BQ2> J>6?+S3:O)UVLXWIM=OO@U MCFX(YZ)W^UVY T2 Q37BB0ORU_!A;;'5)]^G198OP\_^4[_Q[8^';>TH>]W+ M?ZI^=@5/+WF^55);]FVR*FO#F#ED:4V8H[?J__AO_RUT=:[?_73S[NV;EU7+V]^NGZ573S^U>O/MY$YY]^NOKT\@T\TA6 M\'Q]DL4"Z5L9%>DBA8?F*[B3FW17?>[-Y@%>SXNLCI;O=O> CPM94$(+JC[S M,=\!#OB+KM^LS>61;;TO@-86NT,<;5>)4"OCQ-OF05PX MM>WV;;ZYX\TNTWD-@?^E5V-=+]/;%(9=PB5L7F;]3%OV6S_8EGTA[W)OTXU%O$(][4[S/0'R+/3)5%6L(5$ : M]R"@-1'']TFVO 3*NDBV&1Q(#2[K[2H_ 'AYI:L\V3CDK_KTAW0'DANB?E)L M0A?HRJ$S?", F^!8[N&B9 ]I=+[*R_)"D*Q^^T##H" M, QF J-F:$S[\;@[B/N3(3YS!#:,HNWR& L"]_EJ"7+,?X\8CP+7<@$86^3P M*D@QV0:N7EHV$;'P&/R=E( M[4'D0&I&HR$Q(/3"_1%P 8L?X9B Z&VWJVR!AUX309_.U<_?)WCC[],=#+E" M+G\6?=L@QE>N8&PO2G0.>+L$F"8%T&+ )1J@2@#J SC7"T?@:8^_)M>NY17W M4C]]G?[;SB(%IT^>^/A"&VY2ZQ3A0[[Y"!_\^.JGC]&[U]&K?_KTYN,_5^2W M<;1F-2Q%-2SR]*Y3Q3M7]([^Y<=T/4^+&HLRFVI_C C>FPTH!43P&I\SE(^' M>XN4[X.A?(VON12.^>&U1^&$S9^_)4+7-(HAI*^$D#8^62$M;Y2T-(,I#Y#Y M%Z"2;G"BZ$6RHLO/U+%9J*Z_X2#/T;DV)9WS^0M"9N\R[ 841^8483*T4$<:8F\60/V1)PM@2JN("KBS?JK-N9 M]%NNL'^OHNV^6-S#W@)R9/BYM@M8X<3Z#@N76Q+64="O:\(GOM M6Q(X 99!;> 5*<(N#K6:62J/5Q"H]=5GDJ.G,)[!"?:C:8/&^;S5-5N.2$== M!C#R-,YR9#DWM)ZK#S^]^>F')O5;F)!#I.,C-/O9DS:# 2]["L#%QN\X+,$+1]U&7N$RZZ;>WZ8()"3%+YH^MK%%GU*V>(*R?0ABO MW_WX_L.KW\-7;_[P*GKS$_S]ZCF&T:\S63-%?I*(53>OX!OYYMLMW.X">'*1 MDI$YGZ^R.Q(P:OOYM '1:45JT1U22S$8Y!NVWMZN\D>@FOWVW<_/\C"0!/8:T$LX MC^7E5PN@'6$SZY4]2-P4(N!FD<$.-RZ=11#"WX3 Q !13YX?HMQ,D9@IHLNZ M9?8)YOKK^V1SA^<9W2:9FB< 24&U0G\DVY2*E-77MH%8*79U 14+CDE)3^/; MA.GA79# Y<"(3/^T >+33!'#GAR?$ + M8 L$_F.Z6LU3!!5Z7HIMD95I)WJ#J,\L TD[C@02P7*_(!2^+_+]W3W^"TA< M4,P+B4-E>L>WYIS,PJOHO4P*DLM5'%4_)#U]0U.(/4.^2O=D]8I^OL]7*5+L MBTYT8SRGTQC^H(F<>!LD0[?[0@P,)L8)0+R)7@)%10NS&GF'<2.L 7,6":KX M][";_6(!]!L&!E30%T TK1P%P1[N/Y*6'5[O!*2%X@ZF6Z9E=K>1.\\7+0%P MY>ZA.T/CS:'7T:Z,>T*A)=F@[;4 P.]1M\1UP>0?O$%P!9WHO;,$?,Q_QMVR M[#&)'F&FU>$R?\1%&M0Y^(NJ(F,"\%PECXP2!<"?-X(@%W: LP- 0%=B9A5: M#4D&R>)>?4!DY'64X%)5%[N0A>N)!FP$?9:\LR!,PH_TLT#!O<4 UC<1P0JH <%;Q&(%(X1*PK!M%ZF0JZ%C9LSZXXM,08J7ZZ1<&2 M!:+'C*CP$FX?@997C3I3^GGG/%(@O035J>EZW0)>$5>6]X'AI8KN[;A9/RA\ ME8A.Z@I-.A(HXJ AXTRCT3=U+3;Z83W_/=U7_W.ZM 1%._4R6Z(OVC5J8NB@ MWKD;U(F6T8Z$N(D-S<_6:IF.KK M/6NXVQFO>+]%H:!VI W@Z: _3$41(.F%H=@$"YX=_U2"T8(,CX"F!@V*M*@? M=R?ZR/AJ-V^G!MJR2X4_V4 G>"JYP"N^0OK,*%7N5RSZN2QPXXX%2\WJ]#M, M!F#_+$B4]@('+WCKN1\=^VN2&T LE#F+W9'3C>E+(95Z+LO*Q>Q/.G U&VPO M>#4:]_PR?4A7.2F/]B+__.+J)5ZZV,HV90[BMR_"1# VR"19><_"L+=.##8* MX(WY?H5QWG3[D3-%H^XW0!P*$I3AHZ*\S[:T;EB):'?\]>Y+ MLFL5H?!$E=Y$0P"35<3J7IH8;P^'R- %TD6Y2XCPH/)UMK!SP1%.^G $WB;_ M_*?_NVRGIWQL%H4"6S\)1^C:^F0&/]@HB7$T??PBVT6@2$7WP,'R J5 .H< M!2_O5OLG2FSH?R0;BJ(21W[,:_P]RU)E]#9;9T0,X8-HT.]Z#@,FN?!\%<0> MK68&XU!'8T!4D! [-H?V>Y*R%RC(O-DE\&'T$OER-M__,4-)Y::S[5RQ-'GU M^S>"U(_W&4E%Q(I0E*2+*?.ZA^?!XP[0:=N)/A']7H!@A&;C158L]FL4J19( M5W$.@BV=")\[1N!J&'#YCK :='D=/;6L0\7E77Q MLUZW&W>[W9JY],KRA_>PUT5 @PT\BT%LO2'"$Y;QG!&#R6&,HB.1H M/FQ@+6TT'!3=U7Y)^E ^Y R<@/.;=F/5)'BB_TJ56/GW7XES,C>.+30 MF! [%4$H"+5$AP6^E11+0W&S=8@7!]CFD5W*3H!4KGR.!+MB#'8)+BHT)4LE M-0;0$3.CCLMAWB":;:)U\DN.!BA14/!.[AKG6.8IWQD":GBN.)KO=_PD/87J M678+1(:H[>UJG[*&4Z1U@M5H""8AC*=0A>MI].E8W0^2%BT1DF^V5&!W@M M1-8Q-K","%<>(UHI7G65E_N"\!(>04YF* Z-D(7RQ "> !QL%BRZ)O!!B3R M8X62%JIMJ2] %S!XMEWQ!4%0?-H0"2>0$;BNUBFR5.(X/UQ=O2?=Q>*GO?-H M\P#ZOZL0I'(/ERY(D0!9@-6)5RCF@/,API2BL]SY4Z)XMX6*AQ9$,SK^R MY<6%J1,3#&< 9&T%LIG2+& B^XTA'0-RC:L"J/GX?( QQ$,T&?L# M\LV*S$E\ ="W :(!25;VA8MH0Y8+O';D0Z()@(23Y\\LR4JHK)[A @DA*ROL M1"] "]Z71M^I2+E5F=H0?O+ R*V^)S =X.N2,@=!>D.O%D8* <\0 6=Q(&,Y M/+2PIN\'.*B\P*#J SJ84-^&C0)E*]@%@+<%A&A!G[18NUDWM\ T\H+,[E5Q MSZJBL>^4)?ZT.53 )?I(%2+[8B%.JR)!Z"5H/)"9L.Y"./*B#P[9 LB^?^V M/B\AZ1[.W\%4PDG5?F*^2W!F6U*O\]J^ I9BM2,S^K*JC;Y]>&E!-^6.XN2V M%"<'&RWN,E&^O2\T"&=WV(H>@<(L43J?\D#!==))#BKT@E37M"I MX,M2T BTKV)_AX(ZOYF@Q8MMO>1LWJ66C,Q!'L#;*Z\[0KXEZ2:('TW *"P! MC=9IV=B)KW;0'HGPA0._ Z!L".0,J,U>5042G'C6:(-'C4L5(DPFGKN<)23= M#]D.=)6P )VXI"Q6D/DWUDF3HV&;?]>-X/5Z#0NVQ7U(19Z MB)\!(R-K!-# -?%>,LN4Y7[-85J^N6%.3EVT!-@7A !XPH6&_D3"2MG^2^]] MQCN@J%.G@"N=G> ME\V*;3AYD+3= 3HXW$'>;:(K$!97D1%Q6_?\(@<%$J'ZD@Q,R)[(+/) MC%T M7N/I9V@/YF(#P"8>\:B<*>'QNR)9&ULZ14&3C*B1JC-ZRP\#W0?N+>0=A\SRK2#N"W!DW9)SB[='&_R5?YW<&5 M4$1&KM PV-&>N!< Y1*CGT$B*NY8ZSCK3XV# P7T1[=:K?P&0 MU6R@]TAET/3/CR;(QS?D_]^E*LD8XE#:C"V.)B0?!^H#/GG&;8!@1NM#R[7U M0)(TE;N&_0;0T[O(S!!2"S7WP-^/^ .&T/?,K1$IP[5=-!AGIJKXO;;FG*8+ MX-'WDVYJ;Z(8K*(=+1FX!4AC&4FI9J?,,E&#R3B&@Q&X!2D5K%\+_7RVQ@P! MZ*\(EFQ>*,47S8'NLKGRXKN:2/J18.\F4@5,1"BW^E$K31$KOOWJ0Y7&1&>4 MT67_NZJ0EA(^X__=/(N.1/U1-("W@?9R2'41 -89/G4&S_$J\-DV* @^_35V MHZ^W[<5?0O5\;^">_ 5/=]1W5@-_U"$"H,<=P3_/A,E@$$UA@&&O%2J]7A=^ M3F4ER'I;(-%VPD ;[([@C[_*&5<7T9RX]C8-A6-6OS_F*AIVHMHK;T@$7(GQ M!N7^%4=4 $5=9Z5C?P51C:B0M4 ;($4PIF3A44#95AN=!@+#XTN#''&@DJ4 M/J(K6;6G'4AZ#^DEJ1EDR &>5K+)'K4CMH64,:">6,Z'UK7A3 M_C+)MH9!MJ@;&AN5._ "SW?ECQI1[)&W4/4LK=>HG1)9QCM#@CVP"MHW*:.;H(17[VBIDH*3+HT%F?:\-0&\17B#K/$ETB]M*5#[:)IYN)WKY/ 7!EX^,2.+*13-?@9F,K)@DIDVX MC"LV$*,15W,ZR*Q!(I1 DVX(@13/BFPO-KR6E6+^Y>!&1_@,.,P41+3)_MAL^O9D6;,37:M*5&AH,,NW3Q'MK/W["8Y' M(376$B]F$/=,#@1*3I]U\H<"HJR5T(G<$=Z9H,:**&D8JE-T+BA@?'Q,5P]I MZ-F*$F)\P'_^T_\,!;,#\QL.QR2_36RZ,H>#5:\A)1 )M9YKCHU#'S>*7@[> M3B91?]!#%E^QU\F=-A>3\^UB%W8,6N<<3" 2.4NB\]XPNHC.Q_##9G8O%@5' M$_;Z47]BB@<=V&3HX'ZK,P>D@MZ G<*Z/Y-;4UER=#ZB94QP'2ZTO=!_A/-X M(M#V60&&296 U>A&8]T(2>.*N,%D)G>9<7*=?";:O@6)8D.B ]Q\J6:$<&>8 MFA/!FW,V<"P0H1I1'99&7 )8PID7!_&X$.-(/Z,B3#01A([N8%8ORLFQ 3]R M5,.;YO2VQ@>/25! $IK??=445-$4]A J%,8$MD'3,R'.<* +Y)2 E'!EZP-7 M![U.BN* H/L#7:1W)OKMO1GHI&>:MP@";-P'&;;7_P80=]2-ON&/AGWW(P?K M_GNI3GZ4SAO'59J5T>]>;,T/>[B5?[S/]Q7-IH0I;"@_POBG9/,+14?Y&I#[ MF(2(Q35^M/7?>31:4V4UUZ#R)]\;/WK3CN"R28TAEP%J(E]BPH2\F-)W?"^N M$R[MT.& "S+-,Y\R^23];AS=6(_&*RR)V9Q.TGR5I?F,,7#) MSGL7M8N&GUW[X "-.1Y/)_0O/H*EH_PG>O%HUL>?0":OZR4]P4GD&[3MR?C@F( ]*;Q_%P.D,:,XQGDVGD5IN)!I-A- .^->GV MX;W>>$HC24P6B()]8(! CR;#062J"@@G;<^3CF91KSN#-4:#_H .6W&&"FE[ MJ(A*@T18-(]'FJK4($!9E9RA6>$(XB>RC1+X,._,8-A'%*^7Q]\"52*<1+"<55#%%DDTTV4NM:V#HC MB)M QURB2"\E46XX4O9L:3B2)0R29FOXN4E10%?#A;@ ]H6J(^ZF$\9>%F8]!-FKN'*=%3&I_^IBL!%+=D0&,>R6N IDP$N/[V"/R M B&[\?@UQ9E7GR!W*Z5-D)I&^8>OBV2=/N;%K]$53L:A.,R46"QCIT^/2<\@ M]F($V6W@Y\14EKK+[U+BA"2XW6&BFB:-V*AT+?Z&EA%F[X)Q)O4&$:VZ'5=Y M-@-RV"\&0U&HG#%%Q-Y,^RW^V9O%T]$,*/[("6JOP]7+1>3J#ABO7/P*%,V- M_B4[3RVT$"4SJ_:[86'\?6!;1\* Q::%OM]>KS.J%?BM)#)TQM\$]\619DX: MYL(O]8G>_1V99_VJ'&>SF2%POGRB2762&T2!2\W@-*7;&FPXQV)X_2Q8)\C_ M!C>4%$L4=)<4"F*OQ,TU78*/^39;8%)#[-TXU E?8K596\36B;OWX-]R2GXX MN2^9!Q'9U >F5)G6LC_6S()687LNQX3.[$E"Y]7QA7AQD&0QL8OQQ&$ETO8G)(C=S8Q OO<$T?8DOA,Y> J*DG:/NC85*N6 M>)5W70)0+!V4XF!ODL[V?A4IJ?T"WY"=L&SQ;P8T7%-*F9;%)NH?PM/4/N8Y MH]=V'T< ?!9-2.CL3\;BKD$:H14 [?T:H _K'&TQ@Z&X?MJ+7.'(HY$9F5Y% MO;G;G]1$LK_.EH>#KGJHXMYP$MKT!#?=PTV/3]_TT(Q-K]+PTX&)!'@&O8PY M;)T9\5G/%UH;1=9C&$PY=M68!U9*PJ^Z&[U]QFZ,\?EC18^52,CV&:F2P0J( M(O"%JJ[^)22SGJEF2_ZT?7=,2IQ@/*3S>$6Z^MB2BJE>B/D=7LN91"YRO MQK7=:KX]D>:V&@Y2KS\<>D_!.30E05>S8T$.ZW:_J3JM;+A=C9MRZJPU_U2% M8S?AM*:R,'.3_3\IX]D)+(5EI9^W'$&=^=53;%9(8Q66>9KL=P>V=*TT.[[! MCJ9?+R69E,]'_.O,?#D //-B&5@Z+8.;5>[YE+UK9-72/SN3"=N:G3U/=X^H M#+;I";'% \WHL(^CJ.L5Q&A9M9?!;19*_B?D-M-"P=&0!4M,6@"V:U9FY"<,FCD8$EA=Y6:/.S*GF(N'; M365>SGUL.1LZ+XN^4B\ 8LR1/&%G-$8@_\>_]SK=+AN\_%HQ041PSR Q.716 M3^_!:&8IYU[\AEU15U:D7$'L&O:0)N-.=W0!=XV7$ )J#',-.A8T1"A6&OF M9B8Q". (X^DMO%Q"DSHC$\;MJWD"""G)!#YN* E8VTT;X F'AF85K5,V2>. M2.^"F:T]#VGE9 (;52KDFBUQQ9I6Y1$@E]*VZH6@$F$3'11ALV6J'K]J45O< M!6A8\6@TB]X"D?W.^CH]I=QS^Q7I9?I9$C^;0-0#_>4-;V#GQ5)CAB MV8?]&>W8*2?%=>;4IU6*ENWNA0:J8()?)>H(@M&AK[EQ&GHYEL@"2#70^JM: MYZ9:PE6#%33762YS&W'Q3J=3.1;:"H4S@.(73R=#;>W(^F:O&\\F$]$??2 0 M.DA"(7# Z:@GQ[@(GCMC.YWZ.1_Z!9Q4W)_U7?4W8(BI 9!,D',NJ=^V[REH MQK/@TN'@>_%PV(O>". 3VYOO..BM^;?)FQ(U5WX$*/<&4:![8C2()[-9Y/1+ MQ$]Z:L^H:(G3V3!J;6H(+T^[XZC6>C#J]>+QK!%]E M61+TV;H6W.2TTW,EI K!J/#*?:DG)0A(HA06BF2UG?+1:JNA?="MP'1G(>/X M-XHN+7,4F!=[RP[*(C^ D&[, X;8>:OXWFCP@/@+>\L:?(K&SVY04N,*]*_-0M,Y!^OJ;@8*?E ,_C*!<)5>YLF+B#D4PE\V4(5HW^A)+7("4DT^ )T\'Q^X51C8\.4>2<84@3O+"ZB\@ "_5UF M@F@UC2,JDPVR+>B#, MA6A!'^-S^B(>! GA+!J &/,Z><@+)Q;8LM=)-!L(>R;I?SBB/NU']AK<0\LJ M,!)IC('+-5+:IP@E7< ,9$0.N[U3AD\ZK*=.%QG1!2+A;0*GF\-(A0HDW412 M-%4/)+NU8F[NFIPG+!=!RM(<;^(6;?G9PL_C-CYC M:[T1#=.M]&(2S\LGQ] 36R+3&"X$PSE@B53:X?61ZKPGF7_)34;5K2O6;C%D M-I0&KR=>?F%I\$JX@>47IN2401Y;],F:#.1$J(Z=5B]7L8LAA.7@4?[0M%(: M"DX_Q; Y@W8&CPSR='S,]:P4^$9+310VLCC6$\GB0-,YR0AG@\[(?(G![33I M09>E-A&WXH^.3+E*Y,*D,/-PK"E.9U'HS%RXG3UR9Q MJK;K=&01?E0_Y1%4B@FU:?E9Z6XT*ZLHF97Z4BO\&'*\14=!H8N2M1L[-!CH M'NACRO1DPQ.CA+[*?D5K*349NDO8XJ7&+KYBC3!1>58K]]XG6&.@W2E(8L91 M%N"FL"I26FV.:RYS"2SWZ%DTD?);[.S1L )C-;6:J-*(&"_^O)/VL1JSFPT:8.@+<'O,64&WJV*20]8<#!!/A0$GUQI:,@=#4L2M8FP+ M1:GXW5!)A!(\'?!C]:>42OS01HL'XJBUM,56!N;4-'#K]#V%K\:LTT[<4A]. M8D%T?C:J9 M.!^ZS#;$-+=4;7 OP!6;N/FG39K>!2A-/C*T+FP"JECD3!IV) MM0ROXP,[K9WR-=/JDZENNY'D]!0"K*W4[7D=SF"\$PS#DQ MP=@FN,1N>ID<0MX#FLHK(XC0:-^GNS4M/Z8N3[AY'J:X*[X^QQ M7(O.8#$7G4Q*)P#"[3]GLL(]KX_!5%M"SK\V#"'KVG$78AHYQ9Z;QU; ,GXE MSVXK$0'E4R%I*BF; I]4,Y\5;T_$5=VLPUEI3NI<3]-=< ME_#![86S67$MK4P!; L5S4WC%2FV^:CZ2R75FZ))6,"PA73P!K;ZL/5VRIA> M3C$)G;7RKD(JS(Q$WO"L:2P3XDO)JQWT=PAL3BHA8Q\_H1I)4SZG-OME7UTE M]ZD;][MH+QG-XMYD$'G]@GMQ?S2(^O&XWXM:&PE_1T7A%VAVZ?0Q\++?&?6B ME])!M]?IS>"3X4S<(EY4'B)S']==W-2^SE+_P2Z.D#8T B:><35O2\8]4 M\M92R7[/06L0T2I[KB0I 6E<0Y1M?FFY*+*M4"2JUYDL<;ZSGA5XL':HT7BI M5$+?_:YF6>-+;T5AAZ/S#>7HN35R[P+-C(YCMC)4S)7C TY!MX:+$XY%]\"& MS1F!P-ZJ:BWG)]4C,+:!2G*50]B7:M!]3(JE>X?PX=./)H"%(8VY\[*LM"O+5P:B-CKU#5ZBY![5HUQ]<-.#[4;,=9]7 MG':BD\:^]O,7%AKSP%B'D#/8/3\$S%N1E+[6L['"G%3E.!PK0X:J>[N.UZBU ML=FT&@)_%DWCV;!+Z:#3V93^'0TPE+PWC@=P/3VJ=1G!9:8?#"+,U[R,S@<4 M#Q#UNM&Q-M#T=!?C!\[[Y&0^'W='42B-U5T8/D/YJD!=SS!@83+C9&%>A?&5 ME"XI",6 N2OA:A@8($I^3<\?+/N5FB&58V9!<+%?[^OMA3GOM>H?:#SVXTD9 ME>/B+ 3)6R#4"F!IV#U Q0-F _IW"$>@#6-#M#N:=8?1=#H*.Q+&XUXT&73; M;/CCR13^&[7X$H:C232$\\5*4UH1.]%\0N#!HRG\-]15FIAG*IM.SO\$;?2S M4333O!!.B4DUI!:G\ M?!L>M%LQ*V'ZT[-F"1J6.M$K8R1)N,IU4*L-P\'-QJO3N-9X1'H"?DSPQQ1_ M8+$ $+9/6\]9-.PBSQB,B+7UIE3'A)M<2".(VI&YA/M290P3FI$@=YI=()J5 M$_#7\![@2)IUL>(P6'=)7+\M!S5*EC6CF@U(+KN] ?W;[\] 8YQ@*LK>#.IM M94);F&"EC4Z_Y;D956(@%7;4!05TTFU[%BL*#>DG/-^93D;NLY5-N:_"%<0M MC ^XUX_&G0&S=, G'$"_3GH]%J>Q;HM/6(]^'/0F;8\BPN?@>J+/T?P[-A_ MMFWY5!(%V/$0)!%4TWM];^>O]D7NOP 2Y^@BFO9ZP*&!QW=&S>L"^7DXD_\Z MP^;GAGUX1OYKVR<=T) JV@Q-_.?Y&)8/+RH#JUQ[XE>S"4GR@W@@E72P^#*/ M[%]X,2SL-XE)B=5XG_J%USKHCY3!*;TOYNAKQYO%JPO?*!O5A(4;/G-+CL\2 MK^M?&>H-.GQ(Y#FR>97,L,O MB^162ZM4T,@=U\*R5C3%*2 C*1N#F91[Z0#OP8KEFS1Z@7LI[ZMSG%I5ILJE M\>9?H>73<;,XY?6B\C'9LA5%0J:J[I'2K7T"DU!\-][QAF MG!9>';HR=)6>#;2N 1I0&0$:C?AL$(T51RLWQE$CGX*=[:C5@+L=C'OM1B]$ M0"-PO]'K]0X_>! /R?1H3WIC"-Q0%DZ^2-,E]C"F8 +QKP)*49;<(TZ/."R7 MFR^1=8#E:,FA>";Q9UY(L(GU.XM3>[N?P[6W+U IR9VSXP/G!GFWU:_U&$OH MH]1G(Z,VN>DQ!9(+W5*YA8_WJ8,SAD2B6%'NYV28I\73*;JE9,ERB:/ I<8^ M1_W:.DZN6XE6%/K)-U1/93I&V+^]1> M#$Z#_XXN>TFW'0;VHR)_Y.MRB%XBD3'U3S]X?[T7K'U)5!(K/W3AQ8.2BC&0 M:R95WT=NQPA'(H_>OGGQ[@,11M@47 RLY+VB9!3J,RWHM!&!:9I)9>A)=6A^2D9%KTVW M1CAG,JZ(P;S\8TMVH-DP+DBT/*[(O<\8MX^)K+5QAV;BH(K4^ M"PJ!<8=VW.>N%HTQ"(L/7'^P&LR>5J??- TN<6@PA%X]=(E M9QVAQN=C06K5@9G\.0DBMR2%^+TEV8U(N:4J45P( MP^Y5&+8B3Y4JGO0-IS VY]US]AB<-AI8>L>U%S*A["ND^- MVH::S58W'Z"0QUY#6%0)V]%WAK%/DHZ]@,00=N;1DF/O(!5SN"45?4?HV.B M('+5+CZ&;N^4-DF=QV9Z8]0F8$Q]LHH ;1M0\$2^-*GQP4QO%R];O> M$2\_7K]KZ?GRYM;IH8K$5@K?8BB.MH4!I?).-)D'"JP7F_<]17RFQ2+36DA" MXKE7)9Y+)?D=YY9(H%:ZP5"K6!-0(FE?2S2-M"RC[FH$ MD7-B/7-B3E!2P]GQ*HZ=2B?ZCW\'D3OZT7%*_?G_^G])67&L'F78[-'O'C5[ M2%4Q5G$L\I(1P"DV5[$"HNF(=="*Q8TRKRM&C9@Y].D6C8[5TB@$<654/TW# M%V_5BGI_>MOUA>0J)$;_VPSRUS6#_'6L(+W>5[""]&R:UF]N!5E2<%+=!,(F MV_JU^RJF$1JBK+D)?_X]^C8;?^;M>\2_ZQ0>"1 MD=';R0<% TV^6*NU/JAV)4QW&+L*27R"&N:]Z*O!K9Z_(UJQ0NWT]03?=#2T MQ?%%C4Z"T>BY,!K%+9I;TZ%^D4;7+F0]5ZECF&F?]_\U-;E-Y&EQHH@Y(NDU M1^?CKS^@,W!#[/$%ALX_7TMKTH+<6][T3+L?GA2GP)N5MVHJR.A$/:I"+8)J MA[N+ZFT.OG"$P.35:4=/'F74(CP^0RL*J$)?61,*W4W"'28Y@(@'I3G'M:'@ M8%^D C4"\]FZ4>.(?W&EJ7$E?S/:U-FPS5_L6"T&)/KUW3WE<^F0Y7F(FQVY M-)=3/^ K.7:)PJC\+!+N"7Y>N(,;Y,DUO::FU'R) F.@135B _6O&U'D)&6& M4C&"KR>J.%(L0H?C1J)E3A$,E&M(30]00%DE"%HJT'"ZBNCMO[H]BK*A M7.[?4G]LFOXW4+MN4ZM?V2ZF=.PUM1''[J%S"PAYC=H@GW$NWD@4TMRG"G.A#&*'U'3&D\F3R4V#<:TFJYW&+V(A 9(-A5G8 M-O^=>BZSP$T-L/=K-Q?:+3YM9G<:)SOI321,GU"UKA-=+>T=K%:EX?*?\-$9 M*HFZ2"RB&SIA7D%6:$NC@7@MUZJ,DDRI.;9G(V?(4$QJ>+BA/]S3].HZ36DP M!7S]N(->W <5MWH!^GVC"??8)TQ;'1&4W(?K;F%^D+M&D1N[.O:P;_S-PR\9 M&]>.ZGF;1<4%[!'KRO@WL:[4;0>XR[ID9BFG(]0&I:. &;_J)(^/>,F?JI4F M3]%*@_[%^7\VK51SV2V4@HII_3'K9?R;=#+V3W >X@4[X3EXYF1G7[^#NLT".H8I7>]<(A$LC-3OMH1SM(M=O5Q]2!_(BMH5..[? MBK&^!N7W>JH=\#*3B%;#*?VJPX)&H]Y@>B$0*^K.7.")@T45R1VW%O$$ESG@ MH91N\>.,81&2I$!;L4C-HF-2%%C?$#=D5L!4_'_L5_2[9B$CIL=N=O)&'^$% M>ZX%/&WBI:D_,KM_?TL%0T;XWTK%?Q:EPL,$I/T Y(>TX$I4 =M;LIY#2?H M(%GIN V?K(=,V]403U@]5KS,9#)^M37P59>+[FC(QG?XUE0D$ M&]65I68]EE?[ ,!J!\Q-S_K/."HKO-2\IE\LG_9MM^&_+?DTX-DZ,5;S24;8 M+Y-)JYX26-AO+))^D;#X]>2]2A1XDZ7@&=;F^F:>+N+5#,@G6HS53K1K,>S2 M&U\@Y'VAJ;?YS#N2M^3DP7YTC!M,6^P'8J$*:G^5.W96!O1R8HZA3S!73J:=NYND,IV2KWL98*E MB<)9AFA>ZULB3/A46:FW/#S71RG(;2:HR;/=SKC_S3.**_V8LFRZ?!.F?$@?\A75:[P&S 0TL5][>6O' [AP-/MEI\#2FRD5TCOOX\Y_^+;!"MS,:H/=#AAF0)R[ =,[C E%4:5:OQ%9[;0V= MNLH5,5MD:N=R\DTB>AP )NI.CAV!NG&M]HO=7BI1D=2 I9N OJ]]=B;5BR1M M$^:F?!ZA+!N7N //!LW)+S;HM01CX'+U*V[^&+JJ+:>(N,U@2I=5$)V?]1UE M47A3G0Y46YL-9@+NBW80-@E(0=1M%9'L*CN!CD;S4X_TJ2+4U[PPMT P+\DN MY&AH:RQ$O-":3(6YNHUWJOEV\]4"Q@C*('[/<3).@TY;A88%:E+3)7JQ9W7[ MOO@G10=+'YTKU+) +.G"U<;($I%2H[>^0;78.!FCL\'$-KBGPL;:W]<00:/( MP4NK=+?#VCQ(;6E27U471(%CH7,D^G![FU%U1[B!#[DM7.GZ.^OM#@V@3)JQ ML'_L.K%;L0!"P\D]L6\@/T06L$Y3M?;1P%I6",\?&YL\I+7=$ UGM3U?@91_#QV"/<^B M*XJJ M"EP[+31B9[97MX6%Z?) T11(6YQ$;M1$X%N&%$'S.<3^U. R.:D5UX'CVK)" M4(L6AE&-9&OF'R!3+J1(U)>SDITG1+KB3Q$X9[%"@MR-V&"DXV: J[5FOP4- M$H\T36O%L)\AW$@\;B4KVR8%Z)7'UB0-.JG.9\KQ47()NZZ\IW#36O5=8 M7]+9+A4"3#DPBXK.2A2*R";(6TIC'&WC=^*3;-Z1RV@J-L7M?H.HN;)&.(R> M7F*K,OB-=!! 3&K&NS3.RQCCL&'-Z4I;]<%YFHO(;>$YQ*H=HQW[:SNW;3\P MJM_O8/)3XL*3_2Y' L^J%//SA$M@"=_RTN'277?5F7R9%M%P M"(D:U(:F-Z N# 8#R]?@NH8$A8LTJ[PI:(D MX\V!][G+^?XT#<",V[-[QO0P.K=.$'#T(G+#9Y0[9J;;);M+I]NEN1]3K&8F-<:DX1[R'62X M(&Z3M*8++SLK]*2+G_,87[ M6_ U^8 %"Z^PG6M>;'.AG]CO6[^@&X5O_P'V F)FHJ_?[.E2OLRA'=MB?7 J6Q2IR\[/E]]N&W+T9PA:_@ARL,9 M]U]@%N^2$_:SI<)/&(^L7C1S(0R+OK9#O:6A1.G'=7YZ<8/2K$8FOGU[36/C MQU<_Q&CC7X.$MX2#QP ::3-^!LJ([6,DGCQ'K_>W4J&WTZ-DI0(9P;D6]&JG MFVT;8I[G-R9)[BK$VW6-BGHV-L!MN!$&^Y(O7/@+JJ]U&UVM4^P7&$<_=:XZ M7[[LYD5A2R(B>_D="RYFD0U;-6,2A:A^6_(5$='/QT-#7BVR4^G?70JZ5B*M MZ8MT[DH4K%6VXPYG)XHT&5X5KZB)G%$;SQKS5,2VEC:+XA\]IVL:L9/:%[@XG>;Q%MAFYS,VEM#=#?Q@;PN+X[ E KIQ"\'-./Y( MC.(9YN.6Z%YYCCYX=/Y.10H*8_[N,;_4B$F+_76TCRUMX%8T^A)K.)1!@[G& MU)K3Z=4&?ZXRNR?1+ MCK9YQA8D5N>=MCD MX;*6M])]Y1QNT6,"9UY0M3WM56/4/Z04=-<8.XLTV]@ &L-+K(%2>CN(Z4R' M(P=J8*B 1>N$+?U-6K4P"9YWPYL[ \W0!8 M8]X>.&$;5[#,S]E:4D?A[A[1"[^K+ MVOEQ$,&5H9&KV(FW==9%K59I,O7VQBB=5R=LC[7G\K^$\JP.UN"7Z&W@LA?< MLDJZC(GYK5'L.OU$:IUD7IL>XV\VL* ]0?RDAXZ58^]U.U'X1=?TNR^IRDB1 M/; ECG/T1EOR"V_H\9_5!=76ATY;GH*!_2+QQY,""*VL/VU-#&++&=)W?;8 M:W*X0>*UHFM9WJ?D:"1/DXG';%CF"<$:L8WB 5Y5%-QBW91KM2ZM,J7&9BF' MG,AJ.1Y&6\JZ,W/S29#R->N/*6VY+JQ<4LD55GONUX=T'J1AX4^U_ MMU0HADY27/(R>T\8^@O+R(&FXX0DCG$)@%MNQXU94Y?5(M]< U\ M3%:"=? P ZL4R%E)HF'9- MH6'5Z/9W%NJVW*SVXPBOEM+4;P'QPXL%!DW5 MBVN,2'=@.PCA!"PKU!Y>.FAI=D6RTBVP=>J!AG*91C_<9W?W<%.W13[G^ ". M.'1ZT@ZXIDH:"[G09GD52WC.L9'&5)Y5H8)QI>[J\2)^ MNE'\]*K:I]RQ5_N+46AG&8*G^]:MD2\<:AASR,>M."!;81P4'=P9$#=B'\%J MSZ.$T7$IWN^9?+B0J-BQ;=AP )]CDTZ!&4-N\H(@KR0'U5(4.90)9,+ 3?%D M?AM_R;%O3E*1%$1%X1B;DP,LL>L[FZ^K>4I$I]RU]G^#M>:;]/)):^U0GPY: MFZKWFAZ!N@1&%R^=H !>CI=$'(>SGTJE-R2('6%,S1GQBA*.'=N+^-' H^8S MXE70D3BM*IOAQ,\W:-*8U6UJ<9 .8>D[4<9J\0^2[K'6YZG-EO >W+$"M\$& M2]01%!,4476V32'=4$1!4[-/^8! :UI@[$"!FN^-.=?'(;R4FL2SR($$_5$. M*BR\- HI@8Z[M:ZZ1[N5UB,GZXUX3WDF).R8SR171SNOG?U1>*,EGR^]QBSRV0;)#V<9M$NM$?3,>>?U'3$S5*0+F>:E=6IZ QQ= 6$[NFD*>%NX-B,*Z M*^1[O=-MZA-15_'3P)_5[7G![3CE6<_&=OA1_S_EIK^LW#N,#>-K9VX$I7K1 M$64;MC+ VY3ZMU1S_=,:Z]%C@7CXJJ3]TCOV)E99,J=T]!U/J"%DT^1#'Y&< MAJ6.H%:F3;H36>:!, ++7RCJU?AR4$YP+ M/)&^W$K_6L*0JV2(SK)"2_Y5( MV"42K1[1+O-KLVYUDZY69)F] SPN)"^LXM_3"J% '0?41G=*/T?F]Z8>[TUB M?2DZ&EQ=U"[.90)J[#OI1O1O;SQN77C#"(,!O$P_?E:-OI_5%9)MJ#7ZKA:9RUVX2PFI%]BC%\00LUH:R7$CEC<8A2H^G:8ULO;C/3&I M=:ZG!389@+ZSRVPT)&$UG-%P3%TH>\/NL[F!G:J!\!^Q_IY"Y$^ YF],_2OP MK-$\(/*C 0NNH]&,_IP-Z<_I<.:)$N+9^(!B_C7E^Q:4:,ZJI<-8@S8"M@NE MOCZ6BUOR4N/=Y?0DZU=R:-%Q9*8[($K Y:?KXT4JVQMT!T)@L:*J,MDN+_@R MB0/T$7W)F59./<1S$5-EN/'4_F M.BG1.[>1:9RTI.P)\G7=RQ3N@WCB8T<]3;U.8Z=%%U!K_L+Z2^4*TT5UC+!9 M/7O@ZN8Z^IAO04*<(C%MF@U'>FD[.*JOC]/'/1TG831@CL.J4[Y?+3FG6CH2 M:GP0T:N\,'YQDH0QUSHQRSZ(!H%B/>*:(RS#D+O'--V8]#F\)6CZ)*3@4UW; M34@5-<]]#8B*\:7S508$G3,UK+*6@:P%?.? NR!W>;8C4V@^QP@#J=N/F=K. M!]EFN\< -,F$D@6X TO0'E*U>9$G<$1P 5= D]_BOV0>_R?."^2$0#XV0F[> MJ:,E8-Q767)3[5UPQ]Q[&RN:HMFP 3-JO,YN_HY-MFBCR.[NJ0XU0X+HBBZ9 M=]V1O_MHX:^!Q#'#_FO[_G0<%!$_!8"+6V($Y$BBK(3-['9<(&*3*T+ ]A.; MZ772'H$!A;TGEO4&^Q%[']/,2_G>E(+L$0%^6 M"0'>6K"Q]VTO[O8G\A-?"2D_V'1V!-_A?\TZ K:"193ON>H -F-EZ>/2_/LV MZ$WR!S@R#0V'/ZJ2T_/@.QV:GT?@V\4NVO3S9/CVI@/YV09?O&G]HQL?#%'A M&E8AS'+=I?G7A7#[@(@G,]( +VK D?ISPI=!&,G8'J0/<4P'QJ/"J X?-NX< MY]GY(5HECXY?R8; [\O^#. MSC;7FW8AU,KSXA2.,5\%YWEF2)H-W/$U!K+5.PH,*(4^-MP@-KQQ9JIT5/84 M&L2 "E$+.UZ00KJA; =33$8-8K;IB.-2,PP;#X"8M!]@96-R'!I]R%!-!Y@\ M>#M%5T$X:J9UAZ/0#N?.]1<#%GLB%5FM2Q*>LUL+['N987$7"HI4<8(P1@; MT$0=G;''1/.KMN3F,#O/W=IHQ&R)PQA'C""&3@&B L4]60@*-DOK(+RI5JE, M+7+S>PEI0B +@BB>@^+.EEF$W3_"Q: BD5M)FQ2M&B?'(51C(D,TV?PN;U$H M\8MVRS3&%66VL=-B0O38]P)-C-P'"#$2( QJA@H.DW2,%=^?\(P"?U=9/9<& M"[^/40*PSH<< 8*B)*]QLZ<4' M:[ILGEWF>_.Y5O-5-Z_&3>KQ5ROMJ+Q<&MQE4=(@7\#,K55[GF;M;JN_HZ84 MI/,<<>!<;AO!=[?/EIJW[VH=HP:Z8.,)J1)3Z720-\'NQYTW@N\:ZE,J2+T8 M2:M)E\9*T ')DXI)V:(!.( DN3HSWTJ3B.>42].3+U(TPP+IW:5W>:$>/9%* M'"+Z%.=DJQEL 1A%!?LMEQ/W@E)]H]T DBU3^ZUI6(:E)3X+8=U1#5.+(@Y\ MC(V(GW%\71LJR5E3J:^= %TJ'9<3M>98CB<]?%2][G>B]@%<-*>BEY@8RU1T ME=YA)CQW33!GX(?TL\2@ @N&+3. Z(]D#RR//D3\UHX)0, S#"%1?Q"PK#O3 M:P;UM_WN/N<\1@Q;RTJQR;+#'\YXA7:6H@S>B#G2:J]N"$I0X M?;W8;[G2P8W$-+$_J=PC=<&4K^T>,V');$#5R5+WNG&E.7<-)L-*SBY26UJ9 MIA0VOL)T>?N0#F:KAGC0VNZQX,R#U *E#+X"0RO6(,^6L:F9QB7^@/C!E6", MH2*JV*L%X$DI/)WH=;62H>_MP"0EC)\_@G1HM8!5 -,&248>YMJ[NPQ(*18. MW"6?8R-NQ,3?5YABMN>Q@"'L#HZ,+=C0B7Z0T'][(6S-X<1WY%&]!'C[(%]@ MB+FM+HJ^X)+KM=363]1\ER*PC/6*4.'V%G&%[M$6;8J+G;5!B]0CQGIO)1.=9;KFP#2^>92*04M*K/L\60(NPKP2AQ\JW!+FD*30$1_Y M??Z("!V[D(93= ,0X6L\. P&)CLAK72_(B M),L82P1?_,BS( MAABJ_0GO1;_LEWJP)CSK>:Q(%+.P[?S(1%$ [BM4L,+I')5)(C-]:V96S<8NO3XI#? M2H"BHZN=. AJ<13!E6CJ"%:%1'W*!SBB.OL(=J5GYR(B[S%))&UNG':8,UIL M+5+'Z,K]/"D/ZW)^N,1_1;UC&19]&3P@4/5L[=K^.*"7#)VP(-)BS,6E1"<- M'N7;1DX/DR)H: >3%&WV9@ISTCG3&T).G&1;HU!VR/DHJ(]9N"9HK4PK0,)= M.Y*!&SMJ")_"-[8B86RXFR+H*OL5B,A]GB\YZ8O6*"A1M?_F1*R];7"%K\^= MZ.=*VS2'@%I64#_*1U) /*^\+_&ZP,Y*%VQ .H$HV9HYHGE70-.%*4$^U]X/JZ] Z)3%P# M+A>\UQIO).\D2'@3;=;C4V])#:4;GQ6+_1I1?9&R'$846^:@XNR+9!_P.W*J M$M_CQNV)7LL(+Y=7CU=8)2SM-GG("^5\^6JO+#'?T%[6>6'9J',H6FZJA@,W$ M0?%'XB7@]OZZR1\Q@57 K3(!=5MP8IM)_T'NCJ+G+_N"1- F?2 MHIGS4JBPQ"J8E)"CQ]'"_& +Y%"%#[2I%):>6G-FO5C!60F0@RI3Y62BOI0> M"R$G6\%QC8]NUD*5J/D%9[A+!K;WXS)?V_V.W>%>1DE MJ#@:B\E/.9D.-NCV)7,\[N0-!J+EJ)DX9^WF */]$YY[F8%N@"$!-D,84*(3 M5ZJ,58NA8;TBH]1B/;6@5>_.^A;\);_>Z4Q,*?O/JNBE*/%!% MTRFQZ4(O#]3_E*(!JFJ2?L @QA,V0L*U=ILA3U'H.,\WVI M-[/2.$2*I\*Y Z*E5 PU F*9.E "*/>J?B 61J78\ U MR06@)]CXF2]^37?NY?L$F*\!6*5L#6W ](ZU5=^0N'$?7:.HH9HS=YI)*%IL M1=?F+FVJQ)L$J9Z0@L2-$1+SU)>1/EN;0!Q![(@"M1_P3L@?'S,*FE*]M)D: MXB=LS>$X.*5UNX!Y4\(;.Q MTAS..M>N#'!G@?0Q@?L1.&3/NV.D']*-W24'M?Q(:R#&6F.-]"R1)H>#)\SK M"V.JD@6,H(%='$&UIE5\&<+YF(*2B*"!G&H3GATYVXKY+'\ M"R AD560YC%6^B@Q!)J#+4C8!XJLTC*03O2^4A>X0K7BR@MZ45@"XRDU9ATAVAB#RTD8EF^-'IK[8+XXDB_865V MN"TGOB-_S MS7V18^+]Q^8TTROJDF'R*7;NS%\#T!@$!DPC<5Y;6R MI;!X*B7(JYT?'%YEGB-/JHIB>B7L*!ON[C)7"719ET"#-=3P!LAE" B>7FJ. M5[-/8D>JU2_K^W-R+23@_95+L*IPT/;7*^NK-QP3FR@M4ENWDS@JB=OIBL] M9S;#22ORY0=#(GDM*CW\F"V7J]0CH-[,NAPE;G8E3!^K$#.NAL#Z MT7F[%OEN!0IR:@5]LYDZ(@H339=23\#AHQ*;&U)/@G@$V!>64RF<*N/>1.-2D*3< 3TEWPJ<.B5CHQ2^@IF4X9F$N,*%=[C..X)B-O6AA# MJ)'EUW0'OY>T8=#UW4-IO?Q)IF5FDWFZ$T*\-' M0ZLY@5XA2+!_EV1L;!RHL&Y(/D:K'%;TR2?A40/J$PER[5Q\;(Y^5A';;LD; MNL7 ?XKJ]2W_WF-6/4)V](N48C#>6+0!;W[)Y>9;XN\(6=Q;8W-L5[XVN0N= M%J!*8"-/6F$)7+YYF9*PCU9BGL!DV&\RA6K3/DM?=PS3 3*UURP8#C,?*C-W MJY'5> Y&+>S0,2*FO%I,Q@<867P*+])->IO54QP"CS3'7T2?UZOORFVR2/_^ M=UNQ:/U.@C(&V$.P/I;KII5@S=)XU O[ IS[QC..:HN[.8^D#^C'Y!?';'LB M[/B=("T0EYTS[CV02(R>@B<"U5R2C8TICJ3U7C@2?T<&T]+,AIDPO!+9*G(< M^OH]+>9<2HO0PQ=BQ=!&)I,]US!U5EAVR_-FE$@];*"N/]QPP- M/&O#0F5 &,BR3_L9%U?%F%JQC\,%2#A*(G 04NR7"!FO4,O4) #LN1X^)5*@ MA%'6ID-Q@5@(">!B=A?S=V3ROZ4[,-V&KE1T-1.&BCS2FI$O[[>F2%VB.23U M';--FN7")**X"TSO0.KNJ);HFLJ\_,7_<.($9 MEY*[P&>K60DEU :OE?Y -#L]+VM.([]P]MEX;-9UTE;0'F0M*Y:[ M7+M\CEF+STLJ/)2@0$77'+Z@^=)B7'I?Y+" RYM[;O?NL.V/$GFFUGJB&UY\ M"6442,(>B2UV&@N,NN_1S:IE_H28QAWI+*'$A]7:=]DB@HF"?A"4':3Q1NT MD[HGC([I(%[Z M/F_D*:GV7Y*40/TX!Y4Z0>-9N%"0AW5G_;Y;#9LM!UCYFIIBMJRE ^1-VD(8 M.ZLD#()658'ZHZW/(\&^!6&^L%'E?6W%YDR!^J>)\#'UY!^3QK2 BT)A'$> MH].NNZILB#J5;4!%2CC[RLKZ/.BRRG[058E*+O;/NLO$!2WI(1+^Z10&OTMC M:9: X7PBY9!N(7"\A]FM@<.DLQ8VZ1 %?7$P\U"J[-<>A:ZSSJ[ 6Z:E M&<<&LZ#0*EKJ:W0=C91R?(:_$?%2I,H^%5#&_SSI$OX>1KUN-,4:L$ 4_VAC MGHW20[%^HPA+S<*3U>?XMI3NC.!'[VH M:N\P9.T]=MM"N\WQ)XXFI P[4>"MCR0[8,#;@XU,N_5B;OT\L]RIKF)*_51R M0#FMCYT]@RG)VY/6K-(Z/2Q MW39UEW;YTZ#C<+7*\Z;4W)6W-%EY?77,TJ2_Q)&UT9;[#MC<16$;E[ V1"P: M(?N\Q,$JVK_$KL=8DU.9NGNGG_3PT;M%%?O:!G#Y%FT!QK=!&K:6 !JT$.+P'B(:O=H/$&Z#;(P5QVA&BXV3M4# MQFP<]?"_:3?JCV9"=D^#WUDT'!*CZ$ZP1E)_2#^Y?.=I(]CJX8C!M$DU*E6$ M']]2(UH_7:J:X(<"8[Z_NP]=TK^0N'C:[NEZFR*C7RY7GBA(UB[XC1N/=XWF MF==8:=RI)?3T-XY>=2P1=WP4^M18 *B\ :L9W;ZO9\RZ50WBN45#J_HH+8%F M)M\ %PUC.P0M93CM^4L9.0K[UUU+%9)7"ZGR"B.RP19I8Y'>2[[F&ZEP]A9$ MLHLO>OGH<4XHROH) W[T"#8Y),K]>BTM3U&D=@K6)<[0FBC@#BVG,F>UDB1S M B@.@[F:Z-XYK8$_;1S5G)(V!0X8NM1>701? MY5S-ZHOVSD@EVVLMKD%T0:2(*Z?F+Y-W+9@&4I4);AU(X!RR$M( QETJWCSC MZLVS7D_*.(^P4NF[YD,X7]'RQ'J'<0G ?TRJHU>!^)S%?9H#"]7$O7Z//HG[ M8_SJRL33ZR J2;D(\>[Z#=7?X3H['^&L54TX-W8UK,(SZG$1U\MHU(]^0LPX MN@DJ8WT^Q1WW_/7UL+RJ \SALQ@.%7M&5/,6?IGT1D_&'JIWVX8] M$X,]TQ.Q!U!FBKIMWUO<>#3\KX@ZK 9CS+@O1B%\KVTM\F<3)G(GX8]^=^P1 M)@')8,2%.X=?"[OHT@,"P^E-<2Z8@>HU#WJ#)R,784X?#A6D[$%WUHAF\.2( MT80<<31MCV;MT3^GX=T9+_X,N]ZQLW!&B-2?C05]^OTF%)R:>TQ596/V!KT1/3$8?S7BAGC0GTT4 49L)1M. MV44[_LUP$!E=%V>!J<>XB.D@.I],GH)]C"Z]Z8R1C?\"0"$GF(Z$FG4;R>#3 M<+"FFZ149R#Z0"6/0+@\^L#S8J"F6/.G.E+5/L'2)E=?HK38DE\IOT,G$*!^ M]![0=IT R_UTTDS(!U*ZM_/H^2V^C5Y_3!=NYWG%" P<>+>A+NX0E MZ,#DU5PGOV*'7'0P4OZF+BYRJA=+;.@*RT1S^C 6ZRHE4+.ZCOH^K:=9MVN: MBR[]-C*2,_+QZ(HE;DS=T_8QU0+K^R&_KJ3>G32%J3M"F=E$A"0V Z"OPU(> M[*^I>==-<#>0(#-X'W "$R(HRMWAVBKBQ4/0XF!BC#0/K7&(]T#MZ^3T(J5M.;R#,G(C;CP *+. MEL.N<9T2@?"(O9RP8U&Q4\^;MG]8IVC)W@#<4]?CA8&"]>%B;,>\WY$+;KFG M6BS;^QRCM;!]Q#WE;99<1Z R,D*;L&I!=3\]R%&!0W*2-ARH1USJ1VN#9OQ# MKO!7!?DE1NF*9PO7(5OB,XW)RD]I]DAGLX568E)'N7'O RW88YH[MSFP%5C( MV5%(E0XF$M7L Q,!]V/Z.5OD,1(K+&7Q\1YE#*S9\1.6?Y0<<"#:G!6%>5RX M#'P P?03-4; OZ5F6[:[WV-JP6^(2W()&'R*#AB7 !O8F<)CID9"N5]S@C]A MBSG@)M9P[-J&3U2'>91A.+68*H#9D N]YWC3['Q.X9S*<7$X8!P\-@D;A%/8 M%[^F\._-ECHL?]B#<)/4#B>.7MT=MCM[JA_R-1X3G/L?4R YYH"_RB&V0H%" MC7RAB#(K)%E]CGG5EQN,0_=A2^X$I0TU*J8'H.=\01,3A<'0.W^D.'#W+#FY M1W9U;YW_E(*M:(46[:U->=8KJ224'',\F8^(SG@2.Z"QO^$:2I2"D%"YR*H\ M9&-)#["[NX/Q[[O$\^<75R\]U-IH\H6VEJ#^")B6!ALPC10P*N >,_C(A\ + M_/.?_NT59Q#8H3YM5/I81F]VZ1HSLN"=U7Z]L5W ,_R"F"8_+$5Q=O=!*2_6 M4OMNCHS$$E2EK"-RPG-D)]ZK!;%=@X2?>.R890D]MZK I1?=[*U:E>TNV8@[ MCD>B2^:%B'F9>M:WO4D?K;#JQ"-K%T3UW;PP_6TJ7\4UK&E!&D<\-*;HNAO/A/F ?EB7XEHD(CP3U**-2O%P<24LK8_O*7K!L'3A01EPFZB859O* M''O!*;')'52#;SSC'-#]9R&O,2@BRWL1>UFQ- 5J@NL_-A>&" D=$M=E ]X9 M''$5,K].ZUV!$36L672B=_OBJ^ DAU,XP8:XWV,N1E.R[M%Y%U\8C;X)F%XD M;@-XY5)()K9(!7GR<>.E1JN-I=Z_MUJTC M/96N1(I7\HG>0"JD'2!WEBTE< MA/A4[[7&FAOGV[!G(N&/*:8^,B=D3N?6+>'"H1@AJ/-P16433)JOEE(PCYU2 MC_(7:3]J.J L9XF\(RX#$J_32CBN4;)MHR^[TFCQQ#M'&&K400'ITK"P6OW- MAK/0)NXUOF>JNU$%\CV%L] MII6%R61#0'WCH:Y';?I05>!(U9VO1-AL7 3!A;'P20=7J9&5;[! T6.N_E$N MD$6BP;DR7]\W"FSXPJ%QIG^#K*P,+/8D3ZR)W/#]Q3NI,2=23%C>#$@Q 8RK MNG-#>."?2>-Y'!;WI)PUU&8W1I=:/S,?F4+L7^S9/)H##D= 8# MXL#RG(QXI2:Q=T9T%.\^=J0;DP-Y,"!S^6ADVP'WXUZ_V[YK$Y-Z;-?=X91& MQ Z'N/M1=RJ[[H_CT600WO4 =H6>O $YYFJ[QD&Q!\P$!IR.1_J)\_ B)">X07 M[M'[%G/4K/69W:"A85GL/Q^0MYB,\,!QDZS@$C0#]*P%MS =GT@BOX@1(^ M#^(!7)L3B/(7$V#_W[(M_D6$Z4I-VG/G\T\'.&!O4C8[S9>)J"E">S'86<-V\P*P3S M:CF[%GM7O[ZZ>4&EQ[*RQ"ROP--E]&E+(=+X_-7-)WH<9[KL]F,LWT9=UZ6; MT;!_H5[)Z2C1PC^7'5@$1EKPD[W1Z?](%;PEBL<'Y;.G$Z:)^\7].#IUTGII8-\.X%E&W76J MYV.V)\7R+D'-W(GC2;-\4L$2"G&/=1AC<2O-++:B;:*]-"[SV\N] M.KX9%) MJ6:WXRM)!"Z8J/UQEBO( F$"H_5J7$IFE6#NN MQE;H##I2;$T&FLXT.J>]*G;#$!)W\^M #M MPN#$%E'5-[JT7.8D>[ EM]UYCNT-G\=JR22H^J!OF-9*J/8:=9DY[4/#3\-A\#]>> +S*-MK^PN2;NGFF/ *:+;FTU(+S!PZVE\!7 MV-IKM#@FTOV+9IPGBU\]#PNU<^(RG(2T_#Q*_-@5(+:D[):K%N/?'"RRQK@W M2N+%BF^+(J-";S@<$\EQ=]R)WMQRN F[LWAPZU#%>C"7?)=YIOG^()_D3LR+ MY-?( M7K@+ETATI;'9. 89>9A?)S' 3=N1GR"##/_[3%7C/YOL32#_51ZK!U M $9$U/;*,W !SF*W)CG/CJ_$>O >[\F+;4?4#![;[^!?]\G*H(BSGL0Y[4"K M<+,0K-NO!4K0HD?%.*W=DPW41S"HVD!*:*B[8F*Z9-3.HU6^N>.:02EU;;&W MP[D1EJ>ZOCYN-DX5N=2$/C?>/NZR9.ME<_%3$/I,ME2_>T%-P^WI*"-1#EM2 M*3+>C[HM>%.@YUY1O)X=-FWVN\R4?79'NI'(\ M9:L*T:E&1"5.FTK.A;5A,E@?BXKV2='>9,?8E$F'CW2E-:BV6TQ6>DT7:>G$ MF 2,H'P>3IO>.-KR9P6>7:@FTQ4?#@%_[F@)%X32S:M3,^,QK<#@?JCIWI'!0;8V6BE]KV'O7S*G/3[)*NGK:9 MHAM@^X0P]U:-6R-Q-B8K\T(ZZC0T?B>2Z:29.5_Y+E_,(V/SF--2S5)VO(F+ M^SQG%[O2D<#>N3Y=3J=&>(?^T(Q"C:2C"C4I=AIS)E+L +[;EXXJ:;O\;5?[ MDIM1X!.Z&X:1$=6=SL6_LFF0$]/>XI%\O'X<,X\5F&4):7]I-F:KN&-U$ MF%0((I1X5Y$02@B,58/])BX!."ESCNZQ1;' ..MQ;5855?LS73U*D>CFA^\ M4H_2Q%6D;&8(3;QI:TFXA",\D5--'$[5FUU0^0AN.['2R'\)"=HB#NP,-7#: M;SDTDNZ**3#!Q)$^QD'21_?:J(A"E]]I8Z%5VP.W'V[R)%8CPT?*3+T MKGCE=*LG8J0 +V%VKK5@>,5X&?0YS-%L.KRJR$P$45HZ4"3T6CL9*.2:I6MS5LD M@_,+#I9-+Z1^)K?D,!S4()C;!E7D5%O/S@T6#_22IY&$3)"%2M4HK>8(I]B2%&KR<-+5N9BI.BN271C=)I$P M44%D(WO:7G?&TQ_: U?31;MX\Q9LL\@*L,B08SKA291D2LU:G'A++DM;;ZCI M3D$:KQ2MW1<**)N79%J7P1OJ2@1QZ[H,-:X;A9XKB6? M0+KE71L'[[FQ85!_@VC/AF,X9!EL>-F=.2=*+4)*]TLNQG^K8JLY;AH'T!0; M)I 6Y)QX%5>?(34XPC7V,N'+0>'\VO=9^H9:FQPZIP"XQPW6&JWK:_\+"CS4 M.X_ZU7)?[KC!'S;Z*ZD=I_K"%LDV0X5=J*.D9)+0SW1IK?'2.;O9C2K3<[ M5(:$- X&38*^::-FEX2%Z428\81[*RE8A7B=4X0D3Y>QU6",5HV3M&]#H@Y#8:>=4HF[?'$"A2X11T5]&D_YE:"6/SA%&G_XVR@-/&))"=VXX6 F7G M768J@B?&$J#!,D#%[AQF));[!A@DI=76@%C75T69!UH%:%>U]D_1V%_IV6O; M#R)Y>J7B 94]+SD]NXKD%S[]X%;->^84V%;'K+@?.Z*)7U1!G-TPML+/*KF+ M+421[9D,@V3'*:::6E%9%KL0'-N7D\U0"^L,^(&.)C$%2L:9")]\E5$ZZ+G^ M5BO$\4)S7-X[ML&3'A(1VHFD6YBRG,%V[OEM256M39)"G"1N9KJ MMM*)LMBO4LW+OI-BK$:V.P'GG5Z:PK#MJLW!=YZ\2\V13:AAU1RD^(S[WWB& M#W-3X"Z9POGY:F66DZ(IW2VR@PU:4^J(F6"VZ2_8J_UPR532" ;!.0S;%@X= MFLNQY=%33F 0!C"!6$<&/ZGC[3OB0[4VQ4Z%H14TA6I4GM)F#UG-8]8"$JSV MJH5H;CC6JKVMYBGU8GGE3AN$2[=R?7-O!BUP\:2JM$]86+ FXY,F-967JJD\ MO,&G-0UH*'OI9TTE>^I:UXFN-3_.#7S#;H5PY3XI-M/AI[SS M,A;@\P*L7)K9 3N+FFBU\ =!" 0(=R9+V MA0N0-+ =*%X[,G!S7&3"SF?/B<;J+NM5)M.ULD+,SE\D^]+(&:Z"44L,CBWA M)[U=^TT0F ZE+7:381$4+&@$/$.L#XL#F@#(W&E=V*!.+?,B1N4BY5ZJ:@[C MO&Z\+??95M ']& WZ!JKS6!T4$"=='5(3S)C+>=0 0,9GIAJ&1NKK0_!'G+_ MA6QC?=W2"*.@#-D%&YFD%&Y:[<_"#>6_03&3)"15?@.WG="0^V)+TP?MV)7NV@W0GA"P>.VM:&0,Z LJ%;)#CQK!&5>N'J/D2$*K>N M$A4YF1@O'T9R4!R+)#-@T*2D.)C.D,E&Q2X/LN; 6@Z9D(#RUN*GG:N:V3D0 MHQ9]X0FK-5:*W,^&!JV33<(1ZKAY)!V_[)>:OE_S-_OQ0%O1.=R8+VES#!(B MZ>/B 2G+_7HK!:1Y_Q#J=:?45* MZ]OYE \OQ8Y>,$W#L6S0TR(K%OLU*OMD.;_R?,-DQ"87,36%-]8C8_W+U;(/ M5P?CBD5O;P2!) G =YB^*"X)JD&/?)0"]8U3!3/"=VRF9]*/ZUEF6-7(A!D" M_=F799T%,GHY2!D\.HDY++DYVF_,L^MY+V@GTS)CYQ_Q7.HJK/_4-27DS ]: M]_&D8I'^$ L=PJTYA7:NG%UU1Y(O3\J0?$)"FR?O?\ &XU)(P^TT:?^KYC.5 M5%@4_W=#)-R_"\;;[_@GN!Q0IKTJ^R.JN]R?2K)L$0 6%I/&1#+-[IZ>EAWY M5]B-OMZV%W\)U?,](6'P:Y[NJ.^L!OZH0P1 3Z751\^%R6 036& 8:\5*CWJ MX*1)UIB9>$+&8&A'O8FS(TPE_VN<<7415:IBD_E,9EHC^4$B0F3N=;)@=_TU M)X Q %7>USAUA&D6&*"M-%\ZTMSKMPIU6DQUM9+]. MN^!IC9Y"U-D8Z"ODS1PR-M)"<;@)Z3\^IJN'-/1LM?Z\VG$P4MD+W1>!&WO6 M4%7AT02S%"6?4WK*^ZEA''8-@ZU6H40EW"RW5188H95L,HGZ@QZB787G2IX9 M<''),"+#2^S"3L(H[#F8-"I2>+0[&J:CFJ9LV/F.2]_T^E%_$KVU.5:X!(KP MX68XK0H956[03B<'*5TGS3,J2X[.J7[]^63LE&]&:$MDEH7S>"+0KC5=8]O8 MCVS5P/A#?O'D&(1UT3T50&.NF9YBUBXCJFU/?ZWV#W@6[T#7\T[#L?U1V4 MV$N%PA)>^B=@3XF?JL)#@7Z^",IU(/!Q[Y*=\L_">P0D(??PZGYF4WZ'A(%10&\6PP M=M]V'YG"'9@.)EQY'LWM<*JP>=W[>?\"BRUT1_!S,NN>U%#LF?W$S@<7H3XU M@XOS81"(;8]CE7X\%O$.OW!OC[XM$&DB1=3( V1=\DFFV8( M%%$C!#$MS:_S#O=M+=++-3ICBV@X4L)MN2:2)8S%9$?$N8FHP3#."W$;[ NU M.IW;<'!EF?X;U;Y@-W!/.0 CCMXY"?]UKVE[BXLFGG=CNV%=:U#4:S3._D$% ME,# UCEYDN!WY?;3^(AU)C$WLKEH;QMV<,HII4GDF/ 3 M^Z2_*@P&6"TGN4M1#UCGI,AQOLX$H5Q%DV(QO4G8Q'=9[.!=/-P MT7^ ^@Q5'QD,10T(@,=GX!.J1,0CFS(\72S[5*$ ?YTM#P?:**87]X:3T*8G MVD$$V.')FQZ:L<][LNG>=%"3!YTR*BW787&?+O=<1/V-29,4$<8I\GBRPN/F M6IH8#C?^J!5;N?<*J=@VF+8:KT$5.[%2RV@T Q6M!'''B(+F;E4E)Z1J)M*I M@:"#M-Y5**#IVH9*4YX\>M8D&IOJQ/1G-9B[X#2Y+CGH"L440Q,SO",#G#%\0 MMD!< 9GNM4>ZV*+;PELHQ7!NVV8T%0^=PM68!9=.]0B'PUXKRDKK%4*-*Q9! MKTSU72I0;P7+*]'=WOS_[5W)-%:4&X^WOJIH'E6 #'P!0FM M\\=?I+D$ZL'L^&I&U:>Y<(7'*N<8&A2_2>4Z6_/11^,"O$NQLV^QT'7"2+4* ML!YPL/H#A^MV \B"@W'*4LUR0?[W#$]48GJGE<[\$D=?Z&-/\VD9VZ8"+>$9AZW%N'ZZ@D(CM4[ MAD@OX*PW@#LR>34]GUW1MY#A&5!V8"Q61?>&Q[2:#RH30GS*&+N9).\XIG0N M$V_ 5W]!$7,\0)S?KE?+35LOUH0N=I(O.-]B)1K'@XYUX%'!Z979DRNC)RON M"655H"U2RAO,B S=7E:UH/V]3+WQ):<;,"_8]N?)-+KS8/FB 6+E0)*X:2*J M2H%;Q(@Q1/!0E@J_XZ4DPN*S;EJ%5O3C+6[I0Y=L3'?/U92U:X=^+T,(UE*8 MUS#'?U/GU;27E;FPPD&6VO^P(F(ZE:L-=TN;V15\CT<9.*'9D7 J3F9S]![2 MHW0L?E.XKI%:%&&R:9UVOZ22+6"1DEW FAJ'+(5S M?>3TZ_MU1I!Z: /B&L<=#P:5Z,-W:5]'O7%!.-0C1![->V6.E(B#7C[,$LO' M/TR$[O$'J1?N=,3Q(DZ MQ#"2E_%U6QC :TPL>0%IWNVC.36;PD0 @Q2RCA_G;J=!&VL^MM=L@\ZI?+)% M.W:'&=A-\9Y[G..?A9CO:P)T4F4):CI 'E'NI (TP*>U*%22/RV0L;P[H MTF1BZ,:=B:('5Z=%#_"BCT-S&')'1IGXI+*XXDIQIB^&?;_BBA2#MV&U 6*L M\%;#6H/>9_UA4&O"@1]G34H;B+DIY1GWZN,+4"]Y29'+8U/1IW0P:K4 MH4DN*1=?P ''G8)('T6/U,D&Q@1M7GAZO.S$'$(X7?S M+(C'^N7B$_W#276Y#;L-/@'^AR!BG%S:K0#T'OW#%%H)K]V8-LP %L3;IA.+ ME?;0:S^Z.%+)G B< 8*A?AA3U?!EX5DON;8"7C=?Z0D?'&M*\-1\#_59D+$] M;;5A^+4)&_6'!5X[5P9\*.)!43;X]+:2F_ZP&.-/>9<)T9F\GR.(-GT[&Z\R M\5ZVI#-<7ZPY&&XDF+6JKC&.CXO#AKJTA8PXM=]:&J/D$,C=Q&,J938B\0IT MC3KI[Y)R2Z "5OC;F'#YA6]N;#48;^&5//PK9!;? &B<+EFZ7ZY_IC)*NB,T M\A=J4RH%U%*P9RK! \1<3A8_(\;>=#VYEK&F+!E*MUZ421C(@: M%XCF8XY_'8G/#L!+%U7R',:R^5QOHVV8K1[(@:#4\7RCJ@@V=N)%LKF?K#Q0 MXA9JC@X& 7:>CM*\UA@SG#2NKVJ-$(M1H"'Z4SY-3F_7R]V5UE=*2S.I-)2X MLXH&TD9K*XWA,W>QSKAI!6S7<:/MM37^K[7EHV8Z=D=Q>//E9"%7E#&:-#&" MY/AGEHW%"7)8]O]3?/]2J+4*#7'U&4+0^RB+/#=&^\,C;=D7!])A/_8LI'T4 M^%,\?S0:EN:SM4&9KXI]#X90BJ5M(&PB/\K#S8@E$AJ0/_.C-/(LI%"DZ'3! MS_QH%'D6.CX>#?!G*9X=V,_&NH_9"<(1+80/#L?V-+-&CL9MO3# SVB4IL(W M%=[M41GNESBF%F/^[Z@(/U=DXAG^+S9.G* "DTL*=0<-7Q (D*Y;[3M"3VT\ MQ -SWLLYJ>7WG>?WG>?WG><;W'GX]GMTU$^>A0LZ3A:[^HQ7PE>?\DXX>DA/0LTI+?6?]WSE#?IR@H4!B0%^\^*" &(3% MTFP]LPJ)C?-$\NKL^=MW:!OB*_A%6!%\>A+\MB@Y46*UG($]*$.#!F1#;&?P M5S 0A8::CIY)'@JJG;1?QP,)=%B_,&1\MI=H;>P%8#/#FNAA730]Q5+A(MN4 M2ZV-62Y[ M3]IBX;V@S(%9LZR>6M?P>YPOOINW(+)7>TH]S2E9I+J;QQ[Z0% MC]Q"R]VUMW 3 WIP4I1QE5LX;@Q]/('UH/W'.N7%H/ZEAIK=RQ>,PO'='Y)_ M_.5O]G>0]7OD:$E[19_,-_H?DK__-2GZ[KM]]2YZLKGGD5*9%WJ+0M#0HWQ> MCXNNZ_'C]6]"]?!.Z<](W_\R*KYSH0J=MDA(8<(CEQI+R<01\Z9$(S$?=JV< M'L3NYOA5UF47F?I\BL?(AK[[IM$/.A^Z,Q/Z)'?FF"^TA-I/JO7LCJ*PIHBW M>I8$AOEI*]/%%*U24C:%=\->AP).;8=DOZX@ PI6[1QJP8B!6?G\R4?BEX6"4 M""_$?LM,QR&0(O3&,T>\E;>3/E76Z%ROFOZ,D2Q%=Q/KM MV5_VU>P/UN02$H,[FF !0<%V%I@FAW[I.QE?+#)D+*8<^()3G)K UGNIC(E3 M)L.&J[W9V"Q&#J;Y[F+YEC" # P;8G>#:XY54('IM(75_*"[&;0^)&ZE^L1> M6K@;Y(DE]R.Y44QD[D7Z!RU2U%'3#/6@36L\W/M%G:H+U=S:5-C583 M8I?'M-S "L*E"&V!]M@'#6J$K_C^:^4-=@Z'^&MZ-+BI,%^Y)I!Q*'YK>S!8S M +DE^&N9&WV0Y9B'-<*?I?I[*)O1@7-2S&KHE44DFAY< M@((,)6J$-KK';)A75ZNOJKMJGJ3\9\9_YM)M0PR:V14F1$.I!GB*@$Q1JI^$ M5B$LHWJ0L0: 7MY@C"CK#2#HAC\!^^(X7OD%01BJ;J.?\(IOK8+H!\"+P'_A M3QIB$N#RPG]_UD3T3]E3.E1_OO*ZR[: AF90'/RH>WF[Z7=4J)\-^NU#.!=_ MMM8O%-+1SYA^,P!O:1RX.*\8Y!:4GS3HW(X&^''I\)8 MDE.;$,I-C&S*D@=$TQ4LCFL*,>H*,QS%+[=+.F79-=(*U5LZ^9>S*34A+PDQ MF=\ZW4RI3EH%]08]7Y6O63Y<"^T9Q0T47ZP=J);7GACCID9X?/F@XLD*XUIE MS1E8^E37Q2$W+/WS\86!+V[P#S[,H.!.Z.3.&FD0QCX^PM(WPDOC\Z)+U0?@2ANWI*.%_1XQ2.9+(/-@]-BC MY$_5@P4.=[NI%( J,SJ@7T! /G!X.KP&AZ(&2T/-P%>]!4]*#0.80<2.QW"= MSUB;=U#A-64C !TX)_B>0N]SR>_=$A0"F#G/:HB. M$"2Y\*5OYY%/"&JACT'8&@H]16K4N0VX7H&X. LDQX^T:R!L2L&N P2 M:S)[DU# 0WA.8C12', =M'*L;5EPTEE)62L>!V%RR8]MRAV_Y);D4U!:NI/[ MO"\G^(+(DRR8N!1O*N%/M;O3/P^'22DV?^&-B3].D3"E0I:CV_4"<:E@..I6 M< "^\T&!A[14N&/R?RZJ[79>R7(:\I HCA91))3-8+(2)$47]+=&ZQ!OKK4A M_E0!:K5M.YV.4Y%9E_.*X ERTE=V^Y^I?64"T/XW,O,\X5CYAO]9$R_^OX#B MJ)&=BX_(J&(CPFHE.%R*YTK$S'&>HSJEC=GBP5!BBC&\F%%87%.E;HW!"23HB,UA9O0FM0O&W=#44$_AVOH/^/#&J"NSD^&F]:6]AP$RB M1'-!DL)_HWZ2E;(8 MN)W^ !(.#;P/13*CK,"?[NVB6>E$-P->YH(#N*A^&C0G>ZWH)-,7*-;& K4G M)G@.+$/&78Y9HD3ZLXD/^9;C\@%_CSU4K&?@_TV^U+@5+%:%CG0*=?/C/?Y[ M6)@/$^,+?ZM/3\F'A7'I!'$!J6HQEPU'D@\:DJ;VHJ*.P#NU:J,+/=\;A9XF M"C*9E@S+"/].)8CD?961D^.J.4"@F7Q,%]OC-.4;[G*D\!:\DW PQ^XQ!(@8 M-1/J7+EEIP>T1&(;<+KMI5F*O^EE _BG8\T-JUEY$+S*-(BW+\X(517_>R_F M6BZM!XIH%H[N94H7M8> S0J>4L22>!!XPW\P@A&G=O\0E,+0HZ]4%J%ZTF&& M>AR1^K)>GV_?A)31 '[[+VT_;N5R1E5=>+58]&FHQ8#'G.&NN"?KH;DH"FD] M)=YKB[\,T[*S]>"==LQZALIZ1BVM1YC,"/R!S.K< $__^U,1X$0UO" 0+\O M-,WGS@L3>L?P(^L/K(6)59*7=*==[,NZ\*,7!BQF;X2E\3FN? =YFGJLAH[6 9[\0)4I17[3DHI-!GM;W, . MH(":#:"DDT4QHA/GX*O9(&QT?6AE"# 0XL]1+HXUPR[61^:28GTOG8#@2)/C M3C J>37K!Y?!;C;HI-PPJL<[10D8Q@._6BZ@8D:=Z"S.L"06>021([ M,3>HM!'9#3)A$3XD8SSA4N*[BY4>PCO8>XG-0A@VA\D =N"^F''< B5@/#7& M0H5(87$E"N;G6.*QY/?44/%\-H$,H0'ZNWF.7S+ M$5<\#G'T95_"\V<#X1OD_E&+KS4'QR-'/\(9-0B%.-<08&(&I7R.)<9'72*L M3)K1_5.:&$B:(['K_89FU>*L'E=O(;H\!*,:]OJ(KYSVQ0$B9?V68P2G\^HW MS:&X,!V@AT;;HZUD%CWL9<(2TK17(&0R/\J28WK.Q.NXD&&B9$YZIJU#3)E8 MTUI /C4,OM\;(+B3S[:*00_N*#O;%@OUV!9+C(]YB#ZLQ[8 &F3DW$VXZ["6 MRFC8O.]_K769VH= HAR70_@*U7?UWWWC2W%\ 4@:UCT#8NI08F);5U#"38!M M&-&4"6Y4X\V")Y ME2*HU,'\U588&;?,DM)!2+>YML"VL>92%KIL-7?992O,N(3--@ MV,F>\UZ>M6+J>=3BNY,UIUG>0H-Y?^!34W\85]/(_]GO8,UX%>152I&[$143 M91[4@L'@IU 3!XSGO*R[ 96K(W4F_'!QDAP\>4J![>B3/SX_3P[^_M? HV** MCY2=LU"YRWE?$&=3);OT/_)?D\51TH\^8A8GA$ED8M'G-RHH[X%5_#5 [,;E MA0H)D'(-=#*3!(+V!!\4&.5& 5SC)DR_7B2ZH%)E#60^"[#/8'\NB5!//]X<_E3DVM.CZ,\/,U[O:=4]H:(5WSM3+%$:_@BND,S&- MLPDD8&#UP__. '7AXFAU='P4E.X5;G,0+=4(*3^%^":5N="<]B3"Y*_)DP:. M1;5@/8FM5V+G,G>35BL/++F!-8JW('XRWD-)MW9BT&5_/+[<8!J6H\'S=74( M<3J#\8Q0>J<)WW'<6="$QJ'&_3 M*YY^X:2OL.(>*:ZC=O??6KLI>'R[G>?)0QP9G0@\;KRWCQOGZ^6G]>0F[*1H M7P%7:LRY@@PQ0DYG%L5?$_\ZWJ9%\?+KV6)VY/,?$V]J.8/2^LOTVK^U/Q'CK2, \N.V]+ MQS7K[+AB ]&C9 MMZM52&86E+F%HH6Y9(7%<_>BNA>_X9QWYUSB%\1LQB;7H8$=B$3V6/K >\D2 M<=#I\B["OK /HN./[\39&\JAH+;#,289+C[TD1&[)XI]\Q%[?+R]\Q)[Y]SB M)G9\CMU(BIV);$-7')X0BZ\X[++,:1'X-?%^K'(Q62VW0%PD[/IV(4N(8"9( MN[*3@?.V>X?5BUQOZ>7H,.'E(;XPV>S#S@B:_*802^FJQ ARH_U,4?/V;N;H([5.2R,G04^&=SM;J?]1YH6[_[ER%M MC7R:CZ#6[FZW'XO@GH(8-9$+*IL2VW=S''W 0XH=D1%YRF1%_H[-QQEF^C\] MS]<3**<(C_EC[IX^%0NUMV.M::A#T_ -D5"WT?RWP$;MN"4-#,E=/QJ#.GD7 M0N.(??GX>>O/^.EZ&Y\B7!#GV*"Z[7:E7E7*\:8+K"D-;BQ&#,T#-'!A:"$2 M1Y,[MU,LBPDFBR56 +/!88E_0R3H7(=G:J":5I$M<+6ZD8R!ZUF@#6%EG*0Y MC4UX8W +.6(CW9;CF)=<3=QU<*5XP? 6G"U!HC0%(_1#,OVHWT*7NLU?+[$_ M8L(>I@0(\WMFZ/^0:M.^-]RJ*;]=IN[8@MU,T.W>B#?R='_7CJ4[,(8H87?+ M8#%<]:^K.\"IGS]PYKA0=KM#7*? ;FP!ZWGXP8.)*;T.![3 M9HK,:5W]R+5(B?T>LEW83T3]'*7GO;D@Q$?TZ5-]]P4ADG1G1EX%,NYHY4@ M/=WN;.3QSV6E%SK\,'@#"*VRMC5!^O3NO.7=C:8%%7?\QMA=*J0" QNFYC.\ MF2QNKR@R&PNYK0' \3.<2)9 %PUKT&*[7#_(S0>LVCFG*#9D<=H MN7A*WCR(+>23QSS4XPH):D*L*DC_(_X"E\X3L?$]>$Y.C8SM<=4=>S>L4]M< MW.76_[V\4>R>[S6[IQGK:Y?%I3( 7DG^S^XR%+?K.XO;M;N@&.&])YSEC<1( MDM@7 &7U$Y/$=N]*UO>+'_M_K=EE*6%!+^O=FQ[ZF[#7C4>QUEO+1LB#,Q<4 MS^$ONLI$><\C6PL1HOL=?N=C9*+T=D_;VCLF9#2I,%PRZE6NNHZ0KY85^%A' M;)6N2_3QIT_KZA,D+\0/A72HMTZH 8MJPQC?2WS4\&V#R^KY^ H(=G&Y7/[, M&\AA\EQ%'<_]<:[Z"Z=T2O,__5OSI'?7:RZFTR ^"JW>S(+N<02]/-=^ MQZN9ZCK@L#6R3X?>:]-&P]X5NN^ 9=?@*7^)M6[!'+;8EM1])_%'!XFW_%CC MD38,01*9GR.1^0L%.!EZK877T=ZWV.5#VF$A;4WD_;4_["A+>=LUUB$&=_G( MO8A6X>VV+2UX+T1YW3GPX143[J FQ)44?,0Y18P )Y)/.V16^G5\P0T2,!0H MK/C^O<3H,!)V!;^.,&>W7_"_":/I[A95IS]N]PWX+L_XJA_^<.N ?+&%Z NU M?H5M4_/D)HKU,VR -=XYVYRQN5= Z'PBB92#9RWGWA>917J-G+L>YM:7K__; M<(&\(6\W7,U\DK5/2W9\&.RXA0#N$^I84@3&)QT4[8X7X9ECSS:4"$=#GRXELO,F?ZQ9&FP/7C/:8[9^0+"LHBP MU"=L%!%61(2-?,(&MK"8ELN(;$]8EDDBM6S-,"DEAG<;M+O2,YVIQ_#JT^F) M53*WJ%]K>5AKA:^HCQD1_<**\'S">QYAD?DL8CWSS*>68NVP0B^[+C5AB;M^ M(C&)NWTG,8F[?2QAB;L:4DSB;M84D[B;27U[W-O_.OSN;BSWFZ%Z=]96=UW] MMHC@=W6$=PU'6XYP*-2,SF_:]Z?+V-D0J[68^-E*$7SJ3P:GGW1[)3S42X#W MF<(E@_>R;K5>7E75E.]4Z36.Z 6N:20%LK?"V(TV+7PGN8:QK"L.,&$4?/;I M4X41*,"FV]:2"[SBTW[JR_EX5W'B/%'%N.Z_W2U0&Q4W^.]SXT\;AS 9& U% M&*&[@^'0Z2_:FV:?LYNH;F:W-_XI@L^E&V\U)<;6#AU.-U.QP>>%T\V7$ZB> M4E9H,H7OW#^QP[R7?!]XY IUG)F9A#XF:"[69E%_N']4N)Z=X3)V;KU_E+EF MUM8-ZM!*NOM)J'4K;7VM#@+;.4:M!;;UBSH(;.?$=+$'=Z:LB0E[1K!DA2!>]NUUNZ_2V;J7K18$0_"/^F;Y9T0T>_]QQ_^ $J/__-@%]7N%$)X M/7E(TA$UFSK-JDM-Z0A.?16GZCPA!"4L4!XGX*\P3PJ=/1T]PVP).'5",>XB ML5[W)[Y;?ET/Z+U5:%(89NW ZZL)0=#'0RIJ0RKV$Z)B?W7V_.T[[URD0U;* MT*NR86U4P_JHZ"G_@,*SN>M]+759SN/8/\M-$R&GKFN7]W(K;(T@2YT5H%IA M903]<^8.4)QO &\=AJB+$M/2'2,]B*/,XYUPZE1CEUI[N;2U5X%.D_"(B]WX M.N^YN;74E#MJLN:J<.;*>KOHH&2O3A^_93"(A2_LN_LFP:$XR!:_^NQL!IA( MG\:QT=Y>;86X8?09E,--AI+V2=W]Z#.8-R.F_H50^PP8EQF+(990>*I/XG9F2YO>F0('N0@\:&OL1KX? *9 M]_<@'A;<9'4X.>S54'JE&"OD!PKAH)I@ M!77:;IYJ,9>')\*_:/V""8G6PB)I194^F[-S-C;?0EE:!ZT'H0M9M[01;/#P M[-T34/P<5>S-H\?+B7K+L03OZ.-MQDO]3-XN(G=6_EQN^>K[^V5X5?*23?M3 MKKKF9Y]>7U=4K6B$:9CV1]C3.TVG8J1!QY <%!N0$<\QLVN)H(42C4R4;#MP M%SQ>X8GM OFRC0D2BNG:'W=M8<:G8[FV\H])']:ON7'VIWW9' MP&8:AG4Q^])J6 YA4WB"]&C >Z6=49;%\3KB;B\-W3RI-K-/%'F;;+ +5,^F MP@O<H4ISSVD/HHF T*> 2XD!+F0#*]Q6I8 ^+)1DN8ZN'I8[#K;4CP];"> M&H8L/.JO.&PG9O#UFM*J,+XF3G,E(@X6\S2\/'&$7#$<EH0L=A<^$&8@.7>6_I3L,PSQ#NX8<)L&-7MEK4X%H M&%%+341 #IQOL?[ QT$@LR4^L%? :Y)8N1EMI]GS:H=)\[R]XSQZ)'696L_K M.\RV*Z1QQCSOM)^Q;/<9RQXU8]G>9BQ[W(QE^YBQ;(<9RW:;L7SW&_F0S"?W)@V;YOEV-G2:;$[ OL;)!N< =PR5ZLSXX'QV6DOH+=$0 M_"N\!=G0B\UR[7<84!J.[9?;)7D<-BJH0DZ1V*J7LRFU!OZVS-.]M.!',2_B M*-$IXH->$U-Y+5'< #!U^HTZ2:O0\16:']^Q07K0A^R/DZR(56JP!9G MZ7J^O)<@1UPZ@$A<:OP(?K-:S6=7>)I:7@):._[U809 0$(_=Y65%]_O)?YK MW4<-]I)R5G&0A$",WXXL7GA(KE1UMWA.C]*C@NGL^KJ"E\0$5MM[@$5&FV(! M4'4LI9-]07OXA,3JE9-:>PX&",^)29E-0Y%-)+=HO88RV=[]$++J MFT=X??X22,0$^0XJ*+N?+Y/-C.ZHA4:3/U4,[X!(NB8RY40B3@) M_WQX#:2H-K \-P.KP19N -2(MC+[#Q][QHJ] ^2I*9L&J,,Y9'^WL:X,GC4^ M(>=@6^LY?&W^MQF;ZFX)JH!H&/7.@4D%\-6FQHWP<%V*>W]0W:SFRP>A0WY7 M@ORS^=@W/L_4[Z=T4DF@TF)V/;O"J*+XO232//I= [XP_VRK=QR =A =Y"HF M=?:+9F>\FMQOA)J<_7.):'.FO'9DEG.2)]:YV=S#>"'4A,$HH+ZXJM9J3< J M OB?DTI(0.B@T'VK?/*\6BPV#_.[R6(VT7@]4CY-WCEP)N#_8P?GI"6Q"H:C MS:]GT^F\8@I#BIQ9+85=A^V,CMW)\VI17<^VK?E:?.DRHDW@WS@770XK&^%2 M8'FG!I,5O810?!!?C0@Y)1M=*S^'0!314+?+N.2 K IQ*-#7,38X4S2BB_+V M8>28N"L]X_0S@SF AQ,KHE+Q^S6D5(;OFZCW+\RV00L&H6+4GKGA#3>L*7D9 M:<.YB; 1I8R.7DSN,),*6P_>H0."]UK#.<[47JS1IZX4^M3&0I\*,4!03S2J M"=L"=B1&PG0C/$8I&Y &B)5$K$;2%(@P. (U(G;S6:C*2QT>O/^JF-'6E=A@ M%QBA!HL+7!5=5-OMO/)& "F'W.J_-&%OR^?BEVL]:T1I*C]DU%GD[DX#L2#. MM_"=$(<*0II-3Q,.U<90F:,3B2YVCB E")-LW.KQ'J:3 H(0.6(MGP*0&MS" M&@CSU1>&/,,ROM/S"^4Z$S!X.)AQ K6WPK]5+%?6X';@13'$!;ZSLQH.CG&: M:H:EFM;[Z\/0<6SL5KC]:!1"@H[#F\2L.]#@(%W0;"HABKRU??6G,.:WG7SQ MH*H;Z%Q\HRT^XW7U&2S^KE+Q0MC4G^X KM1)?&Q9U1APG'CHOX^_LL3SR _F M*)ZQB,5$0MP1W"2>3YV"$KI=U^](:Y^8(WMQYIC-Y(M:]0[4'N"FE0(>2U/' MG<^:DBT#>N#%^GM8E@Z-=>FMOC((+N$?%L9. @D6[9E#W]!+-_E?[P,([KYA/U_I126#@-7GN9Z[P#P]EBFQL446G M96O1)#JGB+.7;[7SY'KR2^;)PV74N!@3!Z8;N2Y[MVM?7[T/ FT3IJ ]M9+1 M7'@#,7GRG.4-:R4SQ:79:1ZCZZ&/N1U3*9X?.^O%?&:SX'T0SC7S"I+TR,E$ M&>6%-,I=GNU(7=Q15%NZ[*C0'4C$H_(>H74<#R\"MIS=W^@X SL);#WEYOJEUN4CH@0IB_D_*,1)F_)..N843XB+]7NX0#^*)XE0U#]Y;2TX1.^WVRV?_P_ M4$L! A0#% @ /(>%2*8%%-8Q @ \RL !, ( ! M %M#;VYT96YT7U1Y<&5S72YX;6Q02P$"% ,4 " \AX5(2'4%[L4 K M @ "P @ %B @ 7W)E;',O+G)E;'-02P$"% ,4 " \ MAX5(8=AS8F " ![+ &@ @ %0 P >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " \AX5(;+R!>>8# !P$0 $ M @ 'H!0 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( #R' MA4AYY-5R/P$ &D# 1 " ?P) !D;V-0&UL4$L! A0#% @ /(>%2,7I7G>" M @ -@T T ( !JQ$ 'AL+W-T>6QE]UJ$% >%P #P @ %8% >&PO=V]R M:V)O;VLN>&UL4$L! A0#% @ /(>%2%V:BTMJ @ P@@ !@ M ( !)AH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ /(>%2(>;^[C% P %Q, !@ ( !\B, 'AL+W=O MTG !X;"]W;W)K*@ M>&PO=V]R:W-H965T&UL4$L! A0#% @ /(>%2#:.,]DN M P *0T !@ ( !*2\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(>%2!$?_9ZD 0 L0, !D M ( !9CD 'AL+W=O&PO=V]R:W-H M965T5$WHP$ +$# 9 M " 1D] !X;"]W;W)K&UL4$L! M A0#% @ /(>%2"APR2BD 0 L0, !D ( !\SX 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(>% M2&15"OJC 0 L0, !D ( !@T0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(>%2+0WW)^B 0 L0, M !D ( !$DH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(>%2!Y!KA>B 0 L0, !D M ( !GD\ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ /(>%2+NXV2FC 0 L0, !D ( !*U4 'AL+W=O M&PO=V]R:W-H965T!8 M !X;"]W;W)K&UL4$L! A0#% @ /(>%2!S1 MJJ&B 0 L0, !D ( !NUH 'AL+W=OK;H*4! "Q P &0 M @ &47 >&PO=V]R:W-H965T !X;"]W;W)K&UL4$L! A0#% @ /(>%2,ZK\8NE 0 L0, !D M ( !36 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ /(>%2"6!#(7; 0 104 !D ( ! M[V4 'AL+W=O43L ! ![! &0 @ $!: >&PO=V]R:W-H965T&UL4$L! A0#% M @ /(>%2%GD<2,. @ V 8 !D ( !/6P 'AL+W=O&UL4$L! A0#% @ /(>%2(:H"[FF M 0 L0, !D ( !87( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(>%2,9_:F?9 @ =PP !D M ( !!W@ 'AL+W=OP >&PO=V]R M:W-H965T&UL M4$L! A0#% @ /(>%2&+]);SF 0 QP4 !D ( !H80 M 'AL+W=O&PO=V]R:W-H965T) !X;"]W;W)K&UL4$L! A0#% @ M/(>%2'E>9A=Y P ]Q !D ( !&UL4$L! A0#% @ /(>%2.W.GRE< P MBP\ !D ( !KI@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(>%2#;US^X3 @ 5 8 !D M ( !!:, 'AL+W=O&PO=V]R:W-H M965TH !X;"]W;W)K&UL4$L! M A0#% @ /(>%2-H9IS#X 0 ;@4 !D ( !=:P 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(>% M2(;UD[[,!@ RRT !D ( !9[, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(>%2+V,Z=LP!0 A1X M !D ( !?,< 'AL+W=O&PO=V]R:W-H965T'=" M;@8 *XK 9 " 8[3 !X;"]W;W)K&UL4$L! A0#% @ /8>%2+V>9JC4 0 [P4 !D M ( !,]H 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ /8>%2,Q1)"0_ @ #P< !D ( !2.( 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ /8>%2'O* MA8O5!@ T2H !D ( !U>P 'AL+W=O&PO=V]R:W-H965T XML 94 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 96 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 519 339 1 true 141 0 false 14 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://walgreensbootsalliance.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) Sheet http://walgreensbootsalliance.com/role/ConsolidatedCondensedBalanceSheetsUnaudited CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://walgreensbootsalliance.com/role/ConsolidatedCondensedBalanceSheetsUnauditedParenthetical CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) Sheet http://walgreensbootsalliance.com/role/ConsolidatedCondensedStatementOfEquityUnaudited CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) Statements 4 false false R5.htm 020100 - Statement - CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) (Parenthetical) Sheet http://walgreensbootsalliance.com/role/ConsolidatedCondensedStatementOfEquityUnauditedParenthetical CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) (Parenthetical) Statements 5 false false R6.htm 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (UNAUDITED) Sheet http://walgreensbootsalliance.com/role/ConsolidatedCondensedStatementsOfEarningsUnaudited CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (UNAUDITED) Statements 6 false false R7.htm 040000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Sheet http://walgreensbootsalliance.com/role/ConsolidatedCondensedStatementsOfComprehensiveIncomeUnaudited CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Statements 7 false false R8.htm 050000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://walgreensbootsalliance.com/role/ConsolidatedCondensedStatementsOfCashFlowsUnaudited CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 8 false false R9.htm 060100 - Disclosure - Organization Sheet http://walgreensbootsalliance.com/role/Organization Organization Notes 9 false false R10.htm 060200 - Disclosure - Accounting Policies Sheet http://walgreensbootsalliance.com/role/AccountingPolicies Accounting Policies Notes 10 false false R11.htm 060300 - Disclosure - Restructuring Sheet http://walgreensbootsalliance.com/role/Restructuring Restructuring Notes 11 false false R12.htm 060400 - Disclosure - Operating Leases Sheet http://walgreensbootsalliance.com/role/OperatingLeases Operating Leases Notes 12 false false R13.htm 060500 - Disclosure - Equity Method Investments Sheet http://walgreensbootsalliance.com/role/EquityMethodInvestments Equity Method Investments Notes 13 false false R14.htm 060600 - Disclosure - Available-for-Sale Investments Sheet http://walgreensbootsalliance.com/role/AvailableforsaleInvestments Available-for-Sale Investments Notes 14 false false R15.htm 060700 - Disclosure - Acquisitions Sheet http://walgreensbootsalliance.com/role/Acquisitions Acquisitions Notes 15 false false R16.htm 060800 - Disclosure - Goodwill and Other Intangible Assets Sheet http://walgreensbootsalliance.com/role/GoodwillAndOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 16 false false R17.htm 060900 - Disclosure - Short-Term Borrowings and Long-Term Debt Sheet http://walgreensbootsalliance.com/role/ShorttermBorrowingsAndLongtermDebt Short-Term Borrowings and Long-Term Debt Notes 17 false false R18.htm 061000 - Disclosure - Financial Instruments Sheet http://walgreensbootsalliance.com/role/FinancialInstruments Financial Instruments Notes 18 false false R19.htm 061100 - Disclosure - Fair Value Measurements Sheet http://walgreensbootsalliance.com/role/FairValueMeasurements Fair Value Measurements Notes 19 false false R20.htm 061200 - Disclosure - Commitments and Contingencies Sheet http://walgreensbootsalliance.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 061300 - Disclosure - Retirement Benefits Sheet http://walgreensbootsalliance.com/role/RetirementBenefits Retirement Benefits Notes 21 false false R22.htm 061400 - Disclosure - Earnings Per Share Sheet http://walgreensbootsalliance.com/role/EarningsPerShare Earnings Per Share Notes 22 false false R23.htm 061500 - Disclosure - Depreciation and Amortization Sheet http://walgreensbootsalliance.com/role/DepreciationAndAmortization Depreciation and Amortization Notes 23 false false R24.htm 061600 - Disclosure - Supplemental Cash Flow Disclosures Sheet http://walgreensbootsalliance.com/role/SupplementalCashFlowDisclosures Supplemental Cash Flow Disclosures Notes 24 false false R25.htm 061700 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://walgreensbootsalliance.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 25 false false R26.htm 061800 - Disclosure - Segment Reporting Sheet http://walgreensbootsalliance.com/role/SegmentReporting Segment Reporting Notes 26 false false R27.htm 061900 - Disclosure - Recent Accounting Pronouncements Sheet http://walgreensbootsalliance.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 27 false false R28.htm 062000 - Disclosure - Subsequent Event Sheet http://walgreensbootsalliance.com/role/SubsequentEvent Subsequent Event Notes 28 false false R29.htm 070200 - Disclosure - Accounting Policies (Policies) Sheet http://walgreensbootsalliance.com/role/AccountingPoliciesPolicies Accounting Policies (Policies) Policies http://walgreensbootsalliance.com/role/AccountingPolicies 29 false false R30.htm 080300 - Disclosure - Restructuring (Tables) Sheet http://walgreensbootsalliance.com/role/RestructuringTables Restructuring (Tables) Tables http://walgreensbootsalliance.com/role/Restructuring 30 false false R31.htm 080400 - Disclosure - Operating Leases (Tables) Sheet http://walgreensbootsalliance.com/role/OperatingLeasesTables Operating Leases (Tables) Tables http://walgreensbootsalliance.com/role/OperatingLeases 31 false false R32.htm 080500 - Disclosure - Equity Method Investments (Tables) Sheet http://walgreensbootsalliance.com/role/EquityMethodInvestmentsTables Equity Method Investments (Tables) Tables http://walgreensbootsalliance.com/role/EquityMethodInvestments 32 false false R33.htm 080600 - Disclosure - Available-for-Sale Investments (Tables) Sheet http://walgreensbootsalliance.com/role/AvailableforsaleInvestmentsTables Available-for-Sale Investments (Tables) Tables http://walgreensbootsalliance.com/role/AvailableforsaleInvestments 33 false false R34.htm 080700 - Disclosure - Acquisitions (Tables) Sheet http://walgreensbootsalliance.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://walgreensbootsalliance.com/role/Acquisitions 34 false false R35.htm 080800 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://walgreensbootsalliance.com/role/GoodwillAndOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://walgreensbootsalliance.com/role/GoodwillAndOtherIntangibleAssets 35 false false R36.htm 080900 - Disclosure - Short-Term Borrowings and Long-Term Debt (Tables) Sheet http://walgreensbootsalliance.com/role/ShorttermBorrowingsAndLongtermDebtTables Short-Term Borrowings and Long-Term Debt (Tables) Tables http://walgreensbootsalliance.com/role/ShorttermBorrowingsAndLongtermDebt 36 false false R37.htm 081000 - Disclosure - Financial Instruments (Tables) Sheet http://walgreensbootsalliance.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://walgreensbootsalliance.com/role/FinancialInstruments 37 false false R38.htm 081100 - Disclosure - Fair Value Measurements (Tables) Sheet http://walgreensbootsalliance.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://walgreensbootsalliance.com/role/FairValueMeasurements 38 false false R39.htm 081300 - Disclosure - Retirement Benefits (Tables) Sheet http://walgreensbootsalliance.com/role/RetirementBenefitsTables Retirement Benefits (Tables) Tables http://walgreensbootsalliance.com/role/RetirementBenefits 39 false false R40.htm 081500 - Disclosure - Depreciation and Amortization (Tables) Sheet http://walgreensbootsalliance.com/role/DepreciationAndAmortizationTables Depreciation and Amortization (Tables) Tables http://walgreensbootsalliance.com/role/DepreciationAndAmortization 40 false false R41.htm 081700 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://walgreensbootsalliance.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://walgreensbootsalliance.com/role/AccumulatedOtherComprehensiveIncomeLoss 41 false false R42.htm 081800 - Disclosure - Segment Reporting (Tables) Sheet http://walgreensbootsalliance.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://walgreensbootsalliance.com/role/SegmentReporting 42 false false R43.htm 090100 - Disclosure - Organization (Details) Sheet http://walgreensbootsalliance.com/role/OrganizationDetails Organization (Details) Details http://walgreensbootsalliance.com/role/Organization 43 false false R44.htm 090300 - Disclosure - Restructuring (Details) Sheet http://walgreensbootsalliance.com/role/RestructuringDetails Restructuring (Details) Details http://walgreensbootsalliance.com/role/RestructuringTables 44 false false R45.htm 090400 - Disclosure - Operating Leases (Details) Sheet http://walgreensbootsalliance.com/role/OperatingLeasesDetails Operating Leases (Details) Details http://walgreensbootsalliance.com/role/OperatingLeasesTables 45 false false R46.htm 090500 - Disclosure - Equity Method Investments, Equity Method Investments (Details) Sheet http://walgreensbootsalliance.com/role/EquityMethodInvestmentsEquityMethodInvestmentsDetails Equity Method Investments, Equity Method Investments (Details) Details 46 false false R47.htm 090502 - Disclosure - Equity Method Investments (Details) Sheet http://walgreensbootsalliance.com/role/EquityMethodInvestmentsDetails Equity Method Investments (Details) Details http://walgreensbootsalliance.com/role/EquityMethodInvestmentsTables 47 false false R48.htm 090504 - Disclosure - Equity Method Investments, Summarized Financial Information of Equity Method Investees (Details) Sheet http://walgreensbootsalliance.com/role/EquityMethodInvestmentsSummarizedFinancialInformationOfEquityMethodInvesteesDetails Equity Method Investments, Summarized Financial Information of Equity Method Investees (Details) Details 48 false false R49.htm 090600 - Disclosure - Available-for-Sale Investments (Details) Sheet http://walgreensbootsalliance.com/role/AvailableforsaleInvestmentsDetails Available-for-Sale Investments (Details) Details http://walgreensbootsalliance.com/role/AvailableforsaleInvestmentsTables 49 false false R50.htm 090700 - Disclosure - Acquisitions (Details) Sheet http://walgreensbootsalliance.com/role/AcquisitionsDetails Acquisitions (Details) Details http://walgreensbootsalliance.com/role/AcquisitionsTables 50 false false R51.htm 090702 - Disclosure - Acquisitions, Consideration Paid (Details) Sheet http://walgreensbootsalliance.com/role/AcquisitionsConsiderationPaidDetails Acquisitions, Consideration Paid (Details) Details 51 false false R52.htm 090704 - Disclosure - Acquisitions, Identifiable Assets Acquired and Liabilities Assumed Including Noncontrolling Interests (Details) Sheet http://walgreensbootsalliance.com/role/AcquisitionsIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingNoncontrollingInterestsDetails Acquisitions, Identifiable Assets Acquired and Liabilities Assumed Including Noncontrolling Interests (Details) Details 52 false false R53.htm 090706 - Disclosure - Acquisitions, The Identified Definite and Indefinite Lived Intangible Assets (Details) Sheet http://walgreensbootsalliance.com/role/AcquisitionsIdentifiedDefiniteAndIndefiniteLivedIntangibleAssetsDetails Acquisitions, The Identified Definite and Indefinite Lived Intangible Assets (Details) Details 53 false false R54.htm 090708 - Disclosure - Acquisitions, Unaudited Pro Forma Results Prepared for Comparative Purposes (Details) Sheet http://walgreensbootsalliance.com/role/AcquisitionsUnauditedProFormaResultsPreparedForComparativePurposesDetails Acquisitions, Unaudited Pro Forma Results Prepared for Comparative Purposes (Details) Details 54 false false R55.htm 090710 - Disclosure - Acquisitions, Actual Results from Alliance Boots Operations Included in the Consolidated Condensed Statements of Earnings (Details) Sheet http://walgreensbootsalliance.com/role/AcquisitionsActualResultsFromAllianceBootsOperationsIncludedInConsolidatedCondensedStatementsOfEarningsDetails Acquisitions, Actual Results from Alliance Boots Operations Included in the Consolidated Condensed Statements of Earnings (Details) Details 55 false false R56.htm 090800 - Disclosure - Goodwill and Other Intangible Assets, Schedule of Goodwill (Details) Sheet http://walgreensbootsalliance.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails Goodwill and Other Intangible Assets, Schedule of Goodwill (Details) Details 56 false false R57.htm 090802 - Disclosure - Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets by Major Class (Details) Sheet http://walgreensbootsalliance.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfFinitelivedIntangibleAssetsByMajorClassDetails Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets by Major Class (Details) Details 57 false false R58.htm 090804 - Disclosure - Goodwill and Other Intangible Assets (Details) Sheet http://walgreensbootsalliance.com/role/GoodwillAndOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets (Details) Details http://walgreensbootsalliance.com/role/GoodwillAndOtherIntangibleAssetsTables 58 false false R59.htm 090806 - Disclosure - Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) Sheet http://walgreensbootsalliance.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfFinitelivedIntangibleAssetsFutureAmortizationExpenseDetails Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) Details 59 false false R60.htm 090900 - Disclosure - Short-Term Borrowings and Long-Term Debt, Short-Term Borrowings (Details) Sheet http://walgreensbootsalliance.com/role/ShorttermBorrowingsAndLongtermDebtShorttermBorrowingsDetails Short-Term Borrowings and Long-Term Debt, Short-Term Borrowings (Details) Details 60 false false R61.htm 090902 - Disclosure - Short-Term Borrowings and Long-Term Debt, Long-Term Debt (Details) Sheet http://walgreensbootsalliance.com/role/ShorttermBorrowingsAndLongtermDebtLongtermDebtDetails Short-Term Borrowings and Long-Term Debt, Long-Term Debt (Details) Details 61 false false R62.htm 090904 - Disclosure - Short-Term Borrowings and Long-Term Debt (Details) Sheet http://walgreensbootsalliance.com/role/ShorttermBorrowingsAndLongtermDebtDetails Short-Term Borrowings and Long-Term Debt (Details) Details http://walgreensbootsalliance.com/role/ShorttermBorrowingsAndLongtermDebtTables 62 false false R63.htm 090906 - Disclosure - Short-Term Borrowings and Long-Term Debt, Debt Issuance (Details) Sheet http://walgreensbootsalliance.com/role/ShorttermBorrowingsAndLongtermDebtDebtIssuanceDetails Short-Term Borrowings and Long-Term Debt, Debt Issuance (Details) Details 63 false false R64.htm 090908 - Disclosure - Short-Term Borrowings and Long-Term Debt, Other Borrowings (Details) Sheet http://walgreensbootsalliance.com/role/ShorttermBorrowingsAndLongtermDebtOtherBorrowingsDetails Short-Term Borrowings and Long-Term Debt, Other Borrowings (Details) Details 64 false false R65.htm 091000 - Disclosure - Financial Instruments (Details) Sheet http://walgreensbootsalliance.com/role/FinancialInstrumentsDetails Financial Instruments (Details) Details http://walgreensbootsalliance.com/role/FinancialInstrumentsTables 65 false false R66.htm 091100 - Disclosure - Fair Value Measurements (Details) Sheet http://walgreensbootsalliance.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://walgreensbootsalliance.com/role/FairValueMeasurementsTables 66 false false R67.htm 091200 - Disclosure - Commitments and Contingencies (Details) Sheet http://walgreensbootsalliance.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://walgreensbootsalliance.com/role/CommitmentsAndContingencies 67 false false R68.htm 091300 - Disclosure - Retirement Benefits (Details) Sheet http://walgreensbootsalliance.com/role/RetirementBenefitsDetails Retirement Benefits (Details) Details http://walgreensbootsalliance.com/role/RetirementBenefitsTables 68 false false R69.htm 091400 - Disclosure - Earnings Per Share (Details) Sheet http://walgreensbootsalliance.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://walgreensbootsalliance.com/role/EarningsPerShare 69 false false R70.htm 091500 - Disclosure - Depreciation and Amortization (Details) Sheet http://walgreensbootsalliance.com/role/DepreciationAndAmortizationDetails Depreciation and Amortization (Details) Details http://walgreensbootsalliance.com/role/DepreciationAndAmortizationTables 70 false false R71.htm 091600 - Disclosure - Supplemental Cash Flow Disclosures (Details) Sheet http://walgreensbootsalliance.com/role/SupplementalCashFlowDisclosuresDetails Supplemental Cash Flow Disclosures (Details) Details http://walgreensbootsalliance.com/role/SupplementalCashFlowDisclosures 71 false false R72.htm 091700 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://walgreensbootsalliance.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://walgreensbootsalliance.com/role/AccumulatedOtherComprehensiveIncomeLossTables 72 false false R73.htm 091800 - Disclosure - Segment Reporting (Details) Sheet http://walgreensbootsalliance.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://walgreensbootsalliance.com/role/SegmentReportingTables 73 false false R74.htm 092000 - Disclosure - Subsequent Event (Details) Sheet http://walgreensbootsalliance.com/role/SubsequentEventDetails Subsequent Event (Details) Details http://walgreensbootsalliance.com/role/SubsequentEvent 74 false false All Reports Book All Reports wba-20160229.xml wba-20160229.xsd wba-20160229_cal.xml wba-20160229_def.xml wba-20160229_lab.xml wba-20160229_pre.xml true true ZIP 98 0001140361-16-060287-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-16-060287-xbrl.zip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

ARY%F%CV92X2,[%3X"JO#;1)6&"NO#*@@5SL]P%C]%1?R$\Y.( M0F.#KQ\P+BY8[)BD)R]=@5.2EANV;VCM3EY^Q=O[.+T_PWE\GY9EI8 LT M[@,\!')%?^=5\[)TZ*N6(.GQ$[PG7#GJ13A =0Q4!D%-E -T^](KAYI(B(4* M[*@%?\3BZ:17" M4UGE,KDA[^F9+'@?<7,"8%]F>K2?S]M#+2W6'_O)+V1^W MRO/K5-:D(11'J@HMU_T[2YNG8>Q[5S0HT?KU)Z>C\@Q&!Z**?2Y\-/8%_YC6 MS7ZW3]CQH,<[DA7Q/TL&3VEBZ&!P;+:> R=G&>N$=,P[L^CJ4XZUG:Y[#U'4 M>[HX54U!-3GQV+29><'#GMTWUJ_K^^='G.98]'ZU U=J MJ0"X\B<:RN SR0>T'H9" G._?I\7\:X2E#3=TSP@[DY2;[89]WF"*R?AO!_N M K P&=("#EB0E%Z!T@2L78@B]1%KR%"OL%IHRL+^I(2ZUYX\)T642"?/(>$, M-:%QL+YAM6B)S;@^H?T!2G$0EWHH40!C[ZBMP/RD=D &MA&\ \[QM1VJ4'9H MZZ[JN.!?U7& /KY%I$FOYG #M>6O:>)GR=-.Z#]QE-W0\)-Y=3LO@%&IU(O' MH:DDKFZ? ;A)U:XFIF-5E>G9'<;]]9WA"^ZS1)LVH-[">9.ZCQ4S_T&K#FJ"]1.7Q58 M7V\>\':?E"_%GV]Q6L1W,=7:LSI4^9Y?%QD)E#@8G?7),;X<>T:R4+0]Q!5H MN[=O&+R<^$BP/%9U62T9IVM#Y1#E<.T-HRC*$8O&A*B)AWH!PWN%\@VJCCI7 M?/6R$TCF.?XN%Z*[4#1,U/,X%^YN+@$$F6D),%]TH.<+00V?E;]'>2G291GG^,=IA_XI"9M9JS?&M_].7%FXG) MDM"&I!9Z5$XME9:H-$7,-I3#BPQA!B.^JNW!&L!S!)0#<1U"5(9?,I)K]-F# MXFKNU\7]D;T,,!.[^[$,Z=RY6)=_MA/ C+GASDK(40"CYJ2EP%RL?BD8^7I1 M0F0;-./7V;"KYQ&R@Q?JT>>67E@=9MOCJU4=XTV_&E$&$Y^*7/_V99 -A/'& MCT-(0_$])&$TPT9,T,%H>Q$Z (\&.'2';!:OD'RBWKG5Y])\8; MO2HGL^]T86&#V.;5JXC;S2ZM8[;)Z^=@50""+:O=*N.6MMVKPOS9;57I:K08 M[!?4U4:UK6OH?M.3'O84LG\TL-+1M& M#]M5Q+'>-(YI#WOTIU>G&7ULV6G&J*6M)8.6M92,MD:+P7[)'K97!3^(M^QA MJEWPQJ:N!%ZA;OI3TA7SM+''W.I(C MF@3:GWXB2?*!9%^B;'(7I):1NL<<&/F3C%Z8F19[IA$-)6'L:'VFVM7^F9F@ MVB;7F D%[0FF-0]>R"+)Q%#9"U':CYAMH-MB[/+NP]QOHD2ICU6.;'4 MHU&&+/ X:_[ K:#UQW6* MP[\$!5"TZ?^E16UE2.+<_6OXZF!2[5"9K^L2Z'2?9>4UU769/)1;+""M3O1; M9T1,B=6 <4KOGL'EKO,"!+)!UJJ#5E.F@=8;199(\QU!*P"5;C2BJ>.GJ, W M693F2=G/K/B"#;4::K?:R@W35'%\C,&T(@-("/*TOGXD! \KK M92U+=-IA0AE.^1%#A!Z]@<:E8DM"F"%FU4&F??J&@"(65V.D+"F=OT1Q>IE= MD#R_3*^C!%_>767X*2;[/'GY/8WS?(^WUP79_''R\OX?^[AX.4^?J A,3DZV M]E/_G!9^+.EF'-E#6F];%QES[7ROF3DB*7ILC= #3K8(EV79P?UE+[$LT>W1 M2!P#8Z@6QB[[@F)9KR7IXJP#LZZ%-Z:LOE'%%!2A<<5^@L@J_!&(+#]79$GQ M/;L^R5OG5*6"RI]<04N19]E"*X2A>GE'Q7#;\5F<;Q*2 M[S/AE6!FQN/.'VCLBGV@<"[?ZS.*#.(GW&%+V/(RF\OB 6>AG3)M""8>C;6; M6,!KD!\NTS5JL#CU>QN)CK=_W^?%#J?%^)A66.$1M46%'5&9[QY,78T)>TA M"&,E#M;MWKFB*X2BKE08[%2T/X>-ZE;BLX]OQV.;+()WJ+E;206%LD/9JI^Y M]8JAX[>,,\7(P 70%MU!5->N[-5/R_VA(O7F%1EI]K"((_KTG7K49TX8"%\F M9NORDS"(P&TR#OQ%/S$?\_W2/*1/O7E"@G/YY 4P <% *JN$N7[ZNG&A$$-= M8(0@?.(#9B0E1K+G\N@8CD\?XTF]0V%$5MW(,*237F0-QP$YZ P73F$>PL,Y MG04TFCR^SW9F&'\Y[K/KRZXRD2!$E MTG1]XEM*JU'I^KZ\ZI.%&<%I"J+\#4=H[@H-L#JV==N>[M+NJ5^-QER]WM84 MY=&@YEPR:_X5;^_C]/X,Y_%]=8$8YU8N>:'Z*XL*64*5[]9ESR^-((.OQ'!= M/T.]AT%$01.1W,8:UOZ _WQV"D_<;JG:>3E(\ZJ5KW"V4F4QYOKAR@;P]O0NJ6.I"AG15!4%%E\NR\BUI=2_/XM M2NXSC"FQ3PAA_6J2Q!&EW0&%_N8'=(ANF7OTCHY#MB1)HJSR63K[?FD-, ,F M<8*6L4YH.1HJAT$= M&2ZG"%WW#Q0+;5$0N\'=):-ES=$-HX50M!% \C/'A4 MN#S(_*PKU)$[%)_WYV3LM^'\SF0U7+BPFDWE H,) 0)Y!- M@NI!U0F^(QFNRMU$SSA__TPK3K)MG$;9RSG]-OE'^J.S(Y'IN)>:-H>,:T^/ M6$<"3Z581/(^[6)<-^>;+/W7U6Y.QR[Z^GTS]U/YJ3F,J">VE_ ISA>_:F(. MRFA-\CC!INZ$D'%0O>"HK!J!P+O6(SOJ^F?+@SJXJ#; ML6K@_ -@J$RV@$:QFLOX?BF+1[P_1;%9?G9",6D^UF<[ N\-5X4X]GK+(L- M[>=8&.M'G'UIC!/<>G%LXM/U\MBV"O!Z%\BX(-5=(A/AQF"1K.]*>YEL6H^ M%68BGK_%*J6[ MPD]F>@B#>U(.UNGI?@>J-/:D98&]!(&_NU8KP_OD1ISD^P2F>GJRB*#6@$*>4 M$_),_'K:ERF*HV8-W[+A2T%')(\AC4C$S3GAAO2WY[%B8C#E@\"G/ZPXSG:% M,0R!TF61;.Q:/T?OZA)!3"7:(D::-)E"9OEDI,RGKJ)X^GXS]^E8+9NGKI!? M^7.?5(Q=@W#>LUB?1OD#>J3_1#07;7:B%ZQ,(. >M1,/U-,?5X#EJB 7PWT? M2T(WPU&.SW#UW_/T>+/)]G@[J.8+6PB9PEK7LH,\W-*>#M!8/A()S=@*+FEY MZR4< 3!+&RK$N@TGC(0Z&;%5+_:\>'69S.C&=0C6*NDI2Z)WC9-$6U"<)C63=$;IA$1AM2G- M=[0N_T11_9PF>Z'R5HP-%66E+0<@Z\1>R5-!Q-E@Z;>O$89T@TEQ#]-8-+U+ M>>_+]BL JT[7X@BM874HY7GB]=I(>G\11[=Q$A?QY'(8 TMAUR*Q=$YD8:P9 M.AE5;#U6R[U5M]&@E*2'F_*.L )%U?%0;"=(TI4.C=-J&$F)#6I?%;F%3N0, M5\2>%\L>>R9E7(= %O=1%OI0CK#L:2/JO%=&T6TJORLZ$9WF4YAW-8'1;;.Y;2:)#A%:>L ML%L:E'7.WYYW<.<#OY83$D^/JF/[=>^#T$C':V4ISP2-H6)6STQ.IHE_WW#R MV -P(EDA2;9"\V81!A9O4XB%)='E\&<;NLE(NWY,1U/\ODRF"<_Z=3#(VU4LWOC=:B25 W30I_P6XA6>A.",_,JK,[]$][@^(E56-U] M<\H*.^A!6>="TO,^R_AK&D]/$<;VZY;56?OD *5X^9?T $TNY:F@951$[)G) MJ3;Q[QM;'KLA3B0K6(F[DE[!MX8PL-:;0BPLO;XNR.:/!Y)LZ5BA>@?S$TF2 M#R3[$F6<-PQ,K(6:KK!VSD1I/,=O,!B$UN.JVJ.(O'W+?VG>#?_,K%%M'MS$ M.0QG4IJ#&U_%>ZDCN1( ZA"0-%QEF+T^I1D0?W+I@-=H M,1IXS&QUJN"' >)>CR;))>',MY@7O6DQ9_JUK M.+G$6&WH[.9852@/JQF:H6%7R(*<]2^1O1!<(AM6BJT-)>YMLCJ-++I/5N6# M?Z4L+/*L:/9P%3(TK#LHPRY$_EJQK+PAV[L@HMH4 \%VN;]BYL#3!;6Q1I05QIP5AC (-H067 M &ES:^G Q).&&@AJ$:HD_!;]G62G"87(QVB'!>?E&7N "0/?@U]MX,6<41XD MX2T40N@5D"H:(V0=S<)\Y_.#BH<*#EG[PG&E(B+@NH:K(R4M79^[= MG4;6,/686OM5CG&\&55#$-I",;@>00.+("X*-8,57!5D;:VE"&-'&FK K\." M2C"LWD=G-) -^L>;<,8 VC@@)BWTYB9:NLA M':'19H*?UG05X)80>%07*%QU(]01&(/8^.87D<)I*#^07';JJ3HQOE[*F78! MO*>=V@^?VC.K[\^QAG-<*X@RL5BWE]/4[TR$P05N$Q'0[SH!>+_@",M3'XNC MEGM.[_31"*^.3NCMG/E *OALWE'QR<&\85PGPFD4#D)5Q_%VI7C8#.(@WJHJ MGZ("7W^)'G_#NUN<"2#*+S0"Z[B0(]@.W7I8+):$@>"98]BI+WN(V%,ZH*T* M+#ZDE;8H!^GBWY^/^6%Y'OIY'KV!Q>%:K"R$&5)6/*B\(:2(TU-CJ(20@K): M?8CB[*]1LL>_XNT]SH7G(8$M.&HJM'#(%D$,'XF".AR413(O:_80E4]1]3B@ M@V#@:!#P"]!<8JX)C$7$D\9:G(1U?B_-6[AE^&-"QUG+P*O'\:%VNC*UZ[J@ M]\U8D=U6'58OQ&])\= 1FJT,BDN&D9)<94[H5Z=YO+";&*L=^"U'S^)\DY!\ MS[DS7L>H)0?,R)HMD# >+LT+;5 16R:?$Q< MB/V0R?"(L^'9X;!$)Z0;,*^Z<[Y>JFMAJ^('J)=[=29O'ZK"<8X_K"X[#FIJ MB:<#GNFC29^"70QA.F<>^P<,&YF,BH=T"AZG.;@0Q](Q1%>*CU;LZD#3H4,/ M*HF!AY*.RP\4;_FE%+UF5>J3O%V7UIKZ#NCSE)U]LWV*Z.^2WY#CN[LXB6E& ME9]$"?OL^B'*.*?-&-KW5$O3W@$)M")ZT3^3&J@8I>]S_7%?#LS('!TEN$_R@.3/!S%$*ND)A!(M=1A1*+G.OU4( MPEQ_JV7T#6Q9"7/J4O^2?S+F"8T6[,G MA^P18L\.$'L:Q%N/TA8D\%]\R Q>Z3X'Q-Z"03OW\ )Y(0'B'1U!P'?K$_7@ M@P0DA@+D!W$6@*(U)>A7O='/+R]C0!#OY5^PX_2.[S.,R^Z)N]M.6J9A +^, M+0%X7ITOA\BB2#D@M%M_B)Y(5MZZ419JMZ.%\IJ O$F)1@N,6, K/B"!V)\O MK#A;9)9&, +*BHIEB8_NX9L!B& FWQPA2ZY2EY42#6KY#_O"Z&YP.G3G-!7@ M>5:B>C20[%TI7CX-9N@H:*,QD %#P&&Y"7*#&,4L99NENH]W6?IU=) MM.&_L0(H.>PP^"7=]!X\WWZR:FDL0.]CZIEN%T1SXC3+XE] M^T65V_Q;'L<"4DTNGA^@ILQAG!Z6I=XDIF0)NC6HEDW6"ZH%EW>GM&)Q(9!C M<9%6AWE%K*DR=>HVC1'ZEU-#8+:NGK#]F=6S8)@@:3\"_[W'T)^6'F)>Y&TY MK'=WA)Y6[Y.,D2XLT."<4\ 6Y1.7VMF%ZA0R80@IS/E&]?EB]4?AW(TK:3H" M_;%' )^4'.!)%N: M0E:;\=72#3*;JKC"S!WII('\:CLD-)"/:E=]9I;O$E=EPA%\&%#XS 0WHI"C M4@\"N@*BSHA3'_T$**@KB*ZF&"W?J*X-_J5&[-M1\,1O@!'FWK X/J;,P:A(%D7MP,47-TKSFJ M]SY*\KFK0!;09F#4WVO '[D'PS(Y!C3&/^8#=9WASBP#\UD'Y"X&XH(!^%N& MFN$06Q=KRPI[BIN=MQ^B#:OJRPU[_V.BZ(IRK90+RUD32N#9[?!8'D1.()GM MFCWN;?AN2J#/99G%1\.JYB6:+3&FC,!DR!6IWZ X\O[Y,6:O&Y+T+"KP"L 6 M@86$-Q,+#PP:Q?#-)7XX75;QO*QO<+:C0Q#V*:/9IJ)9U+SQ'AZ_1(!0,$W2 M8FK.C8Q5[./&"HJ'O*.T%,4DC'-SI); L6]N08_6DIF*>ZD03MA2-:R".8J3 MM@06*HZ$<.)6KUH2,D@(X!3T'O:;3IQ#$5ZA^GA']FF!;DF6D2]+7P+&;1(! M=&%P%4'4T4!VZ-#AH'7J6*=95_TCT8:Z];H:6#C,A+5P:,/'WZ+G>+??G91D MB]/[T^B1/N',$>J;2KINL:F'[EP4S'<7KXBKV^U+W:WKI[5JLH-5-O7S<.@% M!HXB-8 TJ#I=$'E1I1#RZ$&1^P*G6YSQC_0$%I>0>%C< W'[ 7R3E1-+EZ 3 M%Z+\_ !514,Y#Q0*!04M1@AC*H1OB)A700WG@QJ2LB (NCROB MNO4R6M XG$A@-=;1UX\$P" ""H70!A3LL_,"[R 3?9.RLFRC*^LCU6B\>\\S M1H&TDXR!O7@&L'Q0%@R()N)V5Z46O.8!Y!6-F3*I&/H/BE#=M/X5SF*RU5J] M&IJ EJ\:$Z_K5U60^1:P!O',5[!Z;JK$Y96M78W@ %Z\FC:7SNI590U?ONI' M6Y"*17Q?5NWV\T+CN\VXCOR0L,W$W5"-WK8Z!G]3W[O5OK$RT3A)F=XE;YPR#NYXFWCU(';B**IKWOAVZ]/];I_0CNP) MH[ON%;YH^_=];[I,!;=N5[G-*Q(NOSZ=])NQEB2]TNS0]9PQ.-=II> M!S MQLMUZU51]<[C%1OV.!"6,BK.6%7^XF+@"PY9E7CT!@\M>82\/2^-9 :15?,B M)>M#T1M""D C=:'BX#T4H>\C'UWI-(092(ZFG>G[YTVRWY9["^J?\+>HJ.\> M?_W@.7(/GJ-%N]@\/R4INR(.IQO:0MSW'*6%VBZ67\B:%SRW3J<=91'DK! : MKMDS-'@8R#N-\J8D.C_\F &\\D,&B#V&0X +T<8*94$1$2[<;:D0NO9*B'$4 M+5)R<4GA=CRV_1WTG&ULCRRSO6D1VG MV^J5_6N\J;MX[O*MMEW]JVG865(+',DETW2#RHBGYVM=%B]7@G.VNX)9](ZN M0)U1( O%^@@BEHT[)"[819_'FG%#IC5G!5K3"DYI)VO5P#@STQFXJJWC28?* M 2R"ZZ)&C\;RY7*@ TT*!["PWHVP+^_Z TW!\:_0XBUE5<6MN2H/X):DH%AR M=@)<5/,B-\V\2#!GO(+;GIBUSYAQ67 M%&?Y0_QXA2F6TB*ZQR]M!8NJ0 K/WI1U@[@.<;OZ;MV60(]M M$39^_MO)\=<$7L%J^#SH77)WT;BJBJY'T;\XYZ'C](GG6X=/4K%?>%U?V%02 M5L!U6P9O+PKL8X.0*(8N!%9"#*!H\X]]G"U]D)PI%H RJ +#HH)&4OSR6Y3] M@8L/^W2;\P>#TD*-N D*V0*=Z]:IT,DB2+$N-ER7SU#U$)5/0QE$RMN2Z/SR M(]ASRP_ +_&X& ,^XN(TRA^N,O(4;_'VY.7W'&_/T_I:EO3^>%/$3^4,8[6Z MOJ>?7=+LKWQ'+A=,EKMU6O_.KIQ:,M)--3P,:IU63$9\AX'6S!'ZD) O.6($ M1:T3U'E9^.90QV F/J$TE"0W_OL2YK+&P?#0V?C<;97FH2#+3FD?7?*P<8=N M7] [YI%FJM]S*7F .K^HJ&@[ M]2.0FM5P_F:6TVH9:*1)H$F:TCH)/DTQA;):\BR !%(\3?\ Q3.J<3 L])VF M&%9I'@JJTQ0>)5]IFA(49_72E"!(&V":5H"=N9'"('A MM=,0UQ\.AH MKJ1 KSK^!D2CI."QIV.D'?T$GA?HPM39F,;7_(.[(4P \PT!S3/XGU]P/J_P MC7!V><$BC%LX+SA/-V2'V>D%TVY^^JSKM?O/["6C\^:C3YUX5W!Z5+YDZ/LH M2VG;Y>BX*++X=E\T1Z7\+4K8_084%B>$%/1YDL01)@W/RQ.24X;$L!/ M/^%+5VP$_[&]:S"X[ ZFGK604(MU]2%ZQS[^?H*':J?T:VMWL5 "&S[ X0UP M<*:W-&OHU,D'S*QB_F9TY(NSO)F<,!=G3<'L;.[&>'%6T[^[ MJ9PY%F<-JA+(9*J#Q5FC2 XG5T-?G V*LU[F7?V2-L!$!;@3SNDF=Z>;VQ?> M3#O7/*Q>=?SMGQW-P[YK5F>_'TS)WK7[9@.?DM5%K+/=L+YVKKO;_!K 3O6 M=JC[WYGN?$?Z-\+93&-[WM0NS-[EC!\DHLNW M3TV#@^<-P3Y+T<'-+',TFE5,@WR+WQQLHKE(W?:73%="7 FG-.'U6% IOAQO M-F1?GCE-U2ZE?V[*>Y;SXW1[^D#AB?/SM%\FI@+XF&#QE*J*)(94!NS Z&.:P+H*Y$(&=E -J8 MZ+;&B']"FP&M%)Z78\N>5>+R[A-^)%F9JESC^[)Z8[8H"S9LD12T98O0M5.V MJ*)(V2(W7E?/V8%S65L"Y561A:FB;F"BVQ0CJ@AM!E11>/:*(=<'<*FCF8-I M)4?3TN,ZAW 2S?1F8^/ MLVN*!)6WJ-I[G+D VH63NPBL)MF+U/N2'-KB/+Y/HP)O1=01E>@8,RUA3Y2Q M3\?\$+A7T()K1=E0H+/V"8IR]"O>WE?$H(.Z/9/+<)@A;$X"_OTG/!@7'L&? M[VLQU+=[PYNNC(M\1:GZ-Q"6LF2 P*]+%LA#R)@@LUQWF0)J$XHPP*]J4:+U M\P])(##H$T'JU&H>A((VN4; MT16_LP#E_#WI0E]^L.!L4X3$OP$05E,DU*\JO&9 "$:19HA87E7;UB(DFOZ237K>!;GFX3D^PS?X.?B MA%;SC[%:>G+?2*US][;<=%PAY\?->:J@5!A\A%SWO2ZL)+XP3N;!U4C"'$<: MZ)^7;Q$@9=WUQ9XJ-S=?5T/"EKL3.\?E7;-]UVP6NG6..N^HG/ETD2LZV/CFIA=-)'X<5\B:IPPU0?5?!;'9R M"UE7LJ?>\.3$O3-]"V33TV7Q@+/3?<;.#;B(H]LX*7>G\Z>%(64;#9*7M=46 MF7?WPRA -*D@*.W791%4ET&]0J','X.:GABTT(BC,K,!]]3^?6/,7=X/B60% ML-77B#!1QNL,8HOFHF7ER.XQPP\XS>,GW$TS7K$/REZH+'5%:$^#BS@K.YX3 MG.*[N+BB8,J/MW_?YP7[]",N+N]NHF>NXGN+,N@K/$1QH@#.ZP7NGWZNI"/% M]VS]6-U#^:JI6GK\1%[7#GY\'%@BL1 'J Y23B96Q8=Q4!T(E9$.4!?K@+VI MQ^8<:;QO\N$0SF])/Q9/[=C.28U1.:!X/]F2%G>AG)( 3J?T8+&42J9R42M2 M5RS4 10$!V-9 +85A]X2RPE/E5&"F ([SG,LVA2I*,:9^!H6AX2;V3M*IAS$+6!>+:A;R&::)AZ#7**P6"^P&#P/\M(7GM8 M;IF9.QI<#T?*94I;@]>$L >/!UL %-7NV&L;DXI'6"&PD?LT_B?>HOLH M3ANU8\+6N#ND)HD[3P/IOGK?";H:?ZPJ&PPE1\&EQ>?KA=\$5I_'-^GU=S. MYN4FB]*<'8A=+DR4_TJJ#8,V&S'L@P!2(9L@'G76O%JS)DG6U3058YOJ MX4%O<\UKQX=,G8T LK@VLNI$^4.E]>^?'ZGTC[&H+#?>?S8MYVKCV=BSEQUG M@B"@K69;C)9 PBVD8U-N/O'^'Z#G/G1F\+1FXOQ M/:DRX\*X_0Q'.U7!,M7;>M/WN_(N.K8!. 3^ !H=.&HPGC/02./#7D)NA@Q7 M.(O)EGZ>X2C'9[CZK^B0!6<.-3:MJ1S.L*5-7H599T"UJF2[)PX01+T?Y@"E MU8Q%$3TO?(.V0_QJ;JR#(TA_VYWM7QSS?8W&(W11C. M82JJ;U3U;S>J?M)O5/_,WJG)M-YI].YO$#G\<:M MQI^DX?S.P@F:4^GLS*F?N;M3OQ-WIT:S=J>2*;O3P.;KM'&@GJD# V%QA>-H M--O\&"5LZ^,O49PRQ;Y,SZA6/T4%+9,?9W2(G-Z?[3-V'5^IX?!I"RO?BF&4 MH6]/Z9U1;68\Y,.F?B:9GWF\=6\O<H_>W!(<;9#[-%K;7^9 M<&H!8'D!ZXY2D6]<(+ M58/P^,&SF1)%[-DKDAQKIRR,.8PZ->U*!+;]S1&.I$)K!Z3%I;?>CZ3>#*?> M!N=C YSAUK?_G[UWW8TD-]9%7X58V L> YH^K9*F[5X;*$!]LX73T])I:6QL MS(^-5!5+2D]6LIR9I6[YZ0_)O%1>>&6_ZK/G# >5 MQ[/&P^0^[N:!9 5+>-^1+"/?Z/Q]\$"JIEG;VPF;02!>H#B,WY,;TL)?)KKD M'Y1SJKOFHQE00#6H?1YH!D# !8'$@!!2K0$Q8^4J'W%V1]QA8^0VI;*S"9T M0%%Y30^D#/TG)%06H%%58<05(XLZOK9NFJ(7U[3; M["IE463QW9X_.7]+6 9!TH+^]@E_=IB..,YMSD+[J#@3HG,XC!9"%98U1MT1Z)M M$4([2W:5"5V^Q0Q)/LHY;9_.CR?61_;38W*%7:QKC+);<_S=U);7^\+W)I+-C=FIP!]0'P:GMMRPPT M#E>VY(JM[VOI^C@]N:RR[X(441*872#W)'4FEK?LFR!MFOV#60K$S)E:0$O2 M?IV 7;GV[TM@6BTL[Q[+YZVESA_D4T!JSN2;PKWE%^/T0Y MOMK0+[0EZ4U!5G_T^&XN4/WD)@*>OD=O(L#JN+%1E1LQ5++D_XGJ!A,O2EM M@+@.4I>O>MDV)4TMC8(ZL.5:)$HR=M" M0''*-<96#Z\SLL)XG7^BORT/:Y?\U9DXO;]8%?$C/^TJCP8VTL/08"8-QU@3 M>V&#AD4/# EMK'$.9W1UP2CEMHDA"'\E&0/T<8MPMN5C]>Q]G^-T^CU.&R,&>OH!?I;!0 >0ESDY![><[633R%I=+EQ?U]QF-S,X-"NRQ> M37RBWP-4 G_@-LQBCV"N2^04;'LR"<[- J)]8F??"WC T^C8/<.&(B:=QVP1 MJMD(XU=;,KS"\2->OUPF:(+CF%280XB\VGR@07N-T[4L!@I:](),Q[? P!Y\G\-)_RTAN,0GH-->G_%7S<(D/-S!2.M^V MY9C+'%1PUSD/ALL_HRR+Z)_--K/[K=4[V8?68384:_W@ M9SO-[#GL)G8T+.M_H:A9AL'?<;:*&_[M2C7S()T."_J-1-& &6TB-K^4?@>Q M:R,\\$)O8_=M>:).O8%=MSQ&P-EM6SLB;@X>OHE UQG9X:QXNJ: *2[2]4?Z MU]T6#RX*V O*,GF%('3V)345ED?JAC$_/##Z4/>* :&&:WE8Z945V+)Q73 M389:PW.9"B7-U7;'!'2XD*6S"@9C28&WNX3P_KXKGRS./\3Y*B'Y/L.W^'OQ+A'<"+&5JR.5N9POL4TMV2ZQF:QM M6]I6LMM*U_(K+BC<>.I4MYV8P-9((9Z#V..OJ8H.?^WLC@E5N!AD:Q4,I2P& M==HW4$4'"?0[DT%<:.+"'>-!6!:#@F-XTAA$=>$LPVM^-^8ZRJZRFX)-!OX1 M)7M\S0HC1EF?.W9"=?0Q%/+ELY$9^*T=&[-*,ILK6C9M4'_VO5Z]/#][_?Z-H7SR0C#_!>+9 VSA)6!D+'@3R$_9N$49Q MGN\G/X>N&&\IHP8#I&)/Z5.D5&GI"@.B0"Z[H]\!02)GS#\\09?/'A=&;M44 M&/-QF-R'Y^7P*/VFJ*'0?78;@A*@K3JP,Q68,F?$0'B85)>.DF?4I0.=51HM M'&PI1V3#HF)*6T9.F*'FH'@*Y%=%9MS!)/*R99L9>ED_(!GY7#.)VXP#L.:@?Q2,/S-D2J:=@Z)E;6>ZLO;, !!IBB8=*SZV#G(Y? M?0O!\1;48P]-^8%-X;D/#8\/:!9>W!5ITWKS0^F,UJ%;7D7C4YQ&Z4I9>LE- MNO'WEM+>A+2R%R BN-A7L]9>XRP*+SGBAH ,9I_)5HJZU';HP_@@!@PS3K:! M$B-:KT=4^X*Q9?-7]D1U37]\WP8*!U?"=U4XR"G5E]*QB.Q]MEQ MIGD2TH(\0AD-BWHR@>C4L3(&KT0&70@VU'.(B#_5S?[<.Q9^>$&9EU^:)Q/% M8#&@I'0LS;C9$3+-AZ$R7X:M-Z;9]$! M4Z8;J^REP3F5.SPP&G'1^;#<"ED2PMN.MIS[)IID;L"\%Q, /RYXK4E>-1*" ML">5 '0 $AM!@YO:IBG355IZW(ZKIHS?"4GOR\QU7A-''3PD]#48/SEA)<(R MCBIMC8/)('%(8P\ D(-H<]E"9-,:?3AR1!K$$#A(SB52?"$%SJ^C)_8TEB(\ MB)H)8D*W&2#IVHJ#>G^!(5.ƫ[ FY78=9*6O#RFZQ1O,ADW!X)0R2#86< M-6T)&56&6@.B)XB?%AEQA<[ (_,&Z/J8<&/@;EV ,Q?'^B'F,X2".OVKS:%6 MH\+':B0$[E8J <@=B8U0*\=J,DPC+R M*6W-@H;ES-VT](^UH'0Y.%SQ'V-3(RP!^]3]L5/69^VSJ/QC#R?E,IA#[1]C M'>J5K[#5?ZS,!5SK]:K_8ZE-LKX[WQ) (V+9>#$7'LQSR1[+^[L4;M1I!$;=2-],\8<[ H>Z);AA%\RIQ I"W-@7-V=915/Y\2RX>C*&"4< M"P5YFO92HO0T!@-.&&\^,.&&FJ&7YCBY/@Z:C>%H.X\=G-XQR%Z,=QZ$K\1O(A56*PMZJ,:?DPFHT%\]U-!?NH[F8 M-C"("U3341B&"FW30_!0-/6'KE1YB'1;9TP#;K7X\EKUIL )B@JT(CG]CP3G M[,'4U7Z[+U/T-=YE>!7S=Z&X5+0E61'_9PX/19D@A=B/Z(!:4JD>V33: P,2 M,DQJ#?F@\;0-Q^L&CA\/?(_[,\_!W]L0+/\. 4"F"1Q^+:5:\#5M:^BQ/\P!>)W?O@^[_L\F !UK M,H#<06Y"P-$,Z&ISF;)#HGC--EUO"?7'[Z-=3&UX<9BG\4L![LJ53E0>HZF@7V<7R\T'LU'^;(KSP[ 5!JJ_=9* M!V-+6\ODWLP7FP0:)0-/Y:BSYY>\>C8;+W2UPRP!3^\/FQ+^'LE/J<0[N2H% M]E1NW0#?F0#MEHT;\S D<&F-MFJK#/W$%/[Y.;DX3[ KW)T_U-2NSTV_R@WZ M]'@V/ 7;L('MTC@D/05C*?K]EM]-FLTK:<^!N)(-J3DS=])-KE8!IL\DO9=4 M(M,U:S(.63-OWR16;)P5=-^@5N<%2E-J)Z(0/3S*.[-*#-JQ)7;CT">>6*)+ M)976@- !#%1J(ZZH.6T5?.3 ^=P 9_J""5# D;IL/^1,ZU;S(MNOV"40&A#H MT(LV<%5M&H&^4%H>^L0#=O*X5V2],\<,VX5IY^TOGS;BN91Z];0?OT4F]0K]XQ8>776Y)" MSSZ/XV6: 55Y]^&OK_'OI8#2P[=USH,+%^GZ:WGCD='T,EVQ74/^WRINZ*5$ M7%%)07)';B<8E[0FC;FET<2>&_JYB+ZCU4.4W>,&KNCJ#U !R,RBU7Z&0$,O?;ZEO\7\-O 4HZ_:Z9 /D6;; MHRNHW ,1V0@/-< #$D:V/%%V^L)@)CTY 8FS:<]1%!&=)Z[K>D;B<@S*1HW? M%C?RYI!(+6S&I;"@YHM4<%E_UA2*0K^7'T].$^50$IL?OL\)4?LN%>0:9T. MUM6]#W@3K^+A8KVI@(08(@%@D@Q-!+C=86C2AD$2)0GF@:MIDM667URG]K[O8GZM^J#LFS1A5Y;:DI\D>21 M)?\97L?%IXA=:2F>)(FV0=L#$E5M_>$IUPZ,6:TA#9 U\LNF"2K;H+K1;')R MDU$G#H,S((EL#K?8+)YE.I&+4UHTKUM-XH" M(>/1U?1VDE;9KA._]=)Z4/Z=3/@&1 MQ2M\C;.;ARCK>PU=L]K#29OY>BN)8O 5#8TAI2M1B2[?)R1GV<J1UT8C= /7)*)#I$4VH-B"FP]0J=$5= MG9;S-19D>(,3Q)L@V@;Q1LO+-4X+WL5R MR^!B]>]]G-%_I>O/<73']EO9U>@\WV_QVFC7$EA[;^,23#O0WB50?P+<]@C3 M0Y.-3$B+G;W,6EETV,!$M4+^ &-+):ITHLMTE>S7;-_C"_4;)"WH#YBP?UZF M-!O&DQ?="L4;P59G +"*=SN!#(DV/$&_P_R< &!F':1O(_/_M.L #GK10;&Q M)YA;E>WGR7SI7.(Y47_:F4K]=3[@+'Z,BO@1YY%%&!JU*WG^(T M2E=QE%SC;$.R+?T'IE_Q\&>2QVQ[X#,I'WTRS-#&,CQ(WL(;!G/IH;L:8.EN MY*Z;Q8)1.K/\&YU>Y:7G)]0AY&B]YUOQ[Q_88ZNL_AWZ%,49^D>4T ]:<81^ M\'$6EWDF8*UD("=T'<709YYL_*P<5(!T=J]OS\4Z])+9E$K5LHH/1 MZMQNJ1^U['('U_JD,GV":N,SSG&/WZMI,^/C=6MSRZ>K24'!8CX/^=:)L:$& M18:KU1 @$FALAK@E86_>UC.;:)5XV'IM("I:Z=_\/*(IV#2NS6+T]2Y*HTSG M:XSZ,@.?\6Z?Q^RM>+Z 4+JY_-U3ZU]ZIV&O8N U;%2 N0USHP'GJM:=,/,> MEFH[[J.61:WFJ'RR@SWM%J_Y^V_T;]=1/''Y="\0"KV)&RAD[L1T?$^V.Y+6RQ3L].\U?T##%"EAL/IXS72@5B*AO8' ^N <*:D4T@K/:"%X-J&Z'YC -52-1JPU$( MV,XCZ+ 70XU7@F1-!4L^PZ: :SM]Y4$W#B7&3)=LA.++#ZSX5L+CQ<=H]8#8 MO38JQ$E)"K8,GN=[/)NIE&+H)0LPJB&2K[3TI61+*F+M@1$69.='9L@'7H/= ME;MBQHX=!EL&.PT^X)J'LU84-C'TX=8:!J[=0@,8'XUMAEG-MS5OQET[K185 MC-CBPZ_1OTB&WB=1/ILS'/;0$]+?"0LRIV"L3.PK+/LR P]"DXN8I%%RL25[ MOM%YM2]RVG-V&ORP4U'O;AJO04!H':Y1^&F%FQ3Z]"/D&@= OPSGE=Z6EK4* M5.GH;4JV3WVTE,_%=\$ 7#PYA4*7=.[J8T RM_7O\WS8&6))!Z)/(U&SOR0D MX&E+99NSC=(93R[F3%S]JM,,F3N/B5"K5OE5\8 SM@*?X0>?1Q!KY+-VET7KMQ7K(9<:5FF@4:T'49Z^68,CN: M34ID#".GY1>(51>WQ9;9$%Q[]N0C_:_BJ;YL7^[T7&7L_\WR%6@#]F'"CTX.;HE';2G08HZ1 M4<-E&P-='8_5"/R\(=G/O [[069N,RQ3 (D78,S'5KK4HE8A650QL3MK5G^F M_NNRP-O!LPPNLA;L;LF.P/#&VM@L[QOV97I7GPW;F23BHL^ \D-D6=)>..#V MU&_4V-*_9W\&+D!_N4<9W^W$'2ZF D=[,X-AW(&5;:CK=N(4P.:FW6S\@B76 M'*_6F28&9II<;]3-*DU@QWA;AXK,;C>H!(1W',0"H.?012:"UL;5_F"Y5 MLOQ,TON?;W&VY6?3Y\)5+0*DQ]%U8Z0ZDRZ2E9],EUL:!72!KD"HS/GCK;?X MQ<%7U.#KG#R<[W(6/#:-+DS @',>RT$?\(8&L'5U*>^:@BK_$.>KA.3[3+6'-L"24-QJO.5D MUZJ1\=[0_@P\0+F"_2LN'LBZ?#*0^:KA7S'^$FWQQ?=8OI+DKFK@'UQ4@;D+ M>^-!S*C-A MB&5@T2=VRN:MU5&KLCEJM9_;?-4(+19!TGR&JI*WB7O/8DYJ<);!5-"4NRW! MT/S]+-K1#L[AOE4O'G>5F7+Y\_P.+AC#R(;4P@&V)':CPXK5G7*:AH0.P*:5%4:\@ Q$V"! M0VC#$3"GQX\8[8J""V3FL0[P%;.MQ56QS^+T_B)=?\7\^N^AM*;4LQI+"IY5 MUDH"OI:JL170*YO:-GWHU$1;[PW3E@A_T*D2ZA2EG0U%S1$E>7;48JCE+XIJ ME,A>"S6R/2ZL@SSP:V@7$-.#AWE_@%HVT%.@^AG$,>T:MY6T73P+L!9N9"_, M$H"-:0 7T%U'[S*_9/O=$[K!]VR*^BP(;[;*;CW 3KQ7K\9;]&$&]*\P\!7O M2%;0#E^F_'%!=GSZW5/UH3J=M=8P< ,6&L!<@;'-,.[ UKR92[#3VDD.JD]1 M(XM:PB?D+/X80'F?: ]9!WI$L(]^H%YY-V7K-N!MPRB83%DN: M<&LNN6XOFE[?A>IUTTF(N(:&F M4 *8F0(;(8DI-V?#2YF6(2WGQ3X5!!3DTXR1FGL"817UI+9FP[R6<[C:X2PJ M_U:7FS>>UB7R7Q^861P,KW$$U*Y,P2#UM0?5O+:AV!5 E M+J2OU-ASOV-_.@_P$&7X792SPW%;UB^>%?>IKFQ4\0K7P6:+*C)*3 MYP1MN^00Z$Q&%3@.)DT8:I/5QR.I,A6^/0M&\>I:.E-":ENT$1':T9-#;6T M^"C0?%;.#$::6 ])GR]2H2YI-+JG)PX_ED2MB0HIJMKTR=)M T63MM8 .8;< MBA$_!G(E,U!3-!NQ3^=15TTYEB(ZR'YZ"1':S844&.H+!1+ [$)AP0DAI[7S M;$XFGQP31J39A2M(9I9;Z',*?2X1(H<(YQH'-BP3A](MWI(B2E!^0/[=7$X0 M*T90G2-8Y0::G #6'7;UPCO#H7X'3 P=X7,&@L[O62%A%CZ/C<@_<7S_4.#U MQ2/.HGM#GJ&R!XOJ! MV(RVF0G73-$B2ST,1U*1C"@T2/,3K=41P1HFU34P"H5444)&<3>]@D0'P/0]U*MBP!=3=#K#?\TH3YI0V%I&1Y8AY7.33CJII^ M:J]WB 64,U#%E0] T(1;JNC:<$2,?+GBB#!CNFAA!9K9.-+/LJM!RD8B-_H9 M[OJ/4&V0#1"1!6,R?.Y=ZNG7%/@\FVL\ZL&4\4#XTRM8\%EX.4>A<3H*Q/=I MO(E745I\XSD.TRTL#@=,PLZU6"G_Z6!2=J@9IR@@2^[!BI!F233 MKF2-6&C9_'U.X4<^9,3T1^Z!?]"V W2)INE!?;7A9\P>2+*F4[RR_+WL0(J- M3!_Z:ADH-JBL!"&(@4$CSFCU+-]??;FY^GSYX>+VXP=$__'AXY<;^E\WM_0/ MOW[\+WSY$-(^+[BYN_HT^? MK_YY,WBE=<[+U)^FC3##SC-XT=<_57+/1OI M(1W-I.$8:F(O$&DM3!ORV%BC(;6O?KW^^O'O]*/+?WQ$EU_HOS_.G>16Z!/S MWA824E=@HDCB'L#I].;B2[3"! M 6O2W::Z<\(:U\(/^UX8J(YU1UV0A,JX5O50H+UP-XM:U.*1$<%:5V^ZTTZ( MVUG4E*X[<[/":93%1)5#B-KT4=MM P7>MM8@&!88,(+R0&Y9_V5>7ELX=")8 MRWYI";K;S84@'^J;'NOO]GF^N"T4!T3:@W!!8S7S/60T:\AF0T MI-*%(ZFT9+5(8VU"NI+5'Y=YOL?K#_QYL6M,8_":ERO(+U9TPE1V=QCV+.4: MXAK+>;/7T%* )24[RVHRV^A:7M,?Y"'*,=IE\0HCRJ \7O.2D*QHYXILMR1% M.1=&/\7U?_YY:C+;8HEX#G.?UH8JNMRVLCLFF %7L2RM@B'YM*XV5 J@4@*5 M(B=EO97\!+7%7@J&I:MAH4$\[2I9__##9;I*]FM^0B_C\;0HLOAN7["EDEOR MA8X420LZ:@DOAEM>TY'FGR&4MP,>H'((1P+6'=O0^8BS.V(0/*$[J/5+L :K ME?G_F8%+@H=UWV\% 9/ MX'9&3A X&\P.X9:Y0-FV2UX_\9EZ.D/BOJCZ?ER M=)C)3$_2!6C2#MZUAS:C3/=J*<9Z?H'ZUR \WQH M-Y?9A/4LHF!E)0O7V4#D5!X2! M][^F4$EGY^S-T6$\3='#8])C%?N['/][SZY&/;)[)I*'3-2M:C MT(.W2A-*%B@DEX^/"MJK@#^/%Z2[?9)7O54UTZ, M?LC:IC+- 5E@5\%4*3M@PZQ(H"E2:O+3*\D@*46JUCL;4L@.5&N:22@!=\A9 MHC@D(6Q.'*M$!<%A+B>7=*.J((;!&5^)A(H6<[E#-YS.B-_>T+63SZ2AWM^0 M:0X\FS9_?D,I*YM1S^,U!>WHJF?5VEPSS^]=)>/IM8FX^=M%JWQEVB+<^%*ENSCZG<9?NS)L;Y"\&H$$@,J @E% MEOROB/\91>D:\7]OH^R/?";K5]*A(V8_=Q?Z_99MF(NU!$ "V":O3+DM#$Z[ M.'C> R_9Q;4=^2EW< \DO$C7)JY-U[;MY^1M(: NTQ[& VJL:7F@E'\FOE$[ M]GV^F R1@#LRL0&1U/I#@PS6N>HL>2&L=KLEI!J$S<\+@T),Y9]!,#:QYT[S M#?5=M&\W.'N,5W%ZWRH4=IG2='G/,V>VC).+/Q(N-(90?8@+@*K]&0[6&1]2;TWM,M32R[H!RGD9MEU5 M5W!&50--!IU8CTZ?I5*A+NDTNL,B"S"/U=KQ -5I"U6\2:^.'VUV3(B2)J\0 MD)HV<1UT3>^/]7XX!$L"+"7(;%@20^1E3U!4H!7)BUD[64,J6#E5#?)#.='0 MSM/1:2J=Y7/&@[E+- #$;%R@9*U5VD+D L'650>U,O7&".\NFK8!/IM5 M+/G R1"N7Q0=-)8"?!:'GSL]^D>4['&=?+RGX>E77#P0Y1Q,(R)B@%0$DA(2 M(Z&G9VJSQMQ1J9%.V&;$)ATJ9/0R%WR324@(JK8T$QC!)B<8@! X%:0MO M?9CBG2 F@4J1XP:G2;H#B,[9)$2\C]KPH T& =@VBJ-W#_1F\7)W_] MY>SDS=G;^O4.^M$G?)?M(]IZ\?8$T8%YPS<&_[HX>?/Z[&3QEW/6YF)_OZ=T M.SOE+7Z9&^',Z&7CZ=7,">3% _ML-P^M\L?/%P?&3E4/A$D=)C5PM?F*V9;+ MJN!O;XBW+=IEFT)FEQH@2^4K9);\B0C:HTV N>YG:T266 ]%C MA4RD0PZUWLDH\EN:X]6>ICD?\%WQ?I^QBC$]C*J:5+^$N(DG)T1*;>E@\!:* MPHR*$%*Q9?,)^D**J>>&RL$CYC]V%_*BUFVTR[4%P@187J RX *'TS8>V&=T M:E9^^KQQ(O%'H M=X#$XB@A(2GR[ :)*=]2^4>4Q>R2[]>H$)4JE'UWAQY[8[BN$G!-+=*LP M+119UG]%[,^SJ#\H'29B]M-V4=QOV8:P6,LLX"M<[Y$W$$ 8:(5GJ#(4C(W7 M="1"?2C/8A%',602..N6;89M99">Q4+-/Z,LBR2% 86?5=^V]YDGBCO:P&6ZEGADB,$/V@5KIUD;IP)YZ"$&6UL1:K8:W]-F@)_M^$KF M#>8#/.522BD8O.OLA')VAG8-:&*D MJ>4@9U)SQ18=0W+9#)V0=3H% CZ:V1P/FM!.VM0F$"Y/6\!DYRO*]GP#I54H MZ(5A5ATJ H%VTO""6>?P^N(19]$]_K)G,>]#G.SIW\HSZ5?[(B\B_MS?Q?I? M^[S8#OS"AR>O?BC=@H?F)6\7/V*$-QM,04XVU5EKVB&47TADZALK$05E V4A/ W6K/C MA&33;E@['#/%R]K+5">F23T2)L%#;N M0AA.*&(PS5:'X?<$<25\WENI^4$7FR \$E]F&()EN8-9[-5)JX.N7#J,6Y'9 MLPZSND==W>P[^!*EQB:PKBL,5P%V[D%5"RJ]>S 9:2.W(%-DX _4?1@?X:$C MILXV,+SM8^2<(V-@S-O%PD"@]X]^.5Z]NB>/_\^*'_M>/;'H=][\BT6^\U;D MJ__^?S_^]K5'H]9?JE^$_\61E&U#$$=R!/I$Y!DT6W[<9P15&\#OR3XMLIB5 M[6)_GA;U[=^;R'^P+CKIAPQQP\;3H.AO[ZY[X][Z2]5S_A=?%%$EH"@ZZ%.B MJ&ZV_"V-F5/]?REMUV1[@JXIDM837T)J_]1$_EMU 40_[ "H:3P-@"Z2I+RO MLJ*L%)XJ5+2HOIFPA2_@!$I! 2C7KP2D3&Q)/T"'3V9RO% U=L3\Q^XB6-"X M@VBI,@>$?[N+&'3?O%XLWG+@TC_\WP]XE^%5'+&=,3J7O=B2K(C_P_\I>VG5 M1J3ZMF8BCC W_1JVD%^3%:_"R[7TOI"E31$-K%0L;Q\PHGV),S;;:PX[;$B& MUBT=?($H:FEY-2UGK*!"W(:R2R@3:<8P.TLC(--[]F9KS!>3='[6;HIH6]1N MC'YGS1%O/['K#@E#R/BQX>HQX>CQ>"DDME M(2#H=N5,F'EK**G_EI("[7.JE^;!NXRL]RO6D3^S M?T8H?\H+O*5=*S?",MY)*KN-TK0\$<\,[G 6DW7.>[JJ=G;N<(HW<8$8%U&^ M7SU4]EZA[K>CJ=,^Y=W-V(5+7J&&]G+%7J34?G.6NC?VI;]#]47)(^OQ XXS MA/,BWK+R9M0H2_"944Q="=G2+YK$CSB?.(NSHAUQHT77=9E(UZ[+W-((+ ?) MXFR,^?*;9G&'IJALRU,YWGI& 30D""4Y7 @4^N5PIE:L?;(TR>R+S;L36]*:\(F&C3= M^187#SPWB@YZ>(J$[BJ3)RC%/&LJ:C51_48+3^5XOE55V&:Y7$RS,)HBTLPK M)S0?6R7[-7O#H-\'EIN5>BHOPWI"/T1-.KHAV98FHGN:PCVA**.=HTD9-TG] M K\(0S]")*M\4T+3QP1E_-[,"T'X#G-(FMI'K'[D[TVPP^DYIS,*C4OG2&2''0ZBOAEJAZ& MX9)7STX$( I-<F9E!^>*EB?SRL/:0 ML:W4G+O[HCJT4SS]*6?;63NV $=2MB7$[V?P\SNM/:-JH8/E>S$WBWY*2)[_ MF7UPD21Q1"F#WA'"-L^J72RTIPW3G"3QFJ^IY/N[/%['$3L8S+G]+T*S2_1( MN[%G%T(X=A_B5;GP@OE70MORK2.V]+):L1TPMG9!OT^TVR4Q7K=75II%E:J# M] O4&V,93J)JOXW76_CY+F([>;09^[Q=S=PNXXX1:-)]+TBD^>YX&9@P2\GT;XE9&?1"W&*(.+ZZ+/)R7.@8 MX2?=ZX*$'_B\_#+]%,49?[SJ:M.NFE6&/\7Q)6?YSES=2MY[2F1A#3IS<^V M>IYDJV_YM9O/;:@TVD;9'S1)>^3OFZVJ&565O5UL:3)7_JKO<':/Z3R+9#3S M*Q.@;^T2=G7&-*,3V^X8)0"P$4W'+%1U)V;6?1B;+("+70Z606G2+("QQ(E3 MI.0&Y806\2\1\,KEL;$0#[%D9FD2,E-S[@ H\A<_D.^&@"F1#Y@4\@?\KJ,G M]A+ ASVFG__E*L7"&OPF3:M?1=W4@[4JQ= )G($M&16UHLL+]"V+BP+S<^+; M..?OS.ZB)Q2Q0^3\7Q'-Q^)L3?^:%4\3YU5&8T_LQJC+()5431:]YH#0 DEW M3(RX@HHF,;P)@Q%_W&1-_3AKA4B*9_*: "2.)$D(!)#\4@N==K@M.!-+KG!: MU'#Z4,/HZBAA)(GH$# *&:<7OY@%Z7X[680^M(-$?JTU>&SN&3(&?4?NV4?E MP6#+." :%PW^:Q$I^+LZ0Z$H3!CN6W#"3Q. JP8GE>M<_#)7M^F$%].X:P48 MX(C;5ATPW/;-.,&&!MJS5V]>O_[OPSN:94TC=$-[D[#-['8@/C(TF89?*S0% MG2"?&\Z.S\T"[Z$=:,IY/M:D^-PM\';DGGW@'0RV-/D4C(LN\3S799WGH0)O M6W.@^>^Y8^#M"HH#[^GY7%VE$UZ,)[PV@(&>ZIZ/$GC[9IQ@TY_A'A=:C.>U M-F@)&EC?FJ\\#YM*P^O;4"O/;T=<>1[8,@?\VV-;>1:,O90/XC'2,>*MP4I/ M7W- : 6*O$,CKJ#JQ]_:H;Z=]9*A.XZ, [$]D*##\=O15IZ'EESA1./R+Z\6 MOW0FQ)U _?8(,64)93!?%($I/?7A"L.VT[45J@!1P4J-]N\!?L92S)^9%_1%G,%V:_LN(-MSC;\E!V M+#A1Y?(6. EZ7/.UV3I9OYWTN.9KJ#@GTAK^N.9K\Z@GE7N6P4\YV-(#4X)Q MT9V7>JV9MW9UAD)1H..:KRW"I%Q0N&NU>#TG;^@-%^/3FC9X@3ZM^3I88%69 M<4(-#;.+5W_]RR^FIS6/"TW&IS5MT!0T[AKN3_7;2>-ND/VIQ?E8<==Q?ZHC M]_SCKNF"L6A<=,C7K1=W=89"4:"XZ[H_U1647).8[0:#$UZ, Z\-8* #[SC[ M4WTS3K#AUR04^U-'!A_C2&L#GZ G01:&)T$69I'VT YT1W8QUDF0A5ND[<@] M^T@[&&SIUJQ@7'0[LPO=SNPB5*1M:PYT$F3A&&F[@I*3((NYNDHGO!B?!+$! M#/1)D,4HD;9OQ@DV_"3(N>(DR''!Q_@DB U\PI;HN?U&S(*MH*F\1$^K*6SU MBT9Q^(L2 UL6Y2^ZHL\^]HK&7EX30SA&VI(8C92B)$9/HJ>C/6B)GH$E5SC10'WZZB^*BQ)_.4),F=?K ML<94T(5HP^EQOYUT(3K(]'@QUO1XX3@]7AS5]'@PV-*5(?OI\4*7KBZ"38\7 MP:?'?0M.^)$N1,]V?N.$%^.%:!O 0"]$CS,][IMQ@@U?B#Y5+$0?%WR,%Z)M MX!,TTKXQC+1O#"/MFR"1]LU8D?:-8Z1]-[9!2]# :CB/[;>3!M8@\]C3L>:QIX[SV-.CFL<.!EL*??MY[*DN MI3P--H\]#3Z/[5MPPH_LB9793D&,H[,0.#H+F)^=&5XMZ[>3 MY6=G0:Z6G8UUM>S,\6K9V5%=+1L,M@SZHG'1(/],=]7C+-C5LK/@5\OZ%ISP M(UOX.)OMW2 GO)@F:%: 4[0SL:Y6M8WXP0;?N#]%_F._I'!QS1CLX)/T!W] M4\,=_5.S2'MH![JS=CK6COZI6Z3MR#W[2#L8;.GNFF!<=)MKI[K-M=-0D;:M M.="._JECI.T*BHNGG,[54SK!Q7A#WP8OT!OZIZ,$VKX9)]3PHW-GBJ-SQP4? MX[U\&_@ !MH/^*ZX3/,BX_'GUZC8TXCP]']PU(^T^H;5-U0U] "]7"UTL-5: MDN%>([AD_X6^/=!PRRH+KVEK%#?-49RC?/6 U_NDK#Y\A]%FGR1/*,.[*%Y/ M''L-AI_8#%27#G*9F@\ZK<&0!1* ]2;<,$5#,&N #BU0W02Q-L>!&4D(]@6- M7Q!6ZX:+PGH[;M"A<;B!RM/10$42;GVA AAP/Y/TGE5?90:_X.)#G*_(/BTN MTO6G*,Y^C;(_I/WX.>CHOI=W%1XT,7%('1@]^B#C&/. M*I>7Z2K9LW<$$,V!,^:YV7,"*:5(]<\=R=CWR$]0='^?X7NV][.*LNR)R41; M9H8_2D![\'/!ROG>D2PCW\J7"7+V$)L%4=)^3K""=K27MU'][C^-^7T(Z8=Y3OA]$=H1^,?Z* D]RV!H!/41KVIVX8%:V)?%BVNH. M/Q$FF&+NGQ#)ZC^Q[Y6RAQP21'8XH\/-?L6G%>MQ7/XB.#OA9J,-_6FHM?5^ MQ5OMTXA]@_@_K&_58#'-NPQOX_VV?-.AW6A#AY'VBHTC>F0#B:+#2')S43KU MNHB7/R P_.SZ6Q=MM2=V[\D$[@DD._0Q#NV8:$;)1,L"X3RWI-*H%D=4'C$% MJ-2 N K4TO%RF2#)4J>@@E]FZVK5*N?5G*KPZ0,T)6BF_+Z.NV4(H &,Q\T3 ME&(>A(5AA862.*7Q!^<%RECXSK]%._3IUW^T8LC+Y8LD59^"+X#I?7U6YV9' M"G9?4" M5T:33/8>5Y7PYC252\FV2B[C%&WVZ8IUCZ:"9=Z\>F)R&>;95'OV6-?;$&8/B I#LRQ3; H6E*7M:(4$AY9]]G.$^/!TDZY!N(^E#'G,[X '?VK246Y::EA?-]@U; M0%JU9:LM"S[SW> L*R?"425^4C;.^=R6BO._YS$3_)EM[I3[%"GIEZ51P^'HF M6W;&['(O4D2)-/>R-PP$8IJ9W;*>">-$5(E1/UR=":"C\L]W%Q]>"HYE*5QP M' ,F>%VS)HF=A43UNQA)>!#30#]T F=N4L9$4PVMA*U+PA]IFJ.#L $P<4)8 MUQ\8"-=^P-A.>+: I%\6MCQYP@Z/X#S_GWZD.L2H602G<-B3)%7PX/-+H@R- MF"5/;TOTI?R$XEJ6/EF8] 3AXJ6#4)(1P8/0KT*+H1&K6BW*U5,+@YX0//NO MY7LA^/AD\\CA)RGB @\_P,(N%PE-K^AO]8Z0(A?NABI:5-]3V,*#'P)]T FT MW(2, #*)Y45:YYU;7#P0=CCGD2:?&-<'T5=DNYO^J+1J&(G1[]Y%M:!QC6*I M'GA,@*2)"MV6:*!I8/T)XA_-9.?(?? E>9W]Z _S-F>?=<5N5%P<)I9"MZ5N M5'T;62,/H(I50OLOI149:!5"S\6+:4:5F(Y!%\WB]C6@5=J" 7$J:G5VT.$ MNC;^(6I].A/OY@L*B8]S106@I_NXW27D">.;@JS^N*9 >HAR?)&NKW;,Y#4= MPKQ7&XQ5B>]([3:@5T0S*4,R7U M4N5ZG[&%4^9P=SB+J1^.""DRUYC%36A+6V.A7^08&!M$03Y-&1\5,"U#=23:@_O)>!5$F[" M9O MV=3*%.0I>FO#(,!=F /W)0!6LJP:%K" F\P&=F\>(@I_^RRJ*V>>1=5R83E9 M6ID@B^H8]J!D2\_RRYZGWS0'ROE?C5.F*#VZK*D'.W-2#Q%AS>E2A06GVS;' MPOM865/7(@C2K;*FD@HO :_N69,'8(-G30=3(V=-7<,@P+7(FM!/= I<8O?/ M+P&\[AF4!WA#95"?291^Q2L'BNW%[4<8D;@_%0Y'VH!F2PJ 1[:3R MU=&\G*8Z]:>(@;K)=O(J"6+I$?^ Y4AYE/ U_9*A%%>'UL5#1O;W#XC^COV, MB7Q+<98_Q+N*OW=X0S)<;@Q$^0.[T%F7\BQ[@Z[NV]@R!%"PQGGD4+(9/[H!"' .>)!\2?Z[6N[^2>27>;YGIT(N]J\CW9Q M$26\,SU(NHI7OXB]N =U;(U!YQ..]F4L-(#\E5(NBJPVJA,OY\,O#N22?&A/H?IF7BT7( M&VFN]B$!/_/4;0I<2Y*\,7$-F [R\[$W#R0KZKK$\F/ZBF;M@_K"9KXGL 5* M@QS6E]M1GL66B=%PL:-?C=> [KTPD3.1\F&,\A&*+&.G3LMZT2DIV),/CS'9 MY\D32N*\JB?,DJDB^DY2LIW%(7\5)HCY^ F.= LD.H>ZI1H#00WNN+_"@ O( MFB/__//6PPCS6'*'@(GJZ+\C3OQR Y5FN"49G147M"PZ:/GY&-$BB= ^: &, MN/S"W35.\^HH@##>JAM5WTO6R /78I70D59I109JA="RO,3)5AUH+,WC^[0L MHK#+R&.\QKQB<;R*=Q$+K=_BX@%%:%=J0G(4^?ND?R(L-% MG/&(7#>;QY]Q1 >> M?,/95S:IZB',2J;ZQH8R'I@WL@ =BFV,RBAAKF-9-45\VLL>AV2-3E!4H(2U M1'P*?(+VZ9J5CDQ;SR?REBBZSS /R!.'8#L$$<\QXE*0&80#IES@8FX$\R&]EU!N8BZ$;?:G E*0E M88 )^6 "OR1WM;G(R\DJM]:_UZAN5#^#(&GD4\%:J!(Z\5!:D1:FE@LM;]FC MR\WE0\X#]LYTM1KPC<[IRZ,(M$^L?LY#E*,<4^2NH^RI*5X[]9JZ9LR)Z0CU M:DT+VS=EI17:@L (IF:_4KT]@$[;5U<;V)0P>MZ8D!72=P2%9WE\J5[(@*RV M8@^.11L6ON8Z:T[961R, M2))@;Q(&^J?'[Q.:4Z^O,MJ$:<7K'AT\--2/ M_+AH\*GA;V\/.OMR[X*TR+^CQF4E2!,I+LD0N6ED:@;6R99<7%$,M:R M5%#E6@E)[\LSB^4LZ!6Z?< YKYC)-4<92]-V)*N.*^8XH;_'_0FZQRG.6 *8 MKE&TWL9IG!=LI>V1IGG?V5D,//6I"A]P$Q"T]=XCL%?6O$_@VH_QF0;S@)"[ M;6".G7J1[*420/8JT>@, *RQ\)[7$,XOTZ_4/V:/^!/)JDX\,=/4*>87Z;KJ M(%])83L0<8'H M=TS89;5O4;9F=S%9$4;F%JC6\C$@M@".*D=QN!-ZA^_C-*W?"ZR+.%*^E4LU MZ_:?IP_E\ 0A88$Y<'U@5EH^$;CG,^(W5!X!WJFQF%UF'DPER[LKI?Q.:JT6 MU7IY$EYI1EPU:NFNPR[ZO58_\=G%Y\1F>28S>SI[OM@(W!O(W< 0?1N+UHL. MK;,6K3SCO*X9-&B=3U%__TKB_^?ROC_@]KVB'Q^U 8M'U/V:-B= M03^B_*%>R?R"BZO-S?Z.H_(R79%MWX> ZVT*SH#I]2HE -0+^!(UL!V3UQZ MM+/\@%<9=W MG[C>\R-][4HS^0E*,=]MSBLE[&5RJN5$L#KS]*>\ZTH'+G3R M8C70%"$!T=FOC@!DXE V ;3/<^$V4*46Z>DLGC&,IBIG*#W)F3_ MP5H+W#TGVOJ6]P'L"FS='^".C4)?-E'YP49@-#TG-DXRR?A.;Q;@SSMHG>T';U4E;&[5WVX[?:[[N9.3YD7,?)W(D M+G.HQA"J+*'*5.<)<9K(U=;*J@\_O @PHH_-C8PU.W/J'-PQ[1$Z.I$SH3.Z MST;9QP_?$!JEQ^8;)IDK7J:4R#@O+E8K5MCM,,6PG@M*-5G/]02:1G&: [O3 MS=5D7?'W>F+-R\M4NGD45Q+4O54BQ[U1) >RM8-3(LK5?PV4VOLG2;^F8]G( M4QAI'P+QRV4*#@/H2B F\3I//XBA@<#8^\IRL8I[' M5N6OCR^7[6/8VL\(8.7J7"I5]BZETX>QR31R9MJS#$HCERRT$G^)>/=.,R$ M/U9*V3)IE4B65]L^I@ '=WI= (4^*T->C<;/];V\LNLO$=G>>2($LH=V&/"WPBV35;R4V+ M?T3)'E]MOK 3:[1K2<(>UN-R]>FUJPW3B->5_GA0=GF1FF-=-2?KSZF"IFCTV-1W9])-; M:U5 >3;S26AV6_OX (1Q#1% 7;$/,:"_P7-ST)CGUZTA M?-\/US*PY@/? >M4!L >CQ"2P M_DZW\@#]%?S#$FR/Y-??HH,=%#%#=?'Q04&/UI9U?L)3^M6A;E)SKC-C-H_S MNAR\9[".<4&HYAKDP#IC'^: ?X?GYR9'7KD [_O,'*3+ZL5%",_YPQ=.S*>7 M[@S'6L@ [?0TQ6' O\+,G.+BOY9N/NZ'BYNCB_->U#@6%P>XL*%XVOBWW:[W M^'+E)ZUDJK$RE GSK/?! O0$W<:HPZO>/1V#1[TY>&A"5J ]:UF^YGU2/WJ8 M]A_]1M%]AC'[/A-/6>T0I'_R6SS QB]^'\0-7OSNVQH#LB"3)2MKWF ]-7B" MO@7:8\:C)#4/ TC ]VEXW'F,DFM^HS\/9&T""V ]BGDTKNP".]]J#H M W+E)F;<<7=J KSC I742<.@"M M\Q(I='YP53S@[!JG;+/TF@YT_BMFCZ_W M4&G8NOK6VM8>W-#HAG;-9N9D'#&17I;U<-A: 6^&=F4[M*,-T1I7;XY3C.S8 MIO::G9/(BG@5[R)V5J*Z9GE'L;*)"Y;$LRO"V1P\MBEHB/7(=MFE$:SI9:0_ M+#)!W+:A'0],G@Y!635$O"7ZO6P[\:,N\/B2N&\X@ $Z\ ^4[]0QO"=ID<5W M^Z(R=IT1Z@=N'J*,IG#-,9AWI7OX6+Z >\$O?/<@#*:O^NT ]'F0T=LZ=""! MZI",UC#ZE[]J&,8MR7U#&K>I>YLCMQT(*C 0F Q*Y?\E9=>RZ@/D[-5Y#P M"M:3H$P]96\3E91K*^+Q&96J4*6K=;^@TH8J=:C4]X-P"BC-F7%^F]0@78"K M;PO6G:"\*\^VB^-9%<=^T$D!DSG3"7!#M%.(]FLS(;^)'MG.+NN:<)G%5JSZ M-S@!LUOMU&9T':J8'5K4:.#4E1I+:,Q M@^A#O'I =Z1XX'GS>[+=1>D3GUXWBSE\R1UO=PEYPC@_)-)XXH38&I/$'2]= M[V"JH78"=A9'H@)(3FIK$(($-,,T!/@\5H/&P*DD*PP)5, 5HW]&"=O+ZT;% M@_G;;)\7PK!D+UC]/C:"'GPT-P,=G*PMRYAIJ<@L0-5*^Q/"%I&YXN<>HASP M27R0TV6_N8Z:_[961Z,&2+"R-PE#"AJPC $_CY U%FXE82LT<,-N=EQM/I:> M*+M8K_G['U%BNK&AEY5O8JAD85=CY)9&V)S0&K=89M'H6A[^VMI[6,=Y5>TZ MRIXZ^PHYVD9KC.Y8=*K#45:6)99N0\QO5\$ @_(5&#-H:!=;Y&H4"RLZVV.2 M(-2*O]XJ&/QIV*H^QGP%<<6*9T<'1G2@'*=HM<\R%L@VE!_TXR<<92\)V^8+ M\P' #1C1ONQ9F+S:5'VHUB3;IP9Z_# 7J'X9$P$/KNK50TM.Z?4IKZEJ#%M @+H/7I9I>MN:7J97@* 0)$^:F_/!' M \(7,]@=)^HD'AX:=GZ;IV8VX'9'S>WY@6_QPL$GV:B$!A_@5N,'?%= M+2A_(06^_4:$B[C:=LV45]K.*[.7:(6?RJH-R?-VE=SR]B'.$4[*-:0U+J(X MZ:Z\EM?"V=)I00J:E_^O\U>OT5V<).S#-56.XDK[Y%-1'0Z(Q9#ULW")R"'C M5NH,!3"@::+&@A.T^$$NBHZZ 6(M$&TRDS5*&+A(9VT^>/$]_J10#7FL26/& M"34T3-\>W,R[RLUT@71,^)&>'_+!3\ @?)5BHR \:"<)PJUV@)!OM(8.PGU# MIICORCD$X;\^DR \Q(&$%<(A4Y.B$9&1HJV1-?:39L77U7;6L/$FAT0P=G,W,R1IA(VP3J?9KCU3[#:X2I9G[> MB.M&M7*4,NT3QVM3L!#K$>UR22-8,\I(?UA$@D1S0SL>6&2[JQ)<\98S<=#P M^)($>SB >Z%?L7_WL?4!5Q3.#ZP@OQ9O*)1XC:+[^\Q.V+T\1$/CO78"375 MY\V$O&I_FIB =NI65N4%-HV5+.LV:,<:G1S><&.G%W(4L:.H*];A>US?)*8M M4W:,M#[EPX1*@PQV5$&MDC7F7A_%&ZJI+*%9OC&>%O3G0$73(X19EQ!9T1A2 MUBLX"#]$C_P_V?LCCS'9Y\D3NF.G ZE%5M)H/7G)=2L$$U=\]0M=FL@?:E.: M6QN%-$ 5OVW,^=.%U]6NH-X0AS>GDTQT$$!W /B-E M8]4?GNQ2:\=;]SWUP5'3W'W@?+O.F_O>XX:PM(1P& @#3I%OV=NK^^R)%0$6 MSHKE#:KO*FK@0;"A.NC,2&I!QAN)P/*R7;Z;IAE1@3;)?E7L>2UG\LBRYWB+ MR^R'-MPG_!QSE):U%9,GQI@[G*X>ME'V1[<:."(9_<,:?Y\X)5$,/S$9L"XA MAFUK\,NT@",))%V0J[;#$$T#Z@\0^V0FDT_709=$X!U) MUU(GIVM6?1]Y,P^8RI1"NSV-'1EPE6(OP@5JP4',![)+#)E$30^UQD"8 W&0 M.@,N:*/.\O Q8I_/R6="H$3B/WU@ GKE[JZX3/,BXV[F*U[C\N6)ZPQOX_U6 M=+!!W[I]O$'5VG=+4:X[R%$'K3GE_J)&NJS)]QC%"7\K]W!#[HYD&?G&7"K# M)%_XRAH-;-&+J4#DCMT(%Q7NF\,9" /($.MQ%>Q/R@4[NY0Z_6%Q"7="0F_' M Y'-:8FF&3JT0U7#8\.6ZO $"+@ #E*H#0 ?I] ;\X#8HH)8?(#8T+4=&\14 MYRM ( 9]X%%H+5[APV+B9;I*]FL:=BY6JVR/U_4$PCA[L-*FS2X,M07AH9'M M\;(3F^[8$]E<>WOEF6\E\C=^LO@^9I>?!PO1NV1/YY:EGL/\D=]5NN/5[\LZ M-OQ?JXC5&&YV^UC! );\L".@.)MM\F.'>*UWL8:=J?,Q4JQW3A;]FY:6@9,S MJWX$)*0NN6,,;5&V484J7:A6]H-?$OS,E6"A$E#C#HR1H%IU)B#-!ENNG?26 MD2QNF-4/=S^8)<'-7)D%F'?_(\IBM@S$EOW>U>L_X@/.)DVK7TS=U,,KJ!1# MY[H&MF2$UHJV2H(0_AY.O-W2MAE[F'(3?V=GWM(U>JS4E/L9S?(3LKI)N0ER M:#23_1!(%$DR)0@8 >Z/_%9?7.#GHC_L,6WQ%Z$C-FA9?5-E2P\"*/1">V&] M*1D)=))NMTK*H\!WN"P$VJP81 4Z??677U[_-UKO6:Z%F+&)/;$)3HC5@'8) MI!"J^:/5&PZ$($[8P(8C_*@+;EI45T=H&PZ;F;A@./A('+ _?ORFF!KE<--' M T..**+3OLKMO!@P269G_F "G%5U+9W^]?5K\W@N;2V,Z8+68(P8Z X;VV7F MS*@AEH:/\=3,?&.\'#M";BD'6$6O@:"88A+]80$:(.Y+[7A 4Q#_.;CF[;@A M &:4#?@@##(K$!H(E1E(C7G@C&<(W&D]JPP! FA&F8(/T()E#-S2XM1T]M]O M*9_]'UK"YLVUWA%F_SU3%HES1Q(Z,SA[==;)#!:GL\H,Q#B19]RB =4FW+60 M(N'NZ@T'PE"S_[X-1_A)9_^+TUFZ8Q_XF,_^+?$#/OMO*P\Z^^\;V5 MVWDQ8#*?_5N"*40L'Y8[*".VRF86@0 NB='$18RZJ* M(K_,+8H$!*HN60F 5* TQL!2@)S&T"H$7A<_\*H8TO'P.LR40N'US :OFAHX MMG8A$'O&\O,WW?S\!W![8SL><,]@2\,*ZBE6.)=\VBK]VOG4L[!FKXXB9/HM M5J\JG]EO[99,\Q*;/(6>09U6T4@2[<\_+)/9:M@NBSF0AX4#6%U5@5X+(-1U M4TM_-P\W9S^XBB*H9J,;XKQ@^XQBZV3#&_4B@YE4?XU!)P61&*AM!%MA,#*K MS0H,M+BYQ.Y9\')YX7 ,X^-@&7;YP,P> M (H[BP?=L^2=W>4W,_'UX0&J6SD 1VC8L^>+<^/=YW-US!"U!-ZW.1]O]_G< M+AY().%WG[OGTA;GY@N\_GEHY<)BK; M?3Z?F[OVAH_%[K,=?N!WGUO*P^X^]PPYHHCO/BM.EATAF"QVG^W %/#IP%O: MUNSQ0$%+V1N^[9:0;V8>] :I7*,T9?QP9D_2X1G!TV?RC* ($;+G-<5#IWE? M\R D?6&SKS<\C@],%K? M[< 4+*2?G58WR!8+@[ N;2T,[8+68(P8Z X;XF7FS*@AEH9?;3_MKK8O9A7C MY=@1V5VWDQ8#*?_5N":O_OJ77]I+"*_GDBB8XL[TSI< M$Y97OEY+*&QD<22XCW,+_+5EVF&DQ_!6[>NY19& 0'6]!>Z!U,"WP%\[YC2^ MMVI?6Z8X1GI^(%8^J.,A-O ]\)8EJWO@?G4+>E8A\'K&=N=XM/\!6^G(C@=; MP%O@W.?S MVN"38TQG" V*@+T.(# 1[&4)FS -H M_&6(UXI3P\<+-+.7(3R %O9,T+GQF:!^2_F9H/- 9X+.QSL3=.Y\)N@\[)F@ M;FV.\QF>"1K@1+X/+QI0[3;\N7X;_CS@F:#S$\H>QBH[C;,YN/&*V2*,]1 MM.)A.JE$T#<:B]&&":*[)]HXVY&LH/_X&A<87<1KE!=D]<<#2=9,'XW@.8OA M+,:3#0_S[\EV%Z5/?\K1+B,[DE/9:/7O/6W'#=%6M:J)0[L:/,1PK+L,$C:O MN:/0%0*-(,%;J=T:AS1@EY\QXVA[SEB0Q&8W, "6*OR Z6\<9?@]Q4YQ MM7G_P$HS9$_""9%1VZ;$D;*M5]$0A69H%VMB3%XY1"?;* M"4Y>PLADS(GET/0+ARC$#J5#M+I#@@JHF)&!%6#\EU2_DJL2#;VXF MH=,%KU[(*.JA]!DD&)Z (U##WR6WF[Z:]3Z]F80#(-F-GWEX]--\J"WV:%*Y#E3BMUNE^ M,,8-*O-@#&!R^6N\7B?X0YP76;RB/6AW2IA(F@M4OY6)@ ?_]>JADT%CBS)B M&RIX!DF>!1B(RW!UZ::7K:EE:B4X[D 2,'-3?HBCB579$-4M!P%D'N$@%.PD MB1$T[@"7^2^2)&9+#W_'45(\K*(,7Q81_5/9A;O]?ZC#P#?7%T)7[B9<_3:V MPAY4LS,%[>Z=K,N(Z*!L>9$B_.]]3).Q+2X>R)IF<8\X+S ^1 *^[3IQ+'!$ M$_$=XRY7[?34O'6Q/BJ@0>*(FUDX*-/X4@NA@Q0JQ5!'#MV\VKVZ>#63>#,V MM"5Q:"QL \:G?T;)?89QFK\CI,CKKGS CS@A.^9U_[:]>Q &)P?)ZM>RDO1@ ML84=Z)AD;UK&8EM-SR4:N<"'>(UKEZL62FJB6ML=#[L@X!I)! 7 M:7PI:@DA*O7WF82<\? K"3;A >RW[FMI#+*:CX-I(" O?@#98(C'!C+@:QN476[8NW..&AX;J=W/2 MX,%D!WO0^91[%V3$=M6XI)_1O]"^YKT\B]1:$.%J&%BS1A'*N284<543)U\^ M&"0@H.BZ =EM2MP[L?XA !)TCQL U.!)FVE)"I%42.+2F%T2]!!')7RJ%3P M4O$O2>;&)X!?I7,A'P8+5>/5@8,S^Q4M'G\3-0Z,/ MW(G?DHOUFE^*C9+K*%Y?IN^C75Q$B="#:UMWW+>BM3>%I+JA)^1FYM3L44LO M/WY?X9R?>HSS?(_1+HM7&)%'G*%=E"&2H9R=H5RCQRC9-[L;M,\4*'_*T:K4 M5=Z)1NS$9)EQY3096^'XD0HR["-"I;(N*^/TD22/[.YT1V.IB=L]7+-^A2[3 M5;)?LZG]^E_[O-CRI0$*WZCYN^Q/73YE1DS=XZ_Q875 [=X11OXE5,;5&6TY\H9XGG!D?%/L/\ MRZ]P5D3L>>G37)J3?"5%'>\DQQ2AFU+\VSRS/K\D8LIITD3QC3K_H;S5^+ M=E69#?TU6+^B^_L,W[,3K>6/S+3VOO_/A^^/HCPGM+-L\/@76)7'7%D_=QD[ M5,?J//!?^17Z1$U8J")I\E3KXQI.T)[W&C>=E@_,24?2S7;O"]B9[W_[.40% MO7DJNXOJVIO/>QZ:JE^)VL.'!76;L*K M/],0!B0U\K0?@"HTE:JET3]JAGRL&7+=9DA7":JUO'2"2+*RZ1CBE\5Y&#;+ M[MZ6%$GY?'HMR^\\NQ& *30?_(SS_#"RW869=NTY?5AYZ:219)G3D08P*_V* MH^0C7[M[3_)">+AO,W*?15MAO',1K==5K$1]$E\+0^ K*/:VI1FNK:HE=Z%%1X353V;-4)RC MJ!=^=]1L&937^U49?G.^M16G*QJ7P7;]BN'4[I__*I5U)<($C\ MH-%+;BVT-!FMM>41&0"S).)@% K[IQ7XNS(]O%=2,PDK8\)8MK(Q HX]US L MK4%>SG*Q#87GA1C/+Q?!LF6&$1 ,F'A=Y#DNV,Y:G+$DHF/W_4.4W>-<7%_% M5JXNK6(NYU.$PM0*>$$52\/2 A16>E3+&1'3E*.XT<7SJ0PG_.P-.[;U&!?3 MIU#V>"(>0]VK/6&JHBD[86=S+"##%%*QM0@"858^A;5'!P'4D4"5R$P"S3AP ME=5*"8I7O_3(RA1D;F1M& 2WBR%N7Q9$)5E06(A"%J"GNK?1"N^+>!4E_WR@ M/VH>)5B8\QBUK:(>DN#H-G5;G:E#Q$!7TO^^C>_Z0YMT^CU-3MIG"'_?X31G%PK+$^,LS'0.LY;TI MFT?;^H#[U.7HC7!)+.'3*P>L$FNJ_NIUAP0^3$5X$RO.D&?UW3MM4--H)F$# M%DRR) M->E*FUYXV6J#TN:-Y9PU0ZND?(:;G2/915GS5'?O3$FY>S;U_H89/(CM(/:6 MW91RS5J;@?:@"(39J# RXXZ]4Q/P'1>H9/L-0*CRW%G0Z@?=3C"RYHZN1?O) M>(ZHG)]^2\L?].XX 2;;+0 "6+#).[_-D4;EK6.#:;RBO7!"+VP/ENL*M(>= MY,L-FB7 ,OD?$_\ 6;L*J\+\70,G52(O$!6G]%(;H4D18*E 8)B5!+#PIS7J 3+$>\'- 9+5;X@@XPB?E01>V+=%W> M5[U,FQ.FDKJJ-B+5KV FXD$D$P-@OMO&F(Q)YCJ6=5.>9I2-4:OU;*I<6N&" M.(Y;EU8FXC6S+$Q!D>M3%&?59?!KFBO&9)\G3[^EO.#B^H:5H'OW5);>O*Q> MD>I!VUU!]3NY*/"@H;TYZ%F&4)W>$.JFIG1IL!E?8\'X0@$!;KNS5Y7[>Q<>S$Z]T$"LKMI6-;38,T$JTI&5QMTD$6U,.+2Z-U3 M58T?U0I>)O E@7ULY/M-X]QLPLWKW.W#XG]1X;^I3+0[X/\!)^M^^'B9D)=, M$<>&/.0DDJ47K%0S2Z73]<66IB+Q?_@_WSW]&OV+9.]I]+\GV=,M_EZ\HXK_ MZ,\IW3744TP7#3XS3GM[T+FN>Q>DLU)'C3S;7<+UXOW@A/ M2ABVKGX?;6L/ FMT0V=T9N9DS#21IIE:ZX&9-=]M8L_A'+83HCNR+_BRW+[6 MAYA"MLR(?KBCU8)>:6$'"5J-99I@93ESC0 8"8#U;OVK!$HKDQK-08"%H7=-%1.M5Y^%((E,@J%GC !/#0"==\'3U%=PGF?OGTK=!A:MM5WT[1S@/: M4JW0/E-G2 9QM=SR GW+XJ+ O%;Q-L[Y9LPN>D(1=X;\T3;VF&>VYO?.IC[/ MK1]L8C$N7=Q+16K@:W2&0A&(A]1:<,(/]9&E4ZP:G%0IY^G;F;A)&+Q('*4? M8/PF,DK5<%,8K1DGV/!IRU]>OVY/6]HSEB.#CV26X@R+K< M66>!Z&:_W499_!^\_A2G4C6Z=-+UEG9+M@L,IK'XQ"(4>9/,W#YT-@/5( MQE\@ TOZMWT29;U-];S1@S:UHLY3DY*D.0*KBMAZ4C3M>JP9JD)'52=H(,RU&CKWL_@"M%L=O7G MRCU)MC@W\OGEGS!]@$M4X?H3EH(T]=42C3T=*Z IC78_"*=$T;P)![F7@"DK M:79XCZ\V5_LB+Z*47=%_3[9;DO*3LOU=!6.!>G_!0,!G15BK'GS/P=2B=*W8 M3,'RT(X1F1Q:LF26-D7Y0\1*H+#J#9M-G+ +17EYK)QEO=LHI:)\$R-NH%;E MP=.?);7 $7$9Z=Y*M%:V69,VM!(=9N-K(!6,#9V)X?]A8FGI+_V,PU'B< 9>6=@0$X3#S@ 7AF T!-03)S MBWX0/+,(UM_2J0N4A0+AV3@@/)MVO?I=1(&RPC2>B#0:CW6KL5J1YZN MBSHQZ9*9JD.0LW:Y'8_ELQ-4J45<[VRJG8"CWF-JKT6<_P1?9,)GFJ_H\DSH M.NT:FZI78W"6IID_>.<-G>?#N^#;XOD5*WHI/(EF+J!,#;H"X%ZDK7Z<;6F! M13OJ#Q0L#Y^QFSIE'=+B(:JGC&5EU*9P3UGS-,Y1M/[7/F>WM.O]Y;I&T9_R M,M-OZ@-%64ISV)R5 4I(GN.FMFFC]%#VA]4RXB97M/=Y/(/R/Q9(5+H-&59, M_$%;5LWTH97@H ^8PXI,^<%=D7?FB+>=R7&I4+"SRO_<<1SY MH8]F4"7&Y!@\;O1994'NZ(-\S66]CLM:JS_PI6L4)[5$/ MQ)92]?LNIE(^[R&8V8#.9NS,2A](L-#2>MT^:L1H9D*RXF?J#+;U:;GT_I#3 ML!(TJZ)Y2V$7Q6MT%]$DB#]\'S^R:H44@*L_DJ<3E.^I4)2S(@41KW:(_[UG M251"TGNOS&++*_LWSHCO?[T)6IGYNQA"UQQE3O M)0JVF1@S=O7>FKX5E)'#LX90_9!$,GX!6O MBT><1??X0Q0G3S?,R=U2__..9!EA#B?OQR>SUG5RM%4[X-PU#2G%UM6$=T6!$1<-Q:8. (:X(-:#UZ.46K"ADHG^L."# M<>QF=CQ@=WK '6^&>#O$&J)#RV,#E\QA@Z'+\^TQO0&X.:RA,0^,+8Q\V[%A M3/;X&!C& ">KMQF=1CS@VV]$N*@N^[CZ9L.//;#?5P8=R"7Z9? 6-F]-$8OR M^XBBK-9(B4S^%9L YG\:*"U@61P\6V8S. RR0<[AOY/7I+^_YLN#%?8;Y_35Q M?4.3IO7<3MG4)P=4* :?\^EM29-#G6AK+GC ?-D>-0+TTWO,-_#YF\UL_;9< MU!^TG'K.:((,8C>"O M*=8&.8\*%;*DIR\S3'O$6H/!&'@Z)3/A!N#NE*I* F:9)_NA1CNQC!"GS&:MZZQ9U]HG?U'K!L^=C5%EE'9NMY&Y<&Y M5]UE9(7QFCTAG+)7BXLXW9=/0%*/3NZ**$[Y18(D*9>Z,EQMO>0GZ*XJ-%Z0 M@C*M>GJX7!6C,E0A>^H8?V?ZF<^GP2+>Q/2_M]'W>+O?5A)3Y^.&L"/6V.@E M5&K!)J6!LP3'V\XO"F&P_"PQCD"MRU7*?47YATK;.+M1M?2BBT@R>61@8 MD[)#*]M:EWO.6V%FN""6P]=TC@P81]$RO.D&/G0^0KP#-QR*!P MD@5\$#Q!3O7*4PU7*1;[7LG'W>-MK8_]C[XTR@(=;^OKUYQ]Z387'&\C*9[I M\;;AJ!']+RT\#-.T[!V&Z6D 'GS(XVT#Q3;#WCK>1O\^%W_E,,CJXVU&HPQR MO*VC$?QXVT"[S5@OCF6LU-8@X]]WJ;I M*8..,Q+]TJ=H1,U;<2;EG_/Z'E4+M-[SMX'9$EX9>:9^]DHV>D3_B_<>G>FU M;-Z:$6H !@',2U82Q3;#S]ZM:D:]_N#Y#;'L72J+,?9\A4J@$?#Q*8EVFY%> MM$>Z>+8C+7M"RF*D 6/-#6V&WY?/^>07Z9I7LKC:%?$V_@]WVN])7O0CD)U0 M]3U-A3PP;&8".H99694!WD))5<-E7Y37OE?T Q2GJWW&KLSS4PGE:056# NC MZJFF'$7INJJN15IJN7C.EJ[6^Q7;PJ*M&Y^ '/X3B. T_ #.CSY:>KZXP\QGDKO%=8%GY6?9QYLZ6B" MSDY$RF70'[9=WM+X7QUZH5DW:X!^2B*><:!-G-'_(/OBSRQ_**7H?^&<;51$ M12]WX*4UOSW@LIAG2@?GB=?Q9 4DF\,AM2T*O,91GC*SJUBIB?O$Q79-M'@J95<]I?TLKKC+10 M)_PY?Y49^1EIN12/7)U#FZRLR\ MN;Y%&],Y_)]R:B+;TJYFF(;&/:[FXZQ_54\G/T&B@R QQDO_*+=0X'".6Z$O M#*Z!#OXK]3L@FA_YK^#;?(S*SY\[-*3'_%VQ 7CJ@\TYV.)KWCQ8T(.3O$'U M;40-/* [5 ?MC:469+"5")2SA_O[C*_(\.<[CVA:;Y@.9+_!\X> MXQ6=9M/)P1HS'?-=I%2 @I@,8Y<(P[8U!V1:P/$%XA7EJNV017TA^Z"'G^&Y1RN9^KD<,QF?-QQ,+$ '3ANCTJ<$H M>W\G"!X]7^$Q-0/X$(^-26]4+GJHC%XL*F7O\@1!)6"Z],\H83=.TOP=(45^ MD20Q>\E0F"69-*V^O;JI!Z-4BJ%3(0-;,@)I19<7-*4IG[ J-P8/3_E5V07+ M-Z)TZLS":,R)W=AT&:*2JHFAUQP04B#)@HD15S#1U*!I@G@;5#>:B>N%1)$D M_$/ R"_8Z[3#Q7@32ZY@6KPH,$FB-@28('=8'Z.8]BS!&Y+E48)OV&M(?+)[ M0Y)U?Z/5J''S+I&ZL=?3'2K5X+NO)M;D+W=HA7O[ /RT#XO4>=,4/>!D?5(M M/'S#[$P=;7E/^*/1*,4Q7T6(5&9KJ]\W9 M#FI42_U,Q7YFHXV)81SEI5=7&K6KF(#S(G]=\.U)LX<7""$?$;WBXM;;34)+6W M/"**0=(/%Z-0^#WMO1[??C:^^E,K3YG'='=,'$ORF#& [)?CV%J#RWA<+$/! M>5'#N8WCEX=:258T!FH!,Z:OF!T.Q'3"5+]OS:Z1L2+OQ?OJ+D_>O0 UUO]RH!Z/8@/U@OH+ VZ8S*? 6MG M2?^V3Z*LOB"PSW#G_,V? ]&L6_G+)*5P>.UAK1^S9'*Z7_ M?WM7\]LVCL7_%1Y3(#.+^N*;@33;[A9(VV RP!P&>Z!EVN94%@U*3N+_?OE( M4;9L42+%)UM->VD#\WW8XN]]D'I\)%HJ.1)+2KGD;RV9@&BB95\YV?DQK-:1 MW(_;;..6!:A?!;,E.OH7NXCY3E#,]Y>M!F#M1[)5W,50(3E<6G5/\W7C-G$; MR6&)TD 2YT_.! ZP<'#I:#'R9I:COI*)&M'VJ?^ S=IGFNI[9G2)YN&DL*R$ MZ9?50M? +R1]H2G<[;7+Z8I=/TMV3[WPFZHSPSJC/K(1AZ0!D(25'#J%AV+( MI&P6$3 VDAVF&!"X4Z%@%$0G*(U2\?8GVS2$8F'R%K'@#K7!6$ ,@/\18O'" M4_7D.(3C3^IG/NTS)E?\K)FR#VGYV]I)(W#<)A@[0'KH<@&[DW5V5S7:X%DB M=0K+,^A[P0HXGVUVGZ! :KDK8'.,*52*#4_(G&5LR0N5 QO9YAA:;J5K*8?C M:HG8S&U:7'776'#)DB+=$UHH>,UWA5[EPMT#<-B,K49PU8 7UD08)NIVU\9E M[:];\H!01HG0/DKZ@EA%;$OB ./;P9 CD&. *"ZP=TG'"_ ^FOI":?(30' M4^[Z:!<,K+5R6&-3LC'IIUU1N:+)_X(GN&-'H M==N)RM_E(HI =+-(;'_;JL6%Z1:FF1TC=I"L^#/+[(IG' =@.^94^,Y '=7- M]!;3;=(&@0F*VVL7'PZ0]TT(&8>_BP6%P]?U106BG[.I[ >:L\6W[.XO7JSO ML@7\)W;%74;3?U:F7D(.2S1YK3LZ$I- MXR)]OL]PJ+\-"_0OEVR^UR[6]BE/&)FSXH4QTPQV2;D\''&D=N])T2SAK@ @ MT:=OWD" M7/2%7_/2LYW_=!'JH^TB-H6Z4>:G+MZ:W@>:T]O&98:/0G"WXHGL '8X'2IC3'*6J+=]*H;LSBPSJTO,UO+#3_9^K1@FV<5/&"MM. M_R85>?X.!JH>*J:ERDV^@W*;G.P489:+M&S1D._F.5]P*GEY%=,_@L,M,NIK MP(5"[S1HJ^X0]092^DQT BF5OA1 \6^W*6>+LMI>_SK3YE*_CM1?4%0],$^N MW4N^_V;\"ZS"U;AY55FY'-.; IZAD.KAK"0UB9SFU$7\FVTJ]HQ5-?J-O:ZN MG-9YFY4(AW[=)75Q6F?DIV%@ZT5)W'P5Q=BM2M;*=OKZI503QO3YK;>',D=B MA@FSN&3,1P-F0;6OOABX0;-+ S%H)ZP+GGEVXMG?'M0<218FU- 3JP<5=MTJ M\Z^L^+;\D[XV9EF!O+64RYLWVK(\-0V3C(4I;S>Y$%G#IFFW^B,8I:\F;X%- MK:HMYZ^4;3PI6ZB-BDC3:7)]GF+J?C!(]R6=!&+.%Z@5S3T?X%SR7 M@G1K?CHTI!$SUT>%^S4$ZT=E!(GD6PC?GWC:W(O=D]K6G'11QU05M,M&KT+Q M4N>L-O#@GCWP7,>&[1$-62JB*]N5[YR+X(DY*4-H9ZSJ$7SD#PLLG+H5/ST1 MD()*%DM%CLD(T(VEI@4=7:XJ%S1XQ244'@KP4@A/91$@F[2";#254^@H<\1_ M/)3AQWB5P=UEBT>Z9_)>9(6D2=$6Y#O)ZU&^A3S>6IS"!XKS7?HZ#*:='2YA M,4?[JF;"[F-ZM=-_QUVGMI4JO?VS!66*TVB[=O6J+X)$^"PWVIN3\\3@.C0, M#%3,O*%340Q$#YF#A9I _:,&>7NBV^5B*'W'YN[N((PRF731V N&E MS64M'LRS?S/)GY7V9WBODA=2?YNJB^6:+59,YPFO6Z;[92S8O" \SW?Z;;&D MNG-OL:99_:87E3^8'6J]Q4>)OFM>":ZQ7SFM\$24")WWNNVU\UG+\Y$^*&A1 MD@D_-?WAJA*)DHA8*@)D1-.-Q*]CP\J10F#A"O'8S5=1.,X4-HR4OZ8V$H'P M(SG8/OAC MV[CT95;E,1?PFDS^KI!OWL$_Z_J4:H"LA&*8T^R[W&V+6R-J71ZPE2QAX.(K MG5!-\/=F!W=RF:'_P=+0..TKN^4FK(C62:X;QA&1M8(S/CR@H?C-!IF>$%,> M47\R$M_G/W<.K]8]>8C^ZJE@V\F?DF8YU7?)*6?)^"J[U[E*LB]]9[-'Z\5; M_M9 W@BP!FG"]IM]E+M@'RYK!BQD A<56B;P>L"ELEFUS,E6K&K(#K<9EL=0 MCD9OV"O=;%-3M03E2V2^,TVNE%O;2BV?G[RM"/N$C)1BR? MS9;'$BU5]E*-AFNX(Q+:,B[T-/T"=_>$7P/]];8O>4I*R MP^^!]FUBSI&Y8(,N+D?QTX&7F/CKBX/>I :]4W=7O''H.?(*;.@A9A!_40G' MH?*/9@D/?;<_9U_4(UP#:>,N5@A+^1S\6"+,R4H0HBT6K2C\L*?E8!^,!?R-9=PZ)0T$ M:7A$F X=$:97B C3^(@P'3(B3,<<$4Y!Y&.)#9,<8(C3 $.<7B(B3"\9$:8( M$6$:%A&F/T)$B,1AGXC0$XB($4%?#6\.B'XT_1>:7V]WTI6_NH4NPGB<4K&] M?))=]0N2=+M<[+$JX6S;GZ"N:>\(2:\TPLTZW!8N$V^5M%X>WN=:GK!9F)A4[86N2E)WA9J'#MV<:A!W)][ MXJ]?1%:L'_A%+1UKHHAYOWXN#[T,S*G"^;+1$[*+1E M)-'70B\(7Q*E6XJ7ZK(P$Z*UB&M70[6@1'A-Z\FK\G/BZH6X2PX^Y'!JD=RR M \$&=47\E>@A\O#YP[<_1N(K^\^^JPPH>/HC2WJ:A2(6[K@5!()@HD'PV^8- M@2Y^#X%1A-&MF"$N$U MK2>9XSEQE3.ZY.!##F!:/P;# #$TWFV49S>(^<"4 \[NA=P*J4-*8Z3T9RA_I0]# M!*B[Q6.'56^-+L1["H"^.\W=A6USYG'<_1B "-%GSNK6TLUKC<=7R^#@0PFP M_JKB8*?"[QDA.:("G2.4(V-NKA [J<#;\'KKR\.>Y.?&WN._ ;>U7V M%2*V)O,\%>P J<( !0 M !W8F$M,C Q-C R,CE?<')E+GAM;.V]69,C-[(F^G[-[G^HZ7F]6DHJM5K' M3L\849;'./W[7]Y_^_U?WJ%T@9=QNO[[7W;Y-U&^B.._ M_,__\?_^/__YW[[YYB-*4185:/GN>?_N]N;CY&$5)X0T?S=_F)%_HG M_M^[:[S=9_'ZI7CW_I=??GKWS;L?OG__T[O'W683%^_NXC1*%W&4O)MG<5H0 M!O_?N^GT^MMWDR1Y5Y;*WV4H1]DK6G[[S3>TKB4M"_OFG(OJ$_??/^AV]^?/_M MUWSYEUI$^AE024/^=4!?ZT2,^,MWY=<#*6$4"U@?U";6>_>NLE^&$_2 5N_H M?W]]N.>6_N4[2O%=BHII](P24F59O-AOT=__DL>;;8*:WUXRM&+S2;+LP(9: MYQ=JG?=_I=;Y[T?.WYF(MZ90?,)%E-B1L^0WE'50C;G0GVV95B3R9YM6)BX" MG<#*K6K,A9ZC+,;+VW0YON#]JFP)_UA$V0F@,JS,7('QI581-4K6&4)I_HQQ MD4=)$E/G^.T";ZJ*'G?/.?KW#J7%[2OYGQM41'&2RZ7_\AP1X=[_]?L??OBE M%(W'R(J0:+TA/!_0%F=TU#20DL?)AIB3Q6*WV26TA6;%"\JN\6:;H1=2('Y% M]V1VL4%3G.?ZTJM68 <@6R(8-5J47$?YRUV"O]S$^2+!^8[,54P V-L0XD; M1.Q$)EYT[C-)EY,-;?T_RS_U%8 PM2'\;92E=*Y)?-7C2Y0A?8FYG&R(^8"* M."O;\XK,EE=Q88 - 2\;HI)^0Z;CE'U.&NX:EU-Q,OV/3? ,86I#^+LHSGZ+ MDAWZA"+:4\H:]<46L[,B<+/JN2=3\VQG*J^(FQ6']T+Z<8&RS17.,OR%]A?2 MGE.FELQZ3J7BF&J=5)53J>50 M10;%F)J*JK.A\$>,EU_B)"'5EAW]GLR%TG7\G*!)GJ,BISLYRUV"9BOB]>(" M)62:M^P3W>T*XK;;LX_;KUM2IT&//9%$;P#PE7^T_1OW!VG40FBXSQ M1#FMH1K*4UAB4)>=Y>2_=W$>TYZ33Q;%+DH>4+Y+2,_*\&92DU_1LK,MW9VF M=&01F.R6M#W(!#3'2;RDBT7R[R7M>72CHZAF>+-5LQ@P68Z>5D#;1OTUC7;+ MF.X"9?@.9YNH%G^>H2U9'2W);W2%'5'17]%\EVUQ;K)"L%BW;5/<$_,7\2I& MRQNRW*+=FH#^GC1*]<>4U[=#QLN[H\RA>VE&?S]:V G;D MM2O>*^%%&WZ%,_(9W:>OI T-E] 0IE8VKHA1BOTG5+S@9:L.>A@:9?&?Q,D= MU_(KZ@.I_8C?'Q1#)EYW%"E&-(]U34\A]*ET.86*]60E74]19#3>\QC9V6VE MNU]DTI49G8>PV5BQ8K:.4N,]=B:7,8Z4GJ@_M'&BU# ZX8&2MNR*_$<^B=%6 M \!SG ,.;8GYK$8[(="65(LSQML27\1IBU:8O*X6-]SF8P=C"X6)IMX%UY:CW'24S/ MK9O_ZDTMN,Q&B%LR#UBRU<0+PJNE?(93\L]%-6IJM;:8X1AS80NSX)/.?\>; M^9XDA,I^[-3H4W6[D_1QPJ0LQ$>-M6ZPLF(8/13*;@S4B$L;6XN:\98SEA8R MIUK"C+)X.8+D!&6'J:+CK&6 M&U:6&?9WKPVWK6V-TY)HB68:>(PLT!J_-6HYC7K#"?JXB@KK.XG*S6QT5#T9 ME8RO7'.Z>@R"(9/ME(R]1;R( %>G%-645>= X?%U'%&MJRBA5(\OB,R.QFU# M4%4G5G1TM&1Z+?2NV06?Q+F37%GA+[Z^3"33],B4_=.I" M7PM$E#]8D(IJ1Z52@D:&!"\ZU2;TUCO.)#J2'_XIJF/R3*9 T>*P.$KH)/7[Y8H_H[H^8'^@RK\X9OOW]>7]?\[ M^>F?E00/:!W3BM/B<[1!/15%)+5*;)*N"FUH3+*N.E&V:#B2?W9Q,;CB7U-\ MMRW=P#>+ES@Y0&J5X8UBHV"0AFWI_^,=I()W!7['9HRS)% MLJR^U"O0NE0Y:=_\/1$VKHF>&=V'6**O_QOMF>#@T'30,: )#!YB'4WP,>!< M ^2][P"YWF74QG=Q3@;B_T)1=ILN;\@@U\.(C*PV(9\L&*0 -=4#"Y]YC9DWAQE^"HOR/ _=Z!1.=[8(#@ZV8"AP[7&@P_AP$& M&O> T\<"+_XH T?RV:Z@:0B7K=.V[F@#*- =:KB\:ZC\$A94JMR&[.%YO\O;Z/!$V'* TO[4PT;U*3@X,#0R0T#%L&ET[W=N)T3F M98G<).I/49C?:B/UO@73[B*=]!J^Q[%I>>_W8!O]#IE[&1OV0IJ> ^C1!(,( MB(YF+J''N4&(Z>;J?WXW,.V4_'"20WB50 8S.*^B_+FTPB[_9AU%6XKIG[Y# M29$WOU!P_]0"=_WS/ULQ,8<@ZCFN8FA 8TSO6@,);T=0?Y#8[9>HP31^Q+%=91E>[(T+>\E M]$]057"(F. MSPGZC(K:&OV.!"!M^I.0U%\X*:@(1)&8HWX0AQ?@H5PO-SFYQC:"(8O"ZDC.+24W%F5ZS3,:UU9%'Z%.K4BN:8A.P/N&3 M=?H.B\R9@O,,;U%6[.=D;5_N>)!I\I:N=X?3 0AIK:B8U'$/$#035M*2U26& MS&GG$#,-O(\T%ZM[<.G_7!OM^+/7,.!(#V_R(P/]!<(KRIZQ^P;NWY0GH+W] M6FL0<2MKDZ,!^,N3(SO&\_JY$NRQ#2%YP0E>H,])SEOFJQVN3P M8CX81'PB*R<<*NW/V6PY0RISF3UU#]>NZ"C[K MP]R3R3)P5]$< LZC/3T!%!^OLHEZ!ZM](L_! M)-!2H\AJ%/LQ:+;(>60]V' M6!'3'>'"H_,?,2 -%4'#XQGXV>Q-+?%3]%6*'1!M$\ IIO4<0RJ:JN!(PC?P MO1(I@*2V#! J5O$A $6H.R?*JQ:F34'+26A5;$N?X_)2>H0,HAUV3J\.DVD> MZ*Q.7QS/P[L$>@[G @9(+YSUA@4E1 M9458R;D'OA0K-R,@T)(3MK=Z@H436$U%((GX!KXJ@Z '8M%@,3,"7,1(T5ES MG<'T6O'<4G.&;?=8TY/X),#C-LW]*L S./6M*OD3-X%@#*ZS/L*$=80;DC14 M^CZM(Z[F--<9:>^BR.+G74$WL)\P[5U$=R([$65]GY(1#.6\!=\XS _75NTR M=QB?7 .FU(AU9U) <8A&9E X/,4?I=TQQ!+]0W^;DE1QS@P) E^EMM)+,:_L M(0YA%QH8C5PIG2V'F(QC'V\QWI%EN-]L$[Q'*[W!<333!_T':A2]-)& M/?3I%J\;0;WX&>+5T(9C UE=/(TE_"\5PE.TILEF7'O>!U1$<8J6S7M9K0>$ M;] J7L3]63R\P 'X\@)G"75%.XT/;KE !@>^7DPC8*]??T;%;/44?1W&)^F4 M/D8MJ94^0\R;67#T:8JJ=/KYW+WH#4]9^0;TGKN2XQ/4+<(B.$/82NTP-C)9 M FADC?=K9C$TDW0_4+JG=Y;PD]IA;/BQ!-#/4\\_FSHA^#[%*MCDU&.2T8Y)CG+_C"*O4_ONO6$UG\)(-A0 MA%&/(_5/EFV+I1]DXDFP@\QX_-@D(3GPBFI@H%;4WDJ(#:>BP"\/J-X]U[PB MK7NTX5I\H0*/X.JJ6;T1.-D5+SB+_SR. MODQ@\XB9@!X2GSV0)?8Y+8"'P@0>!\92KWS"'0+:+J$ L WA&P$KTRXN@-H( M$O@-J5;T)7#NH%!B&$7[IF8-ZI8Z8:RM=+X0:O:,P8/"W,D"@'*(X#-Y EL'H%;W;O4Q\@.EKLP'H_<>)JM**6 &PU]\V=^Y\Y'<)V8Y(M1S\=FDX MP-,U@JJS@E>CORON&HC]6]U,U(F)./?TP\$32#U%\/!XZN]4NT8*>Y^,B1<( M:6U6,:G_V%%051%!8L[Z^\VN<=33]P9O2$?ISZ=$-,TH^N]].MPP?B!^\@YG7Z*L?YJO6?KPRK9BZE&N >LX3*W*(LQ/0[+"M?A&(,PD]FNR(LHI=:010HQ2'GA0AW2 M$*&LH+PQ0,5UZ>]">P2[>897<4%32/5 -OQP"$X_?@@10%S%C.'2YJR_J^S) M#79(MC&FEZ[NL?;09(E;^WT7$VXAXM:N"8W!;BQ.X.'G-_%KO$3I,F\-$M=1 M_M(#OHRL>0:+2Q8B5(%*&V.07X_&WKA?B>B&V?4F"V*"C$9QT0VYX@7WEYPJ M1;BY$EE%0H2@AC&,X0BK4V,SWF-HUI1*E^61#'YP7!3M RK&"'L3E0H29KEF,0:=0 ML?Z!@/%22!>"S.LPRN7@$'1^=69<" )NS(P#P=Y%&8TLG2> 8#?,"![D!0_O M.@-@"56W"Z5^509I)GU8J$Z6_]KEU:M_3Y@3"UGVDV=BJR5=T9/E?&G*!T1L ME<<%>D39:[R@5\=CO"2FP>NTY,+*SWZJZ@Z!KV-7%V+7.7$C&/>_\>5M-NN# M/%?W]HCUGS]<#EDM'[(.3.K;,>M[[0.OV]3YWH6E4]9!([VME[D2!2R!^LE1-O4M_V<9_$HXH .620&A]+%-E,-=GL2L']CZ;P!-4TT/\V>HC MQLLR;U"UWY0_XF0X',@(#X, G]!G@( 5!&-%Q#'P]- ?,YSG56AH#R>,+[7= M.E]\1@)?!7#3=U@89%GVX07'1U3NF7U$*)7=/N5[EL/ MLCHI%6H&%& AG\&CI3A\^ %R=Q:'RCP9KA2Z(R:L9KY5U-A]^HJJ\Q'F7$I. MWIE4BY2F"( M,%D9) #V8;#Z&,7I+*.JS%(Z5Y^MYAEZC?$N3_:_$D=)LQR7R^RK?7-L1'L$ MZH]?QGR:28\^'Y]1:,L\\ F5?H7A)G@HKZ/0D\LH?ZELPYYL2>G:5XS8=#Z# M#:H>W/'Q&5I.]'#R?2K:0^B@?XU3XMEWQ+G77AZG^15:X:R^T?04?45Y_^5O M,I_LWX.BY4Y0D[Z;AM?D-[Q/9>(Q MW3!<)(. 5$_\;JUT[4BN4(J&6]P2J@[H&53^ U:FFB+8&.P,PB['VZ"4S"J: M! !"-PHLRW2,TK+^(T?/#)K.2UJ)08BE%Z=LX>:QD:$%GJ^&!P5&7IKW.L<= M/@P[!+%'9&O<>] NWZ2.52_O,[A,S0'&H$9%#50#3'#=T5:$0!&Z D*.%50< M6SS4$Q7Y@F&.LJLHCQ>L!YX]S M-4=?-YBM2@5;]PY+QS])EW7GZL'.C$G=)KI,?(:F M%<. P:I;6P/?4+-Z,/5N#P/M&[3'] H0$,.YB% ,X1(WT1[WJ8#=G]G;S6 MO;G 7BMT_9:Y!K)'#HPDU_"+?B4!YUGFUY08,8G_1$MZ M#:&ZA'!#[/Q:7KK+)UFT8+H7\2HY9BJ.$:U\5.++V#$5.1[YCW0 MU-*G'A45936X[^_#YI7($@T OUV+^!SFC![J?NDWHB:^1%"&=0 M)-X)Q>OT>D>42A?[IXS,TXDEJ_E\^5=2P=9DA6E>":"CFE3R!KJKM38X=:JO=#U+) MPZRXI,.8*@:IRQN/5)QYANF-@>75_E?2,/?I(6_B9%'$K^4Y .L*"\ M[UA:87J)55/SUI8;$Q["9J=B>Y%MGJ2$;;VYV.3WH_EJGC!]/#%=Q GJW,Y] MPD CY-\)JC>%)QLZ(_BS_+UG?)4BM0%A M19QYDY/!"6M9K^N!QA:6^B:8D,Z>X&#F$KI^B=(UF=_>17%6OM,Z6_T>95E$ M[$0D?T )G>8)8*U=OED*J9=_$X WM>OIT:\AKE]W4,E2 M:,:::HF)FKTI#M&;@#'(0J='+T\L9S%"6L\>L?/HJV:_]S-G_2E!JFJWT^,5 M(*%&8(Y?#12X,+>F06@B,4O](#6,8P):?E*M^A=9EZ1+4UL9KFW>X*KZ\> M+D3U!'_/=J@?'0I34EL,0!N#EHNV#FWP:.-K;A=MG7J"WU(NAJWL(AHF0/#[>D/%)XL%WI%)XCS:E\%4 M6;1D),%5*,2%,KM0\- %V,(N5-D5!KX=QS!*V?&ZNM*3W<4BVQ'-XN@Y3LH5 MB7P>KLJ)/S&'U[I6LPMV!2D"O__'[.A4R<,./&H, /'/XI(B)\TK&3RB MH5:Q[JYYM1K+2HI],KMD\(B%6F4$G\NN=8S-O3/=L-7> M#W1R^@ 65?_]:R\08#\>^\0AOF-%>8^O1N WDLW5Q@Y%_[,FY+U9P, U',6VK@^D)]K8!CABH\P?(U-TVF8E>HS-3= M-;=H7X[!3WBR^/::G$)!WT8*7;!@ M WN!1@5%PWR.$5Y/N@("B6. M=Z/E)PW2D #Q,K M\*/LP43NV+/)+*[)3G.?3E:K.(G);&S0";09\*;T ;GU!%,[7>R*3Y ,(U3 M;5M3?>:=E4;D2N H7Q^>7.R/LZUKK9/Z= M+X_&07K7K3]Y ?/!W Z*<^6"W!G^VT"ZKKU.-ZN78MUJR( #7WZ'L[;6Y2H& ML*+5*]WSZ^#2YX1Y(\N-[>/!4M7H_UNP>_5FMK-ZZF?UM.^L.HM5NX[5=TR% MK+O2+V\S\,'L9-Q*X(.R"/JG,)[D"^48XBY.HW1A.?1!DZG8&2HS]6(Q\8"V M]3@[6SV^X*P@RYW-#7H>1#VHE&$L(01E?!L<=-&!]:P$&@,49>HO' 2RZ$=, M^70"=I_G.YK*?;;Z-^+7R^6%@N(FIB=(E;X>:0='SD!V*<\*=U )C^\!.S<%G>FQWI9:7+_?( M&482>$.%T@PW"2I]3C@VLMPI'"M(JL S2)I9SNI6H=4MPK/J*E;M.E;/,172 MX.#]#,Y+S+;3K9R7*(N@'_COR7G)[6J%%L1*MU\7Y>,T#\1NLY3:AK[_2?,$ M_WL7OT8)&F8WURE:-Y9:4>\!;6 )-=BJ5:0?EZ^_)R]X02N_YTC*.753+-5Y M+0M0RMVSS$S!YBB+:0;Y;F:7ODDTBC9V42KJK,NI-CHV,DJW]P'K+E_R4JK3 M()T =UQW#M@)&4&S;$\&QO(I,Q!2.66$$!V4"1^;8C-8!N6@,OW3KFV);S)( M9<798O*?/UQ0R3;$B7"I,9>N<'F;LC?2/)PPZDUMU.:*X#IL;IC_YW<#DT_) M#]4WYJ=.5-+,LG64-@]G M.GLTIR4$63KF.(F7%?+2Y;RE^FQ5KS6CY-"0O(FP59[-PSQV>+I[G,A$_ILX M7R0XWV7HB2#N*AD>2H_%WH;UF>R=N3R[X,2CF[[K1*U(7SZM9%UJFSG(7+KE M.ADX&>?GQ"@+>F+@RFD,1>%X7#EAC281H;MD3?$ZC5?Q@J:A&LC'\WAJA9ID M3,!"[A((RQL2:^K>2_O+K:A,B@2LP%(4KJ,."&S%3%WO I:B"B[5J?T, M7,\Q!3[==G4WS:BJYW@8]L>ZU?L?G?F*2I#9:DJ3W2"Y8P#3=Q05TCOK\IP6 MPNI:=CMQER_MJ0!^9] M>2\D.SOR9LM#/.7_PG%:_$;^(&W Z[^:I9N#;]72 M[@(#V)+*78%Z0;%M_'(.NLV/#0S3=2.*$I1A PHUG\VVPVL4)_39IA7.R&?D M@^=IVQX]-SFBV\E7N&]5JQ8\/+\$+^CP7:J#D/=I+>:G*/L#%;3]!@*GRVN4 M%5&S=_\M+:BHU4-*8XEX!O.V M=L8_9RZS24AXC3?/<2K,T@ A[26B9),Z1N3:T0WP!^N1Q08V)-[;LN M0U15.R>FK(ISF3E]Q'CY)4Z2YC'M7B)0=[Z@)5A?IF.#<)R#5MD:+HIEG;D/ MD)P\-Z)76,5"/K@5/1A@0_-T_8V2#-0!J=9]!G./,KL,<8N;*YQE^ N9:]'9 M%TV54#2I$ESU,EJYU-V(B6I8\(B<.9"N0#Q/(:%B*N=#WY>T"89JUNW-;*ZT MVW*YZ?=/UJ4AE]WT$,MRG](S)[>[*S@]QIS M.O0" TX._8"RU'QG8_URAU&K8] KK&(A M'UR''@RPH7EZ5\949"BO,"G6?2X[L ^HB*N)Q!5*T2IV.)\@3; E@C97&8Z2 M01R/:LECIX*7=),+:49W07@]07C1=A*R)G2,2^8N?JXG$C=<3D;' M4=&'[BYM'0S7KQ?DQN%<1K/Q.9[+!. &$=Z+N'%EDPW."M=\QN7'W7:;E).5 M*&FR.;2V6)QU>I98:*:B(TUPS5*2VF( =1]5BK7PSL&+NTIRH M-#'6MD0OWPF@TB;;#*RR2I#Z- 4YTZO MW4/D*U^5?HJ^\N_DFW Y7MC7X^)R<[,OX6=2MO18QNT9IZUP>TI9,SAY?]^X+P)B82LF8RPB5SE]"C)Y)\ MDU&A!$=MOS86I6V'=73N33 X=90)/""\SZ!//Z %ZN0HR7!*_KEP'-7P&7WA MR40/AII,=VV:.%W$9/['?]+3&L=#LGX+'!V&?.6++-Y6*:H$JI!A[+]0,5GB M;7&$V&%WQ(#'8;M$BX?#EP[LX0C;,6'7JUD0L-J0T1+L7)98C[OG'/U[1YC? MOI+_<;@?TY&#OPB)Q)S@R.HZ*7DQF9*V#X?KU]TC8G,LI M#)_C&4Q;2*K"0Y]D&M717R38( MK>!G/?7:>_)!YDC.F+%[3<)6BVXDA[C7/!2*]7NAG_54N'E6G0 MS#@&20:5*SZ#.48OOZ!C3^,TRR SH((@ 66OZ YG=]$B3N)B?YW@O+Z[6\.B MK)L^=UYG4B +T&Q=VU*0==0NWZ/OM,77PV2%8UE-EM308KWG$]_!R<#FV(5< M,B$:6$DQ_Z%BUD,??(O]7(>GSG XTF+'?*ADR_NXVVRB+/X3+5L7ZUU=.PTWE1VR^.642-@NR6N M]JV_*JS>IP0X!,7W>;Y#RUE&_RN: XU7P6 ST5X%WF?8'-VJ:MDXQQ#'V=K@ MY!W+0M>QT#G.%/XG!_A($WS'1T0+O$[INN9^28P6KV*TK')=EHH3K6@BR#AZ MIEN+=!I#NO,&+86+XY&X,XZ8K' /J$^,84_=[F))%OUGJ%F;SBZR8L5I7*!I M_%HJ?$_FR:OC+_T$L@?3Y/,H*XX^IV5N8=.%2>J5[ZT%P:>_[@9D]U("M7%>-U \!1SK( MG@!PO&UR>0@ .IMN));/C+F4@UDN@S*\?/YPQ;O>0CEYO[ B2T%13B%VQQ_F M@8LR90X#2"IP"!FJNH:R!F$% ?0W)'R!-A:I>[>CY[3MO#2W7VGV.03"O$W6 MO\&9V*7_#GZ\K(5GAJ#2P=I,?E@ M1.:1>_SZBZ*N_;QFO&=@Y&S/819(56H] "''DZS %'\ D%@"JBO.JKXC/6G M8)[L9'=5*P<%AA/F4+0\\(#"$XTF7^-").I^C#;K!FRA.A4H- MR9BJM@3VCRCC"6PB*XM,9O.J5,2&AO#]1MZ(Q;G MYK$S#D?/(J]W&2:SS3G>I/J"0>YA0,=Q#RTZKY$ U4_?/;0XZB]H^>[!F3T[ S8&CWPB0U*6!Q,R M65E>/S@S7G?Z-K >8S(DLEO);6BXBDNX2ZZN-M,X1?<%VHBGD0,JYH2K1>7) M@A)X?L G92XBO=GKE#728/VHL$O)X3U<.MJ[<^NA.Y9X%%Z_T' K+5:6IS-> M[6?(U]O0#0PFIS/8W&8]B>Q\._OR,++MX8E,8@ETHF2RH3F6\MEJMBOR(DJ7 M-#GL0;?M^SN@196LBGLU-EJ.N=<1H<7AZ M%CPK5.3 F"R".9Q/']$UVTC]04&<<"-.CDJRSSB87P<#J?NSC4:2J_WGJ QG M8)UOB(@&.G6)/%!-<,;!)QFH97BV84>IWZ,LB]*"NMC[V** M=.!YJ^ZN98]#R/MLPEZ'0?#EV:S-LEK9L5@%OZ_ =L(8Z-)XQFMM)["Y!#ZC MJP?\&Y3'Z^IR!6-0$!/5%N01>:0:UJU>,?9'.=@#%SB M^-Z#O(2S7B]M.ZRC<]<7\.JH7UV0\P[W+.,S3I<'#9F $E TSZZP*+P&C%PG M.$"8O,+=@)8,!!CL3646;.8J?';G,-D;3%5 ZUTJL+C<@X+\,&1T&!Y-Z 8 MK.ZFGAVD-G+EK;V81]*^U8L]Y:V>ZLABCK+R0FNZ0)/TF%>PV6V<4G%E"0%. M7[%@WVZLBCWHVT,8QY;N+2PW>9Y(8:TY'1Q;FYZ]AKL' M+MYGM;J_/:CJ' Z^FWWY3RBB^OIP\GV0J?4 ..=H&T+:I*$1DKK+^].(59V4 MU,VPG*4/-)LG?9VC?!B(F\E'LWC?*.#BSOP%J*FQL46Z'D-4:9D_1[FR<\G' M^H"*N'(75RA%J]BYUZ"O=Q-Q*RC2-RL:^:3Q,1HE6^^P@TMZL:I8D:G#LFZQ M>1*EK:$N9QUC:I5ES.T!91VN(T72,;XR3T@->!S6HEH\O+(;^Y!50B?0W_)5 MLBOJS.:DR])\4*0"YO:EF*A)S\4ADA Y-<>YZ M7Q\H)9D9S59/T5>.?S'DTKQ9J,O%@VF^2FO+I_]&W ;+ DUNSIR;*9JP;5-V MG9^F>-U9E*989S"O>D1K.LU\0%LZ&J1KQPZP+P['P\G(FD[')7/FH^@34.DB M3JIAF#X)]8K2';HC7:V6-G_"USC-<1(O*1YY[LF<46TD$T;N5L\R &"+%NJM MGCE54X]B4F6XVXQ]K6=;E$74-/,,DT4I]9SF^#9CRL&Z+M.@<&_%9]V@(HH3=\-K6Y:CV:OUX+QE@59T\S'DF3,66^59H\T23P]6 M(M4+OY]0\8*7K1?/Q>%'D$*#=86XD+>F&/Z*REO9C+@C&ZR 9A.SDF)C/%^'GW M)]$2/XA!%HX(/!HV4,75]#*]-]@=AV"8&5RBQ5G?;RX$'41RF<4 M)%6?0]0C:&F&K:Y5U!KI&+5C)D*XVY%2"TTYH8_J!:&+\*D'09"?=]1%TCUI MNFE'0=)LP?7,("=L$ML("/WMJL-&Q HZ*W;&:3NT451)N-WM4YSBC.A^GY(5 M(=%[]B4E*\.7>#M'V8*::HVN]O.RO7I TRA9MX)2R<"@J&\5$VPJU1K\LWWS M:%\?/DP6Q#@9NMKEQ!IYCO*/&<[['A%*7K>#G#PP2"KJ;X)#>57ZJTI/P-=H M5"I8Y8BI+-/TO9R^0X66LZQ\CXH,$\W \?A"&K;^VH.H7:;-O4]+3 .#^RBV M-.D4M@327QU[<5.U,<,UWCS'55JWQP)MN5:Y3VL?@HZ#&*?;V ZS1F+ /M M,A;M:*/#F(E3=Y(/P=Q&0G7,3\.F"@QL,&U-H,6MH0;27WTYHVLK^L(/ M:+O+%B]1CBHEJO>(!+Y,D0/#JX$Y! 8YFQ MC@_:%89[\]=N]"*DG>27@:W(!&K"\[D?_(!HDM-%LL6E3KT!S718L:EU?NA/K"N(S%O$[S#978.43OP@8-E M5H68'&E%3%.''G'348CJ6FJ>H^R5=8T#2,WR_"QJ9UH_D0IZ+Y7*L>S.+FUUV*,DO[ M_68;Q5EU5[/=CUZB;(TX8>^JY9I09W@YOZ&B:P %_"A4$7RLS>UFF^ ]0H^( M9J/E7?:24#6;L3PJOQ$%4TX!/UR&+JY4;>HC6\YJ2T)W6%IQ MZ?P&"U1!!;@(6(X1$N)JC2282V+X-$RP7AI60*TK8/RVUT[2N;V]512KJN!' MSHW,K,7%L,O;;G9SOFT<>SQ9L?>XF-^.\:BM[^YX,V9SPQ&YZ/3,-=E!R.U9N TN;"%BL[#82V.9@4T[K3MQ*# MN8W)_-9-M&A_NY*>X\]?HFP3+?:_/K(OZ$NH#IN6'"K7N=Q8>Y40A9@9V=I; ME!PF+@9R0.N6H=C5VC1* .TLH&>V.)/>][:7*ZF$ B8[R^._/AYJ*=&NB!=1 M\OL+J2*/$O9B D3;7,<3T_J' 17E).TO817NB]JPT1:+AZV>\40LRW"Z+JLW M-T]4F>$8S1TE%5E.\N+JH+S>K)IRLE& :%F'Y$-::T>*VVV&R>*1M,[A@B$I MB:X3G ]N;<"(F\-#";$?&\S<5L"*Z@KVF/MUE,>%$M[CA#JY#YBE7N'VZQ8M MZG^_%W410#%QN"RCF/^PTS2!(@#AM;B838Z.P?N4/G!?_1L.058I.0*[I8(& MH, ]O#7K23?EAJF4"EYG<.60'UCV$E7=2UZ 2L_E.;?#HQ)3%.7T[6:W%[XJ*3BW MNM@?ZX;O?[2U5+M/"5"BA$;\M)[@*&N;XB\H*X]G>H(JE:GE!Y9QUH\YQL=Z MVG:[:9 4-!/C@0Q,V\2J=>QZ?7$X@G?1?2A M)SHC>7J)BM]1LR4URP@)Y3K,Y:+/H0GLU>'@(8+,+2&#E58-+C;7>5@C_B^_ M3^MEQ1W.:@7V5&SB*O/C'+=4OA7>7*O.F9&-P?J(3HNL[1VU5\(,)>F+53G\6NRW'N<Q7)U4Y;\^A)M3N*Y?J5 M.YJU^M]P1QVG#7WIZ-:T\^WI)[@))GF^VU2S\,DSWA5WNV*7H<<=T9H05@^# MM\@IBT-[-;E%'TC#Z+L)ZQ(H.PJ+$KQA5S%6._KB+"SJI[':_:5R%RE:EXJY M-(I/%(D/T!^UNS^6DW'T9G-YP-Y39U9?NQ)!3?V'N>A2=QM%S25,Z";1\ M>LGP;OW2RL8]6W4>$-3N-MHU*7<+>T\FBI9V6?_YPV6?U7R? M=6!%7SI ?Z=5(R]_M=-ZF[*A[LLYV%B',8 #,HM5ZX_TXTS0FZL"9*X2K]-: M =YCGVRBWD.??2(/T0321X8+'A/]AU;&:>$ZD\,<%T2;.$I^39=QOJ /)*!E MM0'3C)^]5EPE^]8E^U;7(.IO>JDFWI(]V37,N16@PU!_Z PZ#1D4A$Y%ID:I%$:=O\+F MJ;#YJ,]]9]AVW'=9;3Y'SZTA^)0+E]>!W];KP):C[WQJEO[SLNEUVW'1(,HT,X9H)AL@VYS+/'(LCM[D ^9XI%GQ M@C+VFU'@ N(1H5,@ & HZZV*$T@%^M-8+QX.LC(X,-M"X#75EA MMOX4IS@CI9J;(*"Q3X^E<'149>FOOU#8O#.RH_U]/55Q@OC8!$JMP3=/RI\4D MSQ$P3$F#GX&)>_P\&RD,4*>YJA79%S*ZJ$NLN^#M23K&/J?G?>LSKEZ]L-B] M>"P->MB0Y9OO9!(K^]7/AL*.<>CC>5>KG4V3^6.8\M$N4_,!KDNO4_5WGYU0([$^LG7@NV#59E9=AUMXR)* M+/0^#D>#?C?@^.9[G-C&?O6U@:QCY$ISC@'0GN](6T_&N\+VY'J#J_3J7/3P MF+7%74<)9P./RN4!47-+3#0E_B<#3H4P..E[XE,[-W?6P@[AO<9/R,BF,0 ME8U]#A8_D_V-+K]++Q.;V+L^UA,V\!W%2W3HJ+W!/'S4,N+5XDNM[M$Y;\W1 M=@]@2T@G&PAH[A\.HNH3#ZCEBU=QY-U1'DN2--6+?B(%KN, M^?#]P<&J%CQX67A!#RXV'=KN#F>/I.V.8HHOZ0/+#:XU2+["C%QH5.TMJA: MT;#09& 6 Z"IU1IX6@#5T0GK.W#E)FGN_2M4> [)5*$3)UA3*-SUEU0,;(KS M2JM?H:S"#'CJP=W^ZR3*2>O_'F59E!:S["%>OQ3- R)'4:_)*A M MK_8U75X3]BUFB5LS?S+EYG7W'R('VS:@NFN8MF^>&@OCUXSN>%-VMIKMBKR( MTF6T,*A(=)93,8P@Y2G[-#-G::M]Z&V%&Q1WQLAB;C&XBX M2?XF(0X/34KJ&R))5E?P!TF']_<-,UB1;'!6T+.7:YP75U$>\[;TS1GU MG; &HX#,:&P^8[,Y] \6P((MV*SK+?2%ZHQ^"L(8S-AQ$27>^X[%8K?9E>^A MEG%;OZ89BA)J@X]1G%[1>0)ZBKZJ]@0UKM#N >5Z[GU&R[HG[4A0"0,/#=2W M PU^L=^[F%R->U>/ZYOM72+K^M&[>A)JK.9^J7I7BM;E$]F>]:^C#?HVD70A M>4%.+Q$5/+.. +;1F%@7":&_C/,NF9_N%I'IPLW6]I&&'('?!=4ZOS0Y+S,X MQ52L-MRDC!HQBL!6D:=DA-<-;9+S2<@X61!3Y#%E[#P ]FJ7$ZCG^37>/,=I MJ2QO?PQ"6F-!3.K!X7XC8+LIKO:MO\31K6K%!T?\T.+.#,40D!';*J'J86% MY95V])^DSS)C5L'T HU[])<'HWB#%MS8&F]&29G[_VS4[\W@4HK7R'J#7E&" MMW2\_;AY?F$B0:-D;42EDF$@1]\8&HA2JLS%NP%"W_(/%"7%RX+8_;Z(R$\W M,1G(X^?=GT17]#B?"-V.6N&>1X(6#@-R1B8Q\&/0^O2C&UPO=&03$:P^ALOM M78QKS MR1WZ"EFC865U^]Z!4T.UA23C'/H#D<(.C^&]IF=4%MNV01GLWN: !O&XYL,9 MIY9P7Q-CJ#[8U.=OM/#V_\6D/BG;#D__#1=QNFY>+LSKB6(_XMN,"=] ("8^ M3>*'C<^>5ZI;1SJ]/U3-F6*"J@S^84IV.I.W_1(@%*>Z-E"#ID(M^D.()VAD MG"H]%FC;,DUS;[OJB?>'E3@7J#99\L^^-%AZ#^\1+*?GE,T$"/Q*3_\Q9$;' MO]K/R\;N(5^C9).*1:6D]SC6MX,:7)7J&2>6RTTJG.J:T7V>[P8370G5,"U. ME\I[;,'T4\,1EZ=^!)DQ9J2O5A[ /MN6BUW\@+:[;/$2Y?4MM,D&[P8NRH # M8SX)YN ]K,SMHC_'!-=7P_&G0 =6QNSB&J=Y3)0J_WC*HC2OE'HOGU-*B_+G MCH*BW@/5P!+&7EI_$B&9TTDF;@$@2**1V13L@(2?@YUGS:-] M]5HYKAP\@18W5 "5G7@/L;\$"[ YG*%[7#S4N M]K=?R5"?KM%#5*#2J2:EJ?I#H&*IVOC@4MZC3D]_-?"!ZZ@Q^$NP&"P7.]4R MYV:7Q>F:+)ECO*SGFZT3M4&(A&*Y0]@$N)SW2-2U@1H6%6II=J%#?5M(?]OQ M+HJSWZ)DAP +!FV6QIO0;9;>HWL$RYUJ$[HM0-,GPCV:H5>U9JO2#$&W MV,O.W_?($K+& 7/)O$FGY&15?N M%7'U(-!IE*RMK50R5!#JF\<*&)6J-TCC[\-[6)?@5O^[P\EB7LTG"OJAL!K7 M1@.:!-^GBV1'WRCF6>0?*%G.LQAG3[C%SF#N;%JC^I1;O\8SZI@C-\>I)_CZ M8NM?N0TJ5LE\?W>T>\^#:*9@\V">53!3@,\*78*9? QFNE^2.N)53)6;Y#DZ MYB&J!JOK:0K>4L*TL?RY?1 ^W>'?($++1.J-V^H]'YO8&C;9=RID1CC=K3IQ'[ MO;"^$3P I[Z++[#:8J%Z!8YNX3Y$-,**JO5A_#T$1F7C[2%T*KMX!'MM%:H[ M8"FF\125K>NL_KF$HZML?9OB=/V$LLT->AYS2P%<]P@. U#WQ7^,UI*ANA. MGAKOD)VO=[FI]7^*OK8^'JTXHG.!5CV";Y%7?7$M8[5CJ)Y%KJ;&XW+GZUB8 MCGCL4U%YI:>:J%Q.24=KNU =B$A!G9< O?<=K3C]V6I*OCV]1.G[[[^?HVQ! MK,"^;7E(@"%W$W;X\SV"*?^WU_FMMHCC?FZJB\Y#AMYW:7WGAT;=IT"C[D2@ MRX+ K#6"';)1Z\6CTR=RM-.-/V*\_!(G_;?*^C_7377\^3Y+JX=WYQEZC?$N3_:_IG&9 MM[E\BO=JWZ3!>B6SH$%63V,^C7/2Y^-]Q[!E(S7<&]2J?ZG'^*%N9IZ-P]Q; M%Z7Z#&K3ZS#P'I?&5E$#I$YU!IFV+UGG-PXQM&B6;Z8=*21\MZHJUAE^0R'J"H7"WSF$FB*]U%2[*^C M;/D/G!"AV)"1D=5&XY.%"!:@TL9(X=<3;A:,IRQ:HDV4_9&3V5?Y!]69#2X0 M;6UL"6V(,%-1WQAKDLK&6!>?$'53%.7HL-5ZG\Z3:('8#DU.V?@T$66(>(.K M;N[91%7IW_OW8O6O,^O&IM-1<(OT12@WRE2K/HYM*]6 JQW#3C K 59]YZPJYOH:S3[TJ@8/@.S M^KZ,_O)P_A)EFVBQG\8+E.:<^;N8J'ENG$,4*FY 2EL!#*^F<-_ T77FV(9W M4VH3UC1*2X2W-I4R&Z]-IE/*-8>[R2)Y;^#RH N;_O*@R^5!%^_GX!7.:)N,4MX9P<^,^$DL@FJ6OT>T1K>F?K 4]B+8YOQ?3NM.W$H,Y&C&_ M-?ITO]D:91[**)9FN5!>,*JB/J*$.>: Z6NQ ?3N>CG3W%A=R5Z7;K.EO1; MSINSW:ZLOSY. "@84#';OD7E>XOS%%)JYQ83%ZL%T=8,VA7Q(DI^?R%5Y%'" M/NT"T78W:GBT_K6WBG*25I>PLCPRG])XH-$6BX>MGO%$+,M(U"ZKMS:#5)G@ MF,PC)?6$FUU=H/RT'[ NC_4;%)$'^+6*^&B$!YPD=SC[$F5+N!D8A>2&Z!1R M9HHFC$ @Z.\H7K\4:#EY15FT1K_F:+5+IO&J'TEL@U6S+6/$RL?H!19$L%6; M@:,86J*46SY&(C@[6;/I"1*6THU=WC/] *Q(QPO(B@0$6PT;Z,(35E7@EYZ4 MAEAQ3 U_+ *WP*%*22!-IZJSC:'ASPC4"\)B0?R8&1R%%'8^KDU I08&D93R M]72=XR?UK*%TF-YSE^ :QQBX/?:8VGU5SVNJ5#?&V'7):V,/.J ,-5!@#'+- M:.Q[C9.WH9%LDL5YG*[OB*T>]RG*UL/7#R"DO?9FDP:' 8#&9KA@5S!&5+\Y M4JZB'"UGZ>3WN*"/DM/_X%TQ2:-DGP^.)M4*]= C*Q05O-DMJ]^; M/^91/^AY$^>+!.>[K._3U H=-H5@A8)!FY85=/35GEJ7MUS3:+8G*]*7O.YQMH@>4[XA/GV>( M-M^2_$:L1OY93FSFNVR+=SE#V^D/;A+$ME9,W1(9?,I^[6M&5?VJLH MCQ?R7@&)P+3MD6&06IAZK&&34\'*^!PX;:\,QG>GF>)^SG>5QO-EQ>YO'QS&>R M*'914A_TT+#1SM[A;(NRRFAD7I[LEO0D[)K\A9-X2=\V)O]>TNB6Y>'"[\0I:*J&+3'CX ^+& O+![3 ZS3^DRR[ZP=TH\%5?-*MIN1GTIN* MF'2R/-]MVO&JO(%BI%KXBV0[M7B/_M/85^_(U;I,X]Q!#W=B&]ZFL!=;\Y>= M85]VA@]#;+HLMP?Z]QZ.1FDH76_RMB0>/"!_N*C$V?75*MN?I,'*>K OW$@L MWOYE4@UV>7M4E^3VI]+7Y^3VEV3FHD%?-9FY;ZGJ+T\7N'VZX)+59 T5O>^)%+-K@GM6N-[U?E-'*$!8*)^<2*!B^\#$BYM>C7+E/M7U M2Y2NN7E&620]H'1)? >(0"$E8'3Y:$PV?ZD D:(UC0;U!1)/693F2=5>RW_M MJ@2!/'"(B7LPX1'[#AB0DDK0X7'42#7K)X@XXLHGR'JA"P\C/GGAU_K4PNGH8'EZKC=C],ZA,/38AMW-095U#T)[ ME=A,%1#&H:?@,:&K_:?H7SB[3J+<^<67RYFH]OM]A]B7?$X6Q\>S_U:4 .O\ MU")'^GRQ$Y "5-H8,OQ[+1^,G'-RFB/2!"5V2E'MF;%"):!I$ ML6F"A!- 77,LL2MQ]CB6'331#/UXLT6%#%)RPMK0(L(0P056W!AAHIHL)^@W MGB7%Z9JLT^?1'F77."V7Y*)IDI2\.T\2D(<((44CV)HI">H+_&FKIRQ:(JHS MVU?Q/M?V'7X.$502)8U!-.3O[ DJ43SI?AHO: XA-A+$1-T(T@%1B*@ *6SN M8#BU6'Y8R@^3504L@ <@;)87 .^(19QSIB MN=6ZN $V.H8_HW[H 8Q8CLV2^!QP.-3:.N;**@PR.^,B2ESO)=RG2[3BJWC[ ME6:NI2\TLR,[=8L?GIE5+1X,- TMHP=6]4KU-_!=NT=&;Y2C%5[D@%!(D8!0 MJ6P!721"*M+?U^<[3S^L;WEESEOPG7I)/GW3(/QV/((!E-NF''/98"7?GP&P\M&8#($?$#V8(_Z#]JQ\$27_A:+^ ;9% MCH!M63!''Q<<<(Q))K)Z=@4O1*1RRN:U8/GT!R=/DEJK68$J_?0%&_6@'@^M M/G/@\<9Z"=MV+OO%0:+@T[MKZ$VJ5[EH"."BWQLJ+F^Q/S#LY[Q'5#*-DW[= MZSYQAW=F$ZP^$^T>43%Y@QV"83W7_:$22?\<*-SN0&C-NT.+B7YW*)F\Q>XP MM)[S[E"*I'\PYBX8%*YW'*E8TJU%,5$-'QZ1!\]!E'9_JAM!_"8$GW3P, 2+U)VR M'6%(;:Q7(40TC7IL&G_T8K\'(:;BZ6;[C8C/N$#Y/-I3+-SL$/W.N9XJH3O< M3N72N4R=+AKR'_)N:,*_RUG 5G[-6G"CZ2!0:XK.GO("*/M*LBB=:?HK65TM=C01.C']]2ZC MG:>GHHBDUHU-XMY?"AH%@Q3CN,PA7]K-V?R"/Z_L#JM'U853E2$9I(74S'QK(!M1-!V))LSQX[6MQ7- MUX54[/N4B+6CF9(^1<4NBXL](X9*3MC:;^,1>@P L'[0]A81$[EKANVDF]D,?BS#A9ZY MJZLF8\S@$S!'0LG)TF 4,"('W0 B\#Q0";/U, M(/"^!X'3OYP A, /0 C\ (3 #X%"@*V?"01^Z$' DW<0AH)^ $+@ Q "'P*% M %L_$PA\Z$% XZ&#TT#@)R $?@)"X*= (<#6SP0"/_4@\#=?(0"\)]&GXT+ M_3T)/0A +DJH0:!_4^(73R'P(W @Z-/Q(/!CH ,!1S\#"/S8'PC>^[J7^ $X M'^S3\3#P(=#Y($<_ PQ\Z,\'W_NZ>_@!Z ?Z=%P,!.H'./J98&#@!SS9+YSD M.9%_.<51RGX8C4_0I UE$'C=W%*-X.W,8M4T\$GSQ /W@H']NT_'W04.M']S M]#/9_QWT;U^W_MX#5WQ].BX& EWQU[V_,[P:KX7X M][YN_KW_&7Y2/"3EQPZ$>U+,U=(H=F!X4OS>ZF:@,[/V PJ!85 B8S8!A7Q6 M9QM2*(V, P44LKB$^ZI;5YLIYS:\A(H9?3?UX#Y\?5LJ1OEL10-!F_LIG)L1 M4/):7SFYK9&ES?TS*B]FX!T!7[J\B^+L4Y3]@8K?HF2')LM_[?*"FI]UE4"7 M12LB7YV%,V\ ;DULQ3I=YR&KO E-5J_T/.[EMW7O(97[O7T3O_L]"(S)]%(' M$(.CL]A)>]>'#ET"IPMF8@\Q$(@*]%C0IXWG*%M0(ZW%5S$A!9E32'%!G]&F M;0 P[E1J<+$\>-+9OI(-N'1K_P8:M+G.U#G@X!FN2#R>E- MY/:XY/.XY/.XY/.XY/,84ESR>5SR>5SR>2A,YR[Y/"[Y/'A*. T--5S@XI'SU]SHM'V!02<58$+=]6&UMJVU9;:D1NV^Y M+0\KV&9OG>ZKMS*4L0.X%4OU]PEDI;S&A)[N<*R ^>OG_1@+0RTI?Q;CAD_9 MQPJ+,@Q\2'74P 2+IU_)/UBBLI-$ B@%8 @C;21<1S,P]!-)>I(&A"$J)R,4 M@)(/AD"R0L%U- +#(#.4)PE!6**R[XD"* 5@"..N*%Q',S#T[XMZDAJ$(2HG M.0B D@^&0!*$P'4T H.W24(8LG)21 H^6@()$T$7$#Q]J>3DIZH#43(0PJ -"B$Q7780P^'J6SN0@[_!<3I3C7K58'S/28F& M1TU[#11)*S!(A6)\4UP/4)(9+K 8%%"!S7G5M+<(J,$LV)--U?8AX?$&!Q-" M$-+>]3(VJ==04= 2#@\QTP82&ENK?L4K7S(M73(MC1L9?5UF6UCL&2'>K$^U MH;J?#(4GCO[;-7[];E$SI<)_./Q%!?_0$KSY_9^3)*G%B,F8P KG%E T&6Q9 M%&[4^7@U[XG?^J46M_S%6>\2F1.SQ.UV)T9QVIW*8JXO2FBVV>VO#[TV:_W2 MQ-?17WQMLZ&XH#8KBUGV>2@_,\2^0@6F%VC6 M\+Z^:G]%[]TS%V0"BN.$84CAK(?"C8TARG6[K91Y[?*&3,-U>;)>BM4!+C=J M/7H &(=K6,E8 O..H&&%R\K%;0T[/KB]V<$86GB?&5M'C@>3MBC,T8-/P%#& M]OCPE*$HWV5[RILY// ):NE8!,ZZG,"6&*!+M[,-F=&^QF+B8BG';,Z/^!5E M*?4-5SA=X05"R_R. /\!;:-]*=AL127M MJ0@AK?44DWK2KX>-A)64%/7SO)VY3\S3]5ZPK9YQ%>5Q_D@TB):SM.W>W@N[ MBKP8L^^(BOF,+TWEP5B#\P\\1WV[4[6CR@5.BT7&<%A=,I_!!%1.RU%U^3G+ M#6+14]5Y3ZYQ/GB6A?N=D46F_NXS+F3JJ'F3+J-PMY6Z>M+'7./L[B\MV ,,$OO+0@P!WIO02/2WY,GFKK*/J E MVFRIA>99O$!'36#]MZ$#X+I(X,2-\2OSR@\BAY.=]EBY.FYKKXW'R&HUU3V79U_&K]RG##5P=MXMT&#,\.M11^-768\&*I:@$^ M-5MW.6_&V4!9H&KN*=E!Z9-QME".9.%@AZN<]B;*D=\H.7&<&7,J?WZ/=V@J MLN64__9>BUW@#Z(H7?,:&MKB$VVV4KV>V'B7)]K&?Z+M>%!P>:[M\ES;Y;FV MRW-M0XK+;8.0IG H%^$EQ/LB0/!?T A, '( 0^! H!MGXF M$/C0@T H:9 O66M#R%KK7Q;DP\NHE<"2YT;%U'WT\*C# U(5PVL\/CZ]5C< MP#-R7@>3TO'&G$!>!H/J9S#F#%X%\R2 ;B HYUD&*1T/ H$\Q0#5SP "P^<7 M/'D8;B@IT UP'DP3T 6& >MNP-OGX(:3&R8$9&3-57,NF=< &H';W\^0X.7 MX"SGU&J'-5$1><<;4CK&/?(>G=>-#]4/WOH"CIX]\]:7=):R$ZM)Z3@8:-$% MA0&>?OH8:'$=;BE/$CT[-.P7;V%T^/GXLF4?UF"I^2L81U=6]VR'*,=#(G M!,@#>L7)*QE#NIHSL0*B/21"%-(&@2 5?=7!).$>[C;J%-&Y2Z,^V^L(2!J_ MPR0) C< [31\#Y-IN)N>;9W9&.$2,(;=L/ ATTP#'0R6?EW>>R+?T%\_W$3[ M2LH)70&5IT?,UR9AU,W3DS+J(&"AIK,Z1J3\]?<,Q[F6\406NW3*!0(,A+:! MBY@V#+ HZ*L!%3%WRPD #1#R!9/1I2PH:>#,!(:,K#83GRP(0 "U5 <#G[%?;P \95&Z>.$&[/(^'QZW M[G\.HM4E6FET_0%#OR[JU?+Q0O-YG[NM[$,@OD8KP^+P%5IY&(9O]2Z>8VL. M$A.J;?K*K7I(4RAE'&YT-DNW8=I"V+F!W*+'!(9[/# M>OS=K+AE[;<;/]Z0LD_15_CS6[#E)WYK9:^]\U9QV/9%XM%[_:O%@/: MHWH%P_5(P^Z"16AD&*7QVYU"X1H$Y*)Y3D;!)[=8A'MV449>/(E3D MI:KMQ M:/S1BWGN+:'BZ>;\E/L:;S8H6\11,H^V*&,Z=2%-K1F'QEG7E;4'AJG5[<0< MIK0+]B&.X_ER"$XGQPL*$ M+21PV]]J4EF7MNM/#V'CGL2 S;21RRSPAZ= \TC(W$AA3LEAYRS)L:7IRH[( MFRY8(9:L3\WDI//)4/@<+;Y=X]?O%C53*OR'PU]4\ \MP9O?_SE)DEJ,&.7, M*:2 HAER611NU/EX->^)W_JE%K?\Q5FG$YD3L\3M=BY&<=JMRF+AKFB9G01# ML->U3IM/.05BE0_73""'+7 X"GZZRR7<>Y L):><_!D@6E&$N >Y-'H+/O&2 M6;Q8]@SHPY88+I;5S\G:U^$&S/Q9)K^B+%JCFRA.]H<9U/&R4'_$AE$WH[>, MVG\4J"FLB HI M&6>_1!ZH&K,5O?IDO0EM$Q1GC_ASZ@@B\FXB)(^SJ#DAVAE&;G_"%-461%>"1"7%)A]R&^4]H1=O*@[C:UTU\@_)XG9:TK*34XU?41"*,6)&[S1^&_(P[&S*R9F.( M2^:5@LQ;'7)"@9+.KP>7R?*KH(]BDN>(DR%.1E:KR"=S-O\ - \&Z]>=@O!9 MTVD(GV6X>5A*G60PD>$C/Q 03"@'>'BZ5^8S3ZL)8,8VC9SK3CCEOOD/) MVT 1DH> &[B^RC 2L@XW\W7;:8(@):-E#$R!@@FHJ>X0Q8>1U239CFW;OQ8) MGKS)S=KIES:!H+YPF^$TX[$5 M'W_*T5I7X'#7X4>-K_:?HX(>8XC&:A;18"SN$GF@VN=HP\[**"(9J-4F\>*$ MY_%+M&6.KF(BQCE.F\B#H8'1&!BH%<_K'UG2?LYC%?B+@]7#T3Q4<+X>CA=Z M7[W%@5@/& &/)SECF 'IN&"LVO%^-*$H[6_>-MX?/EA#==SC[ M$F7+OEMA-R&,^'@/74CL;4,K:0EK>QG+<#,;_!YE6<1Y?HWYK;9;[YNW8!#I M &O['@?]@#8O!NHZ6T*3):$&-L];2$F[.2LXI-Z"0T%#L)\0,'26@8 Y"VVH,6-_3$S4/:H9$'FDFN@H MBDO&5<_Y7EDC"UI.\EJ\X[8N56;!W.,E@ M=SF;%$^@0&/V*2=0/('"W=7Z+P6)QF4&( M9Q"2\>N4A*)9O_)\TPF6!-^B1& [15:+@=BB \A#K(J#T35/F# -$*];6 M^7Y,YU*-QYFY@;8-ARG7=AI!U.Y*IQS+ MZX\H15F43-+E9+F)TY@F%J NL=:3,J9O% J_= 5UZ-ZRU0'^TTYKS^": ?1^4Q:#_0M$S9\QK01R=#(3B8( MH!WHRZ3U(&Q$U&9835E>& FCBFX$ I-UN%/BHV('Q6>KGK9<3,F+#* E*A(2 MPL"J:P--5$/@KU&VE(R_HJ7@ 4H Y1!B0\J@D"515!]00\:!!U#=KE9H4BS<7:$O Y?OTU_3#$5)_"=:-I=0 M9VE'A4Y 3=Y_D,.437,17YN-LSYM!!ELS7)=/Z C5)D$0%N8<.<\4YRNF[=V M>6^I"6F:MR#8-,$"$Z*S'=1Q:@K\'!4\V%L8=!1G 7HUAAL>U.C;SG&B-S'0 MX-";%RAQL+7]W+K^T%FKTEX7EQ&1W)FVK, P>0&W@'-7J--Z6,,8;+>H4'OO MR@JWUL OL"B[2/WNI^DAE2H,-Q*BOO-*T\X_Q.N7(J>7WZ4Y\!5+=6\2RTMY ML"%1Y< 5[Z+R-XJ;S\[ZEVH##7=-Q0<40/Z,+5.CK(1>^"X-VXZRU%-H ^/5 M78#W),!#C)XS4QQ6P)6,<77\[,Y558[OW%Q09<(%G_#ADGXP M@U3*,G?#B-*%NQMVG41D.%C5CFJ6E6Z*]2J-G+#9TQ40^J4F(_!72B=2TG'0 M+U,F9L@O@%*DI^UK1LTH>?L598LXIU"Y3S\1]_1"246IBT!%>NL0<1%GOA;2 M)EA+\:ZW%-33GK&(^;OP=^K0^5D=.C^K0^?GLX .6W%[T/EYI!!=UV;NQV3" M72O MDT\II!IN-&8@"D%SZ+26$H^;ZY!0W\\X7'Q@I:[!,U6M__>Q<7^$RI> M\/(^)=/<@B[LA[^B,CL28QID@U5S^\&(E;LC)(Y8S/D4C+@Y&)(06WO1?D-6 M,3G>90MTA;(U2J]QML75)C9S8(07:-ZQ!Q1P=P8$:Q.LH7?ON$=84?E^/:"" MP'='K3@,K-B3NNU@(D)Y!"2I>IP;_-X-MQ9=O\J(;%:M_J32.+N"G>'F@>[4 M,P;BP>^U:5N_NY69.9(POK3E9H\-)Y3\4_0UWNPV3-F9WVKI>]^<]626?;%8 M]&Y?;#&@G:]7,-P5Q;"[8!$:&49I1H-.H7 - O/Y/"^CXL!;/,)]Y9.IXN"( M2;2+.B 6;:1./;A/QA3L\XX"?[9Z1(M=5CZ]>1TE"5I>[9M-GIH09!-U;B*C MJ7#SJ]\-L<';WM"V&*#'3ML'U,:U.\QK-2+^ZRU,-,_B!3I\/*@]N UAPD.$ M=3F/4!&N:!TKN);7>6:;T["]5-Z09;RA.AW$0-B*)?%<[(*3-LS="4G=O_#1B5:&U!*+3.'J.DQ*<=:LL M:>PZF;YE%+GI\C-.L^;/\H4ZF7$LLNX;TPKKH(W/BJ^RSM>BV5U';QUTN-JW MG,Y=AOZ]HP_E,/9-%4KT[20JX=X"+-F89Y(*)?H6$)7PR@+Y ;7L!\X4B@AL M,"SB/LX:T*A8RP"GYU/-,/J@EW_]K^ MJ(AU!@=.TY@*U6E D3#A!B6UU#LNBF*4T;# _12]HD0\>@,*#0=P82'WIFA[ MR:&HX-%<6E8TIO'+NK?/?;K=%7G99._% SN?LJ\[B]*]5U-J3:RBN'P<1JEBSA*CH=!K)6*F*KQVCPJ9]J5KXZ3UJ P>$39:[P@33Q;,03-Z=7G MG/V)N509@W5M1[NL;5VT>$"$=;PHT))F#V('Q I(FLA8)HDS+S9**V*0);IN MRZ8@99PB4X# ES2?<(KVGZ+L#U3<[=(E^ZT1,5$3XLPA.CL@@JPQ+A1Y(H0[ M:$Y>HSBA2+HAQMZ,9S?X0S%Z_3VZZ+,X$;^_!)E2_;6 M$8"T684(2<\.G@J6&1>D8D'TDXAZ =4Z%%64:4644N5LT2?2?5RX]6H>([/@ M:5TA[2U-'C;V/%),='1_3**S@Q[(&J.[/*8(^JD0O0!CN0?*G1UROM8&'WP] M.]R)]1\7<(.Z:Z3]'.#Y@61+&8^ZQ=H[,V#+0BUN5X;+<4_WN =TK##F^0Y/ M@'!7^#;L,^5Z@G-X_W:$Z0W5UZ CA M[87ABG9=G+2*2S_I<(M"M>AE1:X#N35H52]B"-NY1>I)VH&4BN$M4*]2\ M4P5"MGCFR&X7*%&[B M@'%#[4:8RY\B(L^.V.$F[!CE"KLE7,@3@=B4WA8LQGGDQ 4D1"D?+#6QFJ]G M"&2KU_D$AQ7*D, 3=>BN/3/ 6T;&5*U- M9N^5XR3Z0IS^-=YE].W6%^HSLCWS< Y$>WC14TCK<-4H,3Q6T[._3&1SKUZX M$W)U%CW-A,49F/P4+Y<)G>V5=P]FJ[96[&!]<($F6#36?&[<<* $=KD3&;(W\^JW"7AI*)Y\" TF-X-L.A^4)/[#+0<[#G MQ9O:\S;'1(2V_'"3VGH:?70^ -CYBXU1#,)FCL[ MS!Q^9^T-H&@&>P4!PW!WYO4V-ECVE6^9*M7%-+G=#4Z7^V0/J(BKW I7*$6K MV'UF7M(Z6R)O!;IT>100LCFF6O*X-08OZ<%[C3>DI5*TK)ML3A8S+>0R]\NT MR@Y>9 25=68?L72,KXP-.",>A^T@+1Y>V8VUCR>E$^AO>2?OBGHSTE-GQ0O* MR.HLC^GZGE3$#K2'43>!]S)JAWGO90V 597M9[3G5%"&S,L8A[LVZ>F-B:L_ M# '_0%%2O%SC5Y1%G.?K=(NS^PN@N-\(-#2' B35:PIWAFPV,@V;A>N^Y?:7 M5LMHFW9UX:[W]*91'..KSBNZ#:,D"J]! "*896QO M2?6J;0W(G/TI>8'>9I6H@$=^4-1"6$-]F0-DU-?>W!+5$WC:J%JU\IIN_+PK M:L5N-]L$[U%,'8)Q&V;Y---G0HS9V5S-DUNV#VLS"@;-5LVE"W50&%PFK M.!$A T5FJT:-R7(9ETHD4/S*R_+A*BH;-#K!1K$'1E&5X5Y('5KD,R+C2Q;C M9;RH?[TF:R#.]JAN<>XL1U;<(T-5%\X1E4]J%08MUP0=6H]Z*;!EF0L3OOZR M#BJNE;T&Z=1V3FN-)M48"',L8B[HNL1G@CJ!!<: 7;>Z195KS&A^J=";HG54U+1>@?@! M+? ZC?]$2V*LCU&\=@*Q6LB+^,ZI6,U3WG"J/Y$Y<6I(+VREHS_6NB7RR?%:LP :*:Q^0L 0ZRV/A8YXFAGVG4OUDWVTJ:.S":.R]G M@V*05<; +:]B@S2DN(@2UUE,='=Q=;<*S39R%6H--^F$Q4 "^0&U]< !9I7A MAM;H! YCLYC:040Z5 #:((H5![^KVC]G9 4X0TC%9\6>A"_WQ?H<;5B9 H#4 M8I6/U#YJ+0I"EM/+-;<=E/Q[?==BGF'2&1]?(II:Y=B7G[)=SGOW0+7@X5$$ M>$'7LP] BV$#4S#G'/PZJX4[CS)N@8Q(]:XKIML,5[X<:B"L(-.P9-;L16EL83 MB^J0&/A, H7[JH&CA14*BF8QJO6*PIZ[)CF2"5^4YV? MV"8J_'SKH'JAG-H6!'5HM9!.%5G.,[B9[C@=#R)A?8!=1HSS?IGSP++0$B/@ MM5_?&%F=W+<%=.!7W1K4G -)#K MC!1]>3CQU3*RNNWY9.Y>FTF+>!DG!$JOK3>:;[\NDAUIPSO2*2A$=T5]GCO0 M@#4[M,JSV8VPP].98Y$B!(]CMZZ[X4E1[EK8J?T,$N/<(,)[$3=.N1W1X-H? M"43C7OT ESA,4@$E'$[5C]()5!7HY'1.!V\,+%2H/WF3\JVF#VU^WNQKWQ,] MTG5,YC"'%/9EHI&V&KVF5BE26PQ6)!1H:!A "S*P>IPET+7O4\B_$\0PBL#7 MR(HP?!"_2"@ U#" L<_BUZ-_LW,8I>5RZO&XVVZKX/8HN8[RE[L$?^EDZG [ M_6")=UL'XW/F'RI%FJ1SH"+.O$5S?VP>Q?T]0=:GX_#3^N0N^$RE.;!0HUYH M&8!Q/:"T&(9[<'2?DDZ+GJ*O*&<"@?GU@(7>UX#@(-)+%Q$]GF>PCS59+':; M74(O:)33);ITSM +30CSBBJ%RPM-COTY4,S/J)BM2 /Q7E\VX]+L\.AR<;=W M!I.8%;*H4U3-3JY#&A])MRK[^NV_=W&QIU+BM.SZPX!&$&TS.1#3.M.W)PXS M@%%(T^P1LVE\ #DCXGBR_-'.O%J:DL'@US1#44)/?._35U3IV-P7EF%2J?@0E<#B0>!2QQ3JR 36 M$FY.CJZNC5[T\.0&Y?$Z+4?M[/_LB 56^SA=-_/B?Z#E&D'P:L:2B6%=EJ'@ MVHK)M+"N6W.X>!%/BBHX@4Y G_!G3*:D:4&D(Y6MF]4_&^E:A1M,*Q;V M&+TF9H#B5+$._=N67FSPM[KE4T:F0TG5T.#)*Z#0T+4*"WD,/QVUU=VCD+=& M5@Q/ LA@2UD,6POV]M-$K*EU.2S#O?N@M4N"U?83NC96J;&\CBNN*?"P:* U MIIPK$KK%U3:Z6L5]-U2S=VFV?VJV;^I_=Q[B 9O:2*N33]LQY\KUZW?];9GV M@GB6K'#M $2J7J$5SM #6B11GL>K>%%:EX=Q"YSJMC3B%"3V[=G.O!\8R1+N MODY?*;JB!YCO>I=10%2);#@]8PS6=7/;91UDWQG1NN:=R:YPX>X:B:?:*D.) MVG 1+JS5;#"NVV^#SU8Z+D_ IS&9T9BU!.YBGPF2G1Z=P"MZ4[T ]K2FQ'IVG5P:5\>W@4!"5D3]\DQ6'=?E.3Q5*_M[ZB[!F[/UDYIG'MF^ ^ M7>%L4]KG:E]_9$40&W!H>I0.!V<6N\9ICI-X64I5CK&,0&(Q4:TWC\@CU9C1 MPS(RKGK.8XAG9/(946 U/9@9;R&A:A;2/"J'.6,D[8*ANG6=(X]ON?SE\0LW MK+<,.!.GI>),J(!HVQ?O^+1>PT9%3SAX)%S#7;E(W#\&^U"9+9N( M&SZ[<(-N3"863 M+@VXT:F0;/_1DI(=HHJM='JC5PZ5ZV7<<)"!*<1< MN!W'%"X39R%P@"8N!\)J\(L20&,+Z)G-SJ3W'0!R)96@P&3G+%\,$Q2UJ&A7 MQ(LH^?V%U)-'"6(" D1;VTE"ZQ\05)23@$#"RB!?RP@ :$V":8*C7PE2R\)H M64XKF$!0*M/<[865\0\8.LI* )D.<;%$Q?7 82S-"R>[G"N ;!8EC'I759O M=B6B,D.VLB"15!AN]./1'M4UAT^H>,&M^[O#7Q'BO%UE@]5@_UJ'E>-$$4.Q M!!DC9,2=U!%\XE'>(9(_.21_7+V.3!@ #!5U5\2!F'?BC!E;U,M/)PFPACO%AUH/\#V?SX<%S4_^]CE(,V$N;J!>YB@FNHXJ6'OS:*X2EB#ECW)^YL@8JIF M(X1'%3 B8)K; @BWMG =EIF.6C3BI6F7KKH& /37R"0WSQD"!@U$CUM8445D4: MIYNCHF-Z?S<[O/3; P;S6VVCWK> X2#2TA82>G5H7%(>%02/A Q=UR_.-.\] MS;9%O*G]'&L04BMTB$N$%0H83UIVL04T:.4:MXIM(=#.?*DY<+_&F^LF4BD8,'RU[6,+PBH"U##^:[ POHOB[+*%6Q!4E)GC<*?@T5A^=#C_69+U*2Z7;]$V7JPH24F M:A:;'** 0?2V]KBDE-9#;&_!0LQAMX]? DH^A=!VQ0!(TNNL2U8,6NJ,?6+ MC1=Z>KCC\AWW%9(?'?'ED[HZWNR(QLZL(2-B* MN'U,<*OQ=3<50[4/FD'?O6L(R.KZ'S+"D]F9@QUD(:MF[.HZKE;8)A MBO5&$A[;)I \7F>0 MHN+RK&_0S_H2238X?2SPX@_F0,/]?H@"&'SW]TDSF3*L*SH]=M4)_H#-&)'( M+JXG7UXK.\'(HOTJ&7=\ ;T^%F#\6T_AP2X/>S;,VPSBD[ESO_3=C\.IT2Q[ MB-E233A(>VF'6^/:3;GYT@.9&[]V;27L MIYU=7^-ZPYTSSJ-]F0;A#F.C-IK,*KI"@>;E*^S M!$RVH MA5D?H+_9]G,L3_C_\+4$L! A0#% @ /8>%2+SR"HV!Y $ VYTH ! M ( ! '=B82TR,#$V,#(R.2YX;6Q02P$"% ,4 " ] MAX5(99L=T4\8 #5(P$ $ @ &OY $ =V)A+3(P,38P,C(Y M+GAS9%!+ 0(4 Q0 ( #V'A4CN3X>N7Q@ ,=P 0 4 " M 2S] 0!W8F$M,C Q-C R,CE?8V%L+GAM;%!+ 0(4 Q0 ( #V'A4A2NX&6 M0U0 -VO!0 4 " ;T5 @!W8F$M,C Q-C R,CE?9&5F+GAM M;%!+ 0(4 Q0 ( #V'A4BM7\4P?_P +OJ#@ 4 " 3)J M @!W8F$M,C Q-C R,CE?;&%B+GAM;%!+ 0(4 Q0 ( #V'A4BMB;S/!7L M *G" 4 " >-F P!W8F$M,C Q-C R,CE?<')E+GAM;%!+ 4!08 !@ & (0! :X@, ! end